Mutations	B-Var
in	O
SHP-2	B-Gene
phosphatase	B-Enzyme
that	O
cause	O
hyperactivation	B-PosReg
of	O
its	O
catalytic	B-MPA
activity	I-MPA
have	O
been	O
identified	O
in	O
human	O
leukemias	B-Disease
,	O
particularly	O
juvenile	B-Disease
myelomonocytic	I-Disease
leukemia	I-Disease
,	O
which	O
is	O
characterized	O
by	O
hypersensitivity	O
of	O
myeloid	O
progenitor	O
cells	O
to	O
granulocyte	O
macrophage	O
colony	O
-	O
stimulating	O
factor	O
and	O
interleukin	O
(	O
IL)-3	O
.	O

However	O
,	O
the	O
molecular	O
mechanisms	O
by	O
which	O
gain	O
-	O
of	O
-	O
function	O
(	O
GOF	O
)	O
mutations	O
of	O
SHP-2	O
induce	O
hematopoietic	O
malignancies	O
are	O
not	O
fully	O
understood	O
.	O

Our	O
previous	O
studies	O
have	O
shown	O
that	O
SHP-2	O
plays	O
an	O
essential	O
role	O
in	O
IL-3	O
signal	O
transduction	O
in	O
both	O
catalytic	O
-	O
dependent	O
and	O
-independent	O
manners	O
and	O
that	O
overexpression	O
(	O
5	O
-	O
6-fold	O
)	O
of	O
wild	O
type	O
(	O
WT	O
)	O
SHP-2	O
attenuates	O
IL-3-mediated	O
hematopoietic	O
cell	O
function	O
through	O
accelerated	O
dephosphorylation	O
of	O
STAT5	O
.	O

These	O
results	O
raised	O
the	O
possibility	O
that	O
SHP-2-associated	O
leukemias	O
are	O
not	O
solely	O
attributed	O
to	O
the	O
increased	O
catalytic	O
activity	O
of	O
GOF	O
mutant	O
SHP-2	O
.	O

GOF	O
mutant	O
SHP-2	O
must	O
have	O
gained	O
additional	O
capacities	O
.	O

To	O
test	O
this	O
possibility	O
,	O
we	O
investigated	O
effects	O
of	O
a	O
GOF	O
mutation	O
of	O
SHP-2	O
(	O
SHP-2	O
E76	O
K	O
)	O
on	O
hematopoietic	O
cell	O
function	O
and	O
IL-3	O
signal	O
transduction	O
by	O
comparing	O
with	O
those	O
of	O
overexpressed	O
WT	O
SHP-2	O
.	O

Our	O
results	O
showed	O
that	O
SHP-2	B-Gene
E76	B-Var
K	I-Var
mutation	I-Var
caused	O
myeloproliferative	B-Disease
disease	I-Disease
in	O
mice	O
,	O
while	O
overexpression	O
of	O
WT	O
SHP-2	O
decreased	O
hematopoietic	O
potential	O
of	O
the	O
transduced	O
cells	O
in	O
recipient	O
animals	O
.	O

The	O
E76	B-Var
K	I-Var
mutation	O
in	O
the	O
N	O
-	O
terminal	O
Src	O
homology	O
2	O
domain	O
increased	B-PosReg
interactions	B-Interaction
of	O
mutant	B-Var
SHP-2	B-Gene
with	O
Grb2	B-Protein
,	O
Gab2	O
,	O
and	O
p85	O
,	O
leading	O
to	O
hyperactivation	B-PosReg
of	O
IL-3-induced	B-Pathway
Erk	I-Pathway
and	I-Pathway
phosphatidylinositol	I-Pathway
3-kinase	I-Pathway
(	I-Pathway
PI3	I-Pathway
K	I-Pathway
)	I-Pathway
pathways	I-Pathway
.	O

In	O
addition	O
,	O
despite	O
the	O
substantial	O
increase	B-PosReg
in	O
the	O
catalytic	B-MPA
activity	I-MPA
,	O
dephosphorylation	B-MPA
of	I-MPA
STAT5	I-MPA
by	O
SHP-2	B-Gene
E76	B-Var
K	I-Var
was	O
dampened	B-NegReg
.	O

Furthermore	O
,	O
catalytically	O
inactive	O
SHP-2	B-Gene
E76	B-Var
K	I-Var
with	O
an	O
additional	O
C459S	B-Var
mutation	O
retained	O
the	O
capability	O
to	O
increase	B-PosReg
the	O
interaction	B-Interaction
with	O
Gab2	B-Protein
and	O
to	O
enhance	B-PosReg
the	O
activation	O
of	O
the	O
PI3	B-Pathway
K	I-Pathway
pathway	I-Pathway
.	O

Taken	O
together	O
,	O
these	O
studies	O
suggest	O
that	O
in	O
addition	O
to	O
the	O
elevated	O
catalytic	O
activity	O
,	O
fundamental	O
changes	O
in	O
physical	O
and	O
functional	O
interactions	O
between	O
GOF	O
mutant	O
SHP-2	O
and	O
signaling	O
partners	O
also	O
play	O
an	O
important	O
role	O
in	O
SHP-2-related	O
leukemigenesis	O
.	O

Genetic	O
modifiers	O
of	O
the	O
Drosophila	O
blue	O
cheese	O
gene	O
link	O
defects	O
in	O
lysosomal	O
transport	O
with	O
decreased	O
life	O
span	O
and	O
altered	O
ubiquitinated	O
-	O
protein	O
profiles	O
.	O

Defects	O
in	O
lysosomal	O
trafficking	O
pathways	O
lead	O
to	O
decreased	O
cell	O
viability	O
and	O
are	O
associated	O
with	O
progressive	O
disorders	O
in	O
humans	O
.	O

Previously	O
we	O
have	O
found	O
that	O
loss	O
-	O
of	O
-	O
function	O
(	O
LOF	O
)	O
mutations	B-Var
in	O
the	O
Drosophila	O
gene	O
blue	O
cheese	O
(	B-Gene
bchs	I-Gene
)	I-Gene
lead	O
to	O
reduced	B-NegReg
adult	B-CPA
life	I-CPA
span	I-CPA
,	O
increased	B-PosReg
neuronal	B-CPA
death	I-CPA
,	O
and	O
widespread	B-CPA
CNS	I-CPA
degeneration	B-NegReg
that	O
is	O
associated	O
with	O
the	O
formation	O
of	O
ubiquitinated	O
-	O
protein	O
aggregates	O
.	O

To	O
identify	O
potential	O
genes	O
that	O
participate	O
in	O
the	O
bchs	O
functional	O
pathway	O
,	O
we	O
conducted	O
a	O
genetic	O
modifier	O
screen	O
based	O
on	O
alterations	O
of	O
an	O
eye	O
phenotype	O
that	O
arises	O
from	O
high	O
-	O
level	O
overexpression	O
of	O
Bchs	O
.	O

We	O
found	O
that	O
mutations	O
in	O
select	O
autophagic	O
and	O
endocytic	O
trafficking	O
genes	O
,	O
defects	O
in	O
cytoskeletal	O
and	O
motor	O
proteins	O
,	O
as	O
well	O
as	O
mutations	O
in	O
the	O
SUMO	O
and	O
ubiquitin	O
signaling	O
pathways	O
behave	O
as	O
modifiers	O
of	O
the	O
Bchs	O
gain	O
-	O
of	O
-	O
function	O
(	O
GOF	O
)	O
eye	O
phenotype	O
.	O

Individual	O
mutant	O
alleles	O
that	O
produced	O
viable	O
adults	O
were	O
further	O
examined	O
for	O
bchs	O
-	O
like	O
phenotypes	O
.	O

Mutations	B-Var
in	O
several	O
lysosomal	B-Gene
trafficking	I-Gene
genes	I-Gene
resulted	O
in	O
significantly	O
decreased	B-NegReg
adult	B-CPA
life	I-CPA
spans	I-CPA
and	O
several	O
mutants	O
showed	O
changes	B-Reg
in	O
ubiquitinated	B-MPA
protein	I-MPA
profiles	I-MPA
as	O
young	O
adults	O
.	O

This	O
work	O
represents	O
a	O
novel	O
approach	O
to	O
examine	O
the	O
role	O
that	O
lysosomal	O
transport	O
and	O
function	O
have	O
on	O
adult	O
viability	O
.	O

The	O
genes	O
characterized	O
in	O
this	O
study	O
have	O
direct	O
human	O
homologs	O
,	O
suggesting	O
that	O
similar	O
defects	O
in	O
lysosomal	O
transport	O
may	O
play	O
a	O
role	O
in	O
human	O
health	O
and	O
age	O
-	O
related	O
processes	O
.	O

Isolation	O
and	O
characterization	O
of	O
a	O
novel	O
human	O
RGS	O
mutant	O
displaying	O
gain	O
-	O
of	O
-	O
function	O
activity	O
.	O

Regulator	O
of	O
G	O
protein	O
signaling	O
(	O
RGS	O
)	O
proteins	O
play	O
a	O
crucial	O
role	O
in	O
the	O
adaptation	O
of	O
cells	O
to	O
stimulation	B-PosReg
by	O
G	B-Protein
protein	I-Protein
-	I-Protein
coupled	I-Protein
receptors	I-Protein
via	O
heterotrimeric	B-Protein
G	I-Protein
proteins	I-Protein
.	O

Alterations	B-Var
in	O
RGS	B-Protein
function	O
have	O
been	O
implicated	B-Reg
in	O
a	O
wide	O
range	O
of	O
disease	B-Disease
states	O
,	O
leading	O
to	O
many	O
researchers	O
focusing	O
on	O
controlling	O
the	O
action	O
of	O
these	O
regulatory	O
proteins	O
.	O

Previous	O
studies	O
have	O
centered	O
on	O
reducing	O
or	O
inhibiting	O
the	O
action	O
of	O
RGS	O
proteins	O
,	O
utilizing	O
inactive	O
mutants	O
or	O
small	O
molecular	O
RGS	O
inhibitors	O
.	O

Here	O
we	O
describe	O
the	O
isolation	O
and	O
characterization	O
of	O
a	O
novel	O
human	O
RGS4	B-Var
mutant	I-Var
which	O
displays	O
enhanced	B-PosReg
or	O
gain	B-PosReg
-	I-PosReg
of	I-PosReg
-	I-PosReg
function	I-PosReg
(	O
GOF	O
)	O
activity	O
.	O

RGS4(S30C	O
)	O
demonstrates	O
GOF	O
activity	O
both	O
in	O
an	O
in	O
vivo	O
yeast	B-Pathway
-	I-Pathway
based	I-Pathway
signalling	I-Pathway
pathway	I-Pathway
and	O
in	O
vitro	O
against	O
the	O
Galpha(o1	B-Protein
)	I-Protein
subunit	I-Protein
contained	I-Protein
in	I-Protein
an	I-Protein
alpha(2A)-adrenoreceptor	I-Protein
-	I-Protein
Galpha(o1)(C351I	I-Protein
)	I-Protein
fusion	I-Protein
protein	I-Protein
.	O

Mutational	O
analysis	O
of	O
serine	O
30	O
identified	O
a	O
number	O
of	O
alternative	O
substitutions	O
that	O
result	O
in	O
GOF	O
activity	O
.	O

GOF	O
activity	O
was	O
retained	O
upon	O
transposition	O
of	O
the	O
serine	O
30-cysteine	O
mutation	O
to	O
the	O
equivalent	O
serine	O
residue	O
in	O
human	O
RGS16	O
.	O

As	O
with	O
previously	O
identified	O
GOF	O
mutants	O
,	O
RGS4(S30C	B-Var
/	I-Var
S30F	I-Var
/	I-Var
S30	I-Var
K	I-Var
)	I-Var
demonstrate	O
increased	B-PosReg
steady	O
state	O
protein	B-MPA
levels	I-MPA
,	O
however	O
these	O
mutants	O
also	O
demonstrate	O
enhanced	B-PosReg
GAP	B-MPA
activity	I-MPA
through	O
an	O
additional	O
mechanism	O
distinct	O
from	O
the	O
increased	O
protein	O
content	O
.	O

The	O
identification	O
of	O
human	O
RGS	O
mutants	O
with	O
GOF	O
activity	O
may	O
provide	O
novel	O
therapeutic	O
agents	O
for	O
the	O
treatment	O
of	O
signaling	O
-	O
based	O
diseases	O
and	O
the	O
ability	O
to	O
transpose	O
these	O
mutations	O
to	O
other	O
human	O
RGS	O
proteins	O
extends	O
their	O
application	O
to	O
multiple	O
pathways	O
.	O

Conditional	O
RNA	O
interference	O
in	O
vivo	O
to	O
study	O
mutant	O
p53	O
oncogenic	O
gain	O
of	O
function	O
on	O
tumor	O
malignancy	O
.	O

Mutant	B-Var
p53	B-Gene
proteins	B-Protein
are	O
thought	O
to	O
have	O
acquired	O
a	O
"	B-PosReg
gain	I-PosReg
of	I-PosReg
function	I-PosReg
"	I-PosReg
(	O
GOF	O
)	O
activity	O
that	O
mainly	O
contributes	O
to	O
tumor	B-CPA
aggressiveness	I-CPA
.	O

Previously	O
we	O
reported	O
that	O
constitutive	O
downregulation	B-NegReg
of	O
mutant	B-Var
p53	B-Gene
by	O
RNA	B-MPA
interference	I-MPA
reduces	B-NegReg
the	O
tumorigenicity	B-CPA
of	I-CPA
cancer	I-CPA
cells	I-CPA
in	I-CPA
an	I-CPA
animal	I-CPA
model	I-CPA
;	I-CPA
however	O
,	O
effects	O
of	O
adaptation	O
to	O
long	O
-	O
term	O
mutant	O
p53	O
inhibition	O
could	O
not	O
be	O
excluded	O
.	O

To	O
address	O
this	O
point	O
,	O
mimicking	O
more	O
physiological	O
conditions	O
,	O
we	O
now	O
describe	O
the	O
establishment	O
of	O
a	O
lentiviral	O
-	O
based	O
system	O
for	O
conditional	O
interference	O
with	O
mutant	O
p53	O
expression	O
.	O

In	O
vivo	O
studies	O
assessed	O
the	O
efficacy	O
of	O
conditional	B-MPA
RNA	I-MPA
interference	I-MPA
in	O
inhibiting	B-NegReg
gain	O
of	O
function	O
activity	B-MPA
of	O
mutant	B-Var
p53	B-Gene
proteins	B-Protein
by	O
reducing	O
tumor	O
growth	O
ability	O
.	O

Moreover	O
by	O
using	O
this	O
system	O
,	O
microarray	O
data	O
were	O
validated	O
in	O
vitro	O
and	O
in	O
vivo	O
and	O
putative	O
mutant	O
p53	O
target	O
genes	O
that	O
may	O
contribute	O
to	O
its	O
gain	O
of	O
function	O
effects	O
in	O
cancer	O
were	O
identified	O
.	O

Results	O
are	O
confirmatory	O
that	O
depletion	B-MPA
of	O
mutant	B-Var
p53	B-Gene
protein	B-Protein
impacts	B-Reg
on	O
tumor	B-CPA
malignancy	I-CPA
and	O
validated	O
the	O
inducible	O
lentiviral	O
-	O
based	O
system	O
as	O
an	O
efficient	O
tool	O
to	O
study	O
the	O
gain	O
of	O
function	O
activity	O
of	O
human	O
tumor	O
derived	O
p53	O
mutants	O
.	O

Identification	O
and	O
functional	O
analysis	O
of	O
novel	O
variants	O
of	O
the	O
human	O
melanocortin	O
1	O
receptor	O
found	O
in	O
melanoma	O
patients	O
.	O

The	O
melanocortin	O
1	O
receptor	O
,	O
a	O
Gs	O
protein	O
-	O
coupled	O
receptor	O
expressed	O
in	O
epidermal	O
melanocytes	O
,	O
is	O
a	O
major	O
determinant	O
of	O
skin	O
pigmentation	O
and	O
phototype	O
and	O
an	O
important	O
contributor	O
to	O
melanoma	O
risk	O
.	O

MC1R	O
activation	O
stimulates	O
synthesis	O
of	O
black	O
,	O
strongly	O
photoprotective	O
eumelanin	O
pigments	O
.	O

Several	O
MC1R	O
alleles	O
are	O
associated	O
with	O
red	O
hair	O
,	O
fair	O
skin	O
,	O
increased	O
sensitivity	O
to	O
ultraviolet	O
radiation	O
,	O
and	O
increased	O
skin	O
cancer	O
risk	O
.	O

The	O
MC1R	O
gene	O
is	O
highly	O
polymorphic	O
,	O
but	O
only	O
a	O
few	O
naturally	O
occurring	O
alleles	O
have	O
been	O
functionally	O
characterized	O
,	O
which	O
complicates	O
the	O
establishment	O
of	O
accurate	O
correlations	O
between	O
the	O
signaling	O
properties	O
of	O
mutant	O
alleles	O
and	O
defined	O
cutaneous	O
phenotypes	O
.	O

We	O
report	O
the	O
functional	O
characterization	O
of	O
six	O
MC1R	B-Gene
alleles	O
found	O
in	O
Spanish	O
melanoma	B-Disease
patients	O
.	O

Two	O
variants	O
(	O
c.152T	O
>	O
C	O
,	O
p	O
.	O
Val51Ala	O
and	O
c.865T	O
>	O
C	O
,	O
p	O
.	O
Cys289Arg	O
)	O
have	O
never	O
been	O
described	O
,	O
and	O
the	O
others	O
(	O
c.112G	O
>	O
A	O
,	O
p	O
.	O
Val38Met	O
;	O
c.122C	O
>	O
T	O
,	O
p	O
.	O
Ser41Phe	O
;	O
c.383T	O
>	O
C	O
,	O
p	O
.	O
Met128Thr	O
;	O
and	O
c.842A	O
>	O
G	O
,	O
p	O
.	O
Asn281Ser	O
)	O
have	O
not	O
been	O
analyzed	O
for	O
function	O
.	O

p	B-Var
.	I-Var
Asn281Ser	I-Var
corresponds	O
to	O
a	O
functionally	O
silent	B-NegReg
polymorphism	B-MPA
.	O

The	O
other	O
mutations	O
are	O
associated	O
with	O
varying	O
degrees	O
of	O
loss	O
of	O
function	O
(	O
LOF	O
)	O
,	O
from	O
moderate	O
decreases	B-NegReg
in	O
coupling	B-MPA
to	O
the	O
cAMP	B-Pathway
pathway	I-Pathway
(	B-Var
p	I-Var
.	I-Var
Val38Met	I-Var
and	O
p	B-Var
.	I-Var
Val51Ala	I-Var
)	I-Var
to	O
nearly	O
complete	O
absence	B-NegReg
of	O
functional	B-MPA
coupling	I-MPA
(	B-Var
p	I-Var
.	I-Var
Ser41Phe	I-Var
,	O
p	B-Var
.	I-Var
Met128Thr	I-Var
,	O
and	O
p	B-Var
.	I-Var
Cys289Arg	I-Var
)	I-Var
.	O

The	O
LOF	O
p	B-Var
.	I-Var
Met128Thr	I-Var
and	O
p	B-Var
.	I-Var
Cys289Arg	I-Var
mutants	O
are	O
trafficked	O
to	O
the	O
cell	O
surface	O
,	O
but	O
are	O
unable	B-NegReg
to	O
bind	B-Interaction
agonists	O
efficiently	O
.	O

Conversely	O
,	O
LOF	O
of	O
p	B-Var
.	I-Var
Val38Met	I-Var
,	O
p	B-Var
.	I-Var
Ser41Phe	I-Var
,	O
and	O
p	B-Var
.	I-Var
Val51Ala	I-Var
is	O
due	O
to	O
reduced	B-NegReg
cell	B-CPA
surface	I-CPA
expression	I-CPA
as	O
a	O
consequence	O
of	O
retention	O
in	O
the	O
endoplasmic	O
reticulum	O
(	O
ER	O
)	O
.	O

Therefore	O
,	O
LOF	O
of	O
MC1R	O
alleles	O
is	O
frequently	O
associated	O
with	O
aberrant	O
forward	O
trafficking	O
and	O
accumulation	O
within	O
the	O
ER	O
or	O
with	O
inability	O
to	O
bind	O
properly	O
the	O
activatory	O
ligand	O
.	O

Elevated	O
expression	O
of	O
p53	B-Gene
gain	B-PosReg
-	I-PosReg
of	I-PosReg
-	I-PosReg
function	I-PosReg
mutation	O
R175H	B-Var
in	O
endometrial	O
cancer	O
cells	O
can	O
increase	O
the	O
invasive	O
phenotypes	O
by	O
activation	O
of	O
the	O
EGFR	B-Pathway
/	I-Pathway
PI3K	I-Pathway
/	I-Pathway
AKT	I-Pathway
pathway	I-Pathway
.	O

BACKGROUND	O
:	O
p53	O
is	O
the	O
most	O
commonly	O
mutated	O
tumor	O
suppressor	O
gene	O
in	O
human	O
cancers	O
.	O

In	O
addition	O
to	O
the	O
loss	O
of	O
tumor	O
suppression	O
function	O
and	O
exertion	O
of	O
dominant	O
-	O
negative	O
effects	O
over	O
the	O
remaining	O
wild	O
-	O
type	O
protein	O
,	O
several	O
p53	O
mutants	O
can	O
gain	O
novel	O
oncogenic	O
functions	O
(	O
gain	O
-	O
of	O
-	O
function	O
,	O
GOF	O
)	O
that	O
actively	O
regulate	O
cancer	O
development	O
and	O
progression	O
.	O

In	O
human	O
endometrial	O
cancer	O
,	O
p53	B-Gene
mutation	B-Var
is	O
more	O
often	O
associated	B-Reg
with	O
aggressive	B-Disease
nonendometrioid	I-Disease
cancer	I-Disease
.	O

However	O
,	O
it	O
was	O
unknown	O
if	O
p53	O
mutants	O
contributed	O
to	O
endometrial	O
cancer	O
progression	O
through	O
the	O
GOF	O
properties	O
.	O

METHODS	O
:	O
To	O
clarify	O
the	O
relationship	O
between	O
expression	O
of	O
p53	O
GOF	O
mutation	O
(	O
p53-R175H	O
)	O
and	O
invasive	O
potential	O
of	O
human	O
endometrial	O
cancer	O
KLE	O
cells	O
,	O
we	O
tested	B-Reg
the	O
consequences	O
of	O
up	B-PosReg
-	I-PosReg
regulation	I-PosReg
and	O
down	B-NegReg
-	I-NegReg
regulation	I-NegReg
of	O
p53-R175H	O
in	O
KLE	O
cells	O
by	O
inducing	B-Reg
p53-R175H	B-Protein
expression	I-Protein
vector	I-Protein
or	O
suppressing	B-NegReg
the	O
p53	B-Gene
gene	I-Gene
with	O
short	O
hairpin	O
RNA	O
.	O

RESULTS	O
:	O
We	O
found	O
that	O
forced	O
over	B-PosReg
-	I-PosReg
expression	I-PosReg
of	O
p53-R175H	B-Var
significantly	O
promoted	B-PosReg
cell	B-CPA
migration	I-CPA
and	O
invasion	B-CPA
,	O
and	O
induced	O
activation	B-PosReg
of	O
the	O
epidermal	B-Pathway
growth	I-Pathway
factor	I-Pathway
receptor	I-Pathway
(	I-Pathway
EGFR)/phosphatidylinositol	I-Pathway
3-kinase	I-Pathway
(	I-Pathway
PI3K)/AKT	I-Pathway
pathway	I-Pathway
.	O

Conversely	O
,	O
suppression	B-NegReg
of	O
p53-R175H	B-Protein
with	O
short	B-Gene
hairpin	I-Gene
RNA	I-Gene
significantly	O
inhibited	B-NegReg
cell	B-CPA
migration	I-CPA
and	I-CPA
invasion	I-CPA
,	O
and	O
resulted	O
in	O
attenuation	B-NegReg
of	O
EGFR	B-Pathway
/	I-Pathway
PI3K	I-Pathway
/	I-Pathway
AKT	I-Pathway
pathway	I-Pathway
.	O

CONCLUSION	O
:	O
These	O
findings	O
show	O
for	O
the	O
first	O
time	O
that	O
elevated	B-PosReg
expression	B-MPA
of	O
p53-R175H	B-Var
mutant	O
may	O
exert	O
gain	B-MPA
-	I-MPA
of	I-MPA
-	I-MPA
function	I-MPA
activity	I-MPA
to	O
activate	B-PosReg
the	O
EGFR	B-Pathway
/	I-Pathway
PI3K	I-Pathway
/	I-Pathway
AKT	I-Pathway
pathway	I-Pathway
and	O
thus	O
may	O
contribute	B-Reg
to	O
the	O
invasive	O
phenotype	O
in	O
endometrial	B-Disease
cancer	I-Disease
.	O

The	O
tyrosine	O
phosphatase	O
Shp2	O
in	O
development	O
and	O
cancer	O
.	O

Deregulation	O
of	O
signaling	O
pathways	O
,	O
through	O
mutation	O
or	O
other	O
molecular	O
changes	O
,	O
can	O
ultimately	O
result	O
in	O
disease	O
.	O

The	O
tyrosine	O
phosphatase	O
Shp2	O
has	O
emerged	O
as	O
a	O
major	O
regulator	O
of	O
receptor	O
tyrosine	O
kinase	O
(	O
RTK	O
)	O
and	O
cytokine	O
receptor	O
signaling	O
.	O

In	O
the	O
last	O
decade	O
,	O
germline	O
mutations	O
in	O
the	O
human	O
PTPN11	O
gene	O
,	O
encoding	O
Shp2	O
,	O
were	O
linked	O
to	O
Noonan	O
(	O
NS	O
)	O
and	O
LEOPARD	O
syndromes	O
,	O
two	O
multisymptomatic	O
developmental	O
disorders	O
that	O
are	O
characterized	O
by	O
short	O
stature	O
,	O
craniofacial	O
defects	O
,	O
cardiac	O
defects	O
,	O
and	O
mental	O
retardation	O
.	O

Somatic	O
Shp2	B-Gene
mutations	B-Var
are	O
also	O
associated	B-Reg
with	O
several	O
types	O
of	O
human	O
malignancies	O
,	O
such	O
as	O
the	O
most	O
common	O
juvenile	O
leukemia	O
,	O
juvenile	B-Disease
myelomonocytic	I-Disease
leukemia	I-Disease
(	O
JMML	O
)	O
.	O

Whereas	O
NS	B-Disease
and	O
JMML	B-Disease
are	O
caused	O
by	O
gain	B-PosReg
-	I-PosReg
of	I-PosReg
-	I-PosReg
function	I-PosReg
(	O
GOF	O
)	O
mutations	B-Var
of	O
Shp2	B-Gene
,	O
loss	B-NegReg
-	I-NegReg
of	I-NegReg
-	I-NegReg
function	I-NegReg
(	O
LOF	O
)	O
mutations	B-Var
are	O
thought	O
to	O
be	O
associated	O
with	O
LEOPARD	B-Disease
syndrome	I-Disease
.	O

Animal	O
models	O
that	O
carry	O
conditional	O
LOF	O
and	O
GOF	O
mutations	O
have	O
allowed	O
a	O
better	O
understanding	O
of	O
the	O
mechanism	O
of	O
Shp2	O
function	O
in	O
disease	O
,	O
and	O
shed	O
light	O
on	O
the	O
role	O
of	O
Shp2	O
in	O
signaling	O
pathways	O
that	O
control	O
decisive	O
events	O
during	O
embryonic	O
development	O
or	O
during	O
cellular	O
transformation	O
/	O
tumorigenesis	O
.	O

Mutant	B-Var
p53	B-Gene
facilitates	B-PosReg
somatic	B-CPA
cell	I-CPA
reprogramming	I-CPA
and	O
augments	B-NegReg
the	O
malignant	B-CPA
potential	I-CPA
of	I-CPA
reprogrammed	I-CPA
cells	I-CPA
.	O

p53	B-Gene
deficiency	B-Var
enhances	B-PosReg
the	O
efficiency	O
of	O
somatic	B-CPA
cell	I-CPA
reprogramming	I-CPA
to	O
a	O
pluripotent	O
state	O
.	O

As	O
p53	O
is	O
usually	O
mutated	O
in	O
human	O
tumors	O
and	O
many	O
mutated	B-Var
forms	O
of	O
p53	B-Gene
gain	B-PosReg
novel	O
activities	B-MPA
,	O
we	O
studied	O
the	O
influence	O
of	O
mutant	O
p53	O
(	O
mut	O
-	O
p53	O
)	O
on	O
somatic	O
cell	O
reprogramming	O
.	O

Our	O
data	O
indicate	O
a	O
novel	O
gain	B-PosReg
of	O
function	B-MPA
(	O
GOF	O
)	O
property	O
for	O
mut	B-Var
-	I-Var
p53	I-Var
,	O
which	O
markedly	O
enhanced	B-PosReg
the	O
efficiency	O
of	O
the	O
reprogramming	B-CPA
process	I-CPA
compared	O
with	O
p53	O
deficiency	O
.	O

Importantly	O
,	O
this	O
novel	O
activity	B-MPA
of	O
mut	B-Gene
-	I-Gene
p53	I-Gene
induced	O
alterations	B-Reg
in	O
the	O
characteristics	B-CPA
of	I-CPA
the	I-CPA
reprogrammed	I-CPA
cells	I-CPA
.	O

Although	O
p53	O
knockout	O
(	O
KO	O
)	O
cells	O
reprogrammed	O
with	O
only	O
Oct4	O
and	O
Sox2	O
maintained	O
their	O
pluripotent	B-MPA
capacity	I-MPA
in	O
vivo	O
,	O
reprogrammed	O
cells	O
expressing	O
mutant	B-Var
p53	B-Gene
lost	B-NegReg
this	O
capability	O
and	O
gave	B-Reg
rise	I-Reg
to	O
malignant	B-CPA
tumors	I-CPA
.	O

This	O
novel	O
GOF	O
of	O
mut	O
-	O
p53	O
is	O
not	O
attributed	O
to	O
its	O
effect	O
on	O
proliferation	O
,	O
as	O
both	O
p53	O
KO	O
and	O
mut	O
-	O
p53	O
cells	O
displayed	O
similar	O
proliferation	O
rates	O
.	O

In	O
addition	O
,	O
we	O
demonstrate	O
an	O
oncogenic	B-MPA
activity	I-MPA
of	O
Klf4	O
,	O
as	O
its	O
overexpression	B-PosReg
in	O
either	O
p53	O
KO	O
or	O
mut	B-Gene
-	I-Gene
p53	I-Gene
cells	O
induced	B-PosReg
aggressive	B-CPA
tumors	I-CPA
.	O

Overall	O
,	O
our	O
data	O
show	O
that	O
reprogrammed	O
cells	O
with	O
the	O
capacity	O
to	O
differentiate	O
into	O
the	O
three	O
germ	O
layers	O
in	O
vitro	O
can	O
form	O
malignant	O
tumors	O
,	O
suggesting	O
that	O
in	O
genetically	O
unstable	O
cells	O
,	O
such	O
as	O
those	O
in	O
which	O
p53	B-Gene
is	O
mutated	B-Var
,	O
reprogramming	B-CPA
may	O
result	B-Reg
in	I-Reg
the	O
generation	O
of	O
cells	B-CPA
with	I-CPA
malignant	I-CPA
tumor	I-CPA
-	I-CPA
forming	I-CPA
potential	I-CPA
.	O

The	O
combined	O
impact	O
of	O
CYP2C19	O
and	O
CYP2B6	O
pharmacogenetics	O
on	O
cyclophosphamide	O
bioactivation	O
.	O

AIMS	O
:	O
The	O
role	O
of	O
CYP	O
pharmacogenetics	O
in	O
the	O
bioactivation	O
of	O
cyclophosphamide	O
is	O
still	O
controversial	O
.	O

Recent	O
clinical	O
studies	O
have	O
suggested	O
a	O
role	O
for	O
either	O
CYP2C19	O
or	O
CYP2B6	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
clarify	O
the	O
role	O
of	O
these	O
pharmacogenes	O
.	O

METHODS	O
:	O
We	O
used	O
a	O
combined	O
in	O
vitro	O
-	O
in	O
vivo	O
approach	O
to	O
determine	O
the	O
role	O
of	O
these	O
pharmacogenes	O
in	O
the	O
bioactivation	O
of	O
the	O
prodrug	O
to	O
4-hydroxy	O
cyclophosphamide	O
(	O
4-OHCP	O
)	O
.	O

Cyclophosphamide	O
metabolism	O
was	O
determined	O
in	O
a	O
human	O
liver	O
biobank	O
(	O
n=	O
14	O
)	O
and	O
in	O
patients	O
receiving	O
the	O
drug	O
for	O
treatment	O
of	O
lupus	O
nephritis	O
(	O
n=	O
16	O
)	O
RESULTS	O
:	O
In	O
livers	O
of	O
known	O
CYP2C19	O
and	O
CYP2B6	O
genotype	O
and	O
protein	O
expression	O
we	O
observed	O
that	O
there	O
was	O
a	O
combined	B-Interaction
role	O
for	O
both	O
CYP2C19	B-Var
and	O
CYP2B6	B-Var
in	O
the	O
bioactivation	B-MPA
of	I-MPA
cyclophosphamide	I-MPA
in	O
vitro	O
.	O

The	O
presence	O
of	O
at	O
least	O
one	O
loss	O
of	O
function	O
(	O
LoF	O
)	O
allele	O
at	O
either	O
CYP2C19	B-Var
or	O
CYP2B6	B-Var
resulted	O
in	O
a	O
significant	O
decrease	B-NegReg
in	O
both	O
V(max	B-MPA
)	I-MPA
(	I-MPA
P=	I-MPA
0.028	I-MPA
)	I-MPA
and	I-MPA
CL(int	I-MPA
)	I-MPA
(	I-MPA
P=	I-MPA
0.0017	I-MPA
)	I-MPA
compared	O
with	O
livers	O
with	O
no	O
LoF	O
alleles	O
.	O

This	O
dual	O
genotype	O
relationship	O
was	O
also	O
observed	O
in	O
a	O
preliminary	O
clinical	O
study	O
,	O
with	O
patients	O
who	O
had	O
≥1	O
LoF	O
allele	O
at	O
either	O
CYP2C19	B-Var
or	O
CYP2B6	B-Var
also	O
displaying	O
significantly	O
(	O
P=	O
0.0316	O
)	O
lower	B-NegReg
bioactivation	B-MPA
of	I-MPA
cyclophosphamide	I-MPA
.	O

The	O
mean	O
4-OHCP	O
:	O
CP	O
bioactivation	O
ratio	O
was	O
0.0014	O
(	O
95	O
%	O
CI	O
0.0007	O
,	O
0.002	O
)	O
compared	O
with	O
0.0071	O
(	O
95	O
%	O
CI	O
0.0001	O
,	O
0.014	O
)	O
in	O
patients	O
with	O
no	O
LoF	O
alleles	O
at	O
either	O
of	O
these	O
genes	O
.	O

CONCLUSIONS	O
:	O
The	O
presence	O
of	O
≥1	O
LoF	O
allele(s	O
)	O
at	O
either	O
CYP2B6	B-Var
or	O
CYP2C19	B-Var
appeared	O
to	O
result	O
in	O
decreased	B-NegReg
bioactivation	B-MPA
of	I-MPA
cyclophosphamide	I-MPA
both	O
in	O
vitro	O
and	O
in	O
patients	O
.	O

Further	O
clinical	O
studies	O
to	O
confirm	O
this	O
relationship	O
are	O
warranted	O
.	O

Mutant	O
p53	O
R248Q	O
but	O
not	O
R248W	O
enhances	O
in	O
vitro	O
invasiveness	O
of	O
human	O
lung	O
cancer	O
NCI	O
-	O
H1299	O
cells	O
.	O

More	O
than	O
half	O
of	O
all	O
human	B-Disease
cancers	I-Disease
are	O
associated	B-Reg
with	O
mutations	B-Var
of	O
the	O
TP53	B-Gene
gene	O
.	O

In	O
regard	O
to	O
the	O
functional	O
interaction	O
with	O
the	O
remaining	O
wild	O
-	O
type	O
(	O
WT	O
)	O
p53	O
allele	O
,	O
p53	O
mutations	O
are	O
classified	O
into	O
two	O
types	O
,	O
recessive	O
and	O
dominant	B-Var
-	I-Var
negative	I-Var
(	I-Var
DN	I-Var
)	I-Var
mutations	I-Var
.	O

The	O
latter	O
mutant	O
protein	O
has	O
a	O
DN	B-MPA
activity	I-MPA
over	B-PosReg
the	I-PosReg
remaining	I-PosReg
WT	I-PosReg
allele	I-PosReg
.	O

We	O
previously	O
showed	O
that	O
the	O
DN	O
p53	O
mutant	O
was	O
useful	O
as	O
a	O
predictor	O
of	O
poor	O
outcome	O
or	O
a	O
risk	O
factor	O
for	O
metastatic	O
recurrence	O
in	O
patients	O
with	O
some	O
types	O
of	O
cancers	O
,	O
regardless	O
of	O
the	O
presence	O
or	O
absence	O
of	O
loss	O
of	O
heterozygosity	O
(	O
LOH	O
)	O
of	O
WT	O
p53	O
,	O
suggesting	O
that	O
the	O
DN	B-Var
p53	B-Gene
had	O
'	B-PosReg
gain	I-PosReg
-	I-PosReg
of	I-PosReg
-	I-PosReg
function	I-PosReg
(	I-PosReg
GOF	I-PosReg
)	I-PosReg
'	I-PosReg
activity	I-PosReg
besides	O
the	O
transdominance	O
function	O
.	O

In	O
this	O
study	O
,	O
we	O
investigated	O
GOF	O
activity	O
of	O
two	O
DN	O
p53	O
mutants	O
which	O
had	O
a	O
point	O
mutation	O
at	O
codon	O
248	O
(	O
R248Q	O
and	O
R248W	O
)	O
,	O
one	O
of	O
the	O
hot	O
spots	O
,	O
by	O
transfecting	O
them	O
respectively	O
into	O
H1299	O
cells	O
which	O
originally	O
expressed	O
no	O
p53	O
protein	O
.	O

Growth	O
activity	O
of	O
the	O
transfectants	O
with	O
the	O
two	O
mutants	O
was	O
not	O
different	O
from	O
that	O
of	O
parent	O
or	O
Mock	O
transfectants	O
.	O

Meanwhile	O
,	O
in	O
vitro	B-CPA
invasions	I-CPA
of	I-CPA
Matrigel	I-CPA
and	I-CPA
type	I-CPA
I	I-CPA
collagen	I-CPA
gel	I-CPA
by	O
R248Q	B-Var
-	I-Var
transfectants	I-Var
were	O
significantly	O
higher	B-PosReg
than	O
those	O
by	O
R248W	O
-	O
transfectants	O
or	O
the	O
control	O
cells	O
.	O

However	O
,	O
there	O
were	O
no	O
differences	O
in	O
cell	O
motile	O
activities	O
,	O
expressions	O
of	O
extracellular	O
matrix	O
-	O
degradative	O
enzymes	O
such	O
as	O
matrix	O
metalloproteinases	O
,	O
urokinase	O
-	O
type	O
plasminogen	O
activator	O
and	O
heparanase	O
,	O
and	O
their	O
inhibitors	O
,	O
between	O
R248Q-	O
and	O
R248W	O
-	O
transfectants	O
.	O

These	O
findings	O
indicate	O
that	O
the	O
p53	O
mutants	O
have	O
a	O
different	O
quality	O
in	O
GOF	O
activities	O
even	O
if	O
the	O
mutations	O
occurred	O
at	O
the	O
same	O
codon	O
.	O

And	O
detailed	O
information	O
of	O
the	O
status	O
of	O
p53	O
,	O
including	O
transdominancy	O
and	O
GOF	O
activity	O
,	O
is	O
expected	O
to	O
be	O
useful	O
for	O
diagnosis	O
and	O
therapeutic	O
strategy	O
fitting	O
the	O
individual	O
patients	O
.	O

Gain	O
-	O
of	O
-	O
function	O
mutant	B-Var
p53	B-Gene
upregulates	B-PosReg
CXC	B-MPA
chemokines	I-MPA
and	O
enhances	B-PosReg
cell	B-CPA
migration	I-CPA
.	O

The	O
role	O
of	O
dominant	O
transforming	O
p53	O
in	O
carcinogenesis	O
is	O
poorly	O
understood	O
.	O

Our	O
previous	O
data	O
suggested	O
that	O
aberrant	B-Var
p53	B-Protein
proteins	I-Protein
can	O
enhance	B-PosReg
tumorigenesis	B-CPA
and	I-CPA
metastasis	I-CPA
.	O

Here	O
,	O
we	O
examined	O
potential	O
mechanisms	O
through	O
which	O
gain	O
-	O
of	O
-	O
function	O
(	O
GOF	O
)	O
p53	O
proteins	O
can	O
induce	O
motility	O
.	O

Cells	O
expressing	O
GOF	O
p53	B-Var
-R175H	I-Var
,	O
-R273H	I-Var
and	I-Var
-D281	I-Var
G	I-Var
showed	O
enhanced	B-PosReg
migration	B-CPA
,	O
which	O
was	O
reversed	O
by	O
RNA	O
interference	O
(	O
RNAi	O
)	O
or	O
transactivation	O
-	O
deficient	O
mutants	O
.	O

In	O
cells	O
with	O
engineered	O
or	O
endogenous	O
p53	O
mutants	O
,	O
enhanced	O
migration	O
was	O
reduced	O
by	O
downregulation	O
of	O
nuclear	O
factor	O
-	O
kappaB2	O
,	O
a	O
GOF	O
p53	O
target	O
.	O

We	O
found	O
that	O
GOF	B-Var
p53	I-Var
proteins	O
upregulate	B-PosReg
CXC	B-MPA
-	I-MPA
chemokine	I-MPA
expression	I-MPA
,	O
the	O
inflammatory	O
mediators	O
that	O
contribute	O
to	O
multiple	O
aspects	O
of	O
tumorigenesis	O
.	O

Elevated	B-PosReg
expression	B-MPA
of	O
CXCL5	O
,	O
CXCL8	O
and	O
CXCL12	O
was	O
found	O
in	O
cells	O
expressing	O
oncogenic	B-Var
p53	I-Var
.	O

Transcription	B-MPA
was	O
elevated	B-PosReg
as	O
CXCL5	B-MPA
and	I-MPA
CXCL8	I-MPA
promoter	I-MPA
activity	I-MPA
was	O
higher	B-PosReg
in	O
cells	O
expressing	O
GOF	B-Var
p53	I-Var
,	O
whereas	O
wild	O
-	O
type	O
p53	O
repressed	O
promoter	O
activity	O
.	O

Chromatin	O
immunoprecipitation	O
assays	O
revealed	O
enhanced	O
presence	O
of	O
acetylated	O
histone	O
H3	O
on	O
the	O
CXCL5	O
promoter	O
in	O
H1299	O
/	O
R273H	O
cells	O
,	O
in	O
agreement	O
with	O
increased	O
transcriptional	O
activity	O
of	O
the	O
promoter	O
,	O
whereas	O
RNAi	O
-	O
mediated	O
repression	O
of	O
CXCL5	O
inhibited	O
cell	O
migration	O
.	O

Consistent	O
with	O
this	O
,	O
knockdown	O
of	O
the	O
endogenous	B-Var
mutant	I-Var
p53	B-Gene
in	O
lung	O
cancer	O
or	O
melanoma	O
cells	O
reduced	B-NegReg
CXCL5	B-MPA
expression	I-MPA
and	O
cell	B-CPA
migration	I-CPA
.	O

Furthermore	O
,	O
short	O
hairpin	O
RNA	O
knockdown	O
of	O
mutant	B-Var
p53	B-Gene
in	O
MDA	O
-	O
MB-231	O
cells	O
reduced	B-NegReg
expression	B-MPA
of	I-MPA
a	I-MPA
number	I-MPA
of	I-MPA
key	I-MPA
targets	I-MPA
,	O
including	O
several	O
chemokines	O
and	O
other	O
inflammatory	O
mediators	O
.	O

Finally	O
,	O
CXCL5	B-MPA
expression	I-MPA
was	O
also	O
elevated	B-PosReg
in	O
lung	B-Disease
tumor	I-Disease
samples	O
containing	O
GOF	B-Var
p53	I-Var
,	O
indicating	O
relevance	O
to	O
human	O
cancer	O
.	O

The	O
data	O
suggest	O
a	O
mechanistic	O
link	O
between	O
GOF	O
p53	O
proteins	O
and	O
chemokines	O
in	O
enhanced	O
cell	O
motility	O
.	O

Allele	O
specific	O
gain	B-PosReg
-	I-PosReg
of	I-PosReg
-	I-PosReg
function	I-PosReg
activity	B-MPA
of	O
p53	B-Gene
mutants	B-Var
in	O
lung	B-Disease
cancer	I-Disease
cells	O
.	O

p53	B-Gene
mutations	B-Var
are	O
mostly	O
single	O
amino	O
acid	O
changes	O
resulting	B-Reg
in	I-Reg
expression	B-MPA
of	O
a	O
stable	O
mutant	O
protein	O
with	O
"	B-PosReg
gain	I-PosReg
of	I-PosReg
function	I-PosReg
"	I-PosReg
(	O
GOF	O
)	O
activity	B-MPA
having	O
a	O
dominant	O
oncogenic	O
role	O
rather	O
than	O
simple	O
loss	O
of	O
function	O
of	O
wild	O
-	O
type	O
p53	O
.	O

Knock	O
-	O
down	O
of	O
mutant	O
p53	O
in	O
human	O
lung	O
cancer	O
cell	O
lines	O
with	O
different	O
endogenous	O
p53	B-Gene
mutants	B-Var
results	O
in	O
loss	B-NegReg
of	O
GOF	O
activity	B-MPA
as	O
shown	O
by	O
lowering	B-NegReg
of	O
cell	B-CPA
growth	I-CPA
rate	I-CPA
.	O

Two	O
lung	O
cancer	O
cell	O
lines	O
,	O
ABC1	O
and	O
H1437	O
,	O
carrying	O
endogenous	O
mutants	B-Var
p53-P278S	I-Var
and	I-Var
-R267P	I-Var
,	O
show	O
reduction	B-NegReg
in	O
growth	B-MPA
rate	I-MPA
on	O
knock	O
-	O
down	O
on	O
p53	O
levels	O
.	O

However	O
,	O
whereas	O
reduction	B-NegReg
of	O
the	O
p53	B-Var
level	O
induces	O
loss	B-NegReg
of	O
tumorigenicity	B-MPA
in	O
nude	O
mice	O
for	O
ABC1	O
cells	O
,	O
it	O
escalates	B-PosReg
tumorigenicity	B-MPA
for	O
H1437	O
cells	O
.	O

We	O
have	O
tested	O
their	O
transactivation	O
potential	O
on	O
p53	O
target	O
gene	O
promoters	O
by	O
performing	O
transient	O
transcriptional	O
assays	O
in	O
the	O
p53-null	O
H1299	O
lung	O
cancer	O
cell	O
line	O
.	O

Interestingly	O
,	O
while	O
the	O
mutant	O
p53	O
target	O
promoter	O
Axl	O
was	O
activated	O
by	O
both	O
the	O
mutants	O
,	O
the	O
p21	O
promoter	O
was	O
activated	O
by	O
p53-R267P	O
and	O
wild	O
-	O
type	O
p53	O
but	O
not	O
by	O
p53-P278S	O
;	O
showing	O
a	O
clear	O
difference	O
in	O
transcriptional	O
activity	O
between	O
the	O
two	O
mutants	O
.	O

Our	O
results	O
demonstrate	O
allele	O
specificity	O
between	O
GOF	O
p53	O
mutants	O
and	O
attempt	O
to	O
show	O
that	O
the	O
specificity	O
is	O
dependent	O
on	O
the	O
transactivation	O
property	O
of	O
GOF	O
p53	O
;	O
it	O
also	O
suggests	O
importance	O
of	O
p21	O
activation	O
in	O
tumor	O
suppression	O
by	O
p53	O
.	O

Gain	O
-	O
of	O
-	O
Function	O
Activity	O
of	O
Mutant	O
p53	O
in	O
Lung	O
Cancer	O
through	O
Up	O
-	O
Regulation	O
of	O
Receptor	O
Protein	O
Tyrosine	O
Kinase	O
Axl	O
.	O

p53	O
mutations	O
are	O
present	O
in	O
up	O
to	O
70	O
%	O
of	O
lung	O
cancer	O
.	O

Cancer	O
cells	O
with	O
p53	B-Gene
mutations	B-Var
,	O
in	O
general	O
,	O
grow	B-CPA
more	O
aggressively	B-PosReg
than	O
those	O
with	O
wild	O
-	O
type	O
p53	O
or	O
no	O
p53	O
.	O

Expression	O
of	O
tumor	O
-	O
derived	O
mutant	B-Var
p53	B-Gene
in	O
cells	O
leads	O
to	O
up	B-PosReg
-	I-PosReg
regulated	I-PosReg
expression	B-MPA
of	I-MPA
genes	I-MPA
that	O
may	O
affect	B-Reg
cell	B-CPA
growth	I-CPA
and	O
oncogenesis	B-CPA
.	O

In	O
our	O
study	O
of	O
this	O
aggressive	O
phenotype	O
,	O
we	O
have	O
investigated	O
the	O
receptor	O
protein	O
tyrosine	B-Enzyme
kinase	I-Enzyme
Axl	I-Enzyme
,	O
which	O
is	O
up	B-PosReg
-	I-PosReg
regulated	I-PosReg
by	O
p53	B-Gene
mutants	B-Var
at	O
both	O
RNA	O
and	O
protein	O
levels	O
in	O
H1299	O
lung	O
cancer	O
cells	O
expressing	O
mutants	O
p53-R175H	O
,	O
-R273H	O
,	O
and	O
-D281G.	O
Knockdown	O
of	O
endogenous	O
mutant	O
p53	O
levels	O
in	O
human	O
lung	O
cancer	O
cells	O
H1048	O
(	O
p53-R273C	O
)	O
and	O
H1437	O
(	O
p53-R267P	O
)	O
led	O
to	O
a	O
reduction	O
in	O
the	O
level	O
of	O
Axl	O
as	O
well	O
.	O

This	O
effect	O
on	O
Axl	O
expression	O
is	O
refractory	O
to	O
the	O
mutations	O
at	O
positions	O
22	O
and	O
23	O
of	O
p53	O
,	O
suggesting	O
that	O
p53	O
's	O
transactivation	O
domain	O
may	O
not	O
play	O
a	O
critical	O
role	O
in	O
the	O
up	O
-	O
regulation	O
of	O
Axl	O
gene	O
expression	O
.	O

Chromatin	O
immunoprecipitation	O
(	O
ChIP	O
)	O
assays	O
carried	O
out	O
with	O
acetylated	O
histone	O
antibodies	O
demonstrated	O
induced	O
histone	B-Reg
acetylation	B-MPA
on	I-MPA
the	I-MPA
Axl	I-MPA
promoter	I-MPA
region	I-MPA
by	O
mutant	B-Var
p53	B-Gene
.	O

Direct	O
mutant	O
p53	O
nucleation	O
on	O
the	O
Axl	O
promoter	O
was	O
demonstrated	O
by	O
ChIP	O
assays	O
using	O
antibodies	O
against	O
p53	O
.	O

The	O
Axl	O
promoter	O
has	O
a	O
p53	O
/	O
p63	O
binding	O
site	O
,	O
which	O
however	O
is	O
not	O
required	O
for	O
mutant	O
p53-mediated	O
transactivation	O
.	O

Knockdown	O
of	O
Axl	O
by	O
Axl	O
-	O
specific	O
RNAi	O
caused	O
a	O
reduction	O
of	O
gain	O
-	O
of	O
-	O
function	O
(	O
GOF	O
)	O
activities	O
,	O
reducing	O
the	O
cell	O
growth	O
rate	O
and	O
motility	O
rate	O
in	O
lung	O
cancer	O
cells	O
expressing	O
mutant	O
p53	O
.	O

This	O
indicates	O
that	O
for	O
lung	O
cancer	O
cell	O
lines	O
with	O
mutant	B-Var
p53	B-Gene
,	O
GOF	O
activities	B-MPA
are	O
mediated	B-Reg
in	O
part	O
through	O
Axl	B-Protein
.	O

Gain	O
-	O
of	O
-	O
function	O
mutations	O
in	O
PDR1	O
,	O
a	O
regulator	O
of	O
antifungal	O
drug	O
resistance	O
in	O
Candida	O
glabrata	O
,	O
control	O
adherence	O
to	O
host	O
cells	O
.	O

Candida	O
glabrata	O
is	O
an	O
emerging	O
opportunistic	O
pathogen	O
that	O
is	O
known	O
to	O
develop	O
resistance	O
to	O
azole	O
drugs	O
due	O
to	O
increased	O
drug	O
efflux	O
.	O

The	O
mechanism	O
consists	O
of	O
CgPDR1-mediated	O
upregulation	O
of	O
ATP	O
-	O
binding	O
cassette	O
transporters	O
.	O

A	O
range	O
of	O
gain	B-PosReg
-	I-PosReg
of	I-PosReg
-	I-PosReg
function	I-PosReg
(	O
GOF	O
)	O
mutations	B-Var
in	O
CgPDR1	B-Gene
have	O
been	O
found	O
to	O
lead	B-PosReg
not	O
only	O
to	O
azole	B-MPA
resistance	I-MPA
but	O
also	O
to	O
enhanced	B-PosReg
virulence	B-MPA
.	O

This	O
implicates	B-Reg
CgPDR1	B-Gene
in	O
the	O
regulation	B-MPA
of	O
the	O
interaction	B-Interaction
of	O
C.	O
glabrata	O
with	O
the	O
host	O
.	O

To	O
identify	O
specific	O
CgPDR1-regulated	O
steps	O
of	O
the	O
host	O
-	O
pathogen	O
interaction	O
,	O
we	O
investigated	O
in	O
this	O
work	O
the	O
interaction	O
of	O
selected	O
CgPDR1	O
GOF	O
mutants	O
with	O
murine	O
bone	O
marrow	O
-	O
derived	O
macrophages	O
and	O
human	O
acute	O
monocytic	O
leukemia	O
cell	O
line	O
(	O
THP-1)-derived	O
macrophages	O
,	O
as	O
well	O
as	O
different	O
epithelial	O
cell	O
lines	O
.	O

GOF	O
mutations	B-Var
in	O
CgPDR1	B-Gene
did	O
not	O
influence	O
survival	O
and	O
replication	O
within	O
macrophages	O
following	O
phagocytosis	O
but	O
led	O
to	O
decreased	B-NegReg
adherence	B-CPA
to	I-CPA
and	I-CPA
uptake	I-CPA
by	I-CPA
macrophages	I-CPA
.	O

This	O
may	O
allow	O
evasion	O
from	O
the	O
host	O
's	O
innate	O
cellular	O
immune	O
response	O
.	O

The	O
interaction	O
with	O
epithelial	O
cells	O
revealed	O
an	O
opposite	O
trend	O
,	O
suggesting	O
that	O
GOF	O
mutations	B-Var
in	O
CgPDR1	B-Gene
may	O
favor	B-PosReg
epithelial	B-CPA
colonization	I-CPA
of	O
the	O
host	O
by	O
C.	O
glabrata	O
through	O
increased	B-PosReg
adherence	B-CPA
to	O
epithelial	O
cell	O
layers	O
.	O

These	O
data	O
reveal	O
that	O
GOF	O
mutations	B-Var
in	O
CgPDR1	B-Gene
modulate	B-Reg
the	O
interaction	B-Interaction
with	O
host	O
cells	O
in	O
ways	O
that	O
may	O
contribute	O
to	O
increased	B-PosReg
virulence	B-MPA
.	O

Mutant	O
p53	O
prolongs	O
NF	O
-	O
κB	O
activation	O
and	O
promotes	O
chronic	O
inflammation	O
and	O
inflammation	O
-	O
associated	O
colorectal	O
cancer	O
.	O

The	O
tumor	O
suppressor	O
p53	O
is	O
frequently	O
mutated	O
in	O
human	O
cancer	O
.	O

Common	O
mutant	O
p53	O
(	O
mutp53	O
)	O
isoforms	O
can	O
actively	O
promote	O
cancer	O
through	O
gain	O
-	O
of	O
-	O
function	O
(	O
GOF	O
)	O
mechanisms	O
.	O

We	O
report	O
that	O
mutp53	O
prolongs	O
TNF	O
-	O
α	O
-	O
induced	O
NF	O
-	O
κB	O
activation	O
in	O
cultured	O
cells	O
and	O
intestinal	O
organoid	O
cultures	O
.	O

Remarkably	O
,	O
when	O
exposed	O
to	O
dextran	O
sulfate	O
sodium	O
,	O
mice	O
harboring	O
a	O
germline	O
p53	O
mutation	O
develop	O
severe	O
chronic	O
inflammation	O
and	O
persistent	O
tissue	O
damage	O
,	O
and	O
are	O
highly	O
prone	O
to	O
inflammation	O
-	O
associated	O
colon	O
cancer	O
.	O

This	O
mutp53	O
GOF	O
is	O
manifested	O
by	O
rapid	O
onset	O
of	O
flat	O
dysplastic	O
lesions	O
that	O
progress	B-PosReg
to	O
invasive	B-Disease
carcinoma	I-Disease
with	O
mutp53	B-Var
accumulation	B-PosReg
and	O
augmented	O
NF	B-Protein
-	I-Protein
κB	I-Protein
activation	B-PosReg
,	O
faithfully	O
recapitulating	O
features	O
frequently	O
observed	O
in	O
human	O
colitis	B-Disease
-	I-Disease
associated	I-Disease
colorectal	I-Disease
cancer	I-Disease
(	O
CAC	O
)	O
.	O

These	O
findings	O
might	O
explain	O
the	O
early	O
appearance	O
of	O
p53	O
mutations	O
in	O
human	O
CAC	O
.	O

Clinical	O
relevance	O
of	O
gain	B-PosReg
-	I-PosReg
of	I-PosReg
-	I-PosReg
function	I-PosReg
mutations	B-Var
of	O
p53	B-Gene
in	O
high	B-Disease
-	I-Disease
grade	I-Disease
serous	I-Disease
ovarian	I-Disease
carcinoma	I-Disease
.	O

PURPOSE	O
:	O
Inactivation	O
of	O
TP53	O
,	O
which	O
occurs	O
predominantly	O
by	O
missense	O
mutations	O
in	O
exons	O
4	O
-	O
9	O
,	O
is	O
a	O
major	O
genetic	O
alteration	O
in	O
a	O
subset	O
of	O
human	O
cancer	O
.	O

In	O
spite	O
of	O
growing	O
evidence	O
that	O
gain	B-PosReg
-	I-PosReg
of	I-PosReg
-	I-PosReg
function	I-PosReg
(	O
GOF	O
)	O
mutations	B-Var
of	O
p53	B-Gene
also	O
have	O
oncogenic	B-CPA
activity	I-CPA
,	O
little	O
is	O
known	O
about	O
the	O
clinical	O
relevance	O
of	O
these	O
mutations	O
.	O

METHODS	O
:	O
The	O
clinicopathological	O
features	O
of	O
high	O
-	O
grade	O
serous	O
ovarian	O
carcinoma	O
(	O
HGS	O
-	O
OvCa	O
)	O
patients	O
with	O
GOF	O
p53	O
mutations	O
were	O
evaluated	O
according	O
to	O
a	O
comprehensive	O
somatic	O
mutation	O
profile	O
comprised	O
of	O
whole	O
exome	O
sequencing	O
,	O
mRNA	O
expression	O
,	O
and	O
protein	O
expression	O
profiles	O
obtained	O
from	O
the	O
Cancer	O
Genome	O
Atlas	O
(	O
TCGA	O
)	O
.	O

RESULTS	O
:	O
Patients	O
with	O
a	O
mutant	O
p53	B-Protein
protein	I-Protein
(	O
mutp53	O
)	O
with	O
a	O
GOF	O
mutation	B-Var
showed	O
higher	B-PosReg
p53	B-MPA
mRNA	I-MPA
and	I-MPA
protein	I-MPA
expression	I-MPA
levels	I-MPA
than	O
patients	O
with	O
p53	O
mutation	O
with	O
no	O
evidence	O
of	O
GOF	O
(	O
NE	O
-	O
GOF	O
)	O
.	O

GOF	O
mutations	O
were	O
more	O
likely	O
to	O
occur	O
within	O
mutational	O
hotspots	O
,	O
and	O
at	O
CpG	O
sites	O
,	O
and	O
resulted	O
in	O
mutp53	O
with	O
higher	O
functional	O
severity	O
(	O
FS	O
)	O
scores	O
.	O

Clinically	O
,	O
patients	O
with	O
GOF	O
mutations	B-Var
showed	O
a	O
higher	B-PosReg
frequency	O
of	O
platinum	B-CPA
resistance	I-CPA
(	O
22/58	O
,	O
37.9	O
%	O
)	O
than	O
patients	O
with	O
NE	O
-	O
GOF	O
mutations	O
(	O
12/56	O
,	O
21.4	O
%	O
)	O
(	O
p=0.054	O
)	O
.	O

Furthermore	O
,	O
patients	O
with	O
GOF	O
mutations	B-Var
were	O
more	O
likely	O
to	O
develop	B-PosReg
distant	B-CPA
metastasis	I-CPA
(	O
36/55	O
,	O
65.5	O
%	O
)	O
than	O
local	O
recurrence	O
(	O
19/55	O
,	O
34.5	O
%	O
)	O
,	O
whereas	O
patients	O
with	O
NE	O
-	O
GOF	O
mutations	O
showed	O
a	O
higher	O
frequency	O
of	O
locoregional	O
recurrence	O
(	O
26/47	O
,	O
55.3	O
%	O
)	O
than	O
distant	O
metastasis	O
(	O
21/47	O
,	O
44.7	O
%	O
)	O
(	O
p=0.035	O
)	O
.	O

There	O
were	O
no	O
differences	O
in	O
overall	O
or	O
progression	O
-	O
free	O
survival	O
between	O
patients	O
with	O
GOF	O
or	O
NE	O
-	O
GOF	O
mutp53	O
.	O

CONCLUSION	O
:	O
This	O
study	O
demonstrates	O
that	O
patient	O
with	O
GOF	B-PosReg
mutp53	B-Var
is	O
characterized	O
by	O
a	O
greater	B-PosReg
likelihood	O
of	O
platinum	B-CPA
treatment	I-CPA
resistance	I-CPA
and	O
distant	B-CPA
metastatic	I-CPA
properties	I-CPA
in	O
HGS	B-Disease
-	I-Disease
OvCa	I-Disease
.	O

Spliced	O
MDM2	O
isoforms	O
promote	O
mutant	O
p53	O
accumulation	O
and	O
gain	O
-	O
of	O
-	O
function	O
in	O
tumorigenesis	O
.	O

The	O
tumour	O
suppressor	O
p53	O
is	O
frequently	O
mutated	O
in	O
tumours	O
.	O

Mutant	B-Var
p53	B-Protein
(	O
Mutp53	O
)	O
proteins	O
often	O
gain	B-PosReg
new	I-PosReg
activities	I-PosReg
in	O
promoting	B-CPA
tumorigenesis	I-CPA
,	O
defined	O
as	O
gain	O
-	O
of	O
-	O
function	O
(	O
GOF	O
)	O
.	O

Mutp53	O
can	O
accumulate	O
to	O
high	O
levels	O
in	O
tumours	O
,	O
which	O
promotes	O
mutp53	B-Var
GOF	B-PosReg
in	O
tumorigenesis	B-CPA
.	O

The	O
mechanism	O
of	O
mutp53	O
accumulation	O
is	O
poorly	O
understood	O
.	O

Here	O
we	O
find	O
that	O
MDM2	O
isoforms	O
promote	O
mutp53	O
accumulation	O
in	O
tumours	O
.	O

MDM2	O
isoform	O
B	O
(	O
MDM2-B	O
)	O
,	O
the	O
MDM2	O
isoform	O
most	O
frequently	O
over	O
-	O
expressed	O
in	O
human	O
tumours	O
,	O
interacts	O
with	O
full	O
-	O
length	O
MDM2	O
to	O
inhibit	O
MDM2-mediated	O
mutp53	O
degradation	O
,	O
promoting	O
mutp53	O
accumulation	O
and	O
GOF	O
in	O
tumorigenesis	O
.	O

Furthermore	O
,	O
MDM2-B	O
overexpression	O
correlates	O
with	O
mutp53	O
accumulation	O
in	O
human	O
tumours	O
.	O

In	O
mutp53	O
knock	O
-	O
in	O
mice	O
,	O
a	O
MDM2	O
isoform	O
similar	O
to	O
human	O
MDM2-B	O
is	O
overexpressed	O
in	O
the	O
majority	O
of	O
tumours	O
,	O
which	O
promotes	O
mutp53	O
accumulation	O
and	O
tumorigenesis	O
.	O

Thus	O
,	O
overexpression	O
of	O
MDM2	O
isoforms	O
promotes	O
mutp53	O
accumulation	O
in	O
tumours	O
,	O
contributing	O
to	O
mutp53	B-Var
GOF	B-PosReg
in	O
tumorigenesis	B-CPA
.	O

This	O
may	O
be	O
an	O
important	O
mechanism	O
by	O
which	O
MDM2	O
isoforms	O
promote	O
tumorigenesis	O
.	O

Mutant	B-Var
p53	B-Gene
gain	B-PosReg
of	I-PosReg
function	I-PosReg
can	O
be	O
at	O
the	O
root	O
of	O
dedifferentiation	O
of	O
human	B-Disease
osteosarcoma	I-Disease
MG63	O
cells	O
into	O
3AB	O
-	O
OS	O
cancer	O
stem	O
cells	O
.	O

Osteosarcoma	O
is	O
a	O
highly	O
metastatic	O
tumor	O
affecting	O
adolescents	O
,	O
for	O
which	O
there	O
is	O
no	O
second	O
-	O
line	O
chemotherapy	O
.	O

As	O
suggested	O
for	O
most	O
tumors	O
,	O
its	O
capability	O
to	O
overgrow	O
is	O
probably	O
driven	O
by	O
cancer	O
stem	O
cells	O
(	O
CSCs	O
)	O
,	O
and	O
finding	O
new	O
targets	O
to	O
kill	O
CSCs	O
may	O
be	O
critical	O
for	O
improving	O
patient	O
survival	O
.	O

TP53	O
is	O
the	O
most	O
frequently	O
mutated	O
tumor	O
suppressor	O
gene	O
in	O
cancers	O
and	O
mutant	O
p53	O
protein	O
(	O
mutp53	O
)	O
can	O
acquire	O
gain	O
of	O
function	O
(	O
GOF	O
)	O
strongly	O
contributing	O
to	O
malignancy	O
.	O

Studies	O
thus	O
far	O
have	O
not	O
shown	O
p53-GOF	O
in	O
osteosarcoma	O
.	O

Here	O
,	O
we	O
investigated	O
TP53	O
gene	O
status	O
/	O
role	O
in	O
3AB	O
-	O
OS	O
cells	O
-	O
a	O
highly	O
aggressive	O
CSC	O
line	O
previously	O
selected	O
from	O
human	O
osteosarcoma	O
MG63	O
cells	O
-	O
to	O
evaluate	O
its	O
involvement	O
in	O
promoting	O
proliferation	O
,	O
invasiveness	O
,	O
resistance	O
to	O
apoptosis	O
and	O
stemness	O
.	O

By	O
RT	O
-	O
PCR	O
,	O
methylation	O
-	O
specific	O
PCR	O
,	O
fluorescent	O
in	O
situ	O
hybridization	O
,	O
DNA	O
sequence	O
,	O
western	O
blot	O
and	O
immunofluorescence	O
analyses	O
,	O
we	O
have	O
shown	O
that	O
-	O
in	O
comparison	O
with	O
parental	O
MG63	O
cells	O
where	O
TP53	O
gene	O
is	O
hypermethylated	O
,	O
rearranged	O
and	O
in	O
single	O
copy	O
-	O
in	O
3AB	O
-	O
OS	O
cells	O
,	O
TP53	O
is	O
unmethylated	O
,	O
rearranged	O
and	O
in	O
multiple	O
copies	O
,	O
and	O
mutp53	O
(	O
p53-R248W	O
/	O
P72R	O
)	O
is	O
post	O
-	O
translationally	O
modified	O
and	O
with	O
nuclear	O
localization	O
.	O

p53-R248W	O
/	O
P72R	O
-	O
knockdown	O
by	O
short	O
-	O
interfering	O
RNA	O
reduced	O
the	O
growth	O
and	O
replication	O
rate	O
of	O
3AB	O
-	O
OS	O
cells	O
,	O
markedly	O
increasing	O
cell	O
cycle	O
inhibitor	O
levels	O
and	O
sensitized	O
3AB	O
-	O
OS	O
cells	O
to	O
TRAIL	O
-	O
induced	O
apoptosis	O
by	O
DR5	O
up	O
-	O
regulation	O
;	O
moreover	O
,	O
it	O
strongly	O
decreased	O
the	O
levels	O
of	O
stemness	O
and	O
invasiveness	O
genes	O
.	O

We	O
have	O
also	O
found	O
that	O
the	O
ectopic	O
expression	O
of	O
p53-R248W	B-Var
/	I-Var
P72R	I-Var
in	O
MG63	O
cells	O
promoted	B-PosReg
cancer	B-CPA
stem	I-CPA
-	I-CPA
like	I-CPA
features	I-CPA
,	O
as	O
high	B-CPA
proliferation	I-CPA
rate	I-CPA
,	O
sphere	B-CPA
formation	I-CPA
,	O
clonogenic	B-CPA
growth	I-CPA
,	O
high	B-CPA
migration	I-CPA
and	O
invasive	B-CPA
ability	I-CPA
;	I-CPA
furthermore	O
,	O
it	O
strongly	O
increased	B-PosReg
the	O
levels	B-MPA
of	I-MPA
stemness	I-MPA
proteins	I-MPA
.	O

Overall	O
,	O
the	O
findings	O
suggest	O
the	O
involvement	B-Reg
of	O
p53-R248W	B-Var
/	I-Var
P72R	I-Var
at	O
the	O
origin	B-CPA
of	I-CPA
the	I-CPA
aberrant	I-CPA
characters	I-CPA
of	I-CPA
the	I-CPA
3AB	I-CPA
-	I-CPA
OS	I-CPA
cells	I-CPA
with	O
the	O
hypothesis	O
that	O
its	O
GOF	O
can	O
be	O
at	O
the	O
root	O
of	O
the	O
dedifferentiation	O
of	O
MG63	O
cells	O
into	O
CSCs	O
.	O

Unequal	O
prognostic	O
potentials	O
of	O
p53	O
gain	O
-	O
of	O
-	O
function	O
mutations	O
in	O
human	O
cancers	O
associate	O
with	O
drug	O
-	O
metabolizing	O
activity	O
.	O

Mutation	O
of	O
p53	O
is	O
the	O
most	O
common	O
genetic	O
change	O
in	O
human	O
cancer	O
,	O
causing	O
complex	O
effects	O
including	O
not	O
only	O
loss	O
of	O
wild	O
-	O
type	O
function	O
but	O
also	O
gain	O
of	O
novel	O
oncogenic	O
functions	O
(	O
GOF	O
)	O
.	O

It	O
is	O
increasingly	O
likely	O
that	O
p53-hotspot	O
mutations	O
may	O
confer	O
different	O
types	O
and	O
magnitudes	O
of	O
GOF	O
,	O
but	O
the	O
evidences	O
are	O
mainly	O
supported	O
by	O
cellular	O
and	O
transgenic	O
animal	O
models	O
.	O

Here	O
we	O
combine	O
large	O
-	O
scale	O
cancer	O
genomic	O
data	O
to	O
characterize	O
the	O
prognostic	O
significance	O
of	O
different	O
p53	O
mutations	O
in	O
human	O
cancers	O
.	O

Unexpectedly	O
,	O
only	O
mutations	O
on	O
the	O
Arg248	O
and	O
Arg282	O
positions	O
displayed	O
significant	O
association	O
with	O
shorter	O
patient	O
survival	O
,	O
but	O
such	O
association	O
was	O
not	O
evident	O
for	O
other	O
hotspot	O
GOF	O
mutations	O
.	O

Gene	O
set	O
enrichment	O
analysis	O
on	O
these	O
mutations	B-Var
revealed	O
higher	B-PosReg
activity	B-MPA
of	O
drug	B-Enzyme
-	I-Enzyme
metabolizing	I-Enzyme
enzymes	I-Enzyme
,	O
including	O
the	O
CYP3A4	B-Enzyme
cytochrome	I-Enzyme
P450	I-Enzyme
.	O

Ectopic	B-MPA
expression	I-MPA
of	O
p53	B-Gene
mutant	B-Var
R282W	I-Var
in	O
H1299	O
and	O
SaOS2	O
cells	O
significantly	O
upregulated	B-PosReg
CYP3A4	B-MPA
mRNA	I-MPA
and	I-MPA
protein	I-MPA
levels	I-MPA
,	O
and	O
cancer	O
cell	O
lines	O
bearing	O
mortality	O
-	O
associated	O
p53	B-Gene
mutations	B-Var
display	O
higher	B-PosReg
CYP3A4	B-Enzyme
expression	B-MPA
and	O
resistance	B-CPA
to	O
several	O
CYP3A4-metabolized	O
chemotherapeutic	O
drugs	O
.	O

Our	O
results	O
suggest	O
that	O
p53	O
mutations	O
have	O
unequal	O
GOF	O
activities	O
in	O
human	O
cancers	O
,	O
and	O
future	O
evaluation	O
of	O
p53	O
as	O
a	O
cancer	O
biomarker	O
should	O
consider	O
which	O
mutation	O
is	O
present	O
in	O
the	O
tumor	O
,	O
rather	O
than	O
having	O
comparison	O
between	O
wild	O
-	O
type	O
and	O
mutant	O
genotypes	O
.	O

Disruption	O
of	O
the	O
temporally	O
regulated	O
cloaca	O
endodermal	O
β	O
-	O
catenin	O
signaling	O
causes	O
anorectal	O
malformations	O
.	O

The	O
cloaca	O
is	O
temporally	O
formed	O
and	O
eventually	O
divided	O
by	O
the	O
urorectal	O
septum	O
(	O
URS	O
)	O
during	O
urogenital	O
and	O
anorectal	O
organ	O
development	O
.	O

Although	O
congenital	O
malformations	O
,	O
such	O
as	O
anorectal	B-Disease
malformations	I-Disease
(	O
ARMs	O
)	O
,	O
are	O
frequently	O
observed	O
during	O
this	O
process	O
,	O
the	O
underlying	O
pathogenic	O
mechanisms	O
remain	O
unclear	O
.	O

β	O
-	O
Catenin	O
is	O
a	O
critical	O
component	O
of	O
canonical	O
Wnt	O
signaling	O
and	O
is	O
essential	O
for	O
the	O
regulation	O
of	O
cell	O
differentiation	O
and	O
morphogenesis	O
during	O
embryogenesis	O
.	O

The	O
expression	O
of	O
β	O
-	O
catenin	O
is	O
observed	O
in	O
endodermal	O
epithelia	O
,	O
including	O
URS	O
epithelia	O
.	O

We	O
modulated	O
the	O
β	O
-	O
catenin	O
gene	O
conditionally	O
in	O
endodermal	O
epithelia	O
by	O
utilizing	O
tamoxifen	O
-	O
inducible	O
Cre	O
driver	O
line	O
(	O
Shh(CreERT2	O
)	O
)	O
.	O

Both	O
β	B-Protein
-	I-Protein
catenin	I-Protein
loss-	B-NegReg
and	O
gain	B-PosReg
-	I-PosReg
of	I-PosReg
-	I-PosReg
function	I-PosReg
(	O
LOF	O
and	O
GOF	O
)	O
mutants	B-Var
displayed	O
abnormal	O
clefts	B-CPA
in	I-CPA
the	I-CPA
perineal	I-CPA
region	I-CPA
and	O
hypoplastic	B-CPA
elongation	I-CPA
of	I-CPA
the	I-CPA
URS	I-CPA
.	O

The	O
mutants	B-Var
also	O
displayed	O
reduced	B-NegReg
cell	B-CPA
proliferation	I-CPA
in	I-CPA
the	I-CPA
URS	I-CPA
mesenchyme	I-CPA
.	O

In	O
addition	O
,	O
the	O
β	B-Protein
-	I-Protein
catenin	I-Protein
GOF	O
mutants	B-Var
displayed	O
reduced	O
apoptosis	O
and	O
subsequently	O
increased	O
apoptosis	O
in	O
the	O
URS	O
epithelium	O
.	O

This	O
instability	O
possibly	O
resulted	O
in	O
reduced	B-NegReg
expression	B-MPA
levels	I-MPA
of	O
differentiation	O
markers	O
,	O
such	O
as	O
keratin	B-Protein
1	I-Protein
and	O
filaggrin	B-Protein
,	O
in	O
the	O
perineal	O
epithelia	O
.	O

The	O
expression	B-MPA
of	O
bone	B-Gene
morphogenetic	I-Gene
protein	I-Gene
(	I-Gene
Bmp	I-Gene
)	I-Gene
genes	I-Gene
,	O
such	O
as	O
Bmp4	B-Gene
and	O
Bmp7	B-Gene
,	O
was	O
also	O
ectopically	O
induced	B-PosReg
in	O
the	O
epithelia	O
of	O
the	O
URS	O
in	O
the	O
β	B-Protein
-	I-Protein
catenin	I-Protein
GOF	O
mutants	B-Var
.	O

The	O
expression	B-MPA
of	O
the	O
Msx2	B-Gene
gene	I-Gene
and	O
phosphorylated	O
-	O
Smad1/5/8	O
,	O
possible	O
readouts	B-MPA
of	I-MPA
Bmp	I-MPA
signaling	I-MPA
,	O
was	O
also	O
increased	B-PosReg
in	O
the	O
mutants	B-Var
.	O

Moreover	O
,	O
we	O
introduced	O
an	O
additional	O
mutation	O
for	O
a	O
Bmp	O
receptor	O
gene	O
:	O
BmprIA	O
.	O

The	O
Shh(CreERT2/+	O
)	O
;	O
β	O
-	O
catenin(flox(ex3)/+	O
)	O
;	O
BmprIA(flox/-	O
)	O
mutants	O
displayed	O
partial	O
restoration	O
of	O
URS	O
elongation	O
compared	O
with	O
the	O
β	O
-	O
catenin	O
GOF	O
mutants	O
.	O

These	O
results	O
indicate	O
that	O
some	O
ARM	B-Disease
phenotypes	O
in	O
the	O
β	B-Protein
-	I-Protein
catenin	I-Protein
GOF	B-PosReg
mutants	B-Var
were	O
caused	B-Reg
by	I-Reg
abnormal	O
Bmp	B-MPA
signaling	I-MPA
.	O

The	O
current	O
analysis	O
revealed	O
the	O
close	O
relation	O
of	O
endodermal	O
β	O
-	O
catenin	O
signaling	O
to	O
the	O
ARM	O
phenotypes	O
.	O

These	O
results	O
are	O
considered	O
to	O
shed	O
light	O
on	O
the	O
pathogenic	O
mechanisms	O
of	O
human	O
ARMs	O
.	O

Dysregulation	O
of	O
Wnt	O
inhibitory	O
factor	O
1	O
(	O
Wif1	O
)	O
expression	O
resulted	O
in	O
aberrant	O
Wnt	O
-	O
β	O
-	O
catenin	O
signaling	O
and	O
cell	O
death	O
of	O
the	O
cloaca	O
endoderm	O
,	O
and	O
anorectal	O
malformations	O
.	O

In	O
mammalian	O
urorectal	O
development	O
,	O
the	O
urorectal	O
septum	O
(	O
urs	O
)	O
descends	O
from	O
the	O
ventral	O
body	O
wall	O
to	O
the	O
cloaca	O
membrane	O
(	O
cm	O
)	O
to	O
partition	O
the	O
cloaca	O
into	O
urogenital	O
sinus	O
and	O
rectum	O
.	O

Defective	O
urs	O
growth	O
results	O
in	O
human	O
congenital	O
anorectal	O
malformations	O
(	O
ARMs	O
)	O
,	O
and	O
their	O
pathogenic	O
mechanisms	O
are	O
unclear	O
.	O

Recent	O
studies	O
only	O
focused	O
on	O
the	O
importance	O
of	O
urs	O
mesenchyme	O
proliferation	O
,	O
which	O
is	O
induced	O
by	O
endoderm	O
-	O
derived	O
Sonic	O
Hedgehog	O
(	O
Shh	O
)	O
.	O

Here	O
,	O
we	O
showed	O
that	O
the	O
programmed	O
cell	O
death	O
of	O
the	O
apical	O
urs	O
and	O
proximal	O
cm	O
endoderm	O
is	O
particularly	O
crucial	O
for	O
the	O
growth	O
of	O
urs	O
during	O
septation	O
.	O

The	O
apoptotic	O
endoderm	O
was	O
closely	O
associated	O
with	O
the	O
tempo	O
-	O
spatial	O
expression	O
of	O
Wnt	O
inhibitory	O
factor	O
1	O
(	O
Wif1	O
)	O
,	O
which	O
is	O
an	O
inhibitor	O
of	O
Wnt	O
-	O
β	O
-	O
catenin	O
signaling	O
.	O

In	O
Wif1(lacZ	O
/	O
lacZ	O
)	O
mutant	O
mice	O
and	O
cultured	O
urorectum	O
with	O
exogenous	O
Wif1	O
,	O
cloaca	O
septation	O
was	O
defective	O
with	O
undescended	O
urs	O
and	O
hypospadias	O
-	O
like	O
phenotypes	O
,	O
and	O
such	O
septation	O
defects	O
were	O
also	O
observed	O
in	O
Shh(-/-	O
)	O
mutants	O
and	O
in	O
endodermal	O
β	O
-	O
catenin	O
gain	O
-	O
of	O
-	O
function	O
(	O
GOF	O
)	O
mutants	O
.	O

In	O
addition	O
,	O
Wif1	O
and	O
Shh	O
were	O
expressed	O
in	O
a	O
complementary	O
manner	O
in	O
the	O
cloaca	O
endoderm	O
,	O
and	O
Wif1	O
was	O
ectopically	O
expressed	O
in	O
the	O
urs	O
and	O
cm	O
associated	O
with	O
excessive	O
endodermal	O
apoptosis	O
and	O
septation	O
defects	O
in	O
Shh(-/-	O
)	O
mutants	O
.	O

Furthermore	O
,	O
apoptotic	B-CPA
cells	I-CPA
were	O
markedly	O
reduced	B-NegReg
in	O
the	O
endodermal	B-Protein
β	I-Protein
-	I-Protein
catenin	I-Protein
GOF	B-PosReg
mutant	B-Var
embryos	O
,	O
which	O
counteracted	O
the	O
inhibitory	O
effects	O
of	O
Wif1	O
.	O

Taken	O
altogether	O
,	O
these	O
data	O
suggest	O
that	O
regulated	O
expression	O
of	O
Wif1	O
is	O
critical	O
for	O
the	O
growth	O
of	O
the	O
urs	O
during	O
cloaca	O
septation	O
.	O

Hence	O
,	O
Wif1	O
governs	O
cell	O
apoptosis	O
of	O
urs	O
endoderm	O
by	O
repressing	O
β	O
-	O
catenin	O
signal	O
,	O
which	O
may	O
facilitate	O
the	O
protrusion	O
of	O
the	O
underlying	O
proliferating	O
mesenchymal	O
cells	O
towards	O
the	O
cm	O
for	O
cloaca	O
septation	O
.	O

Dysregulation	O
of	O
this	O
endodermal	O
Shh	O
-	O
Wif1-β	O
-	O
catenin	O
signaling	O
axis	O
contributes	O
to	O
ARM	O
pathogenesis	O
.	O

Significance	O
of	O
the	O
melanocortin	O
1	O
receptor	O
in	O
the	O
DNA	O
damage	O
response	O
of	O
human	O
melanocytes	O
to	O
ultraviolet	O
radiation	O
.	O

Activation	O
of	O
the	O
melanocortin	O
1	O
receptor	O
(	O
MC1R	O
)	O
by	O
α	O
-	O
melanocortin	O
(	O
α	O
-	O
MSH	O
)	O
stimulates	O
eumelanin	O
synthesis	O
and	O
enhances	O
repair	O
of	O
ultraviolet	O
radiation	O
(	O
UV)-induced	O
DNA	O
damage	O
.	O

We	O
report	O
on	O
the	O
DNA	O
damage	O
response	O
(	O
DDR	O
)	O
of	O
human	O
melanocytes	O
to	O
UV	O
and	O
its	O
enhancement	O
by	O
α	O
-	O
MSH	O
.	O

α	O
-	O
MSH	O
up	O
-	O
regulated	O
the	O
levels	O
of	O
XPC	O
,	O
the	O
enzyme	O
that	O
recognizes	O
DNA	O
damage	O
sites	O
,	O
enhanced	O
the	O
UV	O
-	O
induced	O
phosphorylation	O
of	O
the	O
DNA	O
damage	O
sensors	O
ataxia	O
telangiectasia	O
and	O
Rad3-related	O
(	O
ATR	O
)	O
and	O
ataxia	O
telangiectasia	O
mutated	O
(	O
ATM	O
)	O
and	O
their	O
respect	O
-	O
ive	O
substrates	O
checkpoint	O
kinases	O
1	O
and	O
2	O
,	O
and	O
increased	O
phosphorylated	O
H2AX	O
(	O
γH2AX	O
)	O
formation	O
.	O

These	O
effects	O
required	O
functional	O
MC1R	O
and	O
were	O
absent	O
in	O
melanocytes	O
expressing	O
loss	O
of	O
function	O
(	O
LOF	O
)	O
MC1R.	O
The	O
levels	O
of	O
wild	O
-	O
type	O
p53-induced	O
phosphatase	O
1	O
(	O
Wip1	O
)	O
,	O
which	O
dephosphorylates	O
γH2AX	O
,	O
correlated	O
inversely	O
with	O
γH2AX	O
.	O

We	O
propose	O
that	O
α	O
-	O
MSH	O
increases	O
UV	O
-	O
induced	O
γH2AX	O
to	O
facilitate	O
formation	O
of	O
DNA	O
repair	O
complexes	O
and	O
repair	O
of	O
DNA	O
photoproducts	O
,	O
and	O
LOF	B-Var
of	O
MC1R	B-Protein
compromises	B-NegReg
the	O
DDR	B-MPA
and	O
genomic	B-CPA
stability	I-CPA
of	I-CPA
melanocytes	I-CPA
.	O

Assessing	O
the	O
functional	O
consequence	O
of	O
loss	O
of	O
function	O
variants	O
using	O
electronic	O
medical	O
record	O
and	O
large	O
-	O
scale	O
genomics	O
consortium	O
efforts	O
.	O

Estimates	O
from	O
large	O
scale	O
genome	O
sequencing	O
studies	O
indicate	O
that	O
each	O
human	O
carries	O
up	O
to	O
20	O
genetic	O
variants	O
that	O
are	O
predicted	O
to	O
results	O
in	O
loss	O
of	O
function	O
(	O
LOF	O
)	O
of	O
protein	O
-	O
coding	O
genes	O
.	O

While	O
some	O
are	O
known	O
disease	O
-	O
causing	O
variants	O
or	O
common	O
,	O
tolerated	O
,	O
LOFs	O
in	O
non	O
-	O
essential	O
genes	O
,	O
the	O
majority	O
remain	O
of	O
unknown	O
consequence	O
.	O

We	O
explore	O
the	O
possibility	O
of	O
using	O
imputed	O
GWAS	O
data	O
from	O
large	O
biorepositories	O
such	O
as	O
the	O
electronic	O
medical	O
record	O
and	O
genomics	O
(	O
eMERGE	O
)	O
consortium	O
to	O
determine	O
the	O
effects	O
of	O
rare	O
LOFs	O
.	O

Here	O
,	O
we	O
show	O
that	O
two	O
hypocholesterolemia	B-Disease
-	I-Disease
associated	I-Disease
LOF	B-NegReg
mutations	B-Var
in	O
the	O
PCSK9	B-Gene
gene	O
can	O
be	O
accurately	O
imputed	O
into	O
large	O
-	O
scale	O
GWAS	O
datasets	O
which	O
raises	O
the	O
possibility	O
of	O
assessing	O
LOFs	O
through	O
genomics	O
-	O
linked	O
medical	O
records	O
.	O

PDGF	O
,	O
pericytes	O
and	O
the	O
pathogenesis	O
of	O
idiopathic	O
basal	O
ganglia	O
calcification	O
(	O
IBGC	O
)	O
.	O

Platelet	O
-	O
derived	O
growth	O
factors	O
(	O
PDGFs	O
)	O
are	O
important	O
mitogens	O
for	O
various	O
types	O
of	O
mesenchymal	O
cells	O
,	O
and	O
as	O
such	O
,	O
they	O
exert	O
critical	O
functions	O
during	O
organogenesis	O
in	O
mammalian	O
embryonic	O
and	O
early	O
postnatal	O
development	O
.	O

Increased	O
or	O
ectopic	B-Var
PDGF	B-Protein
activity	B-MPA
may	O
also	O
cause	B-Reg
or	O
contribute	B-Reg
to	O
diseases	O
such	O
as	O
cancer	B-Disease
and	O
tissue	B-Disease
fibrosis	I-Disease
.	O

Until	O
recently	O
,	O
no	O
loss	O
-	O
of	O
-	O
function	O
(	O
LOF	O
)	O
mutations	O
in	O
PDGF	O
or	O
PDGF	O
receptor	O
genes	O
were	O
reported	O
as	O
causally	O
linked	O
to	O
a	O
human	O
disease	O
.	O

This	O
changed	O
in	O
2013	O
when	O
reports	O
appeared	O
on	O
presumed	O
LOF	B-NegReg
mutations	B-Var
in	O
the	O
genes	O
encoding	O
PDGF	B-Gene
-	I-Gene
B	I-Gene
and	O
its	O
receptor	O
PDGF	O
receptor	O
-	O
beta	O
(	B-Gene
PDGF	I-Gene
-	I-Gene
Rβ	I-Gene
)	I-Gene
in	O
familial	B-Disease
idiopathic	I-Disease
basal	I-Disease
ganglia	I-Disease
calcification	I-Disease
(	O
IBGC	O
)	O
,	O
a	O
brain	O
disease	O
characterized	O
by	O
anatomically	O
localized	O
calcifications	O
in	O
or	O
near	O
the	O
blood	O
microvessels	O
.	O

Here	O
,	O
we	O
review	O
PDGF	O
-	O
B	O
and	O
PDGF	O
-	O
Rβ	O
biology	O
with	O
special	O
reference	O
to	O
their	O
functions	O
in	O
brain	O
-	O
blood	O
vessel	O
development	O
,	O
pericyte	O
recruitment	O
and	O
the	O
regulation	O
of	O
the	O
blood	O
-	O
brain	O
barrier	O
.	O

We	O
also	O
discuss	O
various	O
scenarios	O
for	O
IBGC	O
pathogenesis	O
suggested	O
by	O
observations	O
in	O
patients	O
and	O
genetically	O
engineered	O
animal	O
models	O
of	O
the	O
disease	O
.	O

Mutant	B-Var
p53	B-Gene
gains	O
new	O
function	O
in	O
promoting	B-PosReg
inflammatory	B-MPA
signals	I-MPA
by	O
repression	B-NegReg
of	O
the	O
secreted	O
interleukin-1	O
receptor	O
antagonist	O
.	O

The	O
TP53	B-Gene
tumor	I-Gene
-	I-Gene
suppressor	I-Gene
gene	I-Gene
is	O
frequently	O
mutated	O
in	O
human	O
cancer	O
.	O

Missense	B-Var
mutations	I-Var
can	O
add	O
novel	O
functions	O
(	O
gain	O
-	O
of	O
-	O
function	O
,	O
GOF	O
)	O
that	O
promote	B-PosReg
tumor	B-CPA
malignancy	I-CPA
.	O

Here	O
we	O
report	O
that	O
mutant	B-Var
(	O
mut	O
)	O
p53	B-Gene
promotes	B-PosReg
tumor	B-CPA
malignancy	I-CPA
by	O
suppressing	B-NegReg
the	O
expression	B-MPA
of	O
a	O
natural	O
occurring	O
anti	O
-	O
inflammatory	O
cytokine	O
,	O
the	O
secreted	O
interleukin-1	O
receptor	O
antagonist	O
(	O
sIL-1Ra	O
,	O
IL1RN	O
)	O
.	O

We	O
show	O
that	O
mutp53	B-Var
but	O
not	O
wild	O
-	O
type	O
(	O
wt	O
)	O
p53	O
suppresses	B-NegReg
the	O
sIL-1Ra	B-MPA
production	I-MPA
in	O
conditioned	O
media	O
of	O
cancer	O
cells	O
.	O

Moreover	O
,	O
mutp53	O
,	O
but	O
not	O
wtp53	O
,	O
binds	O
physically	O
the	O
sIL-1Ra	O
promoter	O
and	O
the	O
protein	O
-	O
protein	O
interaction	O
with	O
the	O
transcriptional	O
co	O
-	O
repressor	O
MAFF	O
(	O
v	O
-	O
MAF	O
musculoaponeurotic	O
fibrosarcoma	O
oncogene	O
family	O
,	O
protein	O
F	O
)	O
is	O
required	O
for	O
mutp53-induced	O
sIL-1Ra	O
suppression	O
.	O

Remarkably	O
,	O
when	O
exposed	O
to	O
IL-1	O
beta	O
(	O
IL-1β	O
)	O
inflammatory	O
stimuli	O
,	O
mutp53	O
sustains	O
a	O
ready	O
-	O
to	O
-	O
be	O
-	O
activated	O
in	O
vitro	O
and	O
in	O
vivo	O
cancer	O
cells	O
'	O
response	O
through	O
the	O
sIL-1Ra	O
repression	O
.	O

Taken	O
together	O
,	O
these	O
results	O
identify	O
sIL-1Ra	O
as	O
a	O
novel	O
mutp53	O
target	O
gene	O
,	O
whose	O
suppression	O
might	O
be	O
required	O
to	O
generate	O
a	O
chronic	O
pro	O
-	O
inflammatory	O
tumor	O
microenvironment	O
through	O
which	O
mutp53	O
promotes	O
tumor	O
malignancy	O
.	O

Rare	O
variants	O
in	O
PPARG	O
with	O
decreased	O
activity	O
in	O
adipocyte	O
differentiation	O
are	O
associated	O
with	O
increased	O
risk	O
of	O
type	O
2	O
diabetes	O
.	O

Peroxisome	O
proliferator	O
-	O
activated	O
receptor	O
gamma	O
(	O
PPARG	O
)	O
is	O
a	O
master	O
transcriptional	O
regulator	O
of	O
adipocyte	O
differentiation	O
and	O
a	O
canonical	O
target	O
of	O
antidiabetic	O
thiazolidinedione	O
medications	O
.	O

In	O
rare	O
families	O
,	O
loss	B-NegReg
-	I-NegReg
of	I-NegReg
-	I-NegReg
function	I-NegReg
(	O
LOF	O
)	O
mutations	B-Var
in	O
PPARG	B-Gene
are	O
known	O
to	O
cosegregate	O
with	O
lipodystrophy	B-Disease
and	O
insulin	B-Disease
resistance	I-Disease
;	I-Disease
in	O
the	O
general	O
population	O
,	O
the	O
common	O
P12A	B-Var
variant	O
is	O
associated	O
with	O
a	O
decreased	B-NegReg
risk	O
of	O
type	B-Disease
2	I-Disease
diabetes	I-Disease
(	O
T2D	O
)	O
.	O

Whether	O
and	O
how	O
rare	O
variants	O
in	O
PPARG	O
and	O
defects	O
in	O
adipocyte	O
differentiation	O
influence	O
risk	O
of	O
T2D	O
in	O
the	O
general	O
population	O
remains	O
undetermined	O
.	O

By	O
sequencing	O
PPARG	O
in	O
19,752	O
T2D	O
cases	O
and	O
controls	O
drawn	O
from	O
multiple	O
studies	O
and	O
ethnic	O
groups	O
,	O
we	O
identified	O
49	O
previously	O
unidentified	O
,	O
nonsynonymous	O
PPARG	O
variants	O
(	O
MAF	O
<	O
0.5	O
%	O
)	O
.	O

Considered	O
in	O
aggregate	O
(	O
with	O
or	O
without	O
computational	O
prediction	O
of	O
functional	O
consequence	O
)	O
,	O
these	O
rare	O
variants	O
showed	O
no	O
association	O
with	O
T2D	O
(	O
OR	O
=	O
1.35	O
;	O
P	O
=	O
0.17	O
)	O
.	O

The	O
function	O
of	O
the	O
49	O
variants	O
was	O
experimentally	O
tested	O
in	O
a	O
novel	O
high	O
-	O
throughput	O
human	O
adipocyte	O
differentiation	O
assay	O
,	O
and	O
nine	O
were	O
found	O
to	O
have	O
reduced	O
activity	O
in	O
the	O
assay	O
.	O

Carrying	O
any	O
of	O
these	O
nine	O
LOF	O
variants	O
was	O
associated	O
with	O
a	O
substantial	O
increase	O
in	O
risk	O
of	O
T2D	O
(	O
OR	O
=	O
7.22	O
;	O
P	O
=	O
0.005	O
)	O
.	O

The	O
combination	O
of	O
large	O
-	O
scale	O
DNA	O
sequencing	O
and	O
functional	O
testing	O
in	O
the	O
laboratory	O
reveals	O
that	O
approximately	O
1	O
in	O
1,000	O
individuals	O
carries	O
a	O
variant	B-Var
in	O
PPARG	B-Gene
that	O
reduces	B-NegReg
function	B-CPA
in	I-CPA
a	I-CPA
human	I-CPA
adipocyte	I-CPA
differentiation	I-CPA
assay	I-CPA
and	O
is	O
associated	B-Reg
with	O
a	O
substantial	O
risk	O
of	O
T2D.	B-Disease
Loss	O
-	O
of	O
-	O
function	O
de	O
novo	O
mutations	O
play	O
an	O
important	O
role	O
in	O
severe	O
human	O
neural	O
tube	O
defects	O
.	O

BACKGROUND	O
:	O
Neural	B-Disease
tube	I-Disease
defects	I-Disease
(	O
NTDs	O
)	O
are	O
very	O
common	O
and	O
severe	O
birth	O
defects	O
that	O
are	O
caused	O
by	O
failure	O
of	O
neural	O
tube	O
closure	O
and	O
that	O
have	O
a	O
complex	O
aetiology	O
.	O

Anencephaly	O
and	O
spina	O
bifida	O
are	O
severe	O
NTDs	O
that	O
affect	O
reproductive	O
fitness	O
and	O
suggest	O
a	O
role	O
for	O
de	O
novo	O
mutations	O
(	O
DNMs	O
)	O
in	O
their	O
aetiology	O
.	O

METHODS	O
:	O
We	O
used	O
whole	O
-	O
exome	O
sequencing	O
in	O
43	O
sporadic	O
cases	O
affected	O
with	O
myelomeningocele	O
or	O
anencephaly	O
and	O
their	O
unaffected	O
parents	O
to	O
identify	O
DNMs	O
in	O
their	O
exomes	O
.	O

RESULTS	O
:	O
We	O
identified	O
42	O
coding	O
DNMs	O
in	O
25	O
cases	O
,	O
of	O
which	O
6	O
were	O
loss	O
of	O
function	O
(	O
LoF	O
)	O
showing	O
a	O
higher	O
rate	O
of	O
LoF	O
DNM	O
in	O
our	O
cohort	O
compared	O
with	O
control	O
cohorts	O
.	O

Notably	O
,	O
we	O
identified	O
two	O
protein	B-NegReg
-	I-NegReg
truncating	I-NegReg
DNMs	B-Var
in	O
two	O
independent	O
cases	O
in	O
SHROOM3	B-Gene
,	O
previously	O
associated	O
with	O
NTDs	O
only	O
in	O
animal	O
models	O
.	O

We	O
have	O
demonstrated	O
a	O
significant	O
enrichment	O
of	O
LoF	B-NegReg
DNMs	B-Var
in	O
this	O
gene	O
in	O
NTDs	B-Disease
compared	O
with	O
the	O
gene	O
specific	O
DNM	O
rate	O
and	O
to	O
the	O
DNM	O
rate	O
estimated	O
from	O
control	O
cohorts	O
.	O

We	O
also	O
identified	O
one	O
nonsense	O
DNM	O
in	O
PAX3	O
and	O
two	O
potentially	O
causative	O
missense	O
DNMs	O
in	O
GRHL3	O
and	O
PTPRS	O
.	O

CONCLUSIONS	O
:	O
Our	O
study	O
demonstrates	O
an	O
important	O
role	O
of	O
LoF	B-NegReg
DNMs	B-Var
in	O
the	O
development	O
of	O
NTDs	B-Disease
and	O
strongly	O
implicates	O
SHROOM3	B-Gene
in	O
its	O
aetiology	O
.	O

Analysis	O
of	O
loss	O
-	O
of	O
-	O
function	O
variants	O
and	O
20	O
risk	O
factor	O
phenotypes	O
in	O
8,554	O
individuals	O
identifies	O
loci	O
influencing	O
chronic	O
disease	O
.	O

A	O
typical	O
human	O
exome	O
harbors	O
dozens	O
of	O
loss	O
-	O
of	O
-	O
function	O
(	O
LOF	O
)	O
variants	O
,	O
which	O
can	O
lower	O
disease	O
risk	O
factor	O
levels	O
and	O
affect	O
drug	O
efficacy	O
.	O

We	O
hypothesized	O
that	O
LOF	O
variants	O
are	O
enriched	O
in	O
genes	O
influencing	O
risk	O
factor	O
levels	O
and	O
the	O
onset	O
of	O
common	O
chronic	O
diseases	O
,	O
such	O
as	O
cardiovascular	O
disease	O
and	O
diabetes	O
.	O

To	O
test	O
this	O
hypothesis	O
,	O
we	O
sequenced	O
the	O
exomes	O
of	O
8,554	O
individuals	O
and	O
analyzed	O
the	O
effects	O
of	O
predicted	O
LOF	O
variants	O
on	O
20	O
chronic	O
disease	O
risk	O
factor	O
phenotypes	O
.	O

Analysis	O
of	O
this	O
sample	O
as	O
discovery	O
and	O
replication	O
strata	O
of	O
equal	O
size	O
verified	O
two	O
relationships	O
in	O
well	O
-	O
studied	O
genes	O
(	O
PCSK9	O
and	O
APOC3	O
)	O
and	O
identified	O
eight	O
new	O
loci	O
.	O

Previously	O
unknown	O
relationships	O
included	O
elevated	B-PosReg
fasting	O
glucose	B-MPA
in	O
carriers	O
of	O
heterozygous	O
LOF	B-NegReg
variation	B-Var
in	O
TXNDC5	B-Gene
,	O
which	O
encodes	O
a	O
biomarker	O
for	O
type	O
1	O
diabetes	O
progression	O
,	O
and	O
apparent	O
recessive	B-NegReg
effects	I-NegReg
of	O
C1QTNF8	B-Gene
on	O
serum	B-MPA
magnesium	I-MPA
levels	I-MPA
.	O

These	O
data	O
demonstrate	O
the	O
utility	O
of	O
functional	O
-	O
variant	O
annotation	O
within	O
a	O
large	O
sample	O
of	O
deeply	O
phenotyped	O
individuals	O
for	O
gene	O
discovery	O
.	O

Mutant	O
p53	O
-	O
Heat	O
Shock	O
Response	O
Oncogenic	O
Cooperation	O
:	O
A	O
New	O
Mechanism	O
of	O
Cancer	O
Cell	O
Survival	O
.	O

The	O
main	O
tumor	O
suppressor	O
function	O
of	O
p53	O
as	O
a	O
"	O
guardian	O
of	O
the	O
genome	O
"	O
is	O
to	O
respond	O
to	O
cellular	O
stress	O
by	O
transcriptional	O
activation	O
of	O
apoptosis	O
,	O
growth	O
arrest	O
,	O
or	O
senescence	O
in	O
damaged	O
cells	O
.	O

Not	O
surprisingly	O
,	O
mutations	O
in	O
the	O
p53	O
gene	O
are	O
the	O
most	O
frequent	O
genetic	O
alteration	O
in	O
human	O
cancers	O
.	O

Importantly	O
,	O
mutant	B-Var
p53	B-Gene
(	O
mutp53	O
)	O
proteins	B-Protein
not	O
only	O
lose	B-NegReg
their	O
wild	O
-	O
type	O
tumor	B-CPA
suppressor	I-CPA
activity	I-CPA
but	O
also	O
can	O
actively	O
promote	B-PosReg
tumor	B-CPA
development	I-CPA
.	O

Two	O
main	O
mechanisms	O
accounting	O
for	O
mutp53	B-Var
proto	O
-	O
oncogenic	O
activity	O
are	O
inhibition	O
of	O
the	O
wild	O
-	O
type	O
p53	O
in	O
a	O
dominant	O
-	O
negative	O
fashion	O
and	O
gain	B-PosReg
of	O
additional	O
oncogenic	B-CPA
activities	I-CPA
known	O
as	O
gain	O
-	O
of	O
-	O
function	O
(	O
GOF	O
)	O
.	O

Here	O
,	O
we	O
discuss	O
a	O
novel	O
mechanism	O
of	O
mutp53	B-Var
GOF	O
,	O
which	O
relies	O
on	O
its	O
oncogenic	O
cooperation	O
with	O
the	O
heat	O
shock	O
machinery	O
.	O

This	O
coordinated	O
adaptive	O
mechanism	O
renders	O
cancer	O
cells	O
more	B-PosReg
resistant	B-CPA
to	O
proteotoxic	O
stress	O
and	O
provides	O
both	O
,	O
a	O
strong	O
survival	B-CPA
advantage	I-CPA
to	O
cancer	O
cells	O
and	O
a	O
promising	O
means	O
for	O
therapeutic	O
intervention	O
.	O

Identification	O
and	O
functional	O
characterization	O
of	O
natural	O
human	O
melanocortin	O
1	O
receptor	O
mutant	O
alleles	O
in	O
Pakistani	O
population	O
.	O

Melanocortin	O
1	O
receptor	O
(	O
MC1R	O
)	O
,	O
a	O
Gs	O
protein	O
-	O
coupled	O
receptor	O
of	O
the	O
melanocyte	O
's	O
plasma	O
membrane	O
,	O
is	O
a	O
major	O
determinant	O
of	O
skin	O
pigmentation	O
and	O
phototype	O
.	O

Upon	O
activation	O
by	O
α	O
-	O
melanocyte	O
stimulating	O
hormone	O
,	O
MC1R	O
triggers	O
the	O
cAMP	O
cascade	O
to	O
stimulate	O
eumelanogenesis	O
.	O

We	O
used	O
whole	O
-	O
exome	O
sequencing	O
to	O
identify	O
causative	O
alleles	O
in	O
Pakistani	O
families	O
with	O
skin	O
and	O
hair	O
hypopigmentation	O
.	O

Six	O
MC1R	O
mutations	O
segregated	O
with	O
the	O
phenotype	O
in	O
seven	O
families	O
,	O
including	O
a	O
p	O
.	O
Val174del	O
in	O
-	O
frame	O
deletion	O
and	O
a	O
p	O
.	O
Tyr298	O
*	O
nonsense	O
mutation	O
,	O
that	O
were	O
analyzed	O
for	O
function	O
in	O
heterologous	O
HEK293	O
cells	O
.	O

p	B-Var
.	I-Var
Tyr298	I-Var
*	I-Var
MC1R	B-Gene
showed	O
no	B-NegReg
agonist	B-MPA
-	I-MPA
induced	I-MPA
signaling	I-MPA
to	O
the	O
cAMP	B-Pathway
or	O
ERK	B-Pathway
pathways	I-Pathway
,	O
nor	B-NegReg
detectable	O
agonist	B-Interaction
binding	I-Interaction
.	O

Conversely	O
,	O
signaling	O
was	O
comparable	O
for	O
p	B-Var
.	I-Var
Val174del	I-Var
and	O
wild	O
-	O
type	O
in	O
HEK	O
cells	O
overexpressing	O
the	O
proteins	O
,	O
but	O
binding	O
analysis	O
suggested	O
impaired	B-NegReg
cell	B-MPA
surface	I-MPA
expression	I-MPA
.	O

Flow	O
cytometry	O
and	O
confocal	O
imaging	O
studies	O
revealed	O
reduced	B-NegReg
plasma	B-MPA
membrane	I-MPA
expression	I-MPA
of	O
p	B-Var
.	I-Var
Val174del	I-Var
and	O
p	B-Var
.	I-Var
Tyr298	I-Var
*	I-Var
.	O

Therefore	O
,	O
p	B-Var
.	I-Var
Tyr298	I-Var
*	I-Var
was	O
a	O
total	O
loss	B-NegReg
-	I-NegReg
of	I-NegReg
-	I-NegReg
function	I-NegReg
(	O
LOF	O
)	O
allele	O
,	O
while	O
p	B-Var
.	I-Var
Val174del	I-Var
displayed	O
a	O
partial	B-NegReg
LOF	I-NegReg
attribute	O
.	O

Gain	O
-	O
of	O
-	O
function	O
p53	O
mutants	O
co	O
-	O
opt	O
chromatin	O
pathways	O
to	O
drive	O
cancer	O
growth	O
.	O

TP53	O
(	O
which	O
encodes	O
p53	O
protein	O
)	O
is	O
the	O
most	O
frequently	O
mutated	O
gene	O
among	O
all	O
human	O
cancers	O
.	O

Prevalent	O
p53	B-Gene
missense	B-Var
mutations	I-Var
abrogate	B-NegReg
its	O
tumour	B-CPA
suppressive	I-CPA
function	I-CPA
and	O
lead	O
to	O
a	O
'	B-PosReg
gain	I-PosReg
-	I-PosReg
of	I-PosReg
-	I-PosReg
function	I-PosReg
'	I-PosReg
(	O
GOF	O
)	O
that	O
promotes	B-PosReg
cancer	B-Disease
.	O

Here	O
we	O
show	O
that	O
p53	B-Gene
GOF	B-PosReg
mutants	B-Var
bind	O
to	O
and	O
upregulate	B-PosReg
chromatin	B-Gene
regulatory	I-Gene
genes	I-Gene
,	O
including	O
the	O
methyltransferases	B-Enzyme
MLL1	I-Enzyme
(	O
also	O
known	O
as	O
KMT2A	O
)	O
,	O
MLL2	B-Enzyme
(	O
also	O
known	O
as	O
KMT2D	O
)	O
,	O
and	O
acetyltransferase	B-Enzyme
MOZ	I-Enzyme
(	O
also	O
known	O
as	O
KAT6A	O
or	O
MYST3	O
)	O
,	O
resulting	O
in	O
genome	O
-	O
wide	O
increases	B-PosReg
of	O
histone	B-MPA
methylation	I-MPA
and	O
acetylation	B-MPA
.	O

Analysis	O
of	O
The	O
Cancer	O
Genome	O
Atlas	O
shows	O
specific	O
upregulation	B-PosReg
of	O
MLL1	B-Enzyme
,	O
MLL2	B-Enzyme
,	O
and	O
MOZ	B-Enzyme
in	O
p53	B-Gene
GOF	B-Var
patient	O
-	O
derived	O
tumours	O
,	O
but	O
not	O
in	O
wild	O
-	O
type	O
p53	O
or	O
p53	O
null	O
tumours	O
.	O

Cancer	O
cell	O
proliferation	O
is	O
markedly	O
lowered	O
by	O
genetic	O
knockdown	O
of	O
MLL1	O
or	O
by	O
pharmacological	O
inhibition	O
of	O
the	O
MLL1	O
methyltransferase	O
complex	O
.	O

Our	O
study	O
reveals	O
a	O
novel	O
chromatin	O
mechanism	O
underlying	O
the	O
progression	O
of	O
tumours	O
with	O
GOF	O
p53	O
,	O
and	O
suggests	O
new	O
possibilities	O
for	O
designing	O
combinatorial	O
chromatin	O
-	O
based	O
therapies	O
for	O
treating	O
individual	O
cancers	O
driven	O
by	O
prevalent	O
GOF	O
p53	O
mutations	O
.	O

DNA	O
damage	O
-	O
induced	O
ephrin	O
-	O
B2	O
reverse	O
signaling	O
promotes	O
chemoresistance	O
and	O
drives	O
EMT	O
in	O
colorectal	O
carcinoma	O
harboring	O
mutant	O
p53	O
.	O

Mutation	O
in	O
the	O
TP53	O
gene	O
positively	O
correlates	O
with	O
increased	O
incidence	O
of	O
chemoresistance	O
in	O
different	O
cancers	O
.	O

In	O
this	O
study	O
,	O
we	O
investigated	O
the	O
mechanism	O
of	O
chemoresistance	O
and	O
epithelial	O
-	O
to	O
-	O
mesenchymal	O
transition	O
(	O
EMT	O
)	O
in	O
colorectal	O
cancer	O
involving	O
the	O
gain	O
-	O
of	O
-	O
function	O
(	O
GOF	O
)	O
mutant	O
p53	O
/	O
ephrin	O
-	O
B2	O
signaling	O
axis	O
.	O

Bioinformatic	O
analysis	O
of	O
the	O
NCI-60	O
data	O
set	O
and	O
subsequent	O
hub	O
prediction	O
identified	O
EFNB2	O
as	O
a	O
possible	O
GOF	O
mutant	O
p53	O
target	O
gene	O
,	O
responsible	O
for	O
chemoresistance	O
.	O

We	O
show	O
that	O
the	O
mutant	B-Var
p53-NF	B-Gene
-	I-Gene
Y	I-Gene
complex	O
transcriptionally	O
upregulates	B-PosReg
EFNB2	B-Gene
expression	B-MPA
in	O
response	B-MPA
to	I-MPA
DNA	I-MPA
damage	I-MPA
.	O

Moreover	O
,	O
the	O
acetylated	O
form	O
of	O
mutant	B-Var
p53	B-Gene
protein	B-Protein
is	O
recruited	B-PosReg
on	O
the	O
EFNB2	O
promoter	O
and	O
positively	O
regulates	B-Reg
its	O
expression	B-MPA
in	O
conjunction	O
with	O
coactivator	O
p300	O
.	O

In	O
vitro	O
cell	O
line	O
and	O
in	O
vivo	O
nude	O
mice	O
data	O
show	O
that	O
EFNB2	O
silencing	O
restores	O
chemosensitivity	O
in	O
mutant	O
p53-harboring	O
tumors	O
.	O

In	O
addition	O
,	O
we	O
observed	O
high	O
expression	O
of	O
EFNB2	O
in	O
patients	O
having	O
neoadjuvant	O
non	O
-	O
responder	O
colorectal	O
carcinoma	O
compared	O
with	O
those	O
having	O
responder	O
version	O
of	O
the	O
disease	O
.	O

In	O
the	O
course	O
of	O
deciphering	O
the	O
drug	O
resistance	O
mechanism	O
,	O
we	O
also	O
show	O
that	O
ephrin	O
-	O
B2	O
reverse	O
signaling	O
induces	B-PosReg
ABCG2	B-Gene
expression	B-MPA
after	O
drug	O
treatment	O
that	O
involves	O
JNK	B-MPA
-	I-MPA
c	I-MPA
-	I-MPA
Jun	I-MPA
signaling	I-MPA
in	O
mutant	B-Var
p53	B-Gene
cells	O
.	O

Moreover	O
,	O
5-fluorouracil	O
-	O
induced	O
ephrin	O
-	O
B2	O
reverse	O
signaling	O
promotes	O
tumorigenesis	O
through	O
the	O
Src	O
-	O
ERK	O
pathway	O
,	O
and	O
drives	O
EMT	O
via	O
the	O
Src	O
-	O
FAK	O
pathway	O
.	O

We	O
thus	O
conclude	O
that	O
targeting	O
ephrin	O
-	O
B2	O
might	O
enhance	O
the	O
therapeutic	O
potential	O
of	O
DNA	O
-	O
damaging	O
chemotherapeutic	O
agents	O
in	O
mutant	O
p53-bearing	O
human	O
tumors	O
.	O

Cell	O
Death	O
and	O
Differentiation	O
advance	O
online	O
publication	O
,	O
23	O
October	O
2015	O
;	O
doi:10.1038	O
/	O
cdd.2015.133	O
.	O

Urine	O
-	O
sample	O
-	O
derived	O
human	O
induced	O
pluripotent	O
stem	O
cells	O
as	O
a	O
model	O
to	O
study	O
PCSK9-mediated	O
autosomal	O
dominant	O
hypercholesterolemia	O
.	O

Proprotein	O
convertase	O
subtilisin	O
kexin	O
type	O
9	O
(	O
PCSK9	O
)	O
is	O
a	O
critical	O
modulator	O
of	O
cholesterol	O
homeostasis	O
.	O

Whereas	O
PCSK9	B-Gene
gain	B-PosReg
-	I-PosReg
of	I-PosReg
-	I-PosReg
function	I-PosReg
(	O
GOF	O
)	O
mutations	B-Var
are	O
associated	O
with	O
autosomal	B-Disease
dominant	I-Disease
hypercholesterolemia	I-Disease
(	O
ADH	O
)	O
and	O
premature	B-Disease
atherosclerosis	I-Disease
,	O
PCSK9	B-Gene
loss	B-NegReg
-	I-NegReg
of	I-NegReg
-	I-NegReg
function	I-NegReg
(	O
LOF	O
)	O
mutations	B-Var
have	B-PosReg
a	O
cardio	B-CPA
-	I-CPA
protective	I-CPA
effect	I-CPA
and	O
in	O
some	O
cases	O
can	O
lead	O
to	O
familial	B-Disease
hypobetalipoproteinemia	I-Disease
(	O
FHBL	O
)	O
.	O

However	O
,	O
limitations	O
of	O
the	O
currently	O
available	O
cellular	O
models	O
preclude	O
deciphering	O
the	O
consequences	O
of	O
PCSK9	O
mutation	O
further	O
.	O

We	O
aimed	O
to	O
validate	O
urine	O
-	O
sample	O
-	O
derived	O
human	O
induced	O
pluripotent	O
stem	O
cells	O
(	O
UhiPSCs	O
)	O
as	O
an	O
appropriate	O
tool	O
to	O
model	O
PCSK9-mediated	O
ADH	O
and	O
FHBL	O
.	O

To	O
achieve	O
our	O
goal	O
,	O
urine	O
-	O
sample	O
-	O
derived	O
somatic	O
cells	O
were	O
reprogrammed	O
into	O
hiPSCs	O
by	O
using	O
episomal	O
vectors	O
.	O

UhiPSC	O
were	O
efficiently	O
differentiated	O
into	O
hepatocyte	O
-	O
like	O
cells	O
(	O
HLCs	O
)	O
.	O

Compared	O
to	O
control	O
cells	O
,	O
cells	O
originally	O
derived	O
from	O
an	O
individual	O
with	O
ADH	O
(	O
HLC	O
-	O
S127R	O
)	O
secreted	O
less	O
PCSK9	O
in	O
the	O
media	O
(	O
-38.5	O
%	O
;	O
P=0.038	O
)	O
and	O
had	O
a	O
71	O
%	O
decrease	O
(	O
P<0.001	O
)	O
of	O
low	O
-	O
density	O
lipoprotein	O
(	O
LDL	O
)	O
uptake	O
,	O
whereas	O
cells	O
originally	O
derived	O
from	O
an	O
individual	O
with	O
FHBL	O
(	O
HLC	O
-	O
R104C	O
/	O
V114A	O
)	O
displayed	O
a	O
strong	O
decrease	O
in	O
PCSK9	O
secretion	O
(	O
-89.7	O
%	O
;	O
P<0.001	O
)	O
and	O
had	O
a	O
106	O
%	O
increase	O
(	O
P=0.0104	O
)	O
of	O
LDL	O
uptake	O
.	O

Pravastatin	O
treatment	O
significantly	O
enhanced	O
LDL	O
receptor	O
(	O
LDLR	O
)	O
and	O
PCSK9	O
mRNA	O
gene	O
expression	O
,	O
as	O
well	O
as	O
PCSK9	O
secretion	O
and	O
LDL	O
uptake	O
in	O
both	O
control	O
and	O
S127R	O
HLCs	O
.	O

Pravastatin	O
treatment	O
of	O
multiple	O
clones	O
led	O
to	O
an	O
average	O
increase	O
of	O
LDL	O
uptake	O
of	O
2.19±0.77-fold	O
in	O
HLC	O
-	O
S127R	O
compared	O
to	O
1.38±0.49	O
fold	O
in	O
control	O
HLCs	O
(	O
P<0.01	O
)	O
,	O
in	O
line	O
with	O
the	O
good	O
response	O
to	O
statin	O
treatment	O
of	O
individuals	O
carrying	O
the	O
S127R	O
mutation	O
(	O
mean	O
LDL	O
cholesterol	O
reduction=60.4	O
%	O
,	O
n=5	O
)	O
.	O

In	O
conclusion	O
,	O
urine	O
samples	O
provide	O
an	O
attractive	O
and	O
convenient	O
source	O
of	O
somatic	O
cells	O
for	O
reprogramming	O
and	O
hepatocyte	O
differentiation	O
,	O
but	O
also	O
a	O
powerful	O
tool	O
to	O
further	O
decipher	O
PCSK9	O
mutations	O
and	O
function	O
.	O

Recurrent	O
MLK4	B-Gene
Loss	B-NegReg
-	I-NegReg
of	I-NegReg
-	I-NegReg
Function	I-NegReg
Mutations	B-Var
Suppress	B-NegReg
JNK	B-Pathway
Signaling	I-Pathway
to	O
Promote	B-PosReg
Colon	B-Disease
Tumorigenesis	I-Disease
.	O

MLK4	O
is	O
a	O
member	O
of	O
the	O
mixed	O
-	O
lineage	O
family	O
of	O
kinases	O
that	O
regulate	O
the	O
JNK	O
,	O
p38	O
,	O
and	O
ERK	O
kinase	O
signaling	O
pathways	O
.	O

MLK4	O
mutations	O
have	O
been	O
identified	O
in	O
various	O
human	O
cancers	O
,	O
including	O
frequently	O
in	O
colorectal	O
cancer	O
,	O
where	O
their	O
function	O
and	O
pathobiological	O
importance	O
have	O
been	O
uncertain	O
.	O

In	O
this	O
study	O
,	O
we	O
assessed	O
the	O
functional	O
consequences	O
of	O
MLK4	O
mutations	O
in	O
colon	O
tumorigenesis	O
.	O

Biochemical	O
data	O
indicated	O
that	O
a	O
majority	O
of	O
MLK4	B-Gene
mutations	B-Var
are	O
loss	B-NegReg
-	I-NegReg
of	I-NegReg
-	I-NegReg
function	I-NegReg
(	O
LOF	O
)	O
mutations	O
that	O
can	O
exert	O
dominant	O
-	O
negative	O
effects	O
.	O

In	O
seeking	O
to	O
understand	O
the	O
abrogated	O
activity	O
of	O
these	O
mutants	O
,	O
we	O
elucidated	O
a	O
new	O
MLK4	O
catalytic	O
domain	O
structure	O
.	O

To	O
determine	O
whether	O
MLK4	O
is	O
required	O
to	O
maintain	O
tumorigenic	O
phenotypes	O
,	O
we	O
reconstituted	O
its	O
signaling	O
axis	O
in	O
colon	O
cancer	O
cells	O
harboring	O
MLK4-inactivating	O
mutations	O
.	O

We	O
found	O
that	O
restoring	O
MLK4	O
activity	O
reduced	O
cell	O
viability	O
,	O
proliferation	O
,	O
and	O
colony	O
formation	O
in	O
vitro	O
and	O
delayed	O
tumor	O
growth	O
in	O
vivo	O
.	O

Mechanistic	O
investigations	O
established	O
that	O
restoring	O
the	O
function	O
of	O
MLK4	O
selectively	O
induced	O
the	O
JNK	O
pathway	O
and	O
its	O
downstream	O
targets	O
,	O
cJUN	O
,	O
ATF3	O
,	O
and	O
the	O
cyclin	O
-	O
dependent	O
kinase	O
inhibitors	O
CDKN1A	O
and	O
CDKN2B.	O
Our	O
work	O
indicates	O
that	O
MLK4	B-Gene
is	O
a	O
novel	O
tumor	O
-	O
suppressing	O
kinase	O
harboring	O
frequent	O
LOF	B-NegReg
mutations	B-Var
that	O
lead	O
to	O
diminished	B-NegReg
signaling	B-MPA
in	O
the	O
JNK	B-Pathway
pathway	I-Pathway
and	O
enhanced	B-PosReg
proliferation	B-CPA
in	O
colon	O
cancer	O
.	O

Cancer	O
Res	O
;	O
76(3	O
)	O
;	O
1	O
-	O
12	O
.	O

©	O
2015	O
AACR	O
.	O

Transcriptome	O
profiling	O
identifies	O
genes	O
and	O
pathways	O
deregulated	O
upon	O
floxuridine	O
treatment	O
in	O
colorectal	O
cancer	O
cells	O
harboring	O
GOF	O
mutant	O
p53	O
.	O

Mutation	O
in	O
TP53	O
is	O
a	O
common	O
genetic	O
alteration	O
in	O
human	O
cancers	O
.	O

Certain	O
tumor	O
associated	O
p53	B-Gene
missense	B-Var
mutants	I-Var
acquire	O
gain	B-PosReg
-	I-PosReg
of	I-PosReg
-	I-PosReg
function	I-PosReg
(	O
GOF	O
)	O
properties	O
and	O
confer	O
oncogenic	O
phenotypes	O
including	O
enhanced	B-PosReg
chemoresistance	B-CPA
.	O

The	O
colorectal	O
cancers	O
(	O
CRC	O
)	O
harboring	O
mutant	O
p53	O
are	O
generally	O
aggressive	O
in	O
nature	O
and	O
difficult	O
to	O
treat	O
.	O

To	O
identify	O
a	O
potential	O
gene	O
expression	O
signature	O
of	O
GOF	O
mutant	O
p53-driven	O
acquired	O
chemoresistance	O
in	O
CRC	O
,	O
we	O
performed	O
transcriptome	O
profiling	O
of	O
floxuridine	O
(	O
FUdR	O
)	O
treated	O
SW480	O
cells	O
expressing	O
mutant	O
p53(R273H	O
)	O
(	O
GEO	O
#	O
:	O
GSE77533	O
)	O
.	O

We	O
obtained	O
several	O
genes	O
differentially	O
regulated	O
between	O
FUdR	O
treated	O
and	O
untreated	O
cells	O
.	O

Further	O
,	O
functional	O
characterization	O
and	O
pathway	O
analysis	O
revealed	O
significant	O
enrichment	O
of	O
crucial	O
biological	O
processes	O
and	O
pathways	O
upon	O
FUdR	O
treatment	O
in	O
SW480	O
cells	O
.	O

Our	O
data	O
suggest	O
that	O
in	O
response	O
to	O
chemotherapeutics	O
treatment	O
,	O
cancer	O
cells	O
with	O
GOF	B-PosReg
mutant	B-Var
p53	B-Gene
can	O
modulate	B-Reg
key	B-Pathway
cellular	I-Pathway
pathways	I-Pathway
to	O
withstand	B-CPA
the	I-CPA
cytotoxic	I-CPA
effect	I-CPA
of	I-CPA
the	I-CPA
drugs	I-CPA
.	O

The	O
genes	O
and	O
pathways	O
identified	O
in	O
the	O
present	O
study	O
can	O
be	O
further	O
validated	O
and	O
targeted	O
for	O
better	O
chemotherapy	O
response	O
in	O
colorectal	O
cancer	O
patients	O
harboring	O
mutant	O
p53	O
.	O

TBR1	O
regulates	O
autism	O
risk	O
genes	O
in	O
the	O
developing	O
neocortex	O
.	O

Exome	O
sequencing	O
studies	O
have	O
identified	O
multiple	O
genes	O
harboring	O
de	O
novo	O
loss	B-NegReg
-	I-NegReg
of	I-NegReg
-	I-NegReg
function	I-NegReg
(	O
LoF	O
)	O
variants	B-Var
in	O
individuals	O
with	O
autism	B-Disease
spectrum	I-Disease
disorders	I-Disease
(	O
ASD	O
)	O
,	O
including	O
TBR1	B-Gene
,	O
a	O
master	O
regulator	O
of	O
cortical	O
development	O
.	O

We	O
performed	O
ChIP	O
-	O
seq	O
for	O
TBR1	O
during	O
mouse	O
cortical	O
neurogenesis	O
and	O
show	O
that	O
TBR1-bound	O
regions	O
are	O
enriched	O
adjacent	O
to	O
ASD	O
genes	O
.	O

ASD	O
genes	O
were	O
also	O
enriched	O
among	O
genes	O
that	O
are	O
differentially	O
expressed	O
in	O
Tbr1	O
knockouts	O
,	O
which	O
together	O
with	O
the	O
ChIP	O
-	O
seq	O
data	O
,	O
suggests	O
direct	O
transcriptional	O
regulation	O
.	O

Of	O
the	O
nine	O
ASD	O
genes	O
examined	O
,	O
seven	O
were	O
misexpressed	O
in	O
the	O
cortices	O
of	O
Tbr1	O
knockout	O
mice	O
,	O
including	O
six	O
with	O
increased	O
expression	O
in	O
the	O
deep	O
cortical	O
layers	O
.	O

ASD	O
genes	O
with	O
adjacent	O
cortical	O
TBR1	O
ChIP	O
-	O
seq	O
peaks	O
also	O
showed	O
unusually	O
low	O
levels	O
of	O
LoF	O
mutations	O
in	O
a	O
reference	O
human	O
population	O
and	O
among	O
Icelanders	O
.	O

We	O
then	O
leveraged	O
TBR1	O
binding	O
to	O
identify	O
an	O
appealing	O
subset	O
of	O
candidate	O
ASD	O
genes	O
.	O

Our	O
findings	O
highlight	O
a	O
TBR1-regulated	O
network	O
of	O
ASD	O
genes	O
in	O
the	O
developing	O
neocortex	O
that	O
are	O
relatively	O
intolerant	O
to	O
LoF	O
mutations	O
,	O
indicating	O
that	O
these	O
genes	O
may	O
play	O
critical	O
roles	O
in	O
normal	O
cortical	O
development	O
.	O

A	O
rare	O
DNA	O
contact	O
mutation	B-Var
in	O
cancer	O
confers	B-PosReg
p53	B-Gene
gain	B-PosReg
-	I-PosReg
of	I-PosReg
-	I-PosReg
function	I-PosReg
and	O
tumor	B-CPA
cell	I-CPA
survival	I-CPA
via	O
TNFAIP8	B-Gene
induction	O
.	O

The	O
p53	O
tumor	O
suppressor	O
gene	O
encodes	O
a	O
sequence	O
-	O
specific	O
transcription	O
factor	O
.	O

Mutations	B-Var
in	O
the	O
coding	O
sequence	O
of	O
p53	B-Gene
occur	O
frequently	O
in	O
human	O
cancer	O
and	O
often	O
result	B-Reg
in	I-Reg
single	O
amino	O
acid	O
substitutions	B-Var
(	O
missense	O
mutations	O
)	O
in	O
the	O
DNA	O
binding	B-Interaction
domain	O
(	O
DBD	O
)	O
,	O
blocking	B-NegReg
normal	O
tumor	B-CPA
suppressive	I-CPA
functions	I-CPA
.	O

In	O
addition	O
to	O
the	O
loss	O
of	O
canonical	O
functions	O
,	O
some	O
missense	B-Var
mutations	I-Var
in	O
p53	B-Gene
confer	O
gain	B-PosReg
-	I-PosReg
of	I-PosReg
-	I-PosReg
function	I-PosReg
(	O
GOF	O
)	O
activities	B-CPA
to	I-CPA
tumor	I-CPA
cells	I-CPA
.	O

While	O
many	O
missense	O
mutations	O
in	O
p53	O
cluster	O
at	O
six	O
"	O
hotspot	O
"	O
amino	O
acids	O
,	O
the	O
majority	O
of	O
mutations	O
in	O
human	O
cancer	O
occur	O
elsewhere	O
in	O
the	O
DBD	O
and	O
at	O
a	O
much	O
lower	O
frequency	O
.	O

We	O
report	O
here	O
that	O
mutations	B-Var
at	I-Var
K120	I-Var
,	O
a	O
non	O
-	O
hotspot	O
DNA	O
contact	O
residue	O
,	O
confer	B-PosReg
p53	B-Gene
with	O
the	O
previously	O
unrecognized	O
ability	B-MPA
to	O
bind	B-Interaction
and	O
activate	B-PosReg
the	O
transcription	B-MPA
of	O
the	O
pro	O
-	O
survival	O
TNFAIP8	B-Gene
gene	O
.	O

Mutant	O
K120	O
p53	O
binds	O
the	O
TNFAIP8	O
locus	O
at	O
a	O
cryptic	O
p53	O
response	O
element	O
that	O
is	O
not	O
occupied	O
by	O
wild	O
-	O
type	O
p53	O
.	O

Furthermore	O
,	O
induction	O
of	O
TNFAIP8	O
is	O
critical	O
for	O
the	O
evasion	O
of	O
apoptosis	O
by	O
tumor	O
cells	O
expressing	O
the	O
K120R	O
variant	O
of	O
p53	O
.	O

These	O
findings	O
identify	O
induction	O
of	O
pro	O
-	O
survival	O
targets	O
as	O
a	O
mechanism	O
of	O
gain	B-PosReg
-	I-PosReg
of	I-PosReg
-	I-PosReg
function	I-PosReg
activity	B-MPA
for	O
mutant	B-Var
p53	B-Gene
and	O
will	O
likely	O
broaden	O
our	O
understanding	O
of	O
this	O
phenomenon	O
beyond	O
the	O
limited	O
number	O
of	O
GOF	O
activities	O
currently	O
reported	O
for	O
hotspot	O
mutants	O
.	O

De	O
Novo	O
Mutations	B-Var
in	O
SON	B-Gene
Disrupt	O
RNA	O
Splicing	O
of	O
Genes	O
Essential	O
for	O
Brain	O
Development	O
and	O
Metabolism	O
,	O
Causing	B-Reg
an	O
Intellectual	B-Disease
-	I-Disease
Disability	I-Disease
Syndrome	I-Disease
.	O

The	O
overall	O
understanding	O
of	O
the	O
molecular	O
etiologies	O
of	O
intellectual	O
disability	O
(	O
ID	O
)	O
and	O
developmental	O
delay	O
(	O
DD	O
)	O
is	O
increasing	O
as	O
next	O
-	O
generation	O
sequencing	O
technologies	O
identify	O
genetic	O
variants	O
in	O
individuals	O
with	O
such	O
disorders	O
.	O

However	O
,	O
detailed	O
analyses	O
conclusively	O
confirming	O
these	O
variants	O
,	O
as	O
well	O
as	O
the	O
underlying	O
molecular	O
mechanisms	O
explaining	O
the	O
diseases	O
,	O
are	O
often	O
lacking	O
.	O

Here	O
,	O
we	O
report	O
on	O
an	O
ID	B-Disease
syndrome	I-Disease
caused	O
by	O
de	O
novo	O
heterozygous	O
loss	B-NegReg
-	I-NegReg
of	I-NegReg
-	I-NegReg
function	I-NegReg
(	O
LoF	O
)	O
mutations	B-Var
in	O
SON	B-Gene
.	O

The	O
syndrome	O
is	O
characterized	O
by	O
ID	O
and/or	O
DD	O
,	O
malformations	O
of	O
the	O
cerebral	O
cortex	O
,	O
epilepsy	O
,	O
vision	O
problems	O
,	O
musculoskeletal	O
abnormalities	O
,	O
and	O
congenital	O
malformations	O
.	O

Knockdown	O
of	O
son	O
in	O
zebrafish	O
resulted	O
in	O
severe	O
malformation	O
of	O
the	O
spine	O
,	O
brain	O
,	O
and	O
eyes	O
.	O

Importantly	O
,	O
analyses	O
of	O
RNA	O
from	O
affected	O
individuals	O
revealed	O
that	O
genes	O
critical	O
for	O
neuronal	B-CPA
migration	I-CPA
and	O
cortex	B-CPA
organization	I-CPA
(	O
TUBG1	O
,	O
FLNA	O
,	O
PNKP	O
,	O
WDR62	O
,	O
PSMD3	O
,	O
and	O
HDAC6	O
)	O
and	O
metabolism	B-CPA
(	O
PCK2	O
,	O
PFKL	O
,	O
IDH2	O
,	O
ACY1	O
,	O
and	O
ADA	O
)	O
are	O
significantly	O
downregulated	B-NegReg
because	O
of	O
the	O
accumulation	B-PosReg
of	O
mis	O
-	O
spliced	O
transcripts	O
resulting	O
from	O
erroneous	B-Var
SON	I-Var
-	I-Var
mediated	I-Var
RNA	I-Var
splicing	I-Var
.	O

Our	O
data	O
highlight	O
SON	O
as	O
a	O
master	O
regulator	O
governing	O
neurodevelopment	O
and	O
demonstrate	O
the	O
importance	O
of	O
SON	O
-	O
mediated	O
RNA	O
splicing	O
in	O
human	O
development	O
.	O

The	O
anti	B-MPA
-	I-MPA
adipogenic	I-MPA
effect	I-MPA
of	O
peripheral	O
blood	O
mononuclear	O
cells	O
is	O
absent	B-NegReg
with	O
PCSK9	B-Gene
loss	B-NegReg
-	I-NegReg
of	I-NegReg
-	I-NegReg
function	I-NegReg
variants	B-Var
.	O

OBJECTIVE	O
:	O
To	O
determine	O
the	O
effect	O
of	O
(	O
1	O
)	O
an	O
oral	O
fat	O
load	O
and	O
(	O
2	O
)	O
pro	O
-	O
protein	O
convertase	O
subtilisin	O
/	O
kexin	O
type	O
(	O
PCSK	O
)	O
9	O
loss	B-NegReg
-	I-NegReg
of	I-NegReg
-	I-NegReg
function	I-NegReg
(	O
LOF	O
)	O
variant	B-Var
status	O
on	O
the	O
ability	O
of	O
peripheral	O
blood	O
mononuclear	O
cells	O
(	O
PBMC	O
)	O
to	O
inhibit	B-NegReg
human	B-MPA
adipogenesis	I-MPA
.	O

METHODS	O
:	O
PBMC	O
from	O
subjects	O
with	O
one	O
or	O
more	O
PCSK9	O
LOF	O
variants	O
versus	O
non	O
-	O
variant	O
controls	O
were	O
compared	O
in	O
the	O
fasting	O
state	O
and	O
after	O
an	O
oral	O
fat	O
load	O
.	O

RESULTS	O
:	O
Fasting	O
triglyceride	O
(	O
TG	O
)	O
levels	O
were	O
lower	O
in	O
the	O
LOF	O
variant	O
versus	O
non	O
-	O
variant	O
group	O
but	O
rose	O
to	O
the	O
same	O
level	O
after	O
the	O
oral	O
fat	O
load	O
.	O

Conditioned	O
medium	O
from	O
PBMC	O
was	O
obtained	O
in	O
fasting	O
(	O
PBMC	O
-	O
CM	O
-	O
F	O
)	O
and	O
4-h	O
postprandial	O
(	O
PBMC	O
-	O
CM	O
-	O
PP	O
)	O
states	O
.	O

PBMC	O
-	O
CM	O
-	O
PP	O
from	O
non	O
-	O
variant	O
controls	O
inhibited	O
adipogenesis	O
of	O
human	O
preadipocytes	O
more	O
than	O
did	O
PBMC	O
-	O
CM	O
-	O
F.	O
In	O
contrast	O
,	O
PBMC	O
-	O
CM	O
-	O
F	O
or	O
-PP	O
from	O
PCSK9	B-Gene
LOF	B-NegReg
variant	B-Var
subjects	O
had	O
no	O
effect	O
on	O
adipogenesis	B-MPA
.	O

After	O
the	O
oral	O
fat	O
load	O
,	O
PBMC	O
from	O
PCSK9	B-Gene
LOF	B-NegReg
variant	B-Var
subjects	O
showed	O
significant	O
increases	B-PosReg
in	O
mRNA	B-MPA
levels	I-MPA
of	I-MPA
interleukin-1β	I-MPA
,	O
tumor	B-MPA
necrosis	I-MPA
factor	I-MPA
-	I-MPA
α	I-MPA
,	O
sterol	B-MPA
regulatory	I-MPA
element	I-MPA
binding	I-MPA
protein-1c	I-MPA
,	O
CD36	B-MPA
,	O
and	O
monocyte	O
chemoattractant	O
protein-1	O
(	O
MCP-1	O
)	O
,	O
only	O
MCP-1	O
mRNA	O
levels	O
increased	O
in	O
PBMC	O
from	O
non	O
-	O
variant	O
controls	O
.	O

CONCLUSIONS	O
:	O
The	O
absence	B-NegReg
of	O
anti	B-MPA
-	I-MPA
adipogenic	I-MPA
action	I-MPA
of	O
PBMC	O
from	O
PCSK9	B-Gene
LOF	O
variant	B-Var
subjects	O
points	O
to	O
a	O
novel	B-PosReg
role	I-PosReg
for	O
PCSK9	O
in	O
PBMC	O
-	O
adipose	O
cell	O
interactions	B-Interaction
.	O

Atopic	O
Dermatitis	O
Susceptibility	O
Variants	O
in	O
Filaggrin	O
Hitchhike	O
Hornerin	O
Selective	O
Sweep	O
.	O

Human	O
skin	O
has	O
evolved	O
rapidly	O
,	O
leaving	O
evolutionary	O
signatures	O
in	O
the	O
genome	O
.	O

The	O
filaggrin	O
(	B-Gene
FLG	I-Gene
)	I-Gene
gene	O
is	O
widely	O
studied	O
for	O
its	O
skin	O
-	O
barrier	O
function	O
in	O
humans	O
.	O

The	O
extensive	B-Var
genetic	I-Var
variation	I-Var
in	O
this	O
gene	O
,	O
especially	O
common	O
loss	B-NegReg
-	I-NegReg
of	I-NegReg
-	I-NegReg
function	I-NegReg
(	O
LoF	O
)	O
mutations	B-Var
,	O
has	O
been	O
established	O
as	O
primary	O
risk	O
factors	O
for	O
atopic	B-Disease
dermatitis	I-Disease
.	O

To	O
investigate	O
the	O
evolution	O
of	O
this	O
gene	O
,	O
we	O
analyzed	O
2,504	O
human	O
genomes	O
and	O
genotyped	O
the	O
copy	O
number	O
variation	O
of	O
filaggrin	O
repeats	O
within	O
FLG	O
in	O
126	O
individuals	O
from	O
diverse	O
ancestral	O
backgrounds	O
.	O

We	O
were	O
unable	O
to	O
replicate	O
a	O
recent	O
study	O
claiming	O
that	O
LoF	O
of	O
FLG	O
is	O
adaptive	O
in	O
northern	O
latitudes	O
with	O
lower	O
ultraviolet	O
light	O
exposure	O
.	O

Instead	O
,	O
we	O
present	O
multiple	O
lines	O
of	O
evidence	O
suggesting	O
that	O
FLG	O
genetic	O
variation	O
,	O
including	O
LoF	O
variants	O
,	O
have	O
little	O
or	O
no	O
effect	O
on	O
fitness	O
in	O
modern	O
humans	O
.	O

Haplotype	O
-	O
level	O
scrutinization	O
of	O
the	O
locus	O
revealed	O
signatures	O
of	O
a	O
recent	O
selective	O
sweep	O
in	O
Asia	O
,	O
which	O
increased	O
the	O
allele	O
frequency	O
of	O
a	O
haplotype	O
group	O
(	O
Huxian	O
haplogroup	O
)	O
in	O
Asian	O
populations	O
.	O

Functionally	O
,	O
we	O
found	O
that	O
the	O
Huxian	O
haplogroup	O
carries	O
dozens	O
of	O
functional	O
variants	O
in	O
FLG	O
and	O
hornerin	O
(	O
HRNR	O
)	O
genes	O
,	O
including	O
those	O
that	O
are	O
associated	O
with	O
atopic	O
dermatitis	O
susceptibility	O
,	O
HRNR	O
expression	O
levels	O
and	O
microbiome	O
diversity	O
on	O
the	O
skin	O
.	O

Our	O
results	O
suggest	O
that	O
the	O
target	O
of	O
the	O
adaptive	O
sweep	O
is	O
HRNR	O
gene	O
function	O
,	O
and	O
the	O
functional	O
FLG	O
variants	O
that	O
involve	O
susceptibility	O
to	O
atopic	O
dermatitis	O
,	O
seem	O
to	O
hitchhike	O
the	O
selective	O
sweep	O
on	O
HRNR	O
.	O

Our	O
study	O
presents	O
a	O
novel	O
case	O
of	O
a	O
locus	O
that	O
harbors	O
clinically	O
relevant	O
common	O
genetic	O
variation	O
with	O
complex	O
evolutionary	O
trajectories	O
.	O

Variants	O
of	O
genes	O
encoding	O
collagens	O
and	O
matrix	O
metalloproteinase	O
system	O
increased	O
the	O
risk	O
of	O
aortic	O
dissection	O
.	O

Aortic	O
dissection	O
(	O
AD	O
)	O
is	O
a	O
devastating	O
,	O
heterogeneous	O
condition	O
of	O
aorta	O
.	O

The	O
homeostasis	O
between	O
collagens	O
and	O
matrix	O
metalloproteases	O
(	O
MMPs)/tissue	O
inhibitors	O
of	O
MMPs	O
(	O
TIMPs	O
)	O
system	O
in	O
the	O
extracellular	O
matrix	O
plays	O
an	O
important	O
role	O
for	O
structure	O
and	O
functions	O
of	O
aorta	O
.	O

However	O
,	O
our	O
knowledge	O
on	O
association	O
between	O
variants	O
of	O
genes	O
in	O
this	O
system	O
and	O
pathogenesis	O
of	O
AD	O
is	O
very	O
limited	O
.	O

We	O
analyzed	O
all	O
yet	O
known	O
coding	O
human	O
genes	O
of	O
collagens	O
(	O
45	O
genes	O
)	O
,	O
MMPs	O
/	O
TIMPs	O
(	O
27	O
genes	O
)	O
in	O
702	O
sporadic	O
AD	O
patients	O
and	O
in	O
163	O
matched	O
healthy	O
controls	O
,	O
by	O
using	O
massively	O
targeted	O
next	O
-	O
generation	O
and	O
Sanger	O
sequencing	O
.	O

To	O
define	O
the	O
pathogenesis	O
of	O
potential	O
disease	O
-	O
causing	O
candidate	O
genes	O
,	O
we	O
performed	O
transcriptome	O
sequencing	O
and	O
pedigree	O
co	O
-	O
segregation	O
analysis	O
in	O
some	O
genes	O
and	O
generated	O
Col5a2	O
knockout	O
rats	O
.	O

We	O
identified	O
257	O
pathogenic	O
or	O
likely	O
pathogenic	O
variants	O
which	O
involved	O
88.89	O
%	O
(	O
64/72	O
)	O
genes	O
in	O
collagens	O
-	O
MMPs	O
/	O
TIMPs	O
system	O
and	O
accounted	O
for	O
31.05	O
%	O
(	O
218/702	O
)	O
sporadic	O
AD	O
patients	O
.	O

In	O
them	O
,	O
84.86	O
%	O
patients	O
(	O
185/218	O
)	O
carried	O
one	O
variant	O
,	O
12.84	O
%	O
two	O
variants	O
and	O
2.30	O
%	O
more	O
than	O
two	O
variants	O
.	O

Importantly	O
,	O
we	O
identified	O
52	O
novel	O
probably	O
pathogenic	O
loss	O
-	O
of	O
-	O
function	O
(	O
LOF	O
)	O
variants	O
(	O
20	O
nonsense	O
,	O
16	O
frameshift	O
,	O
14	O
splice	O
sites	O
,	O
one	O
stop	O
-	O
loss	O
,	O
one	O
initiation	O
codon	O
)	O
in	O
11.06	O
%	O
(	O
50/452	O
)	O
AD	O
patients	O
,	O
which	O
were	O
absent	O
in	O
163	O
controls	O
(	O
P=2.5×10(-5	O
)	O
)	O
.	O

Transcriptome	O
sequencing	O
revealed	O
that	O
identified	O
variants	B-Var
induced	O
dyshomeostasis	B-Reg
in	O
expression	B-CPA
of	I-CPA
collagens	I-CPA
-	I-CPA
TIMPs	I-CPA
/	I-CPA
MMPs	I-CPA
systems	I-CPA
.	O

The	O
Col5a2	B-Gene
(	O
-/-	O
)	O
rats	O
manifested	O
growth	B-CPA
retardation	I-CPA
and	O
aortic	B-CPA
dysplasia	I-CPA
.	O

Our	O
study	O
provides	O
a	O
first	O
comprehensive	O
map	O
of	O
genetic	O
alterations	O
in	O
collagens	O
-	O
MMPs	O
/	O
TIMPs	O
system	O
in	O
sporadic	O
AD	O
patients	O
and	O
suggests	O
that	O
variants	O
of	O
these	O
genes	O
contribute	O
largely	O
to	O
AD	O
pathogenesis	O
.	O

Alanine	O
-	O
scanning	O
mutagenesis	O
of	O
human	O
signal	O
transducer	O
and	O
activator	O
of	O
transcription	O
1	O
to	O
estimate	O
loss-	O
or	O
gain	O
-	O
of	O
-	O
function	O
variants	O
.	O

BACKGROUND	O
:	O
Germline	B-Var
heterozygous	I-Var
mutations	I-Var
in	O
human	O
signal	B-Gene
transducer	I-Gene
and	O
activator	B-Gene
of	I-Gene
transcription	I-Gene
1	I-Gene
(	O
STAT1	O
)	O
can	O
cause	O
loss	B-NegReg
of	I-NegReg
function	I-NegReg
(	O
LOF	O
)	O
,	O
as	O
in	O
patients	O
with	O
Mendelian	O
susceptibility	O
to	O
mycobacterial	B-Disease
diseases	I-Disease
,	O
or	O
gain	B-PosReg
of	I-PosReg
function	I-PosReg
(	O
GOF	O
)	O
,	O
as	O
in	O
patients	O
with	O
chronic	B-Disease
mucocutaneous	I-Disease
candidiasis	I-Disease
.	O

LOF	O
and	O
GOF	O
mutations	B-Var
are	O
equally	O
rare	O
and	O
can	O
affect	B-Reg
the	O
same	O
domains	B-MPA
of	O
STAT1	B-Gene
,	O
especially	O
the	O
coiled	B-MPA
-	I-MPA
coil	I-MPA
domain	I-MPA
(	O
CCD	O
)	O
and	O
DNA	B-MPA
-	I-MPA
binding	I-MPA
domain	I-MPA
(	O
DBD	O
)	O
.	O

Moreover	O
,	O
6	O
%	O
of	O
patients	O
with	O
chronic	O
mucocutaneous	O
candidiasis	O
with	O
a	O
GOF	O
STAT1	O
mutation	O
have	O
mycobacterial	O
disease	O
,	O
obscuring	O
the	O
functional	O
significance	O
of	O
the	O
identified	O
STAT1	O
mutations	O
.	O

Current	O
computational	O
approaches	O
,	O
such	O
as	O
combined	O
annotation	O
-	O
dependent	O
depletion	O
,	O
do	O
not	O
distinguish	O
LOF	O
and	O
GOF	O
variants	O
.	O

OBJECTIVE	O
:	O
We	O
estimated	O
variations	O
in	O
the	O
CCD	O
/	O
DBD	O
of	O
STAT1	O
.	O

METHODS	O
:	O
We	O
mutagenized	O
342	O
individual	O
wild	O
-	O
type	O
amino	O
acids	O
in	O
the	O
CCD	O
/	O
DBD	O
(	O
45.6	O
%	O
of	O
full	O
-	O
length	O
STAT1	O
)	O
to	O
alanine	O
and	O
tested	O
the	O
mutants	O
for	O
STAT1	O
transcriptional	O
activity	O
.	O

RESULTS	O
:	O
Of	O
these	O
342	O
mutants	O
,	O
201	O
were	O
neutral	O
,	O
30	O
were	O
LOF	O
,	O
and	O
111	O
were	O
GOF	O
mutations	O
in	O
a	O
luciferase	O
assay	O
.	O

This	O
assay	O
system	O
correctly	O
estimated	O
all	O
previously	O
reported	O
LOF	O
mutations	O
(	O
100	O
%	O
)	O
and	O
slightly	O
fewer	O
GOF	O
mutations	O
(	O
78.1	O
%	O
)	O
in	O
the	O
CCD	O
/	O
DBD	O
of	O
STAT1	O
.	O

We	O
found	O
that	O
GOF	O
alanine	O
mutants	O
occurred	O
at	O
the	O
interface	O
of	O
the	O
antiparallel	O
STAT1	O
dimer	O
,	O
suggesting	O
that	O
they	O
destabilize	O
this	O
dimer	O
.	O

This	O
assay	O
also	O
precisely	O
predicted	O
the	O
effect	O
of	O
2	O
hypomorphic	O
and	O
dominant	O
negative	O
mutations	O
,	O
E157	O
K	O
and	O
G250E	O
,	O
in	O
the	O
CCD	O
of	O
STAT1	O
that	O
we	O
found	O
in	O
2	O
unrelated	O
patients	O
with	O
Mendelian	O
susceptibility	O
to	O
mycobacterial	O
diseases	O
.	O

CONCLUSION	O
:	O
The	O
systematic	O
alanine	O
-	O
scanning	O
assay	O
is	O
a	O
useful	O
tool	O
to	O
estimate	O
the	O
GOF	O
or	O
LOF	O
status	O
and	O
the	O
effect	O
of	O
heterozygous	O
missense	O
mutations	O
in	O
STAT1	O
identified	O
in	O
patients	O
with	O
severe	O
infectious	O
diseases	O
,	O
including	O
mycobacterial	O
and	O
fungal	O
diseases	O
.	O

Ruxolitinib	O
reverses	O
dysregulated	O
T	O
helper	O
cell	O
responses	O
and	O
controls	O
autoimmunity	O
caused	O
by	O
a	O
novel	O
signal	O
transducer	O
and	O
activator	O
of	O
transcription	O
1	O
(	O
STAT1	O
)	O
gain	O
-	O
of	O
-	O
function	O
mutation	O
.	O

BACKGROUND	O
:	O
Gain	B-PosReg
-	I-PosReg
of	I-PosReg
-	I-PosReg
function	I-PosReg
(	O
GOF	O
)	O
mutations	B-Var
in	O
the	O
human	B-Gene
signal	I-Gene
transducer	I-Gene
and	I-Gene
activator	I-Gene
of	I-Gene
transcription	I-Gene
1	I-Gene
(	O
STAT1	O
)	O
manifest	O
in	O
immunodeficiency	O
and	O
autoimmunity	O
with	O
impaired	B-NegReg
TH17	B-CPA
cell	I-CPA
differentiation	I-CPA
and	O
exaggerated	B-PosReg
responsiveness	B-Interaction
to	I-Interaction
type	I-Interaction
I	I-Interaction
and	I-Interaction
II	I-Interaction
interferons	I-Interaction
.	O

Allogeneic	O
bone	O
marrow	O
transplantation	O
has	O
been	O
attempted	O
in	O
severely	O
affected	O
patients	O
,	O
but	O
outcomes	O
have	O
been	O
poor	O
.	O

OBJECTIVE	O
:	O
We	O
sought	O
to	O
define	O
the	O
effect	O
of	O
increased	O
STAT1	O
activity	O
on	O
T	O
helper	O
cell	O
polarization	O
and	O
to	O
investigate	O
the	O
therapeutic	O
potential	O
of	O
ruxolitinib	O
in	O
treating	O
autoimmunity	O
secondary	O
to	O
STAT1	O
GOF	O
mutations	O
.	O

METHODS	O
:	O
We	O
used	O
in	O
vitro	O
polarization	O
assays	O
,	O
as	O
well	O
as	O
phenotypic	O
and	O
functional	O
analysis	O
of	O
STAT1-mutated	O
patient	O
cells	O
.	O

RESULTS	O
:	O
We	O
report	O
a	O
child	O
with	O
a	O
novel	O
mutation	B-Var
in	I-Var
the	I-Var
linker	I-Var
domain	I-Var
of	O
STAT1	B-Gene
who	O
had	O
life	O
-	O
threatening	O
autoimmune	O
cytopenias	O
and	O
chronic	O
mucocutaneous	O
candidiasis	O
.	O

Naive	O
lymphocytes	O
from	O
the	O
affected	O
patient	O
displayed	O
increased	B-PosReg
TH1	B-CPA
and	I-CPA
follicular	I-CPA
T	I-CPA
helper	I-CPA
cell	I-CPA
and	O
suppressed	B-NegReg
TH17	B-CPA
cell	I-CPA
responses	I-CPA
.	O

The	O
mutation	B-Var
augmented	B-PosReg
cytokine	B-MPA
-	I-MPA
induced	I-MPA
STAT1	I-MPA
phosphorylation	I-MPA
without	O
affecting	O
dephosphorylation	O
kinetics	O
.	O

Treatment	O
with	O
the	O
Janus	O
kinase	O
1/2	O
inhibitor	O
ruxolitinib	O
reduced	O
hyperresponsiveness	O
to	O
type	O
I	O
and	O
II	O
interferons	O
,	O
normalized	O
TH1	O
and	O
follicular	O
T	O
helper	O
cell	O
responses	O
,	O
improved	O
TH17	O
differentiation	O
,	O
cured	O
mucocutaneous	O
candidiasis	O
,	O
and	O
maintained	O
remission	O
of	O
immune	O
-	O
mediated	O
cytopenias	O
.	O

CONCLUSIONS	O
:	O
Autoimmunity	O
and	O
infection	O
caused	O
by	O
STAT1	B-Gene
GOF	B-PosReg
mutations	B-Var
are	O
the	O
result	O
of	O
dysregulated	O
T	B-CPA
helper	I-CPA
cell	I-CPA
responses	I-CPA
.	O

Janus	O
kinase	O
inhibitor	O
therapy	O
could	O
represent	O
an	O
effective	O
targeted	O
treatment	O
for	O
long	O
-	O
term	O
disease	O
control	O
in	O
severely	O
affected	O
patients	O
for	O
whom	O
hematopoietic	O
stem	O
cell	O
transplantation	O
is	O
not	O
available	O
.	O

Complexity	O
of	O
mechanisms	O
among	O
human	O
proprotein	O
convertase	O
subtilisin	O
-	O
kexin	O
type	O
9	O
variants	O
.	O

PURPOSE	O
OF	O
REVIEW	O
:	O
There	O
are	O
many	O
reports	O
of	O
human	O
variants	B-Var
in	O
proprotein	O
convertase	O
subtilisin	O
-	O
kexin	O
type	O
9	O
(	B-Gene
PCSK9	I-Gene
)	I-Gene
that	O
are	O
either	O
gain	B-PosReg
-	I-PosReg
of	I-PosReg
-	I-PosReg
function	I-PosReg
(	O
GOF	O
)	O
or	O
loss	B-NegReg
-	I-NegReg
of	I-NegReg
-	I-NegReg
function	I-NegReg
(	O
LOF	O
)	O
,	O
with	O
downstream	O
effects	B-Reg
on	O
LDL	B-Disease
cholesterol	I-Disease
and	O
cardiovascular	B-Disease
disease	I-Disease
(	O
CVD	O
)	O
risk	O
.	O

However	O
,	O
data	O
on	O
particular	O
mechanisms	O
have	O
only	O
been	O
minimally	O
curated	O
.	O

RECENT	O
FINDINGS	O
:	O
GOF	B-PosReg
variants	B-Var
are	O
individually	O
ultrarare	O
,	O
affect	B-Reg
all	O
domains	B-Protein
of	I-Protein
the	I-Protein
protein	I-Protein
,	O
act	O
to	O
reduce	B-NegReg
LDL	B-Protein
receptor	I-Protein
expression	B-MPA
through	O
several	O
mechanisms	O
,	O
are	O
a	O
minor	O
cause	B-Reg
of	O
familial	B-Disease
hypercholesterolemia	I-Disease
,	O
have	O
been	O
reported	O
mainly	O
within	O
families	O
,	O
have	O
variable	O
LDL	O
cholesterol	O
-	O
raising	O
effects	O
,	O
and	O
are	O
associated	O
with	O
increased	O
CVD	O
risk	O
mainly	O
through	O
observational	O
studies	O
in	O
families	O
and	O
small	O
cohorts	O
.	O

In	O
contrast	O
,	O
LOF	B-NegReg
variants	B-Var
can	O
be	O
either	O
ultrarare	O
mutations	O
or	O
relatively	O
more	O
common	O
polymorphisms	O
seen	O
in	O
populations	O
,	O
affect	B-Reg
all	O
domains	B-Protein
of	I-Protein
the	I-Protein
protein	I-Protein
,	O
act	O
to	O
increase	B-PosReg
LDL	B-Protein
receptor	I-Protein
expression	B-MPA
through	O
several	O
mechanisms	O
,	O
have	O
variable	O
LDL	B-MPA
cholesterol	B-NegReg
-	I-NegReg
lowering	I-NegReg
effects	O
,	O
and	O
have	O
been	O
associated	O
with	O
decreased	B-NegReg
CVD	B-Disease
risk	O
mainly	O
through	O
Mendelian	O
randomization	O
studies	O
in	O
epidemiologic	O
populations	O
.	O

SUMMARY	O
:	O
There	O
is	O
considerable	O
complexity	O
underlying	O
the	O
clinical	O
concept	O
of	O
both	O
LOF	O
and	O
GOF	O
variants	O
of	O
PCSK9	O
.	O

But	O
despite	O
the	O
underlying	O
mechanistic	O
heterogeneity	O
,	O
altered	O
PCSK9	O
secretion	O
or	O
function	O
is	O
ultimately	O
correlated	O
with	O
plasma	O
LDL	O
cholesterol	O
level	O
,	O
which	O
is	O
also	O
the	O
driver	O
of	O
CVD	O
outcomes	O
.	O

Towards	O
trans	O
-	O
diagnostic	O
mechanisms	O
in	O
psychiatry	O
:	O
neurobehavioral	O
profile	O
of	O
rats	O
with	O
a	O
loss	O
-	O
of	O
-	O
function	O
point	O
mutation	O
in	O
the	O
dopamine	O
transporter	O
gene	O
.	O

The	O
research	O
domain	O
criteria	O
(	O
RDoC	O
)	O
matrix	O
has	O
been	O
developed	O
to	O
reorient	O
psychiatric	O
research	O
towards	O
measurable	O
behavioral	O
dimensions	O
and	O
underlying	O
mechanisms	O
.	O

Here	O
,	O
we	O
used	O
a	O
new	O
genetic	O
rat	O
model	O
with	O
a	O
loss	O
-	O
of	O
-	O
function	O
point	O
mutation	O
in	O
the	O
dopamine	O
transporter	O
(	O
DAT	O
)	O
gene	O
(	O
Slc6a3_N157	O
K	O
)	O
to	O
systematically	O
study	O
the	O
RDoC	O
matrix	O
.	O

First	O
,	O
we	O
examined	O
the	O
impact	O
of	O
the	O
Slc6a3_N157	O
K	O
mutation	O
on	O
monoaminergic	O
signaling	O
.	O

We	O
then	O
performed	O
behavioral	O
tests	O
representing	O
each	O
of	O
the	O
five	O
RDoC	O
domains	O
:	O
negative	O
and	O
positive	O
valence	O
systems	O
,	O
cognitive	O
,	O
social	O
and	O
arousal	O
/	O
regulatory	O
systems	O
.	O

The	O
use	O
of	O
RDoC	O
may	O
be	O
particularly	O
helpful	O
for	O
drug	O
development	O
.	O

We	O
studied	O
the	O
effects	O
of	O
a	O
novel	O
pharmacological	O
approach	O
metabotropic	O
glutamate	O
receptor	O
mGluR2/3	O
antagonism	O
,	O
in	O
DAT	O
mutants	O
in	O
a	O
comparative	O
way	O
with	O
standard	O
medications	O
.	O

Loss	B-NegReg
of	O
DAT	B-Gene
functionality	O
in	O
mutant	B-Var
rats	O
not	O
only	O
elevated	B-PosReg
subcortical	B-MPA
extracellular	I-MPA
dopamine	I-MPA
concentration	I-MPA
but	O
also	O
altered	B-Reg
the	O
balance	B-MPA
of	I-MPA
monoaminergic	I-MPA
transmission	I-MPA
.	O

DAT	O
mutant	O
rats	O
showed	O
deficits	O
in	O
all	O
five	O
RDoC	O
domains	O
.	O

Thus	O
,	O
mutant	O
rats	O
failed	O
to	O
show	O
conditioned	O
fear	O
responses	O
,	O
were	O
anhedonic	O
,	O
were	O
unable	O
to	O
learn	O
stimulus	O
-	O
reward	O
associations	O
,	O
showed	O
impaired	O
cognition	O
and	O
social	O
behavior	O
,	O
and	O
were	O
hyperactive	O
.	O

Hyperactivity	O
in	O
mutant	O
rats	O
was	O
reduced	O
by	O
amphetamine	O
and	O
atomoxetine	O
,	O
which	O
are	O
well	O
-	O
established	O
medications	O
to	O
reduce	O
hyperactivity	O
in	O
humans	O
.	O

The	O
mGluR2/3	O
antagonist	O
LY341495	O
also	O
normalized	O
hyperactivity	O
in	O
DAT	O
mutant	O
rats	O
without	O
affecting	O
extracellular	O
dopamine	O
levels	O
.	O

We	O
systematically	O
characterized	O
an	O
altered	O
dopamine	O
system	O
within	O
the	O
context	O
of	O
the	O
RDoC	O
matrix	O
and	O
studied	O
mGluR2/3	O
antagonism	O
as	O
a	O
new	O
pharmacological	O
strategy	O
to	O
treat	O
mental	O
disorders	O
with	O
underlying	O
subcortical	O
dopaminergic	O
hyperactivity	O
.	O

Conformational	O
disruption	O
of	O
PI3Kδ	O
regulation	O
by	O
immunodeficiency	O
mutations	O
in	O
PIK3CD	O
and	O
PIK3R1	O
.	O

Activated	B-Disease
PI3	I-Disease
K	I-Disease
Delta	I-Disease
Syndrome	I-Disease
(	O
APDS	O
)	O
is	O
a	O
primary	O
immunodeficiency	O
disease	O
caused	B-Reg
by	O
activating	O
mutations	B-Var
in	O
either	O
the	O
leukocyte	O
-	O
restricted	O
p110δ	O
catalytic	O
(	B-Gene
PIK3CD	I-Gene
)	I-Gene
subunit	O
or	O
the	O
ubiquitously	O
expressed	O
p85α	O
regulatory	O
(	O
PIK3R1	O
)	O
subunit	O
of	O
class	O
IA	O
phosphoinositide	O
3-kinases	O
(	O
PI3Ks	O
)	O
.	O

There	O
are	O
two	O
classes	O
of	O
APDS	O
:	O
APDS1	O
that	O
arises	O
from	O
p110δ	O
mutations	O
that	O
are	O
analogous	O
to	O
oncogenic	O
mutations	O
found	O
in	O
the	O
broadly	O
expressed	O
p110α	O
subunit	O
and	O
APDS2	O
that	O
occurs	O
from	O
a	O
splice	O
mutation	O
resulting	O
in	O
p85α	O
with	O
a	O
central	O
deletion	O
(	O
Δ434	O
-	O
475	O
)	O
.	O

As	O
p85	O
regulatory	O
subunits	O
associate	O
with	O
and	O
inhibit	O
all	O
class	O
IA	O
catalytic	O
subunits	O
,	O
APDS2	O
mutations	O
are	O
expected	O
to	O
similarly	O
activate	O
p110α	O
,	O
β	O
,	O
and	O
δ	O
,	O
yet	O
APDS2	O
largely	O
phenocopies	O
APDS1	O
without	O
dramatic	O
effects	O
outside	O
the	O
immune	O
system	O
.	O

We	O
have	O
examined	O
the	O
molecular	O
mechanism	O
of	O
activation	O
of	O
both	O
classes	O
of	O
APDS	O
mutations	O
using	O
a	O
combination	O
of	O
biochemical	O
assays	O
and	O
hydrogen	O
-	O
deuterium	O
exchange	O
mass	O
spectrometry	O
.	O

Intriguingly	O
,	O
we	O
find	O
that	O
an	O
APDS2	B-Gene
mutation	B-Var
in	O
p85α	O
leads	O
to	O
substantial	O
basal	O
activation	B-PosReg
of	O
p110δ	B-MPA
(	I-MPA
>	I-MPA
300-fold	I-MPA
)	I-MPA
and	O
disrupts	B-NegReg
inhibitory	B-MPA
interactions	I-MPA
from	O
the	O
nSH2	O
,	O
iSH2	O
,	O
and	O
cSH2	O
domains	O
of	O
p85	O
,	O
whereas	O
p110α	O
is	O
only	O
minimally	O
basally	O
activated	O
(	O
∼2-fold	O
)	O
when	O
associated	O
with	O
mutated	O
p85α	O
.	O

APDS1	O
mutations	O
in	O
p110δ	O
(	O
N334	O
K	O
,	O
E525	O
K	O
,	O
E1021	O
K	O
)	O
mimic	O
the	O
activation	O
mechanisms	O
previously	O
discovered	O
for	O
oncogenic	O
mutations	O
in	O
p110α	O
.	O

All	O
APDS	O
mutations	O
were	O
potently	O
inhibited	O
by	O
the	O
Food	O
and	O
Drug	O
Administration	O
-	O
approved	O
p110δ	O
inhibitor	O
idelalisib	O
.	O

Our	O
results	O
define	O
the	O
molecular	O
basis	O
of	O
how	O
PIK3CD	O
and	O
PIK3R1	O
mutations	O
result	O
in	O
APDS	O
and	O
reveal	O
a	O
potential	O
path	O
to	O
treatment	O
for	O
all	O
APDS	O
patients	O
.	O

N	O
-	O
cadherin	O
Regulation	O
of	O
Bone	O
Growth	O
and	O
Homeostasis	O
Is	O
Osteolineage	O
Stage	O
-	O
Specific	O
.	O

N	O
-	O
cadherin	O
inhibits	O
osteogenic	O
cell	O
differentiation	O
and	O
canonical	O
Wnt	O
/	O
β	O
-	O
catenin	O
signaling	O
in	O
vitro	O
.	O

However	O
,	O
in	O
vivo	O
both	O
conditional	O
Cdh2	O
ablation	O
and	O
overexpression	O
in	O
osteoblasts	O
lead	O
to	O
low	O
bone	O
mass	O
.	O

We	O
tested	O
the	O
hypothesis	O
that	O
N	O
-	O
cadherin	O
has	O
different	O
effects	O
on	O
osteolineage	O
cells	O
depending	O
upon	O
their	O
differentiation	O
stage	O
.	O

Embryonic	O
conditional	O
osteolineage	O
Cdh2	B-Gene
deletion	B-Var
in	O
mice	O
results	O
in	O
defective	B-NegReg
growth	B-MPA
,	O
low	B-NegReg
bone	B-MPA
mass	I-MPA
,	O
and	O
reduced	B-NegReg
osteoprogenitor	B-MPA
number	I-MPA
.	O

These	O
abnormalities	O
are	O
prevented	O
by	O
delaying	O
Cdh2	O
ablation	O
until	O
1	O
month	O
of	O
age	O
,	O
thus	O
targeting	O
only	O
committed	O
and	O
mature	O
osteoblasts	O
,	O
suggesting	O
they	O
are	O
the	O
consequence	O
of	O
N	O
-	O
cadherin	O
deficiency	O
in	O
osteoprogenitors	O
.	O

Indeed	O
,	O
diaphyseal	O
trabecularization	O
actually	O
increases	O
when	O
Cdh2	O
is	O
ablated	O
postnatally	O
.	O

The	O
sclerostin	O
-	O
insensitive	O
Lrp5(A214V	O
)	O
mutant	O
,	O
associated	O
with	O
high	O
bone	O
mass	O
,	O
does	O
not	O
rescue	O
the	O
growth	O
defect	O
,	O
but	O
it	O
overrides	O
the	O
low	O
bone	O
mass	O
of	O
embryonically	O
Cdh2-deleted	O
mice	O
,	O
suggesting	O
N	O
-	O
cadherin	O
interacts	O
with	O
Wnt	O
signaling	O
to	O
control	O
bone	O
mass	O
.	O

Finally	O
,	O
bone	O
accrual	O
and	O
β	O
-	O
catenin	O
accumulation	O
after	O
administration	O
of	O
an	O
anti	O
-	O
Dkk1	O
antibody	O
are	O
enhanced	O
in	O
N	O
-	O
cadherin	O
-	O
deficient	O
mice	O
.	O

Thus	O
,	O
although	O
lack	O
of	O
N	O
-	O
cadherin	O
in	O
embryonic	O
and	O
perinatal	O
age	O
is	O
detrimental	O
to	O
bone	O
growth	O
and	O
bone	O
accrual	O
,	O
in	O
adult	O
mice	O
loss	O
of	O
N	O
-	O
cadherin	O
in	O
osteolineage	O
cells	O
favors	O
bone	O
formation	O
.	O

Hence	O
,	O
N	O
-	O
cadherin	O
inhibition	O
may	O
widen	O
the	O
therapeutic	O
window	O
of	O
osteoanabolic	O
agents	O
.	O

©	O
2017	O
American	O
Society	O
for	O
Bone	O
and	O
Mineral	O
Research	O
.	O

MAX	O
inactivation	O
is	O
an	O
early	O
event	O
in	O
GIST	O
development	O
that	O
regulates	O
p16	O
and	O
cell	O
proliferation	O
.	O

KIT	B-Gene
,	O
PDGFRA	B-Gene
,	O
NF1	B-Gene
and	O
SDH	B-Gene
mutations	B-Var
are	O
alternate	O
initiating	O
events	O
,	O
fostering	B-Reg
hyperplasia	O
in	O
gastrointestinal	B-MPA
stromal	I-MPA
tumours	I-MPA
(	O
GISTs	O
)	O
,	O
and	O
additional	O
genetic	O
alterations	O
are	O
required	O
for	O
progression	O
to	O
malignancy	O
.	O

The	O
most	O
frequent	O
secondary	O
alteration	O
,	O
demonstrated	O
in	O
∼70	O
%	O
of	O
GISTs	O
,	O
is	O
chromosome	O
14q	O
deletion	O
.	O

Here	O
we	O
report	O
hemizygous	O
or	O
homozygous	O
inactivating	O
mutations	O
of	O
the	O
chromosome	O
14q	O
MAX	O
gene	O
in	O
16	O
of	O
76	O
GISTs	O
(	O
21	O
%	O
)	O
.	O

We	O
find	O
MAX	O
mutations	O
in	O
17	O
%	O
and	O
50	O
%	O
of	O
sporadic	O
and	O
NF1-syndromic	O
GISTs	O
,	O
respectively	O
,	O
and	O
we	O
find	O
loss	O
of	O
MAX	O
protein	O
expression	O
in	O
48	O
%	O
and	O
90	O
%	O
of	O
sporadic	O
and	O
NF1-syndromic	O
GISTs	O
,	O
respectively	O
,	O
and	O
in	O
three	O
of	O
eight	O
micro	O
-	O
GISTs	O
,	O
which	O
are	O
early	O
GISTs	O
.	O

MAX	O
genomic	O
inactivation	O
is	O
associated	O
with	O
p16	O
silencing	O
in	O
the	O
absence	O
of	O
p16	O
coding	O
sequence	O
deletion	O
and	O
MAX	O
induction	O
restores	O
p16	O
expression	O
and	O
inhibits	O
GIST	O
proliferation	O
.	O

Hence	O
,	O
MAX	O
inactivation	O
is	O
a	O
common	O
event	O
in	O
GIST	O
progression	O
,	O
fostering	O
cell	O
cycle	O
activity	O
in	O
early	O
GISTs	O
.	O

ATR	B-Gene
Mutations	B-Var
Promote	B-PosReg
the	O
Growth	B-MPA
of	O
Melanoma	B-Disease
Tumors	I-Disease
by	O
Modulating	O
the	O
Immune	O
Microenvironment	O
.	O

Melanomas	O
accumulate	O
a	O
high	O
burden	O
of	O
mutations	B-Var
that	O
could	O
potentially	O
generate	B-Reg
neoantigens	B-MPA
,	O
yet	O
somehow	O
suppress	B-NegReg
the	O
immune	B-MPA
response	I-MPA
to	I-MPA
facilitate	I-MPA
continued	I-MPA
growth	I-MPA
.	O

In	O
this	O
study	O
,	O
we	O
identify	O
a	O
subset	O
of	O
human	O
melanomas	O
that	O
have	O
loss	O
-	O
of	O
-	O
function	O
mutations	O
in	O
ATR	O
,	O
a	O
kinase	O
that	O
recognizes	O
and	O
repairs	O
UV	O
-	O
induced	O
DNA	O
damage	O
and	O
is	O
required	O
for	O
cellular	O
proliferation	O
.	O

ATR	B-Gene
mutant	B-Var
tumors	O
exhibit	O
both	O
the	O
accumulation	O
of	O
multiple	O
mutations	O
and	O
the	O
altered	O
expression	O
of	O
inflammatory	O
genes	O
,	O
resulting	O
in	O
decreased	B-NegReg
T	B-MPA
cell	I-MPA
recruitment	I-MPA
and	O
increased	B-PosReg
recruitment	B-MPA
of	I-MPA
macrophages	I-MPA
known	O
to	O
spur	O
tumor	O
invasion	O
.	O

Taken	O
together	O
,	O
these	O
studies	O
identify	O
a	O
mechanism	O
by	O
which	O
melanoma	O
cells	O
modulate	O
the	O
immune	O
microenvironment	O
to	O
promote	O
continued	O
growth	O
.	O

Regulation	O
of	O
endometrial	O
cell	O
proliferation	O
by	O
estrogen	O
-	O
induced	O
BDNF	O
signaling	O
pathway	O
.	O

Brain	O
-	O
derived	O
neurotrophic	O
factor	O
(	O
BDNF	O
)	O
is	O
a	O
member	O
of	O
the	O
neurotrophin	O
growth	O
factors	O
family	O
.	O

Recent	O
studies	O
indicated	O
that	O
the	O
level	O
of	O
BDNF	O
in	O
follicular	O
fluid	O
is	O
a	O
marker	O
for	O
oocyte	O
quality	O
and	O
infertility	O
.	O

Here	O
,	O
we	O
intend	O
to	O
further	O
investigate	O
the	O
function	O
of	O
BDNF	O
and	O
its	O
signaling	O
pathway	O
in	O
the	O
regulation	O
of	O
endometrial	O
cells	O
proliferation	O
.	O

We	O
found	O
that	O
BDNF	O
is	O
a	O
critical	O
growth	O
factor	O
in	O
endometrial	O
cells	O
.	O

Activation	O
of	O
signal	O
transducer	O
and	O
activator	O
of	O
transcription	O
3	O
signaling	O
pathway	O
is	O
required	O
for	O
BNDF	O
-	O
regulated	O
endometrial	O
cell	O
proliferation	O
.	O

Furthermore	O
,	O
BDNF	O
is	O
an	O
effector	O
of	O
estrogen	O
in	O
endometrial	O
cells	O
.	O

Finally	O
,	O
we	O
investigated	O
the	O
different	O
role	O
of	O
Val66Met	O
,	O
a	O
single	O
-	O
nucleotide	O
polymorphism	O
of	O
the	O
BDNF	O
gene	O
,	O
in	O
regulating	O
endometrial	O
cells	O
proliferation	O
.	O

The	O
results	O
showed	O
that	O
BDNF(V66	B-Gene
M	I-Gene
)	I-Gene
polymorphism	B-Var
is	O
a	O
loss	B-NegReg
-	I-NegReg
of	I-NegReg
-	I-NegReg
function	I-NegReg
polymorphism	B-Var
in	O
the	O
regulation	B-MPA
of	I-MPA
endometrial	I-MPA
cells	I-MPA
growth	I-MPA
.	O

Given	O
the	O
correlation	O
between	O
endometriosis	O
and	O
infertility	O
,	O
it	O
is	O
important	O
to	O
understand	O
the	O
role	O
of	O
BDNF	O
in	O
regulating	O
endometrial	O
cells	O
proliferation	O
and	O
to	O
develop	O
new	O
therapeutic	O
strategies	O
for	O
the	O
treatment	O
of	O
endometriosis	O
-	O
related	O
infertility	O
.	O

Impact	O
of	O
gain	B-PosReg
-	I-PosReg
of	I-PosReg
-	I-PosReg
function	I-PosReg
mutations	B-Var
in	O
the	O
low	O
-	O
density	O
lipoprotein	O
receptor	O
-	O
related	O
protein	O
5	O
(	B-Gene
LRP5	I-Gene
)	I-Gene
on	O
glucose	B-MPA
and	I-MPA
lipid	I-MPA
homeostasis	I-MPA
.	O

LRP5	B-Gene
loss	B-NegReg
-	I-NegReg
of	I-NegReg
-	I-NegReg
function	I-NegReg
mutations	B-Var
have	O
been	O
shown	O
to	O
cause	O
profound	B-MPA
osteoporosis	I-MPA
and	O
have	O
been	O
associated	O
with	O
impaired	B-MPA
insulin	I-MPA
sensitivity	I-MPA
and	O
dysregulated	B-MPA
lipid	I-MPA
metabolism	I-MPA
.	O

We	O
hypothesized	O
that	O
gain	O
-	O
of	O
-	O
function	O
mutations	O
in	O
LRP5	O
would	O
also	O
affect	O
these	O
parameters	O
.	O

We	O
therefore	O
studied	O
individuals	O
with	O
LRP5	B-Gene
gain	B-PosReg
-	I-PosReg
of	I-PosReg
-	I-PosReg
function	I-PosReg
mutations	B-Var
exhibiting	O
high	O
bone	O
mass	O
(	O
HBM	O
)	O
phenotypes	O
and	O
found	O
that	O
while	O
there	O
was	O
no	O
detected	O
change	O
in	O
insulin	O
sensitivity	O
,	O
there	O
was	O
a	O
significant	O
reduction	B-NegReg
in	O
serum	B-MPA
LDL	I-MPA
.	O

INTRODUCTION	O
:	O
Wnt	O
signaling	O
through	O
LRP5	O
represents	O
a	O
newly	O
appreciated	O
metabolic	O
pathway	O
,	O
which	O
potentially	O
represents	O
a	O
target	O
for	O
drug	O
discovery	O
in	O
type	O
2	O
diabetes	O
and	O
hyperlipidemia	O
.	O

Studies	O
in	O
animal	O
models	O
suggest	O
a	O
physiologic	O
link	O
between	O
LRP5	O
and	O
glucose	O
and	O
lipid	O
homeostasis	O
;	O
however	O
,	O
whether	O
it	O
plays	O
a	O
similar	O
role	O
in	O
humans	O
is	O
unclear	O
.	O

As	O
current	O
literature	O
links	O
loss	O
-	O
of	O
-	O
function	O
LRP5	O
to	O
impaired	O
glucose	O
and	O
lipid	O
metabolism	O
,	O
we	O
hypothesized	O
that	O
individuals	O
with	O
an	O
HBM	O
-	O
causing	O
mutation	O
in	O
LRP5	O
would	O
exhibit	O
improved	O
glucose	O
and	O
lipid	O
homeostasis	O
.	O

Since	O
studies	O
in	O
animal	O
models	O
have	O
suggested	O
that	O
Wnt	O
signaling	O
augments	O
insulin	O
secretion	O
,	O
we	O
also	O
examined	O
the	O
effect	O
of	O
Wnt	O
signaling	O
on	O
glucose	O
-	O
stimulated	O
insulin	O
secretion	O
on	O
human	O
pancreatic	O
islets	O
.	O

METHODS	O
:	O
This	O
was	O
a	O
matched	O
case	O
-	O
control	O
study	O
.	O

We	O
used	O
several	O
methods	O
to	O
assess	O
glucose	O
and	O
lipid	O
metabolism	O
in	O
11	O
individuals	O
with	O
HBM	O
-	O
causing	O
mutations	O
in	O
LRP5	O
.	O

Affected	O
study	O
participants	O
were	O
recruited	O
from	O
previously	O
identified	O
kindreds	O
with	O
HBM	O
-	O
causing	O
LRP5	O
mutations	O
and	O
included	O
9	O
males	O
and	O
2	O
females	O
.	O

Two	O
subjects	O
that	O
were	O
being	O
treated	O
with	O
insulin	O
for	O
type	O
2	O
diabetes	O
were	O
excluded	O
from	O
our	O
analysis	O
,	O
as	O
this	O
would	O
have	O
obscured	O
our	O
ability	O
to	O
determine	O
the	O
impact	O
of	O
gain	O
-	O
of	O
-	O
function	O
LRP5	O
mutations	O
on	O
glucose	O
metabolism	O
.	O

The	O
mean	O
age	O
of	O
the	O
evaluated	O
study	O
subjects	O
was	O
55	O
±	O
7	O
with	O
a	O
mean	O
BMI	O
of	O
27.2	O
±	O
2.0	O
.	O

Control	O
subjects	O
were	O
matched	O
and	O
recruited	O
from	O
the	O
general	O
community	O
at	O
an	O
equivalent	O
ratio	O
,	O
with	O
18	O
males	O
and	O
4	O
females	O
(	O
mean	O
age	O
56	O
±	O
4	O
;	O
mean	O
BMI	O
27.2	O
±	O
1.0	O
)	O
.	O

Study	O
testing	O
was	O
conducted	O
at	O
an	O
academic	O
medical	O
center	O
.	O

RESULTS	O
:	O
There	O
were	O
no	O
statistically	O
significant	O
differences	O
between	O
affected	O
and	O
matched	O
control	O
populations	O
for	O
HbA1c	O
(	O
p	O
=	O
0.06	O
)	O
,	O
eAG	O
(	O
p	O
=	O
0.06	O
)	O
,	O
insulin	O
(	O
p	O
=	O
0.82	O
)	O
,	O
HOMA	O
-	O
B	O
(	O
p	O
=	O
0.34	O
)	O
,	O
or	O
HOMA	O
-	O
IR	O
(	O
p	O
=	O
0.66	O
)	O
.	O

The	O
mean	O
Insulin	O
Sensitivity	O
Index	O
(	O
ISI	O
)	O
was	O
also	O
similar	O
between	O
control	O
and	O
affected	O
individuals	O
.	O

Total	O
cholesterol	O
(	O
p	O
=	O
0.43	O
)	O
,	O
triglycerides	O
(	O
TG	O
)	O
(	O
p	O
=	O
0.56	O
)	O
,	O
and	O
HDL	O
(	O
p	O
=	O
0.32	O
)	O
were	O
not	O
different	O
between	O
the	O
same	O
two	O
groups	O
.	O

In	O
a	O
small	O
subset	O
of	O
studied	O
subjects	O
,	O
intramyocellular	O
and	O
hepatic	O
lipid	O
content	O
were	O
similar	O
in	O
the	O
affected	O
individuals	O
and	O
controls	O
when	O
quantified	O
by	O
proton	O
magnetic	O
resonance	O
spectroscopy	O
(	O
MRS	O
)	O
.	O

However	O
,	O
the	O
mean	O
value	O
for	O
serum	O
LDL	O
was	O
significantly	O
lower	O
(	O
p	O
=	O
0.04	O
)	O
in	O
affected	O
individuals	O
.	O

In	O
primary	O
human	O
islets	O
,	O
there	O
were	O
no	O
differences	O
between	O
control	O
and	O
Wnt	O
treatment	O
groups	O
for	O
insulin	O
secretion	O
measured	O
as	O
area	O
under	O
the	O
curve	O
(	O
AUC	O
)	O
for	O
first	O
phase	O
(	O
p	O
=	O
0.17	O
)	O
or	O
second	O
phase	O
(	O
p	O
=	O
0.33	O
)	O
insulin	O
secretion	O
.	O

CONCLUSIONS	O
:	O
Although	O
our	O
sample	O
size	O
was	O
small	O
,	O
our	O
data	O
do	O
not	O
support	O
the	O
hypothesis	O
that	O
HBM	O
-	O
causing	O
LRP5	O
mutations	O
,	O
associated	O
with	O
increased	O
Wnt	O
signaling	O
,	O
improve	O
glucose	O
metabolism	O
in	O
humans	O
.	O

However	O
,	O
it	O
does	O
appear	O
that	O
LRP5	B-Gene
variants	B-Var
may	O
affect	B-Reg
LDL	B-MPA
metabolism	I-MPA
,	O
a	O
major	O
risk	O
factor	O
for	O
coronary	O
artery	O
disease	O
.	O

The	O
molecular	O
mechanisms	O
underpinning	O
this	O
effect	O
warrant	O
further	O
study	O
.	O

The	O
Microtubule	O
-	O
Associated	O
Protein	O
MAP18	O
Affects	O
ROP2	O
GTPase	O
Activity	O
during	O
Root	O
Hair	O
Growth	O
.	O

Establishment	O
and	O
maintenance	O
of	O
the	O
polar	O
site	O
are	O
important	O
for	O
root	O
hair	O
tip	O
growth	O
.	O

We	O
previously	O
reported	O
that	O
Arabidopsis	O
(	O
Arabidopsis	O
thaliana	O
)	O
MICROTUBULE	O
-	O
ASSOCIATED	O
PROTEIN18	O
(	O
MAP18	O
)	O
functions	O
in	O
controlling	O
the	O
direction	O
of	O
pollen	O
tube	O
growth	O
and	O
root	O
hair	O
elongation	O
.	O

Additionally	O
,	O
the	O
Rop	O
GTPase	O
ROP2	O
was	O
reported	O
as	O
a	O
positive	O
regulator	O
of	O
both	O
root	O
hair	O
initiation	O
and	O
tip	O
growth	O
in	O
Arabidopsis	O
.	O

Both	O
loss	B-NegReg
of	I-NegReg
function	I-NegReg
of	O
ROP2	B-Gene
and	O
knockdown	B-Var
of	O
MAP18	B-Gene
lead	O
to	O
a	O
decrease	B-NegReg
in	O
root	B-MPA
hair	I-MPA
length	I-MPA
,	O
whereas	O
overexpression	O
of	O
either	O
MAP18	O
or	O
ROP2	O
causes	O
multiple	O
tips	O
or	O
a	O
branching	O
hair	O
phenotype	O
.	O

However	O
,	O
it	O
is	O
unclear	O
whether	O
MAP18	O
and	O
ROP2	O
coordinately	O
regulate	O
root	O
hair	O
growth	O
.	O

In	O
this	O
study	O
,	O
we	O
demonstrate	O
that	O
MAP18	O
and	O
ROP2	O
interact	O
genetically	O
and	O
functionally	O
.	O

MAP18	O
interacts	O
physically	O
with	O
ROP2	O
in	O
vitro	O
and	O
in	O
vivo	O
and	O
preferentially	O
binds	O
to	O
the	O
inactive	O
form	O
of	O
the	O
ROP2	O
protein	O
.	O

MAP18	O
promotes	O
ROP2	O
activity	O
during	O
root	O
hair	O
tip	O
growth	O
.	O

Further	O
investigation	O
revealed	O
that	O
MAP18	O
competes	O
with	O
RhoGTPase	O
GDP	O
DISSOCIATION	O
INHIBITOR1	O
/	O
SUPERCENTIPEDE1	O
for	O
binding	O
to	O
ROP2	O
,	O
in	O
turn	O
affecting	O
the	O
localization	O
of	O
active	O
ROP2	O
in	O
the	O
plasma	O
membrane	O
of	O
the	O
root	O
hair	O
tip	O
.	O

These	O
results	O
reveal	O
a	O
novel	O
function	O
of	O
MAP18	O
in	O
the	O
regulation	O
of	O
ROP2	O
activation	O
during	O
root	O
hair	O
growth	O
.	O

A	O
Ras	O
GTPase	O
associated	O
protein	O
is	O
involved	O
in	O
the	O
phototropic	O
and	O
circadian	O
photobiology	O
responses	O
in	O
fungi	O
.	O

Light	O
is	O
an	O
environmental	O
signal	O
perceived	O
by	O
most	O
eukaryotic	O
organisms	O
and	O
that	O
can	O
have	O
major	O
impacts	O
on	O
their	O
growth	O
and	O
development	O
.	O

The	O
MadC	O
protein	O
in	O
the	O
fungus	O
Phycomyces	O
blakesleeanus	O
(	O
Mucoromycotina	O
)	O
has	O
been	O
postulated	O
to	O
form	O
part	O
of	O
the	O
photosensory	O
input	O
for	O
phototropism	O
of	O
the	O
fruiting	O
body	O
sporangiophores	O
,	O
but	O
the	O
madC	O
gene	O
has	O
remained	O
unidentified	O
since	O
the	O
1960s	O
when	O
madC	O
mutants	O
were	O
first	O
isolated	O
.	O

In	O
this	O
study	O
the	O
madC	O
gene	O
was	O
identified	O
by	O
positional	O
cloning	O
.	O

All	O
madC	O
mutant	O
strains	O
contain	O
loss	O
-	O
of	O
-	O
function	O
point	O
mutations	O
within	O
a	O
gene	O
predicted	O
to	O
encode	O
a	O
GTPase	O
activating	O
protein	O
(	O
GAP	O
)	O
for	O
Ras	O
.	O

The	O
madC	O
gene	O
complements	O
the	O
Saccharomyces	O
cerevisiae	O
Ras	O
-	O
GAP	O
ira1	O
mutant	O
and	O
the	O
encoded	O
MadC	O
protein	O
interacts	O
with	O
P.	O
blakesleeanus	O
Ras	O
homologs	O
in	O
yeast	O
two	O
-	O
hybrid	O
assays	O
,	O
indicating	O
that	O
MadC	O
is	O
a	O
regulator	O
of	O
Ras	O
signaling	O
.	O

Deletion	B-Var
of	O
the	O
homolog	O
in	O
the	O
filamentous	O
ascomycete	O
Neurospora	O
crassa	O
affects	B-Reg
the	O
circadian	B-MPA
clock	I-MPA
output	I-MPA
,	O
yielding	B-Reg
a	O
pattern	O
of	O
asexual	B-MPA
conidiation	I-MPA
similar	O
to	O
a	O
ras-1	O
mutant	O
that	O
is	O
used	O
in	O
circadian	O
studies	O
in	O
N.	O
crassa	O
.	O

Thus	O
,	O
MadC	O
is	O
unlikely	O
to	O
be	O
a	O
photosensor	O
,	O
yet	O
is	O
a	O
fundamental	O
link	O
in	O
the	O
photoresponses	O
from	O
blue	O
light	O
perceived	O
by	O
the	O
conserved	O
White	O
Collar	O
complex	O
with	O
Ras	O
signaling	O
in	O
two	O
distantly	O
-	O
related	O
filamentous	O
fungal	O
species	O
.	O

Paradoxical	O
gain	O
-	O
of	O
-	O
function	O
mutant	O
of	O
the	O
G	O
-	O
protein	O
-	O
coupled	O
receptor	O
PROKR2	O
promotes	O
early	O
puberty	O
.	O

The	O
human	O
genome	O
encodes	O
~750	O
G	O
-	O
protein	O
-	O
coupled	O
receptors	O
(	O
GPCRs	O
)	O
,	O
including	O
prokineticin	O
receptor	O
2	O
(	O
PROKR2	O
)	O
involved	O
in	O
the	O
regulation	O
of	O
sexual	O
maturation	O
.	O

Previously	O
reported	O
pathogenic	O
gain	O
-	O
of	O
-	O
function	O
mutations	O
of	O
GPCR	O
genes	O
invariably	O
encoded	O
aberrant	O
receptors	O
with	O
excessive	O
signal	O
transduction	O
activity	O
.	O

Although	O
in	O
vitro	O
assays	O
demonstrated	O
that	O
an	O
artificially	O
created	O
inactive	O
mutant	O
of	O
PROKR2	O
exerted	O
paradoxical	O
gain	O
-	O
of	O
-	O
function	O
effects	O
when	O
co	O
-	O
transfected	O
with	O
wild	O
-	O
type	O
proteins	O
,	O
such	O
a	O
phenomenon	O
has	O
not	O
been	O
observed	O
in	O
vivo	O
.	O

Here	O
,	O
we	O
report	O
a	O
heterozygous	O
frameshift	O
mutation	O
of	O
PROKR2	O
identified	O
in	O
a	O
3.5-year	O
-	O
old	O
girl	O
with	O
central	O
precocious	O
puberty	O
.	O

The	O
mutant	B-Var
mRNA	O
escaped	B-NegReg
nonsense	B-MPA
-	I-MPA
mediated	I-MPA
decay	I-MPA
and	O
generated	O
a	O
GPCR	O
lacking	B-NegReg
two	B-MPA
transmembrane	I-MPA
domains	I-MPA
and	O
the	O
carboxyl	O
-	O
terminal	O
tail	O
.	O

The	O
mutant	O
protein	O
had	O
no	O
in	O
vitro	O
signal	O
transduction	O
activity	O
;	O
however	O
,	O
cells	O
co	O
-	O
expressing	O
the	O
mutant	O
and	O
wild	O
-	O
type	O
PROKR2	O
exhibited	O
markedly	O
exaggerated	O
ligand	O
-	O
induced	O
Ca(2	O
+	O
)	O
responses	O
.	O

The	O
results	O
indicate	O
that	O
certain	O
inactive	O
PROKR2	B-Gene
mutants	B-Var
can	O
cause	O
early	O
puberty	O
by	O
enhancing	B-PosReg
the	O
functional	B-MPA
property	O
of	O
coexisting	O
wild	O
-	O
type	O
proteins	O
.	O

Considering	O
the	O
structural	O
similarity	O
among	O
GPCRs	O
,	O
this	O
paradoxical	O
gain	O
-	O
of	O
-	O
function	O
mechanism	O
may	O
underlie	O
various	O
human	O
disorders	O
.	O

The	O
Tension	O
-	O
sensitive	O
Ion	O
Transport	O
Activity	O
of	O
MSL8	O
is	O
Critical	O
for	O
its	O
Function	O
in	O
Pollen	O
Hydration	O
and	O
Germination	O
.	O

All	O
cells	O
respond	O
to	O
osmotic	O
challenges	O
,	O
including	O
those	O
imposed	O
during	O
normal	O
growth	O
and	O
development	O
.	O

Mechanosensitive	O
(	O
MS	O
)	O
ion	O
channels	O
provide	O
a	O
conserved	O
mechanism	O
for	O
regulating	O
osmotic	O
forces	O
by	O
conducting	O
ions	O
in	O
response	O
to	O
increased	O
membrane	O
tension	O
.	O

We	O
previously	O
demonstrated	O
that	O
the	O
MS	O
ion	O
channel	O
MscS	O
-	O
Like	O
8	O
(	O
MSL8	O
)	O
is	O
required	O
for	O
pollen	O
to	O
survive	O
multiple	O
osmotic	O
challenges	O
that	O
occur	O
during	O
the	O
normal	O
process	O
of	O
fertilization	O
,	O
and	O
that	O
it	O
can	O
inhibit	O
pollen	O
germination	O
.	O

However	O
,	O
it	O
remained	O
unclear	O
whether	O
these	O
physiological	O
functions	O
required	O
ion	O
flux	O
through	O
a	O
mechanically	O
gated	O
channel	O
provided	O
by	O
MSL8	O
.	O

We	O
introduced	O
two	O
point	O
mutations	B-Var
into	O
the	O
predicted	O
pore	O
-	O
lining	O
domain	O
of	O
MSL8	B-Gene
that	O
disrupted	B-NegReg
normal	B-MPA
channel	I-MPA
function	I-MPA
in	O
different	O
ways	O
.	O

The	O
Ile711Ser	B-Var
mutation	O
increased	B-PosReg
the	O
tension	B-MPA
threshold	I-MPA
of	O
the	O
MSL8	B-Gene
channel	O
while	O
leaving	B-Reg
conductance	B-MPA
unchanged	I-MPA
,	O
and	O
the	O
Phe720Leu	B-Var
mutation	I-Var
severely	O
disrupted	B-NegReg
the	O
MSL8	B-Gene
channel	B-Pathway
.	O

Both	O
of	O
these	O
mutations	B-Var
impaired	B-NegReg
the	O
ability	B-MPA
of	O
MSL8	O
to	O
preserve	O
pollen	O
viability	O
during	O
hydration	O
and	O
to	O
maintain	B-Reg
the	O
integrity	B-MPA
of	O
the	O
pollen	O
tube	O
when	O
expressed	O
at	O
endogenous	O
levels	O
.	O

When	O
overexpressed	O
in	O
an	O
msl8	O
-	O
4	O
null	O
background	O
,	O
MSL8I711S	O
could	O
partially	O
rescue	O
loss	O
-	O
of	O
-	O
function	O
phenotypes	O
,	O
while	O
MSL8F720L	O
could	O
not	O
.	O

When	O
overexpressed	O
in	O
the	O
wild	O
-	O
type	O
Ler	O
background	O
,	O
MSL8I711S	O
suppressed	O
pollen	O
germination	O
,	O
similar	O
to	O
wild	O
-	O
type	O
MSL8	O
.	O

In	O
contrast	O
,	O
MSL8F720L	O
failed	O
to	O
suppress	O
pollen	O
germination	O
and	O
increased	O
pollen	O
bursting	O
,	O
thereby	O
phenocopying	O
the	O
msl8	O
-	O
4	O
mutant	O
.	O

Thus	O
,	O
an	O
intact	O
MSL8	O
channel	O
is	O
required	O
for	O
normal	O
pollen	O
function	O
during	O
hydration	O
and	O
germination	O
.	O

These	O
data	O
establish	O
MSL8	O
as	O
the	O
first	O
plant	O
MS	O
channel	O
to	O
fulfill	O
previously	O
established	O
criteria	O
for	O
assignment	O
as	O
a	O
mechanotransducer	O
.	O

RACK1	O
cooperates	O
with	O
NRAS(Q61	O
K	O
)	O
to	O
promote	O
melanoma	O
in	O
vivo	O
.	O

Melanoma	O
is	O
the	O
deadliest	O
skin	O
cancer	O
.	O

RACK1	O
(	O
Receptor	O
for	O
activated	O
protein	O
kinase	O
C	O
)	O
protein	O
was	O
proposed	O
as	O
a	O
biological	O
marker	O
of	O
melanoma	O
in	O
human	O
and	O
domestic	O
animal	O
species	O
harboring	O
spontaneous	O
melanomas	O
.	O

As	O
a	O
scaffold	O
protein	O
,	O
RACK1	O
is	O
able	O
to	O
coordinate	O
the	O
interaction	O
of	O
key	O
signaling	O
molecules	O
implicated	O
in	O
both	O
physiological	O
cellular	O
functions	O
and	O
tumorigenesis	O
.	O

A	O
role	O
for	O
RACK1	O
in	O
rewiring	O
ERK	O
and	O
JNK	O
signaling	O
pathways	O
in	O
melanoma	O
cell	O
lines	O
had	O
been	O
proposed	O
.	O

Here	O
,	O
we	O
used	O
a	O
genetic	O
approach	O
to	O
test	O
this	O
hypothesis	O
in	O
vivo	O
in	O
the	O
mouse	O
.	O

We	O
show	O
that	O
Rack1	B-Gene
knock	B-Var
-	I-Var
down	I-Var
in	O
the	O
mouse	O
melanoma	O
cell	O
line	O
B16	O
reduces	B-NegReg
invasiveness	B-MPA
and	O
induces	B-Reg
cell	B-MPA
differentiation	I-MPA
.	O

We	O
have	O
developed	O
the	O
first	O
mouse	O
model	O
for	O
RACK1	O
gain	O
of	O
function	O
,	O
Tyr::Rack1-HA	O
transgenic	O
mice	O
,	O
targeting	O
RACK1	O
to	O
melanocytes	O
in	O
vivo	O
.	O

RACK1	O
overexpression	O
was	O
not	O
sufficient	O
to	O
initiate	O
melanomas	O
despite	O
activated	O
ERK	O
and	O
AKT	O
.	O

However	O
,	O
in	O
a	O
context	O
of	O
melanoma	O
predisposition	O
,	O
RACK1	O
overexpression	O
reduced	O
latency	O
and	O
increased	O
incidence	O
and	O
metastatic	O
rate	O
.	O

In	O
primary	O
melanoma	O
cells	O
from	O
Tyr::Rack1-HA	O
,	O
Tyr::NRas(Q61	O
K	O
)	O
mice	O
,	O
activated	O
JNK	O
(	O
c	O
-	O
Jun	O
N	O
-	O
terminal	O
kinase	O
)	O
and	O
activated	O
STAT3	O
(	O
signal	O
transducer	O
and	O
activator	O
of	O
transcription	O
3	O
)	O
acted	O
as	O
RACK1	O
oncogenic	O
partners	O
in	O
tumoral	O
progression	O
.	O

A	O
sequential	O
and	O
coordinated	O
activation	O
of	O
ERK	O
,	O
JNK	O
and	O
STAT3	O
with	O
RACK1	O
is	O
shown	O
to	O
accelerate	O
aggressive	O
melanoma	O
development	O
in	O
vivo	O
.	O

Identification	O
and	O
characterization	O
of	O
a	O
novel	O
DGAT1	O
missense	O
mutation	O
associated	O
with	O
congenital	O
diarrhea	O
.	O

Acyl	O
-	O
CoA	O
:	O
diacylglycerol	O
acyltransferase	O
(	O
DGAT)1	O
and	O
DGAT2	O
catalyze	O
triglyceride	O
(	O
TG	O
)	O
biosynthesis	O
in	O
humans	O
.	O

Biallelic	O
loss	B-NegReg
-	I-NegReg
of	I-NegReg
-	I-NegReg
function	I-NegReg
mutations	B-Var
in	O
human	O
DGAT1	B-Gene
result	O
in	O
severe	O
congenital	B-Disease
diarrhea	I-Disease
and	O
protein	B-Disease
-	I-Disease
losing	I-Disease
enteropathy	I-Disease
.	O

Additionally	O
,	O
pharmacologic	O
inhibition	O
of	O
DGAT1	O
led	O
to	O
dose	O
-	O
related	O
diarrhea	O
in	O
human	O
clinical	O
trials	O
.	O

Here	O
we	O
identify	O
a	O
previously	O
unknown	O
DGAT1	O
mutation	O
in	O
identical	O
twins	O
of	O
South	O
Asian	O
descent	O
.	O

These	O
male	O
patients	O
developed	O
watery	O
diarrhea	O
shortly	O
after	O
birth	O
,	O
with	O
protein	O
-	O
losing	O
enteropathy	O
and	O
failure	O
to	O
thrive	O
.	O

Exome	O
sequencing	O
revealed	O
a	O
homozygous	O
recessive	O
mutation	O
in	O
DGAT1	O
,	O
c.314T	O
>	O
C	O
,	O
p	O
.	O
L105P.	O

We	O
show	O
here	O
that	O
the	O
p	B-Var
.	I-Var
L105P	I-Var
DGAT1	B-Gene
enzyme	O
produced	O
from	O
the	O
mutant	B-Var
allele	O
is	O
less	B-NegReg
abundant	O
,	O
resulting	O
in	O
partial	O
loss	B-NegReg
of	O
TG	B-MPA
synthesis	I-MPA
activity	I-MPA
and	O
decreased	B-NegReg
formation	B-MPA
of	I-MPA
lipid	I-MPA
droplets	I-MPA
in	O
patient	O
-	O
derived	O
primary	O
dermal	O
fibroblasts	O
.	O

Thus	O
,	O
in	O
contrast	O
with	O
complete	O
loss	O
-	O
of	O
-	O
function	O
alleles	O
of	O
DGAT1	O
,	O
the	O
p	B-Var
.	I-Var
L105P	I-Var
missense	I-Var
allele	O
partially	O
reduces	B-NegReg
TG	B-MPA
synthesis	I-MPA
activity	I-MPA
and	O
causes	B-Reg
a	O
less	B-MPA
severe	I-MPA
clinical	I-MPA
phenotype	I-MPA
.	O

Our	O
findings	O
add	O
to	O
the	O
growing	O
recognition	O
of	O
DGAT1	B-Gene
deficiency	B-Var
as	O
a	O
cause	B-Reg
of	O
congenital	B-Disease
diarrhea	I-Disease
with	O
protein	B-Disease
-	I-Disease
losing	I-Disease
enteropathy	I-Disease
and	O
indicate	O
that	O
DGAT1	B-Gene
mutations	B-Var
result	B-Reg
in	I-Reg
a	O
spectrum	B-Disease
of	I-Disease
diseases	I-Disease
.	O

Hydrocephalus	B-Disease
due	O
to	O
multiple	O
ependymal	O
malformations	O
is	O
caused	B-Reg
by	I-Reg
mutations	B-Var
in	O
the	O
MPDZ	B-Gene
gene	O
.	O

Congenital	O
hydrocephalus	O
is	O
considered	O
as	O
either	O
acquired	O
due	O
to	O
haemorrhage	O
,	O
infection	O
or	O
neoplasia	O
or	O
as	O
of	O
developmental	O
nature	O
and	O
is	O
divided	O
into	O
two	O
subgroups	O
,	O
communicating	O
and	O
obstructive	O
.	O

Congenital	O
hydrocephalus	O
is	O
either	O
syndromic	O
or	O
non	O
-	O
syndromic	O
,	O
and	O
in	O
the	O
latter	O
no	O
cause	O
is	O
found	O
in	O
more	O
than	O
half	O
of	O
the	O
patients	O
.	O

In	O
patients	O
with	O
isolated	B-Disease
hydrocephalus	I-Disease
,	O
L1CAM	B-Gene
mutations	B-Var
represent	O
the	O
most	O
common	B-Reg
aetiology	O
.	O

More	O
recently	O
,	O
a	O
founder	O
mutation	O
has	O
also	O
been	O
reported	O
in	O
the	O
MPDZ	O
gene	O
in	O
foetuses	O
presenting	O
massive	O
hydrocephalus	O
,	O
but	O
the	O
neuropathology	O
remains	O
unknown	O
.	O

We	O
describe	O
here	O
three	O
novel	O
homozygous	O
null	O
mutations	O
in	O
the	O
MPDZ	O
gene	O
in	O
foetuses	O
whose	O
post	O
-	O
mortem	O
examination	O
has	O
revealed	O
a	O
homogeneous	O
phenotype	O
characterized	O
by	O
multiple	O
ependymal	O
malformations	O
along	O
the	O
aqueduct	O
of	O
Sylvius	O
,	O
the	O
third	O
and	O
fourth	O
ventricles	O
as	O
well	O
as	O
the	O
central	O
canal	O
of	O
the	O
medulla	O
,	O
consisting	O
in	O
multifocal	O
rosettes	O
with	O
immature	O
cell	O
accumulation	O
in	O
the	O
vicinity	O
of	O
ependymal	O
lining	O
early	O
detached	O
from	O
the	O
ventricular	O
zone	O
.	O

MPDZ	O
also	O
named	O
MUPP1	O
is	O
an	O
essential	O
component	O
of	O
tight	O
junctions	O
which	O
are	O
expressed	O
from	O
early	O
brain	O
development	O
in	O
the	O
choroid	O
plexuses	O
and	O
ependyma	O
.	O

Alterations	O
in	O
the	O
formation	O
of	O
tight	O
junctions	O
within	O
the	O
ependyma	O
very	O
likely	O
account	O
for	O
the	O
lesions	O
observed	O
and	O
highlight	O
for	O
the	O
first	O
time	O
that	O
primary	O
multifocal	O
ependymal	O
malformations	O
of	O
the	O
ventricular	O
system	O
is	O
genetically	O
determined	O
in	O
humans	O
.	O

Therefore	O
,	O
MPDZ	O
sequencing	O
should	O
be	O
performed	O
when	O
neuropathological	O
examination	O
reveals	O
multifocal	O
ependymal	O
rosette	O
formation	O
within	O
the	O
aqueduct	O
of	O
Sylvius	O
,	O
of	O
the	O
third	O
and	O
fourth	O
ventricles	O
and	O
of	O
the	O
central	O
canal	O
of	O
the	O
medulla	O
.	O

Short	O
hairpin	O
RNA	O
is	O
more	O
effective	O
than	O
long	O
hairpin	O
RNA	O
in	O
eliciting	O
pointed	O
loss	O
-	O
of	O
-	O
function	O
phenotypes	O
in	O
Drosophila	O
.	O

Pointed	O
(	O
Pnt	O
)	O
is	O
a	O
transcriptional	O
activator	O
that	O
functions	O
downstream	O
of	O
the	O
highly	O
conserved	O
Receptor	O
Tyrosine	O
Kinase	O
(	O
RTK	O
)	O
signaling	O
pathway	O
.	O

Pnt	O
is	O
an	O
ETS	O
family	O
transcription	O
factor	O
and	O
encodes	O
for	O
two	O
proteins	O
,	O
PntP1	O
and	O
PntP2	O
.	O

However	O
,	O
while	O
PntP1	O
is	O
constitutively	O
active	O
,	O
PntP2	O
is	O
only	O
active	O
after	O
being	O
phosphorylated	O
by	O
MAPK	O
in	O
the	O
RTK	O
pathway	O
.	O

As	O
mutations	B-Var
in	O
pnt	B-Gene
perturb	B-Reg
the	O
development	B-CPA
of	I-CPA
several	I-CPA
tissues	I-CPA
,	O
we	O
wanted	O
to	O
examine	O
the	O
effect	O
and	O
efficacy	O
of	O
using	O
RNAi	O
to	O
target	O
Pnt	O
.	O

We	O
have	O
expressed	O
pnt	O
RNAi	O
in	O
the	O
eyes	O
,	O
oocyte	O
,	O
and	O
heart	O
cells	O
using	O
three	O
different	O
RNAi	O
lines	O
:	O
Valium20	O
,	O
Valium10	O
,	O
and	O
VDRC	O
.	O

Valium20	O
is	O
distinct	O
since	O
it	O
generates	O
a	O
short	O
hairpin	O
RNA	O
(	O
shRNA	O
)	O
,	O
while	O
Valium10	O
and	O
VDRC	O
produce	O
long	O
hairpin	O
dsRNA	O
.	O

We	O
found	O
that	O
for	O
each	O
tissue	O
examined	O
Valium20	O
exhibited	O
the	O
strongest	O
phenotype	O
while	O
the	O
Valium10	O
and	O
VDRC	O
lines	O
produced	O
varying	O
levels	O
of	O
severity	O
and	O
that	O
the	O
long	O
hairpin	O
RNA	O
produced	O
by	O
the	O
Valium10	O
and	O
VDRC	O
lines	O
are	O
unable	O
to	O
effectively	O
knockdown	O
pnt	O
in	O
embryonic	O
tissues	O
.	O

New	O
gain	B-PosReg
-	I-PosReg
of	I-PosReg
-	I-PosReg
function	I-PosReg
mutation	B-Var
shows	O
CACNA1D	B-Gene
as	O
recurrently	O
mutated	O
gene	O
in	O
autism	B-Disease
spectrum	I-Disease
disorders	I-Disease
and	O
epilepsy	B-Disease
.	O

CACNA1D	O
encodes	O
the	O
pore	O
-	O
forming	O
α1-subunit	O
of	O
Cav1.3	O
,	O
an	O
L	O
-	O
type	O
voltage	O
-	O
gated	O
Ca2	O
+	O
-channel	O
.	O

Despite	O
the	O
recent	O
discovery	O
of	O
two	O
de	O
novo	O
missense	O
gain	O
-	O
of	O
-	O
function	O
mutations	O
in	O
Cav1.3	O
in	O
two	O
individuals	O
with	O
autism	O
spectrum	O
disorder	O
(	O
ASD	O
)	O
and	O
intellectual	O
disability	O
CACNA1D	O
has	O
not	O
been	O
considered	O
a	O
prominent	O
ASD	O
-	O
risk	O
gene	O
in	O
large	O
scale	O
genetic	O
analyses	O
,	O
since	O
such	O
studies	O
primarly	O
focus	O
on	O
likely	O
-	O
disruptive	O
genetic	O
variants	O
.	O

Here	O
we	O
report	O
the	O
discovery	O
and	O
characterization	O
of	O
a	O
third	O
de	O
novo	O
missense	O
mutation	O
in	O
CACNA1D	O
(	O
V401L	O
)	O
in	O
a	O
patient	O
with	O
ASD	O
and	O
epilepsy	O
.	O

For	O
the	O
functional	O
characterization	O
we	O
introduced	O
mutation	O
V401L	O
into	O
two	O
major	O
C	O
-	O
terminal	O
long	O
and	O
short	O
Cav1.3	O
splice	O
variants	O
,	O
expressed	O
wild	O
-	O
type	O
or	O
mutant	O
channel	O
complexes	O
in	O
tsA-201	O
cells	O
and	O
performed	O
whole	O
-	O
cell	O
patch	O
-	O
clamp	O
recordings	O
.	O

Mutation	O
V401L	B-Var
,	O
localized	O
within	O
the	O
channel	O
's	O
activation	O
gate	O
,	O
significantly	O
enhanced	B-PosReg
current	B-MPA
densities	I-MPA
,	O
shifted	O
voltage	O
dependence	O
of	O
activation	O
and	O
inactivation	O
to	O
more	O
negative	O
voltages	O
and	O
reduced	O
channel	O
inactivation	O
in	O
both	O
Cav1.3	O
splice	O
variants	O
.	O

Altogether	O
these	O
gating	O
changes	B-Var
are	O
expected	O
to	O
result	O
in	O
enhanced	B-PosReg
Ca2	B-MPA
+	I-MPA
-influx	I-MPA
through	I-MPA
the	I-MPA
channel	I-MPA
,	O
thus	O
representing	O
a	O
strong	O
gain	O
-	O
of	O
-	O
function	O
phenotype	O
.	O

Additionally	O
,	O
we	O
also	O
found	O
that	O
mutant	O
channels	O
retained	O
full	O
sensitivity	O
towards	O
the	O
clinically	O
available	O
Ca2	O
+	O
-channel	O
blocker	O
isradipine	O
.	O

Our	O
findings	O
strengthen	O
the	O
evidence	O
for	O
CACNA1D	O
as	O
a	O
novel	O
candidate	O
autism	O
risk	O
gene	O
and	O
encourage	O
experimental	O
therapy	O
with	O
available	O
channel	O
-	O
blockers	O
for	O
this	O
mutation	O
.	O

The	O
additional	O
presence	O
of	O
seizures	O
and	O
neurological	O
abnormalities	O
in	O
our	O
patient	O
define	O
a	O
novel	O
phenotype	O
partially	O
overlapping	O
with	O
symptoms	O
in	O
two	O
individuals	O
with	O
PASNA	O
(	O
congential	O
primary	O
aldosteronism	O
,	O
seizures	O
and	O
neurological	O
abnormalities	O
)	O
caused	O
by	O
similar	O
Cav1.3	O
gain	O
-	O
of	O
-	O
function	O
mutations	O
.	O

Proteomic	O
analysis	O
of	O
filaggrin	O
deficiency	O
identifies	O
molecular	O
signatures	O
characteristic	O
of	O
atopic	O
eczema	O
.	O

BACKGROUND	O
:	O
Atopic	B-Disease
eczema	I-Disease
(	O
AE	O
)	O
is	O
characterized	O
by	O
skin	O
barrier	O
and	O
immune	O
dysfunction	O
.	O

Null	B-Var
mutations	I-Var
in	O
filaggrin	O
(	B-Gene
FLG	I-Gene
)	I-Gene
,	O
a	O
key	O
epidermal	O
barrier	O
protein	O
,	O
strongly	O
predispose	B-Reg
to	O
AE	B-Disease
;	I-Disease
however	O
,	O
the	O
precise	O
role	O
of	O
FLG	O
deficiency	O
in	O
AE	O
pathogenesis	O
remains	O
incompletely	O
understood	O
.	O

OBJECTIVES	O
:	O
We	O
sought	O
to	O
identify	O
global	O
proteomic	O
changes	O
downstream	O
of	O
FLG	O
deficiency	O
in	O
human	O
epidermal	O
living	O
skin	O
-	O
equivalent	O
(	O
LSE	O
)	O
models	O
and	O
validate	O
findings	O
in	O
skin	O
of	O
patients	O
with	O
AE	O
.	O

METHODS	O
:	O
Differentially	O
expressed	O
proteins	O
from	O
paired	O
control	O
(	O
nontargeting	O
control	O
short	O
hairpin	O
RNA	O
[	O
shNT	O
]	O
)	O
and	O
FLG	O
knockdown	O
(	O
FLG	O
knockdown	O
short	O
hairpin	O
RNA	O
[	O
shFLG	O
]	O
)	O
LSEs	O
were	O
identified	O
by	O
means	O
of	O
proteomic	O
analysis	O
(	O
liquid	O
chromatography	O
-	O
mass	O
spectrometry	O
)	O
and	O
Ingenuity	O
Pathway	O
Analysis	O
.	O

Expression	O
of	O
key	O
targets	O
was	O
validated	O
in	O
independent	O
LSE	O
samples	O
(	O
quantitative	O
RT	O
-	O
PCR	O
and	O
Western	O
blotting	O
)	O
and	O
in	O
normal	O
and	O
AE	O
skin	O
biopsy	O
specimens	O
(	O
immunofluorescence	O
)	O
.	O

RESULTS	O
:	O
Proteomic	O
analysis	O
identified	O
17	O
(	O
P	O
≤	O
.05	O
)	O
differentially	O
expressed	O
proteins	O
after	O
FLG	O
knockdown	O
,	O
including	O
kallikrein-7	O
(	O
KLK7	O
;	O
2.2-fold	O
)	O
,	O
cyclophilin	O
A	O
(	O
PPIA	O
;	O
0.9-fold	O
)	O
,	O
and	O
cofilin-1	O
(	O
CFL1	O
,	O
1.3-fold	O
)	O
.	O

Differential	O
protein	O
expression	O
was	O
confirmed	O
in	O
shNT	O
/	O
shFLG	O
LSEs	O
;	O
however	O
,	O
only	O
KLK7	O
was	O
transcriptionally	O
dysregulated	O
.	O

Molecular	B-Pathway
pathways	I-Pathway
overrepresented	B-PosReg
after	O
FLG	B-Gene
knockdown	B-Var
included	O
inflammation	O
,	O
protease	O
activity	O
,	O
cell	O
structure	O
,	O
and	O
stress	O
.	O

Furthermore	O
,	O
KLK7	O
(	O
1.8-fold	O
)	O
and	O
PPIA	O
(	O
0.65-fold	O
)	O
proteins	O
were	O
differentially	O
expressed	O
in	O
lesional	O
biopsy	O
specimens	O
from	O
patients	O
with	O
AE	O
relative	O
to	O
normal	O
skin	O
.	O

CONCLUSIONS	O
:	O
For	O
the	O
first	O
time	O
,	O
we	O
show	O
that	O
loss	B-Var
of	O
FLG	B-Gene
in	O
the	O
absence	O
of	O
inflammation	O
is	O
sufficient	O
to	O
alter	B-Reg
the	O
expression	B-MPA
level	I-MPA
of	I-MPA
proteins	I-MPA
relevant	O
to	O
the	O
pathogenesis	O
of	O
AE	O
.	O

These	O
include	O
proteins	O
regulating	O
inflammatory	O
,	O
proteolytic	O
,	O
and	O
cytoskeletal	O
functions	O
.	O

We	O
identify	O
PPIA	O
as	O
a	O
novel	O
protein	O
with	O
levels	O
that	O
are	O
decreased	O
in	O
clinically	O
active	O
AE	O
skin	O
and	O
show	O
that	O
the	O
characteristic	O
upregulation	O
of	O
KLK7	O
expression	O
in	O
patients	O
with	O
AE	O
occurs	O
downstream	O
of	O
FLG	O
loss	O
.	O

Importantly	O
,	O
we	O
highlight	O
disconnect	O
between	O
the	O
epidermal	O
proteome	O
and	O
transcriptome	O
,	O
emphasizing	O
the	O
utility	O
of	O
global	O
proteomic	O
studies	O
.	O

TREM2	O
deficiency	O
impairs	O
chemotaxis	O
and	O
microglial	O
responses	O
to	O
neuronal	O
injury	O
.	O

Sequence	O
variations	B-Var
in	O
the	O
triggering	O
receptor	O
expressed	O
on	O
myeloid	O
cells	O
2	O
(	B-Gene
TREM2	I-Gene
)	I-Gene
have	O
been	O
linked	B-Reg
to	I-Reg
an	O
increased	O
risk	O
for	O
neurodegenerative	O
disorders	O
such	O
as	O
Alzheimer	B-Disease
's	I-Disease
disease	I-Disease
and	O
frontotemporal	B-Disease
lobar	I-Disease
degeneration	I-Disease
.	O

In	O
the	O
brain	O
,	O
TREM2	O
is	O
predominantly	O
expressed	O
in	O
microglia	O
.	O

Several	O
disease	O
-	O
associated	O
TREM2	B-Gene
variants	B-Var
result	O
in	O
a	O
loss	O
of	O
function	O
by	O
reducing	B-NegReg
microglial	B-CPA
phagocytosis	I-CPA
,	O
impairing	B-NegReg
lipid	B-MPA
sensing	I-MPA
,	O
preventing	B-NegReg
binding	B-Interaction
of	O
lipoproteins	B-Protein
and	O
affecting	B-Reg
shielding	B-MPA
of	I-MPA
amyloid	I-MPA
plaques	I-MPA
.	O

We	O
here	O
investigate	O
the	O
consequences	O
of	O
TREM2	O
loss	O
of	O
function	O
on	O
the	O
microglia	O
transcriptome	O
.	O

Among	O
the	O
differentially	O
expressed	O
messenger	O
RNAs	O
in	O
wild	O
-	O
type	O
and	O
Trem2(-/-	O
)	O
microglia	O
,	O
gene	O
clusters	O
are	O
identified	O
which	O
represent	O
gene	O
functions	O
in	O
chemotaxis	O
,	O
migration	O
and	O
mobility	O
.	O

Functional	O
analyses	O
confirm	O
that	O
loss	B-Var
of	O
TREM2	B-Gene
impairs	B-NegReg
appropriate	O
microglial	B-CPA
responses	I-CPA
to	I-CPA
injury	I-CPA
and	I-CPA
signals	I-CPA
that	O
normally	O
evoke	O
chemotaxis	O
on	O
multiple	O
levels	O
.	O

In	O
an	O
ex	O
vivo	O
organotypic	O
brain	O
slice	O
assay	O
,	O
absence	O
of	O
TREM2	O
reduces	O
the	O
distance	O
migrated	O
by	O
microglia	O
.	O

Moreover	O
,	O
migration	O
towards	O
defined	O
chemo	O
-	O
attractants	O
is	O
reduced	O
upon	O
ablation	O
of	O
TREM2	O
and	O
can	O
be	O
rescued	O
by	O
TREM2	O
re	O
-	O
expression	O
.	O

In	O
vivo	O
,	O
microglia	O
lacking	O
TREM2	O
migrate	O
less	O
towards	O
injected	O
apoptotic	O
neurons	O
,	O
and	O
outgrowth	O
of	O
microglial	O
processes	O
towards	O
sites	O
of	O
laser	O
-	O
induced	O
focal	O
CNS	O
damage	O
in	O
the	O
somatosensory	O
cortex	O
is	O
slowed	O
.	O

The	O
apparent	O
lack	O
of	O
chemotactic	O
stimulation	O
upon	O
depletion	O
of	O
TREM2	O
is	O
consistent	O
with	O
a	O
stable	O
expression	O
profile	O
of	O
genes	O
characterizing	O
the	O
homoeostatic	O
signature	O
of	O
microglia	O
.	O

Novel	O
loss	B-NegReg
of	I-NegReg
function	I-NegReg
mutation	B-Var
in	O
KRIT1	B-Gene
/	I-Gene
CCM1	I-Gene
is	O
associated	B-Reg
with	I-Reg
distinctly	O
progressive	O
cerebral	B-Disease
and	I-Disease
spinal	I-Disease
cavernous	I-Disease
malformations	I-Disease
after	O
radiochemotherapy	O
for	O
intracranial	O
malignant	O
germ	O
cell	O
tumor	O
.	O

PURPOSE	O
:	O
Cerebrospinal	B-Disease
cavernous	I-Disease
malformations	I-Disease
(	O
CCMs	O
)	O
are	O
vascular	O
lesions	O
characterized	O
by	O
dilated	O
and	O
leaky	O
capillary	O
caverns	O
.	O

CCMs	O
can	O
cause	O
seizures	O
,	O
focal	O
neurological	O
deficits	O
or	O
acute	O
intracranial	O
hemorrhage	O
;	O
however	O
,	O
most	O
patients	O
are	O
asymptomatic	O
.	O

CCMs	O
occur	O
either	O
sporadically	O
or	O
as	O
a	O
familial	O
autosomal	O
-	O
dominant	O
disorder	O
.	O

We	O
present	O
a	O
clinical	O
and	O
molecular	O
study	O
of	O
a	O
patient	O
with	O
distinctive	O
cerebral	O
and	O
spinal	O
cavernous	O
malformations	O
following	O
radiochemotherapy	O
for	O
a	O
malignant	O
brain	O
tumor	O
.	O

METHODS	O
:	O
The	O
patient	O
had	O
multiple	O
magnet	O
resonance	O
imaging	O
(	O
MRI	O
)	O
examinations	O
of	O
his	O
brain	O
and	O
spine	O
following	O
radiochemotherapy	O
for	O
a	O
primary	O
intracranial	O
germ	O
cell	O
tumor	O
(	O
GCT	O
)	O
,	O
as	O
part	O
of	O
his	O
oncologic	O
follow	O
-	O
up	O
.	O

The	O
MRI	O
sequences	O
included	O
susceptibility	O
-	O
weighted	O
imaging	O
(	O
SWI	O
)	O
.	O

The	O
coding	O
exons	O
and	O
their	O
flanking	O
intronic	O
regions	O
of	O
KRIT1	O
/	O
CCM1	O
gene	O
were	O
analyzed	O
for	O
mutations	O
by	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
and	O
direct	O
sequencing	O
.	O

RESULTS	O
:	O
MRI	O
revealed	O
numerous	O
cerebral	O
and	O
spinal	O
microhemorrhages	O
and	O
pronounced	O
cavernous	O
malformations	O
that	O
progressed	O
with	O
subsequent	O
follow	O
-	O
up	O
imaging	O
.	O

Genetic	O
analysis	O
demonstrated	O
a	O
novel	O
heterozygous	O
KRIT1	B-Gene
/	I-Gene
CCM1	I-Gene
two	O
base	O
pair	O
deletion	O
(	B-Var
c.1535_1536delTG	I-Var
)	I-Var
in	O
exon	O
14	O
.	O

This	O
deletion	O
leads	B-Reg
to	I-Reg
a	O
frameshift	B-Var
with	O
a	O
premature	B-MPA
stop	I-MPA
codon	I-MPA
at	O
nucleotide	O
position	O
1553	O
and	O
a	O
highly	O
likely	O
loss	B-NegReg
of	I-NegReg
function	I-NegReg
of	O
the	O
KRIT1	B-Protein
protein	I-Protein
.	O

CONCLUSION	O
:	O
We	O
describe	O
a	O
patient	O
with	O
a	O
novel	O
heterozygous	O
germ	O
line	O
loss	B-NegReg
of	I-NegReg
function	I-NegReg
mutation	B-Var
in	O
KRIT1	B-Gene
,	O
which	O
is	O
associated	B-Reg
with	I-Reg
rapid	O
-	O
onset	O
and	O
highly	O
progressive	O
CCMs	B-Disease
after	O
radiochemotherapy	O
for	O
a	O
malignant	O
brain	O
tumor	O
.	O

Real	O
-	O
World	O
Data	O
on	O
Prognostic	O
Factors	O
for	O
Overall	O
Survival	O
in	O
EGFR	B-Gene
Mutation	B-Reg
-	I-Reg
Positive	I-Reg
Advanced	O
Non	B-Disease
-	I-Disease
Small	I-Disease
Cell	I-Disease
Lung	I-Disease
Cancer	I-Disease
Patients	O
Treated	O
with	O
First	O
-	O
Line	O
Gefitinib	O
.	O

BACKGROUND	O
:	O
This	O
study	O
aimed	O
to	O
identify	O
independent	O
prognostic	O
factors	O
for	O
overall	O
survival	O
(	O
OS	O
)	O
of	O
patients	O
with	O
advanced	O
non	O
-	O
small	O
cell	O
lung	O
cancer	O
(	O
NSCLC	O
)	O
harboring	O
an	O
activating	O
epidermal	O
growth	O
factor	O
receptor	O
(	O
EGFR	O
)	O
mutation	O
and	O
receiving	O
gefitinib	O
as	O
first	O
-	O
line	O
treatment	O
in	O
real	O
-	O
world	O
practice	O
.	O

MATERIALS	O
AND	O
METHODS	O
:	O
We	O
enrolled	O
226	O
patients	O
from	O
June	O
2011	O
to	O
May	O
2013	O
.	O

During	O
this	O
period	O
,	O
gefitinib	O
was	O
the	O
only	O
EGFR	O
-	O
tyrosine	O
kinase	O
inhibitor	O
reimbursed	O
by	O
the	O
Bureau	O
of	O
National	O
Health	O
Insurance	O
of	O
Taiwan	O
.	O

RESULTS	O
:	O
The	O
median	O
progression	O
-	O
free	O
survival	O
and	O
median	O
OS	O
were	O
11.9	O
months	O
(	O
95	O
%	O
confidence	O
interval	O
[	O
CI	O
]	O
:	O
9.7	O
-	O
14.2	O
)	O
and	O
26.9	O
months	O
(	O
21.2	O
-	O
32.5	O
)	O
,	O
respectively	O
.	O

The	O
Cox	O
proportional	O
hazards	O
regression	O
model	O
revealed	O
that	O
postoperative	O
recurrence	O
,	O
performance	O
status	O
(	O
Eastern	O
Cooperative	O
Oncology	O
Grade	O
[	O
ECOG	O
]	O
≥2	O
)	O
,	O
smoking	O
index	O
(	O
≥20	O
pack	O
-	O
years	O
)	O
,	O
liver	O
metastasis	O
at	O
initial	O
diagnosis	O
,	O
and	O
chronic	O
hepatitis	O
C	O
virus	O
(	O
HCV	O
)	O
infection	O
were	O
independent	O
prognostic	O
factors	O
for	O
OS	O
(	O
hazard	O
ratio	O
[	O
95	O
%	O
CI	O
]	O
0.3	O
[	O
0.11	O
-	O
0.83	O
]	O
,	O
p	O
=	O
.02	O
;	O
2.69	O
[	O
1.60	O
-	O
4.51	O
]	O
,	O
p	O
<	O
.001	O
;	O
1.92	O
[	O
1.24	O
-	O
2.97	O
]	O
,	O
p	O
=	O
.003	O
;	O
2.26	O
[	O
1.34	O
-	O
3.82	O
]	O
,	O
p	O
=	O
.002	O
;	O
3.38	O
[	O
1.85	O
-	O
7.78	O
]	O
,	O
p	O
<	O
.001	O
,	O
respectively	O
)	O
.	O

However	O
,	O
brain	O
metastasis	O
(	O
BM	O
)	O
at	O
initial	O
diagnosis	O
or	O
intracranial	O
progression	O
during	O
gefitinib	O
treatment	O
had	O
no	O
impact	O
on	O
OS	O
(	O
1.266	O
[	O
0.83	O
-	O
1.93	O
]	O
,	O
p	O
=	O
.275	O
and	O
0.75	O
[	O
0.48	O
-	O
1.19	O
]	O
,	O
p	O
=	O
.211	O
,	O
respectively	O
)	O
.	O

CONCLUSION	O
:	O
HCV	O
infection	O
,	O
performance	O
status	O
(	O
ECOG	O
≥2	O
)	O
,	O
newly	O
diagnosed	O
advanced	O
NSCLC	O
without	O
prior	O
operation	O
,	O
and	O
liver	O
metastasis	O
predicted	O
poor	O
OS	O
in	O
EGFR	O
mutation	O
-	O
positive	O
advanced	O
NSCLC	O
patients	O
treated	O
with	O
first	O
-	O
line	O
gefitinib	O
;	O
however	O
,	O
neither	O
BM	O
at	O
initial	O
diagnosis	O
nor	O
intracranial	O
progression	O
during	O
gefitinib	O
treatment	O
had	O
an	O
impact	O
on	O
OS	O
.	O

The	O
Oncologist	O
2017;22:1	O
-	O
9	O
IMPLICATIONS	O
FOR	O
PRACTICE	O
:	O
The	O
finding	O
that	O
chronic	O
hepatitis	O
C	O
virus	O
(	O
HCV	O
)	O
infection	O
might	O
predict	O
poor	O
overall	O
survival	O
(	O
OS	O
)	O
in	O
epidermal	O
growth	O
factor	O
receptor	O
mutation	O
-	O
positive	O
advanced	O
non	O
-	O
small	O
cell	O
lung	O
cancer	O
(	O
NSCLC	O
)	O
patients	O
treated	O
with	O
first	O
-	O
line	O
gefitinib	O
may	O
raise	O
awareness	O
of	O
benefit	O
from	O
anti	O
-	O
HCV	O
treatment	O
in	O
this	O
patient	O
population	O
.	O

Brain	O
metastasis	O
in	O
the	O
initial	O
diagnosis	O
or	O
intracranial	O
progression	O
during	O
gefitinib	O
treatment	O
is	O
not	O
a	O
prognostic	O
factor	O
for	O
OS	O
.	O

This	O
study	O
,	O
which	O
enrolled	O
a	O
real	O
-	O
world	O
population	O
of	O
NSCLC	O
patients	O
,	O
including	O
sicker	O
patients	O
who	O
were	O
not	O
eligible	O
for	O
a	O
clinical	O
trial	O
,	O
may	O
have	O
impact	O
on	O
guiding	O
usual	O
clinical	O
practice	O
.	O

Loss	B-Var
of	O
the	O
homologous	O
recombination	O
gene	O
rad51	B-Gene
leads	B-Reg
to	O
Fanconi	B-Disease
anemia	I-Disease
-	I-Disease
like	I-Disease
symptoms	I-Disease
in	O
zebrafish	O
.	O

RAD51	O
is	O
an	O
indispensable	O
homologous	O
recombination	O
protein	O
,	O
necessary	O
for	O
strand	O
invasion	O
and	O
crossing	O
over	O
.	O

It	O
has	O
recently	O
been	O
designated	O
as	O
a	O
Fanconi	B-Disease
anemia	I-Disease
(	O
FA	O
)	O
gene	O
,	O
following	O
the	O
discovery	O
of	O
two	O
patients	O
carrying	O
dominant	O
-	O
negative	O
mutations	O
.	O

FA	O
is	O
a	O
hereditary	O
DNA	O
-	O
repair	O
disorder	O
characterized	O
by	O
various	O
congenital	O
abnormalities	O
,	O
progressive	O
bone	O
marrow	O
failure	O
,	O
and	O
cancer	O
predisposition	O
.	O

In	O
this	O
report	O
,	O
we	O
describe	O
a	O
viable	O
vertebrate	O
model	O
of	O
RAD51	O
loss	O
.	O

Zebrafish	O
rad51	B-Gene
loss	B-NegReg
-	I-NegReg
of	I-NegReg
-	I-NegReg
function	I-NegReg
mutants	B-Var
developed	O
key	O
features	O
of	O
FA	B-Disease
,	O
including	O
hypocellular	O
kidney	O
marrow	O
,	O
sensitivity	O
to	O
cross	O
-	O
linking	O
agents	O
,	O
and	O
decreased	O
size	O
.	O

We	O
show	O
that	O
some	O
of	O
these	O
symptoms	O
stem	O
from	O
both	O
decreased	O
proliferation	O
and	O
increased	O
apoptosis	O
of	O
embryonic	O
hematopoietic	O
stem	O
and	O
progenitor	O
cells	O
.	O

Comutation	O
of	O
p53	O
was	O
able	O
to	O
rescue	O
the	O
hematopoietic	O
defects	O
seen	O
in	O
the	O
single	O
mutants	O
,	O
but	O
led	O
to	O
tumor	O
development	O
.	O

We	O
further	O
demonstrate	O
that	O
prolonged	O
inflammatory	O
stress	O
can	O
exacerbate	O
the	O
hematological	O
impairment	O
,	O
leading	O
to	O
an	O
additional	O
decrease	O
in	O
kidney	O
marrow	O
cell	O
numbers	O
.	O

These	O
findings	O
strengthen	O
the	O
assignment	O
of	O
RAD51	O
as	O
a	O
Fanconi	O
gene	O
and	O
provide	O
more	O
evidence	O
for	O
the	O
notion	O
that	O
aberrant	O
p53	O
signaling	O
during	O
embryogenesis	O
leads	O
to	O
the	O
hematological	O
defects	O
seen	O
later	O
in	O
life	O
in	O
FA	O
.	O

Further	O
research	O
on	O
this	O
zebrafish	O
FA	O
model	O
will	O
lead	O
to	O
a	O
deeper	O
understanding	O
of	O
the	O
molecular	O
basis	O
of	O
bone	O
marrow	O
failure	O
in	O
FA	O
and	O
the	O
cellular	O
role	O
of	O
RAD51	O
.	O

Gene	O
Co	O
-	O
Expression	O
Network	O
Analysis	O
for	O
Identifying	O
Modules	O
and	O
Functionally	O
Enriched	O
Pathways	O
in	O
SCA2	O
.	O

Spinocerebellar	B-Disease
ataxia	I-Disease
type	I-Disease
2	I-Disease
(	O
SCA2	O
)	O
is	O
an	O
autosomal	O
dominant	O
neurodegenerative	O
disease	O
caused	B-Reg
by	I-Reg
CAG	B-Var
repeat	I-Var
expansion	I-Var
in	O
the	O
ATXN2	B-Gene
gene	O
.	O

The	O
repeat	O
resides	O
in	O
an	O
encoded	O
region	O
of	O
the	O
gene	O
resulting	O
in	O
polyglutamine	O
(	O
polyQ	O
)	O
expansion	O
which	O
has	O
been	O
assumed	O
to	O
result	O
in	O
gain	O
of	O
function	O
,	O
predominantly	O
,	O
for	O
the	O
ATXN2	O
protein	O
.	O

We	O
evaluated	O
temporal	O
cerebellar	O
expression	O
profiles	O
by	O
RNA	O
sequencing	O
of	O
ATXN2Q127	O
mice	O
vs	O
wildtype	O
littermates	O
.	O

ATXN2Q127	O
mice	O
are	O
characterized	O
by	O
a	O
progressive	O
motor	O
phenotype	O
onset	O
,	O
and	O
have	O
progressive	O
cerebellar	O
molecular	O
and	O
neurophysiological	O
(	O
Purkinje	O
cell	O
firing	O
frequency	O
)	O
phenotypes	O
.	O

Our	O
analysis	O
revealed	O
previously	O
uncharacterized	O
early	O
and	O
progressive	O
abnormal	O
patterning	O
of	O
cerebellar	O
gene	O
expression	O
.	O

Weighted	O
Gene	O
Coexpression	O
Network	O
Analysis	O
(	O
WGCNA	O
)	O
revealed	O
four	O
gene	O
modules	O
that	O
were	O
significantly	O
correlated	O
with	O
disease	O
status	O
,	O
composed	O
primarily	O
of	O
genes	O
associated	O
with	O
GTPase	O
signaling	O
,	O
calcium	O
signaling	O
,	O
and	O
cell	O
death	O
.	O

Of	O
these	O
genes	O
,	O
few	O
overlapped	O
with	O
differentially	O
expressed	O
cerebellar	O
genes	O
that	O
we	O
identified	O
in	O
Atxn2-/-	O
knockout	O
mice	O
vs	O
wildtype	O
littermates	O
,	O
suggesting	O
that	O
loss	O
-	O
of	O
-	O
function	O
is	O
not	O
a	O
significant	O
component	O
of	O
disease	O
pathology	O
.	O

We	O
conclude	O
that	O
SCA2	O
is	O
a	O
disease	O
characterized	O
by	O
gain	O
of	O
function	O
for	O
ATXN2	O
.	O

Exposure	O
to	O
phenols	O
,	O
parabens	O
and	O
UV	O
filters	O
:	O
Associations	O
with	O
loss	O
-	O
of	O
-	O
function	O
mutations	O
in	O
the	O
filaggrin	O
gene	O
in	O
men	O
from	O
the	O
general	O
population	O
.	O

BACKGROUND	O
:	O
Filaggrin	O
is	O
an	O
epidermal	O
protein	O
that	O
is	O
important	O
for	O
normal	O
skin	O
barrier	O
functions	O
.	O

Up	O
to	O
10	O
%	O
of	O
Europeans	O
and	O
Asians	O
carry	O
filaggrin	O
gene	O
(	B-Gene
FLG	I-Gene
)	I-Gene
loss	B-NegReg
-	I-NegReg
of	I-NegReg
function	I-NegReg
mutations	B-Var
that	O
appear	O
to	O
facilitate	B-PosReg
trans	B-CPA
-	I-CPA
epidermal	I-CPA
penetration	I-CPA
of	O
certain	O
chemicals	O
.	O

We	O
previously	O
showed	O
that	O
mutation	O
carriers	O
have	O
higher	O
internal	O
exposure	O
to	O
certain	O
phthalates	O
,	O
compared	O
to	O
controls	O
,	O
and	O
hypothesized	O
that	O
they	O
could	O
have	O
increased	O
trans	O
-	O
epidermal	O
penetration	O
of	O
other	O
chemicals	O
.	O

OBJECTIVES	O
:	O
We	O
investigated	O
exposure	O
to	O
non	O
-	O
persistent	O
chemicals	O
in	O
young	O
Danish	O
men	O
with	O
and	O
without	O
FLG	O
mutations	O
.	O

METHODS	O
:	O
Concentrations	O
of	O
eight	O
simple	O
phenols	O
,	O
six	O
parabens	O
and	O
nine	O
UV	O
filters	O
were	O
analysed	O
in	O
urine	O
from	O
65	O
FLG	O
loss	O
-	O
of	O
-	O
function	O
mutation	O
carriers	O
and	O
130	O
non	O
-	O
carriers	O
(	O
controls	O
)	O
.	O

Regression	O
analyses	O
,	O
controlling	O
for	O
urinary	O
dilution	O
and	O
confounders	O
,	O
were	O
performed	O
to	O
estimate	O
associations	O
between	O
FLG	O
mutation	O
status	O
and	O
chemical	O
concentrations	O
in	O
urine	O
.	O

RESULTS	O
:	O
FLG	O
mutation	O
carriers	O
had	O
80	O
%	O
(	O
13	O
-	O
180	O
%	O
)	O
higher	O
urinary	O
concentrations	O
of	O
methyl	O
paraben	O
(	O
MeP	O
)	O
and	O
91	O
%	O
(	O
13	O
-	O
219	O
%	O
)	O
higher	O
concentrations	O
of	O
n	O
-	O
propyl	O
paraben	O
(	O
n	O
-	O
PrP	O
)	O
than	O
controls	O
.	O

For	O
13	O
compounds	O
,	O
levels	O
were	O
higher	O
in	O
FLG	O
mutation	O
carriers	O
,	O
although	O
differences	O
were	O
only	O
statistically	O
significant	O
for	O
MeP	O
and	O
n	O
-	O
PrP.	O
Combined	O
statistical	O
analysis	O
of	O
concentrations	O
of	O
all	O
the	O
18	O
compounds	O
that	O
were	O
detectable	O
in	O
>	O
10	O
%	O
of	O
subjects	O
,	O
suggested	O
that	O
concentrations	O
were	O
generally	O
higher	O
in	O
mutation	O
carriers	O
(	O
p=0.03	O
)	O
.	O

CONCLUSION	O
:	O
FLG	O
loss	O
-	O
of	O
-	O
function	O
mutation	O
carriers	O
have	O
a	O
higher	O
internal	O
exposure	O
to	O
some	O
non	O
-	O
persistent	O
chemicals	O
,	O
independently	O
of	O
atopic	O
dermatitis	O
.	O

This	O
may	O
be	O
due	O
to	O
increased	O
trans	O
-	O
epidermal	O
absorption	O
and/or	O
higher	O
exposure	O
,	O
and	O
mutation	O
carriers	O
may	O
constitute	O
a	O
group	O
susceptible	O
to	O
increased	O
absorption	O
of	O
chemicals	O
and	O
topical	O
medication	O
.	O

GRIN2B	O
gain	O
of	O
function	O
mutations	O
are	O
sensitive	O
to	O
radiprodil	O
,	O
a	O
negative	O
allosteric	O
modulator	O
of	O
GluN2B	O
-	O
containing	O
NMDA	O
receptors	O
.	O

De	O
novo	O
gain	B-PosReg
of	I-PosReg
function	I-PosReg
mutations	B-Var
in	O
GRIN2B	B-Gene
encoding	O
the	O
GluN2B	O
subunit	O
of	O
the	O
N	O
-	O
methyl	O
-	O
d	O
-	O
aspartate	O
(	O
NMDA	O
)	O
receptor	O
have	O
been	O
linked	O
with	O
epileptic	B-Disease
encephalopathies	I-Disease
,	O
including	O
infantile	B-Disease
spasms	I-Disease
.	O

We	O
investigated	O
the	O
effects	O
of	O
radiprodil	O
,	O
a	O
selective	O
GluN2B	O
negative	O
allosteric	O
modulator	O
and	O
other	O
non	O
-	O
selective	O
NMDA	O
receptor	O
inhibitors	O
on	O
glutamate	O
currents	O
mediated	O
by	O
NMDA	O
receptors	O
containing	O
mutated	O
GluN2B	O
subunits	O
.	O

The	O
experiments	O
were	O
performed	O
in	O
Xenopus	O
oocytes	O
co	O
-	O
injected	O
with	O
the	O
following	O
human	O
mRNAs	O
:	O
GRIN1	O
/	O
GRIN2B	O
,	O
GRIN1	O
/	O
GRIN2B	O
-	O
R540H	O
,	O
GRIN1	O
/	O
GRIN2B	O
-	O
N615I	O
and	O
GRIN1	O
/	O
GRIN2B	O
-	O
V618G.	O
Glutamate	O
displayed	O
slightly	O
increased	O
potency	O
in	O
the	O
R540H	O
variant	O
,	O
but	O
not	O
in	O
N615I	O
and	O
V618	O
G	O
variants	O
.	O

However	O
,	O
the	O
inhibition	O
by	O
Mg(2	O
+	O
)	O
was	O
completely	O
abolished	O
in	O
N615I	O
and	O
V618	O
G	O
variants	O
.	O

In	O
fact	O
,	O
Mg(2	O
+	O
)	O
enhanced	O
glutamate	O
responses	O
in	O
those	O
variants	O
.	O

The	O
potency	O
of	O
radiprodil	O
to	O
block	O
glutamate	O
-	O
evoked	O
currents	O
was	O
not	O
affected	O
in	O
any	O
of	O
the	O
variants	O
,	O
while	O
the	O
effects	O
by	O
non	O
-	O
selective	O
NMDA	O
inhibitors	O
were	O
greatly	O
reduced	O
in	O
some	O
of	O
the	O
variants	O
.	O

Additionally	O
,	O
in	O
the	O
Mg(2	O
+	O
)	O
insensitive	O
variants	O
,	O
radiprodil	O
blocked	O
glutamate	O
-	O
activated	O
currents	O
with	O
the	O
same	O
potency	O
as	O
in	O
the	O
absence	O
of	O
Mg(2	O
+	O
)	O
.	O

The	O
gain	O
of	O
function	O
observed	O
in	O
the	O
reported	O
GRIN2B	O
variants	O
could	O
be	O
a	O
key	O
pathophysiological	O
factor	O
leading	O
to	O
neuronal	O
hyper	O
-	O
excitability	O
in	O
epileptic	O
encephalopathies	O
.	O

The	O
GluN2B	O
-	O
selective	O
inhibitor	O
radiprodil	O
fully	O
retained	O
its	O
pharmacological	O
profile	O
under	O
these	O
conditions	O
,	O
while	O
other	O
non	O
-	O
selective	O
NMDA	O
receptor	O
antagonists	O
lost	O
their	O
potency	O
.	O

Consequently	O
,	O
our	O
data	O
suggest	O
that	O
radiprodil	O
may	O
be	O
a	O
valuable	O
therapeutic	O
option	O
for	O
treatment	O
of	O
pediatric	O
epileptic	O
encephalopathies	O
associated	O
with	O
GRIN2B	O
mutations	O
.	O

PAI-1	O
gain	O
-	O
of	O
-	O
function	O
genotype	O
,	O
factors	O
increasing	O
PAI-1	O
levels	O
,	O
and	O
airway	O
obstruction	O
:	O
The	O
GALA	O
II	O
Cohort	O
.	O

BACKGROUND	O
:	O
PAI-1	B-Gene
gain	O
-	O
of	O
-	O
function	O
variants	B-Var
promote	B-PosReg
airway	B-CPA
fibrosis	I-CPA
and	O
are	O
associated	B-Reg
with	I-Reg
asthma	B-Disease
and	O
with	O
worse	O
lung	O
function	O
in	O
subjects	O
with	O
asthma	O
.	O

OBJECTIVE	O
:	O
We	O
sought	O
to	O
determine	O
whether	O
the	O
association	O
of	O
a	O
gain	O
-	O
of	O
-	O
function	O
polymorphism	O
in	O
plasminogen	O
activator	O
inhibitor-1	O
(	O
PAI-1	O
)	O
with	O
airway	O
obstruction	O
is	O
modified	O
by	O
asthma	O
status	O
,	O
and	O
whether	O
any	O
genotype	O
effect	O
persists	O
after	O
accounting	O
for	O
common	O
exposures	O
that	O
increase	O
PAI-1	O
level	O
.	O

METHODS	O
:	O
We	O
studied	O
2070	O
Latino	O
children	O
(	O
8	O
-	O
21y	O
)	O
with	O
genotypic	O
and	O
pulmonary	O
function	O
data	O
from	O
the	O
GALA	O
II	O
cohort	O
.	O

We	O
estimated	O
the	O
relationship	O
of	O
the	O
PAI-1	O
risk	O
allele	O
with	O
FEV1	O
/	O
FVC	O
by	O
multivariate	O
linear	O
regression	O
,	O
stratified	O
by	O
asthma	O
status	O
.	O

We	O
examined	O
the	O
association	O
of	O
the	O
polymorphism	O
with	O
asthma	O
and	O
airway	O
obstruction	O
within	O
asthmatics	O
via	O
multivariate	O
logistic	O
regression	O
.	O

We	O
replicated	O
associations	O
in	O
the	O
SAPPHIRE	O
cohort	O
of	O
African	O
Americans	O
(	O
n=1056	O
)	O
.	O

Secondary	O
analysis	O
included	O
the	O
effect	O
of	O
the	O
at	O
-	O
risk	O
polymorphism	O
on	O
postbronchodilator	O
lung	O
function	O
.	O

RESULTS	O
:	O
There	O
was	O
an	O
interaction	O
between	O
asthma	O
status	O
and	O
the	O
PAI-1	O
polymorphism	O
on	O
FEV1	O
/FVC	O
(	O
P=.03	O
)	O
.	O

The	O
gain	O
-	O
of	O
-	O
function	O
variants	O
,	O
genotypes	O
(	O
AA	O
/	O
AG	O
)	O
,	O
were	O
associated	O
with	O
lower	O
FEV1	O
/FVC	O
in	O
subjects	O
with	O
asthma	O
(	O
β=-1.25	O
,	O
CI	O
:	O
-2.14,-0.35	O
,	O
P=.006	O
)	O
,	O
but	O
not	O
in	O
controls	O
.	O

Subjects	O
with	O
asthma	O
and	O
the	O
AA	O
/	O
AG	O
genotypes	O
had	O
a	O
5	O
%	O
decrease	O
in	O
FEV1	O
/FVC	O
(	O
P<.001	O
)	O
.	O

In	O
asthmatics	O
,	O
the	O
risk	O
genotype	O
(	O
AA	O
/	O
AG	O
)	O
was	O
associated	O
with	O
a	O
39	O
%	O
increase	O
in	O
risk	O
of	O
clinically	O
relevant	O
airway	O
obstruction	O
(	O
OR=1.39	O
,	O
CI	O
:	O
1.01	O
,	O
1.92	O
,	O
P=.04	O
)	O
.	O

These	O
associations	O
persisted	O
after	O
exclusion	O
of	O
factors	O
that	O
increase	O
PAI-1	O
including	O
tobacco	O
exposure	O
and	O
obesity	O
.	O

CONCLUSIONS	O
AND	O
CLINICAL	O
RELEVANCE	O
:	O
The	O
decrease	O
in	O
the	O
FEV1	O
/FVC	O
ratio	O
associated	O
with	O
the	O
risk	O
genotype	O
was	O
modified	O
by	O
asthma	O
status	O
.	O

The	O
genotype	O
increased	O
the	O
odds	O
of	O
airway	O
obstruction	O
by	O
75	O
%	O
within	O
asthmatics	O
only	O
.	O

As	O
exposures	O
known	O
to	O
increase	O
PAI-1	O
levels	O
did	O
not	O
mitigate	O
this	O
association	O
,	O
PAI-1	O
may	O
contribute	O
to	O
airway	O
obstruction	O
in	O
the	O
context	O
of	O
chronic	O
asthmatic	O
airway	O
inflammation	O
.	O

Severe	O
hypertriglyceridemia	B-Disease
due	O
to	O
two	O
novel	O
loss	B-NegReg
-	I-NegReg
of	I-NegReg
-	I-NegReg
function	I-NegReg
lipoprotein	B-Enzyme
lipase	I-Enzyme
gene	O
mutations	O
(	B-Var
C310R	I-Var
/	I-Var
E396V	I-Var
)	I-Var
in	O
a	O
Chinese	O
family	O
associated	B-Reg
with	I-Reg
recurrent	B-Disease
acute	I-Disease
pancreatitis	I-Disease
.	O

Lipoprotein	O
lipase	O
(	O
LPL	O
)	O
is	O
widely	O
expressed	O
in	O
skeletal	O
muscles	O
,	O
cardiac	O
muscles	O
as	O
well	O
as	O
adipose	O
tissue	O
and	O
involved	O
in	O
the	O
catabolism	O
of	O
triglyceride	O
.	O

Herein	O
we	O
have	O
systematically	O
characterized	O
two	O
novel	O
loss	O
-	O
of	O
-	O
function	O
mutations	O
in	O
LPL	O
from	O
a	O
Chinese	O
family	O
in	O
which	O
afflicted	O
members	O
were	O
manifested	O
by	O
severe	O
hypertriglyceridemia	O
and	O
recurrent	O
pancreatitis	O
.	O

DNA	O
sequencing	O
revealed	O
that	O
the	O
proband	O
was	O
a	O
heterozygote	O
carrying	O
a	O
novel	O
c	O
.	O

T928C	O
(	O
p	O
.	O
C310R	O
)	O
mutation	O
in	O
exon	O
6	O
of	O
the	O
LPL	O
gene	O
.	O

Another	O
member	O
of	O
the	O
family	O
was	O
detected	O
to	O
be	O
a	O
compound	O
heterozygote	O
who	O
along	O
with	O
the	O
c	O
.	O

T928C	O
mutation	O
also	O
carried	O
a	O
novel	O
missense	O
mutation	O
c	O
.	O

A1187	O
T	O
(	O
p	O
.	O
E396V	O
)	O
in	O
exon	O
8	O
of	O
the	O
LPL	O
gene	O
.	O

Furthermore	O
,	O
COS-1	O
cells	O
were	O
transfected	O
with	O
lentiviruses	O
containing	O
the	O
mutant	O
LPL	O
genes	O
.	O

While	O
C310R	B-Var
markedly	O
reduced	B-NegReg
the	O
overall	O
LPL	B-MPA
protein	I-MPA
level	I-MPA
,	O
COS-1	O
cells	O
carrying	O
E396V	O
or	O
double	O
mutations	O
contained	O
similar	O
overall	O
LPL	O
protein	O
levels	O
to	O
the	O
wild	O
-	O
type	O
.	O

The	O
specific	O
activity	O
of	O
the	O
LPL	O
mutants	O
remained	O
at	O
comparable	O
magnitude	O
to	O
the	O
wild	O
-	O
type	O
.	O

However	O
,	O
few	O
LPL	O
were	O
detected	O
in	O
the	O
culture	O
medium	O
for	O
the	O
mutants	O
,	O
suggesting	O
that	O
both	O
mutations	B-Var
caused	B-Reg
aberrant	O
triglyceride	B-MPA
catabolism	I-MPA
.	O

More	O
specifically	O
,	O
E396V	B-Var
and	O
double	B-Var
mutations	I-Var
dampened	B-NegReg
the	O
transport	B-MPA
of	I-MPA
LPL	I-MPA
to	I-MPA
the	I-MPA
cell	I-MPA
surface	I-MPA
,	O
while	O
for	O
the	O
C310R	B-Var
mutation	O
,	O
reducing	B-NegReg
LPL	B-MPA
protein	I-MPA
level	I-MPA
might	O
be	O
involved	O
.	O

By	O
characterizing	O
these	O
two	O
novel	O
LPL	O
mutations	O
,	O
this	O
study	O
has	O
expanded	O
our	O
understanding	O
on	O
the	O
pathogenesis	O
of	O
familial	O
hypertriglyceridemia	O
(	O
FHTG	O
)	O
.	O

WNT10A	B-Gene
mutation	B-Var
causes	B-Reg
ectodermal	B-Disease
dysplasia	I-Disease
by	O
impairing	B-NegReg
progenitor	B-CPA
cell	I-CPA
proliferation	I-CPA
and	O
KLF4-mediated	B-CPA
differentiation	I-CPA
.	O

Human	O
WNT10A	O
mutations	O
are	O
associated	O
with	O
developmental	O
tooth	O
abnormalities	O
and	O
adolescent	O
onset	O
of	O
a	O
broad	O
range	O
of	O
ectodermal	O
defects	O
.	O

Here	O
we	O
show	O
that	O
β	O
-	O
catenin	O
pathway	O
activity	O
and	O
adult	O
epithelial	O
progenitor	O
proliferation	O
are	O
reduced	O
in	O
the	O
absence	O
of	O
WNT10A	O
,	O
and	O
identify	O
Wnt	O
-	O
active	O
self	O
-	O
renewing	O
stem	O
cells	O
in	O
affected	O
tissues	O
including	O
hair	O
follicles	O
,	O
sebaceous	O
glands	O
,	O
taste	O
buds	O
,	O
nails	O
and	O
sweat	O
ducts	O
.	O

Human	O
and	O
mouse	O
WNT10A	O
mutant	O
palmoplantar	O
and	O
tongue	O
epithelia	O
also	O
display	O
specific	O
differentiation	O
defects	O
that	O
are	O
mimicked	O
by	O
loss	O
of	O
the	O
transcription	O
factor	O
KLF4	O
.	O

We	O
find	O
that	O
β	O
-	O
catenin	O
interacts	O
directly	O
with	O
region	O
-	O
specific	O
LEF	O
/	O
TCF	O
factors	O
,	O
and	O
with	O
KLF4	O
in	O
differentiating	O
,	O
but	O
not	O
proliferating	O
,	O
cells	O
to	O
promote	O
expression	O
of	O
specialized	O
keratins	O
required	O
for	O
normal	O
tissue	O
structure	O
and	O
integrity	O
.	O

Our	O
data	O
identify	O
WNT10A	O
as	O
a	O
critical	O
ligand	O
controlling	O
adult	O
epithelial	O
proliferation	O
and	O
region	O
-	O
specific	O
differentiation	O
,	O
and	O
suggest	O
downstream	O
β	O
-	O
catenin	O
pathway	O
activation	O
as	O
a	O
potential	O
approach	O
to	O
ameliorate	O
regenerative	O
defects	O
in	O
WNT10A	O
patients	O
.	O

Loss	B-Var
of	I-Var
function	I-Var
in	O
ROBO1	B-Gene
is	O
associated	B-Reg
with	O
tetralogy	B-Disease
of	I-Disease
Fallot	I-Disease
and	O
septal	B-Disease
defects	I-Disease
.	O

BACKGROUND	O
:	O
Congenital	O
heart	O
disease	O
(	O
CHD	O
)	O
is	O
a	O
common	O
birth	O
defect	O
affecting	O
approximately	O
1	O
%	O
of	O
newborns	O
.	O

Great	O
progress	O
has	O
been	O
made	O
in	O
elucidating	O
the	O
genetic	O
aetiology	O
of	O
CHD	O
with	O
advances	O
in	O
genomic	O
technology	O
,	O
which	O
we	O
leveraged	O
in	O
recovering	O
a	O
new	O
pathway	O
affecting	O
heart	O
development	O
in	O
humans	O
previously	O
known	O
to	O
affect	O
heart	O
development	O
in	O
an	O
animal	O
model	O
.	O

METHODS	O
:	O
Four	O
hundred	O
and	O
sixteen	O
individuals	O
from	O
Thailand	O
and	O
the	O
USA	O
diagnosed	O
with	O
CHD	O
and/or	O
congenital	O
diaphragmatic	O
hernia	O
were	O
evaluated	O
with	O
chromosomal	O
microarray	O
and	O
whole	O
exome	O
sequencing	O
.	O

The	O
DECIPHER	O
Consortium	O
and	O
medical	O
literature	O
were	O
searched	O
for	O
additional	O
patients	O
.	O

Murine	O
hearts	O
from	O
ENU	O
-	O
induced	O
mouse	O
mutants	O
and	O
transgenic	O
mice	O
were	O
evaluated	O
using	O
both	O
episcopic	O
confocal	O
histopathology	O
and	O
troponin	O
I	O
stained	O
sections	O
.	O

RESULTS	O
:	O
Loss	O
of	O
function	O
ROBO1	O
variants	O
were	O
identified	O
in	O
three	O
families	O
;	O
each	O
proband	O
had	O
a	O
ventricular	O
septal	O
defect	O
,	O
and	O
one	O
proband	O
had	O
tetralogy	O
of	O
Fallot	O
.	O

Additionally	O
,	O
a	O
microdeletion	O
in	O
an	O
individual	O
with	O
CHD	O
was	O
found	O
in	O
the	O
medical	O
literature	O
.	O

Mouse	O
models	O
showed	O
perturbation	O
of	O
the	O
Slit	O
-	O
Robo	O
signalling	O
pathway	O
,	O
causing	O
septation	O
and	O
outflow	O
tract	O
defects	O
and	O
craniofacial	O
anomalies	O
.	O

Two	O
probands	O
had	O
variable	O
facial	O
features	O
consistent	O
with	O
the	O
mouse	O
model	O
.	O

CONCLUSION	O
:	O
Our	O
findings	O
identify	O
Slit	O
-	O
Robo	O
as	O
a	O
significant	O
pathway	O
in	O
human	O
heart	O
development	O
and	O
CHD	O
.	O

Human	O
IκBα	O
Gain	O
of	O
Function	O
:	O
a	O
Severe	O
and	O
Syndromic	O
Immunodeficiency	O
.	O

Germline	O
heterozygous	O
gain	B-PosReg
-	I-PosReg
of	I-PosReg
-	I-PosReg
function	I-PosReg
(	O
GOF	O
)	O
mutations	B-Var
of	O
NFKBIA	B-Gene
,	O
encoding	O
IκBα	O
,	O
cause	O
an	O
autosomal	O
dominant	O
(	O
AD	O
)	O
form	O
of	O
anhidrotic	B-Disease
ectodermal	I-Disease
dysplasia	I-Disease
with	I-Disease
immunodeficiency	I-Disease
(	O
EDA	O
-	O
ID	O
)	O
.	O

Fourteen	O
unrelated	O
patients	O
have	O
been	O
reported	O
since	O
the	O
identification	O
of	O
the	O
first	O
case	O
in	O
2003	O
.	O

All	O
mutations	B-Var
enhanced	B-PosReg
the	O
inhibitory	B-MPA
activity	I-MPA
of	O
IκBα	B-Protein
,	O
by	O
preventing	B-NegReg
its	O
phosphorylation	B-MPA
on	I-MPA
serine	I-MPA
32	I-MPA
or	I-MPA
36	I-MPA
and	O
its	O
subsequent	O
degradation	B-MPA
.	O

The	O
mutation	O
certainly	O
or	O
probably	O
occurred	O
de	O
novo	O
in	O
13	O
patients	O
,	O
whereas	O
it	O
was	O
inherited	O
from	O
a	O
parent	O
with	O
somatic	O
mosaicism	O
in	O
one	O
patient	O
.	O

Eleven	O
mutations	O
,	O
belonging	O
to	O
two	O
groups	O
,	O
were	O
identified	O
:	O
(	O
i	O
)	O
missense	O
mutations	O
affecting	O
S32	O
,	O
S36	O
,	O
or	O
neighboring	O
residues	O
(	O
8	O
mutations	O
,	O
11	O
patients	O
)	O
and	O
(	O
ii	O
)	O
nonsense	O
mutations	O
upstream	O
from	O
S32	O
associated	O
with	O
the	O
reinitiation	O
of	O
translation	O
downstream	O
from	O
S36	O
(	O
3	O
mutations	O
,	O
3	O
patients	O
)	O
.	O

Thirteen	O
patients	O
had	O
developmental	O
features	O
of	O
EDA	O
,	O
the	O
severity	O
and	O
nature	O
of	O
which	O
differed	O
between	O
cases	O
.	O

All	O
patient	O
cells	O
tested	O
displayed	O
impaired	O
NF	O
-	O
κB	O
-	O
mediated	O
responses	O
to	O
the	O
stimulation	O
of	O
various	O
surface	O
receptors	O
involved	O
in	O
cell	O
-	O
intrinsic	O
(	O
fibroblasts	O
)	O
,	O
innate	O
(	O
monocytes	O
)	O
,	O
and	O
adaptive	O
(	O
B	O
and	O
T	O
cells	O
)	O
immunity	O
,	O
including	O
TLRs	O
,	O
IL-1Rs	O
,	O
TNFRs	O
,	O
TCR	O
,	O
and	O
BCR	O
.	O

All	O
patients	O
had	O
profound	O
B	O
-	O
cell	O
deficiency	O
.	O

Specific	O
immunological	O
features	O
,	O
found	O
in	O
some	O
,	O
but	O
not	O
all	O
patients	O
,	O
included	O
a	O
lack	O
of	O
peripheral	O
lymph	O
nodes	O
,	O
lymphocytosis	O
,	O
dysfunctional	O
α	O
/	O
β	O
T	O
cells	O
,	O
and	O
a	O
lack	O
of	O
circulating	O
γ	O
/	O
δ	O
T	O
cells	O
.	O

The	O
patients	O
had	O
various	O
pyogenic	O
,	O
mycobacterial	O
,	O
fungal	O
,	O
and	O
viral	O
severe	O
infections	O
.	O

Patients	O
with	O
a	O
missense	O
mutation	O
tended	O
to	O
display	O
more	O
severe	O
phenotypes	O
,	O
probably	O
due	O
to	O
higher	O
levels	O
of	O
GOF	O
proteins	O
.	O

In	O
the	O
absence	O
of	O
hematopoietic	O
stem	O
cell	O
transplantation	O
(	O
HSCT	O
)	O
,	O
this	O
condition	O
cause	O
death	O
before	O
the	O
age	O
of	O
1	O
year	O
(	O
one	O
child	O
)	O
.	O

Two	O
survivors	O
have	O
been	O
on	O
prophylaxis	O
(	O
at	O
9	O
and	O
22	O
years	O
)	O
.	O

Six	O
children	O
died	O
after	O
HSCT	O
.	O

Five	O
survived	O
,	O
four	O
of	O
whom	O
have	O
been	O
on	O
prophylaxis	O
(	O
3	O
to	O
21	O
years	O
post	O
HSCT	O
)	O
,	O
whereas	O
one	O
has	O
been	O
well	O
with	O
no	O
prophylaxis	O
.	O

Heterozygous	O
GOF	O
mutations	O
in	O
IκBα	O
underlie	O
a	O
severe	O
and	O
syndromic	O
immunodeficiency	O
,	O
the	O
interindividual	O
variability	O
of	O
which	O
might	O
partly	O
be	O
ascribed	O
to	O
the	O
dichotomy	O
of	O
missense	O
and	O
nonsense	O
mutations	O
,	O
and	O
the	O
hematopoietic	O
component	O
of	O
which	O
can	O
be	O
rescued	O
by	O
HSCT	O
.	O

ARX	B-Gene
polyalanine	B-Var
expansion	I-Var
mutations	I-Var
lead	B-Reg
to	I-Reg
migration	B-CPA
impediment	I-CPA
in	I-CPA
the	I-CPA
rostral	I-CPA
cortex	I-CPA
coupled	I-CPA
with	O
a	O
developmental	B-CPA
deficit	I-CPA
of	I-CPA
calbindin	I-CPA
-	I-CPA
positive	I-CPA
cortical	I-CPA
GABAergic	I-CPA
interneurons	I-CPA
.	O

The	O
Aristaless	O
-	O
related	O
homeobox	O
gene	O
(	O
ARX	O
)	O
is	O
indispensable	O
for	O
interneuron	O
development	O
.	O

Patients	O
with	O
ARX	O
polyalanine	O
expansion	O
mutations	O
of	O
the	O
first	O
two	O
tracts	O
(	O
namely	O
PA1	O
and	O
PA2	O
)	O
suffer	O
from	O
intellectual	O
disability	O
of	O
varying	O
severity	O
,	O
with	O
seizures	O
a	O
frequent	O
comorbidity	O
.	O

The	O
impact	O
of	O
PA1	O
and	O
PA2	O
mutations	O
on	O
the	O
brain	O
development	O
is	O
unknown	O
,	O
hindering	O
the	O
search	O
for	O
therapeutic	O
interventions	O
.	O

Here	O
,	O
we	O
characterized	O
the	O
disturbances	O
to	O
cortical	O
interneuron	O
development	O
in	O
mice	O
modeling	O
the	O
two	O
most	O
common	O
ARX	O
polyalanine	O
expansion	O
mutations	O
in	O
human	O
.	O

We	O
found	O
a	O
consistent	O
∼40	O
-	O
50	O
%	O
reduction	O
of	O
calbindin	O
-	O
positive	O
interneurons	O
,	O
but	O
not	O
Stt+	O
or	O
Cr+	O
interneurons	O
,	O
within	O
the	O
cortex	O
of	O
newborn	O
hemizygous	O
mice	O
(	O
p=0.024	O
)	O
for	O
both	O
mutant	O
strains	O
compared	O
to	O
wildtype	O
(	O
p=0.011	O
)	O
.	O

We	O
demonstrate	O
that	O
this	O
was	O
a	O
consequence	O
of	O
calbindin	O
precursor	O
cells	O
being	O
arrested	O
or	O
delayed	O
at	O
the	O
ventral	O
subpallium	O
en	O
route	O
of	O
tangential	O
migration	O
.	O

Ex	O
-	O
vivo	O
assay	O
validated	O
this	O
migration	O
deficit	O
in	O
PA1	O
cells	O
(	O
p=0.0002	O
)	O
suggesting	O
that	O
the	O
defect	O
is	O
contributed	O
by	O
intrinsic	O
loss	O
of	O
Arx	O
function	O
within	O
migrating	O
cells	O
.	O

Both	O
humans	O
and	O
mice	O
with	O
PA1	O
mutations	O
present	O
with	O
severe	O
clinical	O
features	O
,	O
including	O
intellectual	O
disability	O
and	O
infantile	O
spasms	O
.	O

Our	O
data	O
further	O
demonstrated	O
the	O
pathogenic	O
mechanism	O
was	O
robustly	O
shared	O
between	O
PA1	O
and	O
PA2	O
mutations	O
,	O
as	O
previously	O
reported	O
including	O
Arx	O
protein	O
reduction	O
and	O
overlapping	O
transcriptome	O
profiles	O
within	O
the	O
developing	O
mouse	O
brains	O
.	O

Data	O
from	O
our	O
study	O
demonstrated	O
that	O
cortical	B-CPA
calbindin	I-CPA
interneuron	I-CPA
development	B-CPA
and	O
migration	B-CPA
is	O
negatively	B-NegReg
affected	O
by	O
ARX	B-Gene
polyalanine	B-Var
expansion	I-Var
mutations	I-Var
.	O

Understanding	O
the	O
cellular	O
pathogenesis	O
contributing	O
to	O
disease	O
manifestation	O
is	O
necessary	O
to	O
screen	O
efficacy	O
of	O
potential	O
therapeutic	O
interventions	O
.	O

Inducible	O
activation	O
of	O
FGFR2	O
in	O
adult	O
mice	O
promotes	O
bone	O
formation	O
after	O
bone	O
marrow	O
ablation	O
.	O

Apert	B-Disease
syndrome	I-Disease
is	O
one	O
of	O
the	O
most	O
severe	O
craniosynostoses	O
,	O
resulting	O
from	O
gain	B-PosReg
-	I-PosReg
of	I-PosReg
-	I-PosReg
function	I-PosReg
mutations	B-Var
in	O
fibroblast	O
growth	O
factor	O
receptor	O
2	O
(	B-Gene
FGFR2	I-Gene
)	I-Gene
.	O

Previous	O
studies	O
have	O
shown	O
that	O
gain	O
-	O
of	O
-	O
function	O
mutations	O
of	O
FGFR2	O
(	O
S252W	O
or	O
P253R	O
)	O
cause	O
skull	O
malformation	O
of	O
human	O
Apert	O
syndrome	O
by	O
affecting	O
both	O
chondrogenesis	O
and	O
osteogenesis	O
,	O
underscoring	O
the	O
key	O
role	O
of	O
FGFR2	O
in	O
bone	O
development	O
.	O

However	O
,	O
the	O
effects	O
of	O
FGFR2	O
on	O
bone	O
formation	O
at	O
the	O
adult	O
stage	O
have	O
not	O
been	O
fully	O
investigated	O
.	O

To	O
investigate	O
the	O
role	O
of	O
FGFR2	O
in	O
bone	O
formation	O
,	O
we	O
generated	O
mice	O
with	O
tamoxifen	O
-	O
inducible	O
expression	O
of	O
mutant	O
FGFR2	O
(	O
P253R	O
)	O
at	O
the	O
adult	O
stage	O
.	O

Mechanical	O
bone	O
marrow	O
ablation	O
(	O
BMX	O
)	O
was	O
performed	O
in	O
both	O
wild	O
-	O
type	O
and	O
Fgfr2	B-Gene
mutant	B-Var
(	O
MT	O
)	O
mice	O
.	O

Changes	O
in	O
newly	O
formed	O
trabecular	O
bone	O
were	O
assessed	O
by	O
micro	O
-	O
computed	O
tomography	O
and	O
bone	O
histomorphometry	O
.	O

We	O
found	O
that	O
MT	O
mice	O
exhibited	O
increased	B-PosReg
trabecular	B-CPA
bone	I-CPA
formation	I-CPA
and	O
decreased	B-NegReg
bone	B-CPA
resorption	I-CPA
after	O
BMX	O
accompanied	O
with	O
a	O
remarkable	O
increase	B-PosReg
in	O
bone	B-CPA
marrow	I-CPA
stromal	I-CPA
cell	I-CPA
recruitment	B-CPA
and	O
proliferation	B-CPA
,	O
osteoblast	B-CPA
proliferation	B-CPA
and	O
differentiation	B-CPA
,	O
and	O
enhanced	B-PosReg
Wnt/?-catenin	B-CPA
activity	I-CPA
.	O

Furthermore	O
,	O
pharmacologically	O
inhibiting	O
Wnt	O
/	O
β	O
-	O
catenin	O
signaling	O
can	O
partially	O
reverse	O
the	O
increased	O
trabecular	O
bone	O
formation	O
and	O
decreased	O
bone	O
resorption	O
in	O
MT	O
mice	O
after	O
BMX	O
.	O

Our	O
data	O
demonstrate	O
that	O
gain	B-PosReg
-	I-PosReg
of	I-PosReg
-	I-PosReg
function	I-PosReg
mutation	B-Var
in	O
FGFR2	B-Gene
exerts	B-MPA
a	I-MPA
Wnt	I-MPA
/	I-MPA
β	I-MPA
-	I-MPA
catenin	I-MPA
-	I-MPA
dependent	I-MPA
anabolic	I-MPA
effect	I-MPA
on	O
trabecular	O
bone	O
by	O
promoting	B-PosReg
bone	B-CPA
formation	I-CPA
and	O
inhibiting	B-NegReg
bone	B-CPA
resorption	I-CPA
at	I-CPA
the	I-CPA
adult	I-CPA
stage	I-CPA
.	O

This	O
article	O
is	O
protected	O
by	O
copyright	O
.	O

All	O
rights	O
reserved	O
.	O

Early	B-Disease
-	I-Disease
onset	I-Disease
autoimmune	I-Disease
disease	I-Disease
due	O
to	O
a	O
heterozygous	O
loss	B-NegReg
-	I-NegReg
of	I-NegReg
-	I-NegReg
function	I-NegReg
mutation	B-Var
in	O
TNFAIP3	B-Gene
(	O
A20	O
)	O
.	O

The	O
moving	O
junction	O
protein	O
RON4	O
,	O
although	O
not	O
critical	O
,	O
facilitates	O
host	O
cell	O
invasion	O
and	O
stabilizes	O
MJ	O
members	O
.	O

Toxoplasma	O
gondii	O
is	O
an	O
obligate	O
intracellular	O
parasite	O
of	O
phylum	O
Apicomplexa	O
.	O

To	O
facilitate	O
high	O
-	O
efficiency	O
invasion	O
of	O
host	O
cells	O
,	O
T.	O
gondii	O
secretes	O
various	O
proteins	O
related	O
to	O
the	O
moving	O
junction	O
(	O
MJ	O
)	O
complex	O
from	O
rhoptries	O
and	O
micronemes	O
into	O
the	O
interface	O
between	O
the	O
parasite	O
and	O
host	O
.	O

AMA1	O
/	O
RON2/4/5/8	O
is	O
an	O
important	O
MJ	O
complex	O
,	O
but	O
its	O
mechanism	O
of	O
assembly	O
remains	O
unclear	O
.	O

In	O
this	O
study	O
,	O
we	O
used	O
the	O
CRISPR	O
-	O
Cas9	O
system	O
to	O
generate	O
a	O
derivative	O
of	O
T.	O
gondii	O
strain	O
RH	O
with	O
a	O
null	B-Var
mutation	I-Var
in	O
TgRON4	B-Gene
,	O
thought	O
to	O
be	O
an	O
essential	O
MJ	O
component	O
.	O

Deficiency	B-NegReg
of	O
TgRON4	B-Protein
moderately	O
decreased	B-NegReg
invasion	B-CPA
ability	I-CPA
relative	O
to	O
that	O
of	O
the	O
wild	O
-	O
type	O
parasite	O
.	O

In	O
addition	O
,	O
expression	B-MPA
of	I-MPA
the	I-MPA
endogenous	I-MPA
N	I-MPA
-	I-MPA
terminal	I-MPA
fragment	I-MPA
of	O
RON5	B-Protein
decreased	B-NegReg
in	O
the	O
mutant	B-Var
.	O

Together	O
,	O
the	O
results	O
improve	O
our	O
understanding	O
of	O
the	O
assembly	O
mechanism	O
of	O
the	O
MJ	O
complex	O
of	O
T.	O
gondii	O
and	O
raise	O
the	O
possibility	O
of	O
developing	O
new	O
therapeutic	O
drugs	O
that	O
target	O
this	O
complex	O
.	O

Natural	O
and	O
induced	O
loss	B-NegReg
of	I-NegReg
function	I-NegReg
mutations	B-Var
in	O
SlMBP21	B-Gene
MADS	O
-	O
box	O
gene	O
led	O
to	O
jointless-2	B-CPA
phenotype	I-CPA
in	O
tomato	O
.	O

Abscission	O
is	O
the	O
mechanism	O
by	O
which	O
plants	O
disconnect	O
unfertilized	O
flowers	O
,	O
ripe	O
fruits	O
,	O
senescent	O
or	O
diseased	O
organs	O
from	O
the	O
plant	O
.	O

In	O
tomato	O
,	O
pedicel	O
abscission	O
is	O
an	O
important	O
agronomic	O
factor	O
that	O
controls	O
yield	O
and	O
post	O
-	O
harvest	O
fruit	O
quality	O
.	O

Two	O
non	O
-	O
allelic	O
mutations	O
,	O
jointless	O
(	O
j	O
)	O
and	O
jointless-2	O
(	O
j-2	O
)	O
,	O
controlling	O
pedicel	O
abscission	O
zone	O
formation	O
have	O
been	O
documented	O
but	O
only	O
j-2	O
has	O
been	O
extensively	O
used	O
in	O
breeding	O
.	O

J	O
was	O
shown	O
to	O
encode	O
a	O
MADS	O
-	O
box	O
protein	O
.	O

Using	O
a	O
combination	O
of	O
physical	O
mapping	O
and	O
gene	O
expression	O
analysis	O
we	O
identified	O
a	O
positional	O
candidate	O
,	O
Solyc12g038510	O
,	O
associated	O
with	O
j-2	O
phenotype	O
.	O

Targeted	O
knockout	O
of	O
Solyc12g038510	O
,	O
using	O
CRISPR	O
/	O
Cas9	O
system	O
,	O
validated	O
our	O
hypothesis	O
.	O

Solyc12g038510	O
encodes	O
the	O
MADS	O
-	O
box	O
protein	O
SlMBP21	O
.	O

Molecular	O
analysis	O
of	O
j-2	O
natural	O
variation	O
revealed	O
two	O
independent	O
loss	O
-	O
of	O
-	O
function	O
mutants	O
.	O

The	O
first	O
results	O
of	O
an	O
insertion	O
of	O
a	O
Rider	O
retrotransposable	O
element	O
.	O

The	O
second	O
results	O
of	O
a	O
stop	O
codon	O
mutation	O
that	O
leads	O
to	O
a	O
truncated	O
protein	O
form	O
.	O

To	O
bring	O
new	O
insights	O
into	O
the	O
role	O
of	O
J	O
and	O
J-2	O
in	O
abscission	O
zone	O
formation	O
,	O
we	O
phenotyped	O
the	O
single	O
and	O
the	O
double	O
mutants	O
and	O
the	O
engineered	O
alleles	O
.	O

We	O
showed	O
that	O
J	O
is	O
epistatic	O
to	O
J-2	O
and	O
that	O
the	O
branched	O
inflorescences	O
and	O
the	O
leafy	O
sepals	O
observed	O
in	O
accessions	O
harboring	O
j-2	O
alleles	O
are	O
likely	O
the	O
consequences	O
of	O
linkage	O
drags	O
.	O

Nephron	B-CPA
development	I-CPA
and	O
extrarenal	B-CPA
features	I-CPA
in	O
a	O
child	O
with	O
congenital	O
nephrotic	O
syndrome	O
caused	B-Reg
by	I-Reg
null	O
LAMB2	B-Gene
mutations	B-Var
.	O

BACKGROUND	O
:	O
Congenital	O
nephrotic	O
syndrome	O
(	O
CNS	O
)	O
is	O
a	O
rare	O
disorder	O
caused	O
by	O
various	O
structural	O
and	O
developmental	O
defects	O
of	O
glomeruli	O
.	O

It	O
occurs	O
typically	O
as	O
an	O
isolated	O
kidney	O
disorder	O
but	O
associates	O
sometimes	O
with	O
other	O
systemic	O
,	O
extrarenal	O
manifestations	O
.	O

CASE	O
PRESENTATIONS	O
:	O
An	O
infant	O
presented	O
with	O
severe	O
CNS	O
,	O
which	O
progressed	O
rapidly	O
to	O
renal	O
failure	O
at	O
age	O
of	O
3	O
months	O
and	O
death	O
at	O
27	O
months	O
.	O

The	O
clinical	O
phenotypes	O
and	O
genetic	O
causes	O
were	O
studied	O
,	O
including	O
the	O
renal	O
pathology	O
at	O
autopsy	O
.	O

Besides	O
the	O
CNS	O
,	O
the	O
affected	O
child	O
had	O
remarkable	O
right	O
-	O
side	O
predominant	O
eye	O
-	O
ball	O
hypoplasia	O
with	O
bilateral	O
anterior	O
chamber	O
dysgenesis	O
(	O
microcoria	O
)	O
.	O

Brain	O
MRI	O
revealed	O
grossly	O
normal	O
development	O
in	O
the	O
cerebrum	O
,	O
cerebellum	O
,	O
and	O
brain	O
stem	O
.	O

Auditory	O
brainstem	O
responses	O
were	O
bilaterally	O
blunted	O
,	O
suggesting	O
a	O
defective	O
auditory	O
system	O
.	O

At	O
autopsy	O
,	O
both	O
kidneys	O
were	O
mildly	O
atrophied	O
with	O
persistent	O
fetal	O
lobulation	O
.	O

Microscopic	O
examination	O
showed	O
a	O
diffuse	O
global	O
sclerosis	O
.	O

However	O
,	O
despite	O
of	O
the	O
smaller	O
size	O
of	O
glomeruli	O
,	O
the	O
nephron	O
number	O
remained	O
similar	O
to	O
that	O
of	O
the	O
age	O
-	O
matched	O
control	O
.	O

Whole	O
-	O
exome	O
sequencing	O
revealed	O
that	O
the	O
affected	O
child	O
was	O
compound	O
heterozygous	O
for	O
novel	O
truncating	O
LAMB2	O
mutations	O
:	O
a	O
4-bp	O
insertion	O
(	O
p	O
.	O
Gly1693Alafs*8	O
)	O
and	O
a	O
splicing	O
donor	O
-	O
site	O
substitution	O
(	O
c.1225	O
+	O
1	O
G	O
>	O
A	O
)	O
,	O
presumably	O
deleting	O
the	O
coiled	O
-	O
coil	O
domains	O
that	O
form	O
the	O
laminin	O
5	O
-	O
2	O
-	O
1	O
heterotrimer	O
complex	O
.	O

CONCLUSIONS	O
:	O
Our	O
case	O
represents	O
a	O
variation	O
of	O
Pierson	O
syndrome	O
that	O
accompanies	O
CNS	O
with	O
unilateral	O
ocular	O
hypoplasia	O
.	O

The	O
average	O
number	O
but	O
smaller	O
glomeruli	O
could	O
reflect	O
either	O
mal	O
-	O
development	O
or	O
glomerulosclerosis	O
.	O

Heterogeneous	O
clinical	O
expression	O
of	O
LAMB2	O
defects	O
may	O
associate	O
with	O
the	O
difference	O
in	O
fetal	O
β1	O
subtype	O
compensation	O
among	O
affected	O
tissues	O
.	O

Further	O
study	O
is	O
necessary	O
to	O
evaluate	O
incidence	O
and	O
features	O
of	O
auditory	O
defect	O
under	O
LAMB2	O
deficiency	O
.	O

Exome	O
sequencing	O
reveals	O
independent	O
SGCD	B-Gene
deletions	B-Var
causing	B-Reg
limb	B-Disease
girdle	I-Disease
muscular	I-Disease
dystrophy	I-Disease
in	O
Boston	O
terriers	O
.	O

BACKGROUND	O
:	O
Limb	O
-	O
girdle	O
muscular	O
dystrophies	O
(	O
LGMDs	O
)	O
are	O
a	O
heterogeneous	O
group	O
of	O
inherited	O
autosomal	O
myopathies	O
that	O
preferentially	O
affect	O
voluntary	O
muscles	O
of	O
the	O
shoulders	O
and	O
hips	O
.	O

LGMD	O
has	O
been	O
clinically	O
described	O
in	O
several	O
breeds	O
of	O
dogs	O
,	O
but	O
the	O
responsible	O
mutations	O
are	O
unknown	O
.	O

The	O
clinical	O
presentation	O
in	O
dogs	O
is	O
characterized	O
by	O
marked	O
muscle	O
weakness	O
and	O
atrophy	O
in	O
the	O
shoulder	O
and	O
hips	O
during	O
puppyhood	O
.	O

METHODS	O
:	O
Following	O
clinical	O
evaluation	O
,	O
the	O
identification	O
of	O
the	O
dystrophic	O
histological	O
phenotype	O
on	O
muscle	O
histology	O
,	O
and	O
demonstration	O
of	O
the	O
absence	O
of	O
sarcoglycan	O
-	O
sarcospan	O
complex	O
by	O
immunostaining	O
,	O
whole	O
exome	O
sequencing	O
was	O
performed	O
on	O
five	O
Boston	O
terriers	O
:	O
one	O
affected	O
dog	O
and	O
its	O
three	O
family	O
members	O
and	O
one	O
unrelated	O
affected	O
dog	O
.	O

RESULTS	O
:	O
Within	O
sarcoglycan	O
-	O
δ	O
(	B-Gene
SGCD	I-Gene
)	I-Gene
,	O
a	O
two	O
base	O
pair	O
deletion	O
segregating	O
with	O
LGMD	O
in	O
the	O
family	O
was	O
discovered	O
,	O
and	O
a	O
deletion	O
encompassing	O
exons	O
7	O
and	O
8	O
was	O
found	O
in	O
the	O
unrelated	O
dog	O
.	O

Both	O
mutations	B-Var
are	O
predicted	O
to	O
cause	O
an	O
absence	B-NegReg
of	O
SGCD	B-Gene
protein	B-Protein
,	O
confirmed	O
by	O
immunohistochemistry	O
.	O

The	O
mutations	O
are	O
private	O
to	O
each	O
family	O
.	O

CONCLUSIONS	O
:	O
Here	O
,	O
we	O
describe	O
the	O
first	O
cases	O
of	O
canine	O
LGMD	O
characterized	O
at	O
the	O
molecular	O
level	O
with	O
the	O
classification	O
of	O
LGMD2F.	O
Calcium	O
pumps	O
and	O
interacting	O
BON1	O
protein	O
modulate	O
calcium	O
signature	O
,	O
stomatal	O
closure	O
,	O
and	O
plant	O
immunity	O
.	O

Calcium	O
signaling	O
is	O
essential	O
for	O
environmental	O
responses	O
including	O
immune	O
responses	O
.	O

Here	O
we	O
provide	O
evidence	O
that	O
the	O
evolutionarily	O
conserved	O
protein	O
BONZAI1	O
(	O
BON1	O
)	O
functions	O
together	O
with	O
autoinhibited	O
calcium	O
ATPase	O
10	O
(	O
ACA10	O
)	O
and	O
ACA8	O
to	O
regulate	O
calcium	O
signals	O
in	O
Arabidopsis	O
.	O

BON1	O
is	O
a	O
plasma	O
membrane	O
localized	O
protein	O
that	O
negatively	O
regulates	O
the	O
expression	O
of	O
immune	O
receptor	O
genes	O
and	O
positively	O
regulates	O
stomatal	O
closure	O
.	O

We	O
found	O
that	O
BON1	O
interacts	O
with	O
the	O
autoinhibitory	O
domains	O
of	O
ACA10	O
and	O
ACA8	O
,	O
and	O
the	O
aca10	B-Gene
loss	B-NegReg
of	I-NegReg
function	I-NegReg
(	O
LOF	O
)	O
mutants	B-Var
have	O
an	O
autoimmune	O
phenotype	O
similar	O
to	O
that	O
of	O
the	O
bon1	B-Gene
LOF	B-NegReg
mutants	B-Var
.	O

Genetic	O
evidences	O
indicate	O
that	O
BON1	O
positively	O
regulates	O
the	O
activities	O
of	O
ACA10	O
and	O
ACA8	O
.	O

Consistent	O
with	O
this	O
idea	O
,	O
the	O
steady	B-MPA
level	I-MPA
of	I-MPA
calcium	I-MPA
concentration	I-MPA
is	O
increased	B-PosReg
in	O
both	O
aca10	B-Gene
and	O
bon1	B-Gene
mutants	B-Var
.	O

Most	O
strikingly	O
,	O
cytosolic	O
calcium	O
oscillation	O
imposed	O
by	O
external	O
calcium	O
treatment	O
was	O
altered	O
in	O
aca10	O
,	O
aca8	O
,	O
and	O
bon1	O
mutants	O
in	O
guard	O
cells	O
.	O

In	O
addition	O
,	O
calcium	B-CPA
and	I-CPA
pathogen	I-CPA
induced	I-CPA
stomatal	I-CPA
closure	I-CPA
was	O
compromised	B-NegReg
in	O
the	O
aca10	B-Gene
and	O
bon1	B-Gene
mutants	B-Var
.	O

Taken	O
together	O
,	O
this	O
study	O
indicates	O
that	O
ACA10/8	O
and	O
BON1	O
physically	O
interact	O
on	O
plasma	O
membrane	O
and	O
function	O
in	O
the	O
generation	O
of	O
cytosol	O
calcium	O
signatures	O
that	O
are	O
critical	O
for	O
stomatal	O
movement	O
and	O
impact	O
plant	O
immunity	O
.	O

Extracellular	O
inhibitors	O
can	O
attenuate	O
tumorigenic	O
Wnt	O
pathway	O
activity	O
in	O
adenomatous	O
polyposis	O
coli	O
mutants	O
:	O
Predictions	O
of	O
a	O
validated	O
mathematical	O
model	O
.	O

BACKGROUND	O
:	O
Despite	O
considerable	O
investigational	O
efforts	O
,	O
no	O
method	O
to	O
overcome	O
the	O
pathogenesis	O
caused	O
by	O
loss	O
of	O
function	O
(	O
LoF	O
)	O
mutations	O
in	O
tumor	O
suppressor	O
genes	O
has	O
been	O
successfully	O
translated	O
to	O
the	O
clinic	O
.	O

The	O
most	O
frequent	O
LoF	B-NegReg
mutation	B-Var
in	O
human	O
cancers	O
is	O
Adenomatous	B-Gene
polyposis	I-Gene
coli	I-Gene
(	O
APC	O
)	O
,	O
causing	O
aberrant	O
activation	B-PosReg
of	O
the	O
Wnt	B-Pathway
pathway	I-Pathway
.	O

In	O
nearly	O
all	O
colon	B-Disease
cancer	I-Disease
tumors	I-Disease
,	O
the	O
APC	B-Protein
protein	I-Protein
is	O
truncated	O
,	O
but	O
still	O
retains	B-NegReg
partial	I-NegReg
binding	B-Interaction
abilities	B-MPA
.	O

OBJECTIVE	O
&	O
METHODS	O
:	O
Here	O
,	O
we	O
tested	O
the	O
hypothesis	O
that	O
extracellular	O
inhibitors	O
of	O
the	O
Wnt	O
pathway	O
,	O
although	O
acting	O
upstream	O
of	O
the	O
APC	O
mutation	O
,	O
can	O
restore	O
normal	O
levels	O
of	O
pathway	O
activity	O
in	O
colon	O
cancer	O
cells	O
.	O

To	O
this	O
end	O
,	O
we	O
developed	O
and	O
simulated	O
a	O
mathematical	O
model	O
for	O
the	O
Wnt	O
pathway	O
in	O
different	O
APC	O
mutants	O
,	O
with	O
or	O
without	O
the	O
effects	O
of	O
the	O
extracellular	O
inhibitors	O
,	O
Secreted	O
Frizzled	O
-	O
Related	O
Protein1	O
(	O
sFRP1	O
)	O
and	O
Dickhopf1	O
(	O
Dkk1	O
)	O
.	O

We	O
compared	O
our	O
model	O
predictions	O
to	O
experimental	O
data	O
in	O
the	O
literature	O
.	O

RESULTS	O
:	O
Our	O
model	O
accurately	O
predicts	O
T	O
-	O
cell	O
factor	O
(	O
TCF	O
)	O
activity	O
in	O
mutant	O
cells	O
that	O
vary	O
in	O
APC	O
mutation	O
.	O

Model	O
simulations	O
suggest	O
that	O
both	O
sFRP1	O
and	O
DKK1	O
can	O
reduce	O
TCF	O
activity	O
in	O
APC1638N/1572	O
T	O
and	O
Apcmin	O
/	O
min	O
mutants	O
,	O
but	O
restoration	O
of	O
normal	O
activity	O
levels	O
is	O
possible	O
only	O
in	O
the	O
former	O
.	O

When	O
applied	O
in	O
combination	O
,	O
synergism	O
between	O
the	O
two	O
inhibitors	O
can	O
reduce	O
their	O
effective	O
doses	O
to	O
one	O
-	O
fourth	O
of	O
the	O
doses	O
required	O
under	O
single	O
inhibitor	O
application	O
.	O

Overall	O
,	O
re	O
-	O
establishment	O
of	O
normal	O
Wnt	O
pathway	O
activity	O
is	O
predicted	O
for	O
every	O
APC	O
mutant	O
in	O
whom	O
TCF	O
activity	O
is	O
increased	O
by	O
up	O
to	O
11	O
fold	O
.	O

CONCLUSIONS	O
:	O
Our	O
work	O
suggests	O
that	O
extracellular	O
inhibitors	O
can	O
effectively	O
restore	O
normal	O
Wnt	O
pathway	O
activity	O
in	O
APC	O
-	O
truncated	O
cancer	O
cells	O
,	O
even	O
though	O
these	O
LoF	O
mutations	O
occur	O
downstream	O
of	O
the	O
inhibitory	O
action	O
.	O

The	O
insufficient	O
activity	O
of	O
the	O
truncated	O
APC	O
can	O
be	O
quantitatively	O
balanced	O
by	O
the	O
upstream	O
intervention	O
.	O

This	O
new	O
concept	O
of	O
upstream	O
intervention	O
to	O
control	O
the	O
effects	O
of	O
downstream	O
mutations	O
may	O
be	O
considered	O
also	O
for	O
other	O
partial	O
LoF	O
mutations	O
in	O
other	O
signaling	O
pathways	O
.	O

A	O
case	O
of	O
hypocholesterolemia	B-Disease
and	O
steatosis	B-Disease
in	O
a	O
carrier	O
of	O
a	O
PCSK9	B-Gene
loss	B-NegReg
-	I-NegReg
of	I-NegReg
-	I-NegReg
function	I-NegReg
mutation	B-Var
and	O
polymorphisms	O
predisposing	O
to	O
nonalcoholic	O
fatty	O
liver	O
disease	O
.	O

We	O
report	O
a	O
new	O
case	O
of	O
hypobetalipoproteinemia	O
in	O
a	O
44-year	O
-	O
old	O
man	O
of	O
Peruvian	O
origin	O
exhibiting	O
a	O
heterozygous	O
PCSK9	O
missense	O
mutation	O
(	B-Var
c.946	I-Var
G	I-Var
>	I-Var
T	I-Var
,	O
p.	O
Gly316Cys	O
)	O
.	O

In	O
vitro	O
functional	O
studies	O
demonstrated	O
that	O
this	O
mutation	O
leads	O
to	O
a	O
loss	B-NegReg
of	I-NegReg
function	I-NegReg
of	O
PCSK9	B-Gene
on	O
low	B-MPA
-	I-MPA
density	I-MPA
lipoprotein	I-MPA
receptor	I-MPA
degradation	I-MPA
.	O

This	O
patient	O
exhibited	O
liver	O
steatosis	O
;	O
he	O
was	O
neither	O
diabetic	O
,	O
nor	O
obese	O
or	O
alcoholic	O
,	O
but	O
is	O
a	O
carrier	O
of	O
2	O
polymorphisms	O
,	O
p	O
.	O
Ile148Met	O
(	O
rs738409	O
)	O
and	O
p	O
.	O
Glu167Lys	O
(	O
rs58542926	O
)	O
on	O
PNPLA3	O
and	O
TM6SF2	O
gene	O
,	O
respectively	O
,	O
previously	O
shown	O
to	O
be	O
associated	O
with	O
nonalcoholic	O
steatosis	O
and	O
fibrosis	O
evolution	O
.	O

These	O
data	O
suggested	O
that	O
if	O
a	O
resistance	O
to	O
hepatic	O
steatosis	O
mediated	O
by	O
the	O
PCSK9	O
deficiency	O
exists	O
,	O
as	O
demonstrated	O
in	O
mice	O
,	O
it	O
is	O
not	O
sufficient	O
to	O
prevent	O
hepatic	O
fatty	O
accumulation	O
in	O
the	O
case	O
of	O
genetic	O
factors	O
predisposing	O
to	O
nonalcoholic	O
fatty	O
liver	O
disease	O
.	O

Ovarian	B-Protein
aromatase	I-Protein
loss	B-NegReg
-	I-NegReg
of	I-NegReg
-	I-NegReg
function	I-NegReg
mutant	B-Var
medaka	O
undergo	B-Reg
ovary	B-CPA
degeneration	I-CPA
and	O
partial	B-CPA
female	I-CPA
-	I-CPA
to	I-CPA
-	I-CPA
male	I-CPA
sex	I-CPA
reversal	I-CPA
after	O
puberty	O
.	O

Although	O
estrogens	O
have	O
been	O
generally	O
considered	O
to	O
play	O
a	O
critical	O
role	O
in	O
ovarian	O
differentiation	O
in	O
non	O
-	O
mammalian	O
vertebrates	O
,	O
the	O
specific	O
functions	O
of	O
estrogens	O
during	O
ovarian	O
differentiation	O
remain	O
unclear	O
.	O

We	O
isolated	O
two	O
mutants	O
with	O
premature	O
stops	O
in	O
the	O
ovarian	O
aromatase	O
(	B-Gene
cyp19a1	I-Gene
)	I-Gene
gene	O
from	O
an	O
N	O
-	O
ethyl	O
-	O
N	O
-	O
nitrosourea	O
-	O
based	O
gene	O
-	O
driven	O
mutagenesis	O
library	O
of	O
the	O
medaka	O
,	O
Oryzias	O
latipes	O
.	O

In	O
XX	O
mutants	O
,	O
gonads	O
first	O
differentiated	O
into	O
normal	O
ovaries	O
containing	O
many	O
ovarian	O
follicles	O
that	O
failed	O
to	O
accumulate	O
yolk	O
.	O

Subsequently	O
,	O
ovarian	O
tissues	O
underwent	O
extensive	O
degeneration	O
,	O
followed	O
by	O
the	O
appearance	O
of	O
testicular	O
tissues	O
on	O
the	O
dorsal	O
side	O
of	O
ovaries	O
.	O

In	O
the	O
newly	O
formed	O
testicular	O
tissue	O
,	O
strong	O
expression	O
of	O
gsdf	O
was	O
detected	O
in	O
sox9a2-positive	O
somatic	O
cells	O
surrounding	O
germline	O
stem	O
cells	O
suggesting	O
that	O
gsdf	O
plays	O
an	O
important	O
role	O
in	O
testicular	O
differentiation	O
during	O
estrogen	O
-	O
depleted	O
female	O
-	O
to	O
-	O
male	O
sex	O
reversal	O
.	O

We	O
conclude	O
that	O
endogenous	O
estrogens	O
synthesized	O
after	O
fertilization	O
are	O
not	O
essential	O
for	O
early	O
ovarian	O
differentiation	O
but	O
are	O
critical	O
for	O
the	O
maintenance	O
of	O
adult	O
ovaries	O
.	O

Refining	O
genotype	O
-	O
phenotype	O
correlation	O
in	O
Alström	O
syndrome	O
through	O
study	O
of	O
primary	O
human	O
fibroblasts	O
.	O

BACKGROUND	O
:	O
Alström	B-Disease
syndrome	I-Disease
(	O
AS	O
)	O
,	O
featuring	O
retinal	O
dystrophy	O
,	O
neuronal	O
deafness	O
,	O
cardiomyopathy	O
,	O
metabolic	O
syndrome	O
,	O
and	O
diffuse	O
fibrosis	O
,	O
is	O
caused	O
by	O
biallelic	O
mutations	O
in	O
the	O
centrosomal	O
protein	O
ALMS1	O
.	O

Genotype	O
-	O
phenotype	O
correlation	O
has	O
been	O
suggested	O
without	O
assessment	O
of	O
ALMS1	O
expression	O
.	O

METHODS	O
:	O
ALMS1	O
expression	O
(	O
real	O
-	O
time	O
PCR	O
and	O
immunocytochemistry	O
)	O
and	O
cilia	O
formation	O
(	O
immunocytochemistry	O
)	O
were	O
assessed	O
in	O
fibroblasts	O
from	O
deeply	O
phenotyped	O
volunteers	O
diagnosed	O
with	O
AS	O
recruited	O
from	O
a	O
dedicated	O
AS	O
Service	O
.	O

Exome	O
sequencing	O
was	O
used	O
in	O
two	O
participants	O
without	O
convincing	O
biallelic	O
ALMS1	O
mutations	O
,	O
and	O
BBS2	O
(	O
Bardet	O
-	O
Biedl	O
syndrome	O
2	O
)	O
protein	O
expression	O
was	O
assessed	O
in	O
one	O
patient	O
with	O
biallelic	O
BBS2	O
mutations	O
.	O

Hedgehog	O
-	O
induced	O
GLI1	O
expression	O
and	O
PDGFA	O
signaling	O
was	O
assessed	O
using	O
quantitative	O
real	O
-	O
time	O
PCR	O
,	O
immunoblotting	O
,	O
or	O
immunostaining	O
of	O
fixed	O
cells	O
after	O
stimulation	O
.	O

RESULTS	O
:	O
In	O
16	O
of	O
the	O
patient	O
cell	O
lines	O
examined	O
,	O
ALMS1	B-Gene
protein	B-Protein
was	O
undetectable	B-NegReg
(	O
14	O
with	O
biallelic	O
loss	B-NegReg
-	I-NegReg
of	I-NegReg
-	I-NegReg
function	I-NegReg
(	O
LoF	O
)	O
mutations	B-Var
)	I-Var
,	O
and	O
in	O
two	O
,	O
ALMS1	O
staining	O
was	O
equivocal	O
(	O
one	O
with	O
biallelic	O
LoF	O
mutations	O
)	O
.	O

In	O
five	O
lines	O
,	O
ALMS1	O
expression	O
was	O
normal	O
using	O
at	O
least	O
one	O
fixation	O
method	O
(	O
one	O
with	O
biallelic	O
LoF	O
mutations	O
)	O
.	O

These	O
differences	O
were	O
not	O
accounted	O
for	O
by	O
major	O
differences	O
in	O
ALMS1	O
mRNA	O
expression	O
.	O

Exome	O
sequencing	O
of	O
two	O
participants	O
with	O
normal	O
ALMS1	O
expression	O
identified	O
biallelic	O
LoF	O
BBS2	O
mutations	O
in	O
one	O
.	O

No	O
second	O
,	O
known	O
ciliopathy	O
mutation	O
was	O
found	O
in	O
the	O
other	O
patient	O
,	O
who	O
had	O
one	O
LoF	O
ALMS1	O
mutation	O
.	O

Phenotypes	O
were	O
milder	O
or	O
atypical	O
in	O
participants	O
with	O
preserved	O
ALMS1	O
immunostaining	O
,	O
even	O
when	O
two	O
with	O
likely	O
alternative	O
genetic	O
diagnoses	O
were	O
excluded	O
.	O

All	O
cells	O
studied	O
developed	O
normal	O
cilia	O
,	O
ALMS1	O
and	O
BBS2	O
mutant	O
cells	O
showed	O
normal	O
Hedgehog	O
-	O
induced	O
upregulation	O
of	O
GLI1	O
expression	O
,	O
and	O
PDGFA	O
signaling	O
was	O
normal	O
in	O
ALMS1-deficient	O
cells	O
.	O

CONCLUSION	O
:	O
Milder	O
or	O
atypical	O
presentations	O
of	O
AS	O
should	O
prompt	O
genetic	O
evaluation	O
for	O
alternative	O
,	O
clinically	O
overlapping	O
ciliopathies	O
.	O

A	O
subgroup	O
of	O
patients	O
with	O
bona	O
fide	O
ALMS1	O
defects	O
have	O
milder	O
phenotypes	O
due	O
to	O
residual	O
ALMS1	O
expression	O
,	O
which	O
may	O
be	O
more	O
important	O
than	O
mutation	O
site	O
.	O

Small	O
chaperons	O
and	O
autophagy	O
protected	O
neurons	O
from	O
necrotic	O
cell	O
death	O
.	O

Neuronal	O
necrosis	O
occurs	O
during	O
early	O
phase	O
of	O
ischemic	O
insult	O
.	O

However	O
,	O
our	O
knowledge	O
of	O
neuronal	O
necrosis	O
is	O
still	O
inadequate	O
.	O

To	O
study	O
the	O
mechanism	O
of	O
neuronal	O
necrosis	O
,	O
we	O
previously	O
established	O
a	O
Drosophila	O
genetic	O
model	O
of	O
neuronal	O
necrosis	O
by	O
calcium	O
overloading	O
through	O
expression	O
of	O
a	O
constitutively	O
opened	O
cation	O
channel	O
mutant	O
.	O

Here	O
,	O
we	O
performed	O
further	O
genetic	O
screens	O
and	O
identified	O
a	O
suppressor	O
of	O
neuronal	O
necrosis	O
,	O
CG17259	O
,	O
which	O
encodes	O
a	O
seryl	O
-	O
tRNA	O
synthetase	O
.	O

We	O
found	O
that	O
loss	B-Var
-	I-Var
of	I-Var
-	I-Var
function	I-Var
(	O
LOF	O
)	O
CG17259	B-Gene
activated	B-PosReg
eIF2α	B-Protein
phosphorylation	B-CPA
and	O
subsequent	O
up	B-PosReg
-	I-PosReg
regulation	I-PosReg
of	O
chaperons	B-CPA
(	B-Protein
Hsp26	I-Protein
and	O
Hsp27	B-Protein
)	I-Protein
and	O
autophagy	B-CPA
.	O

Genetically	O
,	O
down	B-NegReg
-	I-NegReg
regulation	I-NegReg
of	O
eIF2α	B-Protein
phosphorylation	B-CPA
,	O
Hsp26	B-Protein
/	I-Protein
Hsp27	I-Protein
or	O
autophagy	B-CPA
reduced	B-NegReg
the	O
protective	B-CPA
effect	I-CPA
of	O
LOF	B-Var
CG17259	B-Gene
,	O
indicating	O
they	O
function	O
downstream	O
of	O
CG17259	O
.	O

The	O
protective	O
effect	O
of	O
these	O
protein	O
degradation	O
pathways	O
indicated	O
activation	O
of	O
a	O
toxic	O
protein	O
during	O
neuronal	O
necrosis	O
.	O

Our	O
data	O
indicated	O
that	O
p53	O
was	O
likely	O
one	O
such	O
protein	O
,	O
because	O
p53	O
was	O
accumulated	O
in	O
the	O
necrotic	O
neurons	O
and	O
down	O
-	O
regulation	O
of	O
p53	O
rescued	O
necrosis	O
.	O

In	O
the	O
SH	O
-	O
SY5Y	O
human	O
cells	O
,	O
tunicamycin	O
(	O
TM	O
)	O
,	O
a	O
PERK	O
activator	O
,	O
promoted	O
transcription	O
of	O
hsp27	O
;	O
and	O
necrosis	O
induced	O
by	O
glutamate	O
could	O
be	O
rescued	O
by	O
TM	O
,	O
associated	O
with	O
reduced	O
p53	O
accumulation	O
.	O

In	O
an	O
ischemic	O
stroke	O
model	O
in	O
rats	O
,	O
p53	O
protein	O
was	O
also	O
increased	O
,	O
and	O
TM	O
treatment	O
could	O
reduce	O
the	O
p53	O
accumulation	O
and	O
brain	O
damage	O
.	O

In	O
vivo	O
CRISPR	O
screening	O
identifies	O
Ptpn2	O
as	O
a	O
cancer	O
immunotherapy	O
target	O
.	O

Immunotherapy	O
with	O
PD-1	O
checkpoint	O
blockade	O
is	O
effective	O
in	O
only	O
a	O
minority	O
of	O
patients	O
with	O
cancer	O
,	O
suggesting	O
that	O
additional	O
treatment	O
strategies	O
are	O
needed	O
.	O

Here	O
we	O
use	O
a	O
pooled	O
in	O
vivo	O
genetic	O
screening	O
approach	O
using	O
CRISPR	O
-	O
Cas9	O
genome	O
editing	O
in	O
transplantable	O
tumours	O
in	O
mice	O
treated	O
with	O
immunotherapy	O
to	O
discover	O
previously	O
undescribed	O
immunotherapy	O
targets	O
.	O

We	O
tested	O
2,368	O
genes	O
expressed	O
by	O
melanoma	O
cells	O
to	O
identify	O
those	O
that	O
synergize	O
with	O
or	O
cause	O
resistance	O
to	O
checkpoint	O
blockade	O
.	O

We	O
recovered	O
the	O
known	O
immune	O
evasion	O
molecules	O
PD	O
-	O
L1	O
and	O
CD47	O
,	O
and	O
confirmed	O
that	O
defects	O
in	O
interferon	O
-	O
γ	O
signalling	O
caused	O
resistance	O
to	O
immunotherapy	O
.	O

Tumours	O
were	O
sensitized	O
to	O
immunotherapy	O
by	O
deletion	O
of	O
genes	O
involved	O
in	O
several	O
diverse	O
pathways	O
,	O
including	O
NF	O
-	O
κB	O
signalling	O
,	O
antigen	O
presentation	O
and	O
the	O
unfolded	O
protein	O
response	O
.	O

In	O
addition	O
,	O
deletion	B-Var
of	O
the	O
protein	O
tyrosine	O
phosphatase	O
PTPN2	B-Gene
in	O
tumour	O
cells	O
increased	B-PosReg
the	O
efficacy	B-CPA
of	I-CPA
immunotherapy	I-CPA
by	O
enhancing	B-PosReg
interferon	B-MPA
-	I-MPA
γ	I-MPA
-	I-MPA
mediated	I-MPA
effects	I-MPA
on	I-MPA
antigen	I-MPA
presentation	I-MPA
and	O
growth	B-CPA
suppression	I-CPA
.	O

In	O
vivo	O
genetic	O
screens	O
in	O
tumour	O
models	O
can	O
identify	O
new	O
immunotherapy	O
targets	O
in	O
unanticipated	O
pathways	O
.	O

A	O
patient	O
with	O
germ	O
-	O
line	O
gain	O
-	O
of	O
-	O
function	O
PDGFRB	O
p	O
.	O
N666H	O
mutation	O
and	O
marked	O
clinical	O
response	O
to	O
imatinib	O
.	O

PurposeHeterozygous	O
germ	O
-	O
line	O
activating	O
mutations	B-Var
in	O
PDGFRB	B-Gene
cause	B-Reg
Kosaki	B-Disease
and	I-Disease
Penttinen	I-Disease
syndromes	I-Disease
and	O
myofibromatosis	B-Disease
.	O

We	O
describe	O
a	O
10-year	O
-	O
old	O
child	O
with	O
a	O
germ	O
-	O
line	O
PDGFRB	B-Gene
p	B-Var
.	I-Var
N666H	I-Var
mutation	O
who	O
responded	B-MPA
to	I-MPA
the	I-MPA
tyrosine	I-MPA
kinase	I-MPA
inhibitor	I-MPA
imatinib	I-MPA
by	O
inhibition	B-NegReg
of	O
PDGFRB.MethodsThe	B-Gene
impact	O
of	O
p	O
.	O
N666H	O
on	O
PDGFRB	O
function	O
and	O
sensitivity	O
to	O
imatinib	O
was	O
studied	O
in	O
cell	O
culture	O
.	O

ResultsCells	O
expressing	O
the	O
p	O
.	O
N666H	O
mutation	O
showed	O
constitutive	O
PDGFRB	O
tyrosine	O
phosphorylation	O
.	O

PDGF	O
-	O
independent	O
proliferation	O
was	O
abolished	O
by	O
imatinib	O
at	O
1	O
μM	O
concentration	O
.	O

Patient	O
fibroblasts	O
showed	O
constitutive	O
receptor	O
tyrosine	O
phosphorylation	O
that	O
was	O
also	O
abrogated	O
by	O
imatinib	O
with	O
reduced	O
proliferation	O
of	O
treated	O
cells	O
.	O

This	O
led	O
to	O
patient	O
treatment	O
with	O
imatinib	O
at	O
400	O
mg	O
daily	O
(	O
340	O
mg	O
/	O
m(2	O
)	O
)	O
for	O
a	O
year	O
with	O
objective	O
improvement	O
of	O
debilitating	O
hand	O
and	O
foot	O
contractures	O
,	O
reduced	O
facial	O
coarseness	O
,	O
and	O
significant	O
improvement	O
in	O
quality	O
of	O
life	O
.	O

New	O
small	O
subcutaneous	O
nodules	O
developed	O
,	O
but	O
remained	O
stable	O
.	O

Transient	O
leukopenia	O
,	O
neutropenia	O
,	O
and	O
fatigue	O
resolved	O
without	O
intervention	O
;	O
however	O
,	O
mildly	O
decreased	O
growth	O
velocity	O
resulted	O
in	O
reducing	O
imatinib	O
dose	O
to	O
200	O
mg	O
daily	O
(	O
170	O
mg	O
/	O
m(2	O
)	O
)	O
.	O

The	O
patient	O
continues	O
treatment	O
with	O
ongoing	O
clinical	O
response	O
.	O

ConclusionTo	O
our	O
knowledge	O
,	O
this	O
is	O
one	O
of	O
the	O
first	O
personalized	O
treatments	O
of	O
a	O
congenital	O
disorder	O
caused	O
by	O
a	O
germ	O
-	O
line	O
PDGF	O
receptor	O
mutation	O
with	O
a	O
PDGFRB	O
inhibitor	O
.	O

GENETICS	O
in	O
MEDICINE	O
advance	O
online	O
publication	O
,	O
20	O
July	O
2017	O
;	O
doi:10.1038	O
/	O
gim.2017.104	O
.	O

Genetic	O
Diseases	O
of	O
PIEZO1	O
and	O
PIEZO2	O
Dysfunction	O
.	O

Mutations	O
in	O
the	O
genes	O
encoding	O
the	O
mechanosensitive	O
cation	O
channels	O
PIEZO1	O
and	O
PIEZO2	O
are	O
responsible	O
for	O
multiple	O
hereditary	O
human	O
diseases	O
.	O

Loss	B-NegReg
-	I-NegReg
of	I-NegReg
-	I-NegReg
function	I-NegReg
mutations	B-Var
in	O
the	O
human	O
PIEZO1	B-Gene
gene	O
cause	O
autosomal	B-Disease
recessive	I-Disease
congenital	I-Disease
lymphatic	I-Disease
dysplasia	I-Disease
.	O

Gain	B-PosReg
-	I-PosReg
of	I-PosReg
-	I-PosReg
function	I-PosReg
mutations	B-Var
in	O
the	O
human	O
PIEZO1	B-Gene
gene	O
cause	O
the	O
autosomal	B-Disease
dominant	I-Disease
hemolytic	I-Disease
anemia	I-Disease
,	O
hereditary	B-Disease
xerocytosis	I-Disease
(	O
also	O
known	O
as	O
dehydrated	B-Disease
stomatocytosis	I-Disease
)	I-Disease
.	O

Loss	B-NegReg
-	I-NegReg
of	I-NegReg
-	I-NegReg
function	I-NegReg
mutations	B-Var
in	O
the	O
human	O
PIEZO2	B-Gene
gene	O
cause	O
an	O
autosomal	B-Disease
recessive	I-Disease
syndrome	I-Disease
of	I-Disease
muscular	I-Disease
atrophy	I-Disease
with	O
perinatal	O
respiratory	O
distress	O
,	O
arthrogryposis	B-Disease
,	O
and	O
scoliosis	B-Disease
.	O

Gain	B-PosReg
-	I-PosReg
of	I-PosReg
-	I-PosReg
function	I-PosReg
mutations	B-Var
in	O
the	O
human	O
PIEZO2	B-Gene
gene	O
cause	O
three	O
clinical	O
types	O
of	O
autosomal	B-Disease
dominant	I-Disease
distal	I-Disease
arthrogryposis	I-Disease
.	O

This	O
chapter	O
will	O
review	O
the	O
hereditary	O
diseases	O
caused	O
by	O
mutations	O
in	O
the	O
PIEZO	O
genes	O
and	O
will	O
discuss	O
additional	O
physiological	O
systems	O
in	O
which	O
PIEZO	O
channel	O
dysfunction	O
may	O
contribute	O
to	O
human	O
disease	O
pathophysiology	O
.	O

Differential	O
calcium	O
sensitivity	O
in	O
NaV	O
1.5	O
mixed	O
syndrome	O
mutants	O
.	O

KEY	O
POINTS	O
:	O
SCN5a	B-Gene
mutations	B-Var
may	O
express	O
gain	B-PosReg
-	I-PosReg
of	I-PosReg
-	I-PosReg
function	I-PosReg
(	B-Disease
Long	I-Disease
QT	I-Disease
Syndrome-3	I-Disease
)	I-Disease
,	O
loss	B-NegReg
-	I-NegReg
of	I-NegReg
-	I-NegReg
function	I-NegReg
(	B-Disease
Brugada	I-Disease
Syndrome	I-Disease
1	I-Disease
)	I-Disease
or	O
both	O
(	O
mixed	O
syndromes	O
)	O
,	O
depending	O
on	O
the	O
mutation	O
and	O
environmental	O
triggers	O
.	O

One	O
such	O
trigger	O
may	O
be	O
an	O
increase	O
in	O
cytosolic	O
calcium	O
,	O
accompanying	O
exercise	O
.	O

Many	O
mixed	O
syndromes	O
mutants	O
,	O
including	O
∆KPQ	O
,	O
E1784	O
K	O
,	O
1795insD	O
and	O
Q1909R	O
,	O
are	O
found	O
in	O
calcium	O
-	O
sensitive	O
regions	O
.	O

Elevated	O
cytosolic	O
calcium	O
attenuates	O
gain	O
-	O
of	O
-	O
function	O
properties	O
in	O
∆KPQ	O
,	O
1795insD	O
and	O
Q1909R	O
,	O
but	O
not	O
in	O
E1784K.	O
By	O
contrast	O
,	O
elevated	O
cytosolic	O
calcium	O
further	O
exacerbates	O
gain	O
-	O
of	O
-	O
function	O
in	O
E1784	O
K	O
by	O
destabilizing	O
slow	O
inactivation	O
.	O

Action	O
potential	O
modelling	O
,	O
using	O
a	O
modified	O
O'Hara	O
Rudy	O
model	O
,	O
suggests	O
that	O
elevated	O
heart	O
rate	O
rescues	O
action	O
potential	O
duration	O
in	O
∆KPQ	O
,	O
1795insD	O
and	O
Q1909R	O
,	O
but	O
not	O
in	O
E1784K.	O
Action	O
potential	O
simulations	O
suggest	O
that	O
E1784	O
K	O
carriers	O
have	O
an	O
increased	O
intracellular	O
sodium	O
-	O
to	O
-	O
calcium	O
ratio	O
under	O
bradycardia	O
and	O
tachycardia	O
conditions	O
.	O

Elevated	O
cytosolic	O
calcium	O
,	O
which	O
is	O
common	O
during	O
high	O
heart	O
rates	O
,	O
ameliorates	O
or	O
exacerbates	O
the	O
mixed	O
syndrome	O
phenotype	O
depending	O
on	O
the	O
genetic	O
signature	O
.	O

ABSTRACT	O
:	O
Inherited	O
arrhythmias	O
may	O
arise	O
from	O
mutations	O
in	O
the	O
gene	O
for	O
SCN5a	O
,	O
which	O
encodes	O
the	O
cardiac	O
voltage	O
-	O
gated	O
sodium	O
channel	O
,	O
NaV	O
1.5	O
.	O

Mutants	O
in	O
NaV	O
1.5	O
result	O
in	O
Brugada	O
Syndrome	O
(	O
BrS1	O
)	O
,	O
Long	O
-	O
QT	O
Syndrome	O
(	O
LQT3	O
)	O
or	O
mixed	O
syndromes	O
(	O
an	O
overlap	O
of	O
BrS1	O
/	O
LQT3	O
)	O
.	O

Exercise	O
is	O
a	O
potential	O
arrhythmogenic	O
trigger	O
in	O
mixed	O
syndromes	O
.	O

We	O
aimed	O
to	O
determine	O
the	O
effects	O
of	O
elevated	O
cytosolic	O
calcium	O
,	O
which	O
is	O
common	O
during	O
exercise	O
,	O
in	O
mixed	O
syndrome	O
NaV	O
1.5	O
mutants	O
.	O

We	O
used	O
whole	O
-	O
cell	O
patch	O
clamp	O
to	O
assess	O
the	O
biophysical	O
properties	O
of	O
NaV	O
1.5	O
wild	O
-	O
type	O
(	O
WT	O
)	O
,	O
∆KPQ	O
,	O
E1784	O
K	O
,	O
1795insD	O
and	O
Q1909R	O
mutants	O
in	O
human	O
embryonic	O
kidney	O
293	O
cells	O
transiently	O
transfected	O
with	O
the	O
NaV	O
1.5	O
α	O
subunit	O
(	O
WT	O
or	O
mutants	O
)	O
,	O
β1	O
subunit	O
and	O
enhanced	O
green	O
fluorescent	O
protein	O
.	O

Voltage	O
-	O
dependence	O
and	O
kinetics	O
were	O
measured	O
at	O
cytosolic	O
calcium	O
levels	O
of	O
approximately	O
0	O
,	O
500	O
and	O
2500	O
nm	O
.	O

In	O
silico	O
,	O
action	O
potential	O
(	O
AP	O
)	O
model	O
simulations	O
were	O
performed	O
using	O
a	O
modified	O
O'Hara	O
Rudy	O
model	O
.	O

Elevated	O
cytosolic	O
calcium	O
attenuates	O
the	O
late	O
sodium	O
current	O
in	O
∆KPQ	O
,	O
1795insD	O
and	O
Q1909R	O
,	O
but	O
not	O
in	O
E1784K.	O
Elevated	O
cytosolic	O
calcium	O
restores	O
steady	O
-	O
state	O
slow	O
inactivation	O
(	O
SSSI	O
)	O
to	O
the	O
WT	O
-	O
form	O
in	O
Q1909R	O
,	O
but	O
depolarized	O
SSSI	O
in	O
E1784K.	O
Our	O
AP	O
simulations	O
showed	O
a	O
frequency	O
-	O
dependent	O
reduction	O
of	O
AP	O
duration	O
in	O
∆KPQ	O
,	O
1795insD	O
and	O
Q1909R	O
carriers	O
.	O

In	O
E1784	O
K	O
,	O
AP	O
duration	O
is	O
relatively	O
prolonged	O
at	O
both	O
low	O
and	O
high	O
heart	O
rates	O
,	O
resulting	O
in	O
a	O
sodium	O
overload	O
.	O

Cellular	O
perturbations	O
during	O
exercise	O
may	O
affect	O
BrS1	O
/	O
LQT3	O
patients	O
differently	O
depending	O
on	O
their	O
individual	O
genetic	O
signature	O
.	O

Thus	O
,	O
exercise	O
may	O
be	O
therapeutic	O
or	O
may	O
be	O
an	O
arrhythmogenic	O
trigger	O
in	O
some	O
SCN5a	O
patients	O
.	O

D242N	O
,	O
a	O
KV7.1	O
LQTS	O
mutation	O
uncovers	O
a	O
key	O
residue	O
for	O
IKs	O
voltage	O
dependence	O
.	O

KV7.1	O
and	O
KCNE1	O
co	O
-	O
assemble	O
to	O
give	O
rise	O
to	O
the	O
IKs	O
current	O
,	O
one	O
of	O
the	O
most	O
important	O
repolarizing	O
currents	O
of	O
the	O
cardiac	O
action	O
potential	O
.	O

Its	O
relevance	O
is	O
underscored	O
by	O
the	O
identification	O
of	O
>	O
500	O
mutations	B-Var
in	O
KV7.1	B-Gene
and	O
,	O
at	O
least	O
,	O
36	O
in	O
KCNE1	B-Gene
,	O
that	O
cause	B-Reg
Long	B-Disease
QT	I-Disease
Syndrome	I-Disease
(	O
LQTS	O
)	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
characterize	O
the	O
biophysical	O
and	O
cellular	O
consequences	O
of	O
the	O
D242N	B-Var
KV7.1	B-Gene
mutation	O
associated	B-Reg
with	O
the	O
LQTS	B-Disease
.	O

The	O
mutation	B-Var
is	O
located	O
in	O
the	O
S4	O
transmembrane	O
segment	O
,	O
within	O
the	O
voltage	O
sensor	O
of	O
the	O
KV7.1	O
channel	O
,	O
disrupting	B-NegReg
the	O
conserved	B-MPA
charge	I-MPA
balance	I-MPA
of	I-MPA
this	I-MPA
region	I-MPA
.	O

Perforated	O
patch	O
-	O
clamp	O
experiments	O
show	O
that	O
,	O
unexpectedly	O
,	O
the	O
mutation	B-Var
did	O
not	O
disrupt	O
the	O
voltage	O
-	O
dependent	O
activation	O
but	O
it	O
removed	B-NegReg
the	O
inactivation	B-MPA
and	O
slowed	B-NegReg
the	O
activation	B-MPA
kinetics	I-MPA
of	O
D242N	B-MPA
KV7.1	I-MPA
channels	I-MPA
.	O

Biotinylation	O
of	O
cell	O
-	O
surface	O
protein	O
and	O
co	O
-	O
immunoprecipitation	O
experiments	O
revealed	O
that	O
neither	O
plasma	O
membrane	O
targeting	O
nor	O
co	O
-	O
assembly	O
between	O
KV7.1	O
and	O
KCNE1	O
was	O
altered	O
by	O
the	O
mutation	O
.	O

However	O
,	O
the	O
association	O
of	O
D242N	O
KV7.1	O
with	O
KCNE1	O
strongly	O
shifted	O
the	O
voltage	O
dependence	O
of	O
activation	O
to	O
more	O
depolarized	O
potentials	O
(	O
+50mV	O
)	O
,	O
hindering	O
IKs	O
current	O
at	O
physiologically	O
relevant	O
membrane	O
potentials	O
.	O

Both	O
functional	O
and	O
computational	O
analysis	O
suggest	O
that	O
the	O
clinical	O
phenotype	O
of	O
the	O
LQTS	O
patients	O
carrying	O
the	O
D242N	B-Var
mutation	O
is	O
due	O
to	O
impaired	B-NegReg
action	B-MPA
potential	I-MPA
adaptation	I-MPA
to	I-MPA
exercise	I-MPA
and	O
,	O
in	O
particular	O
,	O
to	O
increase	B-PosReg
in	O
heart	B-MPA
rate	I-MPA
.	O

Moreover	O
,	O
our	O
data	O
identify	O
D242	O
aminoacidic	O
position	O
as	O
a	O
potential	O
residue	O
involved	O
in	O
the	O
KCNE1-mediated	O
regulation	O
of	O
the	O
voltage	O
dependence	O
of	O
activation	O
of	O
the	O
KV7.1	O
channel	O
.	O

A	O
Gene	O
Implicated	O
in	O
Activation	O
of	O
Retinoic	O
Acid	O
Receptor	O
Targets	O
is	O
a	O
Novel	O
Renal	O
Agenesis	O
Gene	O
in	O
Humans	O
.	O

Renal	B-Disease
agenesis	I-Disease
(	O
RA	O
)	O
is	O
one	O
of	O
the	O
more	O
extreme	O
examples	O
of	O
congenital	O
anomalies	O
of	O
the	O
kidney	O
and	O
urinary	O
tract	O
(	O
CAKUT	O
)	O
.	O

Bilateral	O
renal	O
agenesis	O
is	O
almost	O
invariably	O
fatal	O
at	O
birth	O
,	O
and	O
unilateral	O
renal	O
agenesis	O
can	O
lead	O
to	O
future	O
health	O
issues	O
including	O
end	O
stage	O
renal	O
disease	O
.	O

Genetic	O
investigations	O
have	O
identified	O
several	O
gene	O
variants	B-Var
which	O
cause	B-Reg
RA	B-Disease
,	O
including	O
EYA1	O
,	O
LHX1	O
,	O
and	O
WT1	O
However	O
,	O
whereas	O
compound	O
null	O
mutations	O
of	O
genes	O
encoding	O
α	O
and	O
γ	O
retinoic	O
acid	O
receptors	O
(	O
RARs	O
)	O
cause	O
RA	O
in	O
mice	O
,	O
to	O
date	O
there	O
have	O
been	O
no	O
reports	O
of	O
variants	O
in	O
RAR	O
genes	O
causing	O
RA	O
in	O
humans	O
.	O

In	O
this	O
study	O
,	O
we	O
carried	O
out	O
whole	O
exome	O
sequence	O
analysis	O
of	O
two	O
families	O
showing	O
inheritance	O
of	O
an	O
RA	O
phenotype	O
,	O
and	O
in	O
both	O
identified	O
a	O
single	O
candidate	O
gene	O
,	O
GREB1L	O
Analysis	O
of	O
a	O
zebrafish	O
greb1l	O
loss	B-NegReg
-	I-NegReg
of	I-NegReg
-	I-NegReg
function	I-NegReg
mutant	B-Var
revealed	O
defects	O
in	O
the	O
pronephric	B-MPA
kidney	I-MPA
just	I-MPA
prior	I-MPA
to	I-MPA
death	I-MPA
,	O
and	O
F0	O
CRISPR	O
/	O
Cas9	O
mutagenesis	B-Var
of	O
Greb1l	O
in	O
the	O
mouse	O
revealed	B-Reg
kidney	B-MPA
agenesis	I-MPA
phenotypes	I-MPA
,	O
implicating	O
Greb1l	O
in	O
this	O
disorder	O
.	O

GREB1L	O
resides	O
in	O
a	O
chromatin	O
complex	O
with	O
RAR	O
members	O
,	O
and	O
our	O
data	O
implicate	O
GREB1L	O
as	O
a	O
coactivator	O
for	O
RARs	O
.	O

This	O
study	O
is	O
the	O
first	O
to	O
associate	O
a	O
component	O
of	O
the	O
RAR	O
pathway	O
with	O
renal	O
agenesis	O
in	O
humans	O
.	O

Equivalent	O
missense	B-Var
variant	I-Var
in	O
the	O
FOXP2	B-Gene
and	O
FOXP1	B-Gene
transcription	O
factors	O
causes	B-Reg
distinct	O
neurodevelopmental	B-Disease
disorders	I-Disease
.	O

The	O
closely	O
related	O
paralogues	O
FOXP2	O
and	O
FOXP1	O
encode	O
transcription	O
factors	O
with	O
shared	O
functions	O
in	O
the	O
development	O
of	O
many	O
tissues	O
,	O
including	O
the	O
brain	O
.	O

However	O
,	O
while	O
mutations	B-Var
in	O
FOXP2	B-Gene
lead	B-Reg
to	I-Reg
a	O
speech	O
/	O
language	O
disorder	O
characterized	O
by	O
childhood	B-Disease
apraxia	I-Disease
of	I-Disease
speech	I-Disease
(	O
CAS	O
)	O
,	O
the	O
clinical	O
profile	O
of	O
FOXP1	B-Gene
variants	B-Var
includes	B-Reg
a	O
broader	O
neurodevelopmental	O
phenotype	O
with	O
global	B-Disease
developmental	I-Disease
delay	I-Disease
,	O
intellectual	B-Disease
disability	I-Disease
,	O
and	O
speech	B-Disease
/	I-Disease
language	I-Disease
impairment	I-Disease
.	O

Using	O
clinical	O
whole	O
-	O
exome	O
sequencing	O
,	O
we	O
report	O
an	O
identical	O
de	O
novo	O
missense	O
FOXP1	O
variant	O
identified	O
in	O
three	O
unrelated	O
patients	O
.	O

The	O
variant	O
,	O
p	O
.	O
R514H	O
,	O
is	O
located	O
in	O
the	O
forkhead	O
-	O
box	O
DNA	O
-	O
binding	O
domain	O
and	O
is	O
equivalent	O
to	O
the	O
well	O
-	O
studied	O
p	O
.	O
R553H	O
FOXP2	O
variant	O
that	O
cosegregates	O
with	O
CAS	O
in	O
a	O
large	O
UK	O
family	O
.	O

We	O
present	O
here	O
for	O
the	O
first	O
time	O
a	O
direct	O
comparison	O
of	O
the	O
molecular	O
and	O
clinical	O
consequences	O
of	O
the	O
same	O
mutation	O
affecting	O
the	O
equivalent	O
residue	O
in	O
FOXP1	O
and	O
FOXP2	O
.	O

Detailed	O
functional	O
characterization	O
of	O
the	O
two	O
variants	O
in	O
cell	O
model	O
systems	O
revealed	O
very	O
similar	O
molecular	O
consequences	O
,	O
including	O
aberrant	O
subcellular	O
localization	O
,	O
disruption	O
of	O
transcription	O
factor	O
activity	O
,	O
and	O
deleterious	O
effects	O
on	O
protein	O
interactions	O
.	O

Nonetheless	O
,	O
clinical	O
manifestations	O
were	O
broader	O
and	O
more	O
severe	O
in	O
the	O
three	O
cases	O
carrying	O
the	O
p	O
.	O
R514H	O
FOXP1	O
variant	O
than	O
in	O
individuals	O
with	O
the	O
p	O
.	O
R553H	O
variant	O
related	O
to	O
CAS	O
,	O
highlighting	O
divergent	O
roles	O
of	O
FOXP2	O
and	O
FOXP1	O
in	O
neurodevelopment	O
.	O

Novel	O
PRPS1	O
gain	O
-	O
of	O
-	O
function	O
mutation	O
in	O
a	O
patient	O
with	O
congenital	O
hyperuricemia	O
and	O
facial	O
anomalies	O
.	O

Phosphoribosylpyrophosphate	O
synthetase	O
(	O
PRPPS	O
)	O
superactivity	O
(	O
OMIM	O
300661	O
)	O
is	O
a	O
rare	O
inborn	O
error	O
of	O
purine	O
metabolism	O
that	O
is	O
caused	O
by	O
gain	O
-	O
of	O
-	O
function	O
mutations	O
in	O
the	O
X	O
-	O
chromosomal	O
gene	O
PRPS1	O
(	O
Xq22.3	O
)	O
.	O

Clinical	O
characteristics	O
include	O
congenital	O
hyperuricemia	O
and	O
hyperuricosuria	O
,	O
gouty	O
arthritis	O
,	O
urolithiasis	O
,	O
developmental	O
delay	O
,	O
hypotonia	O
,	O
recurrent	O
infections	O
,	O
short	O
stature	O
,	O
and	O
hearing	O
loss	O
.	O

Only	O
eight	O
families	O
with	O
PRPPS	O
superactivity	O
and	O
PRPS1	O
gain	O
-	O
of	O
-	O
function	O
mutations	O
have	O
been	O
reported	O
to	O
date	O
.	O

We	O
report	O
on	O
a	O
7-year	O
-	O
old	O
boy	O
with	O
congenital	O
hyperuricemia	O
,	O
urolithiasis	O
,	O
developmental	O
delay	O
,	O
short	O
stature	O
,	O
hypospadias	O
,	O
and	O
facial	O
dysmorphisms	O
.	O

His	O
mother	O
also	O
suffered	O
from	O
hyperuricemia	O
that	O
was	O
diagnosed	O
at	O
age	O
13	O
years	O
.	O

A	O
novel	O
PRPS1	O
missense	O
mutation	O
(	O
c.573G	O
>	O
C	O
,	O
p.[Leu191Phe	O
]	O
)	O
was	O
detected	O
in	O
the	O
proband	O
and	O
his	O
mother	O
.	O

Enzyme	O
activity	O
analysis	O
confirmed	O
superactivity	O
of	O
PRPP	O
synthetase	O
.	O

Analysis	O
of	O
the	O
crystal	O
structure	O
of	O
human	O
PRPPS	O
suggests	O
that	O
the	O
Leu191Phe	B-Gene
mutation	B-Var
affects	B-Reg
the	O
architecture	B-MPA
of	O
both	O
allosteric	O
sites	O
,	O
thereby	O
preventing	B-NegReg
the	O
allosteric	B-MPA
inhibition	I-MPA
of	O
the	O
enzyme	B-Enzyme
.	O

The	O
family	O
reported	O
here	O
broadens	O
the	O
clinical	O
spectrum	O
of	O
PRPPS	O
superactivity	O
and	O
indicates	O
that	O
this	O
rare	O
metabolic	O
disorder	O
might	O
be	O
associated	O
with	O
a	O
recognizable	O
facial	O
gestalt	O
.	O

Naturally	O
-	O
Segregating	O
Variation	B-Var
at	O
Ugt86Dd	B-Gene
Contributes	B-Reg
to	O
Nicotine	B-MPA
Resistance	I-MPA
in	I-MPA
Drosophila	I-MPA
melanogaster	I-MPA
.	O

Identifying	O
the	O
sequence	O
polymorphisms	O
underlying	O
complex	O
trait	O
variation	O
is	O
a	O
key	O
goal	O
of	O
genetics	O
research	O
,	O
since	O
knowing	O
the	O
precise	O
causative	O
molecular	O
events	O
allows	O
insight	O
into	O
the	O
pathways	O
governing	O
trait	O
variation	O
.	O

Genetic	O
analysis	O
of	O
complex	O
traits	O
in	O
model	O
systems	O
regularly	O
starts	O
by	O
constructing	O
QTL	O
maps	O
,	O
but	O
generally	O
fails	O
to	O
identify	O
causative	O
sequence	O
polymorphisms	O
.	O

Previously	O
we	O
mapped	O
a	O
series	O
of	O
QTL	O
contributing	O
to	O
resistance	O
to	O
nicotine	O
in	O
a	O
Drosophila	O
melanogaster	O
multiparental	O
mapping	O
resource	O
,	O
and	O
here	O
use	O
a	O
battery	O
of	O
functional	O
tests	O
to	O
resolve	O
QTL	O
to	O
the	O
molecular	O
level	O
.	O

One	O
large	O
-	O
effect	O
QTL	O
resided	O
over	O
a	O
cluster	O
of	O
UDP	O
-	O
glucuronosyltransferases	O
,	O
and	O
quantitative	O
complementation	O
tests	O
using	O
deficiencies	O
eliminating	O
subsets	O
of	O
these	O
detoxification	O
genes	O
revealed	O
allelic	O
variation	O
impacting	O
resistance	O
.	O

RNAseq	O
showed	O
that	O
Ugt86Dd	O
had	O
significantly	O
higher	O
expression	O
in	O
genotypes	O
that	O
are	O
more	O
resistant	O
to	O
nicotine	O
,	O
and	O
anterior	O
midgut	O
-	O
specific	O
RNAi	O
of	O
this	O
gene	O
reduced	O
resistance	O
.	O

We	O
discovered	O
a	O
segregating	O
22-bp	O
frameshift	B-Var
deletion	I-Var
in	O
Ugt86Dd	B-Gene
,	O
and	O
accounting	O
for	O
the	O
InDel	O
during	O
mapping	O
largely	O
eliminates	B-NegReg
the	O
QTL	B-MPA
,	O
implying	O
the	O
event	O
explains	O
the	O
bulk	O
of	O
the	O
effect	O
of	O
the	O
mapped	O
locus	O
.	O

CRISPR	O
/	O
Cas9	O
editing	O
a	O
relatively	O
resistant	O
genotype	O
to	O
generate	O
lesions	B-Var
in	O
Ugt86Dd	B-Gene
that	O
recapitulate	O
the	O
naturally	O
-	O
occurring	O
putative	O
loss	B-NegReg
-	I-NegReg
of	I-NegReg
-	I-NegReg
function	I-NegReg
allele	O
leads	O
to	O
a	O
large	O
reduction	B-NegReg
in	O
resistance	B-MPA
.	O

Despite	O
this	O
major	O
effect	O
of	O
the	O
deletion	O
,	O
the	O
allele	O
appears	O
to	O
be	O
very	O
rare	O
in	O
wild	O
-	O
caught	O
populations	O
,	O
and	O
likely	O
explains	O
only	O
a	O
small	O
fraction	O
of	O
the	O
natural	O
variation	O
for	O
the	O
trait	O
.	O

Nonetheless	O
,	O
this	O
putatively	O
causative	O
coding	O
InDel	O
can	O
be	O
a	O
launchpad	O
for	O
future	O
mechanistic	O
exploration	O
of	O
xenobiotic	O
detoxification	O
.	O

Sequence	B-Var
exchange	I-Var
between	O
R	B-Gene
genes	O
converts	B-Reg
virus	O
resistance	O
into	O
nematode	B-MPA
resistance	I-MPA
,	O
and	O
vice	O
versa	O
.	O

Plants	O
have	O
evolved	O
a	O
limited	O
repertoire	O
of	O
NB	O
-	O
LRR	O
disease	O
resistance	O
(	O
R	O
)	O
genes	O
to	O
protect	O
themselves	O
against	O
a	O
myriad	O
of	O
pathogens	O
.	O

This	O
limitation	O
is	O
thought	O
to	O
be	O
counterbalanced	O
by	O
the	O
rapid	O
evolution	O
of	O
NB	O
-	O
LRR	O
proteins	O
,	O
as	O
only	O
few	O
sequence	O
changes	B-Var
have	O
been	O
shown	O
to	O
be	O
sufficient	O
to	O
alter	B-Reg
resistance	B-MPA
specificities	I-MPA
towards	I-MPA
novel	I-MPA
strains	I-MPA
of	I-MPA
a	I-MPA
pathogen	I-MPA
.	O

However	O
,	O
little	O
is	O
known	O
about	O
the	O
flexibility	O
of	O
NB	O
-	O
LRR	O
genes	O
to	O
switch	O
resistance	O
specificities	O
between	O
phylogenetically	O
unrelated	O
pathogens	O
.	O

To	O
investigate	O
this	O
,	O
we	O
created	O
domain	O
swaps	O
between	O
the	O
close	O
homologs	O
Gpa2	O
and	O
Rx1	O
,	O
which	O
confer	O
resistance	O
in	O
potato	O
to	O
the	O
cyst	O
nematode	O
Globodera	O
pallida	O
and	O
Potato	O
virus	O
X	O
(	O
PVX	O
)	O
,	O
respectively	O
.	O

The	O
genetic	O
fusion	O
of	O
the	O
CC	O
-	O
NB	O
-	O
ARC	O
of	O
Gpa2	O
with	O
the	O
LRR	O
of	O
Rx1	O
(	O
Gpa2CN	O
/	O
Rx1L	O
)	O
resulted	O
in	O
autoactivity	O
,	O
but	O
lowering	O
the	O
protein	O
levels	O
restored	O
its	O
specific	O
activation	O
response	O
including	O
extreme	O
resistance	O
to	O
PVX	O
in	O
potato	O
shoots	O
.	O

The	O
reciprocal	O
construct	O
(	O
Rx1CN	O
/	O
Gpa2L	O
)	O
showed	O
a	O
loss	O
-	O
of	O
-	O
function	O
phenotype	O
,	O
but	O
exchange	B-Var
of	O
the	O
first	O
3	O
LRR	O
repeats	O
of	O
Rx1	B-Gene
was	O
sufficient	O
to	O
regain	B-PosReg
a	O
wild	B-MPA
type	I-MPA
resistance	I-MPA
response	I-MPA
to	I-MPA
G.	I-MPA
pallida	I-MPA
in	I-MPA
the	I-MPA
roots	I-MPA
.	O

These	O
data	O
demonstrate	O
that	O
exchanging	B-Var
the	O
recognition	O
moiety	O
in	O
the	O
LRR	O
is	O
sufficient	O
to	O
convert	B-Reg
extreme	O
virus	O
resistance	O
in	O
the	O
leaves	O
into	O
mild	B-MPA
nematode	I-MPA
resistance	I-MPA
in	I-MPA
the	I-MPA
roots	I-MPA
,	O
and	O
vice	O
versa	O
.	O

In	O
addition	O
,	O
we	O
show	O
that	O
the	O
CC	O
-	O
NB	O
-	O
ARC	O
can	O
operate	O
independently	O
of	O
the	O
recognition	O
specificities	O
defined	O
by	O
the	O
LRR	O
domain	O
,	O
either	O
above	O
or	O
belowground	O
.	O

These	O
data	O
show	O
the	O
versatility	O
of	O
NB	O
-	O
LRR	O
genes	O
to	O
generate	O
resistances	O
to	O
unrelated	O
pathogens	O
with	O
completely	O
different	O
lifestyles	O
and	O
routes	O
of	O
invasion	O
.	O

Lethal	O
digenic	O
mutations	B-Var
in	O
the	O
K(+	O
)	O
channels	O
Kir4.1	O
(	B-Gene
KCNJ10	I-Gene
)	I-Gene
and	O
SLACK	O
(	B-Gene
KCNT1	I-Gene
)	I-Gene
associated	B-Reg
with	O
severe	O
-	O
disabling	O
seizures	B-Disease
and	O
neurodevelopmental	B-Disease
delay	I-Disease
.	O

A	O
2-year	O
-	O
old	O
boy	O
presented	O
profound	O
developmental	O
delay	O
,	O
failure	O
to	O
thrive	O
,	O
ataxia	O
,	O
hypotonia	O
and	O
tonic	O
-	O
clonic	O
seizures	O
that	O
caused	O
the	O
death	O
of	O
the	O
patient	O
.	O

Targeted	O
and	O
whole	O
-	O
exome	O
sequencing	O
revealed	O
two	O
heterozygous	O
missense	O
variants	O
:	O
a	O
novel	O
mutation	O
in	O
KCNJ10	O
gene	O
that	O
encodes	O
for	O
the	O
inwardly	O
-	O
rectifying	O
K(+	O
)	O
channel	O
Kir4.1	O
and	O
another	O
previously	O
characterized	O
mutation	O
in	O
KCNT1	O
that	O
encodes	O
for	O
the	O
Na(+)-activated	O
K(+	O
)	O
channel	O
known	O
as	O
Slo2.2	O
or	O
SLACK	O
.	O

The	O
objectives	O
of	O
this	O
study	O
were	O
to	O
perform	O
the	O
clinical	O
and	O
genetic	O
characterization	O
of	O
the	O
proband	O
and	O
his	O
family	O
and	O
to	O
examine	O
the	O
functional	O
consequence	O
of	O
the	O
Kir4.1	O
mutation	O
.	O

The	O
mutant	O
and	O
wild	O
-	O
type	O
KCNJ10	O
constructs	O
were	O
generated	O
and	O
heterologously	O
expressed	O
in	O
Xenopus	O
laevis	O
oocytes	O
,	O
and	O
whole	O
-	O
cell	O
K(+	O
)	O
currents	O
were	O
measured	O
using	O
the	O
two	O
-	O
electrode	O
voltage	O
-	O
clamp	O
technique	O
.	O

The	O
KCNJ10	B-Gene
mutation	B-Var
c.652C	O
>	O
T	O
resulted	B-Reg
in	I-Reg
a	O
p	O
.	O
L218F	O
substitution	B-Var
at	O
a	O
highly	O
conserved	O
residue	O
site	O
.	O

Wild	O
-	O
type	O
KCNJ10	O
expression	O
yielded	O
robust	O
Kir	O
currents	O
,	O
while	O
currents	O
from	O
oocytes	O
expressing	O
the	O
mutation	O
were	O
reduced	O
.	O

Western	O
Blot	O
analysis	O
revealed	O
reduced	B-NegReg
protein	B-MPA
expression	I-MPA
by	O
the	O
mutation	B-Var
.	O

Kir5.1	O
subunits	O
display	O
selective	O
heteromultimerization	O
with	O
Kir4.1	O
constituting	O
channels	O
with	O
unique	O
kinetics	O
.	O

The	O
effect	O
of	O
the	O
mutation	O
on	O
Kir4.1/5.1	O
channel	O
activity	O
was	O
twofold	O
:	O
a	O
reduction	O
in	O
current	O
amplitudes	O
and	O
an	O
increase	O
in	O
the	O
pH	O
-	O
dependent	O
inhibition	O
.	O

We	O
thus	O
report	O
a	O
novel	O
loss	B-NegReg
-	I-NegReg
of	I-NegReg
-	I-NegReg
function	I-NegReg
mutation	B-Var
in	O
Kir4.1	O
found	O
in	O
a	O
patient	O
with	O
a	O
co	O
-	O
exiting	O
mutation	B-Var
in	O
SLACK	O
channels	O
that	O
results	B-Reg
in	I-Reg
a	O
fatal	B-Disease
disease	I-Disease
.	O

Allelic	O
Complexity	O
in	O
Long	O
QT	O
Syndrome	O
:	O
A	O
Family	O
-	O
Case	O
Study	O
.	O

Congenital	O
long	B-Disease
QT	I-Disease
syndrome	I-Disease
(	O
LQTS	O
)	O
is	O
associated	O
with	O
high	O
genetic	O
and	O
allelic	O
heterogeneity	O
.	O

In	O
some	O
cases	O
,	O
more	O
than	O
one	O
genetic	O
variant	O
is	O
identified	O
in	O
the	O
same	O
(	O
compound	O
heterozygosity	O
)	O
or	O
different	O
(	O
digenic	O
heterozygosity	O
)	O
genes	O
,	O
and	O
subjects	O
with	O
multiple	O
pathogenic	O
mutations	O
may	O
have	O
a	O
more	O
severe	O
disease	O
.	O

Standard	O
-	O
of	O
-	O
care	O
clinical	O
genetic	O
testing	O
for	O
this	O
and	O
other	O
arrhythmia	O
susceptibility	O
syndromes	O
improves	O
the	O
identification	O
of	O
complex	O
genotypes	O
.	O

Therefore	O
,	O
it	O
is	O
important	O
to	O
distinguish	O
between	O
pathogenic	O
mutations	O
and	O
benign	O
rare	O
variants	O
.	O

We	O
identified	O
four	O
genetic	O
variants	O
(	O
KCNQ1-p	O
.	O
R583H	O
,	O
KCNH2-p	O
.	O
C108Y	O
,	O
KCNH2-p	O
.	O
K897	O
T	O
,	O
and	O
KCNE1-p	O
.	O
G38S	O
)	O
in	O
an	O
LQTS	O
family	O
.	O

On	O
the	O
basis	O
of	O
in	O
silico	O
analysis	O
,	O
clinical	O
data	O
from	O
our	O
family	O
,	O
and	O
the	O
evidence	O
from	O
previous	O
studies	O
,	O
we	O
analyzed	O
two	O
mutated	O
channels	O
,	O
KCNQ1-p	O
.	O
R583H	O
and	O
KCNH2-p	O
.	O
C108Y	O
,	O
using	O
the	O
whole	O
-	O
cell	O
patch	O
clamp	O
technique	O
.	O

We	O
found	O
that	O
KCNQ1-p	O
.	O
R583H	O
was	O
not	O
associated	O
with	O
a	O
severe	O
functional	O
impairment	O
,	O
whereas	O
KCNH2-p	B-Var
.	I-Var
C108Y	I-Var
,	O
a	O
novel	O
variant	O
,	O
encoded	B-Reg
a	O
non	B-Pathway
-	I-Pathway
functional	I-Pathway
channel	I-Pathway
that	O
exerts	O
dominant	B-NegReg
-	I-NegReg
negative	I-NegReg
effects	B-MPA
on	O
the	O
wild	O
-	O
type	O
.	O

Notably	O
,	O
the	O
common	O
variants	O
KCNH2-p	O
.	O
K897	O
T	O
and	O
KCNE1-p	O
.	O
G38S	O
were	O
previously	O
reported	O
to	O
produce	O
more	O
severe	O
phenotypes	O
when	O
combined	O
with	O
disease	O
-	O
causing	O
alleles	O
.	O

Our	O
results	O
indicate	O
that	O
the	O
novel	O
KCNH2-C108Y	B-Var
variant	O
can	O
be	O
a	O
pathogenic	B-Reg
LQTS	B-Disease
mutation	O
,	O
whereas	O
KCNQ1-p	O
.	O
R583H	O
,	O
KCNH2-p	O
.	O
K897	O
T	O
,	O
and	O
KCNE1-p	O
.	O
G38S	O
could	O
be	O
LQTS	O
modifiers	O
.	O

POSITIVE	O
REGULATOR	O
OF	O
IRON	O
HOMEOSTASIS	O
1	O
(	O
OsPRI1	O
)	O
positively	O
regulates	O
iron	O
homeostasis	O
in	O
rice	O
.	O

OsHRZ1	O
is	O
a	O
potential	O
iron	O
-	O
binding	O
sensor	O
.	O

However	O
,	O
it	O
is	O
unclear	O
how	O
OsHRZ1	O
transmits	O
signals	O
.	O

In	O
this	O
study	O
,	O
we	O
reveal	O
that	O
OsPRI1	O
interacts	O
with	O
OsHRZ1	O
.	O

A	O
loss	B-NegReg
-	I-NegReg
of	I-NegReg
-	I-NegReg
function	I-NegReg
mutation	B-Var
to	O
OsPRI1	B-Gene
increased	B-PosReg
the	O
sensitivity	B-MPA
of	O
plants	O
to	O
Fe	O
-	O
deficient	O
conditions	O
and	O
downregulated	B-NegReg
the	O
expression	B-MPA
of	O
Fe	O
-	O
deficiency	O
-	O
responsive	O
genes	O
.	O

Yeast	O
one	O
-	O
hybrid	O
and	O
electrophoretic	O
mobility	O
shift	O
assay	O
results	O
suggested	O
that	O
OsPRI1	O
binds	O
to	O
the	O
OsIRO2	O
and	O
OsIRO3	O
promoters	O
.	O

In	O
vitro	O
ubiquitination	O
experiments	O
indicated	O
that	O
OsPRI1	O
is	O
ubiquitinated	O
by	O
OsHRZ1	O
.	O

Cell	O
-	O
free	O
degradation	O
assays	O
revealed	O
that	O
the	O
stability	B-MPA
of	O
OsPRI1	O
decreased	O
in	O
wild	O
type	O
roots	O
,	O
but	O
increased	B-PosReg
in	O
the	O
hrz1	B-Gene
-	I-Gene
2	I-Gene
mutant	B-Var
,	O
suggesting	O
OsHRZ1	O
is	O
responsible	O
for	O
the	O
instability	O
of	O
OsPRI1	O
.	O

The	O
hrz1	O
-	O
2	O
seedlings	O
were	O
insensitive	O
to	O
Fe	O
-	O
deficient	O
conditions	O
.	O

When	O
the	O
pri1	B-Gene
-	I-Gene
1	I-Gene
mutation	B-Var
was	O
introduced	B-Interaction
into	O
hrz1	B-Gene
-	I-Gene
2	I-Gene
mutants	B-Var
,	O
the	O
pri1hrz1	O
double	O
mutant	O
was	O
more	B-PosReg
sensitive	B-MPA
to	I-MPA
Fe	I-MPA
deficiency	I-MPA
than	O
the	O
hrz1	O
-	O
2	O
mutant	O
.	O

Additionally	O
,	O
the	O
expression	O
levels	O
of	O
Fe	O
-	O
deficiency	O
-	O
responsive	O
genes	O
were	O
lower	O
in	O
the	O
hrz1pri1	O
double	O
mutant	O
than	O
in	O
the	O
hrz1	O
-	O
2	O
mutant	O
.	O

Collectively	O
,	O
these	O
results	O
imply	O
that	O
OsPRI1	O
,	O
which	O
is	O
ubiquitinated	O
by	O
OsHRZ1	O
,	O
mediates	O
rice	O
responses	O
to	O
Fe	O
-	O
deficiency	O
by	O
positively	O
regulating	O
OsIRO2	O
and	O
OsIRO3	O
expression	O
as	O
part	O
of	O
the	O
OsHRZ1-OsPRI1-OsIRO2/3	O
signal	O
transduction	O
cascade	O
.	O

Loss	B-NegReg
-	I-NegReg
of	I-NegReg
-	I-NegReg
function	I-NegReg
but	O
not	O
dominant	O
-	O
negative	O
intragenic	O
IKZF1	B-Gene
deletions	B-Var
are	O
associated	O
with	O
an	O
adverse	O
prognosis	O
in	O
adult	O
BCR	O
-	O
ABL	O
-	O
negative	O
acute	B-Disease
lymphoblastic	I-Disease
leukemia	I-Disease
.	O

Genetic	O
alterations	O
of	O
the	O
transcription	O
factor	O
IKZF1	O
(	O
"	O
IKAROS	O
"	O
)	O
are	O
detected	O
in	O
around	O
15	O
-	O
30	O
%	O
of	O
cases	O
of	O
BCR	O
-	O
ABL	O
-	O
negative	O
B	O
-	O
cell	O
precursor	O
acute	O
lymphoblastic	O
leukemia	O
(	O
ALL	O
)	O
.	O

Different	O
types	O
of	O
intragenic	O
deletions	B-Var
have	O
been	O
observed	O
,	O
resulting	O
in	O
a	O
functionally	B-MPA
inactivated	I-MPA
allele	I-MPA
(	B-NegReg
"	I-NegReg
loss	I-NegReg
-	I-NegReg
of	I-NegReg
-	I-NegReg
function	I-NegReg
"	I-NegReg
)	I-NegReg
or	O
in	O
"	B-NegReg
dominant	I-NegReg
-	I-NegReg
negative	I-NegReg
"	I-NegReg
isoforms	B-MPA
.	O

The	O
prognostic	O
impact	O
of	O
these	O
alterations	O
especially	O
in	O
adult	O
acute	O
lymphoblastic	O
leukemia	O
is	O
not	O
well	O
defined	O
.	O

We	O
analyzed	O
482	O
well	O
-	O
characterized	O
cases	O
of	O
adult	O
BCR	O
-	O
ABL	O
-	O
negative	O
B	O
-	O
precursor	O
acute	O
lymphoblastic	O
leukemia	O
uniformly	O
treated	O
in	O
the	O
framework	O
of	O
the	O
GMALL	O
studies	O
and	O
detected	O
IKZF1	O
alterations	O
in	O
128	O
cases	O
(	O
27	O
%	O
)	O
.	O

In	O
20	O
%	O
,	O
the	O
IKZF1	O
alteration	O
was	O
present	O
in	O
a	O
large	O
fraction	O
of	O
leukemic	O
cells	O
(	O
"	O
high	O
deletion	O
load	O
"	O
)	O
while	O
in	O
7	O
%	O
it	O
was	O
detected	O
only	O
in	O
small	O
subclones	O
(	O
"	O
low	O
deletion	O
load	O
"	O
)	O
.	O

Some	O
patients	O
showed	O
more	O
than	O
one	O
IKZF1	O
alteration	O
(	O
8	O
%	O
)	O
.	O

Patients	O
exhibiting	O
a	O
loss	O
-	O
of	O
-	O
function	O
isoform	O
with	O
high	B-Var
deletion	I-Var
load	I-Var
had	O
a	O
shorter	B-NegReg
overall	B-MPA
survival	I-MPA
(	O
OS	O
at	O
5	O
years	O
28	O
%	O
vs.	O
59	O
%	O
,	O
p<0.0001	O
)	O
,	O
also	O
significant	O
in	O
a	O
subgroup	O
analysis	O
of	O
standard	O
risk	O
patients	O
according	O
to	O
GMALL	O
classification	O
(	O
OS	O
at	O
5	O
years	O
37	O
%	O
vs.	O
68	O
%	O
,	O
p=0.0002	O
)	O
.	O

Low	O
deletion	O
load	O
or	O
dominant	O
-	O
negative	O
IKZF1	O
alterations	O
had	O
no	O
prognostic	O
impact	O
.	O

The	O
results	O
thus	O
suggest	O
that	O
there	O
is	O
a	O
clear	O
distinction	O
between	O
loss	O
-	O
of	O
-	O
function	O
and	O
dominant	O
-	O
negative	O
IKZF1	O
deletions	O
.	O

Affected	O
patients	O
should	O
thus	O
be	O
monitored	O
for	O
minimal	O
residual	O
disease	O
carefully	O
to	O
detect	O
incipient	O
relapses	O
at	O
an	O
early	O
stage	O
and	O
they	O
are	O
potential	O
candidates	O
for	O
alternative	O
or	O
intensified	O
treatment	O
regimes	O
.	O

Registered	O
at	O
:	O
NCT00199056	O
,	O
NCT00198991	O
.	O

Stress	O
-	O
Induced	O
Sleep	O
After	O
Exposure	O
to	O
Ultraviolet	O
Light	O
Is	O
Promoted	O
by	O
p53	O
in	O
Caenorhabditis	O
elegans	O
.	O

Stress	O
-	O
induced	O
sleep	O
(	O
SIS	O
)	O
in	O
C.	O
elegans	O
is	O
important	O
for	O
restoration	O
of	O
cellular	O
homeostasis	O
and	O
is	O
a	O
useful	O
model	O
to	O
study	O
the	O
function	O
and	O
regulation	O
of	O
sleep	O
.	O

SIS	O
is	O
triggered	O
when	O
epidermal	O
growth	O
factor	O
(	O
EGF	O
)	O
activates	O
the	O
ALA	O
neuron	O
,	O
which	O
then	O
releases	O
neuropeptides	O
to	O
promote	O
sleep	O
.	O

To	O
further	O
understand	O
this	O
behavior	O
,	O
we	O
established	O
a	O
new	O
model	O
of	O
stress	O
-	O
induced	O
sleep	O
using	O
irradiation	O
by	O
ultraviolet	O
C	O
(	O
UVC	O
)	O
light	O
.	O

While	O
UVC	O
irradiation	O
requires	O
ALA	O
signaling	O
and	O
leads	O
to	O
a	O
sleep	O
state	O
similar	O
to	O
that	O
induced	O
by	O
heat	O
and	O
other	O
stressors	O
,	O
it	O
does	O
not	O
induce	O
the	O
proteostatic	O
stress	O
seen	O
with	O
heat	O
exposure	O
.	O

Based	O
on	O
the	O
known	O
genotoxic	O
effects	O
of	O
UVC	O
irradiation	O
,	O
we	O
tested	O
two	O
genes	O
-	O
atl-1	O
and	O
cep-1-which	O
encode	O
proteins	O
that	O
act	O
in	O
the	O
DNA	O
damage	O
response	O
pathway	O
.	O

Loss	O
of	O
function	O
mutants	O
of	O
atl-1	O
had	O
no	O
defect	O
in	O
UVC	O
induced	O
SIS	O
but	O
a	O
partial	O
loss	B-NegReg
of	I-NegReg
function	I-NegReg
mutant	B-Var
of	O
cep-1	B-Gene
,	O
gk138	O
,	O
had	O
decreased	B-NegReg
movement	B-MPA
quiescence	I-MPA
following	O
UVC	O
irradiation	O
.	O

Germline	O
ablation	O
experiments	O
and	O
tissue	O
-	O
specific	O
RNA	O
interference	O
experiments	O
showed	O
that	O
cep-1	O
is	O
required	O
somatically	O
in	O
neurons	O
for	O
its	O
effect	O
on	O
SIS	O
.	O

The	O
cep-1(gk138	B-Gene
)	I-Gene
mutant	B-Var
suppressed	B-NegReg
body	B-MPA
movement	I-MPA
quiescence	I-MPA
controlled	I-MPA
by	I-MPA
EGF	I-MPA
,	O
indicating	O
that	O
CEP-1	O
acts	O
downstream	O
or	O
in	O
parallel	O
to	O
ALA	O
activation	O
to	O
promote	O
quiescence	O
in	O
response	O
to	O
ultraviolet	O
light	O
.	O

PCSK9	B-Gene
deficiency	B-Var
results	O
in	O
increased	B-PosReg
ectopic	B-MPA
fat	I-MPA
accumulation	I-MPA
in	O
experimental	O
models	O
and	O
in	O
humans	O
.	O

Background	O
Proprotein	O
convertase	O
subtilisin	O
kexin	O
type	O
9	O
(	O
PCSK9	O
)	O
regulates	O
low	O
-	O
density	O
lipoprotein	O
and	O
very	O
low	O
-	O
density	O
lipoprotein	O
receptor	O
expression	O
in	O
several	O
tissues	O
.	O

Here	O
we	O
evaluated	O
whether	O
PCSK9	O
may	O
modulate	O
the	O
handling	O
of	O
triglycerides	O
in	O
the	O
liver	O
and	O
peripheral	O
tissues	O
.	O

Methods	O
Subjects	O
from	O
the	O
PLIC	O
cohort	O
were	O
genotyped	O
for	O
the	O
loss	O
-	O
of	O
-	O
function	O
PCSK9	O
R46L	O
variant	O
and	O
characterized	O
for	O
clinical	O
and	O
biochemical	O
parameters	O
,	O
total	O
and	O
android	O
fat	O
mass	O
,	O
hepatic	O
steatosis	O
and	O
epicardial	O
fat	O
thickness	O
.	O

Visceral	O
adipose	O
tissue	O
and	O
subcutaneous	O
adipose	O
tissue	O
in	O
PCSK9	O
KO	O
and	O
wild	O
type	O
mice	O
were	O
quantified	O
by	O
nuclear	O
magnetic	O
resonance	O
imaging	O
.	O

Results	O
Carriers	O
of	O
the	O
R46L	O
variant	O
(	O
n	O
=	O
13	O
)	O
had	O
lower	O
low	O
-	O
density	O
lipoprotein	O
cholesterol	O
levels	O
,	O
higher	O
body	O
mass	O
index	O
and	O
increased	O
percentage	O
of	O
total	O
and	O
android	O
fat	O
masses	O
compared	O
with	O
non	O
-	O
carriers	O
(	O
n	O
=	O
521	O
)	O
.	O

R46L	B-Gene
variant	B-Var
associated	O
with	O
a	O
two	O
-	O
fold	O
increase	B-PosReg
prevalence	O
of	O
hepatic	B-MPA
steatosis	I-MPA
and	I-MPA
higher	I-MPA
epicardial	I-MPA
fat	I-MPA
thickness	I-MPA
.	O

These	O
observations	O
were	O
replicated	O
in	O
PCSK9	O
KO	O
mice	O
,	O
which	O
showed	O
increased	O
visceral	O
adipose	O
tissue	O
(	O
but	O
not	O
subcutaneous	O
adipose	O
tissue	O
)	O
when	O
fed	O
chow	O
or	O
high	O
-	O
fat	O
diet	O
for	O
20	O
weeks	O
,	O
compared	O
with	O
wild	O
type	O
mice	O
.	O

Conclusions	O
These	O
data	O
suggest	O
that	O
genetically	O
determined	O
PCSK9	B-Gene
deficiency	B-Var
might	O
be	O
associated	B-Reg
with	O
ectopic	B-MPA
fat	I-MPA
accumulation	I-MPA
.	O

A	O
Braf	B-Gene
kinase	O
-	O
inactive	O
mutant	B-Var
induces	B-Reg
lung	B-Disease
adenocarcinoma	I-Disease
.	O

The	O
initiating	O
oncogenic	O
event	O
in	O
almost	O
half	O
of	O
human	O
lung	O
adenocarcinomas	O
is	O
still	O
unknown	O
,	O
a	O
fact	O
that	O
complicates	O
the	O
development	O
of	O
selective	O
targeted	O
therapies	O
.	O

Yet	O
these	O
tumours	O
harbour	O
a	O
number	O
of	O
alterations	O
without	O
obvious	O
oncogenic	O
function	O
including	O
BRAF	O
-	O
inactivating	O
mutations	O
.	O

Inactivating	O
BRAF	O
mutants	O
in	O
lung	O
predominate	O
over	O
the	O
activating	O
V600E	O
mutant	O
that	O
is	O
frequently	O
observed	O
in	O
other	O
tumour	O
types	O
.	O

Here	O
we	O
demonstrate	O
that	O
the	O
expression	O
of	O
an	O
endogenous	O
Braf(D631A	O
)	O
kinase	O
-	O
inactive	O
isoform	O
in	O
mice	O
(	O
corresponding	O
to	O
the	O
human	O
BRAF(D594A	O
)	O
mutation	O
)	O
triggers	O
lung	O
adenocarcinoma	O
in	O
vivo	O
,	O
indicating	O
that	O
BRAF	O
-	O
inactivating	O
mutations	O
are	O
initiating	O
events	O
in	O
lung	O
oncogenesis	O
.	O

Moreover	O
,	O
inactivating	O
BRAF	O
mutations	O
have	O
also	O
been	O
identified	O
in	O
a	O
subset	O
of	O
KRAS	O
-	O
driven	O
human	O
lung	O
tumours	O
.	O

Co	O
-	O
expression	O
of	O
Kras(G12V	B-Var
)	I-Var
and	O
Braf(D631A	B-Var
)	I-Var
in	O
mouse	O
lung	O
cells	O
markedly	O
enhances	B-PosReg
tumour	B-MPA
initiation	I-MPA
,	O
a	O
phenomenon	O
mediated	O
by	O
Craf	O
kinase	O
activity	O
,	O
and	O
effectively	O
accelerates	O
tumour	O
progression	O
when	O
activated	O
in	O
advanced	O
lung	O
adenocarcinomas	O
.	O

We	O
also	O
report	O
a	O
key	O
role	O
for	O
the	O
wild	O
-	O
type	O
Braf	O
kinase	O
in	O
sustaining	O
Kras(G12V)/Braf(D631A)-driven	O
tumours	O
.	O

Ablation	O
of	O
the	O
wild	O
-	O
type	O
Braf	O
allele	O
prevents	O
the	O
development	O
of	O
lung	O
adenocarcinoma	O
by	O
inducing	O
a	O
further	O
increase	O
in	O
MAPK	O
signalling	O
that	O
results	O
in	O
oncogenic	O
toxicity	O
;	O
this	O
effect	O
can	O
be	O
abolished	O
by	O
pharmacological	O
inhibition	O
of	O
Mek	O
to	O
restore	O
tumour	O
growth	O
.	O

However	O
,	O
the	O
loss	B-Var
of	O
wild	O
-	O
type	O
Braf	B-Gene
also	O
induces	B-Reg
transdifferentiation	B-CPA
of	O
club	O
cells	O
,	O
which	O
leads	B-Reg
to	I-Reg
the	O
rapid	B-MPA
development	I-MPA
of	I-MPA
lethal	I-MPA
intrabronchiolar	I-MPA
lesions	I-MPA
.	O

These	O
observations	O
indicate	O
that	O
the	O
signal	O
intensity	O
of	O
the	O
MAPK	O
pathway	O
is	O
a	O
critical	O
determinant	O
not	O
only	O
in	O
tumour	O
development	O
,	O
but	O
also	O
in	O
dictating	O
the	O
nature	O
of	O
the	O
cancer	O
-	O
initiating	O
cell	O
and	O
ultimately	O
the	O
resulting	O
tumour	O
phenotype	O
.	O

Enpp1	O
is	O
an	O
anti	O
-	O
aging	O
factor	O
that	O
regulates	O
Klotho	O
under	O
phosphate	O
overload	O
conditions	O
.	O

Control	O
of	O
phosphate	O
metabolism	O
is	O
crucial	O
to	O
regulate	O
aging	O
in	O
mammals	O
.	O

Klotho	O
is	O
a	O
well	O
-	O
known	O
anti	O
-	O
aging	O
factor	O
that	O
regulates	O
phosphate	O
metabolism	O
:	O
mice	O
mutant	O
or	O
deficient	O
in	O
Klotho	O
exhibit	O
phenotypes	O
resembling	O
human	O
aging	O
.	O

Here	O
we	O
show	O
that	O
ectonucleotide	O
pyrophosphatase	O
/	O
phosphodiesterase	O
1	O
(	O
Enpp1	O
)	O
is	O
required	O
for	O
Klotho	O
expression	O
under	O
phosphate	O
overload	O
conditions	O
.	O

Loss	B-Var
-	I-Var
of	I-Var
-	I-Var
function	I-Var
Enpp1	B-Gene
(	O
ttw	O
/	O
ttw	O
)	O
mice	O
under	O
phosphate	O
overload	O
conditions	O
exhibited	B-Reg
phenotypes	O
resembling	O
human	O
aging	O
and	O
Klotho	O
mutants	O
,	O
such	O
as	O
short	O
life	O
span	O
,	O
arteriosclerosis	B-Disease
and	O
osteoporosis	B-Disease
,	O
with	O
elevated	B-PosReg
serum	B-MPA
1,25(OH)2D3	I-MPA
levels	I-MPA
.	O

Enpp1	O
(	O
ttw	O
/	O
ttw	O
)	O
mice	O
also	O
exhibited	O
significantly	O
reduced	O
renal	O
Klotho	O
expression	O
under	O
phosphate	O
overload	O
conditions	O
,	O
and	O
aging	O
phenotypes	O
in	O
these	O
mice	O
were	O
rescued	O
by	O
Klotho	O
overexpression	O
,	O
a	O
low	O
vitamin	O
D	O
diet	O
or	O
vitamin	O
D	O
receptor	O
knockout	O
.	O

These	O
findings	O
indicate	O
that	O
Enpp1	O
plays	O
a	O
crucial	O
role	O
in	O
regulating	O
aging	O
via	O
Klotho	O
expression	O
under	O
phosphate	O
overload	O
conditions	O
.	O

Characterization	O
of	O
the	O
autophagy	O
-	O
related	O
gene	O
BmATG8	O
in	O
Bipolaris	O
maydis	O
.	O

Autophagy	O
is	O
involved	O
in	O
cellular	O
development	O
and	O
the	O
maintenance	O
of	O
viability	O
under	O
nutrient	O
deprivation	O
in	O
a	O
wide	O
range	O
of	O
eukaryotes	O
.	O

A	O
filamentous	O
ascomycete	O
Bipolaris	O
maydis	O
,	O
responsible	O
for	O
southern	O
corn	O
leaf	O
blight	O
,	O
is	O
also	O
studied	O
as	O
a	O
model	O
fungus	O
for	O
sexual	O
reproduction	O
in	O
filamentous	O
ascomycetes	O
that	O
form	O
filiform	O
ascospores	O
.	O

In	O
order	O
to	O
clarify	O
the	O
roles	O
of	O
autophagy	O
in	O
various	O
stages	O
of	O
the	O
life	O
cycle	O
of	O
B.	O
maydis	O
,	O
we	O
constructed	O
null	O
mutants	O
of	O
BmATG8	O
,	O
an	O
orthologue	O
of	O
the	O
Saccharomyces	O
cerevisiae	O
autophagy	O
gene	O
ATG8	O
in	O
B.	O
maydis	O
.	O

Deletion	B-Var
of	O
BmATG8	B-Gene
impaired	B-NegReg
localization	B-MPA
of	O
cytosolic	O
components	O
to	O
the	O
vacuole	O
under	O
nitrogen	O
starvation	O
,	O
suggesting	O
that	O
autophagy	B-CPA
was	O
deficient	B-NegReg
in	O
the	O
null	O
mutants	O
.	O

Additionally	O
,	O
fluorescent	O
microscopic	O
observations	O
on	O
a	O
eGFP	O
-	O
fused	O
BmATG8	O
expressing	O
strain	O
showed	O
that	O
BmATG8	O
is	O
associated	O
with	O
autophagy	O
-	O
related	O
structures	O
.	O

In	O
vegetative	O
growth	O
,	O
ΔBmATG8	B-Gene
strains	O
showed	O
a	O
reduction	B-NegReg
in	O
conidiation	B-CPA
and	I-CPA
aerial	I-CPA
mycelial	I-CPA
growth	I-CPA
.	O

Interestingly	O
,	O
the	O
mutant	O
conidia	O
indicated	O
loss	O
of	O
the	O
germination	O
rate	O
under	O
starvation	O
conditions	O
and	O
affected	O
longevity	O
.	O

However	O
,	O
germinated	O
mutant	O
conidia	O
were	O
still	O
capable	O
of	O
infecting	O
the	O
host	O
plant	O
via	O
appressoria	O
.	O

In	O
sexual	O
reproduction	O
,	O
ascospores	O
with	O
ΔBmATG8	O
genetic	O
background	O
were	O
aborted	O
.	O

Our	O
results	O
revealed	O
that	O
autophagy	O
plays	O
a	O
crucial	O
role	O
in	O
the	O
function	O
of	O
conidia	O
,	O
not	O
in	O
host	O
infection	O
via	O
appressoria	O
in	O
B.	O
maydis	O
.	O

In	O
addition	O
,	O
conservation	O
of	O
the	O
importance	O
of	O
autophagy	O
in	O
ascospore	O
development	O
is	O
suggested	O
among	O
ascomycetes	O
including	O
species	O
that	O
form	O
bitunicate	O
ascus	O
.	O

Impairment	O
of	O
different	O
protein	O
domains	O
causes	O
variable	O
clinical	O
presentation	O
within	O
Pitt	O
-	O
Hopkins	O
syndrome	O
and	O
suggests	O
intragenic	O
molecular	O
syndromology	O
of	O
TCF4	O
.	O

Pitt	B-Disease
-	I-Disease
Hopkins	I-Disease
syndrome	I-Disease
is	O
a	O
neurodevelopmental	O
disorder	O
characterized	O
by	O
severe	O
intellectual	O
disability	O
and	O
a	O
distinctive	O
facial	O
gestalt	O
.	O

It	O
is	O
caused	B-Reg
by	I-Reg
haploinsufficiency	B-Var
of	O
the	O
TCF4	B-Gene
gene	O
.	O

The	O
TCF4	O
protein	O
has	O
different	O
functional	O
domains	O
,	O
with	O
the	O
NLS	O
(	O
nuclear	O
localization	O
signal	O
)	O
domain	O
coded	O
by	O
exons	O
7	O
-	O
8	O
and	O
the	O
bHLH	O
(	O
basic	O
Helix	O
-	O
Loop	O
-	O
Helix	O
)	O
domain	O
coded	O
by	O
exon	O
18	O
.	O

Several	O
alternatively	O
spliced	O
TCF4	O
variants	O
have	O
been	O
described	O
,	O
allowing	O
for	O
translation	O
of	O
variable	O
protein	O
isoforms	O
.	O

Typical	O
PTHS	O
patients	O
have	O
impairment	O
of	O
at	O
least	O
the	O
bHLH	O
domain	O
.	O

To	O
which	O
extent	O
impairment	O
of	O
the	O
remaining	O
domains	O
contributes	O
to	O
the	O
final	O
phenotype	O
is	O
not	O
clear	O
.	O

There	O
is	O
recent	O
evidence	O
that	O
certain	O
loss	O
-	O
of	O
-	O
function	O
variants	B-Var
disrupting	B-NegReg
TCF4	B-Gene
are	O
associated	O
with	O
mild	B-Disease
ID	I-Disease
,	O
but	O
not	O
with	O
typical	O
PTHS	O
.	O

We	O
describe	O
a	O
frameshift	B-Reg
-	I-Reg
causing	I-Reg
partial	B-Var
gene	I-Var
deletion	I-Var
encompassing	O
exons	O
4	O
-	O
6	O
of	O
TCF4	B-Gene
in	O
an	O
adult	O
patient	O
with	B-Reg
mild	B-Disease
ID	I-Disease
and	O
nonspecific	O
facial	O
dysmorphisms	O
but	O
without	O
the	O
typical	O
features	O
of	O
PTHS	O
,	O
and	O
a	O
c.520C	B-Var
>	I-Var
T	I-Var
nonsense	O
variant	O
within	O
exon	O
8	O
in	O
a	O
child	O
presenting	O
with	B-Reg
a	O
severe	O
phenotype	O
largely	O
mimicking	O
PTHS	B-Disease
,	O
but	O
lacking	O
the	O
typical	O
facial	O
dysmorphism	O
.	O

Investigation	O
on	O
mRNA	O
,	O
along	O
with	O
literature	O
review	O
,	O
led	O
us	O
to	O
suggest	O
a	O
preliminary	O
phenotypic	O
map	O
of	O
loss	O
-	O
of	O
-	O
function	O
variants	O
affecting	O
TCF4	O
.	O

An	O
intragenic	O
phenotypic	O
map	O
of	O
loss	O
-	O
of	O
-	O
function	O
variants	O
in	O
TCF4	O
is	O
suggested	O
here	O
for	O
the	O
first	O
time	O
:	O
variants	O
within	O
exons	O
1	O
-	O
4	O
and	O
exons	O
4	O
-	O
6	O
give	O
rise	O
to	O
a	O
recurrent	O
phenotype	O
with	O
mild	O
ID	O
not	O
in	O
the	O
spectrum	O
of	O
Pitt	O
-	O
Hopkins	O
syndrome	O
(	O
biallelic	O
preservation	O
of	O
both	O
the	O
NLS	O
and	O
bHLH	O
domains	O
)	O
;	O
variants	O
within	O
exons	O
7	O
-	O
8	O
cause	O
a	O
severe	O
phenotype	O
resembling	O
PTHS	O
but	O
in	O
absence	O
of	O
the	O
typical	O
facial	O
dysmorphism	O
(	O
impairment	O
limited	O
to	O
the	O
NLS	O
domain	O
)	O
;	O
variants	O
within	O
exons	O
9	O
-	O
19	O
cause	O
typical	O
Pitt	O
-	O
Hopkins	O
syndrome	O
(	O
impairment	O
of	O
at	O
least	O
the	O
bHLH	O
domain	O
)	O
.	O

Understanding	O
the	O
TCF4	O
molecular	O
syndromology	O
can	O
allow	O
for	O
proper	O
nosology	O
in	O
the	O
current	O
era	O
of	O
whole	O
genomic	O
investigations	O
.	O

ARHGAP29	O
Mutation	O
Is	O
Associated	O
with	O
Abnormal	O
Oral	O
Epithelial	O
Adhesions	O
.	O

Nonsyndromic	B-Disease
cleft	I-Disease
lip	I-Disease
and/or	I-Disease
palate	I-Disease
(	O
NSCL	O
/	O
P	O
)	O
is	O
a	O
prevalent	O
birth	O
defect	O
of	O
complex	O
etiology	O
.	O

Previous	O
studies	O
identified	O
mutations	B-Var
in	O
ARHGAP29	B-Gene
associated	B-Reg
with	O
an	O
increased	O
risk	O
for	O
NSCL	B-Disease
/	I-Disease
P.	I-Disease
To	O
investigate	O
the	O
effects	O
of	O
ARHGAP29	O
in	O
vivo	O
,	O
we	O
generated	O
a	O
novel	O
murine	O
allele	O
by	O
inserting	O
a	O
point	O
mutation	O
identified	O
in	O
a	O
patient	O
with	O
NSCL	O
/	O
P.	O
This	O
single	B-Var
-	I-Var
nucleotide	I-Var
variation	I-Var
of	O
ARHGAP29	B-Gene
translates	O
to	O
an	O
early	O
nonsense	O
mutation	O
(	B-Var
K326X	I-Var
)	I-Var
,	O
presumably	O
resulting	O
in	O
loss	B-NegReg
-	I-NegReg
of	I-NegReg
-	I-NegReg
function	I-NegReg
(	O
LoF	O
)	O
.	O

Embryos	O
from	O
Arhgap29(K326X/+	O
)	O
intercrosses	O
were	O
harvested	O
at	O
various	O
time	O
points	O
.	O

No	O
homozygous	O
Arhgap29(K326X	O
)	O
animals	O
were	O
found	O
in	O
the	O
45	O
analyzed	O
litters	O
,	O
assessed	O
as	O
early	O
as	O
embryonic	O
day	O
8.5	O
(	O
e8.5	O
)	O
.	O

Coronal	O
sectioning	O
of	O
e13.5	O
and	O
e14.5	O
heads	O
revealed	O
that	O
59	O
%	O
of	O
Arhgap29(K326X/+	O
)	O
mice	O
(	O
n	O
=	O
37	O
)	O
exhibited	O
improper	O
epithelial	O
contact	O
between	O
developing	O
oral	O
structures	O
,	O
while	O
none	O
were	O
observed	O
in	O
wild	O
types	O
(	O
n	O
=	O
10	O
)	O
.	O

In	O
addition	O
,	O
Arhgap29(K326X/+	O
)	O
embryos	O
exhibited	O
a	O
significantly	O
higher	O
percentage	O
of	O
maxillary	O
epithelium	O
in	O
contact	O
with	O
mandibular	O
epithelium	O
.	O

Immunofluorescent	O
analyses	O
of	O
the	O
periderm	O
and	O
oral	O
adhesions	O
revealed	O
the	O
presence	O
of	O
Arhgap29	O
in	O
periderm	O
cells	O
.	O

These	O
cells	O
were	O
p63	O
negative	O
,	O
keratin	O
17	O
positive	O
,	O
and	O
keratin	O
6	O
positive	O
and	O
present	O
at	O
sites	O
of	O
adhesion	O
,	O
although	O
occasionally	O
disorganized	O
.	O

Oral	O
adhesions	O
did	O
not	O
appear	O
to	O
impair	O
palatogenesis	O
,	O
as	O
all	O
analyzed	O
Arhgap29(K326X/+	O
)	O
embryos	O
showed	O
confluent	O
palatal	O
mesenchyme	O
and	O
epithelium	O
at	O
e18.5	O
(	O
n	O
=	O
16	O
)	O
,	O
and	O
no	O
mice	O
were	O
found	O
with	O
a	O
cleft	O
at	O
birth	O
.	O

Collectively	O
,	O
our	O
data	O
demonstrate	O
that	O
ARHGAP29	O
is	O
required	O
for	O
embryonic	O
survival	O
and	O
that	O
heterozygosity	O
for	O
LoF	B-NegReg
variants	B-Var
of	O
Arhgap29	B-Gene
increases	B-PosReg
the	O
incidence	B-CPA
and	I-CPA
length	I-CPA
of	I-CPA
oral	I-CPA
adhesions	I-CPA
at	I-CPA
a	I-CPA
critical	I-CPA
time	I-CPA
point	I-CPA
during	I-CPA
orofacial	I-CPA
development	I-CPA
.	O

In	O
conclusion	O
,	O
we	O
validate	O
the	O
LoF	B-NegReg
nature	O
of	O
the	O
human	O
K326X	B-Var
mutation	I-Var
in	O
vivo	O
and	O
reveal	O
a	O
previously	O
unknown	O
effect	O
of	O
Arhgap29	B-Gene
in	O
murine	O
craniofacial	B-CPA
development	I-CPA
.	O

Deciphering	O
the	O
molecular	O
basis	O
of	O
ferroportin	O
resistance	O
to	O
hepcidin	O
:	O
Structure	O
/	O
function	O
analysis	O
of	O
rare	O
SLC40A1	B-Gene
missense	B-Var
mutations	I-Var
found	B-Reg
in	O
suspected	O
hemochromatosis	B-Disease
type	I-Disease
4	I-Disease
patients	O
.	O

Genetic	O
medicine	O
applied	O
to	O
the	O
study	O
of	O
hemochromatosis	O
has	O
identified	O
the	O
systemic	O
loop	O
controlling	O
iron	O
homeostasis	O
,	O
centered	O
on	O
hepcidin	O
-	O
ferroportin	O
interaction	O
.	O

Current	O
challenges	O
are	O
to	O
dissect	O
the	O
molecular	O
pathways	O
underlying	O
liver	O
hepcidin	O
synthesis	O
in	O
response	O
to	O
circulatory	O
iron	O
,	O
HFE	O
,	O
TFR2	O
,	O
HJV	O
,	O
TMPRSS6	O
and	O
BMP6	O
functions	O
,	O
and	O
to	O
define	O
the	O
major	O
structural	O
elements	O
of	O
hepcidin	O
-	O
ferroportin	O
interaction	O
.	O

We	O
built	O
a	O
first	O
3D	O
model	O
of	O
human	O
ferroportin	O
structure	O
,	O
using	O
the	O
crystal	O
structure	O
of	O
EmrD	O
,	O
a	O
bacterial	O
drug	O
efflux	O
transporter	O
of	O
the	O
Major	O
Facilitator	O
Superfamily	O
,	O
as	O
template	O
.	O

The	O
model	O
enabled	O
study	O
of	O
disease	O
-	O
associated	O
mutations	O
,	O
and	O
guided	O
mutagenesis	O
experiments	O
to	O
determine	O
the	O
role	O
of	O
conserved	O
residues	O
in	O
protein	O
stability	O
and	O
iron	O
transport	O
.	O

Results	O
revealed	O
novel	O
amino	O
acids	O
that	O
are	O
critical	O
for	O
the	O
iron	O
export	O
function	O
and	O
the	O
hepcidin	O
-	O
mediated	O
inhibition	O
mechanism	O
:	O
for	O
example	O
,	O
tryptophan	O
42	O
,	O
localized	O
in	O
the	O
extracellular	O
end	O
of	O
the	O
ferroportin	O
pore	O
and	O
involved	O
in	O
both	O
biological	O
functions	O
.	O

Here	O
,	O
we	O
propose	O
a	O
strategy	O
that	O
is	O
not	O
limited	O
to	O
structure	O
analysis	O
,	O
but	O
integrates	O
information	O
from	O
different	O
sources	O
,	O
including	O
human	O
disease	O
-	O
associated	O
mutations	O
and	O
functional	O
in	O
vitro	O
assays	O
.	O

The	O
first	O
major	O
hypothesis	O
of	O
this	O
PhD	O
thesis	O
is	O
that	O
ferroportin	O
resistance	O
to	O
hepcidin	O
relies	O
on	O
different	O
molecular	O
mechanisms	O
that	O
are	O
critical	O
for	O
ferroportin	O
endocytosis	O
,	O
and	O
include	O
at	O
least	O
three	O
fundamental	O
steps	O
:	O
(	O
i	O
)	O
hepcidin	O
binding	O
to	O
ferroportin	O
,	O
(	O
ii	O
)	O
structural	O
reorganization	O
of	O
the	O
N-	O
and	O
C	O
-	O
ter	O
ferroportin	O
lobes	O
,	O
and	O
(	O
iii	O
)	O
ferroportin	O
ubiquitination	O
.	O

Loss	O
-	O
of	O
-	O
function	O
mutations	O
in	O
filaggrin	O
gene	O
and	O
malignant	O
melanoma	O
:	O
a	O
case	O
control	O
study	O
.	O

BACKGROUND	O
:	O
Loss	B-NegReg
-	I-NegReg
of	I-NegReg
-	I-NegReg
function	I-NegReg
mutations	B-Var
in	O
filaggrin	O
gene	O
(	B-Gene
FLG	I-Gene
)	I-Gene
have	O
been	O
suggested	O
to	O
increase	O
the	O
susceptibility	O
of	O
skin	B-Disease
malignancies	I-Disease
due	O
to	O
reduced	B-NegReg
levels	B-MPA
of	I-MPA
epidermal	I-MPA
filaggrin	I-MPA
and	O
its	O
degradation	B-MPA
products	I-MPA
,	O
urocanic	B-MPA
acid	I-MPA
,	O
which	O
may	O
be	O
protective	O
against	O
ultraviolet	O
irradiation	O
.	O

OBJECTIVE	O
:	O
We	O
aimed	O
to	O
investigate	O
the	O
association	O
between	O
FLG	O
mutation	O
status	O
and	O
the	O
occurrence	O
of	O
malignant	O
melanoma	O
(	O
MM	O
)	O
in	O
Danish	O
adults	O
.	O

METHODS	O
:	O
The	O
prevalence	O
of	O
FLG	O
mutations	O
in	O
a	O
sample	O
of	O
MM	O
biopsies	O
was	O
compared	O
with	O
a	O
FLG	O
genotyped	O
cohort	O
from	O
two	O
general	O
population	O
studies	O
.	O

Pearson	O
's	O
chi	O
-	O
square	O
and	O
Fisher	O
's	O
exact	O
tests	O
were	O
used	O
to	O
compare	O
the	O
two	O
groups	O
.	O

RESULTS	O
:	O
A	O
total	O
of	O
867	O
MM	O
biopsies	O
and	O
9965	O
general	O
population	O
controls	O
were	O
genotyped	O
,	O
respectively	O
.	O

In	O
the	O
MM	O
sample	O
2	O
(	O
0.23	O
%	O
)	O
individuals	O
were	O
homozygous	O
and	O
80	O
(	O
9.4	O
%	O
)	O
heterozygous	O
mutation	O
carriers	O
.	O

In	O
the	O
general	O
population	O
controls	O
the	O
prevalence	O
of	O
FLG	O
mutations	O
was	O
18	O
(	O
0.18	O
%	O
)	O
and	O
835	O
(	O
8.4	O
%	O
)	O
for	O
homozygous	O
and	O
heterozygous	O
mutations	O
,	O
respectively	O
.	O

Fisher	O
's	O
exact	O
test	O
and	O
Pearson	O
's	O
chi	O
square	O
test	O
yielded	O
non	O
-	O
significant	O
p	O
-	O
values	O
when	O
the	O
groups	O
were	O
compared	O
.	O

CONCLUSION	O
:	O
FLG	O
mutation	O
was	O
not	O
associated	O
with	O
MM	O
in	O
the	O
studied	O
populations	O
.	O

This	O
finding	O
indicates	O
that	O
epidermal	O
deficiency	O
of	O
filaggrin	O
and	O
its	O
degradation	O
products	O
do	O
not	O
influence	O
the	O
risk	O
of	O
MM	O
significantly	O
.	O

This	O
article	O
is	O
protected	O
by	O
copyright	O
.	O

All	O
rights	O
reserved	O
.	O

A	O
gain	B-PosReg
-	I-PosReg
of	I-PosReg
-	I-PosReg
function	I-PosReg
mutation	B-Var
in	O
TNFRSF13B	B-Gene
is	O
a	O
candidate	O
for	O
predisposition	O
to	O
familial	B-Disease
or	I-Disease
sporadic	I-Disease
immune	I-Disease
thrombocytopenia	I-Disease
.	O

BACKGROUND	O
:	O
Most	O
immune	B-Disease
thrombocytopenia	I-Disease
(	O
ITP	O
)	O
is	O
sporadic	O
but	O
a	O
positive	O
family	O
history	O
of	O
ITP	O
in	O
some	O
patients	O
suggests	O
that	O
hereditary	O
forms	O
exist	O
.	O

Due	O
to	O
the	O
rarity	O
of	O
familial	O
ITP	O
families	O
available	O
for	O
study	O
and	O
the	O
heterogeneity	O
of	O
sporadic	O
ITP	O
,	O
family	O
linkage	O
analysis	O
or	O
genome	O
wide	O
association	O
studies	O
are	O
limited	O
.	O

OBJECTIVES	O
:	O
Based	O
on	O
one	O
ITP	O
pedigree	O
,	O
we	O
try	O
to	O
identify	O
the	O
predisposing	O
gene	O
in	O
familial	O
or	O
sporadic	O
ITP	O
and	O
reveal	O
the	O
way	O
in	O
which	O
it	O
causes	O
thrombocytopenia	O
.	O

METHODS	O
:	O
Gene	O
expression	O
profiling	O
analysis	O
and	O
whole	O
-	O
exome	O
sequencing	O
was	O
performed	O
on	O
samples	O
from	O
familial	O
ITP	O
members	O
,	O
sporadic	O
ITP	O
cases	O
and	O
healthy	O
individuals	O
.	O

We	O
also	O
evaluated	O
the	O
influence	O
of	O
potential	O
pathogenic	O
mutation	O
on	O
immune	O
function	O
and	O
megakaryocyte	O
apoptosis	O
.	O

RESULTS	O
:	O
Whole	O
-	O
exome	O
sequencing	O
identified	O
a	O
potential	O
pathologic	B-Reg
p	B-Var
.	I-Var
G76S	I-Var
heterozygous	O
mutation	O
on	O
the	O
TNFRSF13B	B-Gene
gene	O
in	O
familial	B-Disease
ITP	I-Disease
patients	O
.	O

ITP	O
patients	O
harboring	O
G76S	B-Var
mutation	O
displayed	O
upregulated	B-PosReg
"	B-MPA
cytokine	I-MPA
-	I-MPA
cytokine	I-MPA
receptor	I-MPA
interaction	I-MPA
"	I-MPA
signal	I-MPA
,	O
increased	B-PosReg
serum	B-MPA
TNFα	I-MPA
,	O
IL-17α	I-MPA
,	O
IFNγ	I-MPA
and	I-MPA
BAFF	I-MPA
levels	I-MPA
,	O
and	O
enhanced	B-PosReg
binding	B-Interaction
capacity	I-Interaction
of	I-Interaction
APRIL	I-Interaction
ligand	I-Interaction
to	I-Interaction
B	I-Interaction
cells	I-Interaction
.	O

Additionally	O
,	O
EBV	O
-	O
transformed	O
B	O
cells	O
with	O
the	O
G76S	B-Var
mutation	O
could	O
induce	B-PosReg
human	B-CPA
megakaryocyte	I-CPA
line	I-CPA
(	I-CPA
Meg-01	I-CPA
)	I-CPA
apoptosis	I-CPA
significantly	O
.	O

CONCLUSION	O
:	O
p	B-Var
.	I-Var
G76S	I-Var
mutation	O
on	O
TNFRSF13B	B-Gene
gene	O
is	O
responsible	B-Reg
for	O
ITP	B-Disease
,	O
and	O
is	O
a	O
genetic	O
predisposing	O
factor	O
for	O
familial	O
or	O
sporadic	O
ITP	O
.	O

This	O
article	O
is	O
protected	O
by	O
copyright	O
.	O

All	O
rights	O
reserved	O
.	O

A	O
single	O
active	O
site	O
mutation	O
in	O
the	O
pikromycin	O
thioesterase	O
generates	O
a	O
more	O
effective	O
macrocyclization	O
catalyst	O
.	O

Macrolactonization	O
of	O
natural	O
product	O
analogs	O
presents	O
a	O
significant	O
challenge	O
to	O
both	O
biosynthetic	O
assembly	O
and	O
synthetic	O
chemistry	O
.	O

In	O
the	O
preceding	O
paper	O
,	O
we	O
identified	O
a	O
thioesterase	O
(	O
TE	O
)	O
domain	O
catalytic	O
bottleneck	O
in	O
the	O
processing	O
of	O
un	O
-	O
natural	O
substrates	O
in	O
the	O
pikromycin	O
(	O
Pik	O
)	O
system	O
,	O
preventing	O
the	O
formation	O
of	O
epimerized	O
macrolactones	O
.	O

Here	O
,	O
we	O
perform	O
molecular	O
dynamics	O
(	O
MD	O
)	O
simulations	O
showing	O
the	O
epimerized	O
hexaketide	O
was	O
accommodated	O
within	O
the	O
Pik	O
TE	O
active	O
site	O
;	O
however	O
,	O
intrinsic	O
conformational	O
preferences	O
of	O
the	O
substrate	O
resulted	O
in	O
predominately	O
unproductive	O
conformations	O
,	O
in	O
agreement	O
with	O
the	O
observed	O
hydrolysis	O
.	O

Accordingly	O
,	O
we	O
engineered	O
the	O
stereospecific	O
Pik	O
TE	O
to	O
yield	O
a	O
variant	O
(	O
TES148C	O
)	O
with	O
improved	O
reaction	O
kinetics	O
and	O
gain	O
-	O
of	O
-	O
function	O
processing	O
of	O
an	O
unnatural	O
,	O
epimerized	O
hexaketide	O
.	O

Quantum	O
mechanical	O
(	O
QM	O
)	O
comparison	O
of	O
model	O
TES148C	O
and	O
TEWT	O
reaction	O
coordinate	O
diagrams	O
revealed	O
a	O
change	O
in	O
mechanism	O
from	O
a	O
stepwise	O
addition	O
-	O
elimination	O
(	O
TEWT	O
)	O
to	O
a	O
lower	O
energy	O
concerted	O
acyl	O
substitution	O
(	O
TES148C	O
)	O
,	O
accounting	O
for	O
the	O
gain	O
-	O
of	O
-	O
function	O
and	O
improved	O
reaction	O
kinetics	O
.	O

Finally	O
,	O
we	O
introduced	O
the	O
S148C	B-Var
mutation	O
into	O
a	O
polyketide	O
synthase	O
module	O
(	O
PikAIII	O
-	O
TE	O
)	O
to	O
impart	O
increased	B-PosReg
substrate	B-MPA
flexibility	I-MPA
,	O
enabling	B-PosReg
the	O
production	B-MPA
of	I-MPA
diastereomeric	I-MPA
macrolactones	I-MPA
.	O

A	O
comprehensive	O
functional	O
assessment	O
of	O
carboxylesterase	O
1	O
nonsynonymous	O
polymorphisms	O
.	O

Carboxylesterase	O
1	O
(	O
CES1	O
)	O
is	O
the	O
predominant	O
human	O
hepatic	O
hydrolase	O
responsible	O
for	O
the	O
metabolism	O
of	O
many	O
clinically	O
important	O
medications	O
.	O

CES1	O
expression	O
and	O
activity	O
vary	O
markedly	O
among	O
individuals	O
;	O
and	O
genetic	O
variation	O
is	O
a	O
major	O
contributing	O
factor	O
to	O
CES1	O
interindividual	O
variability	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
comprehensively	O
examined	O
the	O
functions	O
of	O
CES1	O
nonsynonymous	O
single	O
nucleotide	O
polymorphisms	O
(	O
nsSNPs	O
)	O
and	O
haplotypes	O
using	O
transfected	O
cell	O
lines	O
and	O
individual	O
human	O
liver	O
tissues	O
.	O

The	O
20	O
candidate	O
variants	O
include	O
CES1	O
nsSNPs	O
with	O
a	O
minor	O
allele	O
frequency	O
(	O
MAF	O
)	O
>	O
0.5	O
%	O
in	O
a	O
given	O
population	O
or	O
located	O
in	O
close	O
proximity	O
to	O
the	O
CES1	O
active	O
site	O
.	O

Five	O
nsSNPs	O
including	O
L40Ter	O
(	B-Var
rs151291296	I-Var
)	I-Var
,	O
G142E	O
(	B-Var
rs121912777	I-Var
)	I-Var
,	O
G147C	O
(	B-Var
rs146456965	I-Var
)	I-Var
,	O
Y170D	O
(	B-Var
rs148947808	I-Var
)	I-Var
,	O
and	O
R171C	O
(	B-Var
rs201065375	I-Var
)	I-Var
were	O
found	O
to	O
be	O
loss	B-NegReg
-	I-NegReg
of	I-NegReg
-	I-NegReg
function	I-NegReg
variants	O
for	O
metabolizing	B-MPA
the	O
CES1	B-Enzyme
substrates	O
clopidogrel	O
,	O
enalapril	O
,	O
and	O
sacubitril	O
.	O

Additionally	O
,	O
the	O
A158V	O
(	B-Var
rs202121317	I-Var
)	I-Var
,	O
R199H	O
(	B-Var
rs2307243	I-Var
)	I-Var
,	O
E220	O
G	O
(	B-Var
rs200707504	I-Var
)	I-Var
,	O
and	O
T290	O
M	O
(	B-Var
rs202001817	I-Var
)	I-Var
decreased	B-NegReg
CES1	B-Enzyme
activity	B-MPA
to	O
a	O
lesser	O
extent	O
in	O
a	O
substrate	O
-	O
dependent	O
manner	O
.	O

Several	O
nsSNPs	O
including	O
the	O
L40Ter	O
(	B-Var
rs151291296	I-Var
)	I-Var
,	O
G147C	O
(	B-Var
rs146456965	I-Var
)	I-Var
,	O
Y170D	O
(	B-Var
rs148947808	I-Var
)	I-Var
,	O
and	O
R171C	O
(	B-Var
rs201065375	I-Var
)	I-Var
significantly	O
reduced	B-NegReg
CES1	B-Protein
protein	I-Protein
and/or	O
mRNA	B-MPA
expressions	I-MPA
in	O
the	O
transfected	O
cells	O
.	O

Functions	O
of	O
the	O
common	O
nonsynonymous	O
haplotypes	O
D203E	O
-	O
A269S	O
and	O
S75N	O
-	O
D203E	O
-	O
A269S	O
were	O
evaluated	O
using	O
cells	O
stably	O
expressing	O
the	O
haplotypes	O
and	O
a	O
large	O
set	O
of	O
human	O
livers	O
.	O

Neither	O
CES1	O
expression	O
nor	O
activity	O
were	O
affected	O
by	O
the	O
two	O
haplotypes	O
.	O

In	O
sum	O
,	O
the	O
study	O
revealed	O
several	O
functional	O
nsSNPs	O
with	O
impaired	O
activity	O
on	O
the	O
metabolism	O
of	O
CES1	O
substrate	O
drugs	O
.	O

Clinical	O
investigations	O
are	O
warranted	O
to	O
determine	O
whether	O
these	O
nsSNPs	O
can	O
serve	O
as	O
biomarkers	O
for	O
the	O
prediction	O
of	O
therapeutic	O
outcomes	O
of	O
drugs	O
metabolized	O
by	O
CES1	O
.	O

Progranulin	B-Protein
haploinsufficiency	B-Var
reduces	B-NegReg
amyloid	B-MPA
beta	I-MPA
deposition	I-MPA
in	O
Alzheimer	B-Disease
's	I-Disease
disease	I-Disease
model	O
mice	O
.	O

Granulin	O
(	O
Grn	O
)	O
mutations	O
were	O
identified	O
in	O
familial	O
frontotemporal	B-Disease
lobar	I-Disease
degeneration	I-Disease
(	O
FTLD	O
)	O
patients	O
with	O
TAR	O
DNA	O
-	O
binding	O
protein	O
of	O
43	O
kd	O
(	O
TDP-43	O
)	O
pathology	O
.	O

Grn	B-Protein
transcript	O
haploinsufficiency	B-Var
is	O
proposed	O
as	O
a	O
disease	O
mechanism	O
that	O
leads	O
to	O
the	O
loss	B-NegReg
of	I-NegReg
functional	I-NegReg
progranulin	O
(	B-Protein
PGRN	I-Protein
)	I-Protein
protein	O
.	O

Thus	O
,	O
these	O
mutations	B-Var
are	O
strongly	O
involved	B-Reg
in	O
FTLD	B-Disease
pathogenesis	O
.	O

Moreover	O
,	O
recent	O
findings	O
indicate	O
that	O
Grn	B-Protein
mutations	B-Var
are	O
associated	B-Reg
with	O
other	O
neurodegenerative	O
disorders	O
with	O
tau	O
pathology	O
,	O
including	O
Alzheimer	B-Disease
's	I-Disease
disease	I-Disease
.	O

To	O
investigate	O
the	O
influence	O
of	O
PGRN	O
on	O
amyloid	O
beta	O
(	O
Aβ	O
)	O
accumulation	O
,	O
amyloid	O
precursor	O
protein	O
(	O
APP	O
)	O
transgenic	O
mice	O
were	O
interbred	O
with	O
Grn	O
-	O
deficient	O
mice	O
,	O
producing	O
APP	O
transgenic	O
mice	O
harboring	O
the	O
Grn	O
hemizygote	O
(	O
APP	O
/	O
Grn+/-	O
)	O
.	O

Brains	O
were	O
collected	O
from	O
16	O
-	O
18-month	O
-	O
old	O
APP	O
and	O
APP	O
/	O
Grn+/-	O
mice	O
and	O
sequential	O
extraction	O
of	O
proteins	O
,	O
immunoblotting	O
and	O
immunohistochemical	O
analysis	O
were	O
performed	O
.	O

Immunohistochemical	O
analysis	O
showed	O
that	O
the	O
number	O
and	O
area	O
of	O
Aβ	O
plaque	O
was	O
significantly	O
decreased	O
in	O
APP	O
/	O
Grn+/-	O
mice	O
as	O
compared	O
to	O
APP	O
mice	O
.	O

Immunoblotting	O
analysis	O
revealed	O
that	O
Aβ	O
was	O
reduced	O
in	O
the	O
sarkosyl	O
-	O
insoluble	O
fraction	O
of	O
16	O
-	O
18-month	O
-	O
old	O
APP	O
/	O
Grn+/-	O
mice	O
as	O
compared	O
with	O
that	O
of	O
APP	O
transgenic	O
mice	O
.	O

Our	O
data	O
suggest	O
that	O
PGRN	B-Protein
haploinsufficiency	B-Var
may	O
decrease	B-NegReg
accumulation	B-MPA
of	I-MPA
Aβ	I-MPA
.	O

Identification	O
of	O
distinct	O
mutational	O
patterns	O
and	O
new	O
driver	O
genes	O
in	O
oesophageal	O
squamous	O
cell	O
carcinomas	O
and	O
adenocarcinomas	O
.	O

OBJECTIVES	O
:	O
Oesophageal	B-Disease
squamous	I-Disease
cell	I-Disease
carcinoma	I-Disease
(	O
OSCC	O
)	O
and	O
adenocarcinoma	O
(	O
OAC	O
)	O
are	O
distinct	O
cancers	O
in	O
terms	O
of	O
a	O
number	O
of	O
clinical	O
and	O
epidemiological	O
characteristics	O
,	O
complicating	O
the	O
design	O
of	O
clinical	O
trials	O
and	O
biomarker	O
developments	O
.	O

We	O
analysed	O
1048	O
oesophageal	O
tumour	O
-	O
germline	O
pairs	O
from	O
both	O
subtypes	O
,	O
to	O
characterise	O
their	O
genomic	O
features	O
,	O
and	O
biological	O
and	O
clinical	O
significance	O
.	O

DESIGN	O
:	O
Previously	O
exome	O
-	O
sequenced	O
samples	O
were	O
re	O
-	O
analysed	O
to	O
identify	O
significantly	O
mutated	O
genes	O
(	O
SMGs	O
)	O
and	O
mutational	O
signatures	O
.	O

The	O
biological	O
functions	O
of	O
novel	O
SMGs	O
were	O
investigated	O
using	O
cell	O
line	O
and	O
xenograft	O
models	O
.	O

We	O
further	O
performed	O
whole	O
-	O
genome	O
bisulfite	O
sequencing	O
and	O
chromatin	O
immunoprecipitation	O
(	O
ChIP)-seq	O
to	O
characterise	O
epigenetic	O
alterations	O
.	O

RESULTS	O
:	O
OSCC	O
and	O
OAC	O
displayed	O
nearly	O
mutually	O
exclusive	O
sets	O
of	O
driver	O
genes	O
,	O
indicating	O
that	O
they	O
follow	O
independent	O
developmental	O
paths	O
.	O

The	O
combined	O
sample	O
size	O
allowed	O
the	O
statistical	O
identification	O
of	O
a	O
number	O
of	O
novel	O
subtype	O
-	O
specific	O
SMGs	O
,	O
mutational	O
signatures	O
and	O
prognostic	O
biomarkers	O
.	O

Particularly	O
,	O
we	O
identified	O
a	O
novel	O
mutational	O
signature	O
similar	O
to	O
Catalogue	O
Of	O
Somatic	O
Mutations	O
In	O
Cancer	O
(	O
COSMIC)signature	O
16	O
,	O
which	O
has	O
prognostic	O
value	O
in	O
OSCC	O
.	O

Two	O
newly	O
discovered	O
SMGs	O
,	O
CUL3	O
and	O
ZFP36L2	O
,	O
were	O
validated	O
as	O
important	O
tumour	O
-	O
suppressors	O
specific	O
to	O
the	O
OSCC	O
subtype	O
.	O

We	O
further	O
identified	O
their	O
additional	O
loss	O
-	O
of	O
-	O
function	O
mechanisms	O
.	O

CUL3	B-Gene
was	O
homozygously	O
deleted	B-Var
specifically	O
in	B-Reg
OSCC	B-Disease
and	O
other	O
squamous	B-Disease
cell	I-Disease
cancers	I-Disease
(	O
SCCs	O
)	O
.	O

Notably	O
,	O
ZFP36L2	O
is	O
associated	O
with	O
super	O
-	O
enhancer	O
in	O
healthy	O
oesophageal	O
mucosa	O
;	O
DNA	O
hypermethylation	O
in	O
its	O
super	O
-	O
enhancer	O
reduced	O
active	O
histone	O
markers	O
in	O
squamous	O
cancer	O
cells	O
,	O
suggesting	O
an	O
epigenetic	O
inactivation	O
of	O
a	O
super	O
-	O
enhancer	O
-	O
associated	O
SCC	O
suppressor	O
.	O

CONCLUSIONS	O
:	O
These	O
data	O
comprehensively	O
contrast	O
differences	O
between	O
OSCC	O
and	O
OAC	O
at	O
both	O
genomic	O
and	O
epigenomic	O
levels	O
,	O
and	O
reveal	O
novel	O
molecular	O
features	O
for	O
further	O
delineating	O
the	O
pathophysiological	O
mechanisms	O
and	O
treatment	O
strategies	O
for	O
these	O
cancers	O
.	O

Gait	O
disturbance	O
and	O
lower	O
limb	O
pain	O
in	O
a	O
patient	O
with	O
PIK3CA	O
-	O
related	O
disorder	O
.	O

Post	O
-	O
zygotic	O
activating	O
mutations	O
in	O
PIK3CA	O
and	O
other	O
genes	O
encoding	O
members	O
of	O
PI3K	O
-	O
AKT	O
-	O
mTOR	O
pathway	O
have	O
been	O
found	O
in	O
various	O
overgrowth	O
syndromes	O
that	O
have	O
been	O
grouped	O
together	O
as	O
PIK3CA	O
-	O
related	O
overgrowth	O
spectrum	O
(	O
PROS	O
)	O
.	O

We	O
report	O
a	O
female	O
patient	O
with	O
gait	O
disturbance	O
,	O
leg	O
pain	O
,	O
isolated	O
macrodactyly	O
of	O
the	O
foot	O
,	O
and	O
mild	O
intellectual	O
disability	O
.	O

Imaging	O
of	O
the	O
lower	O
limb	O
showed	O
a	O
lipoblastoma	O
of	O
the	O
right	O
thigh	O
.	O

A	O
mosaic	O
gain	B-PosReg
-	I-PosReg
of	I-PosReg
-	I-PosReg
function	I-PosReg
mutation	O
in	O
the	O
catalytic	O
domain	O
of	O
PIK3CA	B-Gene
(	B-Var
c.3140	I-Var
A	I-Var
>	I-Var
G	I-Var
;	I-Var
p	B-Var
.	I-Var
His1047Arg	I-Var
)	I-Var
was	O
detected	O
in	O
the	O
adipose	O
tissue	O
and	O
in	O
skin	O
cultured	O
fibroblasts	O
from	O
the	O
macrodactyly	O
but	O
not	O
in	O
blood	O
.	O

The	O
leg	O
pain	O
and	O
the	O
severe	O
walking	O
disturbance	O
improved	O
slightly	O
over	O
time	O
and	O
serial	O
MRI	O
of	O
the	O
lower	O
limbs	O
suggested	O
that	O
the	O
size	O
of	O
the	O
lipoblastoma	O
relative	O
to	O
the	O
lower	O
limb	O
muscles	O
or	O
to	O
the	O
whole	O
lower	O
limb	O
was	O
unchanged	O
as	O
consequence	O
of	O
limb	O
growth	O
.	O

This	O
case	O
report	O
illustrates	O
that	O
pain	O
and	O
gait	O
disturbance	O
can	O
be	O
features	O
of	O
PROS	O
and	O
highlights	O
the	O
need	O
of	O
better	O
knowledge	O
about	O
the	O
natural	O
history	O
of	O
the	O
disease	O
.	O

Loss	O
-	O
of	O
-	O
Function	O
GRHL3	O
Variants	O
Detected	O
in	O
African	O
Patients	O
with	O
Isolated	O
Cleft	O
Palate	O
.	O

In	O
contrast	O
to	O
the	O
progress	O
that	O
has	O
been	O
made	O
toward	O
understanding	O
the	O
genetic	O
etiology	O
of	O
cleft	O
lip	O
with	O
or	O
without	O
cleft	O
palate	O
,	O
relatively	O
little	O
is	O
known	O
about	O
the	O
genetic	O
etiology	O
for	O
cleft	B-Disease
palate	I-Disease
only	I-Disease
(	O
CPO	O
)	O
.	O

A	O
common	O
coding	O
variant	O
of	O
grainyhead	O
like	O
transcription	O
factor	O
3	O
(	O
GRHL3	O
)	O
was	O
recently	O
shown	O
to	O
be	O
associated	O
with	O
risk	O
for	O
CPO	O
in	O
Europeans	O
.	O

Mutations	O
in	O
this	O
gene	O
were	O
also	O
reported	O
in	O
families	O
with	O
Van	O
der	O
Woude	O
syndrome	O
.	O

To	O
identify	O
rare	O
mutations	O
in	O
GRHL3	O
that	O
might	O
explain	O
the	O
missing	O
heritability	O
for	O
CPO	O
,	O
we	O
sequenced	O
GRHL3	O
in	O
cases	O
of	O
CPO	O
from	O
Africa	O
.	O

We	O
recruited	O
participants	O
from	O
Ghana	O
,	O
Ethiopia	O
,	O
and	O
Nigeria	O
.	O

This	O
cohort	O
included	O
case	O
-	O
parent	O
trios	O
,	O
cases	O
and	O
other	O
family	O
members	O
,	O
as	O
well	O
as	O
controls	O
.	O

We	O
sequenced	O
exons	O
of	O
this	O
gene	O
in	O
DNA	O
from	O
a	O
total	O
of	O
134	O
nonsyndromic	O
cases	O
.	O

When	O
possible	O
,	O
we	O
sequenced	O
them	O
in	O
parents	O
to	O
identify	O
de	O
novo	O
mutations	O
.	O

Five	O
novel	O
mutations	O
were	O
identified	O
:	O
2	O
missense	O
(	O
c.497C	O
>	O
A	O
;	O
p	O
.	O
Pro166His	O
and	O
c.1229A	O
>	O
G	O
;	O
p	O
.	O
Asp410Gly	O
)	O
,	O
1	O
splice	O
site	O
(	O
c.1282A	O
>	O
C	O
p	O
.	O
Ser428Arg	O
)	O
,	O
1	O
frameshift	O
(	O
c.470delC	O
;	O
p	O
.	O
Gly158Alafster55	O
)	O
,	O
and	O
1	O
nonsense	O
(	O
c.1677C	O
>	O
A	O
;	O
p	O
.	O
Tyr559Ter	O
)	O
.	O

These	O
mutations	O
were	O
absent	O
from	O
270	O
sequenced	O
controls	O
and	O
from	O
all	O
public	O
exome	O
and	O
whole	O
genome	O
databases	O
,	O
including	O
the	O
1000	O
Genomes	O
database	O
(	O
which	O
includes	O
data	O
from	O
Africa	O
)	O
.	O

However	O
,	O
4	O
of	O
the	O
5	O
mutations	O
were	O
present	O
in	O
unaffected	O
mothers	O
,	O
indicating	O
that	O
their	O
penetrance	O
is	O
incomplete	O
.	O

Interestingly	O
,	O
1	O
mutation	B-Var
damaged	B-NegReg
a	O
predicted	O
sumoylation	B-MPA
site	I-MPA
,	O
and	O
another	O
disrupted	B-NegReg
a	O
predicted	O
CK1	B-MPA
phosphorylation	I-MPA
site	O
.	O

Overexpression	O
assays	O
in	O
zebrafish	O
and	O
reporter	O
assays	O
in	O
vitro	O
indicated	O
that	O
4	O
variants	O
were	O
functionally	O
null	O
or	O
hypomorphic	O
,	O
while	O
1	O
was	O
dominant	O
negative	O
.	O

This	O
study	O
provides	O
evidence	O
that	O
,	O
as	O
in	O
Caucasian	O
populations	O
,	O
mutations	B-Var
in	O
GRHL3	B-Gene
contribute	O
to	O
the	O
risk	B-Reg
of	O
nonsyndromic	O
CPO	B-Disease
in	O
the	O
African	O
population	O
.	O

The	O
apolipoprotein	B-Protein
C	I-Protein
-	I-Protein
III	I-Protein
(	B-Var
Gln38Lys	I-Var
)	I-Var
variant	O
associated	O
with	O
human	B-Disease
hypertriglyceridemia	I-Disease
is	O
a	O
gain	B-PosReg
-	I-PosReg
of	I-PosReg
-	I-PosReg
function	I-PosReg
mutation	O
.	O

Recent	O
cell	O
culture	O
and	O
animal	O
studies	O
have	O
suggested	O
that	O
expression	O
of	O
human	O
apo	O
C	O
-	O
III	O
in	O
the	O
liver	O
has	O
a	O
profound	O
impact	O
on	O
the	O
triacylglycerol	O
(	O
TAG)-rich	O
VLDL1	O
production	O
under	O
lipid	O
-	O
rich	O
conditions	O
.	O

The	O
apoC	O
-	O
III	O
Gln38Lys	O
variant	O
was	O
identified	O
in	O
subjects	O
of	O
Mexican	O
origin	O
with	O
moderate	O
hypertriglyceridemia	O
.	O

We	O
postulated	O
that	O
Gln38Lys	O
(	O
C3QK	O
)	O
,	O
being	O
a	O
gain	O
-	O
of	O
-	O
function	O
mutation	O
,	O
promotes	O
hepatic	O
VLDL1	O
assembly	O
/	O
secretion	O
.	O

To	O
test	O
this	O
hypothesis	O
,	O
we	O
expressed	O
C3QK	O
in	O
McA	O
-	O
RH7777	O
cells	O
and	O
apoc3-null	O
mice	O
to	O
contrast	O
its	O
effect	O
with	O
WT	O
apoC	O
-	O
III	O
(	O
C3WT	O
)	O
.	O

In	O
both	O
model	O
systems	O
,	O
C3QK	O
expression	O
increased	O
the	O
secretion	O
of	O
VLDL1-TAG	O
(	O
by	O
230	O
%	O
)	O
under	O
lipid	O
-	O
rich	O
conditions	O
.	O

Metabolic	O
labeling	O
experiments	O
with	O
C3QK	O
cells	O
showed	O
an	O
increase	O
in	O
de	B-MPA
novo	I-MPA
lipogenesis	I-MPA
(	O
DNL	O
)	O
.	O

Fasting	O
plasma	O
concentration	O
of	O
TAG	O
,	O
cholesterol	O
,	O
cholesteryl	O
ester	O
,	O
and	O
FA	O
were	O
increased	O
in	O
C3QK	O
mice	O
as	O
compared	O
with	O
C3WT	O
mice	O
.	O

Liver	O
of	O
C3QK	B-Var
mice	O
also	O
displayed	O
an	O
increase	B-PosReg
in	O
DNL	B-MPA
and	O
expression	B-MPA
of	O
lipogenic	B-Gene
genes	I-Gene
as	O
compared	O
with	O
that	O
in	O
C3WT	O
mice	O
.	O

These	O
results	O
suggest	O
that	O
C3QK	B-Var
variant	O
is	O
a	O
gain	O
-	O
of	O
-	O
function	O
mutation	O
that	O
can	O
stimulate	B-PosReg
VLDL1	B-MPA
production	I-MPA
,	O
through	O
enhanced	B-PosReg
DNL	B-MPA
.	O

The	O
Impact	O
of	O
Heterozygous	O
KCNK3	O
Mutations	O
Associated	O
With	O
Pulmonary	O
Arterial	O
Hypertension	O
on	O
Channel	O
Function	O
and	O
Pharmacological	O
Recovery	O
.	O

BACKGROUND	O
:	O
Heterozygous	O
loss	O
of	O
function	O
mutations	B-Var
in	O
the	O
KCNK3	B-Gene
gene	O
cause	B-Reg
hereditary	O
pulmonary	B-Disease
arterial	I-Disease
hypertension	I-Disease
(	O
PAH	O
)	O
.	O

KCNK3	O
encodes	O
an	O
acid	O
-	O
sensitive	O
potassium	O
channel	O
,	O
which	O
contributes	O
to	O
the	O
resting	O
potential	O
of	O
human	O
pulmonary	O
artery	O
smooth	O
muscle	O
cells	O
.	O

KCNK3	O
is	O
widely	O
expressed	O
in	O
the	O
body	O
,	O
and	O
dimerizes	O
with	O
other	O
KCNK3	O
subunits	O
,	O
or	O
the	O
closely	O
related	O
,	O
acid	O
-	O
sensitive	O
KCNK9	O
channel	O
.	O

METHODS	O
AND	O
RESULTS	O
:	O
We	O
engineered	O
homomeric	O
and	O
heterodimeric	O
mutant	O
and	O
nonmutant	O
KCNK3	O
channels	O
associated	O
with	O
PAH	O
.	O

Using	O
whole	O
-	O
cell	O
patch	O
-	O
clamp	O
electrophysiology	O
in	O
human	O
pulmonary	O
artery	O
smooth	O
muscle	O
and	O
COS7	O
cell	O
lines	O
,	O
we	O
determined	O
that	O
homomeric	O
and	O
heterodimeric	O
mutant	O
channels	O
in	O
heterozygous	O
KCNK3	O
conditions	O
lead	O
to	O
mutation	O
-	O
specific	O
severity	O
of	O
channel	O
dysfunction	O
.	O

Both	O
wildtype	O
and	O
mutant	O
KCNK3	O
channels	O
were	O
activated	O
by	O
ONO	O
-	O
RS-082	O
(	O
10	O
μmol	O
/	O
L	O
)	O
,	O
causing	O
cell	O
hyperpolarization	O
.	O

We	O
observed	O
robust	O
gene	O
expression	O
of	O
KCNK3	O
in	O
healthy	O
and	O
familial	O
PAH	O
patient	O
lungs	O
,	O
but	O
no	O
quantifiable	O
expression	O
of	O
KCNK9	O
,	O
and	O
demonstrated	O
in	O
functional	O
studies	O
that	O
KCNK9	O
minimizes	O
the	O
impact	O
of	O
select	O
KCNK3	O
mutations	O
when	O
the	O
2	O
channel	O
subunits	O
co	O
-	O
assemble	O
.	O

CONCLUSIONS	O
:	O
Heterozygous	O
KCNK3	B-Gene
mutations	B-Var
in	O
PAH	O
lead	O
to	O
variable	O
loss	B-NegReg
of	O
channel	B-MPA
function	I-MPA
via	O
distinct	O
mechanisms	O
.	O

Homomeric	O
and	O
heterodimeric	O
mutant	O
KCNK3	O
channels	O
represent	O
novel	O
therapeutic	O
substrates	O
in	O
PAH	O
.	O

Pharmacological	O
and	O
pH	O
-	O
dependent	O
activation	O
of	O
wildtype	O
and	O
mutant	O
KCNK3	O
channels	O
in	O
pulmonary	O
artery	O
smooth	O
muscle	O
cells	O
leads	O
to	O
membrane	O
hyperpolarization	O
.	O

Co	O
-	O
assembly	O
of	O
KCNK3	O
with	O
KCNK9	O
subunits	O
may	O
provide	O
protection	O
against	O
KCNK3	O
loss	O
of	O
function	O
in	O
tissues	O
where	O
both	O
KCNK9	O
and	O
KCNK3	O
are	O
expressed	O
,	O
contributing	O
to	O
the	O
lung	O
-	O
specific	O
phenotype	O
observed	O
clinically	O
in	O
patients	O
with	O
PAH	O
because	O
of	O
KCNK3	O
mutations	O
.	O

Modifiers	O
of	O
GRN	O
-	O
Associated	O
Frontotemporal	O
Lobar	O
Degeneration	O
.	O

Heterozygous	O
loss	B-NegReg
-	I-NegReg
of	I-NegReg
-	I-NegReg
function	I-NegReg
(	O
LOF	O
)	O
mutations	B-Var
in	O
the	O
human	O
progranulin	O
gene	O
(	B-Gene
GRN	I-Gene
)	I-Gene
cause	O
frontotemporal	B-Disease
lobar	I-Disease
degeneration	I-Disease
(	O
FTLD	O
)	O
by	O
a	O
mechanism	O
of	O
haploinsufficiency	O
.	O

Patients	O
present	O
most	O
frequently	O
with	O
frontotemporal	O
dementia	O
,	O
which	O
is	O
the	O
second	O
most	O
common	O
neurodegenerative	O
dementia	O
at	O
young	O
age	O
.	O

Currently	O
,	O
no	O
disease	O
-	O
modifying	O
therapies	O
are	O
available	O
for	O
these	O
patients	O
.	O

Stimulating	O
GRN	O
protein	O
expression	O
or	O
inhibiting	O
its	O
breakdown	O
is	O
an	O
obvious	O
therapeutic	O
strategy	O
,	O
and	O
is	O
indeed	O
the	O
focus	O
of	O
current	O
preclinical	O
research	O
and	O
clinical	O
trials	O
.	O

Multiple	O
studies	O
have	O
demonstrated	O
the	O
heterogeneity	O
in	O
clinical	O
presentation	O
and	O
wide	O
variability	O
in	O
age	O
of	O
onset	O
in	O
patients	O
carrying	O
a	O
GRN	O
LOF	O
mutation	O
.	O

Recently	O
,	O
this	O
heterogeneity	O
became	O
an	O
opportunity	O
to	O
identify	O
disease	O
modifiers	O
,	O
considering	O
that	O
these	O
might	O
constitute	O
suitable	O
targets	O
for	O
developing	O
disease	O
-	O
modifying	O
or	O
disease	O
-	O
delaying	O
therapies	O
.	O

De	O
novo	O
SETD5	B-Gene
loss	B-NegReg
-	I-NegReg
of	I-NegReg
-	I-NegReg
function	I-NegReg
variant	B-Var
as	O
a	O
cause	O
for	O
intellectual	B-Disease
disability	I-Disease
in	O
a	O
10-year	O
old	O
boy	O
with	O
an	O
aberrant	O
blind	O
ending	O
bronchus	O
.	O

Although	O
rare	O
,	O
3p	O
microdeletion	O
cases	O
have	O
been	O
well	O
described	O
in	O
the	O
clinical	O
literature	O
.	O

The	O
clinical	O
phenotype	O
includes	O
;	O
intellectual	O
disability	O
(	O
ID	O
)	O
,	O
growth	O
retardation	O
,	O
facial	O
dysmorphism	O
,	O
and	O
cardiac	O
malformations	O
.	O

Advances	O
in	O
chromosome	O
microarray	O
(	O
CMA	O
)	O
testing	O
narrowed	O
the	O
3p25	O
critical	O
region	O
to	O
a	O
124	O
kb	O
region	O
,	O
and	O
recent	O
Whole	O
Exome	O
Sequencing	O
(	O
WES	O
)	O
studies	O
have	O
suggested	O
that	O
the	O
SETD5	O
gene	O
contributes	O
significantly	O
to	O
the	O
3p25	O
phenotype	O
.	O

Loss	B-NegReg
-	I-NegReg
of	I-NegReg
-	I-NegReg
Function	I-NegReg
(	O
LoF	O
)	O
variants	B-Var
in	O
SETD5	B-Gene
are	O
now	O
considered	O
a	O
likely	O
cause	O
of	O
ID	B-Disease
.	O

We	O
report	O
here	O
a	O
patient	O
with	O
a	O
frameshift	O
LoF	O
variant	O
in	O
exon	O
12	O
of	O
SETD5	O
.	O

This	O
patient	O
has	O
features	O
overlapping	O
with	O
other	O
patients	O
described	O
with	O
LoF	O
SETD5	O
variants	O
to	O
include	O
;	O
similar	O
facial	O
morphology	O
,	O
feeding	O
difficulties	O
,	O
ID	O
,	O
behavioral	O
abnormalities	O
and	O
leg	O
length	O
discrepancy	O
.	O

In	O
addition	O
,	O
he	O
presents	O
with	O
an	O
aberrant	O
blind	O
ending	O
bronchus	O
.	O

This	O
report	O
adds	O
to	O
publications	O
describing	O
intragenic	O
mutations	O
in	O
SETD5	O
and	O
supports	O
the	O
assertion	O
that	O
de	O
novo	O
LoF	O
mutations	O
in	O
SETD5	O
present	O
with	O
an	O
overlapping	O
but	O
distinct	O
phenotype	O
in	O
comparison	O
with	O
3p25	O
microdeletion	O
syndromes	O
.	O

Signal	O
transducer	O
and	O
activator	O
of	O
transcription	O
gain	O
-	O
of	O
-	O
function	O
primary	O
immunodeficiency	O
/	O
immunodysregulation	O
disorders	O
.	O

PURPOSE	O
OF	O
REVIEW	O
:	O
To	O
describe	O
primary	B-Disease
immunodeficiencies	I-Disease
caused	O
by	O
gain	B-PosReg
-	I-PosReg
of	I-PosReg
-	I-PosReg
function	I-PosReg
(	O
GOF	O
)	O
mutations	B-Var
of	O
signal	O
transducer	O
and	O
activator	O
of	O
transcription	O
(	B-Gene
STAT	I-Gene
)	I-Gene
genes	O
,	O
a	O
group	O
of	O
genetically	O
determined	O
disorders	O
characterized	O
by	O
susceptibility	O
to	O
infections	O
and	O
,	O
in	O
many	O
cases	O
,	O
autoimmune	O
manifestations	O
.	O

RECENT	O
FINDINGS	O
:	O
GOF	O
mutations	B-Var
affecting	O
STAT1	B-Gene
result	O
in	O
increased	B-PosReg
STAT	B-MPA
tyrosine	I-MPA
phosphorylation	I-MPA
and	O
secondarily	O
increased	B-PosReg
response	B-MPA
to	I-MPA
STAT1-signaling	I-MPA
cytokines	I-MPA
,	O
such	O
as	O
interferons	O
.	O

In	O
contrast	O
,	O
STAT3	O
hyperactivity	O
is	O
not	O
usually	O
related	O
to	O
hyperphosphorylation	O
but	O
rather	O
to	O
increased	O
STAT3-mediated	O
transcriptional	O
activity	O
.	O

In	O
both	O
cases	O
,	O
heterozygous	O
STAT1	O
and	O
STAT3	O
GOF	O
mutations	O
trigger	O
a	O
distinct	O
set	O
of	O
genes	O
in	O
target	O
cells	O
that	O
lead	O
to	O
abnormal	O
functioning	O
of	O
antimicrobial	O
response	O
and/or	O
autoimmunity	O
and	O
result	O
in	O
autosomal	O
dominant	O
diseases	O
.	O

SUMMARY	O
:	O
Clinical	O
manifestations	O
of	O
patients	O
with	O
STAT1	O
GOF	O
are	O
characterized	O
by	O
mucocutaneous	O
candidiasis	O
and	O
recurrent	O
lower	O
tract	O
respiratory	O
infections	O
.	O

In	O
addition	O
,	O
many	O
patients	O
have	O
thyroiditis	O
,	O
type	O
1	O
diabetes	O
mellitus	O
,	O
autoimmune	O
cytopenias	O
,	O
cancer	O
or	O
aneurysms	O
.	O

Patients	O
with	O
germline	O
STAT3	O
GOF	O
mutations	O
have	O
an	O
increased	O
frequency	O
of	O
early	O
-	O
onset	O
multiorgan	O
autoimmunity	O
(	O
i.e.	O
autoimmune	O
enteropathy	O
,	O
type	O
1	O
diabetes	O
mellitus	O
,	O
autoimmune	O
interstitial	O
lung	O
disease	O
and	O
autoimmune	O
cytopenias	O
)	O
,	O
lymphoproliferation	O
,	O
short	O
stature	O
and	O
,	O
less	O
frequently	O
,	O
severe	O
recurrent	O
infections	O
.	O

Treatment	O
options	O
range	O
from	O
antimicrobial	O
therapy	O
,	O
intravenous	O
or	O
subcutaneous	O
immunoglobulin	O
and	O
immunosuppressive	O
drugs	O
.	O

Some	O
patients	O
with	O
STAT1	O
GOF	O
disorder	O
have	O
undergone	O
hematopoietic	O
stem	O
cell	O
transplantation	O
,	O
although	O
these	O
have	O
been	O
difficult	O
because	O
of	O
the	O
underlying	O
proinflammatory	O
milieu	O
from	O
the	O
mutation	O
.	O

GNPTAB	O
missense	O
mutations	O
cause	O
loss	O
of	O
GlcNAc-1-phosphotransferase	O
activity	O
in	O
mucolipidosis	O
type	O
II	O
through	O
distinct	O
mechanisms	O
.	O

Mucolipidoses	O
(	O
ML	O
)	O
II	O
and	O
III	O
alpha	O
/	O
beta	O
are	O
lysosomal	O
storage	O
diseases	O
caused	O
by	O
pathogenic	O
mutations	O
in	O
GNPTAB	O
encoding	O
the	O
α⁄β	O
-	O
subunit	O
precursor	O
of	O
GlcNAc-1-phosphotransferase	O
.	O

To	O
determine	O
genotype	O
-	O
phenotype	O
correlation	O
and	O
functional	O
analysis	O
of	O
mutant	O
GlcNAc-1-phosphotransferase	O
,	O
13	O
Brazilian	O
patients	O
clinically	O
and	O
biochemical	O
diagnosed	O
for	O
MLII	O
or	O
III	O
alpha	O
/	O
beta	O
were	O
studied	O
.	O

By	O
sequencing	O
of	O
genomic	O
GNPTAB	B-Gene
of	O
the	O
MLII	O
and	O
MLIII	O
alpha	O
/	O
beta	O
patients	O
we	O
identified	O
six	O
novel	O
mutations	O
:	O
p	B-Var
.	I-Var
D76	I-Var
G	I-Var
,	O
p	B-Var
.	I-Var
S385L	I-Var
,	O
p	B-Var
.	I-Var
Q278Kfs*3	I-Var
,	O
p	B-Var
.	I-Var
H588Qfs*27	I-Var
,	O
p	B-Var
.	I-Var
N642Lfs*10	I-Var
and	O
p	B-Var
.	I-Var
Y1111	I-Var
*	I-Var
.	O

Expression	O
analysis	O
by	O
western	O
blotting	O
and	O
immunofluorescence	O
microscopy	O
revealed	O
that	O
the	O
mutant	O
α⁄β	O
-	O
subunit	O
precursor	O
p	B-Var
.	I-Var
D76	I-Var
G	I-Var
is	O
retained	O
in	O
the	O
endoplasmic	O
reticulum	O
whereas	O
the	O
mutant	O
p	B-Var
.	I-Var
S385L	I-Var
is	O
correctly	O
transported	O
to	O
the	O
cis	O
-	O
Golgi	O
apparatus	O
and	O
proteolytically	O
processed	O
.	O

Both	O
mutations	O
lead	O
to	O
complete	O
loss	B-NegReg
of	O
GlcNAc-1-phosphotransferase	B-Enzyme
activity	B-MPA
,	O
consistent	O
with	O
the	O
severe	O
clinical	O
MLII	O
phenotype	O
of	O
the	O
patients	O
.	O

Our	O
study	O
expands	O
the	O
genotypic	O
spectrum	O
of	O
MLII	O
and	O
provides	O
novel	O
insights	O
into	O
structural	O
requirements	O
to	O
ensure	O
GlcNAc-1-phosphotransferase	O
activity	O
.	O

Altered	O
Cav1.2	O
function	O
in	O
the	O
Timothy	O
syndrome	O
mouse	O
model	O
produces	O
ascending	O
serotonergic	O
abnormalities	O
.	O

Polymorphism	O
in	O
the	O
gene	O
CACNA1C	O
,	O
encoding	O
the	O
pore	O
-	O
forming	O
subunit	O
of	O
Cav1.2	O
L	O
-	O
type	O
calcium	O
channels	O
,	O
has	O
one	O
of	O
the	O
strongest	O
genetic	O
linkages	O
to	O
schizophrenia	O
,	O
bipolar	O
disorder	O
and	O
major	O
depressive	O
disorder	O
:	O
psychopathologies	O
in	O
which	O
serotonin	O
signaling	O
has	O
been	O
implicated	O
.	O

Additionally	O
,	O
a	O
gain	B-PosReg
-	I-PosReg
of	I-PosReg
-	I-PosReg
function	I-PosReg
mutation	B-Var
in	O
CACNA1C	B-Gene
is	O
responsible	O
for	O
the	O
neurodevelopmental	O
disorder	O
Timothy	B-Disease
syndrome	I-Disease
that	O
presents	O
with	O
prominent	O
behavioral	O
features	O
on	O
the	O
autism	O
spectrum	O
.	O

Given	O
an	O
emerging	O
role	O
for	O
serotonin	O
in	O
the	O
etiology	O
of	O
autism	O
spectrum	O
disorders	O
(	O
ASD	O
)	O
,	O
we	O
investigate	O
the	O
relationship	O
between	O
Cav1.2	O
and	O
the	O
ascending	O
serotonin	O
system	O
in	O
the	O
Timothy	O
syndrome	O
type	O
2	O
(	O
TS2-neo	O
)	O
mouse	O
,	O
which	O
displays	O
behavioral	O
features	O
consistent	O
with	O
the	O
core	O
triad	O
of	O
ASD	O
.	O

We	O
find	O
that	O
TS2-neo	O
mice	O
exhibit	O
enhanced	O
serotonin	O
tissue	O
content	O
and	O
axon	O
innervation	O
of	O
the	O
dorsal	O
striatum	O
,	O
as	O
well	O
as	O
decreased	O
serotonin	O
turnover	O
in	O
the	O
amygdala	O
.	O

These	O
regionally	O
specific	O
alterations	O
are	O
accompanied	O
by	O
an	O
enhanced	O
active	O
coping	O
response	O
during	O
acute	O
stress	O
(	O
forced	O
swim	O
)	O
,	O
serotonin	O
neuron	O
Fos	O
activity	O
in	O
the	O
caudal	O
dorsal	O
raphe	O
,	O
and	O
serotonin	O
type	O
1A	O
receptor	O
-	O
dependent	O
feedback	O
inhibition	O
of	O
the	O
rostral	O
dorsal	O
raphe	O
nuclei	O
.	O

Collectively	O
,	O
these	O
results	O
suggest	O
that	O
the	O
global	O
gain	O
-	O
of	O
-	O
function	O
Cav1.2	O
mutation	O
associated	O
with	O
Timothy	O
syndrome	O
has	O
pleiotropic	O
effects	O
on	O
the	O
ascending	O
serotonin	O
system	O
including	O
neuroanatomical	O
changes	O
,	O
regional	O
differences	O
in	O
forebrain	O
serotonin	O
metabolism	O
and	O
feedback	O
regulatory	O
control	O
mechanisms	O
within	O
the	O
dorsal	O
raphe	O
.	O

Altered	O
activity	O
of	O
the	O
ascending	O
serotonin	O
system	O
continues	O
to	O
emerge	O
as	O
a	O
common	O
neural	O
signature	O
across	O
several	O
ASD	O
mouse	O
models	O
,	O
and	O
the	O
capacity	O
for	O
Cav1.2	O
L	O
-	O
type	O
calcium	O
channels	O
to	O
impact	O
both	O
serotonin	O
structure	O
and	O
function	O
has	O
important	O
implications	O
for	O
several	O
neuropsychiatric	O
conditions	O
.	O

Localization	O
of	O
Cdc7	O
Protein	O
Kinase	O
During	O
DNA	O
Replication	O
in	O
Saccharomyces	O
cerevisiae	O
.	O

DDK	O
,	O
a	O
conserved	O
serine	O
-	O
threonine	O
protein	O
kinase	O
composed	O
of	O
a	O
regulatory	O
subunit	O
,	O
Dbf4	O
,	O
and	O
a	O
catalytic	O
subunit	O
,	O
Cdc7	O
,	O
is	O
essential	O
for	O
DNA	O
replication	O
initiation	O
during	O
S	O
phase	O
of	O
the	O
cell	O
cycle	O
through	O
MCM2	O
-	O
7	O
helicase	O
phosphorylation	O
.	O

The	O
biological	O
significance	O
of	O
DDK	O
is	O
well	O
characterized	O
,	O
but	O
the	O
full	O
mechanism	O
of	O
how	O
DDK	O
associates	O
with	O
substrates	O
remains	O
unclear	O
.	O

Cdc7	O
is	O
bound	O
to	O
chromatin	O
in	O
the	O
Saccharomyces	O
cerevisiae	O
genome	O
throughout	O
the	O
cell	O
cycle	O
,	O
but	O
there	O
is	O
little	O
empirical	O
evidence	O
as	O
to	O
specific	O
Cdc7	O
binding	O
locations	O
.	O

Using	O
biochemical	O
and	O
genetic	O
techniques	O
,	O
this	O
study	O
investigated	O
the	O
specific	O
localization	O
of	O
Cdc7	O
on	O
chromatin	O
.	O

The	O
Calling	O
Cards	O
method	O
,	O
using	O
Ty5	O
retrotransposons	O
as	O
a	O
marker	O
for	O
DNA	O
-	O
protein	O
binding	O
,	O
suggests	O
Cdc7	O
kinase	O
is	O
preferentially	O
bound	O
to	O
genomic	O
DNA	O
known	O
to	O
replicate	O
early	O
in	O
S	O
phase	O
,	O
including	O
centromeres	O
and	O
origins	O
of	O
replication	O
.	O

We	O
also	O
discovered	O
Cdc7	O
binding	O
throughout	O
the	O
genome	O
,	O
which	O
may	O
be	O
necessary	O
to	O
initiate	O
other	O
cellular	O
processes	O
,	O
including	O
meiotic	O
recombination	O
and	O
translesion	O
synthesis	O
.	O

A	O
kinase	O
dead	O
Cdc7	B-Gene
point	B-Var
mutation	I-Var
increases	B-PosReg
the	O
Ty5	B-MPA
retrotransposon	I-MPA
integration	I-MPA
efficiency	I-MPA
and	O
a	O
55-amino	B-MPA
acid	I-MPA
C	I-MPA
-	I-MPA
terminal	I-MPA
truncation	I-MPA
of	O
Cdc7	B-Gene
,	O
unable	B-NegReg
to	O
bind	B-Interaction
Dbf4	B-Gene
,	O
reduces	B-NegReg
Cdc7	B-Gene
binding	B-Interaction
suggesting	O
a	O
requirement	O
for	O
Dbf4	O
to	O
stabilize	O
Cdc7	O
on	O
chromatin	O
during	O
S	O
phase	O
.	O

Chromatin	O
immunoprecipitation	O
demonstrates	O
that	O
Cdc7	O
binding	O
near	O
specific	O
origins	O
changes	O
during	O
S	O
phase	O
.	O

Our	O
results	O
suggest	O
a	O
model	O
where	O
Cdc7	O
is	O
loosely	O
bound	O
to	O
chromatin	O
during	O
G1	O
At	O
the	O
G1	O
/	O
S	O
transition	O
,	O
Cdc7	O
binding	O
to	O
chromatin	O
is	O
increased	O
and	O
stabilized	O
,	O
preferentially	O
at	O
sites	O
that	O
may	O
become	O
origins	O
,	O
in	O
order	O
to	O
carry	O
out	O
a	O
variety	O
of	O
cellular	O
processes	O
.	O

Gain	B-PosReg
-	I-PosReg
of	I-PosReg
-	I-PosReg
function	I-PosReg
mutation	B-Var
in	O
PTPN11	B-Gene
in	O
histiocytic	B-Disease
sarcomas	I-Disease
of	O
Bernese	O
Mountain	O
Dogs	O
.	O

Histiocytic	O
sarcoma	O
(	O
HS	O
)	O
is	O
an	O
aggressive	O
malignant	O
neoplasm	O
of	O
dendritic	O
cell	O
origin	O
that	O
is	O
common	O
in	O
certain	O
breeds	O
of	O
dogs	O
.	O

High	O
prevalence	O
of	O
fatal	O
,	O
disseminated	O
HS	O
has	O
been	O
described	O
in	O
Bernese	O
Mountain	O
Dogs	O
(	O
BMDs	O
)	O
.	O

Support	O
for	O
genetic	O
predisposition	O
to	O
develop	O
HS	O
has	O
been	O
presented	O
in	O
several	O
studies	O
,	O
but	O
to	O
date	O
,	O
causative	O
genetic	O
events	O
have	O
not	O
been	O
reported	O
.	O

In	O
addition	O
,	O
no	O
driver	O
mutations	O
have	O
been	O
identified	O
in	O
tumours	O
.	O

Recently	O
,	O
E76	B-Var
K	I-Var
gain	B-PosReg
-	I-PosReg
of	I-PosReg
-	I-PosReg
function	I-PosReg
mutation	O
in	O
SHP2	O
encoded	O
by	O
the	O
PTPN11	B-Gene
gene	O
has	O
been	O
described	O
in	O
human	O
histiocytic	B-Disease
malignancies	I-Disease
.	O

In	O
our	O
study	O
,	O
we	O
identified	O
the	O
PTPN11E76	O
K	O
in	O
HS	O
of	O
BMDs	O
.	O

Amplification	O
of	O
exon	O
3	O
of	O
the	O
PTPN11	O
gene	O
followed	O
by	O
Sanger	O
sequencing	O
was	O
used	O
to	O
detect	O
the	O
mutation	O
and	O
estimate	O
the	O
prevalence	O
in	O
HS	O
from	O
30	O
BMDs	O
,	O
13	O
Golden	O
Retrievers	O
and	O
10	O
other	O
dog	O
breeds	O
.	O

The	O
overall	O
prevalence	O
of	O
PTPN11E76	O
K	O
in	O
HS	O
of	O
BMDs	O
was	O
36.67	O
%	O
compared	O
with	O
8.69	O
%	O
in	O
other	O
breeds	O
.	O

No	O
mutation	O
was	O
identified	O
in	O
normal	O
tissues	O
from	O
10	O
BMDs	O
with	O
HS	O
that	O
carried	O
the	O
mutation	O
and	O
12	O
control	O
dogs	O
with	O
no	O
neoplastic	O
disease	O
,	O
including	O
6	O
BMDs	O
.	O

Increased	O
immunoreactivity	O
for	O
AKT	O
,	O
phosphorylated	O
ERK1/2	O
and	O
phosphorylated	O
AKT	O
in	O
a	O
small	O
subset	O
of	O
BMDs	O
with	O
PTPN11E76	O
K	O
suggests	O
that	O
a	O
gain	O
-	O
of	O
-	O
function	O
might	O
be	O
mediated	O
by	O
the	O
ERK	O
and	O
AKT	O
pathways	O
.	O

These	O
data	O
suggest	O
PTPN11E76	O
K	O
as	O
an	O
important	O
driver	O
mutation	O
of	O
HS	O
in	O
BMDs	O
.	O

This	O
information	O
may	O
not	O
only	O
aid	O
in	O
unravelling	O
the	O
tumourigenic	O
events	O
associated	O
with	O
HS	O
in	O
BMDs	O
,	O
but	O
also	O
help	O
in	O
identifying	O
more	O
promising	O
therapeutic	O
strategies	O
.	O

Homozygous	O
KIDINS220	B-Gene
loss	B-NegReg
-	I-NegReg
of	I-NegReg
-	I-NegReg
function	I-NegReg
variants	B-Var
in	O
fetuses	O
with	O
cerebral	B-CPA
ventriculomegaly	I-CPA
and	O
limb	B-CPA
contractures	I-CPA
.	O

Heterozygous	B-Var
mutations	I-Var
in	O
KIDINS220	B-Gene
were	O
recently	O
suggested	O
a	O
cause	B-Reg
of	O
spastic	B-Disease
paraplegia	I-Disease
,	O
intellectual	B-Disease
disability	I-Disease
,	O
nystagmus	B-Disease
and	O
obesity	B-Disease
.	O

All	O
patients	O
carried	O
terminal	O
nonsense	O
de	O
novo	O
mutations	O
that	O
seemed	O
to	O
escape	O
nonsense	O
-	O
mediated	O
mRNA	O
decay	O
.	O

The	O
mechanism	O
for	O
pathogenicity	O
is	O
yet	O
unexplained	O
,	O
as	O
it	O
seems	O
that	O
heterozygous	O
loss	O
-	O
of	O
-	O
function	O
variants	O
of	O
KIDINS220	O
are	O
generally	O
well	O
tolerated	O
.	O

We	O
present	O
a	O
consanguineous	O
couple	O
who	O
experienced	O
four	O
pregnancy	O
terminations	O
due	O
to	O
repeated	O
findings	O
in	O
the	O
fetuses	O
comprising	O
enlarged	O
cerebral	O
ventricles	O
and	O
limb	O
contractures	O
.	O

Exome	O
sequencing	O
in	O
two	O
of	O
the	O
aborted	O
fetuses	O
revealed	O
a	O
shared	O
homozygous	O
frameshift	O
variant	O
in	O
exon	O
24	O
in	O
KIDINS220	O
.	O

Sanger	O
sequencing	O
of	O
the	O
variant	O
in	O
available	O
family	O
members	O
showed	O
complete	O
segregation	O
with	O
the	O
affection	O
status	O
,	O
resulting	O
in	O
a	O
LOD	O
score	O
of	O
2.5	O
under	O
an	O
autozygous	O
inheritance	O
model	O
.	O

mRNA	O
studies	O
revealed	O
destruction	O
of	O
the	O
original	O
splice	O
site	O
,	O
resulting	O
in	O
an	O
out	O
-	O
of	O
-	O
frame	O
transcript	O
and	O
introduction	O
of	O
a	O
premature	O
termination	O
codon	O
in	O
exon	O
25	O
.	O

Premature	O
termination	O
codons	O
in	O
this	O
position	O
are	O
likely	O
to	O
cause	O
activation	O
of	O
nonsense	O
-	O
mediated	O
mRNA	O
decay	O
and	O
result	O
in	O
complete	O
absence	O
of	O
KIDINS220	O
protein	O
in	O
individuals	O
homozygous	O
for	O
the	O
variant	O
.	O

The	O
phenotype	O
of	O
the	O
presented	O
fetuses	O
overlaps	O
with	O
findings	O
in	O
functional	O
studies	O
of	O
knockout	O
Kidins220	O
mice	O
embryos	O
that	O
are	O
non	O
-	O
viable	O
with	O
enlarged	O
cerebral	O
ventricles	O
.	O

The	O
human	O
fetuses	O
also	O
exhibit	O
several	O
similarities	O
to	O
the	O
milder	O
phenotype	O
described	O
in	O
patients	O
with	O
heterozygous	O
KIDINS220	O
mutations	O
.	O

We	O
hence	O
propose	O
that	O
the	O
identified	O
homozygous	O
loss	O
-	O
of	O
-	O
function	O
variant	O
in	O
KIDINS220	O
causes	O
the	O
phenotype	O
in	O
the	O
presented	O
fetuses	O
,	O
and	O
that	O
this	O
represents	O
a	O
hitherto	O
undescribed	O
severe	O
autosomal	O
recessive	O
neurodevelopmental	O
disorder	O
.	O

The	O
GNASR201C	O
mutation	O
associated	O
with	O
clonal	O
hematopoiesis	O
supports	O
transplantable	O
hematopoietic	O
stem	O
cell	O
activity	O
.	O

Genome	O
sequencing	O
efforts	O
have	O
identified	O
virtually	O
all	O
of	O
the	O
important	O
mutations	O
in	O
adult	O
myeloid	O
malignancies	O
.	O

More	O
recently	O
,	O
population	O
studies	O
have	O
identified	O
cancer	O
-	O
associated	O
variants	O
in	O
the	O
blood	O
of	O
otherwise	O
healthy	O
individuals	O
as	O
they	O
age	O
,	O
a	O
phenomenon	O
termed	O
clonal	O
hematopoiesis	O
of	O
indeterminate	O
potential	O
(	O
CHIP	O
)	O
.	O

This	O
suggests	O
that	O
these	O
mutations	O
may	O
occur	O
in	O
hematopoietic	O
stem	O
cells	O
(	O
HSCs	O
)	O
long	O
before	O
any	O
clinical	O
presentation	O
but	O
are	O
not	O
necessarily	O
harbingers	O
of	O
transformation	O
because	O
only	O
a	O
fraction	O
of	O
individuals	O
with	O
CHIP	O
develop	O
hematopoietic	O
pathologies	O
.	O

Delineation	O
between	O
CHIP	O
variants	O
that	O
predispose	O
for	O
disease	O
versus	O
those	O
that	O
are	O
more	O
benign	O
could	O
be	O
used	O
as	O
a	O
prognostic	O
factor	O
to	O
identify	O
individuals	O
at	O
greater	O
risk	O
for	O
transformation	O
.	O

To	O
achieve	O
this	O
,	O
the	O
biological	O
impact	O
of	O
CHIP	O
variants	O
on	O
HSC	O
function	O
must	O
be	O
validated	O
.	O

One	O
variant	O
that	O
has	O
been	O
identified	O
recurrently	O
in	O
CHIP	B-CPA
is	O
a	O
gain	B-PosReg
-	I-PosReg
of	I-PosReg
-	I-PosReg
function	I-PosReg
missense	B-Var
mutation	I-Var
in	O
the	O
imprinted	O
gene	O
GNAS	B-Gene
(	O
Guanine	O
Nucleotide	O
Binding	O
Protein	O
,	O
Alpha	O
Stimulating	O
)	O
.	O

In	O
this	O
study	O
,	O
we	O
examined	O
the	O
effect	O
of	O
the	O
GNASR201C	O
variant	O
on	O
HSC	O
function	O
.	O

Ectopic	O
expression	O
of	O
GNASR201C	B-Var
supported	B-PosReg
transplantable	B-CPA
HSC	I-CPA
activity	I-CPA
and	O
improved	B-PosReg
lymphoid	B-CPA
output	I-CPA
in	O
secondary	O
recipients	O
.	O

Because	O
declining	O
lymphoid	O
output	O
is	O
a	O
hallmark	O
of	O
aging	O
,	O
GNASR201C	O
mutations	O
may	O
sustain	O
lymphoid	O
-	O
biased	O
HSCs	O
over	O
time	O
and	O
maintain	O
them	O
in	O
a	O
developmental	O
state	O
favorable	O
for	O
transformation	O
.	O

N1366S	O
mutation	O
of	O
human	O
skeletal	O
muscle	O
sodium	O
channel	O
causes	O
paramyotonia	O
congenita	O
.	O

KEY	O
POINTS	O
:	O
Paramyotonia	B-Disease
congenita	I-Disease
is	O
a	O
hereditary	O
channelopathy	O
caused	B-Reg
by	O
missense	B-Var
mutations	I-Var
in	O
the	O
SCN4A	B-Gene
gene	O
,	O
which	O
encodes	O
the	O
α	O
subunit	O
of	O
the	O
human	O
skeletal	O
muscle	O
voltage	O
-	O
gated	O
sodium	O
channel	O
NaV1.4	O
.	O

Affected	O
individuals	O
suffered	O
from	O
myotonia	O
and	O
paralysis	O
of	O
muscles	O
,	O
which	O
were	O
aggravated	O
by	O
exposure	O
to	O
cold	O
.	O

We	O
report	O
a	O
three	O
-	O
generation	O
Chinese	O
family	O
with	O
patients	O
presenting	O
paramyotonia	O
congenita	O
and	O
identify	O
a	O
novel	O
N1366S	O
mutation	O
of	O
NaV1.4	O
.	O

Whole	O
-	O
cell	O
electrophysiological	O
recordings	O
of	O
the	O
N1366S	O
channel	O
reveal	O
a	O
gain	O
-	O
of	O
-	O
function	O
change	O
of	O
gating	O
in	O
response	O
to	O
cold	O
.	O

Modelling	O
and	O
molecular	O
dynamic	O
simulation	O
data	O
suggest	O
that	O
an	O
arginine	O
-	O
to	O
-	O
serine	O
substitution	O
at	O
position	O
1366	O
increases	O
the	O
distance	O
from	O
N1366	O
to	O
R1454	O
and	O
disrupts	O
the	O
hydrogen	O
bond	O
formed	O
between	O
them	O
at	O
low	O
temperature	O
.	O

We	O
demonstrate	O
that	O
N1366S	O
is	O
a	O
disease	O
-	O
causing	O
mutation	O
and	O
that	O
the	O
temperature	O
-	O
sensitive	O
alteration	O
of	O
N1366S	O
channel	O
activity	O
may	O
be	O
responsible	O
for	O
the	O
pronounced	O
paramyotonia	O
congenita	O
symptoms	O
of	O
these	O
patients	O
.	O

ABSTRACT	O
:	O
Paramyotonia	B-Disease
congenita	I-Disease
is	O
an	O
autosomal	O
dominant	O
skeletal	O
muscle	O
channelopathy	O
caused	B-Reg
by	O
missense	B-Var
mutations	I-Var
in	O
SCN4A	B-Gene
,	O
the	O
gene	O
encoding	O
the	O
α	O
subunit	O
of	O
the	O
human	O
skeletal	O
muscle	O
voltage	O
-	O
gated	O
sodium	O
channel	O
NaV1.4	O
.	O

We	O
report	O
a	O
three	O
-	O
generation	O
family	O
in	O
which	O
six	O
members	O
present	O
clinical	O
symptoms	O
of	O
paramyotonia	O
congenita	O
characterized	O
by	O
a	O
marked	O
worsening	O
of	O
myotonia	O
by	O
cold	O
and	O
by	O
the	O
presence	O
of	O
clear	O
episodes	O
of	O
paralysis	O
.	O

We	O
identified	O
a	O
novel	O
mutation	O
in	O
SCN4A	O
(	O
Asn1366Ser	O
,	O
N1366S	O
)	O
in	O
all	O
patients	O
in	O
the	O
family	O
but	O
not	O
in	O
healthy	O
relatives	O
or	O
in	O
500	O
normal	O
control	O
subjects	O
.	O

Functional	O
analysis	O
of	O
the	O
channel	O
protein	O
expressed	O
in	O
HEK293	O
cells	O
by	O
whole	O
-	O
cell	O
patch	O
clamp	O
recording	O
revealed	O
that	O
the	O
N1366S	O
mutation	O
led	O
to	O
significant	O
alterations	O
in	O
the	O
gating	O
process	O
of	O
the	O
NaV1.4	O
channel	O
.	O

The	O
N1366S	B-Var
mutant	O
displayed	O
a	O
cold	O
-	O
induced	O
hyperpolarizing	O
shift	O
in	O
the	O
voltage	O
dependence	O
of	O
activation	O
and	O
a	O
depolarizing	O
shift	O
in	O
fast	O
inactivation	O
,	O
as	O
well	O
as	O
a	O
reduced	B-NegReg
rate	B-MPA
of	O
fast	B-MPA
inactivation	I-MPA
and	O
accelerated	B-PosReg
recovery	B-MPA
from	O
fast	B-MPA
inactivation	I-MPA
.	O

In	O
addition	O
,	O
homology	O
modelling	O
and	O
molecular	O
dynamic	O
simulation	O
of	O
N1366S	O
and	O
wild	O
-	O
type	O
NaV1.4	O
channels	O
indicated	O
that	O
the	O
arginine	O
-	O
to	O
-	O
serine	O
substitution	O
disrupted	O
the	O
hydrogen	O
bond	O
formed	O
between	O
N1366	O
and	O
R1454	O
.	O

Together	O
,	O
our	O
results	O
suggest	O
that	O
N1366S	B-Var
is	O
a	O
gain	B-PosReg
-	I-PosReg
of	I-PosReg
-	I-PosReg
function	I-PosReg
mutation	O
of	O
NaV1.4	O
at	O
low	O
temperature	O
and	O
the	O
mutation	O
may	O
be	O
responsible	O
for	O
the	O
clinical	O
symptoms	O
of	O
paramyotonia	B-Disease
congenita	I-Disease
in	O
the	O
affected	O
family	O
and	O
constitute	O
a	O
basis	O
for	O
studies	O
into	O
its	O
pathogenesis	O
.	O

Loss	B-NegReg
-	I-NegReg
of	I-NegReg
-	I-NegReg
function	I-NegReg
variants	B-Var
in	O
NFIA	B-Gene
provide	O
further	O
support	O
that	O
NFIA	O
is	O
a	O
critical	O
gene	O
in	O
1p32-p31	B-Disease
deletion	I-Disease
syndrome	I-Disease
:	I-Disease
A	O
four	O
patient	O
series	O
.	O

The	O
association	O
between	O
1p32-p31	O
contiguous	O
gene	O
deletions	O
and	O
a	O
distinct	O
phenotype	O
that	O
includes	O
anomalies	O
of	O
the	O
corpus	O
callosum	O
,	O
ventriculomegaly	O
,	O
developmental	O
delay	O
,	O
seizures	O
,	O
and	O
dysmorphic	O
features	O
has	O
been	O
long	O
recognized	O
and	O
described	O
.	O

Recently	O
,	O
the	O
observation	O
of	O
overlapping	O
phenotypes	O
in	O
patients	O
with	O
chromosome	O
translocations	O
that	O
disrupt	O
NFIA	O
(	O
Nuclear	O
factor	O
I	O
/	O
A	O
)	O
,	O
a	O
gene	O
within	O
this	O
deleted	O
region	O
,	O
and	O
NFIA	O
intragenic	O
deletions	O
has	O
led	O
to	O
the	O
hypothesis	O
that	O
NFIA	O
is	O
a	O
critical	O
gene	O
within	O
this	O
region	O
.	O

The	O
wide	O
application	O
and	O
increasing	O
accessibility	O
of	O
whole	O
exome	O
sequencing	O
(	O
WES	O
)	O
has	O
helped	O
identify	O
new	O
cases	O
to	O
support	O
this	O
hypothesis	O
.	O

Here	O
,	O
we	O
describe	O
four	O
patients	O
with	O
loss	O
-	O
of	O
-	O
function	O
variants	O
in	O
the	O
NFIA	O
gene	O
identified	O
through	O
WES	O
.	O

The	O
clinical	O
presentation	O
of	O
these	O
patients	O
significantly	O
overlaps	O
with	O
the	O
phenotype	O
described	O
in	O
previously	O
reported	O
cases	O
of	O
1p32-p31	O
deletion	O
syndrome	O
,	O
NFIA	O
gene	O
disruptions	O
and	O
intragenic	O
NFIA	O
deletions	O
.	O

Our	O
cohort	O
includes	O
a	O
mother	O
and	O
daughter	O
as	O
well	O
as	O
an	O
unrelated	O
individual	O
who	O
share	O
the	O
same	O
nonsense	O
variant	O
(	O
c.205C	O
>	O
T	O
,	O
p	O
.	O
Arg69Ter	O
;	O
NM_001145512.1	O
)	O
.	O

We	O
also	O
report	O
a	O
patient	O
with	O
a	O
frameshift	O
NFIA	O
variant	O
(	O
c.159_160dupCC	O
,	O
p	O
.	O
Gln54ProfsTer49	O
)	O
.	O

We	O
have	O
compared	O
published	O
cases	O
of	O
1p32-p31	O
microdeletion	O
syndrome	O
,	O
translocations	O
resulting	O
in	O
NFIA	O
gene	O
disruption	O
,	O
intragenic	O
deletions	O
,	O
and	O
loss	O
-	O
of	O
-	O
function	O
mutations	O
(	O
including	O
our	O
four	O
patients	O
)	O
to	O
reveal	O
that	O
abnormalities	O
of	O
the	O
corpus	O
callosum	O
,	O
ventriculomegaly	O
/	O
hydrocephalus	O
,	O
macrocephaly	O
,	O
Chiari	O
I	O
malformation	O
,	O
dysmorphic	O
features	O
,	O
developmental	O
delay	O
,	O
hypotonia	O
,	O
and	O
urinary	O
tract	O
defects	O
are	O
common	O
findings	O
.	O

The	O
consistent	O
overlap	O
in	O
clinical	O
presentation	O
provides	O
further	O
evidence	O
of	O
the	O
critical	O
role	O
of	O
NFIA	O
haploinsufficiency	O
in	O
the	O
development	O
of	O
the	O
1p32-p31	O
microdeletion	O
syndrome	O
phenotype	O
.	O

Clcn7F318L/+	O
as	O
a	O
new	O
mouse	O
model	O
of	O
Albers	O
-	O
Schönberg	O
disease	O
.	O

Dominant	O
negative	B-NegReg
mutations	B-Var
in	O
CLCN7	B-Gene
,	O
which	O
encodes	O
a	O
homodimeric	O
chloride	O
channel	O
needed	O
for	O
matrix	O
acidification	O
by	O
osteoclasts	O
,	O
cause	O
Albers	B-Disease
-	I-Disease
Schönberg	I-Disease
disease	I-Disease
(	O
also	O
known	O
as	O
autosomal	O
dominant	O
osteopetrosis	O
type	O
2	O
)	O
.	O

More	O
than	O
25	O
different	O
CLCN7	O
mutations	O
have	O
been	O
identified	O
in	O
patients	O
affected	O
with	O
Albers	O
-	O
Schönberg	O
disease	O
,	O
but	O
only	O
one	O
mutation	O
(	O
Clcn7G213R	O
)	O
has	O
been	O
introduced	O
in	O
mice	O
to	O
create	O
an	O
animal	O
model	O
of	O
this	O
disease	O
.	O

Here	O
we	O
describe	O
a	O
mouse	O
with	O
a	O
different	O
osteopetrosis	O
-	O
causing	O
mutation	O
(	O
Clcn7F318L	O
)	O
.	O

Compared	O
to	O
Clcn7+/+	O
mice	O
,	O
12-week	O
-	O
old	O
Clcn7F318L/+	O
mice	O
have	O
significantly	O
increased	B-PosReg
trabecular	B-CPA
bone	I-CPA
volume	I-CPA
,	O
consistent	O
with	O
Clcn7F318L	B-Var
acting	O
as	O
a	O
dominant	O
negative	B-NegReg
mutation	O
.	O

Clcn7F318L	O
/	O
F318L	O
and	O
Clcn7F318L	O
/	O
G213R	O
mice	O
die	O
by	O
1month	O
of	O
age	O
and	O
resemble	O
Clcn7	O
knockout	O
mice	O
,	O
which	O
indicate	O
that	O
p	B-Var
.	I-Var
F318L	I-Var
mutant	O
protein	B-Protein
is	O
non	B-MPA
-	I-MPA
functional	I-MPA
and	O
p	O
.	O
F318L	O
and	O
p	O
.	O
G213R	O
mutant	O
proteins	O
do	O
not	O
complement	O
one	O
another	O
.	O

Since	O
it	O
has	O
been	O
reported	O
that	O
treatment	O
with	O
interferon	O
gamma	O
(	O
IFN	O
-	O
G	O
)	O
improves	O
bone	O
properties	O
in	O
Clcn7G213R/+	O
mice	O
,	O
we	O
treated	O
Clcn7F318L/+	O
mice	O
with	O
IFN	O
-	O
G	O
and	O
observed	O
a	O
decrease	O
in	O
osteoclast	O
number	O
and	O
mineral	O
apposition	O
rate	O
,	O
but	O
no	O
overall	O
improvement	O
in	O
bone	O
properties	O
.	O

Our	O
results	O
suggest	O
that	O
the	O
benefits	O
of	O
IFN	O
-	O
G	O
therapy	O
in	O
patients	O
with	O
Albers	O
-	O
Schönberg	O
disease	O
may	O
be	O
mutation	O
-	O
specific	O
.	O

Highlighting	O
Interleukin-36	O
Signalling	O
in	O
Plaque	O
Psoriasis	O
and	O
Pustular	O
Psoriasis	O
.	O

Plaque	O
psoriasis	O
and	O
pustular	O
psoriasis	O
are	O
overlapping	O
,	O
but	O
distinct	O
,	O
disorders	O
.	O

The	O
therapeutic	O
response	O
to	O
biologics	O
supports	O
the	O
pivotal	O
role	O
of	O
the	O
tumour	O
necrosis	O
alpha	O
(	O
T	O
interleukin	O
(	O
IL)-23	O
/	O
IL-17	O
/	O
IL-22	O
axis	O
in	O
the	O
pathogenesis	O
of	O
these	O
disorders	O
.	O

Recently	O
,	O
functional	O
activation	O
of	O
the	O
IL-36	O
receptor	O
(	O
IL-36R	O
)	O
was	O
discovered	O
to	O
be	O
another	O
driving	O
force	O
in	O
the	O
pathogenesis	O
of	O
psoriasis	O
.	O

This	O
was	O
first	O
highlighted	O
by	O
the	O
discovery	O
that	O
a	O
loss	B-NegReg
-	I-NegReg
of	I-NegReg
-	I-NegReg
function	I-NegReg
mutation	B-Var
of	O
the	O
IL-36R	O
antagonist	O
(	B-Gene
IL-36Ra	I-Gene
)	I-Gene
causes	O
pustular	B-Disease
psoriasis	I-Disease
.	O

Although	O
the	O
TNF-?/IL-23	O
/	O
IL-17	O
/	O
IL-22	O
axis	O
and	O
the	O
functional	O
activation	O
of	O
IL-36R	O
are	O
fundamentally	O
involved	O
in	O
plaque	O
psoriasis	O
and	O
pustular	O
psoriasis	O
,	O
respectively	O
,	O
the	O
2	O
pathways	O
are	O
closely	O
related	O
and	O
mutually	O
reinforced	O
,	O
resulting	O
in	O
full	O
-	O
blown	O
clinical	O
manifestations	O
.	O

This	O
review	O
summarizes	O
current	O
topics	O
on	O
how	O
IL-36	O
agonists	O
(	O
IL-36	O
?	O
,	O
IL-36	O
?	O
,	O
IL-36	O
?	O
)	O
signal	O
IL-36R	O
,	O
the	O
pathological	O
expression	O
of	O
IL-36	O
agonists	O
and	O
IL-36Ra	O
in	O
plaque	O
and	O
pustular	O
psoriatic	O
lesions	O
,	O
and	O
the	O
cross	O
-	O
talk	O
between	O
the	O
TNF-?/IL-23	O
/	O
IL-17	O
/	O
IL-22	O
axis	O
and	O
the	O
functional	O
activation	O
of	O
IL-36R	O
in	O
the	O
epidermal	O
milieu	O
.	O

CCR5Δ32	O
(	O
rs333	O
)	O
polymorphism	O
is	O
associated	O
with	O
decreased	O
risk	O
of	O
chronic	O
and	O
aggressive	O
periodontitis	O
:	O
A	O
case	O
-	O
control	O
analysis	O
based	O
in	O
disease	O
resistance	O
and	O
susceptibility	O
phenotypes	O
.	O

Chronic	O
and	O
aggressive	O
periodontitis	O
are	O
infectious	O
diseases	O
characterized	O
by	O
the	O
irreversible	O
destruction	O
of	O
periodontal	O
tissues	O
,	O
which	O
is	O
mediated	O
by	O
the	O
host	O
inflammatory	O
immune	O
response	O
triggered	O
by	O
periodontal	O
infection	O
.	O

The	O
chemokine	O
receptor	O
CCR5	O
play	O
an	O
important	O
role	O
in	O
disease	O
pathogenesis	O
,	O
contributing	O
to	O
pro	O
-	O
inflammatory	O
response	O
and	O
osteoclastogenesis	O
.	O

CCR5Δ32	O
(	B-Var
rs333	I-Var
)	I-Var
is	O
a	O
loss	B-NegReg
-	I-NegReg
of	I-NegReg
-	I-NegReg
function	I-NegReg
mutation	O
in	O
the	O
CCR5	B-Gene
gene	O
,	O
which	O
can	O
potentially	O
modulate	B-Reg
the	O
host	B-CPA
response	I-CPA
and	O
,	O
consequently	O
periodontitis	O
outcome	O
.	O

Thus	O
,	O
we	O
investigated	O
the	O
effect	O
of	O
the	O
CCR5Δ32	O
mutation	O
over	O
the	O
risk	O
to	O
suffer	O
periodontitis	O
in	O
a	O
cohort	O
of	O
Brazilian	O
patients	O
(	O
total	O
N=699	O
)	O
,	O
representative	O
of	O
disease	O
susceptibility	O
(	O
chronic	O
periodontitis	O
,	O
N=197	O
;	O
and	O
aggressive	O
periodontitis	O
,	O
N=91	O
)	O
or	O
resistance	O
(	O
chronic	O
gingivitis	O
,	O
N=193	O
)	O
phenotypes	O
,	O
and	O
healthy	O
subjects	O
(	O
N=218	O
)	O
.	O

Additionally	O
,	O
we	O
assayed	O
the	O
influence	O
of	O
CCR5Δ32	O
in	O
the	O
expression	O
of	O
the	O
biomarkers	O
TNFα	O
,	O
IL-1β	O
,	O
IL-10	O
,	O
IL-6	O
,	O
IFN	O
-	O
γ	O
and	O
T	O
-	O
bet	O
,	O
and	O
key	O
periodontal	O
pathogens	O
P.	O
gingivalis	O
,	O
T.	O
forsythia	O
,	O
and	O
T.	O
denticola	O
.	O

In	O
the	O
association	O
analysis	O
of	O
resistant	O
versus	O
susceptible	O
subjects	O
,	O
CCR5Δ32	O
mutant	O
allele	O
-	O
carriers	O
proved	O
significantly	O
protected	O
against	O
chronic	O
(	O
OR	O
0.49	O
;	O
95	O
%	O
CI	O
0.29	O
-	O
0.83	O
;	O
p	O
-	O
value	O
0.01	O
)	O
and	O
aggressive	O
(	O
OR	O
0.46	O
;	O
95	O
%	O
CI	O
0.22	O
-	O
0.94	O
;	O
p	O
-	O
value	O
0.03	O
)	O
periodontitis	O
.	O

Further	O
,	O
heterozygous	O
subjects	O
exhibited	O
significantly	O
decreased	B-NegReg
expression	B-MPA
of	O
TNFα	B-Protein
in	O
periodontal	O
tissues	O
,	O
pointing	O
to	O
a	O
functional	O
effect	O
of	O
the	O
mutation	B-Var
in	O
periodontal	O
tissues	O
during	O
the	O
progression	O
of	O
the	O
disease	O
.	O

Conversely	O
,	O
no	O
significant	O
changes	O
were	O
observed	O
in	O
the	O
presence	O
or	O
quantity	O
of	O
the	O
periodontal	O
pathogens	O
P.	O
gingivalis	O
,	O
T.	O
forsythia	O
,	O
and	O
T.	O
denticola	O
in	O
the	O
subgingival	O
biofilm	O
that	O
could	O
be	O
attributable	O
to	O
the	O
mutant	O
genotype	O
.	O

Tacrolimus	O
rescues	O
the	O
signaling	O
and	O
gene	O
expression	O
signature	O
of	O
endothelial	O
ALK1	O
loss	O
-	O
of	O
-	O
function	O
and	O
improves	O
HHT	O
vascular	O
pathology	O
.	O

Hereditary	B-Disease
hemorrhagic	I-Disease
telangiectasia	I-Disease
(	O
HHT	O
)	O
is	O
a	O
highly	O
debilitating	O
and	O
life	O
-	O
threatening	O
genetic	O
vascular	O
disorder	O
arising	O
from	O
endothelial	O
cell	O
(	O
EC	O
)	O
proliferation	O
and	O
hypervascularization	O
,	O
for	O
which	O
no	O
cure	O
exists	O
.	O

Because	O
HHT	B-Disease
is	O
caused	O
by	O
loss	B-NegReg
-	I-NegReg
of	I-NegReg
-	I-NegReg
function	I-NegReg
mutations	B-Var
in	O
bone	O
morphogenetic	O
protein	O
9	O
(	B-MPA
BMP9)-ALK1-Smad1/5/8	I-MPA
signaling	I-MPA
,	O
interventions	O
aimed	O
at	O
activating	O
this	O
pathway	O
are	O
of	O
therapeutic	O
value	O
.	O

We	O
interrogated	O
the	O
whole	O
-	O
transcriptome	O
in	O
human	O
umbilical	O
vein	O
ECs	O
(	O
HUVECs	O
)	O
and	O
found	O
that	O
ALK1	O
signaling	O
inhibition	O
was	O
associated	O
with	O
a	O
specific	O
pro	O
-	O
angiogenic	O
gene	O
expression	O
signature	O
,	O
which	O
included	O
a	O
significant	O
elevation	O
of	O
DLL4	O
expression	O
.	O

By	O
screening	O
the	O
NIH	O
clinical	O
collections	O
of	O
FDA	O
-	O
approved	O
drugs	O
,	O
we	O
identified	O
tacrolimus	O
(	O
FK-506	O
)	O
as	O
the	O
most	O
potent	O
activator	O
of	O
ALK1	O
signaling	O
in	O
BMP9-challenged	O
C2C12	O
reporter	O
cells	O
.	O

In	O
HUVECs	O
,	O
tacrolimus	O
activated	O
Smad1/5/8	O
and	O
opposed	O
the	O
pro	O
-	O
angiogenic	O
gene	O
expression	O
signature	O
associated	O
with	O
ALK1	O
loss	O
-	O
of	O
-	O
function	O
,	O
by	O
notably	O
reducing	O
Dll4	O
expression	O
.	O

In	O
these	O
cells	O
,	O
tacrolimus	O
also	O
inhibited	O
Akt	O
and	O
p38	O
stimulation	O
by	O
vascular	O
endothelial	O
growth	O
factor	O
,	O
a	O
major	O
driver	O
of	O
angiogenesis	O
.	O

In	O
the	O
BMP9/10-immunodepleted	O
postnatal	O
retina	O
-	O
a	O
mouse	O
model	O
of	O
HHT	O
vascular	O
pathology	O
-	O
tacrolimus	O
activated	O
endothelial	O
Smad1/5/8	O
and	O
prevented	O
the	O
Dll4	O
overexpression	O
and	O
hypervascularization	O
associated	O
with	O
this	O
model	O
.	O

Finally	O
,	O
tacrolimus	O
stimulated	O
Smad1/5/8	O
signaling	O
in	O
C2C12	O
cells	O
expressing	O
BMP9-unresponsive	O
ALK1	O
HHT	O
mutants	O
and	O
in	O
HHT	O
patient	O
blood	O
outgrowth	O
ECs	O
.	O

Tacrolimus	O
repurposing	O
has	O
therefore	O
therapeutic	O
potential	O
in	O
HHT	O
.	O

Zebrafish	O
cdc6	O
hypomorphic	O
mutation	O
causes	O
Meier	O
-	O
Gorlin	O
syndrome	O
-	O
like	O
phenotype	O
.	O

Cell	O
Division	O
Cycle	O
6	O
(	O
Cdc6	O
)	O
is	O
a	O
component	O
of	O
pre	O
-	O
replicative	O
complex	O
(	O
preRC	O
)	O
forming	O
on	O
DNA	O
replication	O
origins	O
in	O
eukaryotes	O
.	O

Recessive	O
mutations	B-Var
in	O
ORC1	B-Gene
,	O
ORC4	B-Gene
,	O
ORC6	B-Gene
,	O
CDT1	B-Gene
or	O
CDC6	B-Gene
of	O
the	O
preRC	O
in	O
human	O
cause	B-Reg
Meier	B-Disease
-	I-Disease
Gorlin	I-Disease
syndrome	I-Disease
(	O
MGS	O
)	O
that	O
is	O
characterized	O
by	O
impaired	O
post	O
-	O
natal	O
growth	O
,	O
short	O
stature	O
and	O
microcephaly	O
.	O

However	O
,	O
vertebrate	O
models	O
of	O
MGS	O
have	O
not	O
been	O
reported	O
.	O

Through	O
N	O
-	O
ethyl	O
-	O
N	O
-	O
nitrosourea	O
mutagenesis	O
and	O
Cas9	O
knockout	O
,	O
we	O
generate	O
several	O
cdc6	O
mutant	O
lines	O
in	O
zebrafish	O
.	O

Loss	B-NegReg
-	I-NegReg
of	I-NegReg
-	I-NegReg
function	I-NegReg
mutations	B-Var
of	O
cdc6	B-Gene
,	O
as	O
manifested	O
by	O
cdc6tsu4305	O
and	O
cdc6tsu7cd	O
mutants	O
,	O
lead	O
to	O
embryonic	B-CPA
lethality	I-CPA
due	O
to	O
cell	B-CPA
cycle	I-CPA
arrest	I-CPA
at	I-CPA
the	I-CPA
S	I-CPA
phase	I-CPA
and	O
extensive	O
apoptosis	B-CPA
.	O

Embryos	O
homozygous	O
for	O
a	O
cdc6	O
hypomorphic	O
mutation	O
,	O
cdc6tsu21cd	O
,	O
develop	O
normally	O
during	O
embryogenesis	O
.	O

Later	O
on	O
,	O
compared	O
with	O
their	O
wild	O
-	O
type	O
(	O
WT	O
)	O
siblings	O
,	O
cdc6tsu21cd	B-Var
mutant	I-Var
fish	O
show	O
growth	O
retardation	O
,	O
and	O
their	O
body	B-CPA
weight	I-CPA
and	I-CPA
length	I-CPA
in	O
adulthood	O
are	O
greatly	O
reduced	B-NegReg
,	O
which	O
resemble	O
human	O
MGS	O
.	O

Surprisingly	O
,	O
cdc6tsu21cd	B-Var
mutant	I-Var
fish	O
become	O
males	O
with	O
a	O
short	O
life	O
and	O
fail	O
to	O
mate	O
with	O
WT	O
females	O
,	O
suggesting	O
defective	B-NegReg
reproduction	B-CPA
.	O

Overexpression	O
of	O
Cdc6	O
mutant	O
forms	O
,	O
which	O
mimic	O
human	O
CDC6(T323R	B-Gene
)	I-Gene
mutation	B-Var
found	O
in	O
a	O
MGS	O
patient	O
,	O
in	O
zebrafish	O
cdc6tsu4305	O
mutant	O
embryos	O
partially	O
represses	B-NegReg
cell	B-CPA
death	I-CPA
phenotype	I-CPA
,	O
suggesting	O
that	O
the	O
human	O
CDC6(T323R	O
)	O
mutation	O
is	O
a	O
hypomorph	O
.	O

cdc6tsu21cd	O
mutant	O
fish	O
will	O
be	O
useful	O
to	O
detect	O
more	O
tissue	O
defects	O
and	O
develop	O
medical	O
treatment	O
strategies	O
for	O
MGS	O
patients	O
.	O

Three	O
Cases	O
of	O
KCNT1	O
Mutations	O
:	O
Malignant	O
Migrating	O
Partial	O
Seizures	O
in	O
Infancy	O
with	O
Massive	O
Systemic	O
to	O
Pulmonary	O
Collateral	O
Arteries	O
.	O

KCNT1	B-Gene
mutations	B-Var
are	O
gain	B-PosReg
-	I-PosReg
of	I-PosReg
-	I-PosReg
function	I-PosReg
mutations	O
in	O
potassium	O
channels	O
resulting	O
in	O
severe	O
infantile	B-Disease
epilepsy	I-Disease
.	O

Herein	O
we	O
describe	O
3	O
infants	O
with	O
malignant	O
migrating	O
partial	O
seizures	O
with	O
KCNT1	O
mutations	O
accompanied	O
by	O
massive	O
systemic	O
to	O
pulmonary	O
collateral	O
arteries	O
with	O
life	O
-	O
threatening	O
hemoptysis	O
and	O
heart	O
failure	O
.	O

Homozygous	B-Var
indel	I-Var
mutation	I-Var
in	O
CDH11	B-Gene
as	O
the	O
probable	O
cause	B-Reg
of	O
Elsahy	B-Disease
-	I-Disease
Waters	I-Disease
syndrome	I-Disease
.	O

Two	O
sisters	O
from	O
a	O
consanguineous	O
couple	O
were	O
seen	O
in	O
genetics	O
department	O
for	O
facial	O
dysmorphic	O
features	O
and	O
glaucoma	O
.	O

They	O
both	O
had	O
broad	O
foreheads	O
,	O
hypertelorism	O
,	O
megalocorneas	O
,	O
thick	O
eyebrows	O
with	O
synophrys	O
,	O
flat	O
malar	O
regions	O
,	O
broad	O
and	O
bulbous	O
noses	O
,	O
and	O
mild	O
prognathism	O
.	O

Both	O
had	O
glaucoma	O
,	O
younger	O
one	O
also	O
had	O
cataracts	O
and	O
phthisis	O
bulbi	O
.	O

Other	O
findings	O
included	O
bilateral	O
partial	O
cutaneous	O
syndactyly	O
of	O
2nd	O
and	O
3rd	O
fingers	O
,	O
history	O
of	O
impacted	O
teeth	O
with	O
dentigerous	O
cyst	O
in	O
the	O
elder	O
one	O
,	O
and	O
intellectual	O
disability	O
(	O
mild	O
and	O
borderline	O
)	O
.	O

The	O
sisters	O
were	O
considered	O
to	O
have	O
Elsahy	O
-	O
Waters	O
syndrome	O
.	O

In	O
order	O
to	O
elucidate	O
the	O
underlying	O
molecular	O
cause	O
,	O
sisters	O
and	O
their	O
healthy	O
parents	O
were	O
genotyped	O
by	O
SNP	O
arrays	O
,	O
followed	O
by	O
homozygosity	O
mapping	O
.	O

Homozygous	O
regions	O
were	O
further	O
analyzed	O
by	O
exome	O
sequencing	O
in	O
one	O
affected	O
individual	O
.	O

A	O
homozygous	O
indel	O
variant	O
segregating	O
with	O
the	O
condition	O
was	O
detected	O
in	O
CDH11	O
(	O
c.1116_1117delinsGATCATCAG	O
,	O
p.(Ile372MetfsTer9	O
)	O
)	O
,	O
which	O
was	O
then	O
validated	O
by	O
using	O
Sanger	O
sequencing	O
.	O

CDH11	O
encodes	O
cadherin	O
11	O
(	O
osteo	O
-	O
cadherin	O
)	O
that	O
regulates	O
cell	O
-	O
cell	O
adhesion	O
,	O
cell	O
polarization	O
and	O
migration	O
,	O
as	O
well	O
as	O
osteogenic	O
differentiation	O
.	O

Further	O
experiments	O
revealed	O
that	O
CDH11	O
expression	O
was	O
decreased	O
in	O
patient	O
-	O
derived	O
fibroblasts	O
as	O
compared	O
to	O
the	O
heterozygous	O
parent	O
and	O
another	O
healthy	O
donor	O
.	O

Immunostaining	O
showed	O
absence	O
of	O
the	O
protein	O
expression	O
in	O
patient	O
fibroblasts	O
.	O

In	O
addition	O
,	O
cell	B-CPA
proliferation	I-CPA
rate	I-CPA
was	O
slow	B-NegReg
and	O
osteogenic	B-CPA
differentiation	I-CPA
potential	I-CPA
was	O
delayed	B-NegReg
.	O

We	O
consider	O
that	O
this	O
study	O
reveals	O
loss	O
-	O
of	O
-	O
function	O
mutations	B-Var
in	O
CDH11	B-Gene
as	O
a	O
probable	O
cause	O
of	O
this	O
phenotype	O
.	O

Next	O
generation	O
sequencing	O
in	O
further	O
patients	O
would	O
both	O
prove	O
this	O
gene	O
as	O
causative	O
,	O
and	O
finely	O
delineate	O
this	O
clinical	O
spectrum	O
further	O
contributing	O
in	O
identification	O
of	O
other	O
possibly	O
involved	O
gene(s	O
)	O
.	O

Effect	B-Reg
of	O
Mutant	B-Var
p53	B-Gene
Proteins	B-Protein
on	O
Glycolysis	B-MPA
and	O
Mitochondrial	B-MPA
Metabolism	I-MPA
.	O

TP53	O
is	O
one	O
of	O
the	O
most	O
commonly	O
mutated	O
genes	O
in	O
human	O
cancers	O
.	O

Unlike	O
other	O
tumor	O
suppressors	O
that	O
are	O
frequently	O
deleted	O
or	O
acquire	O
loss	O
-	O
of	O
-	O
function	O
mutations	O
,	O
the	O
majority	O
of	O
TP53	B-Gene
mutations	B-Var
in	O
tumors	O
are	O
missense	B-Var
substitutions	I-Var
,	O
which	O
lead	O
to	O
the	O
expression	B-MPA
of	O
full	O
-	O
length	O
mutant	B-Var
proteins	B-Protein
that	O
accumulate	B-PosReg
in	O
cancer	O
cells	O
and	O
may	O
confer	O
unique	O
gain	B-PosReg
-	I-PosReg
of	I-PosReg
-	I-PosReg
function	I-PosReg
(	O
GOF	O
)	O
activities	B-MPA
to	O
promote	B-PosReg
tumorigenic	B-CPA
events	I-CPA
.	O

Recently	O
,	O
mutant	B-Var
p53	B-Gene
proteins	B-Protein
have	O
been	O
shown	O
to	O
mediate	O
metabolic	B-CPA
changes	I-CPA
as	O
a	O
novel	O
GOF	B-PosReg
to	O
promote	B-PosReg
tumor	B-CPA
development	I-CPA
.	O

There	O
is	O
a	O
strong	O
rationale	O
that	O
the	O
GOF	O
activities	O
,	O
including	O
alterations	O
in	O
cellular	O
metabolism	O
,	O
might	O
vary	O
between	O
the	O
different	O
p53	O
mutants	O
.	O

Accordingly	O
,	O
the	O
effect	O
of	O
different	O
mutant	O
p53	O
proteins	O
on	O
cancer	O
cell	O
metabolism	O
is	O
largely	O
unknown	O
.	O

In	O
this	O
study	O
,	O
we	O
have	O
metabolically	O
profiled	O
several	O
individual	O
frequently	O
occurring	O
p53	O
mutants	O
in	O
cancers	O
,	O
focusing	O
on	O
glycolytic	O
and	O
mitochondrial	O
oxidative	O
phosphorylation	O
pathways	O
.	O

Our	O
investigation	O
highlights	O
the	O
diversity	O
of	O
different	O
p53	O
mutants	O
in	O
terms	O
of	O
their	O
effect	O
on	O
metabolism	O
,	O
which	O
might	O
provide	O
a	O
foundation	O
for	O
the	O
development	O
of	O
more	O
effective	O
targeted	O
pharmacological	O
approaches	O
toward	O
variants	O
of	O
mutant	O
p53	O
.	O

The	O
Roles	O
of	O
the	O
Sole	O
Activator	O
-	O
Type	O
Auxin	O
Response	O
Factor	O
in	O
Pattern	O
Formation	O
of	O
Marchantia	O
polymorpha	O
.	O

Cell	O
division	O
patterning	O
is	O
important	O
to	O
determine	O
body	O
shape	O
in	O
plants	O
.	O

Nuclear	O
auxin	O
signaling	O
mediated	O
by	O
AUXIN	O
RESPONSE	O
FACTOR	O
(	O
ARF	O
)	O
transcription	O
factors	O
affects	O
plant	O
growth	O
and	O
development	O
through	O
regulation	O
of	O
cell	O
division	O
,	O
elongation	O
and	O
differentiation	O
.	O

The	O
evolutionary	O
origin	O
of	O
the	O
ARF	O
-	O
mediated	O
pathway	O
dates	O
back	O
to	O
at	O
least	O
the	O
common	O
ancestor	O
of	O
bryophytes	O
and	O
other	O
land	O
plants	O
.	O

The	O
liverwort	O
Marchantia	O
polymorpha	O
has	O
three	O
phylogenetically	O
distinct	O
ARFs	O
:	O
MpARF1	O
,	O
the	O
sole	O
'	O
activator	O
'	O
ARF	O
;	O
and	O
MpARF2	O
and	O
MpARF3	O
,	O
two	O
'	O
repressor	O
'	O
ARFs	O
.	O

Genetic	O
screens	O
for	O
auxin	O
-	O
resistant	O
mutants	O
revealed	O
that	O
loss	O
of	O
MpARF1	O
function	O
conferred	O
auxin	O
insensitivity	O
.	O

Mparf1	B-Gene
mutants	B-Var
showed	O
reduced	B-NegReg
auxin	B-Gene
-	I-Gene
inducible	I-Gene
gene	I-Gene
expression	B-MPA
and	O
various	O
developmental	B-CPA
defects	I-CPA
,	O
including	O
thallus	O
twisting	O
and	O
gemma	O
malformation	O
.	O

We	O
further	O
investigated	O
the	O
role	O
of	O
MpARF1	O
in	O
gemma	O
development	O
,	O
which	O
is	O
traceable	O
at	O
the	O
cellular	O
level	O
.	O

In	O
wild	O
-	O
type	O
plants	O
,	O
a	O
gemma	O
initial	O
first	O
undergoes	O
several	O
transverse	O
divisions	O
to	O
generate	O
a	O
single	O
-	O
celled	O
stalk	O
and	O
a	O
gemma	O
proper	O
,	O
followed	O
by	O
rather	O
synchronous	O
longitudinal	O
divisions	O
in	O
the	O
latter	O
.	O

Mparf1	O
mutants	O
often	O
contained	O
multicelled	O
stalks	O
and	O
showed	O
defects	O
in	O
the	O
execution	O
and	O
timing	O
of	O
the	O
longitudinal	O
divisions	O
.	O

While	O
wild	O
-	O
type	O
gemmae	O
finally	O
generate	O
two	O
meristem	O
notches	O
,	O
Mparf1	O
gemmae	O
displayed	O
various	O
numbers	O
of	O
ectopic	O
meristems	O
.	O

These	O
results	O
suggest	O
that	O
MpARF1	O
regulates	O
formative	O
cell	O
divisions	O
and	O
axis	O
formation	O
through	O
auxin	O
responses	O
.	O

The	O
mechanism	O
for	O
activator	O
ARF	O
regulation	O
of	O
pattern	O
formation	O
may	O
be	O
shared	O
in	O
land	O
plants	O
and	O
therefore	O
important	O
for	O
the	O
general	O
acquisition	O
of	O
three	O
-	O
dimensional	O
body	O
plans	O
.	O

Loss	O
of	O
the	O
nutrient	O
sensor	O
TAS1R3	O
leads	O
to	O
reduced	O
bone	O
resorption	O
.	O

The	O
taste	O
receptor	O
type	O
1	O
(	O
TAS1R	O
)	O
family	O
of	O
heterotrimeric	O
G	O
protein	O
-	O
coupled	O
receptors	O
participates	O
in	O
monitoring	O
energy	O
and	O
nutrient	O
status	O
.	O

TAS1R	O
member	O
3	O
(	O
TAS1R3	O
)	O
is	O
a	O
bi	O
-	O
functional	O
protein	O
that	O
recognizes	O
amino	O
acids	O
such	O
as	O
L	O
-	O
glycine	O
and	O
L	O
-	O
glutamate	O
or	O
sweet	O
molecules	O
such	O
as	O
sucrose	O
and	O
fructose	O
when	O
dimerized	O
with	O
TAS1R	O
member	O
1	O
(	O
TAS1R1	O
)	O
or	O
TAS1R	O
member	O
2	O
(	O
TAS1R2	O
)	O
,	O
respectively	O
.	O

It	O
was	O
recently	O
reported	O
that	O
deletion	B-Var
of	O
TAS1R3	B-Gene
expression	O
in	O
Tas1R3	O
mutant	O
mice	O
leads	O
to	O
increased	B-PosReg
cortical	B-CPA
bone	I-CPA
mass	I-CPA
but	O
the	O
underlying	O
cellular	O
mechanism	O
leading	O
to	O
this	O
phenotype	O
remains	O
unclear	O
.	O

Here	O
,	O
we	O
independently	O
corroborate	O
the	O
increased	B-PosReg
thickness	B-CPA
of	I-CPA
cortical	I-CPA
bone	I-CPA
in	O
femurs	O
of	O
20-week	O
-	O
old	O
male	O
Tas1R3	B-Gene
mutant	B-Var
mice	O
and	O
confirm	O
that	O
Tas1R3	O
is	O
expressed	O
in	O
the	O
bone	O
environment	O
.	O

Tas1R3	O
is	O
expressed	O
in	O
undifferentiated	O
bone	O
marrow	O
stromal	O
cells	O
(	O
BMSCs	O
)	O
in	O
vitro	O
and	O
its	O
expression	O
is	O
maintained	O
during	O
BMP2-induced	O
osteogenic	O
differentiation	O
.	O

However	O
,	O
levels	O
of	O
the	O
bone	O
formation	O
marker	O
procollagen	O
type	O
I	O
N	O
-	O
terminal	O
propeptide	O
(	O
PINP	O
)	O
are	O
unchanged	O
in	O
the	O
serum	O
of	O
20-week	O
-	O
old	O
Tas1R3	O
mutant	O
mice	O
as	O
compared	O
to	O
controls	O
.	O

In	O
contrast	O
,	O
levels	B-MPA
of	I-MPA
the	I-MPA
bone	I-MPA
resorption	I-MPA
marker	I-MPA
collagen	I-MPA
type	I-MPA
I	I-MPA
C	I-MPA
-	I-MPA
telopeptide	I-MPA
are	O
reduced	B-NegReg
greater	O
than	O
60	O
%	O
in	O
Tas1R3	B-Gene
mutant	B-Var
mice	O
.	O

Consistent	O
with	O
this	O
,	O
Tas1R3	O
and	O
its	O
putative	O
signaling	O
partner	O
Tas1R2	O
are	O
expressed	O
in	O
primary	O
osteoclasts	O
and	O
their	O
expression	O
levels	O
positively	O
correlate	O
with	O
differentiation	O
status	O
.	O

Collectively	O
,	O
these	O
findings	O
suggest	O
that	O
high	B-PosReg
bone	B-CPA
mass	I-CPA
in	O
Tas1R3	B-Gene
mutant	B-Var
mice	O
is	O
due	O
to	O
uncoupled	O
bone	O
remodeling	O
with	O
reduced	B-NegReg
osteoclast	B-CPA
function	I-CPA
and	O
provide	O
rationale	O
for	O
future	O
experiments	O
examining	O
the	O
cell	O
-	O
type	O
-	O
dependent	O
role	O
for	O
TAS1R	O
family	O
members	O
in	O
nutrient	O
sensing	O
in	O
postnatal	O
bone	O
remodeling	O
.	O

Molecular	O
characterization	O
of	O
the	O
llama	O
FGF5	O
gene	O
and	O
identification	O
of	O
putative	O
loss	O
of	O
function	O
mutations	O
.	O

Llama	O
,	O
the	O
most	O
numerous	O
domestic	O
camelid	O
in	O
Argentina	O
,	O
has	O
good	O
fiber	O
-	O
production	O
ability	O
.	O

Although	O
a	O
few	O
genes	O
related	O
to	O
other	O
productive	O
traits	O
have	O
been	O
characterized	O
,	O
the	O
molecular	O
genetic	O
basis	O
of	O
fiber	O
growth	O
control	O
in	O
camelids	O
is	O
still	O
poorly	O
understood	O
.	O

Fibroblast	O
growth	O
factor	O
5	O
(	O
FGF5	O
)	O
is	O
a	O
secreted	O
signaling	O
protein	O
that	O
controls	O
hair	O
growth	O
in	O
humans	O
and	O
other	O
mammals	O
.	O

Mutations	O
in	O
the	O
FGF5	O
gene	O
have	O
been	O
associated	O
with	O
long	O
-	O
hair	O
phenotypes	O
in	O
several	O
species	O
.	O

Here	O
,	O
we	O
sequenced	O
the	O
llama	O
FGF5	O
gene	O
,	O
which	O
consists	O
of	O
three	O
exons	O
encoding	O
813	O
bp	O
.	O

cDNA	O
analysis	O
from	O
hair	O
follicles	O
revealed	O
the	O
expression	O
of	O
two	O
FGF5	O
alternative	O
spliced	O
transcripts	O
,	O
in	O
one	O
of	O
which	O
exon	O
2	O
is	O
absent	O
.	O

DNA	O
variation	O
analysis	O
showed	O
four	O
polymorphisms	O
in	O
the	O
coding	O
region	O
:	O
a	O
synonymous	O
SNP	O
(	O
c.210A	O
>	O
G	O
)	O
,	O
a	O
single	O
base	O
deletion	O
(	B-Var
c.348delA	I-Var
)	I-Var
,	O
a	O
12-bp	O
insertion	O
(	O
c.351_352insCATATAACATAG	O
)	O
and	O
a	O
non	O
-	O
sense	O
mutation	O
(	O
c.499C	O
>	O
T	O
)	O
.	O

The	O
deletion	O
was	O
always	O
found	O
together	O
with	O
the	O
insertion	O
forming	O
a	O
haplotype	O
and	O
producing	O
a	O
putative	O
truncated	O
protein	O
of	O
123	O
amino	O
acids	O
.	O

The	O
c.499C	B-Var
>	I-Var
T	I-Var
mutation	O
also	O
leads	O
to	O
a	O
premature	O
stop	O
codon	O
at	O
position	O
168	O
.	O

In	O
both	O
cases	O
,	O
critical	B-MPA
functional	I-MPA
domains	I-MPA
of	O
FGF5	B-Gene
,	O
including	O
one	O
heparin	B-MPA
binding	I-MPA
site	I-MPA
,	O
are	O
lost	B-NegReg
.	O

All	O
animals	O
analyzed	O
were	O
homozygous	O
for	O
one	O
of	O
the	O
deleterious	O
mutations	O
or	O
compound	O
heterozygous	O
for	O
both	O
(	O
i.e.	O
c.348delA	O
,	O
c.351_352insCATATAACATAG	O
/	O
c.499	O
T	O
)	O
.	O

Sequencing	O
of	O
guanaco	O
samples	O
showed	O
that	O
the	O
FGF5	O
gene	O
encodes	O
a	O
full	O
-	O
length	O
270-amino	O
acid	O
protein	O
.	O

These	O
results	O
suggest	O
that	O
FGF5	O
is	O
likely	O
functional	O
in	O
short	O
-	O
haired	O
wild	O
species	O
and	O
non	O
-	O
functional	O
in	O
the	O
domestic	O
fiber	O
-	O
producing	O
species	O
,	O
the	O
llama	O
.	O

Differential	O
regulation	O
of	O
two	O
FLNA	O
transcripts	O
explains	O
some	O
of	O
the	O
phenotypic	O
heterogeneity	O
in	O
the	O
loss	O
-	O
of	O
-	O
function	O
filaminopathies	O
.	O

Loss	B-NegReg
-	I-NegReg
of	I-NegReg
-	I-NegReg
function	I-NegReg
mutations	B-Var
in	O
the	O
X	O
-	O
linked	O
gene	O
FLNA	B-Gene
can	O
lead	O
to	O
abnormal	B-CPA
neuronal	I-CPA
migration	I-CPA
,	O
vascular	B-CPA
and	I-CPA
cardiac	I-CPA
defects	I-CPA
,	O
and	O
congenital	B-Disease
intestinal	I-Disease
pseudo	I-Disease
-	I-Disease
obstruction	I-Disease
(	O
CIPO	O
)	O
,	O
the	O
latter	O
characterized	O
by	O
anomalous	O
intestinal	O
smooth	O
muscle	O
layering	O
.	O

Survival	O
in	O
male	O
hemizygotes	O
for	O
such	O
mutations	O
is	O
dependent	O
on	O
retention	O
of	O
residual	O
FLNA	O
function	O
but	O
it	O
is	O
unclear	O
why	O
a	O
subgroup	O
of	O
males	O
with	O
mutations	O
in	O
the	O
5	O
'	O
end	O
of	O
the	O
gene	O
can	O
present	O
with	O
CIPO	O
alone	O
.	O

Here	O
,	O
we	O
demonstrate	O
evidence	O
for	O
the	O
presence	O
of	O
two	O
FLNA	O
isoforms	O
differing	O
by	O
28	O
residues	O
at	O
the	O
N	O
-	O
terminus	O
initiated	O
at	O
ATG+1	O
and	O
ATG+82	O
.	O

A	O
male	O
with	O
CIPO	O
(	O
c.18_19del	O
)	O
exclusively	O
expressed	O
FLNA	O
ATG+82	O
,	O
implicating	O
the	O
longer	O
protein	O
isoform	O
(	O
ATG+1	O
)	O
in	O
smooth	O
muscle	O
development	O
.	O

In	O
contrast	O
,	O
mutations	O
leading	O
to	O
reduction	O
of	O
both	O
isoforms	O
are	O
associated	O
with	O
compound	O
phenotypes	O
affecting	O
the	O
brain	O
,	O
heart	O
,	O
and	O
intestine	O
.	O

RNA	O
-	O
seq	O
data	O
revealed	O
three	O
distinct	O
transcription	O
start	O
sites	O
,	O
two	O
of	O
which	O
produce	O
a	O
protein	O
isoform	O
utilizing	O
ATG+1	O
while	O
the	O
third	O
utilizes	O
ATG+82	O
.	O

Transcripts	O
sponsoring	O
translational	O
initiation	O
at	O
ATG+1	O
predominate	O
in	O
intestinal	O
smooth	O
muscle	O
,	O
and	O
are	O
more	O
abundant	O
compared	O
with	O
the	O
level	O
measured	O
in	O
fibroblasts	O
.	O

Together	O
these	O
observations	O
describe	O
a	O
new	O
mechanism	O
of	O
tissue	O
-	O
specific	O
regulation	O
of	O
FLNA	O
that	O
could	O
reflect	O
the	O
differing	O
mechanical	O
requirements	O
of	O
these	O
cell	O
types	O
during	O
development	O
.	O

A	O
disulfide	O
bond	O
A	O
-	O
like	O
oxidoreductase	O
is	O
a	O
strong	O
candidate	O
gene	O
for	O
self	O
-	O
incompatibility	O
in	O
apricot	O
(	O
Prunus	O
armeniaca	O
)	O
pollen	O
.	O

S	O
-	O
RNase	O
based	O
gametophytic	O
self	O
-	O
incompatibility	O
(	O
SI	O
)	O
is	O
a	O
widespread	O
prezygotic	O
reproductive	O
barrier	O
in	O
flowering	O
plants	O
.	O

In	O
the	O
Solanaceae	O
,	O
Plantaginaceae	O
and	O
Rosaceae	O
gametophytic	O
SI	O
is	O
controlled	O
by	O
the	O
pistil	O
-	O
specific	O
S	O
-	O
RNases	O
and	O
the	O
pollen	O
S	O
-	O
locus	O
F	O
-	O
box	O
proteins	O
but	O
non	O
-	O
S	O
-	O
specific	O
factors	O
,	O
namely	O
modifiers	O
,	O
are	O
also	O
required	O
.	O

In	O
apricot	O
,	O
Prunus	O
armeniaca	O
(	O
Rosaceae	O
)	O
,	O
we	O
previously	O
mapped	O
two	O
pollen	O
-	O
part	O
mutations	B-Var
that	O
confer	B-Reg
self	B-MPA
-	I-MPA
compatibility	I-MPA
in	O
cultivars	O
Canino	O
and	O
Katy	O
at	O
the	O
distal	O
end	O
of	O
chromosome	O
3	O
(	O
M	O
-	O
locus	O
)	O
unlinked	O
to	O
the	O
S	O
-	O
locus	O
.	O

Here	O
,	O
we	O
used	O
high	O
-	O
resolution	O
mapping	O
to	O
identify	O
the	O
M	O
-	O
locus	O
with	O
an	O
~134	O
kb	O
segment	O
containing	O
ParM-1	O
-	O
16	O
genes	O
.	O

Gene	O
expression	O
analysis	O
identified	O
four	O
genes	O
preferentially	O
expressed	O
in	O
anthers	O
as	O
modifier	O
gene	O
candidates	O
,	O
ParM-6	O
,	O
-7	O
,	O
-9	O
and	O
-14	O
.	O

Variant	O
calling	O
of	O
WGS	O
Illumina	O
data	O
from	O
Canino	O
,	O
Katy	O
,	O
and	O
10	O
self	O
-	O
incompatible	O
cultivars	O
detected	O
a	O
358	O
bp	O
miniature	O
inverted	O
-	O
repeat	O
transposable	O
element	O
(	O
MITE	O
)	O
insertion	O
in	O
ParM-7	O
shared	O
only	O
by	O
self	O
-	O
compatible	O
apricots	O
,	O
supporting	O
ParM-7	O
as	O
strong	O
candidate	O
gene	O
required	O
for	O
SI	O
.	O

ParM-7	O
encodes	O
a	O
disulfide	O
bond	O
A	O
-	O
like	O
oxidoreductase	O
protein	O
,	O
which	O
we	O
named	O
ParMDO	O
.	O

The	O
MITE	B-Gene
insertion	B-Var
truncates	B-NegReg
the	O
ParMDO	B-MPA
ORF	I-MPA
and	O
produces	O
a	O
loss	B-NegReg
of	O
SI	B-MPA
function	I-MPA
,	O
suggesting	O
that	O
pollen	O
rejection	O
in	O
Prunus	O
is	O
dependent	O
on	O
redox	O
regulation	O
.	O

Based	O
on	O
phylogentic	O
analyses	O
we	O
also	O
suggest	O
that	O
ParMDO	O
may	O
have	O
originated	O
from	O
a	O
tandem	O
duplication	O
followed	O
by	O
subfunctionalization	O
and	O
pollen	O
-	O
specific	O
expression	O
.	O

The	O
Gain	B-PosReg
-	I-PosReg
of	I-PosReg
-	I-PosReg
Function	I-PosReg
Integrin	O
β3	O
Pro33	O
Variant	B-Var
Alters	O
the	O
Serotonin	B-MPA
System	I-MPA
in	O
the	O
Mouse	O
Brain	O
.	O

Engagement	O
of	O
integrins	O
by	O
the	O
extracellular	O
matrix	O
initiates	O
signaling	O
cascades	O
that	O
drive	O
a	O
variety	O
of	O
cellular	O
functions	O
,	O
including	O
neuronal	O
migration	O
and	O
axonal	O
pathfinding	O
in	O
the	O
brain	O
.	O

Multiple	O
lines	O
of	O
evidence	O
link	O
the	O
ITGB3	O
gene	O
encoding	O
the	O
integrin	O
β3	O
subunit	O
with	O
the	O
serotonin	O
(	O
5-HT	O
)	O
system	O
,	O
likely	O
via	O
its	O
modulation	O
of	O
the	O
5-HT	O
transporter	O
(	O
SERT	O
)	O
.	O

The	O
ITGB3	B-Gene
coding	O
polymorphism	O
Leu33Pro	B-Var
(	O
rs5918	O
,	O
PlA2	O
)	O
produces	O
hyperactive	B-PosReg
αvβ3	B-Protein
receptors	I-Protein
that	O
influence	B-Reg
whole	B-MPA
-	I-MPA
blood	I-MPA
5-HT	I-MPA
levels	I-MPA
and	O
may	O
influence	B-Reg
the	O
risk	O
for	O
autism	B-Disease
spectrum	I-Disease
disorder	I-Disease
(	O
ASD	O
)	O
.	O

Using	O
a	O
phenome	O
-	O
wide	O
scan	O
of	O
psychiatric	O
diagnoses	O
,	O
we	O
found	O
significant	O
,	O
male	O
-	O
specific	O
associations	O
between	O
the	O
Pro33	O
allele	O
and	O
attention	O
-	O
deficit	O
hyperactivity	O
disorder	O
and	O
ASDs	O
.	O

Here	O
,	O
we	O
used	O
knock	O
-	O
in	O
(	O
KI	O
)	O
mice	O
expressing	O
an	O
Itgb3	B-Gene
variant	B-Var
that	O
phenocopies	O
the	O
human	O
Pro33	O
variant	O
to	O
elucidate	O
the	O
consequences	O
of	O
constitutively	O
enhanced	B-PosReg
αvβ3	B-MPA
signaling	I-MPA
to	I-MPA
the	I-MPA
5-HT	I-MPA
system	I-MPA
in	O
the	O
brain	O
.	O

KI	O
mice	O
displayed	O
deficits	O
in	O
multiple	O
behaviors	O
,	O
including	O
anxiety	O
,	O
repetitive	O
,	O
and	O
social	O
behaviors	O
.	O

Anatomical	O
studies	O
revealed	O
a	O
significant	O
decrease	O
in	O
5-HT	O
synapses	O
in	O
the	O
midbrain	O
,	O
accompanied	O
by	O
decreases	O
in	O
SERT	O
activity	O
and	O
reduced	O
localization	O
of	O
SERTs	O
to	O
integrin	O
adhesion	O
complexes	O
in	O
synapses	O
of	O
KI	O
mice	O
.	O

Inhibition	O
of	O
focal	O
adhesion	O
kinase	O
(	O
FAK	O
)	O
rescued	O
SERT	O
function	O
in	O
synapses	O
of	O
KI	O
mice	O
,	O
demonstrating	O
that	O
constitutive	O
active	O
FAK	O
signaling	O
downstream	O
of	O
the	O
Pro32Pro33	O
integrin	O
αvβ3	O
suppresses	O
SERT	O
activity	O
.	O

Our	O
studies	O
identify	O
a	O
complex	O
regulation	O
of	O
5-HT	O
homeostasis	O
and	O
behaviors	O
by	O
integrin	O
αvβ3	O
,	O
revealing	O
an	O
important	O
role	O
for	O
integrins	O
in	O
modulating	O
risk	O
for	O
neuropsychiatric	O
disorders	O
.	O

SIGNIFICANCE	O
STATEMENT	O
The	O
integrin	O
β3	O
Leu33Pro	O
coding	O
polymorphism	O
has	O
been	O
associated	O
with	O
autism	O
spectrum	O
disorders	O
(	O
ASDs	O
)	O
within	O
a	O
subgroup	O
of	O
patients	O
with	O
elevated	O
blood	O
5-HT	O
levels	O
,	O
linking	O
integrin	O
β3	O
,	O
5-HT	O
,	O
and	O
ASD	O
risk	O
.	O

We	O
capitalized	O
on	O
these	O
interactions	O
to	O
demonstrate	O
that	O
the	O
Pro33	O
coding	O
variation	O
in	O
the	O
murine	O
integrin	O
β3	O
recapitulates	O
the	O
sex	O
-	O
dependent	O
neurochemical	O
and	O
behavioral	O
attributes	O
of	O
ASD	O
.	O

Using	O
state	O
-	O
of	O
-	O
the	O
-	O
art	O
techniques	O
,	O
we	O
show	O
that	O
presynaptic	O
5-HT	O
function	O
is	O
altered	O
in	O
these	O
mice	O
,	O
and	O
that	O
the	O
localization	O
of	O
5-HT	O
transporters	O
to	O
specific	O
compartments	O
within	O
the	O
synapse	O
,	O
disrupted	O
by	O
the	O
integrin	O
β3	O
Pro33	O
mutation	O
,	O
is	O
critical	O
for	O
appropriate	O
reuptake	O
of	O
5-HT	O
.	O

Our	O
studies	O
provide	O
fundamental	O
insight	O
into	O
the	O
genetic	O
network	O
regulating	O
5-HT	O
neurotransmission	O
in	O
the	O
CNS	O
that	O
is	O
also	O
associated	O
with	O
ASD	O
risk	O
.	O

Parkin	B-Gene
absence	B-Var
accelerates	B-PosReg
microtubule	B-MPA
aging	I-MPA
in	I-MPA
dopaminergic	I-MPA
neurons	I-MPA
.	O

Loss	B-NegReg
-	I-NegReg
of	I-NegReg
-	I-NegReg
function	I-NegReg
caused	O
by	O
mutations	B-Var
in	O
the	O
parkin	O
gene	O
(	B-Gene
PARK2	I-Gene
)	I-Gene
lead	O
to	O
early	B-Disease
-	I-Disease
onset	I-Disease
familial	I-Disease
Parkinson	I-Disease
's	I-Disease
disease	I-Disease
.	O

Recently	O
,	O
mechanistic	O
studies	O
proved	O
the	O
ability	O
of	O
parkin	O
in	O
regulating	O
mitochondria	O
homeostasis	O
and	O
microtubule	O
(	O
MT	O
)	O
stability	O
.	O

Looking	O
at	O
these	O
systems	O
during	O
aging	O
of	O
PARK2	O
knockout	O
mice	O
,	O
we	O
found	O
that	O
loss	B-Var
of	O
parkin	B-Gene
induced	O
an	O
accelerated	B-PosReg
(	B-MPA
over)acetylation	I-MPA
of	O
MT	O
system	O
both	O
in	O
dopaminergic	O
neuron	O
cell	O
bodies	O
and	O
fibers	O
,	O
localized	O
in	O
the	O
substantia	O
nigra	O
and	O
corpus	O
striatum	O
,	O
respectively	O
.	O

Interestingly	O
,	O
in	O
PARK2	O
knockout	O
mice	O
,	O
changes	O
of	O
MT	O
stability	O
preceded	O
the	O
alteration	O
of	O
mitochondria	O
transport	O
.	O

Moreover	O
,	O
in	O
-	O
cell	O
experiments	O
confirmed	O
that	O
loss	B-Var
of	O
parkin	B-Gene
affects	B-Reg
mitochondria	B-MPA
mobility	I-MPA
and	O
showed	O
that	O
this	O
defect	O
depends	O
on	O
MT	O
system	O
as	O
it	O
is	O
rescued	O
by	O
paclitaxel	O
,	O
a	O
well	O
-	O
known	O
MT	O
-	O
targeted	O
agent	O
.	O

Furthermore	O
,	O
both	O
in	O
PC12	O
neuronal	O
cells	O
and	O
in	O
patients	O
'	O
induced	O
pluripotent	O
stem	O
cell	O
-	O
derived	O
midbrain	O
neurons	O
,	O
we	O
observed	O
that	O
parkin	O
deficiencies	O
cause	O
the	O
fragmentation	O
of	O
stable	O
MTs	O
.	O

Therefore	O
,	O
we	O
suggest	O
that	O
parkin	O
acts	O
as	O
a	O
regulator	O
of	O
MT	O
system	O
during	O
neuronal	O
aging	O
,	O
and	O
we	O
endorse	O
the	O
hypothesis	O
that	O
MT	O
dysfunction	O
may	O
be	O
crucial	O
in	O
the	O
pathogenesis	O
of	O
Parkinson	O
's	O
disease	O
.	O

Parkinson	B-Disease
's	I-Disease
Disease	I-Disease
-	I-Disease
Associated	I-Disease
LRRK2	B-Gene
Hyperactive	O
Kinase	O
Mutant	B-Var
Disrupts	B-NegReg
Synaptic	B-MPA
Vesicle	I-MPA
Trafficking	I-MPA
in	I-MPA
Ventral	I-MPA
Midbrain	I-MPA
Neurons	I-MPA
.	O

Parkinson	O
's	O
disease	O
(	O
PD	O
)	O
is	O
characterized	O
pathologically	O
by	O
the	O
selective	O
loss	O
of	O
substantia	O
nigra	O
(	O
SN	O
)	O
dopaminergic	O
(	O
DAergic	O
)	O
neurons	O
.	O

Recent	O
evidence	O
has	O
suggested	O
a	O
role	O
of	O
LRRK2	O
,	O
linked	O
to	O
the	O
most	O
frequent	O
familial	O
PD	O
,	O
in	O
regulating	O
synaptic	O
vesicle	O
(	O
SV	O
)	O
trafficking	O
.	O

However	O
,	O
the	O
mechanism	O
whereby	O
LRRK2	B-Gene
mutants	B-Var
contribute	B-Reg
to	O
nigral	B-MPA
vulnerability	I-MPA
remains	O
unclear	O
.	O

Here	O
we	O
show	O
that	O
the	O
most	O
common	O
PD	O
mutation	B-Var
LRRK2	B-Gene
G2019S	O
impairs	B-NegReg
SV	B-MPA
endocytosis	I-MPA
in	I-MPA
ventral	I-MPA
midbrain	I-MPA
(	I-MPA
MB	I-MPA
)	I-MPA
neurons	I-MPA
,	O
including	I-MPA
DA	I-MPA
neurons	I-MPA
,	O
and	O
the	O
slowed	O
endocytosis	O
can	O
be	O
rescued	O
by	O
inhibition	O
of	O
LRRK2	O
kinase	O
activity	O
.	O

A	O
similar	O
endocytic	O
defect	O
,	O
however	O
,	O
was	O
not	O
observed	O
in	O
LRRK2	O
mutant	O
neurons	O
from	O
the	O
neocortex	O
(	O
hereafter	O
,	O
cortical	O
neurons	O
)	O
or	O
the	O
hippocampus	O
,	O
suggesting	O
a	O
brain	O
region	O
-	O
specific	O
vulnerability	O
to	O
the	O
G2019S	O
mutation	O
.	O

Additionally	O
,	O
we	O
found	O
MB	O
-	O
specific	O
impairment	B-NegReg
of	O
SV	B-MPA
endocytosis	I-MPA
in	I-MPA
neurons	I-MPA
carrying	O
heterozygous	O
deletion	B-Var
of	O
SYNJ1	B-Gene
(	O
PARK20	O
)	O
,	O
a	O
gene	O
that	O
is	O
associated	O
with	O
recessive	O
Parkinsonism	O
.	O

Combining	O
SYNJ1+/-	B-Var
and	O
LRRK2	B-Var
G2019S	I-Var
does	O
not	O
exacerbate	O
SV	O
endocytosis	O
but	O
impairs	B-NegReg
sustained	B-MPA
exocytosis	I-MPA
in	I-MPA
MB	I-MPA
neurons	I-MPA
and	O
alters	B-Reg
specific	B-MPA
motor	I-MPA
functions	I-MPA
of	O
1-year	O
-	O
old	O
male	O
mice	O
.	O

Interestingly	O
,	O
we	O
show	O
that	O
LRRK2	B-Var
directly	O
phosphorylates	O
synaptojanin1	O
in	O
vitro	O
,	O
resulting	B-Reg
in	I-Reg
the	O
disruption	B-MPA
of	I-MPA
endophilin	I-MPA
-	I-MPA
synaptojanin1	I-MPA
interaction	I-MPA
required	I-MPA
for	I-MPA
SV	I-MPA
endocytosis	I-MPA
.	O

Our	O
work	O
suggests	O
a	O
merge	O
of	O
LRRK2	O
and	O
SYNJ1	O
pathogenic	O
pathways	O
in	O
deregulating	O
SV	O
trafficking	O
in	O
MB	O
neurons	O
as	O
an	O
underlying	O
molecular	O
mechanism	O
of	O
early	O
PD	O
pathogenesis	O
.	O

SIGNIFICANCE	O
STATEMENT	O
Understanding	O
midbrain	O
dopaminergic	O
(	O
DAergic	O
)	O
neuron	O
-	O
selective	O
vulnerability	O
in	O
PD	O
is	O
essential	O
for	O
the	O
development	O
of	O
targeted	O
therapeutics	O
.	O

We	O
report	O
,	O
for	O
the	O
first	O
time	O
,	O
a	O
nerve	O
terminal	O
impairment	O
in	O
SV	O
trafficking	O
selectively	O
in	O
MB	O
neurons	O
but	O
not	O
cortical	O
neurons	O
caused	O
by	O
two	O
PARK	O
genes	O
:	O
LRRK2	O
(	O
PARK8	O
)	O
and	O
SYNJ1	O
(	O
PARK20	O
)	O
.	O

We	O
demonstrate	O
that	O
the	O
enhanced	B-PosReg
kinase	B-MPA
activity	I-MPA
resulting	O
from	O
the	O
most	O
frequent	O
G2019S	B-Var
mutation	O
in	O
LRRK2	B-Gene
is	O
the	O
key	O
to	O
this	O
impairment	O
.	O

We	O
provide	O
evidence	O
suggesting	O
that	O
LRRK2	B-Gene
G2019S	B-Var
and	O
SYNJ1	B-Gene
loss	B-NegReg
of	I-NegReg
function	I-NegReg
share	O
a	O
similar	O
pathogenic	O
pathway	O
in	O
deregulating	B-MPA
DAergic	I-MPA
neuron	I-MPA
SV	I-MPA
endocytosis	I-MPA
and	O
that	O
they	O
play	B-Reg
additive	I-Reg
roles	I-Reg
in	O
facilitating	O
each	O
other	O
's	O
pathogenic	O
functions	O
in	O
PD	B-Disease
.	O

From	O
mutational	O
inactivation	O
to	O
aberrant	O
gain	O
-	O
of	O
-	O
function	O
:	O
Unraveling	O
the	O
structural	O
basis	O
of	O
mutant	O
p53	O
oncogenic	O
transition	O
.	O

Various	O
evidence	O
has	O
revealed	O
that	O
mutations	B-Var
in	O
p53	B-Gene
exert	O
activities	O
that	O
go	O
beyond	O
simply	O
inactivation	B-NegReg
of	O
wildtype	B-MPA
functions	I-MPA
but	O
rather	O
elicits	B-Reg
downstream	O
interactions	B-Interaction
that	O
promote	B-PosReg
malignancy	B-Disease
described	O
as	O
mutant	B-Var
p53	B-Gene
gain	B-PosReg
-	I-PosReg
of	I-PosReg
-	I-PosReg
function	I-PosReg
(	O
GOF	O
)	O
.	O

Here	O
we	O
report	O
the	O
first	O
account	O
of	O
the	O
dynamics	O
of	O
mutation	O
-	O
induced	O
structural	O
transition	O
of	O
native	O
p53	O
to	O
an	O
aberrant	O
gain	O
-	O
of	O
-	O
function	O
state	O
,	O
studying	O
the	O
wildtype	O
(	O
WT	O
)	O
and	O
high	O
incidence	O
contact	O
(	B-Var
R273C	I-Var
)	I-Var
and	O
structural	O
(	B-Var
R175H	I-Var
)	I-Var
mutant	O
p53	B-Gene
(	O
mutp53	O
)	O
through	O
molecular	O
dynamics	O
simulation	O
.	O

Result	O
analysis	O
revealed	O
that	O
both	O
mutants	O
exhibited	B-Reg
structural	B-Var
distortion	I-Var
and	O
reduced	B-NegReg
flexibility	B-MPA
,	O
indicative	O
of	O
rigidity	O
and	O
kinetic	O
stability	O
.	O

In	O
addition	O
,	O
surface	O
analysis	O
revealed	O
an	O
increase	O
in	O
the	O
accessible	O
surface	O
area	O
in	O
the	O
p53	O
mutants	O
.	O

This	O
suggests	O
that	O
the	O
GOF	O
transition	O
involves	O
protein	O
unfolding	O
and	O
exposure	O
of	O
buried	O
hydrophobic	O
surface	O
essential	O
for	O
interaction	O
with	O
HSF-1	O
oncogenic	O
partner	O
and	O
wildtype	O
p63	O
,	O
and	O
p73	O
homologs	O
.	O

Further	O
validation	O
revealed	O
binding	O
cavities	O
,	O
similar	O
in	O
the	O
mutants	O
but	O
dissimilar	O
to	O
the	O
WT	O
.	O

Taken	O
together	O
,	O
this	O
study	O
complements	O
experimental	O
findings	O
and	O
reveals	O
the	O
interplay	O
between	O
mutation	B-Reg
-	I-Reg
induced	I-Reg
structural	B-Var
distortion	I-Var
,	O
loss	B-NegReg
of	O
flexibility	B-MPA
,	O
rigidity	B-MPA
,	O
enhanced	B-PosReg
stability	B-MPA
,	O
protein	O
unfolding	O
and	O
ultimately	O
,	O
exposure	O
of	O
binding	O
surfaces	O
as	O
conformational	O
attributes	O
that	O
characterize	O
mutP53	O
structure	O
-	O
GOF	O
activities	O
.	O

This	O
insight	O
is	O
,	O
therefore	O
,	O
of	O
great	O
importance	O
as	O
it	O
opens	O
up	O
a	O
novel	O
therapeutic	O
approach	O
toward	O
the	O
structure	O
based	O
targeting	O
of	O
mutP53	O
oncogenic	O
involvement	O
beyond	O
wildtype	O
inactivation	O
.	O

Furthermore	O
,	O
"	O
exposed	O
"	O
binding	O
site	O
information	O
obtained	O
from	O
this	O
study	O
can	O
be	O
explored	O
for	O
structure	O
-	O
based	O
design	O
of	O
substances	O
best	O
described	O
as	O
"	O
destabilizers	O
"	O
to	O
disrupt	O
the	O
GOF	O
interaction	O
of	O
mutp53	O
.	O

Gain	B-PosReg
-	I-PosReg
of	I-PosReg
-	I-PosReg
function	I-PosReg
HCN2	B-Gene
variants	B-Var
in	O
genetic	O
epilepsy	B-Disease
.	O

Genetic	O
generalized	O
epilepsy	O
(	O
GGE	O
)	O
is	O
a	O
common	O
epilepsy	O
syndrome	O
that	O
encompasses	O
seizure	O
disorders	O
characterized	O
by	O
spike	O
-	O
and	O
-	O
wave	O
discharges	O
(	O
SWDs	O
)	O
.	O

Pacemaker	O
hyperpolarization	O
-	O
activated	O
cyclic	O
nucleotide	O
-	O
gated	O
channels	O
(	O
HCN	O
)	O
are	O
considered	O
integral	O
to	O
SWD	O
genesis	O
,	O
making	O
them	O
an	O
ideal	O
gene	O
candidate	O
for	O
GGE	O
.	O

We	O
identified	O
HCN2	O
missense	O
variants	O
from	O
a	O
large	O
cohort	O
of	O
585	O
GGE	O
patients	O
,	O
recruited	O
by	O
the	O
Epilepsy	O
Phenome	O
-	O
Genome	O
Project	O
(	O
EPGP	O
)	O
,	O
and	O
performed	O
functional	O
analysis	O
using	O
two	O
-	O
electrode	O
voltage	O
clamp	O
recordings	O
from	O
Xenopus	O
oocytes	O
.	O

The	O
p	O
.	O
S632W	O
variant	O
was	O
identified	O
in	O
a	O
patient	O
with	O
idiopathic	O
photosensitive	O
occipital	O
epilepsy	O
and	O
segregated	O
in	O
the	O
family	O
.	O

This	O
variant	O
was	O
also	O
independently	O
identified	O
in	O
an	O
unrelated	O
patient	O
with	O
childhood	O
absence	O
seizures	O
from	O
a	O
European	O
cohort	O
of	O
238	O
familial	O
GGE	O
cases	O
.	O

The	O
p	O
.	O
V246	O
M	O
variant	O
was	O
identified	O
in	O
a	O
patient	O
with	O
photo	O
-	O
sensitive	O
GGE	O
and	O
his	O
father	O
diagnosed	O
with	O
juvenile	O
myoclonic	O
epilepsy	O
.	O

Functional	O
studies	O
revealed	O
that	O
both	O
p	B-Var
.	I-Var
S632W	I-Var
and	O
p	B-Var
.	I-Var
V246	I-Var
M	I-Var
had	O
an	O
identical	O
functional	O
impact	O
including	O
a	O
depolarizing	B-MPA
shift	I-MPA
in	I-MPA
the	I-MPA
voltage	I-MPA
dependence	I-MPA
of	O
activation	B-PosReg
that	O
is	O
consistent	O
with	O
a	O
gain	O
-	O
of	O
-	O
function	O
.	O

In	O
contrast	O
,	O
no	O
biophysical	O
changes	O
resulted	O
from	O
the	O
introduction	O
of	O
common	O
population	O
variants	O
,	O
p	O
.	O
E280	O
K	O
and	O
p	O
.	O
A705	O
T	O
,	O
and	O
the	O
p	O
.	O
R756C	O
variant	O
from	O
EPGP	O
that	O
did	O
not	O
segregate	O
with	O
disease	O
.	O

Our	O
data	O
suggest	O
that	O
HCN2	B-Gene
variants	B-Var
can	O
confer	O
susceptibility	B-MPA
to	O
GGE	O
via	O
a	O
gain	B-PosReg
-	I-PosReg
of	I-PosReg
-	I-PosReg
function	I-PosReg
mechanism	O
.	O

Polymorphism	O
of	O
glutathione	O
S	O
-	O
transferase	O
M1	O
and	O
T1	O
genes	O
and	O
susceptibility	O
to	O
psoriasis	O
disease	O
:	O
A	O
study	O
from	O
North	O
India	O
.	O

BACKGROUND	O
:	O
Increased	O
oxidative	O
stress	O
and	O
resulting	O
inflammation	O
has	O
been	O
emphasized	O
as	O
a	O
factor	O
in	O
the	O
pathogenesis	O
of	O
many	O
diseases	O
including	O
psoriasis	O
.	O

Glutathione	O
S	O
-	O
transferases	O
(	O
GSTs	O
)	O
protect	O
against	O
oxidative	O
stress	O
,	O
inflammation	O
,	O
and	O
genotoxicity	O
.	O

Polymorphisms	B-Var
in	O
the	O
GST	B-Gene
genes	O
may	O
lead	B-Reg
to	I-Reg
an	O
imbalance	B-MPA
in	I-MPA
pro-	I-MPA
and	I-MPA
antioxidant	I-MPA
systems	I-MPA
resulting	O
in	O
the	O
increased	B-PosReg
production	B-MPA
of	I-MPA
reactive	I-MPA
oxygen	I-MPA
species	I-MPA
that	O
could	O
influence	B-Reg
the	O
pathogenesis	O
of	O
psoriasis	B-Disease
.	O

AIM	O
:	O
The	O
aim	O
of	O
this	O
study	O
was	O
to	O
investigate	O
the	O
association	O
between	O
GSTs	O
(	O
GSTM1	O
and	O
GSTT1	O
)	O
gene	O
polymorphism	O
in	O
patients	O
with	O
chronic	O
plaque	O
psoriasis	O
as	O
a	O
factor	O
in	O
the	O
susceptibility	O
and	O
development	O
of	O
psoriasis	O
.	O

MATERIALS	O
AND	O
METHODS	O
:	O
We	O
assessed	O
128	O
patients	O
with	O
psoriasis	O
and	O
250	O
age-	O
and	O
sex	O
-	O
matched	O
healthy	O
controls	O
.	O

Genomic	O
DNA	O
was	O
extracted	O
from	O
peripheral	O
blood	O
by	O
the	O
phenol	O
chloroform	O
method	O
.	O

The	O
null	O
GSTT1	O
and	O
GSTM1	O
genotypes	O
were	O
identified	O
by	O
multiplex	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
method	O
.	O

RESULTS	O
:	O
The	O
null	O
genotype	O
of	O
GSTM1	O
and	O
GSTT1	O
was	O
seen	O
in	O
45.3	O
%	O
and	O
40.6	O
%	O
in	O
psoriasis	O
patients	O
whereas	O
in	O
the	O
controls	O
it	O
was	O
34.4	O
%	O
and	O
20.0	O
%	O
,	O
respectively	O
.	O

A	O
significant	O
association	O
was	O
seen	O
between	O
the	O
null	O
alleles	O
of	O
the	O
GSTT1	O
(	O
OR	O
=	O
2.74	O
)	O
and	O
GSTM1	O
(	O
OR	O
=	O
1.58	O
)	O
alone	O
or	O
in	O
combination	O
with	O
tobacco	O
use	O
(	O
P	O
<	O
0.001	O
)	O
and	O
psoriasis	O
risk	O
.	O

The	O
presence	B-Var
of	O
both	O
null	O
genotypes	O
of	O
GSTM1	B-Gene
and	O
GSTT1	B-Gene
further	O
increased	B-PosReg
the	O
risk	O
of	O
psoriasis	B-Disease
(	O
OR	O
=	O
3.52	O
)	O
when	O
compared	O
with	O
the	O
positive	O
genotypes	O
of	O
GSTM1	O
and	O
GSTT1	O
.	O

LIMITATIONS	O
:	O
A	O
major	O
limitation	O
of	O
this	O
study	O
was	O
the	O
small	O
sample	O
size	O
.	O

A	O
large	O
epidemiological	O
study	O
is	O
necessary	O
to	O
confirm	O
these	O
findings	O
.	O

CONCLUSIONS	O
:	O
The	O
null	O
genotype	O
of	O
GSTT1	O
is	O
a	O
strong	O
predisposing	O
factor	O
for	O
psoriasis	O
in	O
North	O
India	O
.	O

Loss	O
-	O
of	O
-	O
function	O
of	O
ASPARTIC	O
PEPTIDASE	O
NODULE	O
-	O
INDUCED	O
1	O
(	O
APN1	O
)	O
in	O
Lotus	O
japonicus	O
restricts	O
efficient	O
nitrogen	O
-	O
fixing	O
symbiosis	O
with	O
specific	O
Mesorhizobium	O
loti	O
strains	O
.	O

The	O
nitrogen	O
-	O
fixing	O
symbiosis	O
of	O
legumes	O
and	O
Rhizobium	O
bacteria	O
is	O
established	O
by	O
complex	O
interactions	O
between	O
the	O
two	O
symbiotic	O
partners	O
.	O

Legume	O
Fix-	O
mutants	O
form	O
apparently	O
normal	O
nodules	O
with	O
endosymbiotic	O
rhizobia	O
but	O
fail	O
to	O
induce	O
rhizobial	O
nitrogen	O
fixation	O
.	O

These	O
mutants	O
are	O
useful	O
for	O
identifying	O
the	O
legume	O
genes	O
involved	O
in	O
the	O
interactions	O
essential	O
for	O
symbiotic	O
nitrogen	O
fixation	O
.	O

We	O
describe	O
here	O
a	O
Fix-	O
mutant	O
of	O
Lotus	O
japonicus	O
,	O
apn1	O
,	O
which	O
showed	O
a	O
very	O
specific	O
symbiotic	O
phenotype	O
.	O

It	O
formed	O
ineffective	O
nodules	O
when	O
inoculated	O
with	O
the	O
Mesorhizobium	O
loti	O
strain	O
TONO	O
.	O

In	O
these	O
nodules	O
,	O
infected	O
cells	O
disintegrated	O
and	O
successively	O
became	O
necrotic	O
,	O
indicating	B-Reg
premature	B-MPA
senescence	I-MPA
typical	O
of	O
Fix-	B-Var
mutants	I-Var
.	O

However	O
,	O
it	O
formed	O
effective	O
nodules	O
when	O
inoculated	O
with	O
the	O
M.	O
loti	O
strain	O
MAFF303099	O
.	O

Among	O
nine	O
different	O
M.	O
loti	O
strains	O
tested	O
,	O
four	O
formed	O
ineffective	O
nodules	O
and	O
five	O
formed	O
effective	O
nodules	O
on	O
apn1	O
roots	O
.	O

The	O
identified	O
causal	O
gene	O
,	O
ASPARTIC	O
PEPTIDASE	O
NODULE	O
-	O
INDUCED	O
1	O
(	O
LjAPN1	O
)	O
,	O
encodes	O
a	O
nepenthesin	O
-	O
type	O
aspartic	O
peptidase	O
.	O

The	O
well	O
characterized	O
Arabidopsis	O
aspartic	O
peptidase	O
CDR1	O
could	O
complement	O
the	O
strain	O
-	O
specific	O
Fix-	O
phenotype	O
of	O
apn1	O
.	O

LjAPN1	O
is	O
a	O
typical	O
late	O
nodulin	O
;	O
its	O
gene	O
expression	O
was	O
exclusively	O
induced	O
during	O
nodule	O
development	O
.	O

LjAPN1	O
was	O
most	O
abundantly	O
expressed	O
in	O
the	O
infected	O
cells	O
in	O
the	O
nodules	O
.	O

Our	O
findings	O
indicate	O
that	O
LjAPN1	O
is	O
required	O
for	O
the	O
development	O
and	O
persistence	O
of	O
functional	O
(	O
nitrogen	O
-	O
fixing	O
)	O
symbiosis	O
in	O
a	O
rhizobial	O
strain	O
-	O
dependent	O
manner	O
,	O
and	O
thus	O
determines	O
compatibility	O
between	O
M.	O
loti	O
and	O
L.	O
japonicus	O
at	O
the	O
level	O
of	O
nitrogen	O
fixation	O
.	O

[	O
FILAGGRIN	O
GENE	O
NULL	O
-	O
MUTATIONS	O
AND	O
ATOPIC	O
DISEASES	O
]	O
.	O

Null	B-Var
-	I-Var
mutations	I-Var
which	O
cause	O
loss	B-NegReg
of	I-NegReg
function	I-NegReg
of	O
the	O
gene	O
encoding	O
filaggrin	O
(	B-Gene
FLG	I-Gene
)	I-Gene
have	O
been	O
strongly	O
linked	B-Reg
to	O
the	O
development	O
of	O
atopic	O
disorders	O
,	O
predominantly	O
atopic	B-Disease
eczema	I-Disease
/	I-Disease
dermatitis	I-Disease
syndrome	I-Disease
(	O
AEDS	O
)	O
.	O

Filaggrin	O
plays	O
a	O
key	O
role	O
in	O
epidermal	O
barrier	O
function	O
by	O
upholding	O
epidermal	O
structure	O
and	O
moisturization	O
.	O

Up	O
to	O
now	O
,	O
around	O
40	O
variants	O
of	O
FLG	O
null	O
-	O
mutations	O
have	O
been	O
genotyped	O
among	O
different	O
world	O
populations	O
.	O

FLG	O
null	O
-	O
mutations	O
are	O
present	O
in	O
up	O
to	O
10	O
%	O
of	O
the	O
Caucasian	O
population	O
in	O
Western	O
Europe	O
and	O
North	O
America	O
,	O
with	O
R05X	O
and	O
2282del4	O
as	O
the	O
most	O
common	O
null	O
-	O
mutations	O
.	O

Epidemiological	O
studies	O
conducted	O
in	O
Europe	O
indicate	O
a	O
latitude	O
dependent	O
distribution	O
of	O
common	O
FLG	O
null	O
-	O
mutations	O
with	O
a	O
decreasing	O
north	O
-	O
south	O
gradient	O
of	O
R501X	O
and	O
2282del4	O
mutation	O
frequencies	O
.	O

FLG	B-Gene
null	B-Var
-	I-Var
mutation	I-Var
carriers	O
are	O
prone	O
to	O
develop	B-PosReg
unspecific	B-Disease
skin	I-Disease
symptoms	I-Disease
related	O
to	O
atopic	O
and	O
non	O
-	O
atopic	O
skin	O
disorders	O
due	O
to	O
their	O
defect	O
of	O
epidermal	O
barrier	O
function	O
,	O
which	O
allows	O
greater	O
skin	O
penetration	O
of	O
various	O
hazards	O
.	O

Epidemiological	O
studies	O
indicate	O
an	O
association	B-Interaction
of	O
FLG	B-Gene
null	B-Var
-	I-Var
mutations	I-Var
with	O
AEDS	B-Disease
,	O
whereas	O
results	O
regarding	O
an	O
association	O
of	O
FLG	O
null	O
-	O
mutations	O
with	O
sensitization	O
to	O
common	O
inhalant	O
allergens	O
and	O
development	O
of	O
rhinitis	O
and	O
asthma	O
are	O
incoherent	O
.	O

A	O
study	O
conducted	O
in	O
Croatia	O
found	O
a	O
low	O
frequency	O
of	O
FLG	O
null	O
-	O
mutations	O
in	O
general	O
population	O
(	O
2.6	O
%	O
)	O
and	O
did	O
not	O
confirm	O
FLG	O
null	O
-	O
mutations	O
as	O
an	O
etiological	O
factor	O
for	O
atopy	O
and	O
atopic	O
disease	O
in	O
the	O
studied	O
population	O
.	O

FGF	O
-	O
FGFR	O
Mediates	O
the	O
Activity	O
-	O
Dependent	O
Dendritogenesis	O
of	O
Layer	O
IV	O
Neurons	O
during	O
Barrel	O
Formation	O
.	O

Fibroblast	O
growth	O
factors	O
(	O
FGFs	O
)	O
and	O
FGF	O
receptors	O
(	O
FGFRs	O
)	O
are	O
known	O
for	O
their	O
potent	O
effects	O
on	O
cell	O
proliferation	O
/	O
differentiation	O
and	O
cortical	O
patterning	O
in	O
the	O
developing	O
brain	O
.	O

However	O
,	O
little	O
is	O
known	O
regarding	O
the	O
roles	O
of	O
FGFs	O
/	O
FGFRs	O
in	O
cortical	O
circuit	O
formation	O
.	O

Here	O
we	O
show	O
that	O
Fgfr1/2/3	O
and	O
Fgf7/9/10/22	O
mRNAs	O
are	O
expressed	O
in	O
the	O
developing	O
primary	O
somatosensory	O
(	O
S1	O
)	O
barrel	O
cortex	O
.	O

Barrel	O
cortex	O
layer	O
IV	O
spiny	O
stellate	O
cells	O
(	O
bSCs	O
)	O
are	O
the	O
primary	O
recipients	O
of	O
ascending	O
sensory	O
information	O
via	O
thalamocortical	O
axons	O
(	O
TCAs	O
)	O
.	O

Detail	O
quantification	O
revealed	O
distinctive	O
phases	O
for	O
bSC	O
dendritogenesis	O
:	O
orienting	O
dendrites	O
toward	O
TCAs	O
,	O
adding	O
de	O
novo	O
dendritic	O
segments	O
,	O
and	O
elongating	O
dendritic	O
length	O
,	O
while	O
maintaining	O
dendritic	O
patterns	O
.	O

Deleting	O
Fgfr1/2/3	O
in	O
bSCs	O
had	O
minimal	O
impact	O
on	O
dendritic	O
polarity	O
but	O
transiently	O
increased	O
the	O
number	O
of	O
dendritic	O
segments	O
.	O

However	O
,	O
6	O
d	O
later	O
,	O
FGFR1/2/3	O
loss	O
of	O
function	O
reduced	O
dendritic	O
branch	O
numbers	O
.	O

These	O
data	O
suggest	O
that	O
FGFs	O
/	O
FGFRs	O
have	O
a	O
role	O
in	O
stabilizing	O
dendritic	O
patterning	O
.	O

Depolarization	O
of	O
cultured	O
mouse	O
cortical	O
neurons	O
upregulated	O
the	O
levels	O
of	O
several	O
Fgf	O
/	O
Fgfr	O
mRNAs	O
within	O
2	O
h.	O
In	O
vivo	O
,	O
within	O
6	O
h	O
of	O
systemic	O
kainic	O
acid	O
administration	O
at	O
postnatal	O
day	O
6	O
,	O
mRNA	O
levels	O
of	O
Fgf9	O
,	O
Fgf10	O
,	O
Fgfr2c	O
,	O
and	O
Fgfr3b	O
in	O
S1	O
cortices	O
were	O
enhanced	O
,	O
and	O
this	O
was	O
accompanied	O
by	O
exuberant	O
dendritogenesis	O
of	O
bSCs	O
by	O
24	O
h.	O
Deleting	O
Fgfr1/2/3	O
abolished	O
kainic	O
acid	O
-	O
induced	O
bSC	O
dendritic	O
overgrowth	O
.	O

Finally	O
,	O
FGF9/10	O
gain	O
of	O
function	O
also	O
resulted	O
in	O
extensive	O
dendritogenesis	O
.	O

Together	O
,	O
our	O
data	O
suggest	O
that	O
FGFs	O
/	O
FGFRs	O
can	O
be	O
regulated	O
by	O
glutamate	O
transmission	O
to	O
modulate	O
/	O
stabilize	O
bSC	O
dendritic	O
complexity	O
.	O

Both	O
male	O
and	O
female	O
mice	O
were	O
used	O
for	O
our	O
study	O
.	O

SIGNIFICANCE	O
STATEMENT	O
Glutamatergic	O
transmission	O
plays	O
critical	O
roles	O
in	O
cortical	O
circuit	O
formation	O
.	O

Its	O
dysregulation	O
has	O
been	O
proposed	O
as	O
a	O
core	O
factor	O
in	O
the	O
etiology	O
of	O
many	O
neurological	O
diseases	O
.	O

We	O
found	O
that	O
excessive	O
glutamate	O
transmission	O
upregulated	O
mRNA	O
expression	O
of	O
Fgfrs	O
and	O
their	O
ligands	O
Fgfs	O
Deleting	B-Var
Fgfr1/2/3	B-Gene
not	O
only	O
impaired	B-NegReg
bSC	B-MPA
dendritogenesis	I-MPA
but	O
also	O
abolished	B-NegReg
glutamate	B-MPA
transmission	I-MPA
-	I-MPA
induced	I-MPA
dendritic	I-MPA
overgrowth	I-MPA
.	O

Overexpressing	O
FGF9	O
or	O
FGF10	O
in	O
cortical	O
glutamatergic	O
neurons	O
results	O
in	O
excessive	O
dendritic	O
outgrowth	O
within	O
24	O
h	O
,	O
resembling	O
the	O
changes	O
induced	O
by	O
excessive	O
glutamate	O
transmission	O
.	O

Our	O
findings	O
provide	O
strong	O
evidence	O
for	O
the	O
physiological	O
role	O
of	O
fibroblast	O
growth	O
factors	O
(	O
FGFs	O
)	O
and	O
FGF	O
receptors	O
(	O
FGFRs	O
)	O
in	O
establishing	O
and	O
maintaining	O
cortical	O
circuits	O
.	O

Perturbing	O
the	O
expression	O
levels	O
of	O
FGFs	O
/	O
FGFRs	O
by	O
excessive	O
glutamatergic	O
neurotransmission	O
could	O
lead	O
to	O
abnormal	O
neuronal	O
circuits	O
,	O
which	O
may	O
contribute	O
to	O
neurological	O
and	O
psychiatric	O
disease	O
.	O

Why	O
are	O
there	O
hotspot	O
mutations	O
in	O
the	O
TP53	O
gene	O
in	O
human	O
cancers	O
?	O
The	O
p53	O
gene	O
contains	O
homozygous	O
mutations	O
in	O
~50	O
-	O
60	O
%	O
of	O
human	O
cancers	O
.	O

About	O
90	O
%	O
of	O
these	O
mutations	O
encode	O
missense	O
mutant	O
proteins	O
that	O
span	O
~190	O
different	O
codons	O
localized	O
in	O
the	O
DNA	O
-	O
binding	O
domain	O
of	O
the	O
gene	O
and	O
protein	O
.	O

These	O
mutations	B-Var
produce	O
a	O
protein	O
with	O
a	O
reduced	O
capacity	O
to	O
bind	O
to	O
a	O
specific	O
DNA	O
sequence	O
that	O
regulates	B-Reg
the	O
p53	B-Pathway
transcriptional	I-Pathway
pathway	I-Pathway
.	O

Eight	O
of	O
these	O
mutations	O
are	O
localized	O
in	O
codons	O
that	O
account	O
for	O
~28	O
%	O
of	O
the	O
total	O
p53	O
mutations	O
and	O
these	O
alleles	O
appear	O
to	O
be	O
selected	O
for	O
preferentially	O
in	O
human	O
cancers	O
of	O
many	O
tissue	O
types	O
.	O

This	O
article	O
explores	O
the	O
question	O
'	O
Why	O
are	O
there	O
hotspot	O
mutations	O
in	O
the	O
p53	O
gene	O
in	O
human	O
cancers	O
?	O
'	O
Four	O
possible	O
reasons	O
for	O
this	O
are	O
considered	O
;	O
(	O
1	O
)	O
the	O
hotspot	O
mutant	B-Var
alleles	O
produce	O
a	O
protein	O
that	O
has	O
a	O
highly	O
altered	B-Reg
structure	B-MPA
,	O
(	O
2	O
)	O
environmental	O
mutagens	O
produce	O
allele	O
-	O
specific	O
changes	O
in	O
the	O
p53	O
gene	O
,	O
(	O
3	O
)	O
these	O
mutations	O
arise	O
at	O
selected	O
sites	O
in	O
the	O
gene	O
due	O
to	O
a	O
specific	O
DNA	O
sequence	O
,	O
such	O
as	O
a	O
methylated	O
cytosine	O
residue	O
in	O
a	O
CpG	O
dinucleotide	O
,	O
which	O
has	O
a	O
higher	O
mutation	O
rate	O
changing	O
C	O
to	O
T	O
nucleotides	O
,	O
(	O
4	O
)	O
along	O
with	O
the	O
observed	O
change	O
in	O
mutant	O
p53	O
proteins	O
,	O
which	O
produce	O
a	O
loss	O
of	O
function	O
(	O
DNA	O
binding	O
and	O
transcription	O
)	O
,	O
some	O
mutant	B-Var
proteins	B-Protein
have	O
an	O
allele	O
-	O
specific	O
gain	B-PosReg
of	I-PosReg
function	I-PosReg
that	O
promotes	O
cancer	B-Disease
.	O

Evidence	O
is	O
presented	O
that	O
demonstrates	O
the	O
first	O
three	O
possibilities	O
all	O
contribute	O
some	O
property	O
to	O
this	O
list	O
of	O
hotspot	O
mutations	O
.	O

The	O
fourth	O
possibility	O
remains	O
to	O
be	O
tested	O
.	O

Mutant	O
p53	O
partners	O
in	O
crime	O
.	O

Mutant	B-Var
p53	B-Gene
proteins	B-Protein
impart	O
changes	B-Reg
in	O
cellular	B-MPA
behavior	I-MPA
and	O
function	B-MPA
through	O
interactions	B-Interaction
with	O
proteins	B-Protein
that	O
alter	O
gene	O
expression	O
.	O

The	O
milieu	O
of	O
intracellular	O
proteins	O
available	O
to	O
interact	O
with	O
mutant	O
p53	O
is	O
context	O
specific	O
and	O
changes	O
with	O
disease	O
,	O
cell	O
type	O
,	O
and	O
environmental	O
conditions	O
.	O

Varying	O
conformations	O
of	O
mutant	B-Var
p53	B-Gene
largely	O
dictate	B-Reg
protein	B-MPA
-	I-MPA
protein	I-MPA
interactions	I-MPA
as	O
different	O
point	O
mutations	O
within	O
protein	O
-	O
coding	O
regions	O
greatly	O
alter	O
the	O
extent	O
and	O
array	O
of	O
gain	O
-	O
of	O
-	O
function	O
(	O
GOF	O
)	O
activities	O
.	O

Given	O
such	O
variables	O
,	O
how	O
can	O
knowledge	O
regarding	O
p53	O
missense	O
mutations	O
be	O
translated	O
into	O
predicting	O
or	O
altering	O
biologic	O
activity	O
for	O
therapy	O
?	O
How	O
may	O
knowledge	O
regarding	O
mutant	O
p53	O
functions	O
within	O
certain	O
disease	O
contexts	O
be	O
harnessed	O
to	O
blunt	O
or	O
ablate	O
mutant	O
p53	O
GOF	O
for	O
therapy	O
?	O
In	O
this	O
article	O
,	O
we	O
review	O
known	O
proteins	O
that	O
interact	O
with	O
mutant	B-Var
p53	B-Gene
and	O
result	O
in	O
the	O
activation	B-PosReg
of	O
genes	B-Gene
that	O
contribute	O
to	O
p53	O
GOF	O
with	O
particular	O
emphasis	O
on	O
context	O
dependency	O
and	O
an	O
evolving	O
appreciation	O
of	O
GOF	O
mechanisms	O
.	O

Exceptional	O
Response	O
to	O
Temsirolimus	O
in	O
a	O
Metastatic	O
Clear	O
Cell	O
Renal	O
Cell	O
Carcinoma	O
With	O
an	O
Early	O
Novel	O
MTOR	O
-	O
Activating	O
Mutation	O
.	O

mTOR	O
pathway	O
inhibitors	O
are	O
important	O
drugs	O
for	O
the	O
treatment	O
of	O
advanced	O
renal	O
cell	O
carcinoma	O
(	O
RCC	O
)	O
.	O

However	O
,	O
no	O
valid	O
predictive	O
markers	O
have	O
been	O
identified	O
to	O
guide	O
treatment	O
selection	O
and	O
identify	O
patients	O
who	O
are	O
sensitive	O
to	O
these	O
drugs	O
.	O

Mutations	O
activating	O
the	O
mTOR	O
pathway	O
have	O
been	O
suggested	O
to	O
predict	O
response	O
;	O
however	O
,	O
their	O
predictive	O
value	O
is	O
still	O
unclear	O
.	O

Here	O
,	O
we	O
present	O
the	O
genomic	O
and	O
functional	O
characterization	O
of	O
a	O
patient	O
with	O
metastatic	O
clear	O
cell	O
RCC	O
(	O
ccRCC	O
)	O
who	O
experienced	O
a	O
partial	O
response	O
to	O
temsirolimus	O
after	O
a	O
poor	O
response	O
to	O
2	O
previous	O
lines	O
of	O
treatment	O
.	O

At	O
the	O
time	O
of	O
publication	O
,	O
the	O
patient	O
was	O
disease	O
-	O
free	O
8	O
years	O
after	O
temsirolimus	O
treatment	O
.	O

Multiregion	O
whole	O
-	O
exome	O
sequencing	O
(	O
WES	O
)	O
on	O
3	O
regions	O
of	O
the	O
primary	O
tumor	O
,	O
1	O
metastasis	O
,	O
and	O
blood	O
revealed	O
tumor	O
mutations	O
in	O
driver	O
genes	O
in	O
ccRCC	O
:	O
a	O
missense	O
mutation	O
in	O
VHL	O
(	O
p	O
.	O
W88L	O
)	O
,	O
a	O
loss	O
-	O
of	O
-	O
function	O
mutation	O
in	O
BAP1	O
(	O
p	O
.	O
E454Rfs*15	O
)	O
,	O
and	O
a	O
novel	O
missense	O
mutation	O
in	O
MTOR	O
(	O
p	O
.	O
Y1974H	O
)	O
.	O

The	O
MTOR	O
mutation	O
was	O
present	O
in	O
all	O
tumor	O
regions	O
,	O
with	O
similar	O
allele	O
frequency	O
as	O
the	O
VHL	O
mutation	O
,	O
and	O
in	O
vitro	O
functional	O
assessment	O
of	O
the	O
MTOR	B-Gene
variant	B-Var
demonstrated	O
that	O
it	O
increased	B-PosReg
mTORC1	B-MPA
activity	I-MPA
.	O

Consistently	O
,	O
immunohistochemistry	O
in	O
the	O
tumor	O
samples	O
demonstrated	O
increased	O
levels	O
of	O
phospho	O
-	O
S6	O
.	O

In	O
conclusion	O
,	O
multiregion	O
WES	O
identified	O
a	O
novel	O
MTOR	B-Gene
mutation	B-Var
acquired	O
early	O
during	O
tumor	O
development	O
as	O
the	O
event	O
leading	B-Reg
to	I-Reg
a	O
high	B-MPA
sensitivity	I-MPA
to	I-MPA
temsirolimus	I-MPA
treatment	I-MPA
.	O

This	O
study	O
supports	O
tumor	O
multiregion	O
sequencing	O
to	O
detect	O
truncal	O
mutations	O
in	O
the	O
mTOR	O
pathway	O
to	O
identify	O
patients	O
sensitive	O
to	O
mTOR	O
inhibitors	O
.	O

Loss	O
of	O
function	O
JAK1	O
mutations	O
occur	O
at	O
high	O
frequency	O
in	O
cancers	O
with	O
microsatellite	O
instability	O
and	O
are	O
suggestive	O
of	O
immune	O
evasion	O
.	O

Immune	O
evasion	O
is	O
a	O
well	O
-	O
recognized	O
hallmark	O
of	O
cancer	O
and	O
recent	O
studies	O
with	O
immunotherapy	O
agents	O
have	O
suggested	O
that	O
tumors	O
with	O
increased	O
numbers	O
of	O
neoantigens	O
elicit	O
greater	O
immune	O
responses	O
.	O

We	O
hypothesized	O
that	O
the	O
immune	O
system	O
presents	O
a	O
common	O
selective	O
pressure	O
on	O
high	O
mutation	O
burden	O
tumors	O
and	O
therefore	O
immune	O
evasion	O
mutations	O
would	O
be	O
enriched	O
in	O
high	O
mutation	O
burden	O
tumors	O
.	O

The	O
JAK	O
family	O
of	O
kinases	O
is	O
required	O
for	O
the	O
signaling	O
of	O
a	O
host	O
of	O
immune	O
modulators	O
in	O
tumor	O
,	O
stromal	O
,	O
and	O
immune	O
cells	O
.	O

Therefore	O
,	O
we	O
analyzed	O
alterations	O
in	O
this	O
family	O
for	O
the	O
hypothesized	O
signature	O
of	O
an	O
immune	O
evasion	O
mutation	O
.	O

Here	O
,	O
we	O
searched	O
a	O
database	O
of	O
61,704	O
unique	O
solid	O
tumors	O
for	O
alterations	O
in	O
the	O
JAK	O
family	O
kinases	O
(	O
JAK1/2/3	O
,	O
TYK2	O
)	O
.	O

We	O
used	O
The	O
Cancer	O
Genome	O
Atlas	O
and	O
Cancer	O
Cell	O
Line	O
Encyclopedia	O
data	O
to	O
confirm	O
and	O
extend	O
our	O
findings	O
by	O
analyzing	O
gene	O
expression	O
patterns	O
.	O

Recurrent	O
frameshift	B-Var
mutations	I-Var
in	O
JAK1	B-Gene
were	O
associated	B-Reg
with	O
high	B-MPA
mutation	I-MPA
burden	I-MPA
and	O
microsatellite	B-MPA
instability	I-MPA
.	O

These	O
mutations	B-Var
occurred	B-Reg
in	O
multiple	O
tumor	O
types	O
including	O
endometrial	B-Disease
,	O
colorectal	B-Disease
,	O
stomach	B-Disease
,	O
and	O
prostate	B-Disease
carcinomas	B-Disease
.	O

Analyzing	O
gene	O
expression	O
signatures	O
in	O
endometrial	O
and	O
stomach	O
adenocarcinomas	O
revealed	O
that	O
tumors	O
with	O
a	O
JAK1	O
frameshift	O
exhibited	O
reduced	O
expression	O
of	O
interferon	O
response	O
signatures	O
and	O
multiple	O
anti	O
-	O
tumor	O
immune	O
signatures	O
.	O

Importantly	O
,	O
endometrial	O
cancer	O
cell	O
lines	O
exhibited	O
similar	O
gene	O
expression	O
changes	O
that	O
were	O
expected	O
to	O
be	O
tumor	O
cell	O
intrinsic	O
(	O
e.g.	O
interferon	O
response	O
)	O
but	O
not	O
those	O
expected	O
to	O
be	O
tumor	O
cell	O
extrinsic	O
(	O
e.g.	O
NK	O
cells	O
)	O
.	O

From	O
these	O
data	O
,	O
we	O
derive	O
two	O
primary	O
conclusions	O
:	O
1	O
)	O
JAK1	O
frameshifts	O
are	O
loss	O
of	O
function	O
alterations	O
that	O
represent	O
a	O
potential	O
pan	O
-	O
cancer	O
adaptation	O
to	O
immune	O
responses	O
against	O
tumors	O
with	O
microsatellite	O
instability	O
;	O
2	O
)	O
The	O
mechanism	O
by	O
which	O
JAK1	B-Var
loss	B-NegReg
of	I-NegReg
function	I-NegReg
contributes	O
to	O
tumor	B-MPA
immune	I-MPA
evasion	I-MPA
is	O
likely	O
associated	O
with	O
loss	O
of	O
the	O
JAK1-mediated	O
interferon	O
response	O
.	O

Gain	B-PosReg
of	I-PosReg
function	I-PosReg
of	O
TMEM16E	B-Gene
/	I-Gene
ANO5	I-Gene
scrambling	B-MPA
activity	I-MPA
caused	O
by	O
a	O
mutation	B-Var
associated	O
with	O
gnathodiaphyseal	B-Disease
dysplasia	I-Disease
.	O

Mutations	B-Var
in	O
the	O
human	O
TMEM16E	B-Gene
(	O
ANO5	O
)	O
gene	O
are	O
associated	B-Reg
both	O
with	O
the	O
bone	B-Disease
disease	I-Disease
gnathodiaphyseal	B-Disease
dysplasia	I-Disease
(	O
GDD	O
;	O
OMIM	O
:	O
166260	O
)	O
and	O
muscle	B-Disease
dystrophies	I-Disease
(	O
OMIM	O
:	O
611307	O
,	O
613319	O
)	O
.	O

However	O
,	O
the	O
physiological	O
function	O
of	O
TMEM16E	O
has	O
remained	O
unclear	O
.	O

We	O
show	O
here	O
that	O
human	O
TMEM16E	O
,	O
when	O
overexpressed	O
in	O
mammalian	O
cell	O
lines	O
,	O
displayed	O
partial	O
plasma	O
membrane	O
localization	O
and	O
gave	O
rise	O
to	O
phospholipid	O
scrambling	O
(	O
PLS	O
)	O
as	O
well	O
as	O
non	O
-	O
selective	O
ionic	O
currents	O
with	O
slow	O
time	O
-	O
dependent	O
activation	O
at	O
highly	O
depolarized	O
membrane	O
potentials	O
.	O

While	O
the	O
activity	O
of	O
wild	O
-	O
type	O
TMEM16E	O
depended	O
on	O
elevated	O
cytosolic	O
Ca2	O
+	O
levels	O
,	O
a	O
mutant	O
form	O
carrying	O
the	O
GDD	O
-	O
causing	O
T513I	O
substitution	O
showed	O
PLS	O
and	O
large	O
time	O
-	O
dependent	O
ion	O
currents	O
even	O
at	O
low	O
cytosolic	O
Ca2	O
+	O
concentrations	O
.	O

Contrarily	O
,	O
mutation	O
of	O
the	O
homologous	O
position	O
in	O
the	O
Ca2	O
+	O
-activated	O
Cl-	O
channel	O
TMEM16B	O
paralog	O
hardly	O
affected	O
its	O
function	O
.	O

In	O
summary	O
,	O
these	O
data	O
provide	O
the	O
first	O
direct	O
demonstration	O
of	O
Ca2	O
+	O
-dependent	O
PLS	O
activity	O
for	O
TMEM16E	O
and	O
suggest	O
a	O
gain	O
-	O
of	O
-	O
function	O
phenotype	O
related	O
to	O
a	O
GDD	O
mutation	O
.	O

Multiple	O
Legionella	O
pneumophila	O
effector	O
virulence	O
phenotypes	O
revealed	O
through	O
high	O
-	O
throughput	O
analysis	O
of	O
targeted	O
mutant	O
libraries	O
.	O

Legionella	O
pneumophila	O
is	O
the	O
causative	O
agent	O
of	O
a	O
severe	O
pneumonia	O
called	O
Legionnaires	O
'	O
disease	O
.	O

A	O
single	O
strain	O
of	O
L.	O
pneumophila	O
encodes	O
a	O
repertoire	O
of	O
over	O
300	O
different	O
effector	O
proteins	O
that	O
are	O
delivered	O
into	O
host	O
cells	O
by	O
the	O
Dot	O
/	O
Icm	O
type	O
IV	O
secretion	O
system	O
during	O
infection	O
.	O

The	O
large	O
number	O
of	O
L.	O
pneumophila	O
effectors	O
has	O
been	O
a	O
limiting	O
factor	O
in	O
assessing	O
the	O
importance	O
of	O
individual	O
effectors	O
for	O
virulence	O
.	O

Here	O
,	O
a	O
transposon	O
insertion	O
sequencing	O
technology	O
called	O
INSeq	O
was	O
used	O
to	O
analyze	O
replication	O
of	O
a	O
pool	O
of	O
effector	O
mutants	O
in	O
parallel	O
both	O
in	O
a	O
mouse	O
model	O
of	O
infection	O
and	O
in	O
cultured	O
host	O
cells	O
.	O

Loss	B-NegReg
-	I-NegReg
of	I-NegReg
-	I-NegReg
function	I-NegReg
mutations	B-Var
in	O
genes	O
encoding	O
effector	O
proteins	O
resulted	O
in	O
host	B-MPA
-	I-MPA
specific	I-MPA
or	O
broad	B-MPA
virulence	I-MPA
phenotypes	I-MPA
.	O

Screen	O
results	O
were	O
validated	O
for	O
several	O
effector	O
mutants	O
displaying	O
different	O
virulence	O
phenotypes	O
using	O
genetic	O
complementation	O
studies	O
and	O
infection	O
assays	O
.	O

Specifically	O
,	O
loss	B-NegReg
-	I-NegReg
of	I-NegReg
-	I-NegReg
function	I-NegReg
mutations	B-Var
in	O
the	O
gene	O
encoding	O
LegC4	B-Gene
resulted	O
in	O
enhanced	B-PosReg
L.	B-CPA
pneumophila	I-CPA
in	O
the	O
lungs	O
of	O
infected	O
mice	O
but	O
not	O
within	O
cultured	O
host	O
cells	O
,	O
which	O
indicates	O
LegC4	B-Var
augments	B-PosReg
bacterial	B-CPA
clearance	I-CPA
by	O
the	O
host	O
immune	O
system	O
.	O

The	O
effector	O
proteins	O
RavY	O
and	O
Lpg2505	O
were	O
important	O
for	O
efficient	O
replication	O
within	O
both	O
mammalian	O
and	O
protozoan	O
hosts	O
.	O

Further	O
analysis	O
of	O
Lpg2505	O
revealed	O
that	O
this	O
protein	O
functions	O
as	O
a	O
metaeffector	O
that	O
counteracts	O
host	O
cytotoxicity	O
displayed	O
by	O
the	O
effector	O
protein	O
SidI.	O
Thus	O
,	O
this	O
study	O
identified	O
a	O
large	O
cohort	O
of	O
effectors	O
that	O
contribute	O
to	O
L.	O
pneumophila	O
virulence	O
positively	O
or	O
negatively	O
and	O
has	O
demonstrated	O
regulation	O
of	O
effector	O
protein	O
activities	O
by	O
cognate	O
metaeffectors	O
as	O
being	O
critical	O
for	O
host	O
pathogenesis	O
.	O

A	O
Partial	O
Loss	B-NegReg
-	I-NegReg
of	I-NegReg
-	I-NegReg
Function	I-NegReg
Variant	B-Var
in	O
AKT2	B-Gene
Is	O
Associated	O
With	O
Reduced	B-NegReg
Insulin	B-CPA
-	I-CPA
Mediated	I-CPA
Glucose	I-CPA
Uptake	I-CPA
in	O
Multiple	O
Insulin	O
-	O
Sensitive	O
Tissues	O
:	O
A	O
Genotype	O
-	O
Based	O
Callback	O
Positron	O
Emission	O
Tomography	O
Study	O
.	O

Rare	O
fully	O
penetrant	O
mutations	O
in	O
AKT2	O
are	O
an	O
established	O
cause	O
of	O
monogenic	O
disorders	O
of	O
glucose	O
metabolism	O
.	O

Recently	O
,	O
a	O
novel	O
partial	O
loss	O
-	O
of	O
-	O
function	O
AKT2	O
coding	O
variant	O
(	O
p	O
.	O
Pro50Thr	O
)	O
was	O
identified	O
that	O
is	O
nearly	O
specific	O
to	O
Finns	O
(	O
frequency	O
1.1	O
%	O
)	O
,	O
with	O
the	O
low	O
-	O
frequency	O
allele	O
associated	O
with	O
an	O
increase	O
in	O
fasting	O
plasma	O
insulin	O
level	O
and	O
risk	O
of	O
type	O
2	O
diabetes	O
.	O

The	O
effects	O
of	O
the	O
p	O
.	O
Pro50Thr	O
AKT2	O
variant	O
(	O
p	O
.	O
P50T	O
/	O
AKT2	O
)	O
on	O
insulin	O
-	O
stimulated	O
glucose	O
uptake	O
(	O
GU	O
)	O
in	O
the	O
whole	O
body	O
and	O
in	O
different	O
tissues	O
have	O
not	O
previously	O
been	O
investigated	O
.	O

We	O
identified	O
carriers	O
(	O
N	O
=	O
20	O
)	O
and	O
matched	O
noncarriers	O
(	O
N	O
=	O
25	O
)	O
for	O
this	O
allele	O
in	O
the	O
population	O
-	O
based	O
Metabolic	O
Syndrome	O
in	O
Men	O
(	O
METSIM)study	O
and	O
invited	O
these	O
individuals	O
back	O
for	O
positron	O
emission	O
tomography	O
study	O
with	O
[	O
18F]-fluorodeoxyglucose	O
during	O
euglycemic	O
hyperinsulinemia	O
.	O

When	O
we	O
compared	O
p	O
.	O
P50T	O
/	O
AKT2	O
carriers	O
to	O
noncarriers	O
,	O
we	O
found	O
a	O
39.4	O
%	O
reduction	O
in	O
whole	O
-	O
body	O
GU	O
(	O
P	O
=	O
0.006	O
)	O
and	O
a	O
55.6	O
%	O
increase	O
in	O
the	O
rate	O
of	O
endogenous	O
glucose	O
production	O
(	O
P	O
=	O
0.038	O
)	O
.	O

We	O
found	O
significant	O
reductions	O
in	O
GU	O
in	O
multiple	O
tissues	O
-	O
skeletal	O
muscle	O
(	O
36.4	O
%	O
)	O
,	O
liver	O
(	O
16.1	O
%	O
)	O
,	O
brown	O
adipose	O
(	O
29.7	O
%	O
)	O
,	O
and	O
bone	O
marrow	O
(	O
32.9%)-and	O
increases	O
of	O
16.8	O
-	O
19.1	O
%	O
in	O
seven	O
tested	O
brain	O
regions	O
.	O

These	O
data	O
demonstrate	O
that	O
the	O
p	B-Var
.	I-Var
P50	I-Var
T	I-Var
substitution	O
of	O
AKT2	B-Gene
influences	B-Reg
insulin	B-MPA
-	I-MPA
mediated	I-MPA
GU	I-MPA
in	O
multiple	O
insulin	O
-	O
sensitive	O
tissues	O
and	O
may	O
explain	O
,	O
at	O
least	O
in	O
part	O
,	O
the	O
increased	O
risk	O
of	O
type	O
2	O
diabetes	O
in	O
p	O
.	O
P50T	O
/	O
AKT2	O
carriers	O
.	O

Common	O
and	O
rare	O
TBK1	B-Gene
variants	B-Var
in	B-Reg
early	B-Disease
-	I-Disease
onset	I-Disease
Alzheimer	I-Disease
disease	I-Disease
in	O
a	O
European	O
cohort	O
.	O

TANK	O
-	O
binding	O
kinase	O
1	O
(	B-Gene
TBK1	I-Gene
)	I-Gene
loss	B-NegReg
-	I-NegReg
of	I-NegReg
-	I-NegReg
function	I-NegReg
(	O
LoF	O
)	O
mutations	B-Var
are	O
known	O
to	O
cause	O
frontotemporal	B-Disease
dementia	I-Disease
(	O
FTD	O
)	O
and	O
amyotrophic	B-Disease
lateral	I-Disease
sclerosis	I-Disease
(	O
ALS	O
)	O
,	O
often	O
combined	O
with	O
memory	O
deficits	O
early	O
in	O
the	O
disease	O
course	O
.	O

We	O
performed	O
targeted	O
resequencing	O
of	O
TBK1	O
in	O
1253	O
early	O
onset	O
Alzheimer	O
's	O
disease	O
(	O
EOAD	O
)	O
patients	O
from	O
8	O
European	O
countries	O
to	O
investigate	O
whether	O
pathogenic	O
TBK1	O
mutations	O
are	O
enriched	O
among	O
patients	O
with	O
clinical	O
diagnosis	O
of	O
EOAD	O
.	O

Variant	O
frequencies	O
were	O
compared	O
against	O
2117	O
origin	O
-	O
matched	O
controls	O
.	O

We	O
identified	O
only	O
1	O
LoF	O
mutation	O
(	O
p	O
.	O
Thr79del	O
)	O
in	O
a	O
patient	O
clinically	O
diagnosed	O
with	O
Alzheimer	O
's	O
disease	O
and	O
a	O
positive	O
family	O
history	O
of	O
ALS	O
.	O

We	O
did	O
not	O
observe	O
enrichment	O
of	O
rare	O
variants	O
in	O
EOAD	O
patients	O
compared	O
to	O
controls	O
,	O
nor	O
of	O
rare	O
variants	O
affecting	O
NFκB	O
induction	O
.	O

Of	O
3	O
common	O
coding	O
variants	O
,	O
rs7486100	O
showed	O
evidence	O
of	O
association	O
(	O
OR	O
1.46	O
[	O
95	O
%	O
CI	O
1.13	O
-	O
1.9	O
]	O
;	O
p	O
-	O
value	O
0.01	O
)	O
.	O

Homozygous	O
carriers	O
of	O
the	O
risk	O
allele	O
showed	O
reduced	O
expression	O
of	O
TBK1	O
(	O
p	O
-	O
value	O
0.03	O
)	O
.	O

Our	O
findings	O
are	O
not	O
indicative	O
of	O
a	O
significant	O
role	O
for	O
TBK1	O
mutations	O
in	O
EOAD	O
.	O

The	O
association	O
between	O
common	O
variants	O
in	O
TBK1	O
,	O
disease	O
risk	O
and	O
reduced	O
TBK1	O
expression	O
warrants	O
follow	O
-	O
up	O
in	O
FTD	O
/	O
ALS	O
cohorts	O
.	O

Polymorphisms	O
in	O
inflammasome	O
genes	O
and	O
risk	O
of	O
asthma	O
in	O
Brazilian	O
children	O
.	O

Considering	O
its	O
role	O
in	O
inflammation	O
and	O
recently	O
described	O
"	O
alternative	O
"	O
roles	O
in	O
epithelial	O
homeostasis	O
and	O
Th1	O
/	O
Th2	O
balance	O
,	O
we	O
hypothesize	O
that	O
inflammasome	O
genetics	O
could	O
contribute	O
to	O
the	O
development	O
of	O
asthma	O
.	O

Selected	O
functional	O
polymorphisms	O
in	O
inflammasome	O
genes	O
are	O
evaluated	O
in	O
a	O
cohort	O
of	O
asthmatic	O
children	O
and	O
their	O
families	O
.	O

Gain	B-PosReg
-	I-PosReg
of	I-PosReg
-	I-PosReg
function	I-PosReg
NLRP1	B-Gene
variants	B-Var
rs11651270	B-Var
,	O
rs12150220	B-Var
and	O
rs2670660	B-Var
resulted	O
significantly	O
associated	O
to	O
asthma	B-Disease
in	O
trios	O
(	O
TDT	O
)	O
analysis	O
;	O
and	O
rs11651270	B-Var
and	O
rs2670660	B-Var
also	O
with	B-Reg
asthma	B-Disease
severity	O
and	O
total	O
IgE	B-MPA
level	I-MPA
in	O
asthmatic	O
children	O
.	O

NLRP1	O
activators	O
in	O
humans	O
are	O
still	O
unknown	O
,	O
however	O
we	O
hypothesized	O
that	O
individuals	O
with	O
gain	B-PosReg
-	I-PosReg
of	I-PosReg
-	I-PosReg
function	I-PosReg
SNPs	B-Var
in	O
NLRP1	B-Gene
could	O
be	O
more	O
prone	B-PosReg
in	O
activating	B-MPA
inflammasome	I-MPA
in	O
the	O
presence	O
of	O
asthma	O
-	O
related	O
cell	O
stressors	O
(	O
i.e.	O
ER	O
stress	O
or	O
ROS	O
)	O
,	O
and	O
this	O
activation	O
contribute	O
to	O
exacerbate	B-PosReg
inflammatory	B-CPA
response	I-CPA
and	O
asthma	B-CPA
development	I-CPA
.	O

Gain	O
-	O
of	O
-	O
function	O
IL1A	B-Gene
rs17561	B-Var
resulted	O
significantly	O
associated	O
with	O
a	O
reduced	B-NegReg
pulmonary	B-CPA
capacity	I-CPA
in	O
asthmatic	O
children	O
.	O

IL18	B-Gene
rs5744256	B-Var
which	O
lead	O
to	O
lower	B-NegReg
serum	B-MPA
level	I-MPA
of	I-MPA
IL-18	I-MPA
appeared	O
to	O
be	O
associated	O
to	O
a	O
worse	O
response	O
to	O
bronchodilators	O
.	O

Concluding	O
,	O
this	O
work	O
provides	O
evidences	O
about	O
the	O
contribution	O
of	O
inflammasome	O
genetics	O
in	O
the	O
development	O
of	O
paediatric	O
asthma	O
,	O
both	O
considering	O
its	O
inflammatory	O
role	O
in	O
alveolar	O
macrophages	O
(	O
i.e.	O
:	O
NLRP1	O
)	O
or	O
its	O
homeostatic	O
role	O
in	O
lung	O
epithelial	O
cells	O
(	O
i.e.	O
:	O
IL1A	O
,	O
IL18	O
)	O
.	O

MED13L	B-Gene
loss	B-NegReg
-	I-NegReg
of	I-NegReg
-	I-NegReg
function	I-NegReg
variants	B-Var
in	O
two	O
patients	O
with	O
syndromic	O
Pierre	B-Disease
Robin	I-Disease
sequence	I-Disease
.	O

We	O
report	O
two	O
unrelated	O
patients	O
with	O
Pierre	O
Robin	O
sequence	O
(	O
PRS	O
)	O
and	O
a	O
strikingly	O
similar	O
combination	O
of	O
associated	O
features	O
.	O

Whole	O
exome	O
sequencing	O
was	O
performed	O
for	O
both	O
patients	O
.	O

No	O
single	O
gene	O
containing	O
likely	O
pathogenic	O
point	O
mutations	O
in	O
both	O
patients	O
could	O
be	O
identified	O
,	O
but	O
the	O
finding	O
of	O
an	O
essential	O
splice	O
site	O
mutation	O
in	O
mediator	O
complex	O
subunit	O
13	O
like	O
(	O
MED13L	O
)	O
in	O
one	O
patient	O
prompted	O
the	O
investigation	O
of	O
copy	O
number	O
variants	O
in	O
MED13L	O
in	O
the	O
other	O
,	O
leading	O
to	O
the	O
identification	O
of	O
an	O
intragenic	O
deletion	O
.	O

Disruption	B-Var
of	O
MED13L	B-Gene
,	O
encoding	O
a	O
component	O
of	O
the	O
Mediator	O
complex	O
,	O
is	O
increasingly	O
recognized	O
as	O
the	O
cause	B-Reg
of	O
an	O
intellectual	B-Disease
disability	I-Disease
syndrome	I-Disease
with	O
associated	O
facial	B-Disease
dysmorphism	I-Disease
.	O

Our	O
findings	O
suggest	O
that	O
MED13L	O
-	O
related	O
disorders	O
are	O
a	O
possible	O
differential	O
diagnosis	O
for	O
syndromic	O
PRS	O
.	O

Loss	B-Var
-	I-Var
of	I-Var
-	I-Var
activity	I-Var
-	I-Var
mutation	I-Var
in	O
the	O
cardiac	B-MPA
chloride	I-MPA
-	I-MPA
bicarbonate	I-MPA
exchanger	I-MPA
AE3	I-MPA
causes	O
short	B-Disease
QT	I-Disease
syndrome	I-Disease
.	O

Patients	O
with	O
short	O
QT	O
syndrome	O
(	O
SQTS	O
)	O
may	O
present	O
with	O
syncope	O
,	O
ventricular	O
fibrillation	O
or	O
sudden	O
cardiac	O
death	O
.	O

Six	O
SQTS	O
susceptibility	O
genes	O
,	O
encoding	O
cation	O
channels	O
,	O
explain	O
<	O
25	O
%	O
of	O
SQTS	O
cases	O
.	O

Here	O
we	O
identify	O
a	O
missense	B-Var
mutation	I-Var
in	O
the	O
anion	O
exchanger	O
(	O
AE3)-encoding	O
SLC4A3	B-Gene
gene	O
in	O
two	O
unrelated	O
families	O
with	O
SQTS	O
.	O

The	O
mutation	O
causes	O
reduced	B-NegReg
surface	B-MPA
expression	I-MPA
of	I-MPA
AE3	I-MPA
and	O
reduced	B-NegReg
membrane	B-MPA
bicarbonate	I-MPA
transport	I-MPA
.	O

Slc4a3	O
knockdown	O
in	O
zebrafish	O
causes	O
increased	O
cardiac	O
pHi	O
,	O
short	O
QTc	O
,	O
and	O
reduced	O
systolic	O
duration	O
,	O
which	O
is	O
rescued	O
by	O
wildtype	O
but	O
not	O
mutated	O
SLC4A3	O
.	O

Mechanistic	O
analyses	O
suggest	O
that	O
an	O
increase	O
in	O
pHi	O
and	O
decrease	O
in	O
[	O
Cl-]i	O
shortened	O
the	O
action	O
potential	O
duration	O
.	O

However	O
,	O
other	O
mechanisms	O
may	O
also	O
play	O
a	O
role	O
.	O

Altered	O
anion	O
transport	O
represents	O
a	O
mechanism	O
for	O
development	O
of	O
arrhythmia	O
and	O
may	O
provide	O
new	O
therapeutic	O
possibilities	O
.	O

In	O
Silico	O
Approach	O
to	O
Investigate	O
the	O
Structural	O
and	O
Functional	O
Attributes	O
of	O
Familial	O
Hypercholesterolemia	O
Variants	O
Reported	O
in	O
the	O
Saudi	O
Population	O
.	O

Familial	B-Disease
hypercholesterolemia	I-Disease
(	O
FH	O
)	O
is	O
a	O
metabolic	O
disorder	O
that	O
leads	O
primarily	O
to	O
premature	O
cardiovascular	O
diseases	O
,	O
the	O
main	O
cause	O
of	O
mortality	O
in	O
Saudi	O
Arabia	O
(	O
SA	O
)	O
.	O

FH	O
is	O
underreported	O
and	O
underdiagnosed	O
in	O
SA	O
with	O
statistical	O
evidence	O
of	O
high	O
expected	O
prevalence	O
in	O
such	O
a	O
consanguineous	O
community	O
.	O

Lacking	O
knowledge	O
of	O
which	O
and	O
how	O
these	O
alterations	O
are	O
actually	O
impacting	O
lipid	O
metabolism	O
is	O
one	O
of	O
the	O
main	O
reasons	O
why	O
FH	O
is	O
insufficiently	O
diagnosed	O
in	O
the	O
region	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
develop	O
a	O
fast	O
prediction	O
approach	O
using	O
an	O
integrated	O
bioinformatics	O
method	O
for	O
future	O
screening	O
of	O
the	O
potential	O
causative	O
variants	O
from	O
national	O
registries	O
.	O

A	O
total	O
of	O
21	O
variants	O
were	O
detected	O
with	O
majority	O
rate	O
in	O
LDLR	O
(	O
81	O
%	O
)	O
.	O

Variants	O
were	O
classified	O
based	O
on	O
the	O
type	O
of	O
mutation	O
.	O

Missense	O
variants	O
resulting	O
in	O
amino	O
acid	O
changes	O
,	O
c.1429G	B-Var
>	I-Var
A	I-Var
(	O
p	O
.	O
D477N	O
)	O
,	O
c.1474G	B-Var
>	I-Var
A	I-Var
(	O
p	O
.	O
D492N	O
)	O
,	O
c.1731G	B-Var
>	I-Var
T	I-Var
(	O
p	O
.	O
W577C	O
)	O
,	O
and	O
c.1783C	B-Var
>	I-Var
T	I-Var
(	O
p	O
.	O
R595W	O
)	O
in	O
LDLR	B-Gene
gene	O
,	O
in	O
addition	O
to	O
c.9835A	B-Var
>	I-Var
G	I-Var
(	O
p	O
.	O
S3279	O
G	O
)	O
in	O
APOB	B-Gene
,	O
were	O
shown	O
to	O
be	O
deleterious	O
by	O
concordant	O
analysis	O
.	O

Furthermore	O
,	O
functional	B-Interaction
interaction	I-Interaction
deformities	B-Reg
showed	O
a	O
significant	O
loss	B-NegReg
and	O
gain	B-PosReg
of	O
energies	B-MPA
in	I-MPA
the	I-MPA
mutated	I-MPA
proteins	I-MPA
.	O

These	O
findings	O
will	O
help	O
in	O
distinguishing	O
the	O
most	O
harmful	O
mutations	O
needed	O
to	O
be	O
screened	O
for	O
clinically	O
diagnosed	O
FH	O
patients	O
in	O
SA	O
.	O

Such	O
computational	O
research	O
is	O
necessary	O
to	O
avoid	O
time	O
consumption	O
and	O
the	O
usage	O
of	O
expensive	O
biological	O
experiments	O
.	O

This	O
can	O
be	O
a	O
fast	O
track	O
to	O
facilitate	O
the	O
future	O
filtering	O
and	O
screening	O
of	O
causative	O
mutations	O
from	O
national	O
registries	O
.	O

Effects	O
of	O
null	O
mutation	O
of	O
the	O
heat	O
-	O
shock	O
gene	O
htpG	O
on	O
the	O
production	O
of	O
virulence	O
factors	O
by	O
Pseudomonas	O
aeruginosa	O
.	O

AIM	O
:	O
Pseudomonas	O
aeruginosa	O
is	O
one	O
of	O
the	O
most	O
clinically	O
important	O
opportunistic	O
pathogen	O
in	O
humans	O
.	O

The	O
aim	O
of	O
the	O
project	O
was	O
to	O
study	O
effects	O
of	O
HtpG	O
on	O
the	O
selected	O
virulence	O
factors	O
responsible	O
for	O
pathogenesis	O
and	O
biofilm	O
formation	O
of	O
P.	O
aeruginosa	O
.	O

METHODOLOGY	O
:	O
By	O
characterizing	O
a	O
htpG	O
null	O
mutant	O
of	O
P.	O
aeruginosa	O
,	O
we	O
have	O
identified	O
the	O
role	O
of	O
HtpG	O
in	O
the	O
production	O
of	O
selected	O
factors	O
.	O

RESULTS	O
:	O
We	O
showed	O
that	O
ΔhtpG	B-Gene
mutant	B-Var
affects	O
many	O
physiological	O
processes	O
containing	O
:	O
decreased	B-NegReg
activity	B-MPA
of	O
the	O
LasA	B-Enzyme
protease	I-Enzyme
,	O
reduction	B-NegReg
of	O
biofilm	B-MPA
formation	I-MPA
,	O
decreased	B-NegReg
motility	B-CPA
,	O
and	O
diminished	B-NegReg
amount	B-MPA
of	I-MPA
rhamnolipids	I-MPA
and	I-MPA
pyoverdine	I-MPA
/	I-MPA
pyocyanin	I-MPA
.	O

These	O
defects	O
were	O
most	O
evident	O
when	O
the	O
ΔhtpG	O
strain	O
was	O
cultured	O
at	O
42	O
°	O
C	O
.	O

CONCLUSION	O
:	O
Our	O
findings	O
demonstrate	O
the	O
unexplored	O
role	O
of	O
HtpG	O
in	O
the	O
pathogenicity	O
of	O
P.	O
aeruginosa	O
,	O
and	O
indicate	O
potential	O
targets	O
for	O
antibacterial	O
therapeutics	O
.	O

[	O
Formula	O
:	O
see	O
text	O
]	O
.	O

Molecular	O
and	O
cellular	O
issues	O
of	O
KMT2A	B-Gene
variants	B-Var
involved	B-Reg
in	I-Reg
Wiedemann	B-Disease
-	I-Disease
Steiner	I-Disease
syndrome	I-Disease
.	O

Variants	B-Var
in	O
KMT2A	B-Gene
,	O
encoding	O
the	O
histone	O
methyltransferase	O
KMT2A	O
,	O
are	O
a	O
growing	O
cause	B-Reg
of	O
intellectual	B-Disease
disability	I-Disease
(	O
ID	O
)	O
.	O

Up	O
to	O
now	O
,	O
the	O
majority	O
of	O
KMT2A	B-Gene
variants	B-Var
are	O
non	B-Var
-	I-Var
sense	I-Var
and	O
frameshift	B-Var
variants	O
causing	B-Reg
a	O
typical	O
form	O
of	O
Wiedemann	B-Disease
-	I-Disease
Steiner	I-Disease
syndrome	I-Disease
.	O

We	O
studied	O
KMT2A	O
gene	O
in	O
a	O
cohort	O
of	O
200	O
patients	O
with	O
unexplained	O
syndromic	O
and	O
non	O
-	O
syndromic	O
ID	O
and	O
identified	O
four	O
novel	O
variants	O
,	O
one	O
splice	O
and	O
three	O
missense	O
variants	O
,	O
possibly	O
deleterious	O
.	O

We	O
used	O
primary	O
cells	O
from	O
the	O
patients	O
and	O
molecular	O
approaches	O
to	O
determine	O
the	O
deleterious	O
effects	B-Reg
of	O
those	O
variants	B-Var
on	O
KMT2A	B-Gene
expression	B-MPA
and	O
function	B-MPA
.	O

For	O
the	O
putative	O
splice	O
variant	O
c.11322	B-Var
-	I-Var
1G	I-Var
>	I-Var
A	I-Var
,	O
we	O
showed	O
that	O
it	O
led	O
to	O
only	O
one	O
nucleotide	O
deletion	O
and	O
loss	B-NegReg
of	O
the	O
C	B-MPA
-	I-MPA
terminal	I-MPA
part	I-MPA
of	I-MPA
the	I-MPA
protein	I-MPA
.	O

For	O
two	O
studied	O
KMT2A	B-Gene
missense	O
variants	O
,	O
c.3460C	B-Var
>	I-Var
T	I-Var
(	O
p.(Arg1154Trp	O
)	O
)	O
and	O
c.8558T	B-Var
>	I-Var
G	I-Var
(	O
p.(Met2853Arg	O
)	O
)	O
,	O
located	O
at	O
the	O
cysteine	O
-	O
rich	O
CXXC	O
domain	O
and	O
the	O
transactivation	O
domain	O
of	O
the	O
protein	O
,	O
respectively	O
,	O
we	O
found	O
altered	B-Reg
KMT2A	O
target	O
genes	O
expression	B-MPA
in	O
patient	O
's	O
fibroblasts	O
compared	O
to	O
controls	O
.	O

Furthermore	O
,	O
we	O
found	O
a	O
disturbed	B-Reg
subcellular	B-MPA
distribution	I-MPA
of	O
KMT2A	B-Gene
for	O
the	O
c.3460C	B-Var
>	I-Var
T	I-Var
mutant	O
.	O

Taken	O
together	O
,	O
our	O
results	O
demonstrated	O
the	O
deleterious	O
impact	O
of	O
the	O
splice	O
variant	O
and	O
of	O
the	O
missense	O
variants	O
located	O
at	O
two	O
different	O
functional	O
domains	O
and	O
suggested	O
reduction	O
of	O
KMT2A	O
function	O
as	O
the	O
disease	O
-	O
causing	O
mechanism	O
.	O

First	O
Report	O
of	O
Prenatal	O
Ascertainment	O
of	O
a	O
Fetus	O
With	O
Homozygous	O
Loss	O
of	O
the	O
SOX10	O
Gene	O
and	O
Phenotypic	O
Correlation	O
by	O
Autopsy	O
Examination	O
.	O

The	O
SOX10	O
gene	O
plays	O
a	O
vital	O
role	O
in	O
neural	O
crest	O
cell	O
development	O
and	O
migration	O
.	O

Abnormalities	B-Var
in	O
SOX10	B-Gene
are	O
associated	B-Reg
with	O
Waardenburg	B-Disease
syndrome	I-Disease
Types	B-Disease
II	I-Disease
and	O
IV	B-Disease
,	O
and	O
these	O
patients	O
have	O
recognizable	O
clinical	O
features	O
.	O

This	O
case	O
report	O
highlights	O
the	O
first	O
ever	O
reported	O
homozygous	O
loss	O
of	O
function	O
of	O
the	O
SOX10	O
gene	O
in	O
a	O
human	O
.	O

This	O
deletion	O
is	O
correlated	O
using	O
family	O
history	O
,	O
prenatal	O
ultrasound	O
,	O
microarray	O
analysis	O
of	O
amniotic	O
fluid	O
,	O
and	O
ultimately	O
,	O
a	O
medical	O
autopsy	O
examination	O
to	O
further	O
elucidate	O
phenotypic	O
effects	O
of	O
this	O
genetic	O
variation	O
.	O

Incorporating	O
the	O
use	O
of	O
molecular	O
pathology	O
into	O
the	O
autopsy	O
examination	O
of	O
fetuses	O
with	O
suspected	O
congenital	O
anomalies	O
is	O
vital	O
for	O
appropriate	O
family	O
counseling	O
,	O
and	O
with	O
the	O
ability	O
to	O
use	O
formalin	O
-	O
fixed	O
and	O
paraffin	O
-	O
embedded	O
tissues	O
,	O
has	O
become	O
a	O
practical	O
approach	O
in	O
autopsy	O
pathology	O
.	O

A	O
novel	O
NR2F2	B-Gene
loss	B-NegReg
-	I-NegReg
of	I-NegReg
-	I-NegReg
function	I-NegReg
mutation	B-Var
predisposes	O
to	O
congenital	B-Disease
heart	I-Disease
defect	I-Disease
.	O

Congenital	O
heart	O
defect	O
(	O
CHD	O
)	O
is	O
the	O
most	O
common	O
type	O
of	O
birth	O
defect	O
in	O
humans	O
and	O
a	O
leading	O
cause	O
of	O
infant	O
morbidity	O
and	O
mortality	O
.	O

Previous	O
studies	O
have	O
demonstrated	O
that	O
genetic	O
defects	O
play	O
a	O
pivotal	O
role	O
in	O
the	O
pathogenesis	O
of	O
CHD	O
.	O

However	O
,	O
the	O
genetic	O
basis	O
of	O
CHD	O
remains	O
poorly	O
understood	O
due	O
to	O
substantial	O
genetic	O
heterogeneity	O
.	O

In	O
this	O
study	O
,	O
the	O
coding	O
exons	O
and	O
splicing	O
boundaries	O
of	O
the	O
NR2F2	O
gene	O
,	O
which	O
encodes	O
a	O
pleiotropic	O
transcription	O
factor	O
required	O
for	O
normal	O
cardiovascular	O
development	O
,	O
were	O
sequenced	O
in	O
168	O
unrelated	O
patients	O
with	O
CHD	O
,	O
and	O
a	O
novel	O
mutation	O
(	O
c.247	O
G	O
>	O
T	O
,	O
equivalent	O
to	O
p	O
.	O
G83X	O
)	O
was	O
detected	O
in	O
a	O
patient	O
with	O
double	O
outlet	O
right	O
ventricle	O
as	O
well	O
as	O
ventricular	O
septal	O
defect	O
.	O

Genetic	O
scanning	O
of	O
the	O
mutation	O
carrier	O
's	O
relatives	O
available	O
showed	O
that	O
the	O
mutation	O
was	O
present	O
in	O
all	O
affected	O
family	O
members	O
but	O
absent	O
in	O
unaffected	O
family	O
members	O
.	O

Analysis	O
of	O
the	O
index	O
patient	O
's	O
pedigree	O
displayed	O
that	O
the	O
mutation	O
co	O
-	O
segregated	O
with	O
CHD	O
,	O
which	O
was	O
transmitted	O
as	O
an	O
autosomal	O
dominant	O
trait	O
with	O
complete	O
penetrance	O
.	O

The	O
nonsense	O
mutation	O
was	O
absent	O
in	O
230	O
unrelated	O
,	O
ethnically	O
-	O
matched	O
healthy	O
individuals	O
used	O
as	O
controls	O
.	O

Functional	O
deciphers	O
by	O
using	O
a	O
dual	O
-	O
luciferase	O
reporter	O
assay	O
system	O
revealed	O
that	O
the	O
mutant	B-Var
NR2F2	B-Gene
protein	O
had	O
no	B-NegReg
transcriptional	B-MPA
activity	I-MPA
as	O
compared	O
with	O
its	O
wild	O
-	O
type	O
counterpart	O
.	O

Furthermore	O
,	O
the	O
mutation	B-Var
abrogated	B-NegReg
the	O
synergistic	B-MPA
transcriptional	I-MPA
activation	I-MPA
between	O
NR2F2	B-Gene
and	O
GATA4	B-Gene
,	O
another	O
core	O
cardiac	O
transcription	O
factor	O
associated	O
with	O
CHD	O
.	O

This	O
study	O
firstly	O
associates	O
NR2F2	O
loss	O
-	O
of	O
-	O
function	O
mutation	O
with	O
an	O
increased	O
susceptibility	O
to	O
double	O
outlet	O
right	O
ventricle	O
in	O
humans	O
,	O
which	O
provides	O
further	O
significant	O
insight	O
into	O
the	O
molecular	O
mechanisms	O
underpinning	O
CHD	O
,	O
suggesting	O
potential	O
implications	O
for	O
genetic	O
counseling	O
of	O
CHD	O
families	O
and	O
personalized	O
treatment	O
of	O
CHD	O
patients	O
.	O

Potential	O
pathogenic	O
mechanisms	O
underlying	O
Fragile	O
X	O
Tremor	O
Ataxia	O
Syndrome	O
:	O
RAN	O
translation	O
and/or	O
RNA	O
gain	O
-	O
of	O
-	O
function	O
?	O
Fragile	B-Disease
X	I-Disease
-	I-Disease
associated	I-Disease
tremor	I-Disease
/	I-Disease
ataxia	I-Disease
syndrome	I-Disease
(	O
FXTAS	O
)	O
is	O
an	O
inherited	O
neurodegenerative	O
disease	O
caused	B-Reg
by	I-Reg
an	O
expansion	B-Var
of	I-Var
55	I-Var
-	I-Var
200	I-Var
CGG	I-Var
repeats	I-Var
located	O
in	O
the	O
FMR1	B-Gene
gene	O
.	O

The	O
main	O
clinical	O
and	O
neuropathological	O
features	O
of	O
FXTAS	O
are	O
progressive	O
intention	O
tremor	O
and	O
gait	O
ataxia	O
associated	O
with	O
brain	O
atrophy	O
,	O
neuronal	O
cell	O
loss	O
and	O
presence	O
of	O
ubiquitin	O
-	O
positive	O
intranuclear	O
inclusions	O
in	O
both	O
neurons	O
and	O
astrocytes	O
.	O

At	O
the	O
molecular	O
level	O
,	O
FXTAS	O
is	O
characterized	O
by	O
increased	O
expression	O
of	O
FMR1	O
sense	O
and	O
antisense	O
RNA	O
containing	O
expanded	O
CGG	O
or	O
GGC	O
repeats	O
,	O
respectively	O
.	O

Here	O
,	O
we	O
discuss	O
the	O
putative	O
molecular	O
mechanisms	O
underlying	O
FXTAS	O
and	O
notably	O
recent	O
reports	O
that	O
expanded	O
CGG	O
and	O
GGC	O
repeats	O
may	O
be	O
pathogenic	O
through	O
RAN	O
translation	O
into	O
toxic	O
proteins	O
.	O

Deleterious	O
variants	B-Var
in	O
DCHS1	B-Gene
are	O
prevalent	B-Reg
in	O
sporadic	O
cases	O
of	O
mitral	B-Disease
valve	I-Disease
prolapse	I-Disease
.	O

BACKGROUND	O
:	O
A	O
recent	O
study	O
identified	O
DCHS1	O
as	O
a	O
causal	O
gene	O
for	O
mitral	O
valve	O
prolapse	O
.	O

The	O
goal	O
of	O
this	O
study	O
is	O
to	O
investigate	O
the	O
presence	O
and	O
frequency	O
of	O
known	O
and	O
novel	O
variants	O
in	O
this	O
gene	O
in	O
100	O
asymptomatic	O
patients	O
with	O
moderate	O
to	O
severe	O
organic	O
mitral	O
regurgitation	O
.	O

METHODS	O
:	O
DNA	O
sequencing	O
assays	O
were	O
developed	O
for	O
two	O
previously	O
identified	O
functional	O
missense	O
variants	O
,	O
namely	O
p	B-Var
.	I-Var
R2330C	I-Var
and	O
p	B-Var
.	I-Var
R2513H	I-Var
,	O
and	O
all	O
21	O
exons	O
of	O
DCHS1	B-Gene
.	O

Pathogenicity	O
of	O
variants	O
was	O
evaluated	O
in	O
silico	O
.	O

RESULTS	O
:	O
p	O
.	O
R2330C	O
and	O
p	O
.	O
R2513H	O
were	O
not	O
identified	O
in	O
this	O
cohort	O
.	O

Sequencing	O
all	O
coding	O
regions	O
revealed	O
eight	O
missense	O
variants	O
including	O
six	O
considered	O
deleterious	O
.	O

This	O
includes	O
one	O
novel	O
variant	O
(	O
p	O
.	O
A2464P	O
)	O
and	O
two	O
rare	O
variants	O
(	O
p	O
.	O
R2770Q	O
and	O
p	O
.	O
R2462Q	O
)	O
.	O

These	O
variants	O
are	O
predicted	O
to	O
be	O
deleterious	O
with	O
combined	O
annotation	O
-	O
dependent	O
depletion	O
(	O
CADD	O
)	O
scores	O
greater	O
than	O
25	O
,	O
which	O
are	O
in	O
the	O
same	O
range	O
as	O
p	O
.	O
R2330C	O
(	O
CADD	O
=	O
28.0	O
)	O
and	O
p	O
.	O
R2513H	O
(	O
CADD	O
=	O
24.3	O
)	O
.	O

More	O
globally	O
,	O
24	O
of	O
100	O
cases	O
were	O
carriers	O
of	O
at	O
least	O
one	O
in	O
silico	O
-	O
predicted	O
deleterious	O
missense	O
variant	O
in	O
DCHS1	O
,	O
suggesting	O
that	O
this	O
single	O
gene	O
may	O
account	O
for	O
a	O
substantial	O
portion	O
of	O
cases	O
.	O

CONCLUSION	O
:	O
This	O
study	O
reveals	O
an	O
important	O
contribution	O
of	O
germline	O
variants	O
in	O
DCHS1	O
in	O
unrelated	O
patients	O
with	O
mitral	O
valve	O
prolapse	O
and	O
supports	O
genetic	O
testing	O
of	O
this	O
gene	O
to	O
screen	O
individuals	O
at	O
risk	O
.	O

Primary	B-Disease
Ovarian	I-Disease
Insufficiency	I-Disease
and	O
Azoospermia	B-Disease
in	O
Carriers	B-Reg
of	O
a	O
Homozygous	O
PSMC3IP	B-Gene
Stop	O
Gain	O
Mutation	B-Var
.	O

Context	O
:	O
The	O
etiology	O
of	O
primary	O
ovarian	O
insufficiency	O
(	O
POI	O
)	O
remains	O
unknown	O
in	O
most	O
cases	O
.	O

Objective	O
:	O
We	O
sought	O
to	O
identify	O
the	O
genes	O
causing	O
POI	O
.	O

Design	O
:	O
The	O
study	O
was	O
a	O
familial	O
genetic	O
study	O
.	O

Setting	O
:	O
The	O
study	O
was	O
performed	O
at	O
two	O
academic	O
institutions	O
.	O

Patients	O
:	O
We	O
identified	O
a	O
consanguineous	O
Yemeni	O
family	O
in	O
which	O
four	O
daughters	O
had	O
POI	O
.	O

A	O
brother	O
had	O
azoospermia	O
.	O

Intervention	O
:	O
DNA	O
was	O
subjected	O
to	O
whole	O
genome	O
sequencing	O
.	O

Shared	O
regions	O
of	O
homozygosity	O
were	O
identified	O
using	O
Truploidy	O
and	O
prioritized	O
using	O
the	O
Variant	O
Annotation	O
,	O
Analysis	O
,	O
and	O
Search	O
Tool	O
with	O
control	O
data	O
from	O
387	O
healthy	O
subjects	O
.	O

Imaging	O
and	O
quantification	O
of	O
protein	O
localization	O
and	O
mitochondrial	O
function	O
were	O
examined	O
in	O
cell	O
lines	O
.	O

Main	O
Outcome	O
:	O
Homozygous	O
recessive	O
gene	O
variants	O
shared	O
by	O
the	O
four	O
sisters	O
.	O

Results	O
:	O
The	O
sisters	O
shared	O
a	O
homozygous	O
stop	O
gain	O
mutation	O
in	O
exon	O
6	O
of	O
PSMC3IP	O
(	O
c.489	O
C	O
>	O
G	O
,	O
p	O
.	O
Tyr163Ter	O
)	O
and	O
a	O
missense	O
variant	O
in	O
exon	O
1	O
of	O
CLPP	O
(	B-Var
c.100C	I-Var
>	I-Var
T	I-Var
,	O
p	O
.	O
Pro34Ser	O
)	O
.	O

The	O
affected	O
brother	O
also	O
carried	O
the	O
homozygous	O
PSMC3IP	O
mutation	O
.	O

Functional	O
studies	O
demonstrated	B-Reg
mitochondrial	B-CPA
fragmentation	I-CPA
in	O
cells	O
infected	O
with	O
the	O
CLPP	B-Gene
mutation	B-Var
.	O

However	O
,	O
no	O
abnormality	O
was	O
found	O
in	O
mitochondrial	O
targeting	O
or	O
respiration	O
.	O

Conclusions	O
:	O
The	O
PSMC3IP	O
mutation	O
provides	O
additional	O
evidence	O
that	O
mutations	O
in	O
meiotic	O
homologous	O
recombination	O
and	O
DNA	O
repair	O
genes	O
result	O
in	O
distinct	O
female	O
and	O
male	O
reproductive	O
phenotypes	O
,	O
including	O
delayed	O
puberty	O
and	O
primary	O
amenorrhea	O
caused	O
by	O
POI	O
(	O
XX	O
gonadal	O
dysgenesis	O
)	O
in	O
females	O
but	O
isolated	O
azoospermia	O
with	O
normal	O
pubertal	O
development	O
in	O
males	O
.	O

The	O
findings	O
also	O
suggest	O
that	O
the	O
N	O
-	O
terminal	O
missense	O
mutation	O
in	O
CLPP	O
does	O
not	O
cause	O
substantial	O
mitochondrial	O
dysfunction	O
or	O
contribute	O
to	O
ovarian	O
insufficiency	O
in	O
an	O
oligogenic	O
manner	O
.	O

HOP-1	O
Presenilin	O
Deficiency	O
Causes	O
a	O
Late	O
-	O
Onset	O
Notch	O
Signaling	O
Phenotype	O
That	O
Affects	O
Adult	O
Germline	O
Function	O
in	O
Caenorhabditis	O
elegans	O
.	O

Functionally	O
redundant	O
genes	O
present	O
a	O
puzzle	O
as	O
to	O
their	O
evolutionary	O
preservation	O
,	O
and	O
offer	O
an	O
interesting	O
opportunity	O
for	O
molecular	O
specialization	O
.	O

In	O
Caenorhabditis	O
elegans	O
,	O
either	O
one	O
of	O
two	O
presenilin	O
genes	O
(	O
sel-12	O
or	O
hop-1	O
)	O
facilitate	O
Notch	O
activation	O
,	O
providing	O
the	O
catalytic	O
subunit	O
for	O
the	O
γ	O
secretase	O
proteolytic	O
enzyme	O
complex	O
.	O

For	O
all	O
known	O
Notch	O
signaling	O
events	O
,	O
sel-12	O
can	O
mediate	O
Notch	O
activation	O
,	O
so	O
the	O
conservation	O
of	O
hop-1	O
remains	O
a	O
mystery	O
.	O

Here	O
,	O
we	O
uncover	O
a	O
novel	O
"	O
late	O
-	O
onset	O
"	O
germline	O
Notch	O
phenotype	O
in	O
which	O
HOP-1-deficient	O
worms	O
fail	O
to	O
maintain	O
proliferating	O
germline	O
stem	O
cells	O
during	O
adulthood	O
.	O

Either	O
SEL-12	O
or	O
HOP-1	O
presenilin	O
can	O
impart	O
sufficient	O
Notch	O
signaling	O
for	O
the	O
establishment	O
and	O
expansion	O
of	O
the	O
germline	O
,	O
but	O
maintenance	O
of	O
an	O
adult	O
stem	O
cell	O
pool	O
relies	O
exclusively	O
on	O
HOP-1-mediated	O
Notch	O
signaling	O
.	O

We	O
also	O
show	O
that	O
HOP-1	O
is	O
necessary	O
for	O
maximum	O
fecundity	O
and	O
reproductive	O
span	O
.	O

The	O
low	B-CPA
-	I-CPA
fecundity	I-CPA
phenotype	O
of	O
hop-1	B-Gene
mutants	B-Var
can	O
be	O
phenocopied	O
by	O
switching	B-NegReg
off	I-NegReg
glp-1	B-MPA
/	I-MPA
Notch	I-MPA
function	I-MPA
during	O
the	O
last	O
stage	O
of	O
larval	O
development	O
.	O

We	O
propose	O
that	O
at	O
the	O
end	O
of	O
larval	O
development	O
,	O
dual	O
presenilin	O
usage	O
switches	O
exclusively	O
to	O
HOP-1	O
,	O
perhaps	O
offering	O
opportunities	O
for	O
differential	O
regulation	O
of	O
the	O
germline	O
during	O
adulthood	O
.	O

Additional	O
defects	B-NegReg
in	O
oocyte	B-CPA
size	I-CPA
and	O
production	B-CPA
rate	O
in	O
hop-1	B-Gene
and	O
glp-1	B-Gene
mutants	B-Var
indicate	O
that	O
the	O
process	O
of	O
oogenesis	O
is	O
compromised	O
when	O
germline	O
Notch	O
signaling	O
is	O
switched	O
off	O
.	O

We	O
calculate	O
that	O
in	O
wild	O
-	O
type	O
adults	O
,	O
as	O
much	O
as	O
86	O
%	O
of	O
cells	O
derived	O
from	O
the	O
stem	O
cell	O
pool	O
function	O
to	O
support	O
oogenesis	O
.	O

This	O
work	O
suggests	O
that	O
an	O
important	O
role	O
for	O
Notch	O
signaling	O
in	O
the	O
adult	O
germline	O
is	O
to	O
furnish	O
a	O
large	O
and	O
continuous	O
supply	O
of	O
nurse	O
cells	O
to	O
support	O
the	O
efficiency	O
of	O
oogenesis	O
.	O

Mild	O
Telomere	O
Dysfunction	O
as	O
a	O
Force	O
for	O
Altering	O
the	O
Adaptive	O
Potential	O
of	O
Subtelomeric	O
Genes	O
.	O

Subtelomeric	O
regions	O
have	O
several	O
unusual	O
characteristics	O
,	O
including	O
complex	O
repetitive	O
structures	O
,	O
increased	O
rates	O
of	O
evolution	O
,	O
and	O
enrichment	O
for	O
genes	O
involved	O
in	O
niche	O
adaptation	O
.	O

The	O
adaptive	O
telomere	O
failure	O
hypothesis	O
suggests	O
that	O
certain	O
environmental	O
stresses	O
can	O
induce	O
a	O
low	O
level	O
of	O
telomere	O
failure	O
,	O
potentially	O
leading	O
to	O
elevated	O
subtelomeric	O
recombination	O
that	O
could	O
result	O
in	O
adaptive	O
mutational	O
changes	O
within	O
subtelomeric	O
genes	O
.	O

Here	O
,	O
we	O
tested	O
a	O
key	O
prediction	O
of	O
the	O
adaptive	O
telomere	O
failure	O
hypothesis	O
-	O
that	O
telomere	O
dysfunction	O
mild	O
enough	O
to	O
have	O
little	O
or	O
no	O
overall	O
effect	O
on	O
cell	O
fitness	O
could	O
still	O
lead	O
to	O
substantial	O
increases	O
in	O
the	O
mutation	O
rates	O
of	O
subtelomeric	O
genes	O
.	O

Our	O
results	O
show	O
that	O
a	O
mutant	O
of	O
Kluyveromyces	O
lactis	O
with	O
stably	O
short	O
telomeres	O
produced	O
a	O
large	O
increase	O
in	O
the	O
frequency	O
of	O
mutations	O
affecting	O
the	O
native	O
subtelomeric	O
β	O
-	O
galactosidase	O
(	O
LAC4	O
)	O
gene	O
.	O

All	O
lac4	B-Gene
mutants	B-Var
examined	O
from	O
strains	O
with	O
severe	O
telomere	O
dysfunction	O
underwent	B-Reg
terminal	B-MPA
deletion	I-MPA
/	I-MPA
duplication	I-MPA
events	O
consistent	O
with	O
being	O
due	O
to	O
break	O
-	O
induced	O
replication	O
.	O

In	O
contrast	O
,	O
although	O
cells	O
with	O
mild	O
telomere	O
dysfunction	O
also	O
exhibited	O
similar	O
terminal	O
deletion	O
and	O
duplication	O
events	O
,	O
up	O
to	O
50	O
%	O
of	O
lac4	B-Gene
mutants	B-Var
from	O
this	O
background	O
unexpectedly	O
contained	B-Reg
base	B-MPA
changes	I-MPA
within	O
the	O
LAC4	O
coding	O
region	O
.	O

This	O
mutational	O
bias	O
for	O
producing	O
base	O
changes	O
demonstrates	O
that	O
mild	O
telomere	O
dysfunction	O
can	O
be	O
well	O
suited	O
as	O
a	O
force	O
for	O
altering	O
the	O
adaptive	O
potential	O
of	O
subtelomeric	O
genes	O
.	O

Patients	O
with	O
a	O
Kabuki	O
syndrome	O
phenotype	O
demonstrate	O
DNA	O
methylation	O
abnormalities	O
.	O

Kabuki	B-Disease
syndrome	I-Disease
is	O
a	O
monogenic	O
disorder	O
caused	O
by	O
loss	B-NegReg
of	I-NegReg
function	I-NegReg
variants	B-Var
in	O
either	O
of	O
two	O
genes	O
encoding	O
histone	O
-	O
modifying	O
enzymes	O
.	O

We	O
performed	O
targeted	O
sequencing	O
in	O
a	O
cohort	O
of	O
27	O
probands	O
with	O
a	O
clinical	O
diagnosis	O
of	O
Kabuki	O
syndrome	O
.	O

Of	O
these	O
,	O
12	O
had	O
causative	O
variants	O
in	O
the	O
two	O
known	O
Kabuki	O
syndrome	O
genes	O
.	O

In	O
2	O
,	O
we	O
identified	O
presumptive	O
loss	O
of	O
function	O
de	O
novo	O
variants	B-Var
in	O
KMT2A	B-Gene
(	O
missense	O
and	O
splice	O
site	O
variants	O
)	O
,	O
a	O
gene	O
that	O
encodes	O
another	O
histone	O
modifying	O
enzyme	O
previously	O
exclusively	O
associated	B-Reg
with	O
Wiedermann	B-Disease
-	I-Disease
Steiner	I-Disease
syndrome	I-Disease
.	O

Although	O
Kabuki	O
syndrome	O
is	O
a	O
disorder	O
of	O
histone	O
modification	O
,	O
we	O
also	O
find	O
alterations	O
in	O
DNA	O
methylation	O
among	O
individuals	O
with	O
a	O
Kabuki	O
syndrome	O
diagnosis	O
relative	O
to	O
matched	O
normal	O
controls	O
,	O
regardless	O
of	O
whether	O
they	O
carry	O
a	O
variant	O
in	O
KMT2A	O
or	O
KMT2D	O
or	O
not	O
.	O

Furthermore	O
,	O
we	O
observed	O
characteristic	O
global	O
abnormalities	O
of	O
DNA	O
methylation	O
that	O
distinguished	O
patients	O
with	O
a	O
loss	O
of	O
function	O
variant	O
in	O
KMT2D	O
or	O
missense	O
or	O
splice	O
site	O
variants	O
in	O
either	O
KMT2D	O
or	O
KMT2A	O
from	O
normal	O
controls	O
.	O

Our	O
results	O
provide	O
new	O
insights	O
into	O
the	O
relationship	O
of	O
genotype	O
to	O
epigenotype	O
and	O
phenotype	O
and	O
indicate	O
cross	O
-	O
talk	O
between	O
histone	O
and	O
DNA	O
methylation	O
machineries	O
exposed	O
by	O
inborn	O
errors	O
of	O
the	O
epigenetic	O
apparatus	O
.	O

A	O
novel	O
homozygous	O
ARL13B	B-Gene
variant	B-Var
in	O
patients	O
with	O
Joubert	O
syndrome	O
impairs	B-NegReg
its	O
guanine	B-MPA
nucleotide	I-MPA
-	I-MPA
exchange	I-MPA
factor	I-MPA
activity	I-MPA
.	O

ARL13B	O
encodes	O
for	O
the	O
ADP	O
-	O
ribosylation	O
factor	O
-	O
like	O
13B	O
GTPase	O
,	O
which	O
is	O
required	O
for	O
normal	O
cilia	O
structure	O
and	O
Sonic	O
hedgehog	O
(	O
Shh	O
)	O
signaling	O
.	O

Disruptions	O
in	O
cilia	O
structure	O
or	O
function	O
lead	O
to	O
a	O
class	O
of	O
human	O
disorders	O
called	O
ciliopathies	O
.	O

Joubert	O
syndrome	O
is	O
characterized	O
by	O
a	O
wide	O
spectrum	O
of	O
symptoms	O
,	O
including	O
a	O
variable	O
degree	O
of	O
intellectual	O
disability	O
,	O
ataxia	O
,	O
and	O
ocular	O
abnormalities	O
.	O

Here	O
we	O
report	O
a	O
novel	O
homozygous	O
missense	O
variant	O
c.[223G	O
>	O
A	O
]	O
(	O
p.(Gly75Arg	O
)	O
in	O
the	O
ARL13B	O
gene	O
,	O
which	O
was	O
identified	O
by	O
whole	O
-	O
exome	O
sequencing	O
of	O
a	O
trio	O
from	O
a	O
consanguineous	O
family	O
with	O
multiple	O
-	O
affected	O
individuals	O
suffering	O
from	O
intellectual	O
disability	O
,	O
ataxia	O
,	O
ocular	O
defects	O
,	O
and	O
epilepsy	O
.	O

The	O
same	O
variant	O
was	O
also	O
identified	O
in	O
a	O
second	O
family	O
.	O

We	O
saw	O
a	O
striking	O
difference	O
in	O
the	O
severity	O
of	O
ataxia	O
between	O
affected	O
male	O
and	O
female	O
individuals	O
in	O
both	O
families	O
.	O

Both	O
ARL13B	O
and	O
ARL13B	O
-	O
c.[223G	O
>	O
A	O
]	O
(	O
p.(Gly75Arg	O
)	O
expression	O
rescued	O
the	O
cilia	O
length	O
and	O
Shh	O
defects	O
displayed	O
by	O
Arl13b	O
hennin	O
(	O
null	O
)	O
cells	O
,	O
indicating	O
that	O
the	O
variant	O
did	O
not	O
disrupt	O
either	O
ARL13B	O
function	O
.	O

In	O
contrast	O
,	O
ARL13B	B-Var
-	I-Var
c.[223G	I-Var
>	I-Var
A	I-Var
]	I-Var
(	O
p.(Gly75Arg	O
)	O
displayed	O
a	O
marked	O
loss	B-NegReg
of	O
ARL3	B-MPA
guanine	I-MPA
nucleotide	I-MPA
-	I-MPA
exchange	I-MPA
factor	I-MPA
activity	I-MPA
,	O
with	O
retention	O
of	O
its	O
GTPase	O
activities	O
,	O
highlighting	O
the	O
correlation	O
between	O
its	O
loss	O
of	O
function	O
as	O
an	O
ARL3	O
guanine	O
nucleotide	O
-	O
exchange	O
factor	O
and	O
Joubert	B-Disease
syndrome	I-Disease
.	O

Cantu	O
syndrome	O
-	O
associated	O
SUR2	O
(	B-Gene
ABCC9	I-Gene
)	I-Gene
mutations	B-Var
in	O
distinct	O
structural	O
domains	O
result	O
in	O
KATP	B-MPA
channel	I-MPA
gain	B-PosReg
-	I-PosReg
of	I-PosReg
-	I-PosReg
function	I-PosReg
by	O
differential	O
mechanisms	O
.	O

The	O
complex	O
disorder	O
Cantu	B-Disease
syndrome	I-Disease
(	O
CS	O
)	O
arises	O
from	O
gain	B-PosReg
-	I-PosReg
of	I-PosReg
-	I-PosReg
function	I-PosReg
mutations	B-Var
in	O
either	O
KCNJ8	B-Gene
or	O
ABCC9	B-Gene
,	O
the	O
genes	O
encoding	O
the	O
Kir6.1	O
and	O
SUR2	O
subunits	O
of	O
ATP	O
-	O
sensitive	O
potassium	O
(	O
KATP	O
)	O
channels	O
,	O
respectively	O
.	O

Recent	O
reports	O
indicate	O
that	O
such	O
mutations	B-Var
can	O
increase	B-PosReg
channel	B-MPA
activity	I-MPA
by	O
multiple	O
molecular	O
mechanisms	O
.	O

In	O
this	O
study	O
,	O
we	O
determined	O
the	O
mechanism	O
by	O
which	O
KATP	B-MPA
function	I-MPA
is	O
altered	B-Reg
by	O
several	O
substitutions	O
in	O
distinct	O
structural	O
domains	O
of	O
SUR2	B-Gene
:	I-Gene
D207E	B-Var
in	O
the	O
intracellular	O
L0-linker	O
and	O
Y985S	B-Var
,	O
G989E	B-Var
,	O
M1060I	B-Var
,	O
and	O
R1154Q	B-Var
/	I-Var
R1154W	I-Var
in	O
TMD2	O
.	O

We	O
engineered	O
substitutions	O
at	O
their	O
equivalent	O
positions	O
in	O
rat	O
SUR2A	O
(	O
D207E	O
,	O
Y981S	O
,	O
G985E	O
,	O
M1056I	O
,	O
and	O
R1150Q	O
/	O
R1150W	O
)	O
and	O
investigated	O
functional	O
consequences	O
using	O
macroscopic	O
rubidium	O
(	O
86Rb+	O
)	O
efflux	O
assays	O
and	O
patch	O
-	O
clamp	O
electrophysiology	O
.	O

Our	O
results	O
indicate	O
that	O
D207E	B-Var
increases	B-PosReg
KATP	B-MPA
channel	I-MPA
activity	I-MPA
by	O
increasing	B-PosReg
intrinsic	B-MPA
stability	I-MPA
of	I-MPA
the	I-MPA
open	I-MPA
state	I-MPA
,	O
whereas	O
the	O
cluster	O
of	O
Y981S	B-Var
/	I-Var
G985E	I-Var
/	I-Var
M1056I	I-Var
substitutions	O
,	O
as	O
well	O
as	O
R1150Q	B-Var
/	I-Var
R1150W	I-Var
,	O
augmented	B-PosReg
Mg	B-MPA
-	I-MPA
nucleotide	I-MPA
activation	I-MPA
.	O

We	O
also	O
tested	O
the	O
responses	O
of	O
these	O
channel	O
variants	O
to	O
inhibition	O
by	O
the	O
sulfonylurea	O
drug	O
glibenclamide	O
,	O
a	O
potential	O
pharmacotherapy	O
for	O
CS	O
.	O

None	O
of	O
the	O
D207E	O
,	O
Y981S	O
,	O
G985E	O
,	O
or	O
M1056I	O
substitutions	O
had	O
a	O
significant	O
effect	O
on	O
glibenclamide	O
sensitivity	O
.	O

However	O
,	O
Gln	O
and	O
Trp	O
substitution	O
at	O
Arg-1150	O
significantly	O
decreased	O
glibenclamide	O
potency	O
.	O

In	O
summary	O
,	O
these	O
results	O
provide	O
additional	O
confirmation	O
that	O
mutations	O
in	O
CS	O
-	O
associated	O
SUR2	O
mutations	O
result	O
in	O
KATP	O
gain	O
-	O
of	O
-	O
function	O
.	O

They	O
help	O
link	O
CS	O
genotypes	O
to	O
phenotypes	O
and	O
shed	O
light	O
on	O
the	O
underlying	O
molecular	O
mechanisms	O
,	O
including	O
consequences	O
for	O
inhibitory	O
drug	O
sensitivity	O
,	O
insights	O
that	O
may	O
inform	O
the	O
development	O
of	O
therapeutic	O
approaches	O
to	O
manage	O
CS	O
.	O

Arabidopsis	O
Phospholipase	O
C3	O
is	O
Involved	O
in	O
Lateral	O
Root	O
Initiation	O
and	O
ABA	O
Responses	O
in	O
Seed	O
Germination	O
and	O
Stomatal	O
Closure	O
.	O

Phospholipase	O
C	O
(	O
PLC	O
)	O
is	O
well	O
known	O
for	O
its	O
role	O
in	O
animal	O
signaling	O
,	O
where	O
it	O
generates	O
the	O
second	O
messengers	O
,	O
inositol	O
1,4,5-trisphosphate	O
(	O
IP3	O
)	O
and	O
diacylglycerol	O
(	O
DAG	O
)	O
,	O
by	O
hydrolyzing	O
the	O
minor	O
phospholipid	O
,	O
phosphatidylinositol	O
4,5-bisphosphate	O
(	O
PIP2	O
)	O
,	O
upon	O
receptor	O
stimulation	O
.	O

In	O
plants	O
,	O
PLC	O
's	O
role	O
is	O
still	O
unclear	O
,	O
especially	O
because	O
the	O
primary	O
targets	O
of	O
both	O
second	O
messengers	O
are	O
lacking	O
,	O
i.e.	O
the	O
ligand	O
-	O
gated	O
Ca2	O
+	O
channel	O
and	O
protein	O
kinase	O
C	O
,	O
and	O
because	O
PIP2	O
levels	O
are	O
extremely	O
low	O
.	O

Nonetheless	O
,	O
the	O
Arabidopsis	O
genome	O
encodes	O
nine	O
PLCs	O
.	O

We	O
used	O
a	O
reversed	O
-	O
genetic	O
approach	O
to	O
explore	O
PLC	O
's	O
function	O
in	O
Arabidopsis	O
,	O
and	O
report	O
here	O
that	O
PLC3	B-Gene
is	O
required	O
for	O
proper	O
root	O
development	O
,	O
seed	O
germination	O
and	O
stomatal	O
opening	O
.	O

Two	O
independent	O
knock	B-Var
-	I-Var
down	I-Var
mutants	I-Var
,	O
plc3	O
-	O
2	O
and	O
plc3	O
-	O
3	O
,	O
were	O
found	O
to	O
exhibit	O
reduced	B-NegReg
lateral	B-CPA
root	I-CPA
densities	I-CPA
by	O
10	O
-	O
20	O
%	O
.	O

Mutant	B-Var
seeds	O
germinated	B-CPA
more	O
slowly	B-NegReg
but	O
were	O
less	O
sensitive	O
to	O
ABA	O
to	O
prevent	O
germination	O
.	O

Guard	O
cells	O
of	O
plc3	O
were	O
also	O
compromised	O
in	O
ABA	O
-	O
dependent	O
stomatal	O
closure	O
.	O

Promoter	O
-	O
β	O
-	O
glucuronidase	O
(	O
GUS	O
)	O
analyses	O
confirmed	O
PLC3	O
expression	O
in	O
guard	O
cells	O
and	O
germinating	O
seeds	O
,	O
and	O
revealed	O
that	O
the	O
majority	O
is	O
expressed	O
in	O
vascular	O
tissue	O
,	O
most	O
probably	O
phloem	O
companion	O
cells	O
,	O
in	O
roots	O
,	O
leaves	O
and	O
flowers	O
.	O

In	O
vivo	O
32Pi	O
labeling	O
revealed	O
that	O
ABA	O
stimulated	O
the	O
formation	B-MPA
of	I-MPA
PIP2	I-MPA
in	O
germinating	O
seeds	O
and	O
guard	O
cell	O
-	O
enriched	O
leaf	O
peels	O
,	O
which	O
was	O
significantly	O
reduced	B-NegReg
in	O
plc3	B-Gene
mutants	B-Var
.	O

Overexpression	O
of	O
PLC3	O
had	O
no	O
effect	O
on	O
root	O
system	O
architecture	O
or	O
seed	O
germination	O
,	O
but	O
increased	O
the	O
plant	O
's	O
tolerance	O
to	O
drought	O
.	O

Our	O
results	O
provide	O
genetic	O
evidence	O
for	O
PLC	O
's	O
involvement	O
in	O
plant	O
development	O
and	O
ABA	O
signaling	O
,	O
and	O
confirm	O
earlier	O
observations	O
that	O
overexpression	O
increases	O
drought	O
tolerance	O
.	O

Potential	O
molecular	O
mechanisms	O
for	O
the	O
above	O
observations	O
are	O
discussed	O
.	O

Rare	O
loss	B-NegReg
of	I-NegReg
function	I-NegReg
mutations	B-Var
in	O
N	B-Protein
-	I-Protein
methyl	I-Protein
-	I-Protein
D	I-Protein
-	I-Protein
aspartate	I-Protein
glutamate	I-Protein
receptors	I-Protein
and	O
their	O
contributions	O
to	O
schizophrenia	B-Disease
susceptibility	O
.	O

In	O
schizophrenia	O
(	O
SCZ	O
)	O
and	O
autism	O
spectrum	O
disorder	O
(	O
ASD	O
)	O
,	O
the	O
dysregulation	O
of	O
glutamate	O
transmission	O
through	O
N	O
-	O
methyl	O
-	O
D	O
-	O
aspartate	O
receptors	O
(	O
NMDARs	O
)	O
has	O
been	O
implicated	O
as	O
a	O
potential	O
etiological	O
mechanism	O
.	O

Previous	O
studies	O
have	O
accumulated	O
evidence	O
supporting	O
NMDAR	O
-	O
encoding	O
genes	O
'	O
role	O
in	O
etiology	O
of	O
SCZ	O
and	O
ASD	O
.	O

We	O
performed	O
a	O
screening	O
study	O
for	O
exonic	O
regions	O
of	O
GRIN1	O
,	O
GRIN2A	O
,	O
GRIN2C	O
,	O
GRIN2D	O
,	O
GRIN3A	O
,	O
and	O
GRIN3B	O
,	O
which	O
encode	O
NMDAR	O
subunits	O
,	O
in	O
562	O
participates	O
(	O
370	O
SCZ	O
and	O
192	O
ASD	O
)	O
.	O

Forty	O
rare	O
variants	O
were	O
identified	O
including	O
38	O
missense	O
,	O
1	O
frameshift	O
mutation	O
in	O
GRIN2C	O
and	O
1	O
splice	O
site	O
mutation	O
in	O
GRIN2D.	O
We	O
conducted	O
in	O
silico	O
analysis	O
for	O
all	O
variants	O
and	O
detected	O
seven	O
missense	O
variants	O
with	O
deleterious	O
prediction	O
.	O

De	O
novo	O
analysis	O
was	O
conducted	O
if	O
pedigree	O
samples	O
were	O
available	O
.	O

The	O
splice	O
site	O
mutation	O
in	O
GRIN2D	O
is	O
predicted	O
to	O
result	O
in	O
intron	O
retention	O
by	O
minigene	O
assay	O
.	O

Furthermore	O
,	O
the	O
frameshift	O
mutation	O
in	O
GRIN2C	O
and	O
splice	O
site	O
mutation	O
in	O
GRIN2D	O
were	O
genotyped	O
in	O
an	O
independent	O
sample	O
set	O
comprising	O
1877	O
SCZ	O
cases	O
,	O
382	O
ASD	O
cases	O
,	O
and	O
2040	O
controls	O
.	O

Both	O
of	O
them	O
were	O
revealed	O
to	O
be	O
singleton	O
.	O

Our	O
study	O
gives	O
evidence	O
in	O
support	O
of	O
the	O
view	O
that	O
ultra	O
-	O
rare	O
variants	O
with	O
loss	B-NegReg
of	I-NegReg
function	I-NegReg
(	B-Var
frameshift	I-Var
,	O
nonsense	B-Var
or	I-Var
splice	I-Var
site	I-Var
)	I-Var
in	O
NMDARs	B-Gene
genes	O
may	O
contribute	O
to	O
possible	O
risk	O
of	O
SCZ	B-Disease
.	O

FRUCTOKINASE	O
-	O
LIKE	O
PROTEIN	O
1	O
interacts	O
with	O
TRXz	O
to	O
regulate	O
chloroplast	O
development	O
in	O
rice	O
.	O

Chloroplast	O
genes	O
are	O
transcribed	O
by	O
the	O
plastid	O
-	O
encoded	O
RNA	O
polymerase	O
(	O
PEP	O
)	O
or	O
nucleus	O
-	O
encoded	O
RNA	O
polymerase	O
.	O

FRUCTOKINASE	O
-	O
LIKE	O
PROTEINS	O
(	O
FLNs	O
)	O
are	O
phosphofructokinase	O
-	O
B	O
(	O
PfkB)-type	O
carbohydrate	O
kinases	O
that	O
act	O
as	O
part	O
of	O
the	O
PEP	O
complex	O
;	O
however	O
,	O
the	O
molecular	O
mechanisms	O
underlying	O
FLN	O
activity	O
in	O
rice	O
remain	O
elusive	O
.	O

Previously	O
,	O
we	O
identified	O
and	O
characterized	O
a	O
heat	O
-	O
stress	O
sensitive	O
albino	O
(	O
hsa1	O
)	O
mutant	O
in	O
rice	O
.	O

Map	O
-	O
based	O
cloning	O
revealed	O
that	O
HSA1	O
encodes	O
a	O
putative	O
OsFLN2	O
.	O

Here	O
,	O
we	O
further	O
demonstrated	O
that	O
knockdown	O
or	O
knockout	O
of	O
the	O
OsFLN1	O
,	O
a	O
close	O
homolog	O
of	O
HSA1	O
/	O
OsFLN2	O
,	O
considerably	O
inhibits	O
chloroplast	O
biogenesis	O
and	O
the	O
fln1	O
knockout	O
mutants	O
,	O
created	O
by	O
clustered	O
regularly	O
interspaced	O
short	O
palindromic	O
repeats	O
(	O
CRISPR	O
)	O
and	O
CRISPR	O
-	O
associate	O
protein	O
9	O
,	O
exhibit	O
severe	O
albino	O
phenotype	O
and	O
seedling	O
lethality	O
.	O

Moreover	O
,	O
OsFLN1	O
localizes	O
to	O
the	O
chloroplast	O
.	O

Yeast	O
two	O
-	O
hybrid	O
,	O
pull	O
-	O
down	O
and	O
bimolecular	O
fluorescence	O
complementation	O
experiments	O
revealed	O
that	O
OsFLN1	O
and	O
HSA1	O
/	O
OsFLN2	O
interact	O
with	O
THIOREDOXINZ	O
(	O
OsTRXz	O
)	O
to	O
regulate	O
chloroplast	O
development	O
.	O

In	O
agreement	O
with	O
this	O
,	O
knockout	O
of	O
OsTRXz	O
resulted	O
in	O
a	O
similar	O
albino	O
and	O
seedling	O
lethality	O
phenotype	O
to	O
that	O
of	O
the	O
fln1	O
mutants	O
.	O

Quantitative	O
reverse	O
transcription	O
polymerase	O
chain	O
reaction	O
and	O
immunoblot	O
analysis	O
revealed	O
that	O
the	O
transcription	B-MPA
and	O
translation	B-MPA
of	O
PEP	B-Gene
-	I-Gene
dependent	I-Gene
genes	I-Gene
were	O
strongly	O
inhibited	B-NegReg
in	O
fln1	B-Gene
and	O
trxz	O
mutants	B-Var
,	O
indicating	O
that	O
loss	O
of	O
OsFLN1	O
,	O
HSA1	O
/	O
OsFLN2	O
,	O
or	O
OsTRXz	O
function	O
perturbs	B-NegReg
the	O
stability	B-CPA
of	I-CPA
the	I-CPA
transcriptionally	I-CPA
active	I-CPA
chromosome	I-CPA
complex	I-CPA
and	O
PEP	B-Enzyme
activity	B-MPA
.	O

These	O
results	O
show	O
that	O
OsFLN1	O
and	O
HSA1	O
/	O
OsFLN2	O
contribute	O
to	O
chloroplast	O
biogenesis	O
and	O
plant	O
growth	O
.	O

The	O
gain	B-PosReg
-	I-PosReg
of	I-PosReg
-	I-PosReg
function	I-PosReg
mutation	O
E76	B-Var
K	I-Var
in	O
SHP2	B-Gene
promotes	B-PosReg
CAC	B-Disease
tumorigenesis	B-CPA
and	O
induces	B-PosReg
EMT	B-CPA
via	O
the	O
Wnt	B-Pathway
/	I-Pathway
β	I-Pathway
-	I-Pathway
catenin	I-Pathway
signaling	I-Pathway
pathway	I-Pathway
.	O

SHP2	O
is	O
encoded	O
by	O
the	O
protein	O
tyrosine	O
phosphatase	O
11	O
(	O
Ptpn11	O
)	O
gene	O
.	O

Several	O
gain	O
-	O
of	O
-	O
function	O
(	O
GOF	O
)	O
mutations	O
in	O
Ptpn11	O
have	O
been	O
identified	O
in	O
human	O
hematopoietic	O
malignancies	O
and	O
solid	O
tumors	O
.	O

In	O
addition	O
,	O
the	O
mutation	B-Var
rate	O
for	O
SHP2	B-Gene
is	O
the	O
highest	B-Reg
for	O
colorectal	B-Disease
cancer	I-Disease
(	O
CRC	O
)	O
among	O
solid	O
tumors	O
.	O

The	O
E76	O
K	O
GOF	O
mutation	O
is	O
the	O
most	O
common	O
and	O
active	O
SHP2	O
mutation	O
;	O
however	O
,	O
the	O
pathogenic	O
effects	O
and	O
function	O
of	O
this	O
mutation	O
in	O
CRC	O
tumor	O
progression	O
have	O
not	O
been	O
well	O
characterized	O
.	O

The	O
Wnt	O
/	O
β	O
-	O
catenin	O
(	O
CTNNB1	O
)	O
signaling	O
pathway	O
is	O
crucial	O
for	O
CRC	O
,	O
and	O
excessive	O
activation	O
of	O
this	O
pathway	O
has	O
been	O
observed	O
in	O
several	O
tumors	O
.	O

We	O
used	O
Ptpn11E76	O
K	O
conditional	O
knock	O
-	O
in	O
mice	O
to	O
study	O
this	O
GOF	O
mutation	O
in	O
colitis	O
-	O
associated	O
CRC	O
(	O
CAC	O
)	O
and	O
used	O
the	O
CRC	O
cell	O
lines	O
HT29	O
and	O
HCT116	O
to	O
determine	O
the	O
relationship	O
between	O
SHP2	O
and	O
Wnt	O
/	O
β	O
-	O
catenin	O
signaling	O
.	O

Ptpn11E76	B-Var
K	I-Var
conditional	O
knock	O
-	O
in	O
mice	O
exhibited	O
aggravated	B-PosReg
inflammation	B-CPA
and	O
increased	B-PosReg
CAC	B-Disease
tumorigenesis	B-CPA
.	O

In	O
vitro	O
,	O
SHP2E76	B-Var
K	I-Var
and	O
SHP2WT	O
promoted	B-PosReg
malignant	B-CPA
biological	I-CPA
behaviors	I-CPA
of	I-CPA
CRC	I-CPA
cells	I-CPA
and	O
induced	B-PosReg
epithelial	B-CPA
-	I-CPA
mesenchymal	I-CPA
transition	I-CPA
(	O
EMT	O
)	O
via	O
the	O
Wnt	O
/	O
β	O
-	O
catenin	O
signaling	O
pathway	O
.	O

Together	O
,	O
our	O
results	O
showed	O
that	O
SHP2E76	B-Var
K	I-Var
acts	O
as	O
an	O
oncogene	O
that	O
promotes	B-PosReg
the	O
tumorigenesis	B-CPA
and	O
metastasis	B-CPA
of	O
CRC	B-Disease
.	O

Recessive	O
loss	O
of	O
function	O
PIGN	B-Gene
alleles	O
,	O
including	O
an	O
intragenic	O
deletion	B-Var
with	O
founder	O
effect	O
in	O
La	O
Réunion	O
Island	O
,	O
in	O
patients	O
with	O
Fryns	O
syndrome	O
.	O

Fryns	O
syndrome	O
(	O
FS	O
)	O
is	O
a	O
multiple	O
malformations	O
syndrome	O
with	O
major	O
features	O
of	O
congenital	O
diaphragmatic	O
hernia	O
,	O
pulmonary	O
hypoplasia	O
,	O
craniofacial	O
dysmorphic	O
features	O
,	O
distal	O
digit	O
hypoplasia	O
,	O
and	O
a	O
range	O
of	O
other	O
lower	O
frequency	O
malformations	O
.	O

FS	O
is	O
typically	O
lethal	O
in	O
the	O
fetal	O
or	O
neonatal	O
period	O
.	O

Inheritance	O
is	O
presumed	O
autosomal	O
recessive	O
.	O

Although	O
no	O
major	O
genetic	O
cause	O
has	O
been	O
identified	O
for	O
FS	O
,	O
biallelic	B-Var
truncating	I-Var
variants	I-Var
in	O
PIGN	B-Gene
,	O
encoding	O
a	O
component	O
of	O
the	O
glycosylphosphatidylinositol	O
(	O
GPI)-anchor	O
biosynthesis	O
pathway	O
,	O
have	O
been	O
identified	B-Reg
in	O
a	O
limited	O
number	O
of	O
cases	O
with	O
a	O
phenotype	O
compatible	O
with	O
FS	B-Disease
.	O

Biallelic	O
variants	O
in	O
PIGN	B-Gene
,	O
typically	O
missense	B-Var
or	O
compound	B-Var
missense	I-Var
with	O
truncating	B-MPA
,	O
also	O
cause	B-Reg
multiple	B-Disease
congenital	I-Disease
anomalies	I-Disease
-	I-Disease
hypotonia	I-Disease
-	I-Disease
seizures	I-Disease
syndrome	I-Disease
1	I-Disease
(	O
MCAHS1	O
)	O
.	O

Here	O
we	O
report	O
six	O
further	O
patients	O
with	O
FS	O
with	O
or	O
without	O
congenital	O
diaphragmatic	O
hernia	O
and	O
recessive	O
loss	O
of	O
function	O
PIGN	O
alleles	O
,	O
including	O
an	O
intragenic	O
deletion	O
with	O
a	O
likely	O
founder	O
effect	O
in	O
La	O
Réunion	O
and	O
other	O
Indian	O
Ocean	O
islands	O
.	O

Our	O
results	O
support	O
the	O
hypothesis	O
that	O
a	O
spectrum	O
of	O
phenotypic	O
severity	O
is	O
associated	O
with	O
recessive	O
PIGN	O
variants	O
,	O
ranging	O
from	O
FS	O
at	O
the	O
extreme	O
end	O
,	O
caused	O
by	O
complete	O
loss	O
of	O
function	O
,	O
to	O
MCAHS1	O
,	O
in	O
which	O
some	O
residual	O
PIGN	O
function	O
may	O
remain	O
.	O

Our	O
data	O
add	O
FS	O
resulting	O
from	O
PIGN	O
variants	O
to	O
the	O
catalog	O
of	O
inherited	O
GPI	O
deficiencies	O
caused	O
by	O
the	O
disruption	O
of	O
the	O
GPI	O
-	O
anchor	O
biosynthesis	O
pathway	O
.	O

New	O
insights	O
into	O
ANGPLT3	O
in	O
controlling	O
lipoprotein	O
metabolism	O
and	O
risk	O
of	O
cardiovascular	O
diseases	O
.	O

Dyslipidemia	O
,	O
characterized	O
by	O
elevation	O
of	O
plasma	O
low	O
density	O
lipoprotein	O
cholesterol	O
(	O
LDL	O
-	O
C	O
)	O
,	O
triglyceride	O
(	O
TG	O
)	O
and	O
reduction	O
of	O
plasma	O
high	O
density	O
lipoprotein	O
cholesterol	O
(	O
HDL	O
-	O
C	O
)	O
,	O
has	O
been	O
verified	O
as	O
a	O
causal	O
risk	O
factor	O
for	O
cardiovascular	O
diseases	O
(	O
CVD	O
)	O
,	O
leading	O
to	O
a	O
high	O
mortality	O
rate	O
in	O
general	O
population	O
.	O

It	O
is	O
important	O
to	O
understand	O
the	O
molecular	O
metabolism	O
underlying	O
dyslipidemia	O
in	O
order	O
to	O
reduce	O
the	O
risk	O
and	O
to	O
develop	O
effective	O
therapeutic	O
approaches	O
against	O
CVD	O
.	O

ANGPTL3	O
(	O
human	O
)	O
or	O
Angptl3	O
(	O
mouse	O
)	O
,	O
one	O
member	O
of	O
the	O
angiopoietin	O
-	O
like	O
protein	O
(	O
ANGPTL	O
)	O
family	O
,	O
has	O
been	O
identified	O
as	O
an	O
important	O
regulator	O
of	O
lipid	O
metabolism	O
by	O
inhibiting	O
LPL	O
and	O
EL	O
activity	O
.	O

Results	O
have	O
demonstrated	O
that	O
inactivation	O
of	O
Angptl3	O
in	O
mice	O
could	O
obviously	O
reduce	O
the	O
level	O
of	O
TG	O
,	O
LDL	O
-	O
C	O
and	O
the	O
atherosclerotic	O
lesion	O
size	O
,	O
leading	O
to	O
a	O
lower	O
risk	O
for	O
dyslipidemia	O
and	O
CVD	O
.	O

Additionally	O
,	O
in	O
humans	O
,	O
carriers	O
with	O
homozygous	O
LOF	B-NegReg
mutations	B-Var
in	O
ANGPTL3	B-Gene
have	O
lower	B-NegReg
plasma	B-MPA
LDL	I-MPA
-	I-MPA
C	I-MPA
,	O
TG	B-MPA
levels	I-MPA
and	O
lower	O
risk	O
of	O
atherosclerosis	O
compared	O
to	O
the	O
non	O
-	O
carriers	O
.	O

Here	O
,	O
we	O
collect	O
the	O
latest	O
data	O
and	O
results	O
,	O
giving	O
a	O
new	O
insight	O
into	O
the	O
important	O
role	O
of	O
ANGPTL3	O
in	O
controlling	O
lipoprotein	O
metabolism	O
.	O

Finally	O
,	O
we	O
introduce	O
two	O
update	O
reports	O
on	O
the	O
antisense	O
oligonucleotide	O
and	O
monoclonal	O
antibody	O
-	O
based	O
inactivation	O
of	O
ANGPTL3	O
in	O
human	O
clinical	O
trials	O
,	O
to	O
identify	O
that	O
ANGPTL3	O
could	O
be	O
a	O
novel	O
and	O
effective	O
target	O
for	O
the	O
treatment	O
of	O
dyslipidemia	O
and	O
CVD	O
.	O

Clonal	O
evolution	O
mechanisms	B-Reg
in	O
NT5C2	B-Gene
mutant	B-Disease
-	I-Disease
relapsed	I-Disease
acute	I-Disease
lymphoblastic	I-Disease
leukaemia	I-Disease
.	O

Relapsed	B-Disease
acute	I-Disease
lymphoblastic	I-Disease
leukaemia	I-Disease
(	O
ALL	O
)	O
is	O
associated	O
with	O
resistance	O
to	O
chemotherapy	O
and	O
poor	O
prognosis	O
.	O

Gain	B-PosReg
-	I-PosReg
of	I-PosReg
-	I-PosReg
function	I-PosReg
mutations	B-Var
in	O
the	O
5'-nucleotidase	O
,	O
cytosolic	O
II	O
(	B-Gene
NT5C2	I-Gene
)	I-Gene
gene	O
induce	B-PosReg
resistance	B-MPA
to	I-MPA
6-mercaptopurine	I-MPA
and	O
are	O
selectively	O
present	O
in	O
relapsed	O
ALL	O
.	O

Yet	O
,	O
the	O
mechanisms	O
involved	O
in	O
NT5C2	O
mutation	O
-	O
driven	O
clonal	O
evolution	O
during	O
the	O
initiation	O
of	O
leukaemia	O
,	O
disease	O
progression	O
and	O
relapse	O
remain	O
unknown	O
.	O

Here	O
we	O
use	O
a	O
conditional	O
-	O
and	O
-	O
inducible	O
leukaemia	O
model	O
to	O
demonstrate	O
that	O
expression	O
of	O
NT5C2(R367Q	B-Var
)	I-Var
,	O
a	O
highly	O
prevalent	O
relapsed	B-Disease
-	I-Disease
ALL	I-Disease
NT5C2	B-Gene
mutation	O
,	O
induces	B-PosReg
resistance	B-MPA
to	I-MPA
chemotherapy	I-MPA
with	I-MPA
6-mercaptopurine	I-MPA
at	O
the	O
cost	O
of	O
impaired	O
leukaemia	O
cell	O
growth	O
and	O
leukaemia	O
-	O
initiating	O
cell	O
activity	O
.	O

The	O
loss	B-NegReg
-	I-NegReg
of	I-NegReg
-	I-NegReg
fitness	I-NegReg
phenotype	B-CPA
of	O
NT5C2+/R367Q	B-Var
mutant	O
cells	O
is	O
associated	O
with	O
excess	B-PosReg
export	B-MPA
of	I-MPA
purines	I-MPA
to	I-MPA
the	I-MPA
extracellular	I-MPA
space	I-MPA
and	O
depletion	B-MPA
of	I-MPA
the	I-MPA
intracellular	I-MPA
purine	I-MPA
-	I-MPA
nucleotide	I-MPA
pool	I-MPA
.	O

Consequently	O
,	O
blocking	O
guanosine	O
synthesis	O
by	O
inhibition	O
of	O
inosine-5'-monophosphate	O
dehydrogenase	O
(	O
IMPDH	O
)	O
induced	O
increased	O
cytotoxicity	O
against	O
NT5C2-mutant	O
leukaemia	O
lymphoblasts	O
.	O

These	O
results	O
identify	O
the	O
fitness	O
cost	O
of	O
NT5C2	O
mutation	O
and	O
resistance	O
to	O
chemotherapy	O
as	O
key	O
evolutionary	O
drivers	O
that	O
shape	O
clonal	O
evolution	O
in	O
relapsed	O
ALL	O
and	O
support	O
a	O
role	O
for	O
IMPDH	O
inhibition	O
in	O
the	O
treatment	O
of	O
ALL	O
.	O

The	O
protective	O
role	O
of	O
DOT1L	O
in	O
UV	O
-	O
induced	O
melanomagenesis	O
.	O

The	O
DOT1L	O
histone	O
H3	O
lysine	O
79	O
(	O
H3K79	O
)	O
methyltransferase	O
plays	O
an	O
oncogenic	O
role	O
in	O
MLL	O
-	O
rearranged	O
leukemogenesis	O
.	O

Here	O
,	O
we	O
demonstrate	O
that	O
,	O
in	O
contrast	O
to	O
MLL	O
-	O
rearranged	O
leukemia	O
,	O
DOT1L	O
plays	O
a	O
protective	O
role	O
in	O
ultraviolet	O
radiation	O
(	O
UVR)-induced	O
melanoma	O
development	O
.	O

Specifically	O
,	O
the	O
DOT1L	B-Gene
gene	O
is	O
located	O
in	O
a	O
frequently	O
deleted	O
region	O
and	O
undergoes	O
somatic	O
mutation	O
in	O
human	O
melanoma	O
.	O

Specific	O
mutations	B-Var
functionally	O
compromise	B-NegReg
DOT1L	B-Gene
methyltransferase	B-Enzyme
enzyme	I-Enzyme
activity	B-MPA
leading	O
to	O
reduced	B-NegReg
H3K79	B-Protein
methylation	B-MPA
.	O

Importantly	O
,	O
in	O
the	O
absence	O
of	O
DOT1L	O
,	O
UVR	O
-	O
induced	O
DNA	O
damage	O
is	O
inefficiently	O
repaired	O
,	O
so	O
that	O
DOT1L	B-Gene
loss	B-NegReg
promotes	B-PosReg
melanoma	B-CPA
development	I-CPA
in	O
mice	O
after	O
exposure	O
to	O
UVR	O
.	O

Mechanistically	O
,	O
DOT1L	O
facilitates	O
DNA	O
damage	O
repair	O
,	O
with	O
DOT1L	O
-	O
methylated	O
H3K79	O
involvement	O
in	O
binding	O
and	O
recruiting	O
XPC	O
to	O
the	O
DNA	O
damage	O
site	O
for	O
nucleotide	O
excision	O
repair	O
(	O
NER	O
)	O
.	O

This	O
study	O
indicates	O
that	O
DOT1L	O
plays	O
a	O
protective	O
role	O
in	O
UVR	O
-	O
induced	O
melanomagenesis	O
.	O

Biallelic	B-Var
variants	I-Var
in	O
KIF14	B-Gene
cause	B-Reg
intellectual	B-Disease
disability	I-Disease
with	O
microcephaly	B-Disease
.	O

Kinesin	O
proteins	O
are	O
critical	O
for	O
various	O
cellular	O
functions	O
such	O
as	O
intracellular	O
transport	O
and	O
cell	O
division	O
,	O
and	O
many	O
members	O
of	O
the	O
family	O
have	O
been	O
linked	O
to	O
monogenic	O
disorders	O
and	O
cancer	O
.	O

We	O
report	O
eight	O
individuals	O
with	O
intellectual	O
disability	O
and	O
microcephaly	O
from	O
four	O
unrelated	O
families	O
with	O
parental	O
consanguinity	O
.	O

In	O
the	O
affected	O
individuals	O
of	O
each	O
family	O
,	O
homozygosity	O
for	O
likely	O
pathogenic	B-CPA
variants	O
in	O
KIF14	B-Gene
were	O
detected	O
;	O
two	O
loss	B-NegReg
-	I-NegReg
of	I-NegReg
-	I-NegReg
function	I-NegReg
(	B-Var
p	I-Var
.	I-Var
Asn83Ilefs*3	I-Var
and	O
p	B-Var
.	I-Var
Ser1478fs	I-Var
)	I-Var
,	O
and	O
two	O
missense	B-Reg
substitutions	I-Reg
(	B-Var
p	I-Var
.	I-Var
Ser841Phe	I-Var
and	O
p	B-Var
.	I-Var
Gly459Arg	I-Var
)	I-Var
.	O

KIF14	O
is	O
a	O
mitotic	O
motor	O
protein	O
that	O
is	O
required	O
for	O
spindle	O
localization	O
of	O
the	O
mitotic	O
citron	O
rho	O
-	O
interacting	O
kinase	O
,	O
CIT	B-Gene
,	O
also	O
mutated	B-Var
in	B-Reg
microcephaly	B-Disease
.	O

Our	O
results	O
demonstrate	O
the	O
involvement	O
of	O
KIF14	O
in	O
development	O
and	O
reveal	O
a	O
wide	O
phenotypic	O
variability	O
ranging	O
from	O
fetal	O
lethality	O
to	O
moderate	O
developmental	O
delay	O
and	O
microcephaly	O
.	O

APOC3	B-Gene
Loss	B-NegReg
-	I-NegReg
of	I-NegReg
-	I-NegReg
Function	I-NegReg
Mutations	B-Var
,	O
Remnant	O
Cholesterol	O
,	O
Low	O
-	O
Density	O
Lipoprotein	O
Cholesterol	O
,	O
and	O
Cardiovascular	O
Risk	O
:	O
Mediation-	O
and	O
Meta	O
-	O
Analyses	O
of	O
137	O
895	O
Individuals	O
.	O

OBJECTIVE	O
:	O
Loss	B-NegReg
-	I-NegReg
of	I-NegReg
-	I-NegReg
function	I-NegReg
mutations	B-Var
in	O
APOC3	B-Gene
associate	O
with	O
low	B-NegReg
remnant	B-MPA
cholesterol	I-MPA
levels	I-MPA
and	O
low	O
risk	O
of	O
ischemic	O
vascular	O
disease	O
(	O
IVD	O
)	O
.	O

Because	O
some	O
studies	O
show	O
an	O
additional	O
association	O
with	O
low	O
levels	O
of	O
low	O
-	O
density	O
lipoprotein	O
cholesterol	O
(	O
LDL	O
-	O
C	O
)	O
,	O
low	O
LDL	O
-	O
C	O
may	O
explain	O
the	O
low	O
risk	O
of	O
IVD	O
in	O
APOC3	O
loss	O
-	O
of	O
-	O
function	O
heterozygotes	O
.	O

We	O
tested	O
to	O
what	O
extent	O
the	O
low	O
risk	O
of	O
IVD	O
in	O
APOC3	O
loss	O
-	O
of	O
-	O
function	O
heterozygotes	O
is	O
mediated	O
by	O
low	O
plasma	O
remnant	O
cholesterol	O
and	O
LDL	O
-	O
C.	O
APPROACH	O
AND	O
RESULTS	O
:	O
In	O
APOC3	O
loss	O
-	O
of	O
-	O
function	O
heterozygotes	O
versus	O
noncarriers	O
,	O
we	O
first	O
determined	O
remnant	O
cholesterol	O
and	O
LDL	O
-	O
C	O
levels	O
in	O
meta	O
-	O
analyses	O
of	O
137	O
895	O
individuals	O
.	O

Second	O
,	O
we	O
determined	O
whether	O
the	O
association	O
with	O
LDL	O
-	O
C	O
was	O
masked	O
by	O
lipid	O
-	O
lowering	O
therapy	O
.	O

Finally	O
,	O
using	O
mediation	O
analysis	O
,	O
we	O
determined	O
the	O
fraction	O
of	O
the	O
low	O
risk	O
of	O
IVD	O
and	O
ischemic	O
heart	O
disease	O
mediated	O
by	O
remnant	O
cholesterol	O
and	O
LDL	O
-	O
C.	O
In	O
meta	O
-	O
analyses	O
,	O
remnant	O
cholesterol	O
was	O
43	O
%	O
lower	O
(	O
95	O
%	O
confidence	O
interval	O
,	O
40%-47	O
%	O
)	O
,	O
and	O
LDL	O
-	O
C	O
was	O
4	O
%	O
lower	O
(	O
1%-6	O
%	O
)	O
in	O
loss	O
-	O
of	O
-	O
function	O
heterozygotes	O
(	O
n=776	O
)	O
versus	O
noncarriers	O
.	O

In	O
the	O
general	O
population	O
,	O
LDL	O
-	O
C	O
was	O
3	O
%	O
lower	O
in	O
loss	O
-	O
of	O
-	O
function	O
heterozygotes	O
versus	O
noncarriers	O
,	O
4	O
%	O
lower	O
when	O
correcting	O
for	O
lipid	O
-	O
lowering	O
therapy	O
,	O
and	O
3	O
%	O
lower	O
in	O
untreated	O
individuals	O
(	O
P	O
values	O
,	O
0.06	O
-	O
0.008	O
)	O
.	O

Remnant	O
cholesterol	O
mediated	O
37	O
%	O
of	O
the	O
observed	O
41	O
%	O
lower	O
risk	O
of	O
IVD	O
and	O
54	O
%	O
of	O
the	O
observed	O
36	O
%	O
lower	O
risk	O
of	O
ischemic	O
heart	O
disease	O
;	O
corresponding	O
values	O
mediated	O
by	O
LDL	O
-	O
C	O
were	O
1	O
%	O
and	O
2	O
%	O
.	O

CONCLUSIONS	O
:	O
The	O
low	O
risk	O
of	O
IVD	O
observed	O
in	O
APOC3	B-Gene
loss	B-NegReg
-	I-NegReg
of	I-NegReg
-	I-NegReg
function	I-NegReg
heterozygotes	O
is	O
mainly	O
mediated	O
by	O
the	O
associated	O
low	B-NegReg
remnant	B-MPA
cholesterol	I-MPA
and	O
not	O
by	O
low	O
LDL	O
-	O
C.	O
Furthermore	O
,	O
the	O
contribution	O
of	O
LDL	O
-	O
C	O
to	O
IVD	O
risk	O
was	O
not	O
masked	O
by	O
lipid	O
-	O
lowering	O
therapy	O
.	O

This	O
suggests	O
APOC3	O
and	O
remnant	O
cholesterol	O
as	O
important	O
new	O
targets	O
for	O
reducing	O
cardiovascular	O
risk	O
.	O

Key	O
apoptotic	B-Gene
genes	I-Gene
APAF1	B-Gene
and	O
CASP9	B-Gene
implicated	O
in	O
recurrent	O
folate	O
-	O
resistant	O
neural	O
tube	O
defects	O
.	O

Neural	O
tube	O
defects	O
(	O
NTDs	O
)	O
remain	O
one	O
of	O
the	O
most	O
serious	O
birth	O
defects	O
,	O
and	O
although	O
genes	O
in	O
several	O
pathways	O
have	O
been	O
implicated	O
as	O
risk	O
factors	O
for	O
neural	O
tube	O
defects	O
via	O
knockout	O
mouse	O
models	O
,	O
very	O
few	O
molecular	O
causes	O
in	O
humans	O
have	O
been	O
identified	O
.	O

Whole	O
exome	O
sequencing	O
identified	O
deleterious	O
variants	O
in	O
key	O
apoptotic	O
genes	O
in	O
two	O
families	O
with	O
recurrent	O
neural	O
tube	O
defects	O
.	O

Functional	O
studies	O
in	O
fibroblasts	O
indicate	O
that	O
these	O
variants	B-Var
are	O
loss	B-NegReg
-	I-NegReg
of	I-NegReg
-	I-NegReg
function	I-NegReg
,	O
as	O
apoptosis	B-CPA
is	O
significantly	O
reduced	B-NegReg
.	O

This	O
is	O
the	O
first	O
report	O
of	O
variants	B-Var
in	O
apoptotic	B-Gene
genes	I-Gene
contributing	B-Reg
to	O
neural	B-Disease
tube	I-Disease
defect	I-Disease
risk	O
in	O
humans	O
.	O

Congenital	O
diaphragmatic	O
hernia	O
as	O
a	O
part	O
of	O
Nance	O
-	O
Horan	O
syndrome	O
?	O
Nance	O
-	O
Horan	O
syndrome	O
is	O
a	O
rare	O
X	O
-	O
linked	O
developmental	O
disorder	O
characterized	O
by	O
bilateral	O
congenital	O
cataract	O
,	O
dental	O
anomalies	O
,	O
facial	O
dysmorphism	O
,	O
and	O
intellectual	O
disability	O
.	O

Here	O
,	O
we	O
identify	O
a	O
patient	O
with	O
Nance	B-Disease
-	I-Disease
Horan	I-Disease
syndrome	I-Disease
caused	B-Reg
by	I-Reg
a	O
new	O
nonsense	B-Var
NHS	B-Gene
variant	O
.	O

In	O
addition	O
,	O
the	O
patient	O
presented	O
congenital	B-Disease
diaphragmatic	I-Disease
hernia	I-Disease
.	O

NHS	O
gene	O
expression	O
in	O
murine	O
fetal	O
diaphragm	O
was	O
demonstrated	O
,	O
suggesting	O
a	O
possible	O
involvement	O
of	O
NHS	O
in	O
diaphragm	O
development	O
.	O

Congenital	B-Disease
diaphragmatic	I-Disease
hernia	I-Disease
could	O
result	B-Reg
from	I-Reg
NHS	B-Gene
loss	B-NegReg
of	I-NegReg
function	I-NegReg
in	O
pleuroperitoneal	O
fold	O
or	O
in	O
somites	O
-	O
derived	O
muscle	O
progenitor	O
cells	O
leading	O
to	O
an	O
impairment	O
of	O
their	O
cells	B-CPA
migration	I-CPA
.	O

[	O
The	O
formation	O
of	O
skin	O
barrier	O
and	O
defective	O
barrier	O
-	O
associated	O
skin	O
diseases	O
]	O
.	O

Since	O
the	O
discovery	O
of	O
loss	B-NegReg
-	I-NegReg
of	I-NegReg
-	I-NegReg
function	I-NegReg
mutations	B-Var
in	O
filaggrin	O
(	B-Gene
FLG	I-Gene
)	I-Gene
gene	O
in	O
atopic	B-Disease
dermatitis	I-Disease
(	O
AD	O
)	O
individuals	O
,	O
significant	O
attention	O
has	O
been	O
paid	O
against	O
the	O
skin	O
barrier	O
as	O
an	O
initial	O
starting	O
point	O
of	O
atopic	O
march	O
.	O

Although	O
FLG	O
is	O
a	O
significant	O
cornification	O
-	O
associated	O
gene	O
,	O
skin	O
barrier	O
formation	O
is	O
a	O
complex	O
process	O
mediated	O
by	O
an	O
array	O
of	O
genes	O
with	O
specific	O
functions	O
.	O

In	O
this	O
article	O
,	O
the	O
mechanism	O
of	O
physical	O
skin	O
barrier	O
formation	O
is	O
reviewed	O
in	O
detail	O
,	O
focusing	O
on	O
specific	O
gene	O
functions	O
and	O
inherited	O
disorders	O
caused	O
by	O
genetic	O
aberrations	O
.	O

Additionally	O
,	O
the	O
mechanism	O
of	O
percutaneous	O
sensitization	O
with	O
environmental	O
allergens	O
in	O
association	O
with	O
FLG	O
-	O
deficiency	O
is	O
reviewed	O
in	O
order	O
to	O
clarify	O
the	O
link	O
between	O
defective	O
skin	O
barrier	O
and	O
atopic	O
march	O
.	O

Finally	O
,	O
updated	O
knowledge	O
of	O
psoriasis	O
pathophysiology	O
in	O
connection	O
with	O
genetic	O
defect	O
in	O
skin	O
barrier	O
is	O
reviewed	O
.	O

This	O
article	O
would	O
provide	O
a	O
novel	O
opportunity	O
to	O
understand	O
the	O
allergic	O
/	O
autoimmune	O
disorders	O
from	O
the	O
viewpoint	O
of	O
non	O
-	O
classical	O
immune	O
cells	O
.	O

Tryptophan	O
hydroxylase	O
(	B-Gene
TRH	I-Gene
)	I-Gene
loss	B-NegReg
of	I-NegReg
function	I-NegReg
mutations	B-Var
induce	O
growth	B-CPA
and	I-CPA
behavioral	I-CPA
defects	I-CPA
in	O
Daphnia	O
magna	O
.	O

Tryptophan	O
hydroxylase	O
(	O
TRH	O
)	O
is	O
the	O
rate	O
limiting	O
enzyme	O
in	O
the	O
serotonin	O
synthesis	O
.	O

CRISPR	O
-	O
Cas9	O
technology	O
was	O
used	O
to	O
generate	O
seven	O
indel	O
TRH	O
mutants	O
in	O
Daphnia	O
magna	O
.	O

Mono	O
-	O
allelic	O
indel	O
TRH-/+	O
clones	O
showed	O
normal	O
levels	O
of	O
serotonin	O
,	O
measured	O
by	O
both	O
immunohistochemistry	O
and	O
mass	O
spectrometry	O
(	O
LC	O
-	O
MS	O
/	O
MS	O
)	O
,	O
whereas	O
bi	O
-	O
allelic	O
indel	O
TRH-/-	O
clones	O
showed	O
no	O
detectable	O
levels	O
of	O
serotonin	O
.	O

Life	O
history	O
and	O
behavioral	O
responses	O
of	O
TRH-/-	O
clones	O
showed	O
the	O
anti	O
-	O
phenotype	O
of	O
those	O
exposed	O
to	O
selective	O
serotonin	O
reuptake	O
inhibitors	O
(	O
SSRI	O
)	O
.	O

Mutants	B-Var
lacking	B-NegReg
serotonin	B-MPA
grew	B-CPA
less	B-NegReg
and	O
hence	O
reproduced	B-CPA
latter	O
,	O
produced	O
smaller	B-NegReg
clutches	B-CPA
of	O
smaller	B-NegReg
offspring	B-CPA
and	O
responded	O
to	O
a	O
greater	O
extent	O
to	O
light	O
than	O
wild	O
type	O
individuals	O
.	O

Mono	O
-	O
allelic	O
indel	O
TRH-/+	O
individuals	O
showed	O
the	O
intermediate	O
phenotype	O
.	O

The	O
SSRI	O
fluoxetine	O
enhanced	O
offspring	O
production	O
in	O
all	O
clones	O
and	O
decreased	O
the	O
response	O
to	O
light	O
only	O
in	O
those	O
clones	O
having	O
serotonin	O
,	O
thus	O
indication	O
that	O
behavioral	O
effects	O
of	O
this	O
drug	O
in	O
D.	O
magna	O
are	O
associated	O
to	O
serotonin	O
.	O

Results	O
obtained	O
with	O
the	O
TRH	O
mutants	O
are	O
in	O
line	O
with	O
reported	O
ones	O
in	O
TRH	O
knockouts	O
of	O
Caenorhabditis	O
elegans	O
,	O
Drosophila	O
and	O
mice	O
,	O
indicating	O
that	O
there	O
is	O
one	O
gene	O
encoding	O
TRH	O
,	O
which	O
is	O
the	O
serotonin	O
limiting	O
enzyme	O
in	O
both	O
the	O
central	O
and	O
the	O
periphery	O
nervous	O
system	O
in	O
Daphnia	O
and	O
that	O
deprivation	O
of	O
serotonin	O
increases	O
anxiety	O
-	O
like	O
behavior	O
.	O

Internal	B-Var
tandem	I-Var
duplication	I-Var
mutations	I-Var
in	O
the	O
tyrosine	O
kinase	O
domain	O
of	O
FLT3	B-Gene
display	O
a	O
higher	B-PosReg
oncogenic	B-CPA
potential	I-CPA
than	O
the	O
activation	O
loop	O
D835Y	O
mutation	O
.	O

Acute	B-Disease
myeloid	I-Disease
leukemia	I-Disease
(	O
AML	O
)	O
remains	O
the	O
most	O
common	O
form	O
of	O
acute	O
leukemia	O
among	O
adults	O
and	O
accounts	O
for	O
a	O
large	O
number	O
of	O
leukemia	O
-	O
related	O
deaths	O
.	O

Mutations	B-Var
in	O
FMS	O
-	O
like	O
tyrosine	O
kinase	O
3	O
(	B-Gene
FLT3	I-Gene
)	I-Gene
is	O
one	O
of	O
the	O
most	O
prevalent	B-Reg
findings	O
in	O
this	O
heterogeneous	O
disease	O
.	O

The	O
major	O
types	O
of	O
mutations	O
in	O
FLT3	O
can	O
be	O
categorized	O
as	O
internal	O
tandem	O
duplications	O
(	O
ITD	O
)	O
and	O
point	O
mutations	O
.	O

Recent	O
studies	O
suggest	O
that	O
ITDs	O
not	O
only	O
occur	O
in	O
the	O
juxtamembrane	O
region	O
as	O
originally	O
described	O
,	O
but	O
also	O
in	O
the	O
kinase	O
domain	O
.	O

Although	O
the	O
juxtamembrane	O
ITDs	O
have	O
been	O
well	O
characterized	O
,	O
the	O
tyrosine	O
kinase	O
domain	O
ITDs	O
have	O
not	O
yet	O
been	O
thoroughly	O
studied	O
due	O
to	O
their	O
recent	O
discovery	O
.	O

For	O
this	O
reason	O
,	O
we	O
compared	O
ITD	O
mutations	O
in	O
the	O
juxtamembrane	O
domain	O
with	O
those	O
in	O
the	O
tyrosine	O
kinase	O
domain	O
,	O
as	O
well	O
as	O
with	O
the	O
most	O
common	O
activating	O
point	O
mutation	O
in	O
the	O
tyrosine	O
kinase	O
domain	O
,	O
D835Y.	O
The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
understand	O
whether	O
it	O
is	O
the	O
nature	O
of	O
the	O
mutation	O
or	O
the	O
location	O
of	O
the	O
mutation	O
that	O
plays	O
the	O
main	O
role	O
in	O
leukemogenesis	O
.	O

The	O
various	O
FLT3	O
mutants	O
were	O
expressed	O
in	O
the	O
murine	O
pro	O
-	O
B	O
cell	O
line	O
Ba	O
/	O
F3	O
and	O
examined	O
for	O
their	O
capacity	O
to	O
form	O
colonies	O
in	O
semisolid	O
medium	O
.	O

The	O
size	O
and	O
number	O
of	O
colonies	O
formed	O
by	O
Ba	O
/	O
F3	O
cells	O
expressing	O
either	O
the	O
internal	O
tandem	O
duplication	O
within	O
juxtamembrane	O
domain	O
of	O
the	O
receptor	O
(	O
JMD	O
-	O
ITD	O
)	O
or	O
the	O
tyrosine	O
kinase	O
domain	O
(	O
TKD)-ITD	O
were	O
indistinguishable	O
,	O
while	O
Ba	O
/	O
F3	O
cells	O
expressing	O
D835Y	O
/	O
FLT3	O
failed	O
to	O
form	O
colonies	O
.	O

Cell	B-CPA
proliferation	I-CPA
and	O
cell	B-CPA
survival	I-CPA
was	O
also	O
significantly	O
higher	B-PosReg
in	O
TKD	B-Var
-	I-Var
ITD	I-Var
expressing	O
cells	O
,	O
compared	O
to	O
cells	O
expressing	O
D835Y	O
/	O
FLT3	O
.	O

Furthermore	O
,	O
TKD	B-Var
-	I-Var
ITD	I-Var
is	O
capable	O
of	O
inducing	B-PosReg
phosphorylation	B-MPA
of	O
STAT5	B-Protein
,	O
while	O
D835Y	O
/	O
FLT3	O
fails	O
to	O
induce	O
tyrosine	O
phosphorylation	O
of	O
STAT5	O
.	O

Other	O
signal	O
transduction	O
pathways	O
such	O
as	O
the	O
RAS	O
/	O
ERK	O
and	O
the	O
PI3K	O
/	O
AKT	O
pathways	O
were	O
activated	O
to	O
the	O
same	O
level	O
in	O
TKD	O
-	O
ITD	O
cells	O
as	O
compared	O
to	O
D835Y	O
/	O
FLT3	O
expressing	O
cells	O
.	O

Taken	O
together	O
,	O
our	O
data	O
suggest	O
that	O
TKD	O
-	O
ITD	O
displays	O
similar	O
oncogenic	O
potential	O
to	O
the	O
JMD	O
-	O
ITD	O
but	O
a	O
higher	O
oncogenic	O
potential	O
than	O
the	O
D835Y	O
point	O
mutation	O
.	O

Reversal	O
of	O
end	O
-	O
stage	O
heart	O
failure	O
in	O
juvenile	O
hemochromatosis	O
with	O
iron	O
chelation	O
therapy	O
:	O
a	O
case	O
report	O
.	O

BACKGROUND	O
:	O
Juvenile	O
hemochromatosis	O
is	O
the	O
most	O
severe	O
form	O
of	O
iron	O
overloading	O
phenotype	O
.	O

Although	O
rare	O
,	O
it	O
should	O
be	O
suspected	O
in	O
patients	O
who	O
present	O
with	O
hypogonadotropic	O
hypogonadism	O
,	O
diabetes	O
mellitus	O
,	O
or	O
cardiomyopathy	O
without	O
a	O
clear	O
cause	O
.	O

CASE	O
PRESENTATION	O
:	O
A	O
young	O
Serbian	O
male	O
presenting	O
with	O
end	O
-	O
stage	O
heart	O
failure	O
was	O
referred	O
for	O
extracorporeal	O
membrane	O
oxygenation	O
.	O

An	O
endomyocardial	O
biopsy	O
revealed	O
cytoplasmic	O
iron	O
deposits	O
in	O
myocytes	O
.	O

His	O
condition	O
was	O
stabilized	O
with	O
biventricular	O
assist	O
devices	O
and	O
he	O
was	O
listed	O
for	O
heart	O
transplantation	O
.	O

Iron	O
chelation	O
therapy	O
was	O
commenced	O
and	O
resulted	O
in	O
rapid	O
removal	O
of	O
iron	O
burden	O
.	O

Serial	O
outpatient	O
echocardiograms	O
demonstrated	O
myocardial	O
recovery	O
such	O
that	O
a	O
successful	O
biventricular	O
assist	O
device	O
explant	O
occurred	O
131	O
days	O
after	O
initial	O
implant	O
.	O

Targeted	O
gene	O
sequencing	O
revealed	O
a	O
loss	B-NegReg
-	I-NegReg
of	I-NegReg
-	I-NegReg
function	I-NegReg
mutation	B-Var
within	O
the	O
HJV	B-Gene
gene	O
,	O
which	O
is	O
consistent	O
with	O
juvenile	B-Disease
hemochromatosis	I-Disease
.	O

CONCLUSIONS	O
:	O
This	O
rare	O
case	O
of	O
a	O
patient	O
with	O
juvenile	B-Disease
hemochromatosis	I-Disease
associated	B-Reg
with	O
a	O
HJV	B-Gene
mutation	B-Var
provides	O
histologic	O
evidence	O
documenting	O
the	O
reversal	O
of	O
associated	O
end	O
-	O
stage	O
heart	O
failure	O
,	O
requiring	O
emergent	O
mechanical	O
circulatory	O
support	O
,	O
with	O
iron	O
chelation	O
therapy	O
.	O

TRPV1	B-Gene
gain	B-PosReg
-	I-PosReg
of	I-PosReg
-	I-PosReg
function	I-PosReg
mutation	B-Var
impairs	B-NegReg
pain	B-CPA
and	I-CPA
itch	I-CPA
sensations	I-CPA
in	O
mice	O
.	O

Transient	O
receptor	O
potential	O
vanilloid	O
1	O
(	O
TRPV1	O
)	O
is	O
a	O
non	O
-	O
selective	O
cation	O
channel	O
,	O
which	O
can	O
detect	O
various	O
noxious	O
stimuli	O
that	O
cause	O
pain	O
,	O
inflammation	O
,	O
hyperalgesia	O
,	O
and	O
itch	O
.	O

TRPV1	O
knock	O
-	O
out	O
mice	O
show	O
deficiency	O
in	O
nociception	O
,	O
but	O
the	O
in	O
vivo	O
effects	O
of	O
persistent	O
activation	O
of	O
TRPV1	O
are	O
not	O
completely	O
understood	O
.	O

Here	O
,	O
we	O
generated	O
TRPV1	O
knock	O
-	O
in	O
mice	O
with	O
a	O
G564S	O
mutation	O
.	O

In	O
the	O
heterologous	O
expression	O
system	O
,	O
an	O
electrophysiological	O
study	O
showed	O
that	O
the	O
G564S	B-Var
mutation	O
in	O
mouse	O
TRPV1	B-Gene
caused	O
increased	B-PosReg
basal	B-CPA
current	I-CPA
and	O
a	O
leftward	B-CPA
shift	I-CPA
of	I-CPA
voltage	I-CPA
dependence	I-CPA
.	O

Intriguingly	O
,	O
using	O
behavioral	O
analysis	O
,	O
we	O
found	O
that	O
knock	O
-	O
in	O
mice	O
showed	O
a	O
thermosensory	B-CPA
defect	B-NegReg
,	O
impaired	B-NegReg
inflammatory	B-MPA
thermal	I-MPA
pain	I-MPA
,	O
and	O
capsaicin	B-CPA
sensitivity	I-CPA
.	O

We	O
also	O
demonstrated	O
an	O
attenuated	O
behavioral	O
response	O
to	O
the	O
pruritic	O
agent	O
histamine	O
in	O
the	O
knock	O
-	O
in	O
mice	O
.	O

Indeed	O
,	O
calcium	O
imaging	O
together	O
with	O
electrophysiology	O
showed	O
that	O
the	O
overactive	O
mutant	O
had	O
decreased	O
capsaicin	O
sensitivity	O
.	O

Western	O
blot	O
analysis	O
revealed	O
that	O
the	O
G564S	B-Var
mutant	O
reduced	B-NegReg
TRPV1	B-Protein
phosphorylation	B-MPA
and	O
cell	B-CPA
membrane	I-CPA
trafficking	I-CPA
.	O

Together	O
,	O
we	O
have	O
generated	O
a	O
mouse	O
model	O
with	O
a	O
gain	B-PosReg
-	I-PosReg
of	I-PosReg
-	I-PosReg
function	I-PosReg
mutation	B-Var
in	O
Trpv1	B-Gene
gene	O
and	O
demonstrated	O
that	O
the	O
pain	B-CPA
and	I-CPA
histamine	I-CPA
-	I-CPA
dependent	I-CPA
itch	I-CPA
sensations	I-CPA
in	O
these	O
mice	O
are	O
impaired	B-NegReg
due	O
to	O
a	O
decreased	B-NegReg
phosphorylation	B-MPA
level	I-MPA
and	O
reduced	B-NegReg
membrane	B-MPA
localization	I-MPA
of	O
TRPV1	B-Protein
.	O

Loss	B-NegReg
-	I-NegReg
of	I-NegReg
-	I-NegReg
Function	I-NegReg
Mutations	B-Var
in	O
UNC45A	B-Gene
Cause	O
a	O
Syndrome	B-Disease
Associating	O
Cholestasis	B-Disease
,	O
Diarrhea	B-Disease
,	O
Impaired	B-Disease
Hearing	I-Disease
,	O
and	O
Bone	B-Disease
Fragility	I-Disease
.	O

Despite	O
the	O
rapid	O
discovery	O
of	O
genes	O
for	O
rare	O
genetic	O
disorders	O
,	O
we	O
continue	O
to	O
encounter	O
individuals	O
presenting	O
with	O
syndromic	O
manifestations	O
.	O

Here	O
,	O
we	O
have	O
studied	O
four	O
affected	O
people	O
in	O
three	O
families	O
presenting	O
with	O
cholestasis	B-Disease
,	O
congenital	B-Disease
diarrhea	I-Disease
,	O
impaired	B-Disease
hearing	I-Disease
,	O
and	O
bone	B-Disease
fragility	I-Disease
.	O

Whole	O
-	O
exome	O
sequencing	O
of	O
all	O
affected	O
individuals	O
and	O
their	O
parents	O
identified	O
biallelic	B-Var
mutations	I-Var
in	O
Unc-45	O
Myosin	O
Chaperone	O
A	O
(	B-Gene
UNC45A	I-Gene
)	I-Gene
as	O
a	O
likely	O
driver	O
for	O
this	O
disorder	O
.	O

Subsequent	O
in	O
vitro	O
and	O
in	O
vivo	O
functional	O
studies	O
of	O
the	O
candidate	O
gene	O
indicated	O
a	O
loss	B-NegReg
-	I-NegReg
of	I-NegReg
-	I-NegReg
function	I-NegReg
paradigm	O
,	O
wherein	O
mutations	O
attenuated	B-NegReg
or	O
abolished	B-NegReg
protein	B-Protein
activity	B-MPA
with	O
concomitant	O
defects	B-NegReg
in	O
gut	B-CPA
development	I-CPA
and	O
function	O
.	O

Loss	O
-	O
of	O
-	O
function	O
and	O
gain	O
-	O
of	O
-	O
function	O
mutations	O
in	O
PPP3CA	O
cause	O
two	O
distinct	O
disorders	O
.	O

Calcineurin	O
is	O
a	O
calcium	O
(	O
Ca2+)/calmodulin	O
-	O
regulated	O
protein	O
phosphatase	O
that	O
mediates	O
Ca2	O
+	O
-dependent	O
signal	O
transduction	O
.	O

Here	O
,	O
we	O
report	O
six	O
heterozygous	O
mutations	O
in	O
a	O
gene	O
encoding	O
the	O
alpha	O
isoform	O
of	O
the	O
calcineurin	O
catalytic	O
subunit	O
(	O
PPP3CA	O
)	O
.	O

Notably	O
,	O
mutations	O
were	O
observed	O
in	O
different	O
functional	O
domains	O
:	O
in	O
addition	O
to	O
three	O
catalytic	O
domain	O
mutations	O
,	O
two	O
missense	O
mutations	O
were	O
found	O
in	O
the	O
auto	O
-	O
inhibitory	O
(	O
AI	O
)	O
domain	O
.	O

One	O
additional	O
frameshift	O
insertion	O
that	O
caused	O
premature	O
termination	O
was	O
also	O
identified	O
.	O

Detailed	O
clinical	O
evaluation	O
of	O
the	O
six	O
individuals	O
revealed	O
clinically	O
unexpected	O
consequences	O
of	O
the	O
PPP3CA	B-Gene
mutations	O
.	O

First	O
,	O
the	O
catalytic	B-Var
domain	I-Var
mutations	I-Var
and	O
frameshift	B-Var
mutation	I-Var
were	O
consistently	O
found	B-Reg
in	O
patients	O
with	O
nonsyndromic	B-Disease
early	I-Disease
onset	I-Disease
epileptic	I-Disease
encephalopathy	I-Disease
.	O

In	O
contrast	O
,	O
the	O
AI	B-Var
domain	I-Var
mutations	I-Var
were	O
associated	B-Reg
with	O
multiple	B-Disease
congenital	I-Disease
abnormalities	I-Disease
including	O
craniofacial	B-Disease
dysmorphism	I-Disease
,	O
arthrogryposis	B-Disease
and	O
short	B-Disease
stature	I-Disease
.	O

In	O
addition	O
,	O
one	O
individual	O
showed	O
severe	O
skeletal	O
developmental	O
defects	O
,	O
namely	O
,	O
severe	O
craniosynostosis	O
and	O
gracile	O
bones	O
(	O
severe	O
bone	O
slenderness	O
and	O
perinatal	O
fractures	O
)	O
.	O

Using	O
a	O
yeast	O
model	O
system	O
,	O
we	O
showed	O
that	O
the	O
catalytic	O
and	O
AI	B-Var
domain	I-Var
mutations	I-Var
visibly	O
result	O
in	O
decreased	O
and	O
increased	B-PosReg
calcineurin	B-MPA
signaling	I-MPA
,	O
respectively	O
.	O

These	O
findings	O
indicate	O
that	O
different	O
functional	O
effects	O
of	O
PPP3CA	B-Gene
mutations	O
are	O
associated	O
with	O
two	O
distinct	O
disorders	O
and	O
suggest	O
that	O
functional	O
approaches	O
using	O
a	O
simple	O
cellular	O
system	O
provide	O
a	O
tool	O
for	O
resolving	O
complex	O
genotype	O
-	O
phenotype	O
correlations	O
.	O

Genetic	O
Suppression	O
of	O
Basement	O
Membrane	O
Defects	O
in	O
Caenorhabditis	O
elegans	O
by	O
Gain	O
of	O
Function	O
in	O
Extracellular	O
Matrix	O
and	O
Cell	O
-	O
Matrix	O
Attachment	O
Genes	O
.	O

Basement	O
membranes	O
are	O
extracellular	O
matrices	O
essential	O
for	O
embryonic	O
development	O
in	O
animals	O
.	O

Peroxidasins	O
are	O
extracellular	O
peroxidases	O
implicated	O
in	O
the	O
unique	O
sulfilimine	O
cross	O
-	O
links	O
between	O
type	O
IV	O
basement	O
membrane	O
collagens	O
.	O

Loss	B-NegReg
of	I-NegReg
function	I-NegReg
in	O
the	O
Caenorhabditis	B-Enzyme
elegans	I-Enzyme
peroxidasin	I-Enzyme
PXN-2	I-Enzyme
results	O
in	O
fully	B-CPA
penetrant	I-CPA
embryonic	I-CPA
or	O
larval	B-CPA
lethality	I-CPA
.	O

Using	O
genetic	O
suppressor	O
screening	O
,	O
we	O
find	O
that	O
the	O
requirement	O
for	O
PXN-2	O
in	O
development	O
can	O
be	O
bypassed	O
by	O
gain	O
of	O
function	O
in	O
multiple	O
genes	O
encoding	O
other	O
basement	O
membrane	O
components	O
,	O
or	O
proteins	O
implicated	O
in	O
cell	O
-	O
matrix	O
attachment	O
.	O

We	O
identify	O
multiple	O
alleles	O
of	O
let-805	O
,	O
encoding	O
the	O
transmembrane	O
protein	O
myotactin	O
,	O
which	O
suppress	O
phenotypes	O
of	O
pxn-2	O
null	O
mutants	O
and	O
of	O
other	O
basement	O
membrane	O
mutants	O
such	O
as	O
F	O
-	O
spondin	O
/	O
spon-1	O
These	O
let-805	B-Gene
suppressor	O
alleles	O
cause	O
missense	B-Var
alterations	I-Var
in	O
two	O
pairs	O
of	O
FNIII	O
repeats	O
in	O
the	O
extracellular	O
domain	O
;	O
they	O
act	O
dominantly	O
and	O
have	O
no	O
detectable	O
phenotypes	O
alone	O
,	O
suggesting	O
they	O
cause	O
gain	B-PosReg
of	I-PosReg
function	I-PosReg
.	O

We	O
also	O
identify	O
suppressor	O
missense	O
mutations	O
affecting	O
basement	O
membrane	O
components	O
type	O
IV	O
collagen	O
(	O
emb-9	O
,	O
let-2	O
)	O
and	O
perlecan	O
(	O
unc-52	O
)	O
,	O
as	O
well	O
as	O
a	O
mutation	O
affecting	O
spectraplakin	O
(	O
vab-10	O
)	O
,	O
a	O
component	O
of	O
the	O
epidermal	O
cytoskeleton	O
.	O

These	O
suppressor	O
alleles	O
do	O
not	O
bypass	O
the	O
developmental	O
requirement	O
for	O
core	O
structural	O
proteins	O
of	O
the	O
basement	O
membrane	O
such	O
as	O
laminin	O
or	O
type	O
IV	O
collagen	O
.	O

In	O
conclusion	O
,	O
putative	O
gain	O
-	O
of	O
-	O
function	O
alterations	O
in	O
matrix	O
proteins	O
or	O
in	O
cell	O
-	O
matrix	O
receptors	O
can	O
overcome	O
the	O
requirement	O
for	O
certain	O
basement	O
membrane	O
proteins	O
in	O
embryonic	O
development	O
,	O
revealing	O
previously	O
unknown	O
plasticity	O
in	O
the	O
genetic	O
requirements	O
for	O
the	O
extracellular	O
matrix	O
.	O

Biallelic	B-Var
inactivating	I-Var
variants	I-Var
in	O
the	O
GTPBP2	B-Gene
gene	O
cause	B-Reg
a	O
neurodevelopmental	B-Disease
disorder	I-Disease
with	O
severe	O
intellectual	O
disability	O
.	O

Congenital	O
neurological	O
disorders	O
are	O
genetically	O
highly	O
heterogeneous	O
.	O

Rare	O
forms	O
of	O
hereditary	O
neurological	O
disorders	O
are	O
still	O
difficult	O
to	O
be	O
adequately	O
diagnosed	O
.	O

Pertinent	O
studies	O
,	O
especially	O
when	O
reporting	O
only	O
single	O
families	O
,	O
need	O
independent	O
confirmation	O
.	O

We	O
present	O
three	O
unrelated	O
families	O
in	O
which	O
whole	O
-	O
exome	O
sequencing	O
identified	O
the	O
homozygous	O
non	O
-	O
sense	O
variants	O
c.430[C	B-Var
>	I-Var
T];[C	I-Var
>	I-Var
T	I-Var
]	I-Var
p.(Arg144	I-Var
*	I-Var
)	I-Var
,	O
c.1219[C	B-Var
>	I-Var
T];[C	I-Var
>	I-Var
T	I-Var
]	I-Var
p.(Gln407	I-Var
*	I-Var
)	I-Var
and	O
c.1408[C	B-Var
>	I-Var
T];[C	I-Var
>	I-Var
T	I-Var
]	I-Var
p.(Arg470	I-Var
*	I-Var
)	I-Var
in	O
GTPBP2	B-Gene
.	O

Their	O
clinical	O
presentations	O
include	O
early	O
onset	O
and	O
apparently	O
non	B-CPA
-	I-CPA
progressive	I-CPA
motor	I-CPA
and	I-CPA
cognitive	I-CPA
impairment	I-CPA
,	O
and	O
thereby	O
overlap	O
with	O
findings	O
in	O
a	O
recently	O
described	O
family	O
harbouring	O
a	O
homozygous	O
GTPBP2	O
splice	O
site	O
variant	O
.	O

Notable	O
differences	O
include	O
structural	B-CPA
brain	I-CPA
abnormalities	I-CPA
(	O
e.g.	O
,	O
agenesis	B-CPA
of	I-CPA
the	I-CPA
corpus	I-CPA
callosum	I-CPA
,	O
exclusive	O
to	O
our	O
patients	O
)	O
,	O
and	O
evidence	O
for	O
brain	B-CPA
iron	I-CPA
accumulation	I-CPA
(	O
exclusive	O
to	O
the	O
previously	O
described	O
family	O
)	O
.	O

This	O
report	O
confirms	O
pathogenicity	O
of	O
biallelic	O
GTPBP2	O
inactivation	O
and	O
broadens	O
the	O
phenotypic	O
spectrum	O
.	O

It	O
also	O
underlines	O
that	O
a	O
potential	O
involvement	O
of	O
brain	O
iron	O
accumulation	O
needs	O
clarification	O
.	O

Further	O
patients	O
will	O
have	O
to	O
be	O
identified	O
and	O
characterised	O
in	O
order	O
to	O
fully	O
define	O
the	O
core	O
features	O
of	O
GTPBP2-associated	O
neurological	O
disorder	O
,	O
but	O
future	O
approaches	O
to	O
molecular	O
diagnosis	O
of	O
neurodevelopmental	O
disorders	O
should	O
implement	O
GTPBP2	O
.	O

Bi	B-Var
-	I-Var
allelic	I-Var
inactivating	I-Var
variants	I-Var
in	O
the	O
COCH	B-Gene
gene	O
cause	B-Reg
autosomal	B-Disease
recessive	I-Disease
prelingual	I-Disease
hearing	I-Disease
impairment	I-Disease
.	O

Pathogenic	O
variant	O
in	O
COCH	O
are	O
a	O
known	O
cause	O
of	O
DFNA9	O
autosomal	O
dominant	O
progressive	O
hearing	O
loss	O
and	O
vestibular	O
dysfunction	O
with	O
adult	O
onset	O
.	O

Hitherto	O
,	O
only	O
dominant	O
nonsynonymous	O
variants	O
and	O
in	O
-	O
frame	O
deletions	O
with	O
a	O
presumed	O
dominant	O
negative	O
or	O
gain	O
-	O
of	O
-	O
function	O
effect	O
have	O
been	O
described	O
.	O

Here	O
,	O
we	O
describe	O
two	O
brothers	O
with	O
congenital	O
prelingual	O
deafness	O
and	O
a	O
homozygous	O
nonsense	O
c.292C	B-Var
>	I-Var
T(p	I-Var
.	I-Var
Arg98	I-Var
*	I-Var
)	I-Var
COCH	B-Gene
variant	O
,	O
suggesting	O
a	O
loss	B-NegReg
-	I-NegReg
of	I-NegReg
-	I-NegReg
function	I-NegReg
effect	O
.	O

Vestibular	B-Disease
dysfunction	I-Disease
starting	O
in	O
the	O
first	O
decade	O
was	O
observed	O
in	O
the	O
older	O
patient	O
.	O

The	O
heterozygous	O
parents	O
and	O
sibling	O
have	O
normal	O
hearing	O
and	O
vestibular	O
function	O
,	O
except	O
for	O
the	O
mother	O
,	O
who	O
shows	O
vestibular	O
hyporeflexia	O
and	O
abnormal	O
smooth	O
pursuit	O
tests	O
,	O
most	O
likely	O
due	O
to	O
concomitant	O
disease	O
.	O

This	O
is	O
the	O
first	O
report	O
of	O
autosomal	O
recessive	O
inheritance	O
of	O
cochlea	O
-	O
vestibular	O
dysfunction	O
caused	O
by	O
a	O
pathogenic	O
variant	O
in	O
the	O
COCH	O
gene	O
.	O

An	O
earlier	O
onset	O
of	O
hearing	O
impairment	O
and	O
vestibular	O
dysfunction	O
compared	O
to	O
the	O
dominant	O
hearing	O
loss	O
causing	O
COCH	O
variants	O
is	O
observed	O
.	O

Serum	O
vitamin	O
C	O
levels	O
modulate	O
the	O
lifespan	O
and	O
endoplasmic	O
reticulum	O
stress	O
response	O
pathways	O
in	O
mice	O
synthesizing	O
a	O
nonfunctional	O
mutant	O
WRN	O
protein	O
.	O

Werner	B-Disease
syndrome	I-Disease
(	O
WS	O
)	O
is	O
a	O
premature	O
aging	O
disorder	O
caused	B-Reg
by	I-Reg
mutations	B-Var
in	O
a	O
RecQ	B-Protein
-	I-Protein
family	I-Protein
DNA	I-Protein
helicase	I-Protein
(	O
WRN	O
)	O
.	O

Mice	O
lacking	O
part	O
of	O
the	O
helicase	O
domain	O
of	O
the	O
WRN	O
ortholog	O
exhibit	O
several	O
phenotypic	O
features	O
of	O
WS	O
.	O

In	O
this	O
study	O
,	O
we	O
generated	O
a	O
Wrn	O
mutant	O
line	O
that	O
,	O
like	O
humans	O
,	O
relies	O
entirely	O
on	O
dietary	O
sources	O
of	O
vitamin	O
C	O
(	O
ascorbate	O
)	O
to	O
survive	O
,	O
by	O
crossing	O
them	O
to	O
mice	O
that	O
lack	O
the	O
gulonolactone	O
oxidase	O
enzyme	O
required	O
for	O
ascorbate	O
synthesis	O
.	O

In	O
the	O
presence	O
of	O
0.01	O
%	O
ascorbate	O
(	O
w	O
/	O
v	O
)	O
in	O
drinking	O
water	O
,	O
double	O
-	O
mutant	O
mice	O
exhibited	O
a	O
severe	O
reduction	O
in	O
lifespan	O
,	O
small	O
size	O
,	O
sterility	O
,	O
osteopenia	O
,	O
and	O
metabolic	O
profiles	O
different	O
from	O
wild	O
-	O
type	O
(	O
WT	O
)	O
mice	O
.	O

Although	O
increasing	O
the	O
dose	O
of	O
ascorbate	O
to	O
0.4	O
%	O
improved	O
dramatically	O
the	O
phenotypes	O
of	O
double	O
-	O
mutant	O
mice	O
,	O
the	O
metabolic	O
and	O
cytokine	O
profiles	O
were	O
different	O
from	O
age	O
-	O
matched	O
WT	O
mice	O
.	O

Finally	O
,	O
double	O
-	O
mutant	O
mice	O
treated	O
with	O
0.01	O
%	O
ascorbate	O
revealed	O
a	O
permanent	O
activation	O
of	O
all	O
the	O
3	O
branches	O
of	O
the	O
ER	O
stress	O
response	O
pathways	O
due	O
to	O
a	O
severe	O
chronic	O
oxidative	O
stress	O
in	O
the	O
ER	O
compartment	O
.	O

In	O
addition	O
,	O
markers	O
associated	O
with	O
the	O
ubiquitin	O
-	O
proteasome	O
-	O
dependent	O
ER	O
-	O
associated	O
degradation	O
pathway	O
were	O
increased	O
.	O

Augmenting	O
the	O
dose	O
of	O
ascorbate	O
reversed	O
the	O
activation	O
of	O
this	O
pathway	O
to	O
WT	O
levels	O
rendering	O
this	O
pathway	O
a	O
potential	O
therapeutic	O
target	O
in	O
WS.-Aumailley	O
,	O
L.	O
,	O
Dubois	O
,	O
M.	O
J.	O
,	O
Brennan	O
,	O
T.	O
A.	O
,	O
Garand	O
,	O
C.	O
,	O
Paquet	O
,	O
E.	O
R.	O
,	O
Pignolo	O
,	O
R.	O
J.	O
,	O
Marette	O
,	O
A.	O
,	O
Lebel	O
,	O
M.	O
Serum	O
vitamin	O
C	O
levels	O
modulate	O
the	O
lifespan	O
and	O
endoplasmic	O
reticulum	O
stress	O
response	O
pathways	O
in	O
mice	O
synthesizing	O
a	O
nonfunctional	O
mutant	O
WRN	O
protein	O
.	O

CgPDR1	B-Gene
gain	B-PosReg
-	I-PosReg
of	I-PosReg
-	I-PosReg
function	I-PosReg
mutations	B-Var
lead	B-Reg
to	I-Reg
azole	B-MPA
-	I-MPA
resistance	I-MPA
and	O
increased	B-PosReg
adhesion	B-MPA
in	O
clinical	O
Candida	O
glabrata	O
strains	O
.	O

Recently	O
,	O
Candida	O
glabrata	O
has	O
emerged	O
as	O
a	O
health	O
-	O
threatening	O
pathogen	O
and	O
the	O
rising	O
resistance	O
to	O
antifungal	O
agent	O
in	O
C.	O
glabrata	O
often	O
leads	O
to	O
clinical	O
treatment	O
failure	O
.	O

To	O
investigate	O
the	O
evolution	O
of	O
drug	O
resistance	O
and	O
adherence	O
ability	O
in	O
four	O
paired	O
clinical	O
isolates	O
collected	O
before	O
and	O
after	O
antifungal	O
treatment	O
.	O

Sequence	O
analysis	O
,	O
gene	O
disruption	O
,	O
drug	O
-	O
susceptibility	O
,	O
adhesion	O
tests	O
and	O
real	O
-	O
time	O
quantitative	O
PCR	O
were	O
performed	O
.	O

The	O
azole	O
-	O
susceptible	O
strains	O
acquired	O
azole	O
resistance	O
after	O
antifungal	O
therapy	O
.	O

Four	O
gain	O
-	O
of	O
-	O
function	O
(	O
GOF	O
)	O
mutations	O
in	O
CgPDR1	O
were	O
revealed	O
by	O
sequence	O
analysis	O
,	O
namely	O
G1099D	O
,	O
G346D	O
,	O
L344S	O
and	O
P927S	O
,	O
the	O
last	O
being	O
reported	O
for	O
the	O
first	O
time	O
.	O

CDR1	B-MPA
,	O
CDR2	I-MPA
and	I-MPA
SNQ2	I-MPA
efflux	I-MPA
pump	I-MPA
gene	I-MPA
expression	I-MPA
levels	I-MPA
were	O
elevated	B-PosReg
in	O
strains	O
harbouring	O
GOF	B-PosReg
mutations	B-Var
in	O
CgPDR1	B-Gene
,	O
resulting	O
in	O
decreased	B-NegReg
azole	B-MPA
susceptibility	I-MPA
.	O

CgPDR1	O
alleles	O
with	O
distinct	O
GOF	O
mutations	O
displayed	O
different	O
expression	O
profiles	O
for	O
the	O
drug	O
-	O
related	O
genes	O
.	O

CgPDR1GOF	B-PosReg
mutations	B-Var
led	O
to	O
increased	B-PosReg
efflux	B-MPA
pumps	I-MPA
expression	I-MPA
levels	I-MPA
in	O
a	O
strain	O
background	O
independent	O
way	O
.	O

Hyperactive	O
Pdr1G1099D	O
and	O
Pdr1P927S	O
displayed	O
strain	O
background	O
-	O
dependent	O
increased	O
adherence	O
to	O
host	O
cells	O
via	O
upregulation	O
of	O
EPA1	O
transcription	O
.	O

Interestingly	O
,	O
the	O
drug	O
transporter	O
gene	O
expression	O
levels	O
did	O
not	O
always	O
correspond	O
with	O
that	O
of	O
the	O
adhesin	O
EPA1	O
gene	O
.	O

GOF	B-PosReg
mutations	B-Var
in	O
CgPDR1	B-Gene
conferred	B-Reg
drug	B-MPA
resistance	I-MPA
and	O
increased	B-PosReg
adherence	B-MPA
in	O
the	O
clinical	O
strains	O
,	O
possibly	O
endowing	O
C.	O
glabrata	O
with	O
increased	O
viability	O
and	O
pathogenicity	O
.	O

Loss	O
of	O
Function	O
of	O
the	O
Nuclear	O
Receptor	O
NR2F2	O
,	O
Encoding	O
COUP	O
-	O
TF2	O
,	O
Causes	O
Testis	O
Development	O
and	O
Cardiac	O
Defects	O
in	O
46,XX	O
Children	O
.	O

Emerging	O
evidence	O
from	O
murine	O
studies	O
suggests	O
that	O
mammalian	O
sex	O
determination	O
is	O
the	O
outcome	O
of	O
an	O
imbalance	O
between	O
mutually	O
antagonistic	O
male	O
and	O
female	O
regulatory	O
networks	O
that	O
canalize	O
development	O
down	O
one	O
pathway	O
while	O
actively	O
repressing	O
the	O
other	O
.	O

However	O
,	O
in	O
contrast	O
to	O
testis	O
formation	O
,	O
the	O
gene	O
regulatory	O
pathways	O
governing	O
mammalian	O
ovary	O
development	O
have	O
remained	O
elusive	O
.	O

We	O
performed	O
exome	O
or	O
Sanger	O
sequencing	O
on	O
79	O
46,XX	O
SRY	O
-	O
negative	O
individuals	O
with	O
either	O
unexplained	O
virilization	O
or	O
with	O
testicular	O
/	O
ovotesticular	O
disorders	O
/	O
differences	O
of	O
sex	O
development	O
(	O
TDSD	O
/	O
OTDSD	O
)	O
.	O

We	O
identified	O
heterozygous	O
frameshift	O
mutations	O
in	O
NR2F2	B-Gene
,	O
encoding	O
COUP	O
-	O
TF2	O
,	O
in	O
three	O
children	O
.	O

One	O
carried	O
a	O
c.103_109delGGCGCCC	O
(	B-Var
p	I-Var
.	I-Var
Gly35Argfs∗75	I-Var
)	I-Var
mutation	O
,	O
while	O
two	O
others	O
carried	O
a	O
c.97_103delCCGCCCG	O
(	B-Var
p	I-Var
.	I-Var
Pro33Alafs∗77	I-Var
)	I-Var
mutation	O
.	O

In	O
two	O
of	O
three	O
children	O
the	O
mutation	O
was	O
de	O
novo	O
.	O

All	O
three	O
children	O
presented	B-Reg
with	I-Reg
congenital	B-Disease
heart	I-Disease
disease	I-Disease
(	O
CHD	O
)	O
,	O
one	O
child	O
with	O
congenital	O
diaphragmatic	O
hernia	O
(	O
CDH	O
)	O
,	O
and	O
two	O
children	O
with	O
blepharophimosis	O
-	O
ptosis	O
-	O
epicanthus	O
inversus	O
syndrome	O
(	O
BPES	O
)	O
.	O

The	O
three	O
children	O
had	O
androgen	O
production	O
,	O
virilization	O
of	O
external	O
genitalia	O
,	O
and	O
biochemical	O
or	O
histological	O
evidence	O
of	O
testicular	O
tissue	O
.	O

We	O
demonstrate	O
a	O
highly	O
significant	O
association	O
between	O
the	O
NR2F2	B-Gene
loss	B-NegReg
-	I-NegReg
of	I-NegReg
-	I-NegReg
function	I-NegReg
mutations	B-Var
and	O
this	O
syndromic	B-Disease
form	I-Disease
of	I-Disease
DSD	I-Disease
(	O
p	O
=	O
2.44	O
×	O
10	O
-	O
8	O
)	O
.	O

We	O
show	O
that	O
COUP	O
-	O
TF2	O
is	O
highly	O
abundant	O
in	O
a	O
FOXL2-negative	O
stromal	O
cell	O
population	O
of	O
the	O
fetal	O
human	O
ovary	O
.	O

In	O
contrast	O
to	O
the	O
mouse	O
,	O
these	O
data	O
establish	O
COUP	O
-	O
TF2	O
as	O
a	O
human	O
"	O
pro	O
-	O
ovary	O
"	O
and	O
"	O
anti	O
-	O
testis	O
"	O
sex	O
-	O
determining	O
factor	O
in	O
female	O
gonads	O
.	O

Furthermore	O
,	O
the	O
data	O
presented	O
here	O
provide	O
additional	O
evidence	O
of	O
the	O
emerging	O
importance	O
of	O
nuclear	O
receptors	O
in	O
establishing	O
human	O
ovarian	O
identity	O
and	O
indicate	O
that	O
nuclear	O
receptors	O
may	O
have	O
divergent	O
functions	O
in	O
mouse	O
and	O
human	O
biology	O
.	O

Biallelic	B-Var
Mutations	I-Var
in	O
ATP5F1D	B-Gene
,	O
which	O
Encodes	O
a	O
Subunit	O
of	O
ATP	O
Synthase	O
,	O
Cause	B-Reg
a	O
Metabolic	B-MPA
Disorder	I-MPA
.	O

ATP	O
synthase	O
,	O
H+	O
transporting	O
,	O
mitochondrial	O
F1	O
complex	O
,	O
δ	O
subunit	O
(	O
ATP5F1D	O
;	O
formerly	O
ATP5D	O
)	O
is	O
a	O
subunit	O
of	O
mitochondrial	O
ATP	O
synthase	O
and	O
plays	O
an	O
important	O
role	O
in	O
coupling	O
proton	O
translocation	O
and	O
ATP	O
production	O
.	O

Here	O
,	O
we	O
describe	O
two	O
individuals	O
,	O
each	O
with	O
homozygous	O
missense	B-Var
variants	I-Var
in	O
ATP5F1D	B-Gene
,	O
who	O
presented	B-Reg
with	O
episodic	B-MPA
lethargy	I-MPA
,	O
metabolic	B-MPA
acidosis	I-MPA
,	O
3-methylglutaconic	B-MPA
aciduria	I-MPA
,	O
and	O
hyperammonemia	B-Disease
.	O

Subject	O
1	O
,	O
homozygous	O
for	O
c.245C	O
>	O
T	O
(	O
p	O
.	O
Pro82Leu	O
)	O
,	O
presented	O
with	O
recurrent	O
metabolic	O
decompensation	O
starting	O
in	O
the	O
neonatal	O
period	O
,	O
and	O
subject	O
2	O
,	O
homozygous	O
for	O
c.317T	O
>	O
G	O
(	O
p	O
.	O
Val106Gly	O
)	O
,	O
presented	O
with	O
acute	O
encephalopathy	O
in	O
childhood	O
.	O

Cultured	O
skin	O
fibroblasts	O
from	O
these	O
individuals	O
exhibited	O
impaired	O
assembly	O
of	O
F1FO	O
ATP	O
synthase	O
and	O
subsequent	O
reduced	O
complex	O
V	O
activity	O
.	O

Cells	O
from	O
subject	O
1	O
also	O
exhibited	O
a	O
significant	O
decrease	O
in	O
mitochondrial	O
cristae	O
.	O

Knockdown	O
of	O
Drosophila	O
ATPsynδ	O
,	O
the	O
ATP5F1D	O
homolog	O
,	O
in	O
developing	O
eyes	O
and	O
brains	O
caused	O
a	O
near	O
complete	O
loss	O
of	O
the	O
fly	O
head	O
,	O
a	O
phenotype	O
that	O
was	O
fully	O
rescued	O
by	O
wild	O
-	O
type	O
human	O
ATP5F1D.	O
In	O
contrast	O
,	O
expression	O
of	O
the	O
ATP5F1D	O
c.245C	O
>	O
T	O
and	O
c.317T	O
>	O
G	O
variants	B-Var
rescued	B-PosReg
the	O
head	B-MPA
-	I-MPA
size	I-MPA
phenotype	I-MPA
but	O
recapitulated	B-NegReg
the	O
eye	B-MPA
and	O
antennae	B-MPA
defects	I-MPA
seen	O
in	O
other	O
genetic	O
models	O
of	O
mitochondrial	O
oxidative	O
phosphorylation	O
deficiency	O
.	O

Our	O
data	O
establish	O
c.245C	O
>	O
T	O
(	O
p	O
.	O
Pro82Leu	O
)	O
and	O
c.317T	O
>	O
G	O
(	O
p	O
.	O
Val106Gly	O
)	O
in	O
ATP5F1D	O
as	O
pathogenic	O
variants	B-Var
leading	B-Reg
to	I-Reg
a	O
Mendelian	B-Disease
mitochondrial	I-Disease
disease	I-Disease
featuring	O
episodic	O
metabolic	O
decompensation	O
.	O

Multifocal	O
atrial	O
and	O
ventricular	O
premature	O
contractions	O
with	O
an	O
increased	O
risk	O
of	O
dilated	B-Disease
cardiomyopathy	I-Disease
caused	O
by	O
a	O
Nav1.5	B-Gene
gain	B-PosReg
-	I-PosReg
of	I-PosReg
-	I-PosReg
function	I-PosReg
mutation	O
(	B-Var
G213D	I-Var
)	I-Var
.	O

BACKGROUND	O
:	O
SCN5A	O
mutations	B-Var
can	O
lead	B-Reg
to	I-Reg
different	O
cardiac	B-Disease
diseases	I-Disease
.	O

Recently	O
,	O
SCN5A	O
mutations	O
have	O
been	O
linked	O
to	O
the	O
clinical	O
entity	O
multifocal	O
ectopic	O
Purkinje	O
-	O
related	O
premature	O
contractions	O
(	O
MEPPC	O
)	O
characterized	O
by	O
ventricular	O
ectopy	O
and	O
dilated	O
cardiomyopathy	O
.	O

METHODS	O
&	O
RESULTS	O
:	O
A	O
family	O
with	O
a	O
uniform	O
MEPPC	O
-	O
like	O
phenotype	O
,	O
associated	O
with	O
complex	O
atrial	O
and	O
ventricular	O
arrhythmias	O
and	O
dilated	O
cardiomyopathy	O
caused	O
by	O
a	O
high	O
frequency	O
of	O
ventricular	O
ectopy	O
was	O
clinically	O
assessed	O
.	O

Screening	O
of	O
the	O
SCN5A	B-Gene
gene	O
revealed	O
a	O
missense	B-Var
mutation	I-Var
in	O
the	O
linker	O
between	O
segments	O
3	O
and	O
4	O
in	O
domain	O
1	O
of	O
the	O
Nav1.5	O
protein	O
,	O
resulting	B-Reg
in	I-Reg
a	O
glycine	O
to	O
aspartate	O
substitution	O
at	O
position	O
213	O
(	B-Var
G213D	I-Var
)	I-Var
.	O

The	O
phenotype	O
co	O
-	O
segregated	O
with	O
the	O
missense	O
mutation	O
.	O

Electrophysiological	O
studies	O
of	O
wild	O
type	O
(	O
WT	O
)	O
hNav1.5	O
and	O
hNav1.5_G213D	O
expressed	O
in	O
CHO	O
-	O
K	O
cells	O
showed	O
that	O
the	O
voltage	O
of	O
half	O
-	O
maximal	O
activation	O
(	O
V½	O
)	O
was	O
significantly	O
more	O
negative	O
for	O
hNav1.5_G213D	O
compared	O
to	O
WT	O
(	O
V½=-38.7±0.5mV	O
for	O
WT	O
and	O
V½=-42.4±0.5mV	O
for	O
G213D	O
;	O
P<0.001	O
)	O
.	O

This	O
suggests	O
activation	O
of	O
Nav1.5_G231D	O
at	O
more	O
negative	O
potentials	O
.	O

The	O
V½	O
of	O
steady	O
-	O
state	O
inactivation	O
was	O
significantly	O
shifted	O
towards	O
more	O
positive	O
values	O
for	O
Nav1.5_G213D	O
(	O
V½=-86.7±0.2mV	O
for	O
WT	O
and	O
-82.2±0.3mV	O
for	O
G213D	O
;	O
P<0.001	O
)	O
,	O
also	O
contributing	O
to	O
a	O
gain	O
-	O
of	O
-	O
function	O
phenotype	O
.	O

Flecainide	O
and	O
amiodarone	O
markedly	O
reduced	O
premature	O
atrial	O
and	O
ventricular	O
contractions	O
in	O
four	O
patients	O
.	O

CONCLUSION	O
:	O
The	O
Nav1.5_G213D	B-Var
mutation	O
is	O
associated	O
with	O
a	O
gain	B-PosReg
-	I-PosReg
of	I-PosReg
-	I-PosReg
function	I-PosReg
phenotype	O
,	O
multifocal	O
atrial	O
and	O
ventricular	O
ectopy	O
and	O
dilated	B-Disease
cardiomyopathy	I-Disease
.	O

Since	O
patients	O
with	O
a	O
MEPPC	O
-	O
like	O
phenotype	O
may	O
specifically	O
benefit	O
from	O
Class-1	O
antiarrhythmic	O
drugs	O
or	O
amiodarone	O
,	O
clinical	O
identification	O
of	O
this	O
disease	O
entity	O
is	O
important	O
.	O

The	O
Molecular	O
Chaperone	O
HSP90	O
Promotes	O
Notch	O
Signaling	O
in	O
the	O
Germline	O
of	O
Caenorhabditis	O
elegans	O
.	O

In	O
a	O
genetic	O
screen	O
to	O
identify	O
genes	O
that	O
promote	O
GLP-1	O
/	O
Notch	O
signaling	O
in	O
Caenorhabditis	O
elegans	O
germline	O
stem	O
cells	O
,	O
we	O
found	O
a	O
single	O
mutation	O
,	O
om40	O
,	O
defining	O
a	O
gene	O
called	O
ego-3	O
.	O

ego-3(om40	B-Var
)	I-Var
causes	B-Reg
several	O
defects	B-MPA
in	O
the	O
soma	O
and	O
the	O
germline	O
,	O
including	O
paralysis	B-Disease
during	O
larval	O
development	O
,	O
sterility	B-Disease
,	O
delayed	B-CPA
proliferation	I-CPA
of	O
germline	O
stem	O
cells	O
,	O
and	O
ectopic	B-CPA
germline	I-CPA
stem	I-CPA
cell	I-CPA
proliferation	I-CPA
.	O

Whole	O
genome	O
sequencing	O
identified	O
om40	O
as	O
an	O
allele	O
of	O
hsp-90	O
,	O
previously	O
known	O
as	O
daf-21	O
,	O
which	O
encodes	O
the	O
C.	O
elegans	O
ortholog	O
of	O
the	O
cytosolic	O
form	O
of	O
HSP90	O
.	O

This	O
protein	O
is	O
a	O
molecular	O
chaperone	O
with	O
a	O
central	O
position	O
in	O
the	O
protein	O
homeostasis	O
network	O
,	O
which	O
is	O
responsible	O
for	O
proper	O
folding	O
,	O
structural	O
maintenance	O
,	O
and	O
degradation	O
of	O
proteins	O
.	O

In	O
addition	O
to	O
its	O
essential	O
role	O
in	O
cellular	O
function	O
,	O
HSP90	O
plays	O
an	O
important	O
role	O
in	O
stem	O
cell	O
maintenance	O
and	O
renewal	O
.	O

Complementation	O
analysis	O
using	O
a	O
deletion	O
allele	O
of	O
hsp-90	O
confirmed	O
that	O
ego-3	O
is	O
the	O
same	O
gene	O
.	O

hsp-90(om40	O
)	O
is	O
an	O
I→N	O
conservative	O
missense	O
mutation	O
of	O
a	O
highly	O
conserved	O
residue	O
in	O
the	O
middle	O
domain	O
of	O
HSP-90	O
RNA	O
interference	O
-	O
mediated	O
knockdown	O
of	O
hsp-90	O
expression	O
partially	O
phenocopied	O
hsp-90(om40	O
)	O
,	O
confirming	O
the	O
loss	O
-	O
of	O
-	O
function	O
nature	O
of	O
hsp-90(om40	O
)	O
Furthermore	O
,	O
reduced	O
HSP-90	O
activity	O
enhanced	O
the	O
effect	O
of	O
reduced	O
function	O
of	O
both	O
the	O
GLP-1	O
receptor	O
and	O
the	O
downstream	O
LAG-1	O
transcription	O
factor	O
.	O

Taken	O
together	O
,	O
our	O
results	O
provide	O
the	O
first	O
experimental	O
evidence	O
of	O
an	O
essential	O
role	O
for	O
HSP90	O
in	O
Notch	O
signaling	O
in	O
development	O
.	O

Impact	O
of	O
CYP2C19	O
Polymorphisms	O
on	O
Clinical	O
Outcomes	O
and	O
Antiplatelet	O
Potency	O
of	O
Clopidogrel	O
in	O
Caucasian	O
Poststroke	O
Survivors	O
.	O

BACKGROUND	O
:	O
Variable	O
response	O
after	O
clopidogrel	O
is	O
well	O
documented	O
and	O
may	O
affect	O
major	O
adverse	O
clinical	O
events	O
after	O
stroke	O
.	O

Impact	O
of	O
CYP2C19	O
genetic	O
polymorphisms	O
is	O
an	O
established	O
marker	O
linked	O
to	O
variable	O
response	O
after	O
clopidogrel	O
.	O

However	O
,	O
the	O
association	O
of	O
certain	O
genetic	O
polymorphisms	O
with	O
prediction	O
of	O
major	O
adverse	O
clinical	O
events	O
following	O
stroke	O
still	O
remains	O
controversial	O
,	O
especially	O
in	O
Caucasians	O
.	O

STUDY	O
QUESTION	O
:	O
The	O
primary	O
aim	O
was	O
to	O
evaluate	O
the	O
impact	O
of	O
CYP2C19	O
allele	O
*	O
2	O
in	O
heterozygote	O
form	O
on	O
major	O
adverse	O
clinical	O
events	O
in	O
Caucasian	O
poststroke	O
survivors	O
treated	O
with	O
clopidogrel	O
.	O

The	O
secondary	O
aim	O
was	O
to	O
analyze	O
the	O
potential	O
link	O
between	O
CYP2C19	O
genetic	O
polymorphism	O
and	O
variable	O
response	O
after	O
clopidogrel	O
.	O

STUDY	O
DESIGN	O
:	O
One	O
hundred	O
thirty	O
patients	O
of	O
Caucasian	O
origin	O
following	O
documented	O
ischemic	O
stroke	O
were	O
included	O
.	O

Platelet	O
reactivity	O
was	O
assessed	O
by	O
light	O
transmittance	O
aggregometry	O
(	O
LTA	O
)	O
and	O
matched	O
with	O
various	O
CYP2C19	O
loss	O
-	O
of	O
-	O
function	O
genetic	O
polymorphisms	O
and	O
major	O
adverse	O
clinical	O
events	O
(	O
composite	O
of	O
vascular	O
deaths	O
,	O
stroke	O
/	O
transient	O
ischemic	O
attack	O
,	O
and	O
myocardial	O
infarction	O
)	O
.	O

RESULTS	O
:	O
Over	O
the	O
mean	O
follow	O
-	O
up	O
of	O
14.9	O
months	O
,	O
19	O
patients	O
experienced	O
major	O
adverse	O
clinical	O
events	O
.	O

The	O
risk	O
of	O
major	B-MPA
adverse	I-MPA
clinical	I-MPA
events	I-MPA
was	O
nearly	O
3-fold	O
in	O
loss	B-NegReg
-	I-NegReg
of	I-NegReg
-	I-NegReg
function	I-NegReg
allele	B-Var
carriers	O
(	O
hazard	O
ratio	O
=	O
2.904	O
;	O
95	O
%	O
confidence	O
interval	O
,	O
1.083	O
-	O
7.786	O
;	O
P	O
=	O
0.013	O
)	O
,	O
whereas	O
the	O
risk	O
of	O
ischemic	B-MPA
stroke	I-MPA
or	O
transient	B-MPA
ischemic	I-MPA
attack	I-MPA
alone	I-MPA
was	O
also	O
higher	O
(	O
hazard	O
ratio	O
=	O
3.170	O
;	O
95	O
%	O
confidence	O
interval	O
,	O
1.281	O
-	O
7.849	O
;	O
P	O
=	O
0.034	O
)	O
.	O

Platelet	B-MPA
activity	I-MPA
was	O
strongly	O
associated	B-Interaction
with	O
allele	B-Var
*	I-Var
2	I-Var
status	I-Var
(	O
rs	O
=	O
0.21	O
,	O
P	O
=	O
0.016	O
)	O
but	O
not	O
with	O
other	O
genetic	O
polymorphisms	O
.	O

Carriers	O
of	O
allele*2	O
exhibited	O
lower	O
platelet	O
response	O
to	O
adenosine	O
diphosphate	O
-	O
mean	O
LTA	O
(	O
30.1	O
%	O
vs.	O
42.0	O
%	O
;	O
P	O
=	O
0.017	O
)	O
.	O

There	O
were	O
no	O
significant	O
differences	O
in	O
LTA	O
results	O
with	O
other	O
agonists	O
.	O

Strong	O
association	O
of	O
increase	O
in	O
adenosine	O
diphosphate	O
-	O
induced	O
aggregation	O
with	O
diabetes	O
mellitus	O
(	O
rs	O
=	O
0.20	O
,	O
P	O
=	O
0.023	O
)	O
,	O
increasing	O
age	O
(	O
rs	O
=	O
0.23	O
,	O
P	O
=	O
0.008	O
)	O
,	O
and	O
conversely	O
diminishing	O
over	O
increased	O
weight	O
(	O
rs	O
=	O
0.23	O
,	O
P	O
=	O
0.009	O
)	O
was	O
also	O
detected	O
.	O

The	O
carriers	O
of	O
other	O
gene	O
allele	O
variants	O
lack	O
uniformed	O
impact	O
on	O
variable	O
response	O
after	O
clopidogrel	O
.	O

CONCLUSIONS	O
:	O
Even	O
heterozygous	O
CYP2C19	O
*	O
2	O
allele	O
carriers	O
among	O
Caucasian	O
patients	O
after	O
ischemic	O
stroke	O
had	O
a	O
higher	O
risk	O
of	O
major	O
adverse	O
clinical	O
events	O
.	O

The	O
LTA	O
,	O
however	O
,	O
did	O
not	O
predict	O
major	O
adverse	O
clinical	O
events	O
.	O

The	O
exact	O
clinical	O
utility	O
of	O
these	O
findings	O
is	O
still	O
uncertain	O
and	O
requires	O
large	O
outcome	O
-	O
driven	O
randomized	O
trial	O
in	O
Caucasians	O
for	O
proof	O
of	O
concept	O
.	O

The	O
Arabidopsis	O
thaliana	O
Mediator	O
subunit	O
MED8	O
regulates	O
plant	O
immunity	O
to	O
Botrytis	O
Cinerea	O
through	O
interacting	O
with	O
the	O
basic	O
helix	O
-	O
loop	O
-	O
helix	O
(	O
bHLH	O
)	O
transcription	O
factor	O
FAMA	O
.	O

The	O
Mediator	O
complex	O
is	O
at	O
the	O
core	O
of	O
transcriptional	O
regulation	O
and	O
plays	O
a	O
central	O
role	O
in	O
plant	O
immunity	O
.	O

The	O
MEDIATOR25	O
(	O
MED25	O
)	O
subunit	O
of	O
Arabidopsis	O
thaliana	O
regulates	O
jasmonate	O
-	O
dependent	O
resistance	O
to	O
Botrytis	O
cinerea	O
through	O
interacting	O
with	O
the	O
basic	O
helix	O
-	O
loop	O
-	O
helix	O
(	O
bHLH	O
)	O
transcription	O
factor	O
of	O
jasmonate	O
signaling	O
,	O
MYC2	O
.	O

Another	O
Mediator	O
subunit	O
,	O
MED8	O
,	O
acts	O
independently	O
or	O
together	O
with	O
MED25	O
in	O
plant	O
immunity	O
.	O

However	O
,	O
unlike	O
MED25	O
,	O
the	O
underlying	O
action	O
mechanisms	O
of	O
MED8	O
in	O
regulating	O
B.	O
cinerea	O
resistance	O
are	O
still	O
unknown	O
.	O

Here	O
,	O
we	O
demonstrated	O
that	O
MED8	O
regulated	O
plant	O
immunity	O
to	O
B.	O
cinerea	O
through	O
interacting	O
with	O
another	O
bHLH	O
transcription	O
factor	O
,	O
FAMA	O
,	O
which	O
was	O
previously	O
shown	O
to	O
control	O
the	O
final	O
proliferation	O
/	O
differentiation	O
switch	O
during	O
stomatal	O
development	O
.	O

Our	O
research	O
demonstrates	O
that	O
FAMA	O
is	O
also	O
an	O
essential	O
component	O
of	O
B.	O
cinerea	O
resistance	O
.	O

The	O
fama	B-Gene
loss	B-NegReg
-	I-NegReg
of	I-NegReg
-	I-NegReg
function	I-NegReg
mutants	B-Var
(	O
fama-1	O
and	O
fama-2	O
)	O
increased	B-PosReg
susceptibility	B-MPA
to	I-MPA
B.	I-MPA
cinerea	I-MPA
infection	I-MPA
and	O
reduced	B-NegReg
defense	B-MPA
-	I-MPA
gene	I-MPA
expression	I-MPA
.	O

On	O
the	O
contrary	O
,	O
transgenic	O
lines	O
constitutively	O
overexpressing	O
FAMA	O
showed	O
opposite	O
B.	O
cinerea	O
responses	O
compared	O
with	O
the	O
fama	O
loss	O
-	O
of	O
-	O
function	O
mutants	O
.	O

FAMA	O
-	O
overexpressed	O
plants	O
displayed	O
enhanced	O
resistance	O
to	O
B.	O
cinerea	O
infection	O
and	O
increased	O
expression	O
levels	O
of	O
defensin	O
genes	O
following	O
B.	O
cinerea	O
treatment	O
.	O

Genetic	O
analysis	O
of	O
MED8	O
and	O
FAMA	O
suggested	O
that	O
FAMA	O
-	O
regulated	O
pathogen	O
resistance	O
was	O
dependent	O
on	O
MED8	O
.	O

In	O
addition	O
,	O
MED8	O
and	O
FAMA	O
were	O
both	O
associated	O
with	O
the	O
G	O
-	O
box	O
region	O
in	O
the	O
promoter	O
of	O
ORA59	O
.	O

Our	O
findings	O
indicate	O
that	O
the	O
MED8	O
subunit	O
of	O
the	O
A.	O
thaliana	O
Mediator	O
regulates	O
plant	O
immunity	O
to	O
B.	O
cinerea	O
through	O
interacting	O
with	O
the	O
transcription	O
factor	O
FAMA	O
,	O
which	O
was	O
discovered	O
to	O
be	O
a	O
key	O
component	O
in	O
B.	O
cinerea	O
resistance	O
.	O

A	O
Gain	O
-	O
of	O
-	O
Function	O
Mutation	O
in	O
EPO	O
in	O
Familial	O
Erythrocytosis	O
.	O

Familial	B-Disease
erythrocytosis	I-Disease
with	O
elevated	O
erythropoietin	O
levels	O
is	O
frequently	O
caused	B-Reg
by	O
mutations	B-Var
in	O
genes	O
that	O
regulate	O
oxygen	O
-	O
dependent	O
transcription	O
of	O
the	O
gene	O
encoding	O
erythropoietin	O
(	O
EPO	B-Gene
)	I-Gene
.	O

We	O
identified	O
a	O
mutation	O
in	O
EPO	O
that	O
cosegregated	O
with	O
disease	O
with	O
a	O
logarithm	O
of	O
the	O
odds	O
(	O
LOD	O
)	O
score	O
of	O
3.3	O
in	O
a	O
family	O
with	O
autosomal	O
dominant	O
erythrocytosis	O
.	O

This	O
mutation	B-Var
,	O
a	O
single	O
-	O
nucleotide	O
deletion	O
(	O
c.32delG	O
)	O
,	O
introduces	O
a	O
frameshift	O
in	O
exon	O
2	O
that	O
interrupts	B-NegReg
translation	O
of	O
the	O
main	B-MPA
EPO	I-MPA
messenger	I-MPA
RNA	I-MPA
(	I-MPA
mRNA	I-MPA
)	I-MPA
transcript	I-MPA
but	O
initiates	O
excess	O
production	O
of	O
erythropoietin	O
from	O
what	O
is	O
normally	O
a	O
noncoding	O
EPO	O
mRNA	O
transcribed	O
from	O
an	O
alternative	O
promoter	O
located	O
in	O
intron	O
1	O
.	O

(	O
Funded	O
by	O
the	O
Gebert	O
Rüf	O
Foundation	O
and	O
others	O
.	O

)	O
.	O

Inactivation	B-Var
of	O
Fgfr2	B-Gene
gene	O
in	O
mouse	O
secondary	O
palate	O
mesenchymal	O
cells	O
leads	B-Reg
to	I-Reg
cleft	B-Disease
palate	I-Disease
.	O

Numerous	O
studies	O
have	O
been	O
conducted	O
to	O
understand	O
the	O
molecular	O
mechanisms	O
controlling	O
mammalian	O
secondary	O
palate	O
development	O
such	O
as	O
growth	O
,	O
reorientation	O
and	O
fusion	O
.	O

However	O
,	O
little	O
is	O
known	O
about	O
the	O
signaling	O
factors	O
regulating	O
palate	O
initiation	O
.	O

Mouse	O
fibroblast	O
growth	O
factor	O
(	O
FGF	O
)	O
receptor	O
2	O
gene	O
(	O
Fgfr2	O
)	O
is	O
expressed	O
on	O
E11.5	O
in	O
the	O
palate	O
outgrowth	O
within	O
the	O
maxillary	O
process	O
,	O
in	O
a	O
region	O
that	O
is	O
responsible	O
for	O
palate	O
cell	O
specification	O
and	O
shelf	O
initiation	O
.	O

Fgfr2	O
continues	O
to	O
express	O
in	O
palate	O
on	O
E12.5	O
and	O
E13.5	O
in	O
both	O
epithelial	O
and	O
mesenchymal	O
cells	O
,	O
and	O
inactivation	B-Var
of	O
Fgfr2	B-Gene
expression	O
in	O
mesenchymal	O
cells	O
using	O
floxed	O
Fgfr2	O
allele	O
and	O
Osr2-Cre	O
leads	B-Reg
to	I-Reg
cleft	B-Disease
palate	I-Disease
at	O
various	O
stages	O
including	O
reorientation	O
,	O
horizontal	O
growth	O
and	O
fusion	O
.	O

Notably	O
,	O
some	O
mutant	O
embryos	O
displayed	O
no	O
sign	O
of	O
palate	O
shelf	O
formation	O
suggesting	O
that	O
FGF	O
receptor	O
2	O
mediated	O
FGF	O
signaling	O
may	O
play	O
an	O
important	O
role	O
in	O
palate	O
initiation	O
.	O

MIB-1	O
Is	O
Required	O
for	O
Spermatogenesis	O
and	O
Facilitates	O
LIN-12	O
and	O
GLP-1	O
Activity	O
in	O
Caenorhabditis	O
elegans	O
.	O

Covalent	O
attachment	O
of	O
ubiquitin	O
to	O
substrate	O
proteins	O
changes	O
their	O
function	O
or	O
marks	O
them	O
for	O
proteolysis	O
,	O
and	O
the	O
specificity	O
of	O
ubiquitin	O
attachment	O
is	O
mediated	O
by	O
the	O
numerous	O
E3	O
ligases	O
encoded	O
by	O
animals	O
.	O

Mind	O
Bomb	O
is	O
an	O
essential	O
E3	O
ligase	O
during	O
Notch	O
pathway	O
signaling	O
in	O
insects	O
and	O
vertebrates	O
.	O

While	O
Caenorhabditis	O
elegans	O
encodes	O
a	O
Mind	O
Bomb	O
homolog	O
(	O
mib-1	O
)	O
,	O
it	O
has	O
never	O
been	O
recovered	O
in	O
the	O
extensive	O
Notch	O
suppressor	O
/	O
enhancer	O
screens	O
that	O
have	O
identified	O
numerous	O
pathway	O
components	O
.	O

Here	O
,	O
we	O
show	O
that	O
C.	O
elegans	O
mib-1	B-Gene
null	O
mutants	B-Var
have	O
a	O
spermatogenesis	B-Disease
-	I-Disease
defective	I-Disease
phenotype	I-Disease
that	O
results	B-Reg
in	I-Reg
a	O
heterogeneous	B-MPA
mixture	I-MPA
of	I-MPA
arrested	I-MPA
spermatocytes	I-MPA
,	O
defective	O
spermatids	O
,	O
and	O
motility	O
-	O
impaired	O
spermatozoa	O
.	O

mib-1	O
mutants	O
also	O
have	O
chromosome	O
segregation	O
defects	O
during	O
meiosis	O
,	O
molecular	O
null	O
mutants	O
are	O
intrinsically	O
temperature	O
-	O
sensitive	O
,	O
and	O
many	O
mib-1	O
spermatids	O
contain	O
large	O
amounts	O
of	O
tubulin	O
.	O

These	O
phenotypic	O
features	O
are	O
similar	O
to	O
the	O
endogenous	O
RNA	O
intereference	O
(	O
RNAi	O
)	O
mutants	O
,	O
but	O
mib-1	O
mutants	O
do	O
not	O
affect	O
RNAi	O
.	O

MIB-1	O
protein	O
is	O
expressed	O
throughout	O
the	O
germ	O
line	O
with	O
peak	O
expression	O
in	O
spermatocytes	O
followed	O
by	O
segregation	O
into	O
the	O
residual	O
body	O
during	O
spermatid	O
formation	O
.	O

C.	O
elegans	O
mib-1	O
expression	O
,	O
while	O
upregulated	O
during	O
spermatogenesis	O
,	O
also	O
occurs	O
somatically	O
,	O
including	O
in	O
vulva	O
precursor	O
cells	O
.	O

Here	O
,	O
we	O
show	O
that	O
mib-1	B-Gene
mutants	B-Var
suppress	B-NegReg
both	O
lin-12	B-Gene
and	O
glp-1	B-Gene
(	O
C.	O
elegans	O
Notch	O
)	O
gain	B-PosReg
-	I-PosReg
of	I-PosReg
-	I-PosReg
function	I-PosReg
mutants	B-Var
,	O
restoring	B-PosReg
anchor	B-MPA
cell	I-MPA
formation	I-MPA
and	O
a	O
functional	B-MPA
vulva	I-MPA
to	O
the	O
former	O
and	O
partly	O
restoring	O
oocyte	B-MPA
production	I-MPA
to	O
the	O
latter	O
.	O

However	O
,	O
suppressed	O
hermaphrodites	O
are	O
only	O
observed	O
when	O
grown	O
at	O
25	O
°	O
,	O
and	O
they	O
are	O
self	O
-	O
sterile	O
.	O

This	O
probably	O
explains	O
why	O
mib-1	O
was	O
not	O
previously	O
recovered	O
as	O
a	O
Notch	O
pathway	O
component	O
in	O
suppressor	O
/	O
enhancer	O
selection	O
experiments	O
.	O

The	O
curious	O
case	O
of	O
Gαs	O
gain	O
-	O
of	O
-	O
function	O
in	O
neoplasia	O
.	O

BACKGROUND	O
:	O
Mutations	B-Var
activating	B-PosReg
the	O
α	O
subunit	O
of	O
heterotrimeric	B-Protein
Gs	I-Protein
protein	I-Protein
are	O
associated	O
with	O
a	O
number	O
of	O
highly	O
specific	O
pathological	O
molecular	O
phenotypes	O
.	O

One	O
of	O
the	O
best	O
characterized	O
is	O
the	O
McCune	B-Disease
Albright	I-Disease
syndrome	I-Disease
.	O

The	O
disease	O
presents	O
with	O
an	O
increased	O
incidence	O
of	O
neoplasias	O
in	O
specific	O
tissues	O
.	O

MAIN	O
BODY	O
:	O
A	O
similar	O
repertoire	O
of	O
neoplasms	O
can	O
develop	O
whether	O
mutations	O
occur	O
spontaneously	O
in	O
somatic	O
tissues	O
during	O
fetal	O
development	O
or	O
after	O
birth	O
.	O

Glands	O
are	O
the	O
most	O
"	O
permissive	O
"	O
tissues	O
,	O
recently	O
found	O
to	O
include	O
the	O
entire	O
gastrointestinal	O
tract	O
.	O

High	O
frequency	O
of	O
activating	B-PosReg
Gαs	B-Gene
mutations	B-Var
is	O
associated	O
with	O
precise	O
diagnoses	O
(	O
e.g.	O
,	O
IPMN	B-Disease
,	O
Pyloric	B-Disease
gland	I-Disease
adenoma	I-Disease
,	O
pituitary	B-Disease
toxic	I-Disease
adenoma	I-Disease
)	I-Disease
.	O

Typically	O
,	O
most	O
neoplastic	O
lesions	O
,	O
from	O
thyroid	O
to	O
pancreas	O
,	O
remain	O
well	O
differentiated	O
but	O
may	O
be	O
a	O
precursor	O
to	O
aggressive	O
cancer	O
.	O

CONCLUSIONS	O
:	O
Here	O
we	O
propose	O
the	O
possibility	O
that	O
gain	B-PosReg
-	I-PosReg
of	I-PosReg
-	I-PosReg
function	I-PosReg
mutations	B-Var
of	O
Gαs	B-Gene
interfere	B-NegReg
with	O
signals	O
in	O
the	O
microenvironment	B-MPA
of	I-MPA
permissive	I-MPA
tissues	O
and	O
lead	B-Reg
to	I-Reg
a	O
transversal	B-MPA
neoplastic	I-MPA
phenotype	I-MPA
.	O

Dissecting	O
the	O
genetic	O
basis	O
of	O
heavy	O
panicle	O
hybrid	O
rice	O
uncovered	O
Gn1a	O
and	O
GS3	O
as	O
key	O
genes	O
.	O

KEY	O
MESSAGE	O
:	O
Shuhui498	O
(	O
R498	O
)	O
is	O
an	O
elite	O
parent	O
of	O
heavy	O
panicle	O
hybrid	O
rice	O
by	O
pyramiding	O
the	O
rare	O
gn1a	O
and	O
null	O
gs3	O
alleles	O
.	O

This	O
finding	O
reveals	O
the	O
genetic	O
basis	O
and	O
great	O
potential	O
application	O
in	O
future	O
breeding	O
of	O
R498	O
.	O

The	O
heavy	O
panicle	O
trait	O
,	O
defined	O
as	O
5	O
g	O
or	O
more	O
of	O
grain	O
weight	O
per	O
panicle	O
,	O
is	O
one	O
of	O
the	O
target	O
traits	O
in	O
super	O
-	O
high	O
-	O
yield	O
rice	O
breeding	O
programs	O
.	O

The	O
use	O
of	O
heavy	O
panicle	O
-	O
type	O
hybrid	O
rice	O
has	O
been	O
shown	O
to	O
be	O
a	O
successful	O
strategy	O
for	O
super	O
-	O
high	O
-	O
yield	O
breeding	O
programs	O
,	O
particularly	O
under	O
the	O
environmental	O
conditions	O
of	O
high	O
humidity	O
and	O
deficient	O
solar	O
radiation	O
in	O
southwestern	O
China	O
.	O

However	O
,	O
the	O
genetic	O
components	O
of	O
the	O
heavy	O
panicle	O
trait	O
in	O
hybrid	O
rice	O
remain	O
elusive	O
.	O

Here	O
,	O
we	O
report	O
that	O
the	O
combination	O
of	O
loss	B-NegReg
-	I-NegReg
of	I-NegReg
-	I-NegReg
function	I-NegReg
mutations	B-Var
in	O
Grain	O
number	O
1a	O
(	B-Gene
Gn1a	I-Gene
)	I-Gene
and	O
Grain	O
Size	O
3	O
(	B-Gene
GS3	I-Gene
)	I-Gene
is	O
responsible	B-Reg
for	O
the	O
heavy	B-MPA
panicle	I-MPA
phenotype	I-MPA
of	O
the	O
elite	O
hybrid	O
rice	O
restorer	O
line	O
Shuhui498	O
(	O
R498	O
)	O
.	O

The	O
null	O
gn1a	O
allele	O
is	O
the	O
determinant	O
factor	O
for	O
heavy	O
panicles	O
through	O
increased	O
grain	O
number	O
,	O
while	O
gs3	O
is	O
associated	O
with	O
grain	O
size	O
and	O
weight	O
.	O

R498	O
pyramided	O
the	O
two	O
major	O
null	O
alleles	O
,	O
resulting	O
in	O
heavy	O
panicles	O
with	O
a	O
high	O
grain	O
number	O
and	O
large	O
grains	O
.	O

Clustering	O
analysis	O
revealed	O
that	O
the	O
null	O
gn1aR498	O
allele	O
is	O
a	O
rare	O
haplotype	O
which	O
has	O
been	O
innovatively	O
utilized	O
in	O
R498	O
,	O
underscoring	O
the	O
great	O
potential	O
of	O
R498	O
for	O
breeding	O
purposes	O
.	O

Our	O
research	O
thus	O
sheds	O
light	O
on	O
the	O
distinct	O
genetic	O
compositions	O
of	O
heavy	O
panicle	O
-	O
type	O
rice	O
and	O
may	O
potentially	O
facilitate	O
super	O
-	O
high	O
-	O
yield	O
rice	O
breeding	O
.	O

A	O
Protein	O
-	O
Truncating	O
HSD17B13	O
Variant	O
and	O
Protection	O
from	O
Chronic	O
Liver	O
Disease	O
.	O

BACKGROUND	O
:	O
Elucidation	O
of	O
the	O
genetic	O
factors	O
underlying	O
chronic	O
liver	O
disease	O
may	O
reveal	O
new	O
therapeutic	O
targets	O
.	O

METHODS	O
:	O
We	O
used	O
exome	O
sequence	O
data	O
and	O
electronic	O
health	O
records	O
from	O
46,544	O
participants	O
in	O
the	O
DiscovEHR	O
human	O
genetics	O
study	O
to	O
identify	O
genetic	O
variants	O
associated	O
with	O
serum	O
levels	O
of	O
alanine	O
aminotransferase	O
(	O
ALT	O
)	O
and	O
aspartate	O
aminotransferase	O
(	O
AST	O
)	O
.	O

Variants	B-Var
that	O
were	O
replicated	O
in	O
three	O
additional	O
cohorts	O
(	O
12,527	O
persons	O
)	O
were	O
evaluated	O
for	O
association	B-Interaction
with	O
clinical	O
diagnoses	O
of	O
chronic	B-Disease
liver	I-Disease
disease	I-Disease
in	O
DiscovEHR	O
study	O
participants	O
and	O
two	O
independent	O
cohorts	O
(	O
total	O
of	O
37,173	O
persons	O
)	O
and	O
with	O
histopathological	O
severity	O
of	O
liver	O
disease	O
in	O
2391	O
human	O
liver	O
samples	O
.	O

RESULTS	O
:	O
A	O
splice	B-Var
variant	I-Var
(	O
rs72613567	O
:	O
TA	O
)	O
in	O
HSD17B13	B-Gene
,	O
encoding	O
the	O
hepatic	O
lipid	O
droplet	O
protein	O
hydroxysteroid	O
17-beta	O
dehydrogenase	O
13	O
,	O
was	O
associated	O
with	O
reduced	B-NegReg
levels	O
of	O
ALT	B-MPA
(	O
P=4.2×10	O
-	O
12	O
)	O
and	O
AST	B-MPA
(	O
P=6.2×10	O
-	O
10	O
)	O
.	O

Among	O
DiscovEHR	O
study	O
participants	O
,	O
this	O
variant	B-Var
was	O
associated	O
with	O
a	O
reduced	B-NegReg
risk	O
of	O
alcoholic	B-Disease
liver	I-Disease
disease	I-Disease
(	O
by	O
42	O
%	O
[	O
95	O
%	O
confidence	O
interval	O
{	O
CI	O
}	O
,	O
20	O
to	O
58	O
]	O
among	O
heterozygotes	O
and	O
by	O
53	O
%	O
[	O
95	O
%	O
CI	O
,	O
3	O
to	O
77	O
]	O
among	O
homozygotes	O
)	O
,	O
nonalcoholic	B-Disease
liver	I-Disease
disease	I-Disease
(	O
by	O
17	O
%	O
[	O
95	O
%	O
CI	O
,	O
8	O
to	O
25	O
]	O
among	O
heterozygotes	O
and	O
by	O
30	O
%	O
[	O
95	O
%	O
CI	O
,	O
13	O
to	O
43	O
]	O
among	O
homozygotes	O
)	O
,	O
alcoholic	B-Disease
cirrhosis	I-Disease
(	O
by	O
42	O
%	O
[	O
95	O
%	O
CI	O
,	O
14	O
to	O
61	O
]	O
among	O
heterozygotes	O
and	O
by	O
73	O
%	O
[	O
95	O
%	O
CI	O
,	O
15	O
to	O
91	O
]	O
among	O
homozygotes	O
)	O
,	O
and	O
nonalcoholic	B-Disease
cirrhosis	I-Disease
(	O
by	O
26	O
%	O
[	O
95	O
%	O
CI	O
,	O
7	O
to	O
40	O
]	O
among	O
heterozygotes	O
and	O
by	O
49	O
%	O
[	O
95	O
%	O
CI	O
,	O
15	O
to	O
69	O
]	O
among	O
homozygotes	O
)	O
.	O

Associations	O
were	O
confirmed	O
in	O
two	O
independent	O
cohorts	O
.	O

The	O
rs72613567	O
:	O
TA	O
variant	B-Var
was	O
associated	O
with	O
a	O
reduced	B-NegReg
risk	O
of	O
nonalcoholic	B-Disease
steatohepatitis	I-Disease
,	O
but	O
not	O
steatosis	O
,	O
in	O
human	O
liver	O
samples	O
.	O

The	O
rs72613567	O
:	O
TA	O
variant	B-Var
mitigated	B-NegReg
liver	B-Disease
injury	I-Disease
associated	O
with	O
the	O
risk	O
-	O
increasing	O
PNPLA3	O
p	O
.	O
I148	O
M	O
allele	O
and	O
resulted	O
in	O
an	O
unstable	O
and	O
truncated	O
protein	O
with	O
reduced	O
enzymatic	O
activity	O
.	O

CONCLUSIONS	O
:	O
A	O
loss	B-NegReg
-	I-NegReg
of	I-NegReg
-	I-NegReg
function	I-NegReg
variant	B-Var
in	O
HSD17B13	B-Gene
was	O
associated	O
with	O
a	O
reduced	B-NegReg
risk	O
of	O
chronic	B-Disease
liver	I-Disease
disease	I-Disease
and	O
of	O
progression	O
from	O
steatosis	O
to	O
steatohepatitis	O
.	O

(	O
Funded	O
by	O
Regeneron	O
Pharmaceuticals	O
and	O
others	O
.	O

)	O
.	O

Gain	O
-	O
of	O
-	O
function	O
mutations	O
in	O
granulocyte	O
colony	O
-	O
stimulating	O
factor	O
receptor	O
(	O
CSF3R	O
)	O
reveal	O
distinct	O
mechanisms	O
of	O
CSF3R	O
activation	O
.	O

Granulocyte	O
colony	O
-	O
stimulating	O
factor	O
(	O
G	O
-	O
CSF	O
or	O
CSF3	O
)	O
and	O
its	O
receptor	O
CSF3R	O
regulate	O
granulopoiesis	O
,	O
neutrophil	O
function	O
,	O
and	O
hematopoietic	O
stem	O
cell	O
mobilization	O
.	O

Recent	O
studies	O
have	O
uncovered	O
an	O
oncogenic	O
role	O
of	O
mutations	B-Var
in	O
the	O
CSF3R	B-Gene
gene	O
in	O
many	O
hematologic	B-Disease
malignancies	I-Disease
.	O

To	O
find	O
additional	O
CSF3R	O
mutations	O
that	O
give	O
rise	O
to	O
cell	O
transformation	O
,	O
we	O
performed	O
a	O
cellular	O
transformation	O
assay	O
in	O
which	O
murine	O
interleukin	O
3	O
(	O
IL-3)-dependent	O
Ba	O
/	O
F3	O
cells	O
were	O
transduced	O
with	O
WT	O
CSF3R	O
plasmid	O
and	O
screened	O
for	O
spontaneous	O
growth	O
in	O
the	O
absence	O
of	O
IL-3	O
.	O

Any	O
outgrowth	O
clones	O
were	O
sequenced	O
to	O
identify	O
CSF3R	O
mutations	O
with	O
transformation	O
capacity	O
.	O

We	O
identified	O
several	O
novel	O
mutations	B-Var
and	O
determined	O
that	O
they	O
transform	B-Reg
cells	B-CPA
via	O
four	O
distinct	O
mechanisms	O
:	O
1	O
)	O
cysteine-	B-MPA
and	I-MPA
disulfide	I-MPA
bond	I-MPA
-	I-MPA
mediated	I-MPA
dimerization	I-MPA
(	O
S581C	O
)	O
;	O
2	O
)	O
polar	B-Var
,	O
noncharged	I-Var
amino	I-Var
acid	I-Var
substitution	I-Var
at	O
the	O
transmembrane	O
helix	O
dimer	O
interface	O
at	O
residue	O
Thr-640	O
;	O
3	O
)	O
increased	B-PosReg
internalization	B-MPA
by	O
a	O
Glu-524	O
substitution	O
that	O
mimics	O
a	O
low	O
G	O
-	O
CSF	O
dose	O
;	O
and	O
4	O
)	O
hydrophobic	B-Var
amino	I-Var
acid	I-Var
substitutions	I-Var
in	O
the	O
membrane	O
-	O
proximal	O
residues	O
Thr-612	O
,	O
Thr-615	O
,	O
and	O
Thr-618	O
.	O

Furthermore	O
,	O
the	O
change	O
in	O
signaling	O
activation	O
was	O
related	O
to	O
an	O
altered	O
CSF3R	O
localization	O
.	O

We	O
also	O
found	O
that	O
CSF3R	O
-	O
induced	O
STAT3	O
and	O
ERK	O
activations	O
require	O
CSF3R	O
internalization	O
,	O
whereas	O
STAT5	O
activation	O
occurred	O
at	O
the	O
cell	O
surface	O
.	O

Cumulatively	O
,	O
we	O
have	O
expanded	O
the	O
regions	O
of	O
the	O
CSF3R	O
extracellular	O
and	O
transmembrane	O
domains	O
in	O
which	O
missense	B-Var
mutations	I-Var
exhibit	B-PosReg
leukemogenic	B-Disease
capacity	O
and	O
have	O
further	O
elucidated	O
the	O
mechanistic	O
underpinnings	O
that	O
underlie	O
altered	O
CSF3R	O
expression	O
,	O
dimerization	O
,	O
and	O
signaling	O
activation	O
.	O

Biallelic	O
loss	B-NegReg
-	I-NegReg
of	I-NegReg
-	I-NegReg
function	I-NegReg
WNT5A	B-Gene
mutations	B-Var
in	O
an	O
infant	O
with	O
severe	O
and	O
atypical	O
manifestations	O
of	O
Robinow	B-Disease
syndrome	I-Disease
.	O

Robinow	O
syndrome	O
(	O
RS	O
)	O
is	O
a	O
well	O
-	O
recognized	O
Mendelian	O
disorder	O
known	O
to	O
demonstrate	O
both	O
autosomal	O
dominant	O
and	O
autosomal	O
recessive	O
inheritance	O
.	O

Typical	O
manifestations	O
include	O
short	O
stature	O
,	O
characteristic	O
facies	O
,	O
and	O
skeletal	O
anomalies	O
.	O

Recessive	O
inheritance	O
has	O
been	O
associated	O
with	O
mutations	O
in	O
ROR2	O
while	O
dominant	O
inheritance	O
has	O
been	O
observed	O
for	O
mutations	O
in	O
WNT5A	O
,	O
DVL1	O
,	O
and	O
DVL3	O
.	O

Through	O
trio	O
whole	O
genome	O
sequencing	O
,	O
we	O
identified	O
a	O
homozygous	B-Var
frameshifting	I-Var
single	I-Var
nucleotide	I-Var
deletion	I-Var
in	O
WNT5A	B-Gene
in	O
a	O
previously	O
reported	O
,	O
deceased	O
infant	O
with	O
a	O
unique	O
constellation	O
of	O
features	O
comprising	O
a	O
46,XY	O
disorder	O
of	O
sex	O
development	O
with	O
multiple	O
congenital	O
malformations	O
including	O
congenital	B-Disease
diaphragmatic	I-Disease
hernia	I-Disease
,	O
ambiguous	B-Disease
genitalia	I-Disease
,	O
dysmorphic	B-Disease
facies	I-Disease
,	O
shortened	B-Disease
long	I-Disease
bones	I-Disease
,	O
adactyly	B-Disease
,	O
and	O
ventricular	B-Disease
septal	I-Disease
defect	I-Disease
.	O

The	O
parents	O
,	O
who	O
are	O
both	O
heterozygous	O
for	O
the	O
deletion	O
,	O
appear	O
clinically	O
unaffected	O
.	O

In	O
conjunction	O
with	O
published	O
observations	O
of	O
Wnt5a	O
double	O
knockout	O
mice	O
,	O
we	O
provide	O
evidence	O
for	O
the	O
possibility	O
of	O
autosomal	O
recessive	O
inheritance	O
in	O
association	O
with	O
WNT5A	O
loss	O
-	O
of	O
-	O
function	O
mutations	O
in	O
RS	O
.	O

Species	O
-	O
conserved	O
SYNGAP1	O
phenotypes	O
associated	O
with	O
neurodevelopmental	O
disorders	O
.	O

SYNGAP1	B-Gene
loss	B-NegReg
-	I-NegReg
of	I-NegReg
-	I-NegReg
function	I-NegReg
variants	B-Var
are	O
causally	O
associated	O
with	O
intellectual	B-Disease
disability	I-Disease
,	O
severe	B-Disease
epilepsy	I-Disease
,	O
autism	B-Disease
spectrum	I-Disease
disorder	I-Disease
and	O
schizophrenia	B-Disease
.	O

While	O
there	O
are	O
hundreds	O
of	O
genetic	O
risk	O
factors	O
for	O
neurodevelopmental	O
disorders	O
(	O
NDDs	O
)	O
,	O
this	O
gene	O
is	O
somewhat	O
unique	O
because	O
of	O
the	O
frequency	O
and	O
penetrance	O
of	O
loss	O
-	O
of	O
-	O
function	O
variants	O
found	O
in	O
patients	O
combined	O
with	O
the	O
range	O
of	O
brain	O
disorders	O
associated	O
with	O
SYNGAP1	O
pathogenicity	O
.	O

These	O
clinical	O
findings	O
indicate	O
that	O
SYNGAP1	O
regulates	O
fundamental	O
neurodevelopmental	O
processes	O
that	O
are	O
necessary	O
for	O
brain	O
development	O
.	O

Here	O
,	O
we	O
describe	O
four	O
phenotypic	O
domains	O
that	O
are	O
controlled	O
by	O
Syngap1	O
expression	O
across	O
vertebrate	O
species	O
.	O

Two	O
domains	O
,	O
the	O
maturation	O
of	O
cognitive	O
functions	O
and	O
maintenance	O
of	O
excitatory	O
-	O
inhibitory	O
balance	O
,	O
are	O
defined	O
exclusively	O
through	O
a	O
review	O
of	O
the	O
current	O
literature	O
.	O

Two	O
additional	O
domains	O
are	O
defined	O
by	O
integrating	O
the	O
current	O
literature	O
with	O
new	O
data	O
indicating	O
that	O
SYNGAP1	O
/	O
Syngap1	O
regulates	O
innate	O
survival	O
behaviors	O
and	O
brain	O
structure	O
.	O

These	O
four	O
phenotypic	O
domains	O
are	O
commonly	O
disrupted	O
in	O
NDDs	O
,	O
suggesting	O
that	O
a	O
deeper	O
understanding	O
of	O
developmental	O
Syngap1	O
functions	O
will	O
be	O
generalizable	O
to	O
other	O
NDDs	O
of	O
known	O
or	O
unknown	O
etiology	O
.	O

Therefore	O
,	O
we	O
discuss	O
the	O
known	O
molecular	O
and	O
cellular	O
functions	O
of	O
Syngap1	O
and	O
consider	O
how	O
these	O
functions	O
may	O
contribute	O
to	O
the	O
emergence	O
of	O
disease	O
-	O
relevant	O
phenotypes	O
.	O

Finally	O
,	O
we	O
identify	O
major	O
unexplored	O
areas	O
of	O
Syngap1	O
neurobiology	O
and	O
discuss	O
how	O
a	O
deeper	O
understanding	O
of	O
this	O
gene	O
may	O
uncover	O
general	O
principles	O
of	O
NDD	O
pathobiology	O
.	O

Loss	O
-	O
of	O
-	O
function	O
PCSK9	O
mutants	O
evade	O
the	O
unfolded	O
protein	O
response	O
sensor	O
GRP78	O
and	O
fail	O
to	O
induce	O
endoplasmic	O
reticulum	O
stress	O
when	O
retained	O
.	O

The	O
proprotein	O
convertase	O
subtilisin	O
/	O
kexin	O
type-9	O
(	B-Var
PCSK9	I-Var
)	I-Var
plays	O
a	O
central	O
role	O
in	O
cardiovascular	B-Disease
disease	I-Disease
(	O
CVD	O
)	O
by	O
degrading	B-NegReg
hepatic	B-MPA
low	I-MPA
-	I-MPA
density	I-MPA
lipoprotein	I-MPA
receptor	I-MPA
(	O
LDLR	O
)	O
.	O

As	O
such	O
,	O
loss	B-NegReg
-	I-NegReg
of	I-NegReg
-	I-NegReg
function	I-NegReg
(	O
LOF	O
)	O
PCSK9	B-Gene
variants	B-Var
that	O
fail	O
to	O
exit	O
the	O
endoplasmic	O
reticulum	O
(	O
ER	O
)	O
increase	B-PosReg
hepatic	B-MPA
LDLR	I-MPA
levels	I-MPA
and	O
lower	B-NegReg
the	O
risk	B-MPA
of	I-MPA
developing	I-MPA
CVD	I-MPA
.	O

The	O
retention	O
of	O
misfolded	O
protein	O
in	O
the	O
ER	O
can	O
cause	O
ER	O
stress	O
and	O
activate	O
the	O
unfolded	O
protein	O
response	O
(	O
UPR	O
)	O
.	O

In	O
this	O
study	O
,	O
we	O
investigated	O
whether	O
a	O
variety	O
of	O
LOF	O
PCSK9	O
variants	O
that	O
are	O
retained	O
in	O
the	O
ER	O
can	O
cause	O
ER	O
stress	O
and	O
hepatic	O
cytotoxicity	O
.	O

Although	O
overexpression	B-PosReg
of	O
these	O
PCSK9	B-Gene
variants	B-Var
caused	O
an	O
accumulation	B-PosReg
in	O
the	O
ER	B-MPA
of	I-MPA
hepatocytes	I-MPA
,	O
UPR	O
activation	O
or	O
apoptosis	O
was	O
not	O
observed	O
.	O

Furthermore	O
,	O
ER	O
retention	O
of	O
endogenous	O
PCSK9	O
via	O
splice	O
switching	O
also	O
failed	O
to	O
induce	O
the	O
UPR	O
.	O

Consistent	O
with	O
these	O
in	O
vitro	O
studies	O
,	O
overexpression	O
of	O
PCSK9	O
in	O
the	O
livers	O
of	O
mice	O
had	O
no	O
impact	O
on	O
UPR	O
activation	O
.	O

To	O
elucidate	O
the	O
cellular	O
mechanism	O
to	O
explain	O
these	O
surprising	O
findings	O
,	O
we	O
observed	O
that	O
the	O
94-kDa	O
glucose	O
-	O
regulated	O
protein	O
(	O
GRP94	O
)	O
sequesters	O
PCSK9	O
away	O
from	O
the	O
78-kDa	O
glucose	O
-	O
regulated	O
protein	O
(	O
GRP78	O
)	O
,	O
the	O
major	O
activator	O
of	O
the	O
UPR	O
.	O

As	O
a	O
result	O
,	O
GRP94	O
knockdown	O
increased	O
the	O
stability	O
of	O
GRP78-PCSK9	O
complex	O
and	O
resulted	O
in	O
UPR	O
activation	O
following	O
overexpression	O
of	O
ER	O
-	O
retained	O
PCSK9	O
variants	O
relative	O
to	O
WT	O
secreted	O
controls	O
.	O

Given	O
that	O
overexpression	O
of	O
these	O
LOF	O
PCSK9	O
variants	O
does	O
not	O
cause	O
UPR	O
activation	O
under	O
normal	O
homeostatic	O
conditions	O
,	O
therapeutic	O
strategies	O
aimed	O
at	O
blocking	O
the	O
autocatalytic	O
cleavage	O
of	O
PCSK9	O
in	O
the	O
ER	O
represent	O
a	O
viable	O
strategy	O
for	O
reducing	O
circulating	O
PCSK9	O
.	O

CBL	B-Gene
mutation	B-Var
and	O
MEFV	B-Gene
single	B-Var
-	I-Var
nucleotide	I-Var
variant	I-Var
are	O
important	O
genetic	O
predictors	O
of	O
tumor	B-Disease
reduction	B-NegReg
in	O
glucocorticoid	O
-	O
treated	O
patients	O
with	O
chronic	B-Disease
myelomonocytic	I-Disease
leukemia	I-Disease
.	O

Glucocorticoid	O
(	O
GC	O
)	O
therapy	O
occasionally	O
relieves	O
tumor	O
-	O
related	O
fever	O
and	O
promotes	O
tumor	O
reduction	O
in	O
patients	O
with	O
chronic	O
myelomonocytic	O
leukemia	O
(	O
CMML	O
)	O
.	O

A	O
mutation	O
analysis	O
of	O
24	O
patients	O
with	O
CMML	O
revealed	O
the	O
relationship	O
of	O
GC	O
effectiveness	O
,	O
defined	O
as	O
a	O
monocyte	O
reduction	O
of	O
>	O
50	O
%	O
within	O
3	O
days	O
of	O
methylprednisolone	O
administration	O
,	O
with	O
the	O
MEFV	O
single	O
-	O
nucleotide	O
variant	O
(	O
SNV	O
)	O
and	O
CBL	O
mutation	O
.	O

Lipopolysaccharide	O
-	O
stimulated	O
monocytes	O
harboring	O
MEFV	O
E148Q	O
produced	O
greater	O
amounts	O
of	O
IL-1β	O
and	O
TNF	O
-	O
α	O
than	O
did	O
wild	O
-	O
type	O
monocytes	O
;	O
this	O
was	O
effectively	O
suppressed	O
by	O
GC	O
.	O

Primary	O
CMML	O
cells	O
harboring	O
the	O
MEFV	O
SNV	O
and	O
CBL	O
mutation	O
,	O
and	O
the	O
myelomonocytic	O
leukemia	O
cell	O
line	O
GDM-1	O
,	O
harboring	O
the	O
CBL	O
mutation	O
,	O
were	O
both	O
more	O
significantly	O
suppressed	O
than	O
non	O
-	O
mutated	O
cells	O
following	O
GC	O
treatment	O
in	O
the	O
presence	O
of	O
GM	O
-	O
CSF	O
.	O

A	O
loss	B-NegReg
-	I-NegReg
of	I-NegReg
-	I-NegReg
function	I-NegReg
CBL	B-Gene
mutation	B-Var
prolonged	B-PosReg
STAT5	B-MPA
phosphorylation	I-MPA
after	O
GM	O
-	O
CSF	O
stimulation	O
,	O
which	O
was	O
rapidly	O
terminated	O
in	O
both	O
patient	O
samples	O
and	O
GDM-1	O
cells	O
.	O

In	O
conclusion	O
,	O
GC	O
therapy	O
effectively	O
treats	O
CMML	O
cells	O
harboring	O
the	O
MEFV	O
SNV	O
and	O
CBL	O
mutation	O
by	O
reducing	O
inflammatory	O
cytokine	O
production	O
and	O
terminating	O
prolonged	O
STAT5	O
phosphorylation	O
in	O
the	O
GM	O
-	O
CSF	O
signaling	O
pathway	O
.	O

Identification	O
of	O
a	O
unique	O
loss	B-NegReg
-	I-NegReg
of	I-NegReg
-	I-NegReg
function	I-NegReg
mutation	B-Var
in	O
IGF1R	B-Gene
and	O
a	O
crosstalk	B-Reg
between	O
IGF1R	B-Gene
and	O
Wnt	B-Pathway
/	I-Pathway
β	I-Pathway
-	I-Pathway
catenin	I-Pathway
signaling	I-Pathway
pathways	I-Pathway
.	O

IGF1R	O
is	O
a	O
ubiquitous	O
receptor	O
tyrosine	O
kinase	O
that	O
plays	O
critical	O
roles	O
in	O
cell	O
proliferation	O
,	O
growth	O
and	O
survival	O
.	O

Clinical	O
studies	O
have	O
demonstrated	O
upregulation	O
of	O
IGF1R	O
mediated	O
signaling	O
in	O
a	O
number	O
of	O
malignancies	O
including	O
colon	O
,	O
breast	O
,	O
and	O
lung	O
cancers	O
.	O

Overexpression	O
of	O
the	O
IGF1R	O
in	O
these	O
malignancies	O
is	O
associated	O
with	O
a	O
poor	O
prognosis	O
and	O
overall	O
survival	O
.	O

IGF1R	O
specific	O
kinase	O
inhibitors	O
have	O
failed	O
in	O
multiple	O
clinical	O
trials	O
partly	O
because	O
of	O
the	O
complex	O
nature	O
of	O
IGF1R	O
signaling	O
.	O

Thus	O
identifying	O
new	O
binding	O
partners	O
and	O
allosteric	O
sites	O
on	O
IGF1R	O
are	O
emerging	O
areas	O
of	O
research	O
.	O

More	O
recently	O
,	O
IGF1R	O
has	O
been	O
shown	O
to	O
translocate	O
into	O
the	O
nucleus	O
and	O
perform	O
many	O
functions	O
.	O

In	O
this	O
study	O
,	O
we	O
generated	O
a	O
library	O
of	O
IGF1R	O
deletion	O
and	O
point	O
mutants	O
to	O
examine	O
IGF1R	O
subcellular	O
localization	O
and	O
activation	O
of	O
downstream	O
signaling	O
pathways	O
.	O

We	O
show	O
that	O
the	O
nuclear	O
localization	O
of	O
IGF1R	O
is	O
primarily	O
defined	O
by	O
its	O
cytoplasmic	O
domain	O
.	O

We	O
identified	O
a	O
cross	O
-	O
talk	O
between	O
IGF1R	O
and	O
Wnt	O
/	O
β	O
-	O
catenin	O
signaling	O
pathways	O
and	O
showed	O
,	O
for	O
the	O
first	O
time	O
,	O
that	O
IGF1R	O
is	O
associated	O
with	O
upregulation	O
of	O
TCF	O
-	O
mediated	O
β	O
-	O
catenin	O
transcriptional	O
activity	O
.	O

Using	O
loss	O
-	O
of	O
-	O
function	O
mutants	O
,	O
deletion	O
analysis	O
and	O
IGF1R	O
specific	O
inhibitor(s	O
)	O
,	O
we	O
show	O
that	O
cytoplasmic	O
and	O
nuclear	O
activities	O
are	O
two	O
independent	O
functions	O
of	O
IGF1R.	O
Furthermore	O
,	O
we	O
identified	O
a	O
unique	O
loss	O
-	O
of	O
-	O
function	O
mutation	O
in	O
IGF1R.	O
This	O
unique	O
loss	O
-	O
of	O
-	O
function	O
mutant	O
retains	O
only	O
nuclear	O
functions	O
and	O
sits	O
in	O
a	O
pocket	O
,	O
outside	O
ATP	O
and	O
substrate	O
binding	O
region	O
,	O
that	O
is	O
suited	O
for	O
designing	O
allosteric	O
inhibitors	O
of	O
IGF1R.	O
Clinical	O
variability	O
and	O
onset	O
age	O
modifiers	O
in	O
an	O
extended	O
Belgian	O
GRN	O
founder	O
family	O
.	O

We	O
previously	O
reported	B-Reg
a	O
granulin	O
(	B-Gene
GRN	I-Gene
)	I-Gene
null	O
mutation	B-Var
,	O
originating	O
from	O
a	O
common	O
founder	O
,	O
in	O
multiple	O
Belgian	O
families	O
with	O
frontotemporal	B-Disease
dementia	I-Disease
.	O

Here	O
,	O
we	O
used	O
data	O
of	O
a	O
10-year	O
follow	O
-	O
up	O
study	O
to	O
describe	O
in	O
detail	O
the	O
clinical	O
heterogeneity	O
observed	O
in	O
this	O
extended	O
founder	O
pedigree	O
.	O

We	O
identified	O
85	O
patients	O
and	O
40	O
unaffected	O
mutation	O
carriers	O
,	O
belonging	O
to	O
29	O
branches	O
of	O
the	O
founder	O
pedigree	O
.	O

Most	O
patients	O
(	O
74.4	O
%	O
)	O
were	O
diagnosed	O
with	O
frontotemporal	O
dementia	O
,	O
while	O
others	O
had	O
a	O
clinical	O
diagnosis	O
of	O
unspecified	O
dementia	O
,	O
Alzheimer	O
's	O
dementia	O
or	O
Parkinson	O
's	O
disease	O
.	O

The	O
observed	O
clinical	O
heterogeneity	O
can	O
guide	O
clinical	O
diagnosis	O
,	O
genetic	O
testing	O
,	O
and	O
counseling	O
of	O
mutation	O
carriers	O
.	O

Onset	O
of	O
initial	O
symptomatology	O
is	O
highly	O
variable	O
,	O
ranging	O
from	O
age	O
45	O
to	O
80	O
years	O
.	O

Analysis	O
of	O
known	O
modifiers	O
,	O
suggested	O
effects	O
of	O
GRN	O
rs5848	O
,	O
microtubule	O
-	O
associated	O
protein	O
tau	O
H1	O
/	O
H2	O
,	O
and	O
chromosome	O
9	O
open	O
reading	O
frame	O
72	O
G4C2	O
repeat	O
length	O
on	O
onset	O
age	O
but	O
explained	O
only	O
a	O
minor	O
fraction	O
of	O
the	O
variability	O
.	O

Contrary	O
,	O
the	O
extended	O
GRN	O
founder	O
family	O
is	O
a	O
valuable	O
source	O
for	O
identifying	O
other	O
onset	O
age	O
modifiers	O
based	O
on	O
exome	O
or	O
genome	O
sequences	O
.	O

These	O
modifiers	O
might	O
be	O
interesting	O
targets	O
for	O
developing	O
disease	O
-	O
modifying	O
therapies	O
.	O

A	O
rare	O
variant	B-Var
in	O
MLKL	B-Gene
confers	O
susceptibility	B-Reg
to	O
ApoE	O
ɛ4-negative	O
Alzheimer	B-Disease
's	I-Disease
disease	I-Disease
in	O
Hong	O
Kong	O
Chinese	O
population	O
.	O

Alzheimer	O
's	O
disease	O
(	O
AD	O
)	O
is	O
the	O
most	O
common	O
neurodegenerative	O
disorders	O
in	O
the	O
elderly	O
.	O

To	O
identify	O
rare	O
genetic	O
factors	O
other	O
than	O
apolipoprotein	O
E	O
ɛ4	O
allele	O
(	O
ApoE	O
ɛ4	O
)	O
contributing	O
to	O
the	O
pathogenesis	O
of	O
late	O
-	O
onset	O
AD	O
(	O
LOAD	O
)	O
,	O
we	O
conducted	O
a	O
whole	O
-	O
exome	O
analysis	O
of	O
246	O
ApoE	O
ɛ4-negative	O
LOAD	O
cases	O
and	O
172	O
matched	O
controls	O
in	O
Hong	O
Kong	O
Chinese	O
population	O
.	O

LOAD	O
patients	O
showed	O
a	O
significantly	O
higher	O
burden	O
of	O
rare	O
loss	O
-	O
of	O
-	O
function	O
variants	O
in	O
genes	O
related	O
to	O
immune	O
function	O
than	O
healthy	O
controls	O
.	O

Among	O
the	O
genes	O
involved	O
in	O
immune	O
function	O
,	O
we	O
identified	O
a	O
rare	O
stop	O
-	O
gain	O
variant	O
(	O
p	O
.	O
Q48X	O
)	O
in	O
mixed	O
lineage	O
kinase	O
domain	O
like	O
pseudokinase	O
(	O
MLKL	O
)	O
gene	O
present	O
exclusively	O
in	O
6	O
LOAD	O
cases	O
.	O

MLKL	B-Gene
is	O
expressed	O
in	O
neurons	O
,	O
and	O
the	O
its	O
expression	B-MPA
levels	I-MPA
in	O
the	O
p	B-Var
.	I-Var
Q48X	I-Var
carriers	O
were	O
significantly	O
lower	B-NegReg
than	O
that	O
in	O
age	O
-	O
matched	O
wild	O
-	O
type	O
controls	O
.	O

The	O
ratio	O
of	O
Aβ42	O
to	O
Aβ40	O
significantly	O
increased	O
in	O
MLKL	O
knockdown	O
cells	O
compared	O
to	O
scramble	O
controls	O
.	O

MLKL	B-Gene
loss	B-NegReg
-	I-NegReg
of	I-NegReg
-	I-NegReg
function	I-NegReg
mutation	B-Var
might	O
contribute	O
to	O
late	O
-	O
onset	O
ApoE	O
ɛ4-negative	O
AD	B-Disease
in	O
the	O
Hong	O
Kong	O
Chinese	O
population	O
.	O

Investigation	O
of	O
TRPV1	O
loss	O
-	O
of	O
-	O
function	O
phenotypes	O
in	O
TRPV1	O
Leu206Stop	O
mice	O
generated	O
by	O
N	O
-	O
ethyl	O
-	O
N	O
-	O
nitrosourea	O
mutagenesis	O
.	O

N	O
-	O
ethyl	O
-	O
N	O
-	O
nitrosourea	O
(	O
ENU	O
)	O
random	O
mutagenesis	O
was	O
used	O
to	O
generate	O
a	O
mouse	O
model	O
for	O
the	O
analysis	O
of	O
the	O
transient	O
receptor	O
potential	O
vanilloid	O
1	O
(	B-Gene
TRPV1	I-Gene
)	I-Gene
cation	O
channel	O
.	O

A	O
transversion	O
from	O
T→A	O
in	O
exon	O
4	O
led	O
to	O
a	O
Leu206Stop	B-Var
mutation	O
generating	O
a	O
loss	B-NegReg
-	I-NegReg
of	I-NegReg
-	I-NegReg
function	I-NegReg
mutant	O
.	O

The	O
TRPV1	O
agonist	O
capsaicin	O
was	O
used	O
to	O
analyze	O
functional	O
and	O
nociceptive	O
parameters	O
in	O
vitro	O
and	O
in	O
vivo	O
in	O
TRPV1	O
Leu206Stop	O
mice	O
and	O
congenic	O
C3HeB	O
/	O
FeJ	O
controls	O
.	O

Capsaicin	B-MPA
-	I-MPA
induced	I-MPA
[	I-MPA
Ca2+]i	I-MPA
changes	O
in	O
small	O
diameter	O
DRG	B-CPA
neurons	I-CPA
were	O
significantly	O
diminished	B-NegReg
in	O
TRPV1	B-Gene
Leu206Stop	B-Var
mice	O
and	O
administration	O
of	O
capsaicin	O
induced	O
neither	O
hypothermia	O
nor	O
nocifensive	O
behaviour	O
in	O
vivo	O
.	O

TRPV1	O
Leu206Stop	O
mice	O
were	O
tested	O
in	O
the	O
spinal	O
nerve	O
ligation	O
of	O
mononeuropathic	O
pain	O
and	O
developed	O
mechanical	O
hypersensitivity	O
two	O
weeks	O
after	O
nerve	O
injury	O
.	O

In	O
the	O
open	O
field	O
test	O
,	O
a	O
significant	O
increase	B-PosReg
in	O
spontaneous	B-CPA
locomotion	I-CPA
was	O
detected	O
in	O
TRPV1	B-Gene
Leu206Stop	B-Var
mice	O
as	O
compared	O
to	O
wildtype	O
controls	O
.	O

TRPV1	O
knockout	O
mice	O
have	O
been	O
reported	O
to	O
carry	O
a	O
similar	O
phenotype	O
regarding	O
capsaicin	O
-	O
evoked	O
responses	O
in	O
vitro	O
and	O
in	O
vivo	O
.	O

However	O
,	O
in	O
contrast	O
to	O
TRPV1	O
Leu206Stop	O
mice	O
,	O
TRPV1	O
knockout	O
mice	O
did	O
not	O
differ	O
in	O
spontaneous	O
locomotion	O
as	O
compared	O
to	O
congenic	O
C57BL/6	O
mice	O
,	O
suggesting	O
subtle	O
ENU	O
-	O
dependent	O
or	O
independent	O
strain	O
differences	O
between	O
TRPV1	O
Leu206Stop	O
mice	O
and	O
their	O
wildtype	O
controls	O
.	O

In	O
summary	O
,	O
these	O
data	O
revealed	O
a	O
target	O
-	O
related	O
(	O
i.e.	O
capsaicin	O
-	O
evoked	O
)	O
phenotype	O
of	O
TRPV1	O
Leu206Stop	O
mice	O
closely	O
resembling	O
that	O
of	O
published	O
TRPV1	O
knockout	O
mice	O
.	O

However	O
,	O
since	O
ENU	O
-	O
mutant	O
mice	O
are	O
congenic	O
with	O
the	O
mouse	O
strain	O
initially	O
used	O
in	O
random	O
mutagenesis	O
,	O
direct	O
phenotypic	O
comparison	O
with	O
the	O
respective	O
wildtype	O
controls	O
is	O
possible	O
,	O
and	O
the	O
time	O
-	O
consuming	O
backcrossing	O
in	O
lines	O
with	O
targeted	O
mutations	O
is	O
avoided	O
.	O

Biallelic	O
TP53	B-Gene
gain	B-PosReg
of	I-PosReg
function	I-PosReg
mutations	B-Var
in	O
rapidly	B-Disease
progressing	I-Disease
solid	I-Disease
tumors	I-Disease
.	O

Recent	O
studies	O
are	O
discovering	O
TP53	B-Gene
mutations	B-Var
with	O
gain	B-PosReg
of	I-PosReg
function	I-PosReg
(	O
GOF	O
)	O
properties	O
that	O
promote	O
tumorigenesis	B-CPA
via	O
a	O
variety	O
of	O
mechanisms	O
.	O

To	O
our	O
knowledge	O
,	O
all	O
reported	O
compound	O
mutations	O
are	O
allelic	O
.	O

We	O
identified	O
two	O
patients	O
with	O
biallelic	O
GOF	O
TP53	O
mutations	O
in	O
their	O
tumors	O
and	O
a	O
third	O
with	O
allelic	O
compound	O
variants	O
.	O

The	O
correlation	O
with	O
p53	O
expression	O
was	O
also	O
examined	O
.	O

Genomic	O
DNA	O
was	O
extracted	O
from	O
formalin	O
-	O
fixed	O
,	O
paraffin	O
-	O
embedded	O
tissue	O
and	O
mutational	O
analysis	O
was	O
performed	O
using	O
Ion	O
AmpliSeq	O
™	O
Cancer	O
HotSpot	O
Panel	O
V2	O
.	O

Biallelic	O
GOF	B-PosReg
mutations	O
(	B-Var
p	I-Var
.	I-Var
R273H	I-Var
and	O
p	B-Var
.	I-Var
R273C	I-Var
)	I-Var
were	O
identified	O
in	O
a	O
19-year	O
-	O
old	O
male	O
with	O
glioblastoma	B-Disease
(	O
allele	O
frequencies	O
94	O
%	O
and	O
48	O
%	O
)	O
and	O
a	O
54-year	O
-	O
old	O
with	O
pT3	O
penile	O
squamous	O
cell	O
carcinoma	O
(	O
allele	O
frequencies	O
19	O
%	O
and	O
27	O
%	O
)	O
.	O

Immunohistochemistry	O
showed	O
nuclear	O
accumulation	O
of	O
p53	O
.	O

The	O
third	O
patient	O
,	O
a	O
62-year	O
-	O
old	O
female	O
with	O
metastatic	B-Disease
lung	I-Disease
adenocarcinoma	I-Disease
,	O
had	O
allelic	O
p	B-Var
.	I-Var
P278S	I-Var
(	B-PosReg
GOF	I-PosReg
)	I-PosReg
and	O
p	B-Var
.	I-Var
R283L	I-Var
(	B-Reg
non	I-Reg
-	I-Reg
GOF	I-Reg
)	I-Reg
variants	O
at	O
frequencies	O
of	O
61	O
%	O
but	O
with	O
null	O
staining	O
for	O
p53	O
.	O

Germline	O
testing	O
for	O
Patient	O
1	O
confirmed	O
wildtype	O
TP53	O
.	O

No	O
other	O
variants	O
were	O
discovered	O
among	O
the	O
genes	O
tested	O
in	O
these	O
cases	O
.	O

All	O
patients	O
succumbed	O
within	O
two	O
years	O
of	O
diagnosis	O
despite	O
aggressive	O
treatment	O
.	O

In	O
conclusion	O
,	O
implementation	O
of	O
TP53	O
mutation	O
analysis	O
in	O
clinical	O
practice	O
may	O
predict	O
patient	O
outcome	O
,	O
and	O
inhibition	O
of	O
GOF	O
p53	O
could	O
represent	O
an	O
attractive	O
target	O
for	O
therapy	O
.	O

Germline	O
pathogenic	O
variants	O
in	O
PALB2	O
and	O
other	O
cancer	O
-	O
predisposing	O
genes	O
in	O
families	O
with	O
hereditary	O
diffuse	O
gastric	O
cancer	O
without	O
CDH1	O
mutation	O
:	O
a	O
whole	O
-	O
exome	O
sequencing	O
study	O
.	O

BACKGROUND	O
:	O
Germline	O
pathogenic	O
variants	B-Var
in	O
the	O
E	O
-	O
cadherin	O
gene	O
(	B-Gene
CDH1	I-Gene
)	I-Gene
are	O
strongly	O
associated	B-Reg
with	I-Reg
the	O
development	O
of	O
hereditary	B-Disease
diffuse	I-Disease
gastric	I-Disease
cancer	I-Disease
.	O

There	O
is	O
a	O
paucity	O
of	O
data	O
to	O
guide	O
risk	O
assessment	O
and	O
management	O
of	O
families	O
with	O
hereditary	O
diffuse	O
gastric	O
cancer	O
that	O
do	O
not	O
carry	O
a	O
CDH1	O
pathogenic	O
variant	O
,	O
making	O
it	O
difficult	O
to	O
make	O
informed	O
decisions	O
about	O
surveillance	O
and	O
risk	O
-	O
reducing	O
surgery	O
.	O

We	O
aimed	O
to	O
identify	O
new	O
candidate	O
genes	O
associated	O
with	O
predisposition	O
to	O
hereditary	O
diffuse	O
gastric	O
cancer	O
in	O
affected	O
families	O
without	O
pathogenic	O
CDH1	O
variants	O
.	O

METHODS	O
:	O
We	O
did	O
whole	O
-	O
exome	O
sequencing	O
on	O
DNA	O
extracted	O
from	O
the	O
blood	O
of	O
39	O
individuals	O
(	O
28	O
individuals	O
diagnosed	O
with	O
hereditary	O
diffuse	O
gastric	O
cancer	O
and	O
11	O
unaffected	O
first	O
-	O
degree	O
relatives	O
)	O
in	O
22	O
families	O
without	O
pathogenic	O
CDH1	O
variants	O
.	O

Genes	O
with	O
loss	O
-	O
of	O
-	O
function	O
variants	O
were	O
prioritised	O
using	O
gene	O
-	O
interaction	O
analysis	O
to	O
identify	O
clusters	O
of	O
genes	O
that	O
could	O
be	O
involved	O
in	O
predisposition	O
to	O
hereditary	O
diffuse	O
gastric	O
cancer	O
.	O

FINDINGS	O
:	O
Protein	O
-	O
affecting	O
germline	O
variants	O
were	O
identified	O
in	O
probands	O
from	O
six	O
families	O
with	O
hereditary	O
diffuse	O
gastric	O
cancer	O
;	O
variants	O
were	O
found	O
in	O
genes	O
known	O
to	O
predispose	O
to	O
cancer	O
and	O
in	O
lesser	O
-	O
studied	O
DNA	O
repair	O
genes	O
.	O

A	O
frameshift	B-Var
deletion	I-Var
in	O
PALB2	B-Gene
was	O
found	B-Reg
in	O
one	O
member	O
of	O
a	O
family	O
with	O
a	O
history	O
of	O
gastric	B-Disease
and	O
breast	B-Disease
cancer	I-Disease
.	O

Two	O
different	O
MSH2	O
variants	O
were	O
identified	O
in	O
two	O
unrelated	O
affected	O
individuals	O
,	O
including	O
one	O
frameshift	O
insertion	O
and	O
one	O
previously	O
described	O
start	O
-	O
codon	O
loss	O
.	O

One	O
family	O
had	O
a	O
unique	O
combination	O
of	O
variants	O
in	O
the	O
DNA	O
repair	O
genes	O
ATR	O
and	O
NBN	O
.	O

Two	O
variants	O
in	O
the	O
DNA	O
repair	O
gene	O
RECQL5	O
were	O
identified	O
in	O
two	O
unrelated	O
families	O
:	O
one	O
missense	O
variant	O
and	O
a	O
splice	O
-	O
acceptor	O
variant	O
.	O

INTERPRETATION	O
:	O
The	O
results	O
of	O
this	O
study	O
suggest	O
a	O
role	O
for	O
the	O
known	O
cancer	O
predisposition	O
gene	O
PALB2	O
in	O
families	O
with	O
hereditary	O
diffuse	O
gastric	O
cancer	O
and	O
no	O
detected	O
pathogenic	O
CDH1	O
variants	O
.	O

We	O
also	O
identified	O
new	O
candidate	O
genes	O
associated	O
with	O
disease	O
risk	O
in	O
these	O
families	O
.	O

FUNDING	O
:	O
UK	O
Medical	O
Research	O
Council	O
(	O
Sackler	O
programme	O
)	O
,	O
European	O
Research	O
Council	O
under	O
the	O
European	O
Union	O
's	O
Seventh	O
Framework	O
Programme	O
(	O
2007	O
-	O
13	O
)	O
,	O
National	O
Institute	O
for	O
Health	O
Research	O
Cambridge	O
Biomedical	O
Research	O
Centre	O
,	O
Experimental	O
Cancer	O
Medicine	O
Centres	O
,	O
and	O
Cancer	O
Research	O
UK	O
.	O

Melanocortin	O
4	O
Receptor	O
Pathway	O
Dysfunction	O
in	O
Obesity	O
:	O
Patient	O
Stratification	O
Aimed	O
at	O
MC4R	O
Agonist	O
Treatment	O
.	O

Context	O
:	O
The	O
hypothalamic	O
melanocortin	O
4	O
receptor	O
(	O
MC4R	O
)	O
pathway	O
serves	O
a	O
critical	O
role	O
in	O
regulating	O
body	O
weight	O
.	O

Loss	B-NegReg
of	I-NegReg
function	I-NegReg
(	O
LoF	O
)	O
mutations	B-Var
in	O
the	O
MC4R	B-Pathway
pathway	I-Pathway
,	O
including	O
mutations	O
in	O
the	O
pro	O
-	O
opiomelanocortin	O
(	B-Gene
POMC	I-Gene
)	I-Gene
,	O
prohormone	O
convertase	O
1	O
(	B-Gene
PCSK1	I-Gene
)	I-Gene
,	O
leptin	O
receptor	O
(	B-Gene
LEPR	I-Gene
)	I-Gene
,	O
or	O
MC4R	B-Gene
genes	O
,	O
have	O
been	O
shown	O
to	O
cause	O
early	B-Disease
-	I-Disease
onset	I-Disease
severe	I-Disease
obesity	I-Disease
.	O

Methods	O
:	O
Through	O
a	O
comprehensive	O
epidemiological	O
analysis	O
of	O
known	O
and	O
predicted	O
LoF	O
variants	O
in	O
the	O
POMC	O
,	O
PCSK1	O
,	O
and	O
LEPR	O
genes	O
,	O
we	O
sought	O
to	O
estimate	O
the	O
number	O
of	O
US	O
individuals	O
with	O
biallelic	O
MC4R	O
pathway	O
LoF	O
variants	O
.	O

Results	O
:	O
We	O
predict	O
~650	O
α	O
-	O
melanocyte	O
-	O
stimulating	O
hormone	O
(	O
MSH)/POMC	O
,	O
8500	O
PCSK1	O
,	O
and	O
3600	O
LEPR	O
homozygous	O
and	O
compound	O
heterozygous	O
individuals	O
in	O
the	O
United	O
States	O
,	O
cumulatively	O
enumerating	O
>	O
12,800	O
MC4R	O
pathway	O
-	O
deficient	O
obese	O
patients	O
.	O

Few	O
of	O
these	O
variants	O
have	O
been	O
genetically	O
diagnosed	O
to	O
date	O
.	O

These	O
estimates	O
increase	O
when	O
we	O
include	O
a	O
small	O
subset	O
of	O
less	O
rare	O
variants	O
:	O
β	O
-	O
MSH	O
/	O
POMC	O
,	O
PCSK1	O
N221D	O
,	O
and	O
a	O
PCSK1	O
LoF	O
variant	O
(	O
T640A	O
)	O
.	O

To	O
further	O
define	O
the	O
MC4R	O
pathway	O
and	O
its	O
potential	O
impact	O
on	O
obesity	O
,	O
we	O
tested	O
associations	O
between	O
body	O
mass	O
index	O
(	O
BMI	O
)	O
and	O
LoF	O
mutation	O
burden	O
in	O
the	O
POMC	O
,	O
PCSK1	O
,	O
and	O
LEPR	O
genes	O
in	O
various	O
populations	O
.	O

We	O
show	O
that	O
the	O
cumulative	O
allele	O
burden	O
in	O
individuals	O
with	O
two	O
or	O
more	O
LoF	O
alleles	O
in	O
one	O
or	O
more	O
genes	O
in	O
the	O
MC4R	O
pathway	O
are	O
predisposed	O
to	O
a	O
higher	O
BMI	O
than	O
noncarriers	O
or	O
heterozygous	O
LoF	O
carriers	O
with	O
a	O
defect	O
in	O
only	O
one	O
gene	O
.	O

Conclusions	O
:	O
Our	O
analysis	O
represents	O
a	O
genetically	O
rationalized	O
study	O
of	O
the	O
hypothalamic	O
MC4R	O
pathway	O
aimed	O
at	O
genetic	O
patient	O
stratification	O
to	O
determine	O
which	O
obese	O
subpopulations	O
should	O
be	O
studied	O
to	O
elucidate	O
MC4R	O
agonist	O
(	O
e.g.	O
,	O
setmelanotide	O
)	O
treatment	O
responsiveness	O
.	O

Mutations	B-Var
in	O
C11orf70	B-Gene
Cause	B-Reg
Primary	B-Disease
Ciliary	I-Disease
Dyskinesia	I-Disease
with	O
Randomization	O
of	O
Left	O
/	O
Right	O
Body	O
Asymmetry	O
Due	O
to	O
Defects	B-NegReg
of	O
Outer	B-Protein
and	I-Protein
Inner	I-Protein
Dynein	I-Protein
Arms	I-Protein
.	O

Primary	O
ciliary	O
dyskinesia	O
(	O
PCD	O
)	O
is	O
characterized	O
by	O
chronic	O
airway	O
disease	O
,	O
male	O
infertility	O
,	O
and	O
randomization	O
of	O
the	O
left	O
/	O
right	O
body	O
axis	O
as	O
a	O
result	O
of	O
defects	O
of	O
motile	O
cilia	O
and	O
sperm	O
flagella	O
.	O

We	O
identified	O
loss	O
-	O
of	O
-	O
function	O
mutations	O
in	O
the	O
open	O
-	O
reading	O
frame	O
C11orf70	O
in	O
PCD	O
individuals	O
from	O
five	O
distinct	O
families	O
.	O

Transmission	O
electron	O
microscopy	O
analyses	O
and	O
high	O
-	O
resolution	O
immunofluorescence	O
microscopy	O
demonstrate	O
that	O
loss	B-NegReg
-	I-NegReg
of	I-NegReg
-	I-NegReg
function	I-NegReg
mutations	B-Var
in	O
C11orf70	B-Gene
cause	O
immotility	B-CPA
of	O
respiratory	B-CPA
cilia	I-CPA
and	O
sperm	B-CPA
flagella	I-CPA
,	O
respectively	O
,	O
as	O
a	O
result	O
of	O
the	O
loss	B-NegReg
of	O
axonemal	B-Protein
outer	I-Protein
(	O
ODAs	O
)	O
and	O
inner	B-Protein
dynein	I-Protein
arms	I-Protein
(	O
IDAs	O
)	O
,	O
indicating	O
that	O
C11orf70	O
is	O
involved	O
in	O
cytoplasmic	O
assembly	O
of	O
dynein	O
arms	O
.	O

Expression	O
analyses	O
of	O
C11orf70	O
showed	O
that	O
C11orf70	O
is	O
expressed	O
in	O
ciliated	O
respiratory	O
cells	O
and	O
that	O
the	O
expression	O
of	O
C11orf70	O
is	O
upregulated	O
during	O
ciliogenesis	O
,	O
similar	O
to	O
other	O
previously	O
described	O
cytoplasmic	O
dynein	O
-	O
arm	O
assembly	O
factors	O
.	O

Furthermore	O
,	O
C11orf70	O
shows	O
an	O
interaction	O
with	O
cytoplasmic	O
ODA	O
/	O
IDA	O
assembly	O
factor	O
DNAAF2	O
,	O
supporting	O
our	O
hypothesis	O
that	O
C11orf70	O
is	O
a	O
preassembly	O
factor	O
involved	O
in	O
the	O
pathogenesis	O
of	O
PCD	O
.	O

The	O
identification	O
of	O
additional	O
genetic	O
defects	O
that	O
cause	O
PCD	O
and	O
male	O
infertility	O
is	O
of	O
great	O
importance	O
for	O
the	O
clinic	O
as	O
well	O
as	O
for	O
genetic	O
counselling	O
.	O

De	O
novo	O
and	O
inherited	O
private	O
variants	B-Var
in	O
MAP1B	B-Gene
in	O
periventricular	B-Disease
nodular	I-Disease
heterotopia	I-Disease
.	O

Periventricular	O
nodular	O
heterotopia	O
(	O
PVNH	O
)	O
is	O
a	O
malformation	O
of	O
cortical	O
development	O
commonly	O
associated	O
with	O
epilepsy	O
.	O

We	O
exome	O
sequenced	O
202	O
individuals	O
with	O
sporadic	O
PVNH	O
to	O
identify	O
novel	O
genetic	O
risk	O
loci	O
.	O

We	O
first	O
performed	O
a	O
trio	O
-	O
based	O
analysis	O
and	O
identified	O
219	O
de	O
novo	O
variants	O
.	O

Although	O
no	O
novel	O
genes	O
were	O
implicated	O
in	O
this	O
initial	O
analysis	O
,	O
PVNH	O
cases	O
were	O
found	O
overall	O
to	O
have	O
a	O
significant	O
excess	O
of	O
nonsynonymous	O
de	O
novo	O
variants	O
in	O
intolerant	O
genes	O
(	O
p	O
=	O
3.27x10	O
-	O
7	O
)	O
,	O
suggesting	O
a	O
role	O
for	O
rare	O
new	O
alleles	O
in	O
genes	O
yet	O
to	O
be	O
associated	O
with	O
the	O
condition	O
.	O

Using	O
a	O
gene	O
-	O
level	O
collapsing	O
analysis	O
comparing	O
cases	O
and	O
controls	O
,	O
we	O
identified	O
a	O
genome	O
-	O
wide	O
significant	O
signal	O
driven	O
by	O
four	O
ultra	O
-	O
rare	O
loss	B-NegReg
-	I-NegReg
of	I-NegReg
-	I-NegReg
function	I-NegReg
heterozygous	O
variants	B-Var
in	O
MAP1B	B-Gene
,	O
including	O
one	O
de	O
novo	O
variant	O
.	O

In	O
at	O
least	O
one	O
instance	O
,	O
the	O
MAP1B	B-Gene
variant	B-Var
was	O
inherited	B-Reg
from	I-Reg
a	O
parent	O
with	O
previously	O
undiagnosed	O
PVNH	B-Disease
.	O

The	O
PVNH	O
was	O
frontally	O
predominant	O
and	O
associated	O
with	O
perisylvian	O
polymicrogyria	O
.	O

These	O
results	O
implicate	O
MAP1B	O
in	O
PVNH	O
.	O

More	O
broadly	O
,	O
our	O
findings	O
suggest	O
that	O
detrimental	O
mutations	O
likely	O
arising	O
in	O
immediately	O
preceding	O
generations	O
with	O
incomplete	O
penetrance	O
may	O
also	O
be	O
responsible	O
for	O
some	O
apparently	O
sporadic	O
diseases	O
.	O

Protein	B-Enzyme
kinase	I-Enzyme
Cα	I-Enzyme
gain	B-PosReg
-	I-PosReg
of	I-PosReg
-	I-PosReg
function	I-PosReg
variant	B-Var
in	O
Alzheimer	B-Disease
's	I-Disease
disease	I-Disease
displays	O
enhanced	B-PosReg
catalysis	B-MPA
by	O
a	O
mechanism	O
that	O
evades	O
down	O
-	O
regulation	O
.	O

Conventional	O
protein	O
kinase	O
C	O
(	O
PKC	O
)	O
family	O
members	O
are	O
reversibly	O
activated	O
by	O
binding	O
to	O
the	O
second	O
messengers	O
Ca2	O
+	O
and	O
diacylglycerol	O
,	O
events	O
that	O
break	O
autoinhibitory	O
constraints	O
to	O
allow	O
the	O
enzyme	O
to	O
adopt	O
an	O
active	O
,	O
but	O
degradation	O
-	O
sensitive	O
,	O
conformation	O
.	O

Perturbing	O
these	O
autoinhibitory	O
constraints	O
,	O
resulting	O
in	O
protein	O
destabilization	O
,	O
is	O
one	O
of	O
many	O
mechanisms	O
by	O
which	O
PKC	O
function	O
is	O
lost	O
in	O
cancer	O
.	O

Here	O
,	O
we	O
address	O
how	O
a	O
gain	B-PosReg
-	I-PosReg
of	I-PosReg
-	I-PosReg
function	I-PosReg
germline	B-Var
mutation	I-Var
in	O
PKCα	B-Enzyme
in	O
Alzheimer	B-Disease
's	I-Disease
disease	I-Disease
(	O
AD	O
)	O
enhances	B-PosReg
signaling	B-MPA
without	O
increasing	O
vulnerability	O
to	O
down	O
-	O
regulation	O
.	O

Biochemical	O
analyses	O
of	O
purified	O
protein	O
demonstrate	O
that	O
this	O
mutation	B-Var
results	O
in	O
an	O
∼30	O
%	O
increase	B-PosReg
in	O
the	O
catalytic	B-MPA
rate	O
of	O
the	O
activated	O
enzyme	O
,	O
with	O
no	O
changes	O
in	O
the	O
concentrations	O
of	O
Ca2	O
+	O
or	O
lipid	O
required	O
for	O
half	O
-	O
maximal	O
activation	O
.	O

Molecular	O
dynamics	O
simulations	O
reveal	O
that	O
this	O
mutation	B-Var
has	O
both	O
localized	O
and	O
allosteric	O
effects	O
,	O
most	O
notably	O
decreasing	B-NegReg
the	O
dynamics	B-MPA
of	I-MPA
the	I-MPA
C	I-MPA
-	I-MPA
helix	I-MPA
,	O
a	O
key	O
determinant	O
in	O
the	O
catalytic	O
turnover	O
of	O
kinases	O
.	O

Consistent	O
with	O
this	O
mutation	O
not	O
altering	O
autoinhibitory	O
constraints	O
,	O
live	O
-	O
cell	O
imaging	O
studies	O
reveal	O
that	O
the	O
basal	O
signaling	O
output	O
of	O
PKCα	O
-	O
M489V	O
is	O
unchanged	O
.	O

However	O
,	O
the	O
mutant	B-Var
enzyme	B-Enzyme
in	O
cells	O
displays	O
increased	B-PosReg
sensitivity	B-MPA
to	O
an	O
inhibitor	O
that	O
is	O
ineffective	O
toward	O
scaffolded	O
PKC	O
,	O
suggesting	O
the	O
altered	O
dynamics	O
of	O
the	O
kinase	O
domain	O
may	O
influence	B-Reg
protein	B-Protein
interactions	B-Interaction
.	O

Finally	O
,	O
we	O
show	O
that	O
phosphorylation	B-MPA
of	O
a	O
key	O
PKC	O
substrate	O
,	O
myristoylated	B-MPA
alanine	I-MPA
-	I-MPA
rich	I-MPA
C	I-MPA
-	I-MPA
kinase	I-MPA
substrate	I-MPA
,	O
is	O
increased	B-PosReg
in	O
brains	O
of	O
CRISPR	O
-	O
Cas9	O
genome	O
-	O
edited	O
mice	O
containing	O
the	O
PKCα	B-Var
-	I-Var
M489V	I-Var
mutation	I-Var
.	O

Our	O
results	O
unveil	O
how	O
an	O
AD	B-Reg
-	I-Reg
associated	I-Reg
mutation	B-Var
in	O
PKCα	B-Enzyme
permits	O
enhanced	B-PosReg
agonist	B-MPA
-	I-MPA
dependent	I-MPA
signaling	I-MPA
via	O
a	O
mechanism	O
that	O
evades	B-NegReg
the	O
cell	O
's	O
homeostatic	B-MPA
down	I-MPA
-	I-MPA
regulation	I-MPA
of	O
constitutively	B-Enzyme
active	I-Enzyme
PKCα	I-Enzyme
.	O

Gain	B-PosReg
-	I-PosReg
of	I-PosReg
-	I-PosReg
function	I-PosReg
KCNJ6	B-Gene
Mutation	B-Var
in	O
a	O
Severe	B-Disease
Hyperkinetic	I-Disease
Movement	I-Disease
Disorder	I-Disease
Phenotype	O
.	O

Here	O
,	O
we	O
describe	O
a	O
fourth	O
case	O
of	O
a	O
human	O
with	O
a	O
de	O
novo	O
KCNJ6	B-Gene
(	O
GIRK2	O
)	O
mutation	B-Var
,	O
who	O
presented	B-Reg
with	O
clinical	O
findings	O
of	O
severe	B-Disease
hyperkinetic	I-Disease
movement	I-Disease
disorder	I-Disease
and	O
developmental	B-CPA
delay	I-CPA
,	O
similar	O
to	O
the	O
Keppen	O
-	O
Lubinsky	O
syndrome	O
but	O
without	O
lipodystrophy	O
.	O

Whole	O
-	O
exome	O
sequencing	O
of	O
the	O
patient	O
's	O
DNA	O
revealed	O
a	O
heterozygous	O
de	O
novo	O
variant	O
in	O
the	O
KCNJ6	B-Gene
(	B-Var
c.512T	I-Var
>	I-Var
G	I-Var
,	O
p	B-Var
.	I-Var
Leu171Arg	I-Var
)	I-Var
.	O

We	O
conducted	O
in	O
vitro	O
functional	O
studies	O
to	O
determine	O
if	O
this	O
Leu	O
-	O
to	O
-	O
Arg	O
mutation	O
alters	O
the	O
function	O
of	O
GIRK2	O
channels	O
.	O

Heterologous	O
expression	O
of	O
the	O
mutant	B-Var
GIRK2	B-Gene
channel	O
alone	O
produced	B-PosReg
an	O
aberrant	O
basal	B-MPA
inward	I-MPA
current	I-MPA
that	O
lacked	B-NegReg
G	B-Protein
protein	I-Protein
activation	B-MPA
,	O
lost	B-NegReg
K+	B-MPA
selectivity	I-MPA
and	O
gained	B-PosReg
Ca2	B-MPA
+	I-MPA
permeability	I-MPA
.	O

Notably	O
,	O
the	O
inward	O
current	O
was	O
inhibited	O
by	O
the	O
Na+	O
channel	O
blocker	O
QX-314	O
,	O
similar	O
to	O
the	O
previously	O
reported	O
weaver	O
mutation	O
in	O
murine	O
GIRK2	O
.	O

Expression	O
of	O
a	O
tandem	O
dimer	O
containing	O
GIRK1	O
and	O
GIRK2(p	O
.	O
Leu171Arg	O
)	O
did	O
not	O
lead	O
to	O
any	O
currents	O
,	O
suggesting	O
heterotetramers	O
are	O
not	O
functional	O
.	O

In	O
neurons	O
expressing	O
p	B-Var
.	I-Var
Leu171Arg	I-Var
GIRK2	B-Gene
channels	O
,	O
these	O
changes	O
in	O
channel	O
properties	O
would	O
be	O
expected	O
to	O
generate	O
a	O
sustained	O
depolarization	B-NegReg
,	O
instead	O
of	O
the	O
normal	O
G	B-MPA
protein	I-MPA
-	I-MPA
gated	I-MPA
inhibitory	I-MPA
response	I-MPA
,	O
which	O
could	O
be	O
mitigated	O
by	O
expression	O
of	O
other	O
GIRK	O
subunits	O
.	O

The	O
identification	O
of	O
the	O
p	O
.	O
Leu171Arg	O
GIRK2	O
mutation	O
potentially	O
expands	O
the	O
Keppen	O
-	O
Lubinsky	O
syndrome	O
phenotype	O
to	O
include	O
severe	O
dystonia	O
and	O
ballismus	O
.	O

Our	O
study	O
suggests	O
screening	O
for	O
dominant	O
KCNJ6	O
mutations	O
in	O
the	O
evaluation	O
of	O
patients	O
with	O
severe	O
movement	O
disorders	O
,	O
which	O
could	O
provide	O
evidence	O
to	O
support	O
a	O
causal	O
role	O
of	O
KCNJ6	O
in	O
neurological	O
channelopathies	O
.	O

De	O
Novo	O
and	O
Inherited	O
Loss	B-NegReg
-	I-NegReg
of	I-NegReg
-	I-NegReg
Function	I-NegReg
Variants	B-Var
in	O
TLK2	B-Gene
:	I-Gene
Clinical	O
and	O
Genotype	O
-	O
Phenotype	O
Evaluation	O
of	O
a	O
Distinct	B-Disease
Neurodevelopmental	I-Disease
Disorder	I-Disease
.	O

Next	O
-	O
generation	O
sequencing	O
is	O
a	O
powerful	O
tool	O
for	O
the	O
discovery	O
of	O
genes	O
related	O
to	O
neurodevelopmental	O
disorders	O
(	O
NDDs	O
)	O
.	O

Here	O
,	O
we	O
report	O
the	O
identification	O
of	O
a	O
distinct	O
syndrome	O
due	O
to	O
de	O
novo	O
or	O
inherited	O
heterozygous	O
mutations	O
in	O
Tousled	O
-	O
like	O
kinase	O
2	O
(	O
TLK2	O
)	O
in	O
38	O
unrelated	O
individuals	O
and	O
two	O
affected	O
mothers	O
,	O
using	O
whole	O
-	O
exome	O
and	O
whole	O
-	O
genome	O
sequencing	O
technologies	O
,	O
matchmaker	O
databases	O
,	O
and	O
international	O
collaborations	O
.	O

Affected	O
individuals	O
had	O
a	O
consistent	O
phenotype	O
,	O
characterized	O
by	O
mild	O
-	O
borderline	O
neurodevelopmental	O
delay	O
(	O
86	O
%	O
)	O
,	O
behavioral	O
disorders	O
(	O
68	O
%	O
)	O
,	O
severe	O
gastro	O
-	O
intestinal	O
problems	O
(	O
63	O
%	O
)	O
,	O
and	O
facial	O
dysmorphism	O
including	O
blepharophimosis	O
(	O
82	O
%	O
)	O
,	O
telecanthus	O
(	O
74	O
%	O
)	O
,	O
prominent	O
nasal	O
bridge	O
(	O
68	O
%	O
)	O
,	O
broad	O
nasal	O
tip	O
(	O
66	O
%	O
)	O
,	O
thin	O
vermilion	O
of	O
the	O
upper	O
lip	O
(	O
62	O
%	O
)	O
,	O
and	O
upslanting	O
palpebral	O
fissures	O
(	O
55	O
%	O
)	O
.	O

Analysis	O
of	O
cell	O
lines	O
from	O
three	O
affected	O
individuals	O
showed	O
that	O
mutations	O
act	O
through	O
a	O
loss	O
-	O
of	O
-	O
function	O
mechanism	O
in	O
at	O
least	O
two	O
case	O
subjects	O
.	O

Genotype	O
-	O
phenotype	O
analysis	O
and	O
comparison	O
of	O
computationally	O
modeled	O
faces	O
showed	O
that	O
phenotypes	O
of	O
these	O
and	O
other	O
individuals	O
with	O
loss	O
-	O
of	O
-	O
function	O
variants	O
significantly	O
overlapped	O
with	O
phenotypes	O
of	O
individuals	O
with	O
other	O
variant	O
types	O
(	O
missense	O
and	O
C	O
-	O
terminal	O
truncating	O
)	O
.	O

This	O
suggests	O
that	O
haploinsufficiency	O
of	O
TLK2	O
is	O
the	O
most	O
likely	O
underlying	O
disease	O
mechanism	O
,	O
leading	O
to	O
a	O
consistent	O
neurodevelopmental	O
phenotype	O
.	O

This	O
work	O
illustrates	O
the	O
power	O
of	O
international	O
data	O
sharing	O
,	O
by	O
the	O
identification	O
of	O
40	O
individuals	O
from	O
26	O
different	O
centers	O
in	O
7	O
different	O
countries	O
,	O
allowing	O
the	O
identification	O
,	O
clinical	O
delineation	O
,	O
and	O
genotype	O
-	O
phenotype	O
evaluation	O
of	O
a	O
distinct	O
NDD	O
caused	O
by	O
mutations	O
in	O
TLK2	O
.	O

Progranulin	O
as	O
a	O
therapeutic	O
target	O
for	O
dementia	O
.	O

INTRODUCTION	O
:	O
Progranulin	O
(	O
PGRN	O
)	O
is	O
an	O
acrosomal	O
glycoprotein	O
that	O
is	O
synthesized	O
during	O
spermatogenesis	O
.	O

It	O
is	O
overexpressed	O
in	O
tumors	O
and	O
has	O
anti	O
-	O
inflammatory	O
properties	O
.	O

The	O
protein	O
may	O
be	O
cleaved	O
into	O
granulins	O
which	O
display	O
pro	O
-	O
inflammatory	O
properties	O
.	O

In	O
2006	O
,	O
mutations	B-Var
in	O
progranulin	O
gene	O
(	B-Gene
GRN	I-Gene
)	I-Gene
that	O
cause	O
haploinsufficiency	O
were	O
found	O
in	O
familial	O
cases	B-Reg
of	O
frontotemporal	B-Disease
dementia	I-Disease
(	O
FTD	O
)	O
.	O

Patients	O
with	O
null	O
mutations	O
in	O
GRN	O
display	O
very	O
low	O
-	O
plasma	O
PGRN	O
levels	O
;	O
this	O
analysis	O
is	O
useful	O
for	O
identifying	O
mutation	O
carriers	O
,	O
independent	O
of	O
the	O
clinical	O
presentation	O
,	O
and	O
in	O
those	O
before	O
the	O
appearance	O
of	O
symptoms	O
.	O

Areas	O
covered	O
:	O
Here	O
,	O
we	O
review	O
the	O
current	O
knowledge	O
of	O
PGRN	O
physiological	O
functions	O
and	O
GRN	O
mutations	O
associated	O
with	O
FTD	O
;	O
we	O
also	O
summarize	O
state	O
of	O
the	O
art	O
clinical	O
trials	O
and	O
those	O
compounds	O
able	O
to	O
replace	O
PGRN	O
loss	O
in	O
preclinical	O
models	O
.	O

Expert	O
opinion	O
:	O
PGRN	O
represents	O
a	O
promising	O
therapeutic	O
target	O
for	O
FTD	O
.	O

Cohorts	O
suitable	O
for	O
treatment	O
,	O
ideally	O
at	O
the	O
preclinical	O
stage	O
,	O
where	O
pathogenic	O
mechanisms	O
ongoing	O
in	O
the	O
brain	O
are	O
targeted	O
,	O
are	O
available	O
.	O

However	O
,	O
PGRN	O
may	O
have	O
side	O
effects	O
,	O
such	O
as	O
the	O
risk	O
of	O
tumorigenesis	O
,	O
and	O
the	O
risk	O
/	O
benefit	O
ratio	O
of	O
any	O
intervention	O
can	O
not	O
be	O
predicted	O
.	O

Furthermore	O
,	O
at	O
present	O
,	O
the	O
situation	O
is	O
complicated	O
by	O
the	O
absence	O
of	O
adequate	O
outcome	O
measures	O
.	O

Quantitative	O
phosphoproteomic	O
analysis	O
of	O
the	O
molecular	O
substrates	O
of	O
sleep	O
need	O
.	O

Sleep	O
and	O
wake	O
have	O
global	O
effects	O
on	O
brain	O
physiology	O
,	O
from	O
molecular	O
changes1	O
-	O
4	O
and	O
neuronal	O
activities	O
to	O
synaptic	O
plasticity3	O
-	O
7	O
.	O

Sleep	O
-	O
wake	O
homeostasis	O
is	O
maintained	O
by	O
the	O
generation	O
of	O
a	O
sleep	O
need	O
that	O
accumulates	O
during	O
waking	O
and	O
dissipates	O
during	O
sleep8	O
-	O
11	O
.	O

Here	O
we	O
investigate	O
the	O
molecular	O
basis	O
of	O
sleep	O
need	O
using	O
quantitative	O
phosphoproteomic	O
analysis	O
of	O
the	O
sleep	O
-	O
deprived	O
and	O
Sleepy	O
mouse	O
models	O
of	O
increased	O
sleep	O
need	O
.	O

Sleep	O
deprivation	O
induces	O
cumulative	O
phosphorylation	O
of	O
the	O
brain	O
proteome	O
,	O
which	O
dissipates	O
during	O
sleep	O
.	O

Sleepy	O
mice	O
,	O
owing	O
to	O
a	O
gain	B-PosReg
-	I-PosReg
of	I-PosReg
-	I-PosReg
function	I-PosReg
mutation	B-Var
in	O
the	O
Sik3	B-Gene
gene	O
12	O
,	O
have	O
a	O
constitutively	O
high	O
sleep	O
need	O
despite	O
increased	O
sleep	O
amount	O
.	O

The	O
brain	B-Protein
proteome	I-Protein
of	O
these	O
mice	O
exhibits	O
hyperphosphorylation	B-MPA
,	O
similar	O
to	O
that	O
seen	O
in	O
the	O
brain	O
of	O
sleep	O
-	O
deprived	O
mice	O
.	O

Comparison	O
of	O
the	O
two	O
models	O
identifies	O
80	O
mostly	O
synaptic	O
sleep	O
-	O
need	O
-	O
index	O
phosphoproteins	O
(	O
SNIPPs	O
)	O
,	O
in	O
which	O
phosphorylation	O
states	O
closely	O
parallel	O
changes	O
of	O
sleep	O
need	O
.	O

SLEEPY	O
,	O
the	O
mutant	B-Var
SIK3	B-Gene
protein	B-Protein
,	O
preferentially	B-PosReg
associates	B-Interaction
with	I-Interaction
and	O
phosphorylates	B-MPA
SNIPPs	B-Protein
.	O

Inhibition	O
of	O
SIK3	O
activity	O
reduces	O
phosphorylation	O
of	O
SNIPPs	O
and	O
slow	O
wave	O
activity	O
during	O
non	O
-	O
rapid	O
-	O
eye	O
-	O
movement	O
sleep	O
,	O
the	O
best	O
known	O
measurable	O
index	O
of	O
sleep	O
need	O
,	O
in	O
both	O
Sleepy	O
mice	O
and	O
sleep	O
-	O
deprived	O
wild	O
-	O
type	O
mice	O
.	O

Our	O
results	O
suggest	O
that	O
phosphorylation	O
of	O
SNIPPs	O
accumulates	O
and	O
dissipates	O
in	O
relation	O
to	O
sleep	O
need	O
,	O
and	O
therefore	O
SNIPP	O
phosphorylation	O
is	O
a	O
molecular	O
signature	O
of	O
sleep	O
need	O
.	O

Whereas	O
waking	O
encodes	O
memories	O
by	O
potentiating	O
synapses	O
,	O
sleep	O
consolidates	O
memories	O
and	O
restores	O
synaptic	O
homeostasis	O
by	O
globally	O
downscaling	O
excitatory	O
synapses4	O
-	O
6	O
.	O

Thus	O
,	O
the	O
phosphorylation	O
-	O
dephosphorylation	O
cycle	O
of	O
SNIPPs	O
may	O
represent	O
a	O
major	O
regulatory	O
mechanism	O
that	O
underlies	O
both	O
synaptic	O
homeostasis	O
and	O
sleep	O
-	O
wake	O
homeostasis	O
.	O

Germline	O
mutations	O
and	O
somatic	O
inactivation	O
of	O
TRIM28	O
in	O
Wilms	O
tumour	O
.	O

Wilms	O
tumour	O
is	O
a	O
childhood	O
tumour	O
that	O
arises	O
as	O
a	O
consequence	O
of	O
somatic	O
and	O
rare	O
germline	O
mutations	O
,	O
the	O
characterisation	O
of	O
which	O
has	O
refined	O
our	O
understanding	O
of	O
nephrogenesis	O
and	O
carcinogenesis	O
.	O

Here	O
we	O
report	O
that	O
germline	O
loss	B-NegReg
of	I-NegReg
function	I-NegReg
mutations	B-Var
in	O
TRIM28	B-Gene
predispose	O
children	O
to	O
Wilms	B-Disease
tumour	I-Disease
.	O

Loss	O
of	O
function	O
of	O
this	O
transcriptional	O
co	O
-	O
repressor	O
,	O
which	O
has	O
a	O
role	O
in	O
nephrogenesis	O
,	O
has	O
not	O
previously	O
been	O
associated	O
with	O
cancer	O
.	O

Inactivation	B-NegReg
of	O
TRIM28	B-Gene
,	O
either	O
germline	O
or	O
somatic	O
,	O
occurred	O
through	O
inactivating	B-Var
mutations	I-Var
,	O
loss	B-Var
of	I-Var
heterozygosity	I-Var
or	O
epigenetic	B-Var
silencing	I-Var
.	O

TRIM28-mutated	O
tumours	O
had	O
a	O
monomorphic	O
epithelial	O
histology	O
that	O
is	O
uncommon	O
for	O
Wilms	O
tumour	O
.	O

Critically	O
,	O
these	O
tumours	O
were	O
negative	O
for	O
TRIM28	O
immunohistochemical	O
staining	O
whereas	O
the	O
epithelial	O
component	O
in	O
normal	O
tissue	O
and	O
other	O
Wilms	O
tumours	O
stained	O
positively	O
.	O

These	O
data	O
,	O
together	O
with	O
a	O
characteristic	O
gene	O
expression	O
profile	O
,	O
suggest	O
that	O
inactivation	O
of	O
TRIM28	O
provides	O
the	O
molecular	O
basis	O
for	O
defining	O
a	O
previously	O
described	O
subtype	O
of	O
Wilms	O
tumour	O
,	O
that	O
has	O
early	O
age	O
of	O
onset	O
and	O
excellent	O
prognosis	O
.	O

Mutational	O
and	O
functional	O
studies	O
on	O
NR5A1	B-Gene
gene	O
in	O
46,XY	B-Disease
disorders	I-Disease
of	I-Disease
sex	I-Disease
development	I-Disease
:	I-Disease
identification	O
of	O
six	O
novel	O
loss	B-NegReg
of	I-NegReg
function	I-NegReg
mutations	B-Var
.	O

OBJECTIVE	O
:	O
To	O
study	O
the	O
functional	O
properties	O
of	O
six	O
novel	O
missense	O
mutations	O
of	O
the	O
NR5A1	O
gene	O
encoding	O
the	O
steroidogenic	O
factor	O
1	O
(	O
SF-1	O
)	O
identified	O
in	O
six	O
patients	O
with	O
46,XY	O
disorders	O
of	O
sex	O
development	O
(	O
DSD	O
)	O
and	O
to	O
describe	O
their	O
relative	O
phenotype	O
-	O
genotype	O
relationship	O
.	O

DESIGN	O
:	O
Genetic	O
and	O
functional	O
studies	O
.	O

SETTING	O
:	O
University	O
department	O
.	O

PATIENT(S	O
)	O
:	O
Six	O
46,XY	O
DSD	O
patients	O
.	O

INTERVENTION(S	O
)	O
:	O
None	O
.	O

MAIN	O
OUTCOME	O
MEASURE(S	O
)	O
:	O
Sanger	O
sequencing	O
and	O
multiplex	O
ligation	O
-	O
dependent	O
probe	O
amplification	O
analysis	O
to	O
identify	O
the	O
mutations	O
or	O
deletions	O
/	O
duplications	O
of	O
the	O
NR5A1	O
gene	O
.	O

Functional	O
studies	O
by	O
transactivation	O
assays	O
to	O
predict	O
the	O
impact	O
of	O
mutations	O
on	O
molecular	O
function	O
.	O

RESULT(S	O
)	O
:	O
NR5A1	B-Gene
exons	O
sequencing	O
identified	B-Reg
in	I-Reg
six	O
46,XY	B-Disease
DSD	I-Disease
patients	O
six	O
novel	O
mutations	O
:	O
p	B-Var
.	I-Var
T40R	I-Var
,	O
p	B-Var
.	I-Var
T47C	I-Var
,	O
p	B-Var
.	I-Var
G328W	I-Var
,	O
p	B-Var
.	I-Var
A351E	I-Var
,	O
p	B-Var
.	I-Var
R427W	I-Var
,	O
and	O
p	B-Var
.	I-Var
Q460R.	I-Var
Five	O
missense	O
variants	O
were	O
heterozygous	O
,	O
and	O
one	O
was	O
homozygous	O
(	O
p	O
.	O
R427W	O
)	O
.	O

Functional	O
analysis	O
revealed	O
a	O
significant	O
loss	B-NegReg
of	O
DNA	B-Interaction
-	I-Interaction
binding	I-Interaction
and	O
transactivation	B-MPA
ability	O
for	O
all	O
variants	O
,	O
except	O
for	O
p	O
.	O
Q460R	O
,	O
which	O
showed	O
a	O
modest	O
reduced	O
activity	O
compared	O
with	O
that	O
of	O
the	O
wild	O
-	O
type	O
protein	O
.	O

Phenotypes	O
associated	O
with	O
these	O
mutations	O
varied	O
from	O
males	O
with	O
spontaneous	O
puberty	O
,	O
substantial	O
T	O
production	O
,	O
and	O
possible	O
fertility	O
,	O
to	O
females	O
with	O
and	O
without	O
müllerian	O
structures	O
and	O
primary	O
amenorrhea	O
.	O

CONCLUSION(S	O
)	O
:	O
We	O
describe	O
six	O
novel	O
mutations	B-Var
in	O
NR5A1	B-Gene
gene	O
and	O
showed	O
that	O
they	O
might	O
affect	B-Reg
protein	B-MPA
structure	I-MPA
,	O
therefore	O
compromising	B-NegReg
seriously	O
the	O
SF-1	B-MPA
role	O
in	O
regulating	O
gonadal	B-CPA
development	I-CPA
.	O

Clinically	O
,	O
we	O
suggest	O
that	O
NR5A1	O
analysis	O
should	O
be	O
performed	O
whenever	O
atypical	O
sex	O
organs	O
are	O
evidenced	O
or	O
there	O
is	O
an	O
abnormal	O
sexual	O
development	O
,	O
to	O
have	O
proper	O
diagnosis	O
and	O
better	O
management	O
of	O
patients	O
.	O

Multiple	O
regions	O
in	O
the	O
extracellular	O
domain	O
of	O
the	O
glycine	O
receptor	O
determine	O
receptor	O
activity	O
.	O

Glycine	O
receptors	O
(	O
GlyRs	O
)	O
are	O
Cys	O
-	O
loop	O
receptors	O
that	O
mediate	O
fast	O
synaptic	O
inhibition	O
in	O
the	O
brain	O
stem	O
and	O
spinal	O
cord	O
.	O

They	O
are	O
involved	O
in	O
the	O
generation	O
of	O
motor	O
rhythm	O
,	O
reflex	O
circuit	O
coordination	O
,	O
and	O
sensory	O
signal	O
processing	O
and	O
therefore	O
represent	O
targets	O
for	O
therapeutic	O
interventions	O
.	O

The	O
extracellular	O
domains	O
(	O
ECDs	O
)	O
of	O
Cys	O
-	O
loop	O
receptors	O
typically	O
contain	O
many	O
aromatic	O
amino	O
acids	O
,	O
but	O
only	O
those	O
in	O
the	O
receptor	O
binding	O
pocket	O
have	O
been	O
extensively	O
studied	O
.	O

Here	O
,	O
we	O
show	O
that	O
many	O
Phe	O
residues	O
in	O
the	O
ECD	O
that	O
are	O
not	O
located	O
in	O
the	O
binding	O
pocket	O
are	O
also	O
involved	O
in	O
GlyR	O
function	O
.	O

We	O
examined	O
these	O
Phe	O
residues	O
by	O
creating	O
several	O
GlyR	O
variants	O
,	O
characterizing	O
these	O
variants	O
with	O
the	O
two	O
-	O
electrode	O
voltage	O
clamp	O
technique	O
in	O
Xenopus	O
oocytes	O
,	O
and	O
interpreting	O
changes	O
in	O
receptor	O
parameters	O
by	O
using	O
currently	O
available	O
structural	O
information	O
on	O
the	O
open	O
and	O
closed	O
states	O
of	O
the	O
GlyR.	O
Substitution	B-Var
of	O
six	O
of	O
the	O
eight	O
Phe	O
residues	O
in	O
the	O
ECD	O
with	O
Ala	O
resulted	O
in	O
loss	B-NegReg
of	O
function	B-MPA
or	O
significantly	O
increased	B-PosReg
the	O
EC50	B-MPA
and	O
also	O
altered	B-Reg
the	O
maximal	B-MPA
response	I-MPA
to	I-MPA
the	I-MPA
partial	I-MPA
GlyR	I-MPA
agonist	I-MPA
taurine	I-MPA
compared	O
with	O
glycine	O
in	O
those	O
receptor	O
variants	O
that	O
were	O
functional	O
.	O

Substitutions	O
with	O
other	O
amino	O
acids	O
,	O
combined	O
with	O
examination	O
of	O
nearby	O
residues	O
that	O
could	O
potentially	O
interact	O
with	O
these	O
Phe	O
residues	O
,	O
suggested	O
interactions	O
that	O
could	O
be	O
important	O
for	O
GlyR	O
function	O
,	O
and	O
possibly	O
similar	O
interactions	O
could	O
contribute	O
to	O
the	O
function	O
of	O
other	O
members	O
of	O
the	O
Cys	O
-	O
loop	O
receptor	O
family	O
.	O

Overall	O
,	O
our	O
results	O
suggest	O
that	O
many	O
ECD	O
regions	O
are	O
important	O
for	O
GlyR	O
function	O
and	O
that	O
these	O
regions	O
could	O
inform	O
the	O
design	O
of	O
therapeutic	O
agents	O
targeting	O
GlyR	O
activity	O
.	O

RES	O
complex	O
is	O
associated	O
with	O
intron	O
definition	O
and	O
required	O
for	O
zebrafish	O
early	O
embryogenesis	O
.	O

Pre	O
-	O
mRNA	O
splicing	O
is	O
a	O
critical	O
step	O
of	O
gene	O
expression	O
in	O
eukaryotes	O
.	O

Transcriptome	O
-	O
wide	O
splicing	O
patterns	O
are	O
complex	O
and	O
primarily	O
regulated	O
by	O
a	O
diverse	O
set	O
of	O
recognition	O
elements	O
and	O
associated	O
RNA	O
-	O
binding	O
proteins	O
.	O

The	O
retention	O
and	O
splicing	O
(	O
RES	O
)	O
complex	O
is	O
formed	O
by	O
three	O
different	O
proteins	O
(	O
Bud13p	O
,	O
Pml1p	O
and	O
Snu17p	O
)	O
and	O
is	O
involved	O
in	O
splicing	O
in	O
yeast	O
.	O

However	O
,	O
the	O
importance	O
of	O
the	O
RES	O
complex	O
for	O
vertebrate	O
splicing	O
,	O
the	O
intronic	O
features	O
associated	O
with	O
its	O
activity	O
,	O
and	O
its	O
role	O
in	O
development	O
are	O
unknown	O
.	O

In	O
this	O
study	O
,	O
we	O
have	O
generated	O
loss	B-NegReg
-	I-NegReg
of	I-NegReg
-	I-NegReg
function	I-NegReg
mutants	B-Var
for	O
the	O
three	O
components	O
of	O
the	O
RES	O
complex	O
in	O
zebrafish	O
and	O
showed	O
that	O
they	O
are	O
required	O
during	O
early	O
development	O
.	O

The	O
mutants	O
showed	O
a	O
marked	O
neural	O
phenotype	O
with	O
increased	O
cell	O
death	O
in	O
the	O
brain	O
and	O
a	O
decrease	B-NegReg
in	O
differentiated	B-CPA
neurons	I-CPA
.	O

Transcriptomic	O
analysis	O
of	O
bud13	B-Gene
,	O
snip1	B-Gene
(	O
pml1	O
)	O
and	O
rbmx2	B-Gene
(	O
snu17	O
)	O
mutants	B-Var
revealed	O
a	O
global	O
defect	B-NegReg
in	O
intron	B-MPA
splicing	I-MPA
,	O
with	O
strong	O
mis	B-MPA
-	I-MPA
splicing	I-MPA
of	I-MPA
a	I-MPA
subset	I-MPA
of	I-MPA
introns	I-MPA
.	O

We	O
found	O
these	O
RES	O
-	O
dependent	O
introns	O
were	O
short	O
,	O
rich	O
in	O
GC	O
and	O
flanked	O
by	O
GC	O
depleted	O
exons	O
,	O
all	O
of	O
which	O
are	O
features	O
associated	O
with	O
intron	O
definition	O
.	O

Using	O
these	O
features	O
,	O
we	O
developed	O
and	O
validated	O
a	O
predictive	O
model	O
that	O
classifies	O
RES	O
dependent	O
introns	O
.	O

Altogether	O
,	O
our	O
study	O
uncovers	O
the	O
essential	O
role	O
of	O
the	O
RES	O
complex	O
during	O
vertebrate	O
development	O
and	O
provides	O
new	O
insights	O
into	O
its	O
function	O
during	O
splicing	O
.	O

Mutant	B-Var
p53	B-Gene
gain	B-PosReg
of	I-PosReg
function	I-PosReg
induces	B-Reg
HER2	B-Protein
over	B-MPA
-	I-MPA
expression	I-MPA
in	O
cancer	O
cells	O
.	O

BACKGROUND	O
:	O
HER2	O
over	O
-	O
expression	O
is	O
related	O
with	O
a	O
poor	O
prognosis	O
in	O
patients	O
with	O
invasive	O
breast	O
cancer	O
tumors	O
.	O

Clinical	O
associations	O
have	O
reported	O
that	O
somatic	O
mutations	O
of	O
p53	O
more	O
frequently	O
detected	O
in	O
cases	O
of	O
sporadic	O
breast	O
cancer	O
of	O
the	O
HER2	O
subtypes	O
,	O
besides	O
a	O
high	O
percentage	O
of	O
HER2-amplifying	O
tumors	O
carry	O
germline	O
mutations	O
of	O
p53	O
.	O

The	O
mechanisms	O
responsible	O
for	O
the	O
acquisition	O
of	O
oncogenic	O
functions	O
of	O
p53	O
mutant	O
proteins	O
(	O
mtp53	O
)	O
,	O
known	O
as	O
Gain	O
of	O
Function	O
(	O
GOF	O
)	O
,	O
over	O
HER2	O
expression	O
have	O
not	O
been	O
reported	O
.	O

The	O
objective	O
of	O
this	O
study	O
was	O
to	O
evaluate	O
a	O
possible	O
relationship	O
between	O
p53	O
mutants	O
and	O
HER2	O
regulation	O
.	O

METHODS	O
:	O
HER2	O
expression	O
(	O
transcription	O
and	O
protein	O
)	O
,	O
as	O
well	O
as	O
HER2	O
protein	O
stabilization	O
have	O
been	O
evaluated	O
after	O
inducing	O
or	O
silencing	O
of	O
p53	O
mutants	O
'	O
expression	O
in	O
cell	O
lines	O
.	O

Finally	O
,	O
we	O
evaluated	O
the	O
interaction	O
of	O
the	O
p53	O
mutants	O
over	O
the	O
HER2	O
receptor	O
promoter	O
.	O

RESULTS	O
:	O
Higher	B-PosReg
HER2	B-Protein
expression	B-MPA
in	O
cell	O
lines	O
harboring	O
endogenous	O
mtp53	B-Var
compared	O
with	O
wt	O
or	O
null	O
expression	O
of	O
p53	O
cell	O
lines	O
.	O

Transfection	O
of	O
p53	B-Gene
mutants	O
(	B-Var
R248Q	I-Var
and	O
R273C	B-Var
)	I-Var
in	O
cell	O
lines	O
increased	B-PosReg
the	O
expression	B-MPA
of	O
HER2	B-Protein
.	O

Silencing	O
of	O
p53	O
mutants	O
,	O
decrease	O
HER2	O
expression	O
.	O

The	O
p53	B-Gene
mutants	O
R248Q	B-Var
and	O
R273C	B-Var
significantly	O
increase	B-PosReg
the	O
luciferase	B-Enzyme
activity	B-MPA
on	O
the	O
HER2	O
promoter	O
,	O
and	O
both	O
mutants	O
also	O
promote	B-PosReg
acetylation	B-MPA
of	O
H3	B-Protein
and	O
H4	B-Protein
histones	I-Protein
binding	B-Interaction
in	O
it	O
.	O

CONCLUSIONS	O
:	O
These	O
findings	O
show	O
for	O
the	O
first	O
time	O
that	O
p53	B-Gene
mutants	B-Var
induce	B-Reg
over	B-MPA
-	I-MPA
expression	I-MPA
of	O
HER2	B-Protein
at	O
transcriptional	O
level	O
of	O
the	O
HER2	O
protein	O
.	O

Our	O
results	O
could	O
have	O
clinical	O
implications	O
in	O
breast	O
cancer	O
and	O
other	O
types	O
of	O
cancer	O
where	O
HER2	O
is	O
over	O
-	O
expressed	O
and	O
used	O
as	O
a	O
therapy	O
target	O
.	O

Mice	O
harboring	O
the	O
human	O
SLC30A8	B-Gene
R138X	B-Var
loss	B-NegReg
-	I-NegReg
of	I-NegReg
-	I-NegReg
function	I-NegReg
mutation	O
have	O
increased	B-PosReg
insulin	B-MPA
secretory	I-MPA
capacity	I-MPA
.	O

SLC30A8	O
encodes	O
a	O
zinc	O
transporter	O
that	O
is	O
primarily	O
expressed	O
in	O
the	O
pancreatic	O
islets	O
of	O
Langerhans	O
.	O

In	O
β	O
-	O
cells	O
it	O
transports	O
zinc	O
into	O
insulin	O
-	O
containing	O
secretory	O
granules	O
.	O

Loss	O
-	O
of	O
-	O
function	O
(	O
LOF	O
)	O
mutations	O
in	O
SLC30A8	O
protect	O
against	O
type	O
2	O
diabetes	O
in	O
humans	O
.	O

In	O
this	O
study	O
,	O
we	O
generated	O
a	O
knockin	O
mouse	O
model	O
carrying	O
one	O
of	O
the	O
most	O
common	O
human	O
LOF	O
mutations	O
for	O
SLC30A8	O
,	O
R138X.	O
The	O
R138X	O
mice	O
had	O
normal	O
body	O
weight	O
,	O
glucose	O
tolerance	O
,	O
and	O
pancreatic	O
β	O
-	O
cell	O
mass	O
.	O

Interestingly	O
,	O
in	O
hyperglycemic	O
conditions	O
induced	O
by	O
the	O
insulin	O
receptor	O
antagonist	O
S961	O
,	O
the	O
R138X	B-Var
mice	O
showed	O
a	O
50	O
%	O
increase	B-PosReg
in	O
insulin	B-MPA
secretion	I-MPA
.	O

This	O
effect	O
was	O
not	O
associated	O
with	O
enhanced	O
β	O
-	O
cell	O
proliferation	O
or	O
mass	O
.	O

Our	O
data	O
suggest	O
that	O
the	O
SLC30A8	B-Gene
R138X	O
LOF	B-NegReg
mutation	B-Var
may	O
exert	O
beneficial	B-PosReg
effects	I-PosReg
on	O
glucose	B-MPA
metabolism	I-MPA
by	O
increasing	B-PosReg
the	O
capacity	O
of	O
β	O
-	O
cells	O
to	O
secrete	B-MPA
insulin	I-MPA
under	O
hyperglycemic	O
conditions	O
.	O

The	O
lateral	O
meningocele	O
syndrome	O
mutation	O
causes	O
marked	O
osteopenia	O
in	O
mice	O
.	O

Lateral	O
meningocele	O
syndrome	O
(	O
LMS	O
)	O
is	O
a	O
rare	O
genetic	O
disorder	O
characterized	O
by	O
neurological	O
complications	O
and	O
osteoporosis	O
.	O

LMS	B-Disease
is	O
associated	O
with	O
mutations	B-Var
in	I-Var
exon	I-Var
33	I-Var
of	O
NOTCH3	B-Gene
leading	O
to	O
a	O
truncated	B-MPA
protein	B-Protein
lacking	B-NegReg
sequences	B-MPA
for	I-MPA
NOTCH3	I-MPA
degradation	I-MPA
and	O
presumably	O
causing	O
NOTCH3	B-Gene
gain	B-PosReg
of	I-PosReg
function	I-PosReg
.	O

To	O
create	O
a	O
mouse	O
model	O
reproducing	O
human	O
LMS	O
-	O
associated	O
mutations	O
,	O
we	O
utilized	O
CRISPR	O
/	O
Cas9	O
to	O
introduce	O
a	O
tandem	O
termination	O
codon	O
at	O
bases	O
6691	O
-	O
6696	O
(	O
ACCAAG→TAATGA	O
)	O
and	O
verified	O
this	O
mutation	O
(	O
Notch3tm1.1Ecan	O
)	O
by	O
DNA	O
sequencing	O
of	O
F1	O
mice	O
.	O

One	O
-	O
month	O
-	O
old	O
male	O
and	O
female	O
heterozygous	O
Notch3tm1.1Ecan	B-Var
mice	O
had	O
cancellous	B-CPA
and	I-CPA
cortical	I-CPA
bone	I-CPA
osteopenia	B-NegReg
but	O
exhibited	O
no	O
obvious	O
neurological	O
alterations	O
,	O
and	O
histopathology	O
of	O
multiple	O
organs	O
revealed	O
no	O
abnormalities	O
.	O

Microcomputed	O
tomography	O
of	O
these	O
mutants	B-Var
revealed	O
a	O
35	O
-	O
60	O
%	O
decrease	B-NegReg
in	O
cancellous	B-CPA
bone	I-CPA
volume	I-CPA
associated	O
with	O
a	O
reduction	B-NegReg
in	O
trabecular	B-CPA
number	I-CPA
and	O
decreased	B-NegReg
connectivity	B-CPA
.	O

During	O
maturation	O
,	O
cancellous	O
and	O
cortical	O
bones	O
were	O
restored	O
in	O
female	O
but	O
not	O
in	O
male	O
mice	O
,	O
which	O
exhibited	O
cancellous	O
bone	O
osteopenia	O
at	O
4	O
months	O
.	O

Cancellous	O
bone	O
histomorphometry	O
revealed	O
increased	O
osteoblast	O
and	O
osteocyte	O
numbers	O
and	O
a	O
modest	O
increase	O
in	O
osteoclast	O
surface	O
and	O
bone	O
formation	O
rate	O
.	O

Notch3tm1.1Ecan	B-Var
calvarial	B-CPA
osteoblasts	I-CPA
had	O
increased	B-PosReg
proliferation	O
and	O
increased	B-PosReg
bone	B-Protein
γ	I-Protein
-	I-Protein
carboxyglutamate	I-Protein
protein	I-Protein
(	I-Protein
Bglap	I-Protein
)	I-Protein
and	O
TNF	B-Gene
superfamily	I-Gene
member	I-Gene
11	I-Gene
(	I-Gene
Tnfsf11	I-Gene
)	I-Gene
mRNA	B-MPA
levels	I-MPA
and	O
lower	B-NegReg
Tnfrsf11b	B-MPA
levels	I-MPA
.	O

Tnfsf11	O
mRNA	O
was	O
increased	O
in	O
osteocyte	O
-	O
rich	O
femora	O
from	O
Notch3tm1.1Ecan	O
mice	O
.	O

Cultures	O
of	O
bone	O
marrow	O
-	O
derived	O
macrophages	O
from	O
Notch3tm1.1Ecan	O
mice	O
revealed	O
increased	O
osteoclast	O
formation	O
,	O
particularly	O
in	O
cocultures	O
with	O
osteoblasts	O
from	O
Notch3tm1.1Ecan	O
mice	O
.	O

In	O
conclusion	O
,	O
the	O
Notch3tm1.1Ecan	B-Var
mutation	I-Var
causes	O
osteopenia	B-Disease
despite	O
an	O
increase	B-PosReg
in	O
osteoblast	B-CPA
proliferation	I-CPA
and	O
function	B-CPA
and	O
is	O
associated	O
with	O
enhanced	B-PosReg
Tnfsf11	B-Gene
expression	B-MPA
in	O
osteoblasts	O
and	O
osteocytes	O
.	O

Heterogeneous	O
nature	O
of	O
diabetes	B-Disease
in	O
a	O
family	O
with	O
a	O
gain	B-PosReg
-	I-PosReg
of	I-PosReg
-	I-PosReg
function	I-PosReg
mutation	B-Var
in	O
the	O
ATP	O
-	O
binding	O
cassette	O
subfamily	O
C	O
member	O
8	O
(	B-Gene
ABCC8	I-Gene
)	I-Gene
gene	O
.	O

Gain	B-PosReg
-	I-PosReg
of	I-PosReg
-	I-PosReg
function	I-PosReg
ATP	O
-	O
binding	O
cassette	O
subfamily	O
C	O
member	O
8	O
(	B-Gene
ABCC8	I-Gene
)	I-Gene
mutations	B-Var
are	O
known	O
to	O
cause	B-Reg
neonatal	B-Disease
diabetes	I-Disease
mellitus	I-Disease
and	O
maturity	B-Disease
-	I-Disease
onset	I-Disease
diabetes	I-Disease
in	O
the	O
young	O
.	O

However	O
,	O
the	O
intrafamilial	O
heterogeneous	O
nature	O
of	O
diabetes	O
caused	O
by	O
the	O
ABCC8	O
mutation	O
is	O
not	O
fully	O
understood	O
to	O
date	O
.	O

To	O
clarify	O
the	O
intrafamilial	O
heterogeneous	O
nature	O
of	O
monogenetic	O
diabetes	O
,	O
we	O
conducted	O
a	O
case	O
study	O
on	O
a	O
family	O
with	O
ABCC8	O
mutations	O
.	O

We	O
investigated	O
eight	O
family	O
members	O
,	O
including	O
a	O
neonatal	O
diabetes	O
patient	O
,	O
based	O
on	O
metabolic	O
features	O
and	O
genetic	O
analysis	O
.	O

All	O
coding	O
exons	O
and	O
exon	O
-	O
intron	O
boundaries	O
of	O
the	O
KCNJ11	O
,	O
ABCC8	O
,	O
GCK	O
,	O
HNF1A	O
,	O
and	O
HNF4A	O
genes	O
were	O
amplified	O
from	O
genomic	O
DNA	O
and	O
directly	O
sequenced	O
.	O

Five	O
gene	O
mutation	O
carriers	O
with	O
ABCC8	O
(	O
c.1819G	O
>	O
A	O
/	O
p	O
.	O
V607	O
M	O
)	O
were	O
identified	O
in	O
this	O
family	O
,	O
and	O
the	O
onset	O
and	O
severity	O
of	O
diabetes	O
progressively	O
worsened	O
across	O
the	O
three	O
generations	O
.	O

Each	O
of	O
the	O
ABCC8	O
gene	O
mutation	O
carrier	O
family	O
members	O
were	O
diagnosed	O
with	O
diabetes	O
as	O
follows	O
:	O
the	O
grandfather	O
with	O
type	O
2	O
diabetes	O
at	O
35	O
years	O
of	O
age	O
,	O
the	O
aunt	O
with	O
slowly	O
-	O
progressive	O
insulin	O
-	O
dependent	O
diabetes	O
at	O
18	O
years	O
of	O
age	O
,	O
the	O
mother	O
with	O
ketosis	O
-	O
onset	O
insulin	O
-	O
dependent	O
diabetes	O
at	O
14	O
years	O
of	O
age	O
,	O
the	O
sister	O
with	O
impaired	O
glucose	O
tolerance	O
at	O
9	O
years	O
of	O
age	O
,	O
and	O
the	O
proband	O
with	O
transient	O
neonatal	O
diabetes	O
at	O
birth	O
.	O

The	O
present	O
study	O
shows	O
the	O
heterogeneous	O
nature	O
of	O
diabetes	O
in	O
a	O
family	O
with	O
a	O
gain	O
-	O
of	O
-	O
function	O
mutation	O
in	O
the	O
ABCC8	O
gene	O
.	O

Activating	O
human	O
epidermal	O
growth	O
factor	O
receptor	O
2	O
(	O
HER2	O
)	O
gene	O
mutation	O
in	O
bone	O
metastases	O
from	O
breast	O
cancer	O
.	O

In	O
addition	O
to	O
amplification	O
,	O
point	B-Var
mutations	I-Var
of	O
the	O
human	O
epidermal	O
growth	O
factor	O
receptor	O
2	O
(	O
HER2	O
)	O
gene	O
(	B-Gene
ERBB2	I-Gene
)	I-Gene
have	O
been	O
shown	O
to	O
activate	B-PosReg
the	O
corresponding	O
signaling	B-Pathway
pathway	I-Pathway
in	O
breast	B-Disease
cancer	I-Disease
.	O

The	O
prevalence	O
of	O
ERBB2	O
/	O
HER2	O
mutation	O
in	O
bone	O
metastasis	O
of	O
breast	O
cancer	O
and	O
the	O
associated	O
phenotype	O
are	O
not	O
known	O
.	O

In	O
this	O
study	O
,	O
bone	O
metastases	O
from	O
breast	O
cancer	O
patients	O
(	O
n	O
=	O
231	O
)	O
were	O
analyzed	O
for	O
ERBB2	O
/	O
HER2	O
mutation	O
.	O

In	O
7	O
patients	O
(	O
3	O
%	O
;	O
median	O
age	O
70	O
years	O
,	O
range	O
50	O
-	O
83	O
years	O
)	O
,	O
gain	O
-	O
of	O
-	O
function	O
mutations	O
of	O
ERBB2	O
/	O
HER2	O
were	O
detected	O
.	O

The	O
most	O
frequent	O
mutation	O
was	O
p	O
.	O
L755S	O
(	O
71	O
%	O
)	O
.	O

In	O
29	O
%	O
of	O
mutated	O
cases	O
,	O
p	O
.	O
V777L	O
was	O
found	O
.	O

Lobular	O
breast	O
cancer	O
was	O
present	O
in	O
71	O
%	O
of	O
mutated	O
cases	O
(	O
n	O
=	O
5	O
)	O
and	O
in	O
49	O
%	O
of	O
all	O
samples	O
(	O
n	O
=	O
231	O
;	O
p	O
=	O
0.275	O
)	O
.	O

Mutation	O
frequency	O
was	O
4.4	O
%	O
in	O
the	O
lobular	O
subgroup	O
and	O
17.4	O
%	O
in	O
the	O
pleomorphic	O
subtype	O
of	O
lobular	O
cancer	O
(	O
n	O
=	O
23	O
)	O
,	O
respectively	O
.	O

All	O
but	O
one	O
mutated	O
lobular	O
cancers	O
were	O
of	O
the	O
pleomorphic	O
subtype	O
(	O
p	O
=	O
0.006	O
)	O
.	O

Mutated	O
cancers	O
belonged	O
either	O
to	O
the	O
luminal	O
(	O
n	O
=	O
4	O
)	O
or	O
to	O
the	O
triple	O
-	O
negative	O
types	O
(	O
n	O
=	O
3	O
)	O
.	O

With	O
regard	O
to	O
protein	O
expression	O
and	O
gene	O
amplification	O
,	O
HER2	O
was	O
negative	O
in	O
all	O
mutated	O
cases	O
.	O

Among	O
the	O
14	O
%	O
of	O
metastatic	O
luminal	O
cancers	O
with	O
estrogen	O
receptor	O
gene	O
(	O
ESR1	O
)	O
mutation	O
,	O
conveying	O
resistance	O
against	O
aromatase	O
inhibitors	O
,	O
no	O
concomitant	O
ERBB2	O
/	O
HER2	O
mutation	O
occurred	O
.	O

We	O
conclude	O
that	O
activating	B-PosReg
HER2	B-Gene
mutation	B-Var
is	O
present	O
in	O
about	O
3	O
%	O
of	O
bone	B-CPA
metastases	I-CPA
from	O
breast	B-Disease
cancers	I-Disease
,	O
with	O
significantly	O
higher	B-PosReg
rates	I-PosReg
in	O
the	O
pleomorphic	O
subtype	O
of	O
lobular	O
cancer	O
.	O

Since	O
mutated	O
cases	O
appear	O
to	O
be	O
HER2-negative	O
by	O
conventional	O
testing	O
,	O
the	O
opportunity	O
for	O
specific	O
anti	O
-	O
HER2	O
therapy	O
may	O
be	O
missed	O
.	O

Altered	O
ER	O
-	O
mitochondria	O
contact	O
impacts	O
mitochondria	O
calcium	O
homeostasis	O
and	O
contributes	O
to	O
neurodegeneration	O
in	O
vivo	O
in	O
disease	O
models	O
.	O

Calcium	O
(	O
Ca2	O
+	O
)	O
homeostasis	O
is	O
essential	O
for	O
neuronal	O
function	O
and	O
survival	O
.	O

Altered	O
Ca2	O
+	O
homeostasis	O
has	O
been	O
consistently	O
observed	O
in	O
neurological	O
diseases	O
.	O

How	O
Ca2	O
+	O
homeostasis	O
is	O
achieved	O
in	O
various	O
cellular	O
compartments	O
of	O
disease	O
-	O
relevant	O
cell	O
types	O
is	O
not	O
well	O
understood	O
.	O

Here	O
we	O
show	O
in	O
Drosophila	O
Parkinson	O
's	O
disease	O
(	O
PD	O
)	O
models	O
that	O
Ca2	O
+	O
transport	O
from	O
the	O
endoplasmic	O
reticulum	O
(	O
ER	O
)	O
to	O
mitochondria	O
through	O
the	O
ER	O
-	O
mitochondria	O
contact	O
site	O
(	O
ERMCS	O
)	O
critically	O
regulates	O
mitochondrial	O
Ca2	O
+	O
(	O
mito	O
-	O
Ca2	O
+	O
)	O
homeostasis	O
in	O
dopaminergic	O
(	O
DA	O
)	O
neurons	O
,	O
and	O
that	O
the	O
PD	O
-	O
associated	O
PINK1	O
protein	O
modulates	O
this	O
process	O
.	O

In	O
PINK1	B-Gene
mutant	B-Var
DA	O
neurons	O
,	O
the	O
ERMCS	B-MPA
is	O
strengthened	B-PosReg
and	O
mito	B-MPA
-	I-MPA
Ca2	I-MPA
+	I-MPA
level	I-MPA
is	O
elevated	B-PosReg
,	O
resulting	O
in	O
mitochondrial	B-MPA
enlargement	B-PosReg
and	O
neuronal	O
death	O
.	O

Miro	O
,	O
a	O
well	O
-	O
characterized	O
component	O
of	O
the	O
mitochondrial	O
trafficking	O
machinery	O
,	O
mediates	O
the	O
effects	O
of	O
PINK1	O
on	O
mito	O
-	O
Ca2	O
+	O
and	O
mitochondrial	O
morphology	O
,	O
apparently	O
in	O
a	O
transport	O
-	O
independent	O
manner	O
.	O

Miro	O
overexpression	O
mimics	O
PINK1	O
loss	O
-	O
of	O
-	O
function	O
effect	O
,	O
whereas	O
inhibition	O
of	O
Miro	O
or	O
components	O
of	O
the	O
ERMCS	O
,	O
or	O
pharmacological	O
modulation	O
of	O
ERMCS	O
function	O
,	O
rescued	O
PINK1	O
mutant	O
phenotypes	O
.	O

Mito	O
-	O
Ca2	O
+	O
homeostasis	O
is	O
also	O
altered	O
in	O
the	O
LRRK2-G2019S	O
model	O
of	O
PD	O
and	O
the	O
PAR-1	O
/	O
MARK	O
model	O
of	O
neurodegeneration	O
,	O
and	O
genetic	O
or	O
pharmacological	O
restoration	O
of	O
mito	O
-	O
Ca2	O
+	O
level	O
is	O
beneficial	O
in	O
these	O
models	O
.	O

Our	O
results	O
highlight	O
the	O
importance	O
of	O
mito	O
-	O
Ca2	O
+	O
homeostasis	O
maintained	O
by	O
Miro	O
and	O
the	O
ERMCS	O
to	O
mitochondrial	O
physiology	O
and	O
neuronal	O
integrity	O
.	O

Targeting	O
this	O
mito	O
-	O
Ca2	O
+	O
homeostasis	O
pathway	O
holds	O
promise	O
for	O
a	O
therapeutic	O
strategy	O
for	O
neurodegenerative	O
diseases	O
.	O

Bronchiectasis	B-Disease
and	O
Recurrent	B-Disease
Respiratory	I-Disease
Infections	I-Disease
with	O
a	O
De	O
Novo	O
STAT1	B-Gene
Gain	B-PosReg
-	I-PosReg
of	I-PosReg
-	I-PosReg
Function	I-PosReg
Variant	B-Var
:	I-Var
First	O
Case	O
in	O
Korea	O
.	O

Bronchiectasis	O
is	O
a	O
chronic	O
disease	O
characterized	O
by	O
airway	O
infection	O
and	O
inflammation	O
,	O
leading	O
to	O
permanent	O
dilation	O
of	O
the	O
bronchi	O
.	O

Evaluation	O
of	O
underlying	O
etiology	O
is	O
important	O
in	O
managing	O
young	O
bronchiectasis	O
patients	O
with	O
recurrent	O
infections	O
caused	O
by	O
unusual	O
pathogens	O
.	O

The	O
signal	O
transducer	O
and	O
activator	O
of	O
transcription	O
1	O
(	O
STAT1	O
)	O
protein	O
plays	O
a	O
key	O
role	O
in	O
STAT	O
signaling	O
and	O
immune	O
system	O
regulation	O
.	O

Heterozygotes	O
for	O
gain	B-PosReg
-	I-PosReg
of	I-PosReg
-	I-PosReg
function	I-PosReg
(	O
GOF	O
)	O
alleles	B-Var
of	O
the	O
STAT1	B-Gene
gene	O
usually	O
display	O
autosomal	B-Disease
dominant	I-Disease
chronic	I-Disease
mucocutaneous	I-Disease
candidiasis	I-Disease
(	O
CMC	O
)	O
and	O
a	O
wide	O
range	O
of	O
clinical	O
features	O
,	O
such	O
as	O
bronchiectasis	B-Disease
.	O

Here	O
,	O
we	O
report	O
on	O
a	O
patient	O
with	O
CMC	O
and	O
bronchiectasis	O
with	O
various	O
types	O
of	O
infections	O
who	O
carried	O
a	O
pathogenic	O
variant	O
of	O
the	O
STAT1	O
gene	O
.	O

The	O
24-year	O
-	O
old	O
female	O
presented	O
with	O
recurrent	O
respiratory	B-Disease
bacterial	I-Disease
and	I-Disease
nontuberculous	I-Disease
mycobacterial	I-Disease
infections	I-Disease
complicated	O
by	O
severe	O
bronchiectasis	B-Disease
and	O
CMC	B-Disease
.	O

Whole	O
-	O
exome	O
sequencing	O
revealed	B-Reg
a	O
c.800C	B-Var
>	I-Var
T	I-Var
(	O
p	O
.	O
Ala267Val	O
)	O
heterozygous	O
mutation	O
in	O
the	O
STAT1	B-Gene
gene	O
.	O

Further	O
analysis	O
by	O
Sanger	O
sequencing	O
of	O
STAT1	O
from	O
the	O
patient	O
and	O
her	O
parents	O
revealed	O
the	O
patient	O
had	O
a	O
de	O
novo	O
occurrence	O
of	O
the	O
variant	O
.	O

This	O
is	O
the	O
first	O
report	O
of	O
a	O
Korean	O
patient	O
with	O
a	O
GOF	O
pathogenic	O
variant	O
in	O
STAT1	O
.	O

Physicians	O
should	O
be	O
aware	O
of	O
the	O
existence	O
of	O
this	O
variant	O
as	O
a	O
genetic	O
factor	O
associated	O
with	O
CMC	O
and	O
bronchiectasis	O
complicated	O
by	O
recurrent	O
infection	O
.	O

Single	O
copy	O
/	O
knock	O
-	O
in	O
models	O
of	O
ALS	O
SOD1	O
in	O
C.	O
elegans	O
suggest	O
loss	O
and	O
gain	O
of	O
function	O
have	O
different	O
contributions	O
to	O
cholinergic	O
and	O
glutamatergic	O
neurodegeneration	O
.	O

Mutations	B-Var
in	O
Cu	O
/	O
Zn	O
superoxide	O
dismutase	O
1	O
(	B-Gene
SOD1	I-Gene
)	I-Gene
lead	B-Reg
to	I-Reg
Amyotrophic	B-Disease
Lateral	I-Disease
Sclerosis	I-Disease
(	O
ALS	O
)	O
,	O
a	O
neurodegenerative	O
disease	O
that	O
disproportionately	O
affects	O
glutamatergic	O
and	O
cholinergic	O
motor	O
neurons	O
.	O

Previous	O
work	O
with	O
SOD1	O
overexpression	O
models	O
supports	O
a	O
role	O
for	O
SOD1	O
toxic	O
gain	O
of	O
function	O
in	O
ALS	O
pathogenesis	O
.	O

However	O
,	O
the	O
impact	O
of	O
SOD1	O
loss	O
of	O
function	O
in	O
ALS	O
can	O
not	O
be	O
directly	O
examined	O
in	O
overexpression	O
models	O
.	O

In	O
addition	O
,	O
overexpression	O
may	O
obscure	O
the	O
contribution	O
of	O
SOD1	O
loss	O
of	O
function	O
in	O
the	O
degeneration	O
of	O
different	O
neuronal	O
populations	O
.	O

Here	O
,	O
we	O
report	O
the	O
first	O
single	O
-	O
copy	O
,	O
ALS	O
knock	O
-	O
in	O
models	O
in	O
C.	O
elegans	O
generated	O
by	O
transposon-	O
or	O
CRISPR	O
/	O
Cas9-	O
mediated	O
genome	O
editing	O
of	O
the	O
endogenous	O
sod-1	O
gene	O
.	O

Introduction	O
of	O
ALS	O
patient	O
amino	O
acid	O
changes	O
A4V	O
,	O
H71Y	O
,	O
L84V	O
,	O
G85R	O
or	O
G93A	O
into	O
the	O
C.	O
elegans	O
sod-1	O
gene	O
yielded	O
single	O
-	O
copy	O
/	O
knock	O
-	O
in	O
ALS	O
SOD1	O
models	O
.	O

These	O
differ	O
from	O
previously	O
reported	O
overexpression	O
models	O
in	O
multiple	O
assays	O
.	O

In	O
single	O
-	O
copy	O
/	O
knock	O
-	O
in	O
models	O
,	O
we	O
observed	O
differential	O
impact	O
of	O
sod-1	O
ALS	O
alleles	O
on	O
glutamatergic	O
and	O
cholinergic	O
neurodegeneration	O
.	O

A4V	O
,	O
H71Y	O
,	O
G85R	O
,	O
and	O
G93A	O
animals	O
showed	O
increased	O
SOD1	O
protein	O
accumulation	O
and	O
oxidative	O
stress	O
induced	O
degeneration	O
,	O
consistent	O
with	O
a	O
toxic	O
gain	O
of	O
function	O
in	O
cholinergic	O
motor	O
neurons	O
.	O

By	O
contrast	O
,	O
H71Y	O
,	O
L84V	O
,	O
and	O
G85R	O
lead	O
to	O
glutamatergic	O
neuron	O
degeneration	O
due	O
to	O
sod-1	O
loss	O
of	O
function	O
after	O
oxidative	O
stress	O
.	O

However	O
,	O
dopaminergic	O
and	O
serotonergic	O
neuronal	O
populations	O
were	O
spared	O
in	O
single	O
-	O
copy	O
ALS	O
models	O
,	O
suggesting	O
a	O
neuronal	O
-	O
subtype	O
specificity	O
previously	O
not	O
reported	O
in	O
invertebrate	O
ALS	O
SOD1	O
models	O
.	O

Combined	O
,	O
these	O
results	O
suggest	O
that	O
knock	O
-	O
in	O
models	O
may	O
reproduce	O
the	O
neurotransmitter	O
-	O
type	O
specificity	O
of	O
ALS	O
and	O
that	O
both	O
SOD1	O
loss	O
and	O
gain	O
of	O
toxic	O
function	O
differentially	O
contribute	O
to	O
ALS	O
pathogenesis	O
in	O
different	O
neuronal	O
populations	O
.	O

A	O
homozygous	O
loss	B-NegReg
-	I-NegReg
of	I-NegReg
-	I-NegReg
function	I-NegReg
mutation	B-Var
leading	O
to	O
CYBC1	B-Gene
deficiency	O
causes	O
chronic	B-Disease
granulomatous	I-Disease
disease	I-Disease
.	O

Mutations	B-Var
in	O
genes	O
encoding	O
subunits	O
of	O
the	O
phagocyte	O
NADPH	O
oxidase	O
complex	O
are	O
recognized	O
to	O
cause	B-Reg
chronic	B-Disease
granulomatous	I-Disease
disease	I-Disease
(	O
CGD	O
)	O
,	O
a	O
severe	O
primary	O
immunodeficiency	O
.	O

Here	O
we	O
describe	O
how	O
deficiency	O
of	O
CYBC1	O
,	O
a	O
previously	O
uncharacterized	O
protein	O
in	O
humans	O
(	O
C17orf62	O
)	O
,	O
leads	O
to	O
reduced	O
expression	O
of	O
NADPH	O
oxidase	O
's	O
main	O
subunit	O
(	O
gp91phox	O
)	O
and	O
results	O
in	O
CGD	O
.	O

Analyzing	O
two	O
brothers	O
diagnosed	O
with	O
CGD	O
we	O
identify	O
a	O
homozygous	O
loss	B-NegReg
-	I-NegReg
of	I-NegReg
-	I-NegReg
function	I-NegReg
mutation	O
,	O
p	B-Var
.	I-Var
Tyr2Ter	I-Var
,	O
in	O
CYBC1	B-Gene
.	O

Imputation	O
of	O
p	O
.	O
Tyr2Ter	O
into	O
155	O
K	O
chip	O
-	O
genotyped	O
Icelanders	O
reveals	O
six	O
additional	O
homozygotes	O
,	O
all	O
with	O
signs	O
of	O
CGD	O
,	O
manifesting	O
as	O
colitis	O
,	O
rare	O
infections	O
,	O
or	O
a	O
severely	O
impaired	O
PMA	O
-	O
induced	O
neutrophil	O
oxidative	O
burst	O
.	O

Homozygosity	O
for	O
p	B-Var
.	I-Var
Tyr2Ter	I-Var
consequently	O
associates	B-Reg
with	I-Reg
inflammatory	B-Disease
bowel	I-Disease
disease	I-Disease
(	O
IBD	O
)	O
in	O
Iceland	O
(	O
P	O
=	O
8.3	O
×	O
10	O
-	O
8	O
;	O
OR	O
=	O
67.6	O
)	O
,	O
as	O
well	O
as	O
reduced	O
height	O
(	O
P	O
=	O
3.3	O
×	O
10	O
-	O
4	O
;	O
-8.5	O
cm	O
)	O
.	O

Overall	O
,	O
we	O
find	O
that	O
CYBC1	O
deficiency	O
results	O
in	O
CGD	O
characterized	O
by	O
colitis	O
and	O
a	O
distinct	O
profile	O
of	O
infections	O
indicative	O
of	O
macrophage	O
dysfunction	O
.	O

Loss	O
of	O
Function	O
in	O
Zeaxanthin	O
Epoxidase	O
of	O
Dunaliella	O
tertiolecta	O
Caused	O
by	O
a	O
Single	O
Amino	O
Acid	O
Mutation	O
within	O
the	O
Substrate	O
-	O
Binding	O
Site	O
.	O

The	O
zea1	O
mutant	O
of	O
marine	O
microalga	O
Dunaliella	O
tertiolecta	O
accumulates	O
zeaxanthin	O
under	O
normal	O
growth	O
conditions	O
,	O
and	O
its	O
phenotype	O
has	O
been	O
speculated	O
to	O
be	O
related	O
to	O
zeaxanthin	O
epoxidase	O
(	O
ZEP	O
)	O
.	O

In	O
this	O
study	O
,	O
we	O
isolated	O
the	O
ZEP	O
gene	O
from	O
both	O
wild	O
-	O
type	O
D.	O
tertiolecta	O
and	O
the	O
mutant	O
.	O

We	O
found	O
that	O
the	O
zea1	O
mutant	O
has	O
a	O
point	B-Var
mutation	I-Var
of	O
the	O
1337th	O
nucleotide	O
of	O
the	O
ZEP	B-Gene
sequence	O
(	O
a	O
change	O
from	O
guanine	O
to	O
adenine	O
)	O
,	O
resulting	O
in	O
a	O
change	B-Reg
of	O
glycine	B-MPA
to	I-MPA
aspartate	I-MPA
in	I-MPA
a	I-MPA
highly	I-MPA
conserved	I-MPA
region	I-MPA
in	I-MPA
the	I-MPA
catalytic	I-MPA
domain	I-MPA
.	O

Similar	O
expression	O
levels	O
of	O
ZEP	O
mRNA	O
and	O
protein	O
in	O
both	O
wild	O
-	O
type	O
and	O
zea1	O
were	O
confirmed	O
by	O
using	O
qRT	O
-	O
PCR	O
and	O
western	O
blot	O
analysis	O
,	O
respectively	O
.	O

Additionally	O
,	O
the	O
enzyme	O
activity	O
analysis	O
of	O
ZEPs	O
in	O
the	O
presence	O
of	O
cofactors	O
showed	O
that	O
the	O
inactivation	O
of	O
ZEP	O
in	O
zea1	O
was	O
not	O
caused	O
by	O
deficiency	O
in	O
the	O
levels	O
of	O
cofactors	O
.	O

From	O
the	O
predicted	O
three	O
-	O
dimensional	O
ZEP	O
structure	O
of	O
zea1	O
,	O
we	O
observed	O
a	O
conformational	O
change	O
on	O
the	O
substrate	O
-	O
binding	O
site	O
in	O
the	O
ZEP	O
.	O

A	O
comparative	O
analysis	O
of	O
the	O
ZEP	B-Enzyme
structures	O
suggested	O
that	O
the	O
conformational	B-MPA
change	I-MPA
induced	O
by	O
a	O
single	B-Var
amino	I-Var
acid	I-Var
mutation	I-Var
might	O
impact	B-NegReg
the	O
interaction	B-Interaction
between	I-Interaction
the	I-Interaction
substrate	I-Interaction
and	I-Interaction
substrate	I-Interaction
-	I-Interaction
binding	I-Interaction
site	I-Interaction
,	O
resulting	O
in	O
loss	B-NegReg
of	O
zeaxanthin	B-Enzyme
epoxidase	I-Enzyme
function	B-MPA
.	O

LZTR1	O
is	O
a	O
regulator	O
of	O
RAS	O
ubiquitination	O
and	O
signaling	O
.	O

In	O
genetic	O
screens	O
aimed	O
at	O
understanding	O
drug	O
resistance	O
mechanisms	O
in	O
chronic	O
myeloid	O
leukemia	O
cells	O
,	O
inactivation	B-Var
of	O
the	O
cullin	O
3	O
adapter	O
protein	O
-	O
encoding	O
leucine	O
zipper	O
-	O
like	O
transcription	O
regulator	O
1	O
(	B-Gene
LZTR1	I-Gene
)	I-Gene
gene	O
led	O
to	O
enhanced	B-PosReg
mitogen	B-Pathway
-	I-Pathway
activated	I-Pathway
protein	I-Pathway
kinase	I-Pathway
(	I-Pathway
MAPK	I-Pathway
)	I-Pathway
pathway	I-Pathway
activity	B-MPA
and	O
reduced	B-NegReg
sensitivity	B-MPA
to	I-MPA
tyrosine	I-MPA
kinase	I-MPA
inhibitors	I-MPA
.	O

Knockdown	O
of	O
the	O
Drosophila	O
LZTR1	O
ortholog	O
CG3711	O
resulted	O
in	O
a	O
Ras	O
-	O
dependent	O
gain	O
-	O
of	O
-	O
function	O
phenotype	O
.	O

Endogenous	O
human	O
LZTR1	O
associates	O
with	O
the	O
main	O
RAS	O
isoforms	O
.	O

Inactivation	B-Var
of	O
LZTR1	B-Gene
led	O
to	O
decreased	B-NegReg
ubiquitination	B-MPA
and	O
enhanced	B-PosReg
plasma	B-MPA
membrane	I-MPA
localization	I-MPA
of	O
endogenous	O
KRAS	O
(	O
V	O
-	O
Ki	O
-	O
ras2	O
Kirsten	O
rat	O
sarcoma	O
viral	O
oncogene	O
homolog	O
)	O
.	O

We	O
propose	O
that	O
LZTR1	O
acts	O
as	O
a	O
conserved	O
regulator	O
of	O
RAS	O
ubiquitination	O
and	O
MAPK	O
pathway	O
activation	O
.	O

Because	O
LZTR1	O
disease	O
mutations	O
failed	O
to	O
revert	O
loss	O
-	O
of	O
-	O
function	O
phenotypes	O
,	O
our	O
findings	O
provide	O
a	O
molecular	O
rationale	O
for	O
LZTR1	O
involvement	O
in	O
a	O
variety	O
of	O
inherited	O
and	O
acquired	O
human	O
disorders	O
.	O

Association	O
Between	O
Titin	O
Loss	O
-	O
of	O
-	O
Function	O
Variants	O
and	O
Early	O
-	O
Onset	O
Atrial	O
Fibrillation	O
.	O

Importance	O
:	O
Atrial	O
fibrillation	O
(	O
AF	O
)	O
is	O
the	O
most	O
common	O
arrhythmia	O
affecting	O
1	O
%	O
of	O
the	O
population	O
.	O

Young	O
individuals	O
with	O
AF	O
have	O
a	O
strong	O
genetic	O
association	O
with	O
the	O
disease	O
,	O
but	O
the	O
mechanisms	O
remain	O
incompletely	O
understood	O
.	O

Objective	O
:	O
To	O
perform	O
large	O
-	O
scale	O
whole	O
-	O
genome	O
sequencing	O
to	O
identify	O
genetic	O
variants	O
related	O
to	O
AF	O
.	O

Design	O
,	O
Setting	O
,	O
and	O
Participants	O
:	O
The	O
National	O
Heart	O
,	O
Lung	O
,	O
and	O
Blood	O
Institute	O
's	O
Trans	O
-	O
Omics	O
for	O
Precision	O
Medicine	O
Program	O
includes	O
longitudinal	O
and	O
cohort	O
studies	O
that	O
underwent	O
high	O
-	O
depth	O
whole	O
-	O
genome	O
sequencing	O
between	O
2014	O
and	O
2017	O
in	O
18	O
526	O
individuals	O
from	O
the	O
United	O
States	O
,	O
Mexico	O
,	O
Puerto	O
Rico	O
,	O
Costa	O
Rica	O
,	O
Barbados	O
,	O
and	O
Samoa	O
.	O

This	O
case	O
-	O
control	O
study	O
included	O
2781	O
patients	O
with	O
early	O
-	O
onset	O
AF	O
from	O
9	O
studies	O
and	O
identified	O
4959	O
controls	O
of	O
European	O
ancestry	O
from	O
the	O
remaining	O
participants	O
.	O

Results	O
were	O
replicated	O
in	O
the	O
UK	O
Biobank	O
(	O
346	O
546	O
participants	O
)	O
and	O
the	O
MyCode	O
Study	O
(	O
42	O
782	O
participants	O
)	O
.	O

Exposures	O
:	O
Loss	O
-	O
of	O
-	O
function	O
(	O
LOF	O
)	O
variants	O
in	O
genes	O
at	O
AF	O
loci	O
and	O
common	O
genetic	O
variation	O
across	O
the	O
whole	O
genome	O
.	O

Main	O
Outcomes	O
and	O
Measures	O
:	O
Early	O
-	O
onset	O
AF	O
(	O
defined	O
as	O
AF	O
onset	O
in	O
persons	O
<	O
66	O
years	O
of	O
age	O
)	O
.	O

Due	O
to	O
multiple	O
testing	O
,	O
the	O
significance	O
threshold	O
for	O
the	O
rare	O
variant	O
analysis	O
was	O
P	O
=	O
4.55	O
×	O
10	O
-	O
3	O
.	O

Results	O
:	O
Among	O
2781	O
participants	O
with	O
early	O
-	O
onset	O
AF	O
(	O
the	O
case	O
group	O
)	O
,	O
72.1	O
%	O
were	O
men	O
,	O
and	O
the	O
mean	O
(	O
SD	O
)	O
age	O
of	O
AF	O
onset	O
was	O
48.7	O
(	O
10.2	O
)	O
years	O
.	O

Participants	O
underwent	O
whole	O
-	O
genome	O
sequencing	O
at	O
a	O
mean	O
depth	O
of	O
37.8	O
fold	O
and	O
mean	O
genome	O
coverage	O
of	O
99.1	O
%	O
.	O

At	O
least	O
1	O
LOF	O
variant	O
in	O
TTN	O
,	O
the	O
gene	O
encoding	O
the	O
sarcomeric	O
protein	O
titin	O
,	O
was	O
present	O
in	O
2.1	O
%	O
of	O
case	O
participants	O
compared	O
with	O
1.1	O
%	O
in	O
control	O
participants	O
(	O
odds	O
ratio	O
[	O
OR	O
]	O
,	O
1.76	O
[	O
95	O
%	O
CI	O
,	O
1.04	O
-	O
2.97	O
]	O
)	O
.	O

The	O
proportion	O
of	O
individuals	O
with	O
early	B-Disease
-	I-Disease
onset	I-Disease
AF	I-Disease
who	O
carried	O
a	O
LOF	B-PosReg
variant	B-Var
in	O
TTN	B-Gene
increased	B-PosReg
with	O
an	O
earlier	O
age	O
of	O
AF	O
onset	O
(	O
P	O
value	O
for	O
trend	O
,	O
4.92	O
×	O
10	O
-	O
4	O
)	O
,	O
and	O
6.5	O
%	O
of	O
individuals	O
with	O
AF	O
onset	O
prior	O
to	O
age	O
30	O
carried	O
a	O
TTN	O
LOF	O
variant	O
(	O
OR	O
,	O
5.94	O
[	O
95	O
%	O
CI	O
,	O
2.64	O
-	O
13.35	O
]	O
;	O
P	O
=	O
1.65	O
×	O
10	O
-	O
5	O
)	O
.	O

The	O
association	O
between	O
TTN	O
LOF	O
variants	O
and	O
AF	O
was	O
replicated	O
in	O
an	O
independent	O
study	O
of	O
1582	O
patients	O
with	O
early	O
-	O
onset	O
AF	O
(	O
cases	O
)	O
and	O
41	O
200	O
control	O
participants	O
(	O
OR	O
,	O
2.16	O
[	O
95	O
%	O
CI	O
,	O
1.19	O
-	O
3.92	O
]	O
;	O
P	O
=	O
.01	O
)	O
.	O

Conclusions	O
and	O
Relevance	O
:	O
In	O
a	O
case	O
-	O
control	O
study	O
,	O
there	O
was	O
a	O
statistically	O
significant	B-Reg
association	I-Reg
between	O
an	O
LOF	B-NegReg
variant	B-Var
in	O
the	O
TTN	B-Gene
gene	O
and	O
early	B-Disease
-	I-Disease
onset	I-Disease
AF	I-Disease
,	O
with	O
the	O
variant	O
present	O
in	O
a	O
small	O
percentage	O
of	O
participants	O
with	O
early	O
-	O
onset	O
AF	O
(	O
the	O
case	O
group	O
)	O
.	O

Further	O
research	O
is	O
necessary	O
to	O
understand	O
whether	O
this	O
is	O
a	O
causal	O
relationship	O
.	O

HDX	O
-	O
MS	O
reveals	O
dysregulated	O
checkpoints	O
that	O
compromise	O
discrimination	O
against	O
self	O
RNA	O
during	O
RIG	O
-	O
I	O
mediated	O
autoimmunity	O
.	O

Retinoic	O
acid	O
inducible	O
gene	O
-	O
I	O
(	O
RIG	O
-	O
I	O
)	O
ensures	O
immune	O
surveillance	O
of	O
viral	O
RNAs	O
bearing	O
a	O
5'-triphosphate	O
(	O
5'ppp	O
)	O
moiety	O
.	O

Mutations	O
in	O
RIG	B-Gene
-	I-Gene
I	I-Gene
(	B-Var
C268F	I-Var
and	O
E373A	B-Var
)	I-Var
lead	O
to	O
impaired	B-NegReg
ATPase	B-Protein
activity	B-MPA
,	O
thereby	O
driving	O
hyperactive	B-PosReg
signaling	B-MPA
associated	O
with	O
autoimmune	O
diseases	O
.	O

Here	O
we	O
report	O
,	O
using	O
hydrogen	O
/	O
deuterium	O
exchange	O
,	O
mechanistic	O
models	O
for	O
dysregulated	O
RIG	O
-	O
I	O
proofreading	O
that	O
ultimately	O
result	O
in	O
the	O
improper	O
recognition	O
of	O
cellular	O
RNAs	O
bearing	O
7-methylguanosine	O
and	O
N1	O
-	O
2'-O	O
-	O
methylation	O
(	O
Cap1	O
)	O
on	O
the	O
5	O
'	O
end	O
.	O

Cap1-RNA	O
compromises	O
its	O
ability	O
to	O
stabilize	O
RIG	O
-	O
I	O
helicase	O
and	O
blunts	O
caspase	O
activation	O
and	O
recruitment	O
domains	O
(	O
CARD	O
)	O
partial	O
opening	O
by	O
threefold	O
.	O

RIG	B-Gene
-	I-Gene
I	I-Gene
H830A	B-Var
mutation	I-Var
restores	B-PosReg
Cap1-helicase	B-Protein
engagement	B-MPA
as	O
well	O
as	O
CARDs	B-MPA
partial	I-MPA
opening	I-MPA
event	I-MPA
to	O
a	O
level	O
comparable	O
to	O
that	O
of	O
5'ppp	O
.	O

However	O
,	O
E373A	B-Var
RIG	B-Gene
-	I-Gene
I	I-Gene
locks	O
the	O
receptor	O
in	O
an	O
ATP	O
-	O
bound	O
state	O
,	O
resulting	O
in	O
enhanced	B-PosReg
Cap1-helicase	B-Protein
engagement	B-MPA
and	O
a	O
sequential	B-MPA
CARDs	I-MPA
stimulation	I-MPA
.	O

C268F	B-Var
mutation	I-Var
renders	O
a	O
more	B-PosReg
tethered	B-MPA
ring	I-MPA
architecture	I-MPA
and	O
results	B-Reg
in	I-Reg
constitutive	B-MPA
CARDs	I-MPA
signaling	I-MPA
in	O
an	O
ATP	O
-	O
independent	O
manner	O
.	O

Variant	O
Prolactin	O
Receptor	O
in	O
Agalactia	O
and	O
Hyperprolactinemia	O
.	O

A	O
loss	O
-	O
of	O
-	O
function	O
variant	O
in	O
the	O
gene	O
encoding	O
the	O
prolactin	O
receptor	O
(	O
PRLR	O
)	O
was	O
reported	O
previously	O
in	O
a	O
woman	O
with	O
persistent	O
postpartum	O
galactorrhea	O
;	O
however	O
,	O
this	O
paradoxical	O
phenotype	O
is	O
not	O
completely	O
understood	O
.	O

Here	O
we	O
describe	O
a	O
35-year	O
-	O
old	O
woman	O
who	O
presented	O
with	O
idiopathic	O
hyperprolactinemia	B-Disease
that	O
was	O
associated	O
with	O
a	O
complete	O
lack	O
of	O
lactation	O
after	O
each	O
of	O
her	O
two	O
deliveries	O
.	O

She	O
is	O
a	O
compound	O
heterozygote	O
for	O
loss	B-NegReg
-	I-NegReg
of	I-NegReg
-	I-NegReg
function	I-NegReg
variants	B-Var
of	O
PRLR	B-Gene
.	O

Her	O
unaffected	O
parents	O
are	O
heterozygotes	O
.	O

These	O
findings	O
are	O
consistent	O
with	O
previous	O
work	O
showing	O
that	O
mice	O
deficient	O
in	O
functional	O
Prlr	O
do	O
not	B-NegReg
lactate	B-CPA
.	O

WRKY12	O
represses	O
GSH1	O
expression	O
to	O
negatively	O
regulate	O
cadmium	O
tolerance	O
in	O
Arabidopsis	O
.	O

KEY	O
MESSAGE	O
:	O
The	O
WRKY	O
transcription	O
factor	O
WRKY12	O
negatively	O
regulates	O
Cd	O
tolerance	O
in	O
Arabidopsis	O
via	O
the	O
glutathione	O
-	O
dependent	O
phytochelatin	O
synthesis	O
pathway	O
by	O
directly	O
targeting	O
GSH1	O
and	O
indirectly	O
repressing	O
phytochelatin	O
synthesis	O
-	O
related	O
gene	O
expression	O
.	O

Cadmium	O
(	O
Cd	O
)	O
is	O
a	O
widespread	O
pollutant	O
toxic	O
to	O
plants	O
.	O

The	O
glutathione	O
(	O
GSH)-dependent	O
phytochelatin	O
(	O
PC	O
)	O
synthesis	O
pathway	O
plays	O
key	O
roles	O
in	O
Cd	O
detoxification	O
.	O

However	O
,	O
its	O
regulatory	O
mechanism	O
remains	O
largely	O
unknown	O
.	O

Here	O
,	O
we	O
showed	O
a	O
previously	O
unknown	O
function	O
of	O
the	O
WRKY	O
transcription	O
factor	O
WRKY12	O
in	O
the	O
regulation	O
of	O
Cd	O
tolerance	O
by	O
repressing	O
the	O
expression	O
of	O
PC	O
synthesis	O
-	O
related	O
genes	O
.	O

The	O
expression	O
of	O
WRKY12	O
was	O
inhibited	O
by	O
Cd	O
stress	O
.	O

Enhanced	B-PosReg
Cd	B-CPA
tolerance	I-CPA
was	O
observed	O
in	O
the	O
WRKY12	B-Gene
loss	B-NegReg
-	I-NegReg
of	I-NegReg
-	I-NegReg
function	I-NegReg
mutants	B-Var
,	O
whereas	O
increased	O
Cd	O
sensitivity	O
was	O
found	O
in	O
the	O
WRKY12-overexpressing	O
plants	O
.	O

Overexpression	O
and	O
loss	B-NegReg
-	I-NegReg
of	I-NegReg
-	I-NegReg
function	I-NegReg
of	O
WRKY12	B-Gene
were	O
associated	O
respectively	O
with	O
increased	O
and	O
decreased	B-NegReg
Cd	B-CPA
accumulation	I-CPA
by	O
repressing	O
or	O
releasing	B-PosReg
the	O
expression	B-MPA
of	O
the	O
genes	O
involved	O
in	O
the	O
PC	O
synthesis	O
pathway	O
.	O

Transient	O
expression	O
assay	O
showed	O
that	O
WRKY12	O
repressed	O
the	O
expression	O
of	O
GSH1	B-Gene
,	O
GSH2	B-Gene
,	O
PCS1	B-Gene
,	O
and	O
PCS2	B-Gene
.	O

Further	O
analysis	O
indicated	O
that	O
WRKY12	O
could	O
directly	O
bind	O
to	O
the	O
W	O
-	O
box	O
of	O
the	O
promoter	O
in	O
GSH1	O
but	O
not	O
in	O
GSH2	O
,	O
PCS1	O
,	O
and	O
PCS2	O
in	O
vivo	O
.	O

Together	O
,	O
our	O
results	O
suggest	O
that	O
WRKY12	O
directly	O
targets	O
GSH1	O
and	O
indirectly	O
represses	O
PC	O
synthesis	O
-	O
related	O
gene	O
expression	O
to	O
negatively	O
regulate	O
Cd	O
accumulation	O
and	O
tolerance	O
in	O
Arabidopsis	O
.	O

Loss	B-NegReg
-	I-NegReg
of	I-NegReg
-	I-NegReg
function	I-NegReg
mutations	B-Var
in	O
QRICH2	B-Gene
cause	B-Reg
male	B-Disease
infertility	I-Disease
with	O
multiple	O
morphological	O
abnormalities	O
of	O
the	O
sperm	O
flagella	O
.	O

Aberrant	B-Var
sperm	B-CPA
flagella	I-CPA
impair	B-NegReg
sperm	B-CPA
motility	I-CPA
and	O
cause	B-Reg
male	B-Disease
infertility	I-Disease
,	O
yet	O
the	O
genes	O
which	O
have	O
been	O
identified	O
in	O
multiple	O
morphological	O
abnormalities	O
of	O
the	O
flagella	O
(	O
MMAF	O
)	O
can	O
only	O
explain	O
the	O
pathogenic	O
mechanisms	O
of	O
MMAF	O
in	O
a	O
small	O
number	O
of	O
cases	O
.	O

Here	O
,	O
we	O
identify	O
and	O
functionally	O
characterize	O
homozygous	O
loss	O
-	O
of	O
-	O
function	O
mutations	O
of	O
QRICH2	O
in	O
two	O
infertile	O
males	O
with	O
MMAF	O
from	O
two	O
consanguineous	O
families	O
.	O

Remarkably	O
,	O
Qrich2	O
knock	O
-	O
out	O
(	O
KO	O
)	O
male	O
mice	O
constructed	O
by	O
CRISPR	O
-	O
Cas9	O
technology	O
present	O
MMAF	O
phenotypes	O
and	O
sterility	O
.	O

To	O
elucidate	O
the	O
mechanisms	O
of	O
Qrich2	O
functioning	O
in	O
sperm	O
flagellar	O
formation	O
,	O
we	O
perform	O
proteomic	O
analysis	O
on	O
the	O
testes	O
of	O
KO	O
and	O
wild	O
-	O
type	O
mice	O
.	O

Furthermore	O
,	O
in	O
vitro	O
experiments	O
indicate	O
that	O
QRICH2	O
is	O
involved	O
in	O
sperm	O
flagellar	O
development	O
through	O
stabilizing	O
and	O
enhancing	O
the	O
expression	O
of	O
proteins	O
related	O
to	O
flagellar	O
development	O
.	O

Our	O
findings	O
strongly	O
suggest	O
that	O
the	O
genetic	O
mutations	B-Var
of	O
human	O
QRICH2	B-Gene
can	O
lead	B-Reg
to	I-Reg
male	B-Disease
infertility	I-Disease
with	O
MMAF	B-CPA
and	O
that	O
QRICH2	O
is	O
essential	O
for	O
sperm	O
flagellar	O
formation	O
.	O

